[ { "form_type": "10-Q", "accession_number": "0000038723-24-000084", "filing_date": 1715770525000, "quarter_ending": "20240331", "company_name": "1st FRANKLIN FINANCIAL CORP", "text": "During the three months ended March\u00a031, 2024, and 2023, the Company recognized interest related revenue of $76.1\u00a0million and $69.0\u00a0million, respectively, insurance related revenue of $15.0\u00a0million and $13.8\u00a0million, respectively, and other revenue from contracts with customers of $1.9 million and $1.6 million, respectively. ", "entities": [ { "start_character": 184, "end_character": 188, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 15000000.0 }, { "start_character": 202, "end_character": 206, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 13800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001860782-24-000027", "filing_date": 1709827368000, "quarter_ending": "20231231", "company_name": "2seventy bio, Inc.", "text": ", the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated and combined financial statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the year ended December\u00a031, 2023, the Company incurred a net loss of $217.6 million and used $166.9 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the near future.", "entities": [ { "start_character": 468, "end_character": 473, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -217600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001860782-24-000081", "filing_date": 1715270621000, "quarter_ending": "20240331", "company_name": "2seventy bio, Inc.", "text": ", the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the three months ended March 31, 2024, the Company incurred a net loss of $52.7 million and used $41.9 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the near future.", "entities": [ { "start_character": 470, "end_character": 474, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -52700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000066740-24-000053", "filing_date": 1714477095000, "quarter_ending": "20240331", "company_name": "3M CO", "text": "Net sales includes rental revenue from durable medical devices as part of operating lease arrangements (reported within the Medical Surgical Division), which was $139 million and $139 million during the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 163, "end_character": 166, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 139000000.0 }, { "start_character": 180, "end_character": 183, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 139000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-005348", "filing_date": 1708100158000, "quarter_ending": "20231231", "company_name": "ABBOTT LABORATORIES", "text": "EARNINGS PER SHARE \u2014 Unvested restricted stock units and awards that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares in 2023, 2022 and 2021 were $5.701 billion, $6.905 billion and $7.042 billion, respectively.", "entities": [ { "start_character": 416, "end_character": 421, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5701000000.0 }, { "start_character": 432, "end_character": 437, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 6905000000.0 }, { "start_character": 451, "end_character": 456, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7042000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020011", "filing_date": 1714666270000, "quarter_ending": "20240331", "company_name": "ABBOTT LABORATORIES", "text": "Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended March\u00a031, 2024 and 2023 were $1.220 billion and $1.313 billion, respectively.", "entities": [ { "start_character": 415, "end_character": 420, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1220000000.0 }, { "start_character": 434, "end_character": 439, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1313000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010190", "filing_date": 1710747357000, "quarter_ending": "20231231", "company_name": "ABEONA THERAPEUTICS INC.", "text": "Since\nits inception, the Company has funded its operations primarily with proceeds from sales of shares of its stock. The Company has\nincurred recurring losses since its inception, including net losses contributable to Common Shareholders of $54.2\nmillion and $43.5\nmillion for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company had an accumulated\ndeficit of $749.5\nmillion. To date, the Company has not generated any significant revenues and expects to continue to generate operating losses for\nthe foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its existing\ncash, cash equivalents, restricted cash and short-term investments of $52.6\nmillion as of December 31, 2023 in addition to the $20\nmillion received in January 2024 as part of a credit facility with Avenue Venture Opportunities Fund, L.P. (see Footnote 15) and the $5.3 million in net proceeds from the Company\u2019s common stock sales subsequent to December 31, 2023, will\nbe sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the issuance\ndate of these consolidated financial statements.", "entities": [ { "start_character": 243, "end_character": 247, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -54200000.0 }, { "start_character": 261, "end_character": 265, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -43500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019459", "filing_date": 1715758544000, "quarter_ending": "20240331", "company_name": "ABEONA THERAPEUTICS INC.", "text": "Since\nits inception, the Company has funded its operations primarily with proceeds from sales of shares of its stock. The Company has incurred\nrecurring losses since its inception, including net losses of $31.6 million and $9.1 million for the three months ended March 31, 2024\nand 2023, respectively. As of March 31, 2024, the Company had an accumulated deficit of approximately $781.1 million. To date the Company\nhas not generated any significant revenues and expects to continue to generate operating losses for the foreseeable future. As of the\nissuance date of these unaudited interim condensed consolidated financial statements, the Company expects that its existing cash, cash\nequivalents, restricted cash and short-term investments of $62.7 million as of March 31, 2024 plus the gross proceeds of $75.0 million\nfrom its underwritten offering that closed on May 7, 2024, will be sufficient to fund its operating expenses and capital expenditure\nrequirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements.", "entities": [ { "start_character": 206, "end_character": 210, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -31600000.0 }, { "start_character": 224, "end_character": 227, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -9100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001962918-24-000032", "filing_date": 1711642898000, "quarter_ending": "20231231", "company_name": "ACELYRIN, Inc.", "text": "The Company has incurred significant losses and negative cash flows from operations since its inception. During the years ended December\u00a031, 2023, 2022 and 2021, the Company incurred net losses of $381.6 million, $64.8 million and $41.8 million, respectively. The net loss of $381.6 million in the year ended December\u00a031, 2023 includes $123.1\u00a0million of expenses related to acquired in-process research and development assets without alternative future use and $10.0 million license fee payment to Pierre Fabre incurred in connection with the ValenzaBio acquisition. As of December\u00a031, 2023, the Company had an accumulated deficit of $488.7 million. Cash used in operating activities was $169.7 million, $61.5 million and $5.0 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 198, "end_character": 203, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -381600000.0 }, { "start_character": 214, "end_character": 218, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -64800000.0 }, { "start_character": 232, "end_character": 236, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -41800000.0 }, { "start_character": 277, "end_character": 282, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -381600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001962918-24-000052", "filing_date": 1715703767000, "quarter_ending": "20240331", "company_name": "ACELYRIN, Inc.", "text": "The Company has incurred significant losses and negative cash flows from operations since its inception. During the three months ended March\u00a031, 2024 and 2023, the Company incurred net losses of $35.0 million and $176.5 million, respectively. The net loss of $35.0 million in the three months ended March\u00a031, 2024 includes $37.0\u00a0million of other income related to payments in the quarter. The net loss of $176.5 million in the three months ended March\u00a031, 2023 includes $123.1 million of expenses related to acquired in-process research and development assets without alternative future use and $10.0 million license fee payment to Pierre Fabre incurred in connection with the ValenzaBio acquisition. As of March\u00a031, 2024, the Company had an accumulated deficit of $523.7 million. Cash used in operating activities was $57.3 million and $25.3 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 196, "end_character": 200, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -35000000.0 }, { "start_character": 214, "end_character": 219, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -176500000.0 }, { "start_character": 260, "end_character": 264, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -35000000.0 }, { "start_character": 406, "end_character": 411, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -176500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020450", "filing_date": 1714977491000, "quarter_ending": "20240331", "company_name": "ADC Therapeutics SA", "text": "Income tax expense for the three months ended March\u00a031, 2024 was $0.2 million relative to loss before income taxes of $45.8 million. The income tax expense for the three months ended March\u00a031, 2023 was $0.5 million relative to loss before income taxes of $57.5 million. The expense for the three months ended March\u00a031, 2024 is the result of income generated by our UK operations for which tax expense has been recognized based on a full year estimated income tax liability, and the inability to recognize benefit on losses in the U.S. and Switzerland. Whereas the expense for the three months ended March\u00a031, 2023 was the result of income generated in the U.S. and UK. The decrease in U.S. income in the first quarter of 2024 is due to a change in the Company operating and transfer pricing model which was implemented in October 2023. We remain a full valuation allowance against all deferred tax assets, and each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction and adjust our estimates as more information becomes available.", "entities": [ { "start_character": 119, "end_character": 123, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -45800000.0 }, { "start_character": 257, "end_character": 261, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -57500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001703056-24-000020", "filing_date": 1709141245000, "quarter_ending": "20231231", "company_name": "ADT Inc.", "text": "From the acquisition date, December\u00a08, 2021 through December\u00a031, 2021, revenue and net loss of $47\u00a0million and $7\u00a0million, respectively, attributable to ADT Solar are included in the Consolidated Statements of Operations.", "entities": [ { "start_character": 112, "end_character": 113, "label": "earnings", "start_date_for_period": "2021-12-08", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001703056-24-000051", "filing_date": 1714061386000, "quarter_ending": "20240331", "company_name": "ADT Inc.", "text": "Potential shares of Common Stock include (i) incremental shares related to the vesting or exercise of share-based compensation awards, warrants, and other options to purchase additional shares of the Company\u2019s Common Stock calculated using the treasury stock method and (ii) incremental shares of Common Stock issuable upon the conversion of Class B Common Stock. Additionally, the basic and diluted earnings per share computations for Common Stock exclude approximately 9 million unvested shares as their vesting is contingent upon achievement of certain performance requirements.", "entities": [ { "start_character": 471, "end_character": 472, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 9000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001818644-24-000003", "filing_date": 1711486632000, "quarter_ending": "20231231", "company_name": "AEye, Inc.", "text": "Since its inception, the Company has incurred net losses and negative cash flows from operations. As of December\u00a031, 2023, the Company had an accumulated deficit of $337,635. For the twelve months ended December 31, 2023 and 2022, the Company incurred a net loss of $87,126 and $98,714, respectively, and the Company had net cash outflows from operating activities of $50,725 and $71,649, respectively. As of December\u00a031, 2023, the Company had $36,523 of cash and marketable securities. As the Company is still in its early stages, it is expected to incur additional operating losses and negative cash flows as it continues to focus on achieving commercialization of its lidar solutions. ", "entities": [ { "start_character": 267, "end_character": 273, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -87126000.0 }, { "start_character": 279, "end_character": 285, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -98714000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001818644-24-000006", "filing_date": 1715705623000, "quarter_ending": "20240331", "company_name": "AEye, Inc.", "text": "Since its inception, the Company has incurred net losses and negative cash flows from operations. As of March\u00a031, 2024, the Company had an accumulated deficit of $347,854. For the three months ended March 31, 2024 and 2023, the Company incurred a net loss of $10,219 and $26,265, respectively, and the Company had net cash outflows from operating activities of $7,885 and $17,195, respectively. As of March\u00a031, 2024, the Company had $28,909 of cash and marketable securities. As the Company is still in its early stages, it is expected to incur additional operating losses and negative cash flows as it continues to focus on achieving commercialization of its lidar solutions. ", "entities": [ { "start_character": 260, "end_character": 266, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -10219000.0 }, { "start_character": 272, "end_character": 278, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -26265000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006637", "filing_date": 1707926758000, "quarter_ending": "20231231", "company_name": "AG Acquisition Group III, Inc.", "text": "Since\nthe inception of the Company through December 31, 2023, the Company has not generated cash or revenue. For the three months ended December\n31, 2023 and 2022, the Company incurred a net loss of $1,575 and $6,688, respectively. For the six months ended December 31, 2023 and\n2022, the Company incurred a net loss of $11,125 and $10,500 respectively. For the three months ended December 31, 2023, the Company used\nnet cash in operating activities of $8,260. The Company had a working capital deficiency of $2,865 as of December 31, 2023. The Company\u2019s\ncontinuation as a going concern is dependent on its ability to obtain additional financing from its stockholders or other sources, as\nmay be required, to meet its financial obligations as they become due.", "entities": [ { "start_character": 200, "end_character": 205, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1575.0 }, { "start_character": 211, "end_character": 216, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -6688.0 }, { "start_character": 321, "end_character": 327, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -11125.0 }, { "start_character": 333, "end_character": 339, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -10500.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-23-086450", "filing_date": 1699952436000, "quarter_ending": "20230930", "company_name": "AGBA Group Holding Ltd.", "text": "For\nthe nine months ended September 30, 2023, the Company reported $35,578,728 net loss and $33,364,662 net cash outflows from operating\nactivities. As of September 30, 2023, the Company had an accumulated deficit of $74,973,861 and cash and cash equivalents of $1,622,425.", "entities": [ { "start_character": 68, "end_character": 78, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -35578728.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012418", "filing_date": 1711989093000, "quarter_ending": "20231231", "company_name": "AGRIFORCE GROWING SYSTEMS LTD.", "text": "The\nCompany has incurred substantial operating losses since its inception, and expects to continue to incur significant operating losses\nfor the foreseeable future and may never become profitable. As reflected in the financial statements, the Company had an accumulated\ndeficit of approximately $44.5 million at December 31, 2023, a net loss of approximately $11.7 million, and approximately $6.5 million\nof net cash used in operating activities for the year ended December 31, 2023. The accompanying financial statements have been prepared\non a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.\nThe financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or\nthe amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company anticipates incurring\nadditional losses until such time, if ever, that it can obtain marketing approval to sell, and then generate significant sales, of its\ntechnology that is currently in development. The Company will need to raise additional capital in order to fund its\noperations and to develop and commercialize its technology. These factors raise substantial doubt about the Company\u2019s ability to\ncontinue as a going concern. The Company is seeking additional financing to support its growth plans. The sale of additional equity may\ndilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding common\nshares.", "entities": [ { "start_character": 360, "end_character": 364, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -11700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019561", "filing_date": 1715763798000, "quarter_ending": "20240331", "company_name": "AGRIFORCE GROWING SYSTEMS LTD.", "text": "The\nCompany has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for\nthe foreseeable future. As reflected in the interim financial statements for the three months ended March 31, 2024, the Company had a\nnet loss of $3.3 million, $1.3 million of net cash used in operating activities, and the Company had a working capital deficit of $0.7\nmillion.", "entities": [ { "start_character": 287, "end_character": 290, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3300000.0 } ] }, { "form_type": "10-K", "accession_number": "0000353184-24-000062", "filing_date": 1719421254000, "quarter_ending": "20240331", "company_name": "AIR T INC", "text": "We recognized rental and other revenues related to operating lease payments of $1.6 million and $1.4 million, respectively, of which variable lease payments were $0.7 million and $0.6 million during the fiscal years ended March\u00a031, 2024 and 2023, respectively. Future minimum rental payments to be received do not include variable lease payments that may be received under certain leases because amounts are based on usage. The following table sets forth the undiscounted cash flows for future minimum base rents to be received from customers for office leases in effect as of March\u00a031, 2024:", "entities": [ { "start_character": 80, "end_character": 83, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 }, { "start_character": 97, "end_character": 100, "label": "revenues", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001086222-24-000040", "filing_date": 1709137282000, "quarter_ending": "20231231", "company_name": "AKAMAI TECHNOLOGIES INC", "text": "The Company has implemented software and hardware initiatives to manage its global network more efficiently and, as a result, the expected average useful life of its servers increased from five years to six years, effective January 1, 2023. These changes decreased depreciation expense by $62.7\u00a0million for the year ended December\u00a031, 2023, and increased net income by $52.3\u00a0million, or $0.34 per share, for the year ended December\u00a031, 2023.", "entities": [ { "start_character": 370, "end_character": 374, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 52300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000003499-24-000015", "filing_date": 1714984094000, "quarter_ending": "20240331", "company_name": "ALEXANDERS INC", "text": "Bloomberg L.P. (\u201cBloomberg\u201d) accounted for revenue of $29,963,000 and $29,516,000 for the three months ended March 31, 2024 and 2023, respectively, representing approximately 49% and 56% of our rental revenues in each period, respectively. No other tenant accounted for more than 10% of our rental revenues. If we were to lose Bloomberg as a tenant, or if Bloomberg were to be unable to fulfill its obligations under its lease, it would adversely affect our results of operations and financial condition. In order to assist us in our continuing assessment of Bloomberg\u2019s creditworthiness, we receive certain confidential financial information and metrics from Bloomberg. In addition, we access and evaluate financial information regarding Bloomberg from other private sources, as well as publicly available data.", "entities": [ { "start_character": 55, "end_character": 65, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 29963000.0 }, { "start_character": 71, "end_character": 81, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 29516000.0 } ] }, { "form_type": "10-K", "accession_number": "0001097149-24-000011", "filing_date": 1709140427000, "quarter_ending": "20231231", "company_name": "ALIGN TECHNOLOGY INC", "text": "In September 2023, we completed an assessment of the useful lives of certain manufacturing equipment used in cutting, forming, assembling and scanning. We adjusted the estimated useful life from ten (10) years to thirteen (13) years. This change in accounting estimate was effective beginning September 2023. These updated useful lives were applied to applicable assets in service as of the date of change and will be applied prospectively as assets are placed in service. Based on the carrying amount of the assets recorded in our property, plant and equipment, net balance prior to the change, the effect of this change in estimate for fiscal year 2023 was a reduction in depreciation expense of approximately $5.4\u00a0million and an increase in net income of $3.7\u00a0million, or $0.05 per share basic and diluted, for the year ended December\u00a031, 2023.", "entities": [ { "start_character": 759, "end_character": 762, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001097149-24-000011", "filing_date": 1709140427000, "quarter_ending": "20231231", "company_name": "ALIGN TECHNOLOGY INC", "text": "For the year ended December\u00a031, 2023 and 2022, operating lease income was $16.6\u00a0million and $12.3 million, respectively and for the year ended December 31, 2021, operating lease income was not material. Operating lease income is recorded in net revenues in our Consolidated Statements of Operations.", "entities": [ { "start_character": 75, "end_character": 79, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 16600000.000000002 }, { "start_character": 93, "end_character": 97, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 12300000.0 }, { "start_character": 189, "end_character": 191, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0000899051-24-000013", "filing_date": 1708524598000, "quarter_ending": "20231231", "company_name": "ALLSTATE CORP", "text": "The NCRF provides automobile liability insurance to drivers that private market insurers are not otherwise willing to insure. All insurers licensed to write automobile insurance in North Carolina are members of the NCRF. Premiums, losses and expenses are assigned to the NCRF. North Carolina law allows the NCRF to recoup operating losses for certain insureds through a surcharge to policyholders. As of September 30, 2023, the NCRF reported a deficit of $122 million in members\u2019 equity. The NCRF implemented a loss recoupment surcharge on all private passenger and commercial fleet policies effective October 1, 2023, through March 31, 2024. Member companies are assessed the recoupment surcharge. The loss recoupment surcharge will be adjusted on April 1, 2024 and discontinued once losses are recovered. The NCRF results are shared by the member companies in proportion to their respective North Carolina automobile liability writings. For the fiscal year ending September 30, 2023, net gain was $25 million, including $1.2 billion of earned premiums, $364 million of certain private passenger auto risk recoupment and $153 million of member loss recoupments. As of December 31, 2023, the NCRF recoverables on paid claims is $83 million and recoverables on unpaid claims is $299 million. Paid recoverable balances, if covered, are typically settled within sixty days of monthly filing.", "entities": [ { "start_character": 1023, "end_character": 1026, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1200000000.0 }, { "start_character": 1056, "end_character": 1059, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 364000000.0 }, { "start_character": 1123, "end_character": 1126, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 153000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000899051-24-000013", "filing_date": 1708524598000, "quarter_ending": "20231231", "company_name": "ALLSTATE CORP", "text": "The results of operations of the Reciprocal Exchanges are included in the Company\u2019s Allstate Protection segment and generated $224 million, $164 million and $181 million of earned premiums in 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 127, "end_character": 130, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 224000000.0 }, { "start_character": 141, "end_character": 144, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 164000000.0 }, { "start_character": 158, "end_character": 161, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 181000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000899051-24-000024", "filing_date": 1714580254000, "quarter_ending": "20240331", "company_name": "ALLSTATE CORP", "text": "The Reciprocal Exchanges generated $61 million of earned premiums for the three months ended March\u00a031, 2024 compared to $57\u00a0million for the three months ended March\u00a031, 2023. Total costs and expenses were $87 million for the three months ended March\u00a031, 2024 compared to $59 million for the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 36, "end_character": 38, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 61000000.0 }, { "start_character": 121, "end_character": 123, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 57000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001018724-24-000083", "filing_date": 1714502309000, "quarter_ending": "20240331", "company_name": "AMAZON COM INC", "text": "We review the useful lives of equipment on an ongoing basis, and effective January\u00a01, 2024 we changed our estimate of the useful lives for our servers from five to six years. The longer useful lives are due to continuous improvements in our hardware, software, and data center designs. The effect of this change in estimate for Q1 2024, based on servers that were included in \u201cProperty and equipment, net\u201d as of December\u00a031, 2023 and those acquired during the three months ended March 31, 2024, was a reduction in depreciation and amortization expense of $897 million and a benefit to net income of $695 million, or $0.07 per basic share and $0.07 per diluted share.", "entities": [ { "start_character": 600, "end_character": 603, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 695000000.0 }, { "start_character": 617, "end_character": 621, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": null, "value": 0.07 }, { "start_character": 643, "end_character": 647, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": null, "value": 0.07 } ] }, { "form_type": "10-K", "accession_number": "0000896262-24-000014", "filing_date": 1708606814000, "quarter_ending": "20231231", "company_name": "AMEDISYS INC", "text": "AssistedCare contributed $7.0\u00a0million in net service revenue and operating income of $0.5\u00a0million during the year ended December 31, 2023 and $6.1\u00a0million in net service revenue and operating income of $0.8\u00a0million during the year ended December 31, 2022.", "entities": [ { "start_character": 86, "end_character": 89, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 }, { "start_character": 203, "end_character": 206, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001002910-24-000056", "filing_date": 1709218102000, "quarter_ending": "20231231", "company_name": "AMEREN CORP", "text": "In December 2023 and 2022, Ameren Missouri achieved certain energy-efficiency spending goals for the MEEIA 2019 program. As a result of achieving these spending goals and MoPSC orders issued in August 2022 and September 2021, Ameren Missouri recognized performance incentive revenues of $12\u00a0million, $22\u00a0million, and $9\u00a0million in 2023, 2022, and 2021, respectively.", "entities": [ { "start_character": 288, "end_character": 290, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 12000000.0 }, { "start_character": 301, "end_character": 303, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 22000000.0 }, { "start_character": 318, "end_character": 319, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 9000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001002910-24-000056", "filing_date": 1709218102000, "quarter_ending": "20231231", "company_name": "AMEREN CORP", "text": "In August 2023, the MoPSC issued an order approving a nonunanimous stipulation and agreement to extend Ameren Missouri\u2019s MEEIA 2019 program for an additional year through 2024. For 2024, the order approved the establishment of a portfolio of customer energy-efficiency programs and performance incentives that will provide Ameren Missouri an opportunity to earn revenues, including $12\u00a0million of performance incentive revenues if Ameren Missouri achieves certain program spending goals. In 2024, Ameren Missouri expects to invest $76\u00a0million in energy-efficiency programs.", "entities": [ { "start_character": 383, "end_character": 385, "label": "revenues", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-08-31", "currency_/_unit": "iso4217:USD", "value": 12000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001002910-24-000056", "filing_date": 1709218102000, "quarter_ending": "20231231", "company_name": "AMEREN CORP", "text": "Since November 2013, the allowed base ROE for FERC-regulated transmission rate base under the MISO tariff has been subject to customer complaint cases and has been changed by various FERC orders. In May 2020, the FERC issued an order, which set the allowed base ROE to 10.02%, and required refunds, with interest, for the periods November 2013 to February 2015 and from late September 2016 forward. Ameren and Ameren Illinois paid these refunds, including interest, by March 31, 2022. In June and July 2020, Ameren Missouri, Ameren Illinois, and ATXI, as well as various customers, petitioned the United States Court of Appeals for the District of Columbia Circuit for review of the May 2020 order, challenging certain aspects of the new ROE methodology established. The petition filed by Ameren Missouri, Ameren Illinois, and ATXI challenged the refunds required for the period from September 2016 to May 2020. In August 2022, the court issued a ruling that granted the customers\u2019 petition for review, vacated the FERC\u2019s previous MISO ROE-determining orders, and remanded the proceedings to the FERC. The court elected not to rule on the issues raised by Ameren Missouri, Ameren Illinois, and ATXI. The currently allowed base ROE of 10.02% will remain effective for customer billings, but the transmission rates charged during previous periods and the currently effective rates may be subject to refund if the base ROE is changed by the FERC in a future order. The FERC is under no deadline to issue an order related to these proceedings. A 50-basis-point change in the FERC-allowed ROE would affect Ameren\u2019s and Ameren Illinois\u2019 annual revenue by an estimated $21\u00a0million and $15\u00a0million, respectively, based on each company\u2019s 2024 projected rate base.", "entities": [ { "start_character": 1663, "end_character": 1665, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 21000000.0 }, { "start_character": 1679, "end_character": 1681, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 15000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001002910-24-000090", "filing_date": 1715009266000, "quarter_ending": "20240331", "company_name": "AMEREN CORP", "text": "Since November 2013, the allowed base ROE for FERC-regulated transmission rate base under the MISO tariff has been subject to customer complaint cases and has been changed by various FERC orders. In May 2020, the FERC issued an order, which set the allowed base ROE to 10.02% and required refunds, with interest, for the periods November 2013 to February 2015 and from late September 2016 forward. Ameren and Ameren Illinois paid these refunds, including interest, by March 31, 2022. In June and July 2020, Ameren Missouri, Ameren Illinois, and ATXI, as well as various customers, petitioned the United States Court of Appeals for the District of Columbia Circuit for review of the May 2020 order, challenging certain aspects of the new ROE methodology established. The petition filed by Ameren Missouri, Ameren Illinois, and ATXI challenged the refunds required for the period from September 2016 to May 2020. In August 2022, the court issued a ruling that granted the customers\u2019 petition for review, vacated the FERC\u2019s previous MISO ROE-determining orders, and remanded the proceedings to the FERC. The court elected not to rule on the issues raised by Ameren Missouri, Ameren Illinois, and ATXI. The currently allowed base ROE of 10.02% will remain effective for customer billings, but the transmission rates charged during previous periods and the currently effective rates may be subject to refund if the base ROE is changed by the FERC in a future order. The FERC is under no deadline to issue an order related to these proceedings. A 50-basis-point change in the FERC-allowed ROE would affect Ameren\u2019s and Ameren Illinois\u2019 annual revenue by an estimated $21\u00a0million and $15\u00a0million, respectively, based on each company\u2019s 2024 projected rate base.", "entities": [ { "start_character": 1662, "end_character": 1664, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 21000000.0 }, { "start_character": 1678, "end_character": 1680, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 15000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-028635", "filing_date": 1711985126000, "quarter_ending": "20231231", "company_name": "AMERICAN BATTERY MATERIALS, INC.", "text": "The\naccompanying consolidated financial statements have been prepared on a going concern basis. The Company had net loss of $2,384,802\u00a0during\nthe year ended December 31, 2023, has accumulated losses totaling $20,239,639, and has a working capital deficit of $3,222,893\u00a0as\nof December 31, 2023. These factors, among others, indicate that the Company may be unable to continue as a going concern. The consolidated\nfinancial statements do not include any adjustments that might result from the outcome of these uncertainties.", "entities": [ { "start_character": 125, "end_character": 134, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -2384802.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020044", "filing_date": 1715794087000, "quarter_ending": "20240331", "company_name": "AMERICAN BATTERY TECHNOLOGY Co", "text": "During\nthe nine months ended March 31, 2024, the Company incurred a net loss of $29.1 million and used cash of $12.4 million for operating activities.\nAt March 31, 2024, the Company has a cash balance of $6.0 million and an accumulated deficit of $189.9 million.", "entities": [ { "start_character": 81, "end_character": 85, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -29100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001401521-24-000024", "filing_date": 1710519728000, "quarter_ending": "20231231", "company_name": "AMERICAN COASTAL INSURANCE Corp", "text": "Pretax earnings attributable to our commercial lines operating segment for the year ended December\u00a031, 2023 increased by $82,287,000 to pretax income of $118,128,000, compared to pretax income of $35,841,000 for the year ended December\u00a031, 2022. The increase in pretax earnings was primarily due to an increase in revenue driven by increased gross written premium described below. This was partially offset by increased ceded premiums, driven by the changes in our quota share contracts. In addition, all of our expenses related to commercial lines decreased year-over-year, as described below. ", "entities": [ { "start_character": 154, "end_character": 165, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 118128000.0 } ] }, { "form_type": "10-K", "accession_number": "0001401521-24-000024", "filing_date": 1710519728000, "quarter_ending": "20231231", "company_name": "AMERICAN COASTAL INSURANCE Corp", "text": "Pretax losses attributable to our personal lines operating segment for the year ended December\u00a031, 2023 decreased by $38,300,000 to a pretax loss of $13,854,000, compared to a pretax loss of $52,154,000 for the year ended December\u00a031, 2022. The decrease in pretax net loss was primarily due to a $29,766,000 decrease in gross written premiums, as described below, and a $31,100,000 decrease in losses and LAE during 2023, driven by decreased catastrophe losses. We also experienced a $13,303,000 decrease in general and administrative costs year-over-year, as described below.", "entities": [ { "start_character": 150, "end_character": 160, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -13854000.0 } ] }, { "form_type": "10-K", "accession_number": "0000004962-24-000013", "filing_date": 1707487688000, "quarter_ending": "20231231", "company_name": "AMERICAN EXPRESS CO", "text": "Represents net income less (i) earnings allocated to participating share awards of $64 million, $57 million and $56 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively, (ii) dividends on preferred shares of $58 million, $57 million and $71 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively, and (iii) equity-related adjustments of $16\u00a0million related to the redemption of preferred shares for the year ended December 31, 2021.", "entities": [ { "start_character": 84, "end_character": 86, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 64000000.0 }, { "start_character": 97, "end_character": 99, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 57000000.0 }, { "start_character": 113, "end_character": 115, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 56000000.0 }, { "start_character": 244, "end_character": 246, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 57000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000004962-24-000031", "filing_date": 1713524283000, "quarter_ending": "20240331", "company_name": "AMERICAN EXPRESS CO", "text": "Represents net income less (i) earnings allocated to participating share awards of $18 million and $14 million for the three months ended March\u00a031, 2024 and 2023, respectively, and (ii) dividends on preferred shares of $14 million for both the three months ended March\u00a031, 2024 and 2023.", "entities": [ { "start_character": 84, "end_character": 86, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 18000000.0 }, { "start_character": 100, "end_character": 102, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 }, { "start_character": 220, "end_character": 222, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001042046-24-000009", "filing_date": 1708703672000, "quarter_ending": "20231231", "company_name": "AMERICAN FINANCIAL GROUP INC", "text": "Although basic earnings per share only considers shares of common stock outstanding during the period, the calculation of diluted earnings per share includes the following adjustments to weighted average common shares related to stock-based compensation plans: 2023 \u2013 0.1\u00a0million, 2022 \u2013 0.2\u00a0million and 2021 \u2013 0.5\u00a0million.", "entities": [ { "start_character": 268, "end_character": 271, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 100000.0 }, { "start_character": 288, "end_character": 291, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 200000.0 }, { "start_character": 311, "end_character": 314, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001042046-24-000012", "filing_date": 1714743270000, "quarter_ending": "20240331", "company_name": "AMERICAN FINANCIAL GROUP INC", "text": "Although basic earnings per share only considers shares of common stock outstanding during the period, the calculation of diluted earnings per share includes the following adjustments to weighted average common shares related to stock-based compensation plans: first three months of 2024 and 2023 \u2014 0.1\u00a0million and 0.2\u00a0million.", "entities": [ { "start_character": 299, "end_character": 302, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 100000.0 }, { "start_character": 315, "end_character": 318, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001829126-23-007347", "filing_date": 1699903858000, "quarter_ending": "20230930", "company_name": "AMERIGUARD SECURITY SERVICES, INC.", "text": "The\ncompany generated approximately $15,468,700 and $18,578,000 in guard service revenue for the six-month ending September 30, 2023 and 2022\nrespectively. Of the total guard service revenue, approximately 87% was earned from four federal contracts operated by the company. The\ncontracts, their respective terms and approximate revenues are as follows:", "entities": [ { "start_character": 37, "end_character": 47, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 15468700.0 }, { "start_character": 53, "end_character": 63, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 18578000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000318154-24-000020", "filing_date": 1714678077000, "quarter_ending": "20240331", "company_name": "AMGEN INC", "text": "The income tax provisions for the three months ended March 31, 2024 and 2023, were tax expenses of $45 million and $601 million, respectively, on a pretax loss of $68 million and a pretax income of $3,442 million, respectively. The effective tax rates for the three months ended March 31, 2024 and 2023, were (66.2)% and 17.5%, respectively.", "entities": [ { "start_character": 164, "end_character": 166, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -68000000.0 }, { "start_character": 199, "end_character": 204, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3442000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001047127-24-000094", "filing_date": 1714577379000, "quarter_ending": "20240331", "company_name": "AMKOR TECHNOLOGY, INC.", "text": "We periodically assess the estimated useful lives of our property, plant and equipment. Based on our assessment of test equipment and its increased interchangeability enabling broader and longer use, we extended the estimated useful lives of test equipment from five years to seven years as of January 1, 2024. As a result, the reduction in depreciation expense of approximately $15 million benefited net income and diluted earnings per share by approximately $13 million and $0.05 for the first quarter of 2024, respectively.", "entities": [ { "start_character": 463, "end_character": 465, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 13000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001023024-24-000057", "filing_date": 1715324964000, "quarter_ending": "20240331", "company_name": "ANI PHARMACEUTICALS INC", "text": "The income tax expense resulted from applying an estimated annual worldwide effective tax expense rate of 34.9% to pre-tax consolidated income of $2.2 million reported during the period. There were no material discrete items occurring during the ", "entities": [ { "start_character": 147, "end_character": 150, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2200000.0 } ] }, { "form_type": "10-K", "accession_number": "0000006845-24-000088", "filing_date": 1714142834000, "quarter_ending": "20240302", "company_name": "APOGEE ENTERPRISES, INC.", "text": "Our export net sales from U.S. operations were $47.6 million, $56.2 million, and $59.5 million in fiscal 2024, 2023, and 2022, respectively, representing approximately 3%, 4%, and 5% of consolidated net sales in each of these fiscal years, respectively.", "entities": [ { "start_character": 48, "end_character": 52, "label": "revenues", "start_date_for_period": "2023-02-26", "end_date_for_period": "2024-03-02", "currency_/_unit": "iso4217:USD", "value": 47600000.0 }, { "start_character": 63, "end_character": 67, "label": "revenues", "start_date_for_period": "2022-02-27", "end_date_for_period": "2023-02-25", "currency_/_unit": "iso4217:USD", "value": 56200000.0 }, { "start_character": 82, "end_character": 86, "label": "revenues", "start_date_for_period": "2021-02-28", "end_date_for_period": "2022-02-26", "currency_/_unit": "iso4217:USD", "value": 59500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007573", "filing_date": 1709136162000, "quarter_ending": "20231231", "company_name": "APi Group Corp", "text": "The Company holds investments in joint ventures, the majority of which are accounted for under the equity method of accounting as the Company does not exercise control over the joint ventures. The Company exercises control over one joint venture that is consolidated into the Company's financial statements and the results for that joint venture as of December\u00a031, 2023 were immaterial. The Company\u2019s share of earnings from the non-consolidated joint ventures was $7, $3, and $3, during the years ended December\u00a031, 2023, 2022, and 2021, respectively. The earnings are recorded within investment income and other, net in the consolidated statements of operations. The investment balances were $4 and $4 as of December\u00a031, 2023 and 2022, respectively, and are recorded within other assets in the consolidated balance sheets.", "entities": [ { "start_character": 466, "end_character": 467, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 7000000.0 }, { "start_character": 470, "end_character": 471, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3000000.0 }, { "start_character": 478, "end_character": 479, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-019929", "filing_date": 1714659297000, "quarter_ending": "20240331", "company_name": "APi Group Corp", "text": "The Company holds investments in joint ventures, the majority of which are accounted for under the equity method of accounting as the Company does not exercise control over the joint ventures. The Company exercises control over one joint venture that is consolidated into the Company's financial statements and the results for that joint venture for the three months ended March 31, 2024 were immaterial. The Company\u2019s share of earnings from the non-consolidated joint ventures was $2 and $2 during the three months ended March 31, 2024 and 2023, respectively. The earnings are recorded within investment expense (income) and other, net in the condensed consolidated statements of operations. The investment balances were $5 and $4 as of March\u00a031, 2024 and December\u00a031, 2023, respectively, and are recorded within other assets in the condensed consolidated balance sheets.", "entities": [ { "start_character": 383, "end_character": 384, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 385, "end_character": 386, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001305168-24-000025", "filing_date": 1709225216000, "quarter_ending": "20231231", "company_name": "ARC DOCUMENT SOLUTIONS, INC.", "text": "Included in revenues are fees charged to customers for shipping, handling, and delivery services. Such revenues amounted to $11.0 million and $11.3 million for 2023 and 2022, respectively.", "entities": [ { "start_character": 125, "end_character": 129, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 11000000.0 }, { "start_character": 143, "end_character": 147, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 11300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001305168-24-000049", "filing_date": 1715182027000, "quarter_ending": "20240331", "company_name": "ARC DOCUMENT SOLUTIONS, INC.", "text": "The Company recorded an income tax provision of $1.1 million in relation to pretax income of $3.5 million for the three months ended March\u00a031, 2024, which resulted in an effective income tax rate of 31.5%, primarily impacted by state taxes, non-deductible compensation, certain stock-based compensation, other non-deductible expenses, and U.S. taxes on foreign income. The Company recorded an income tax provision of $1.2 million in relation to pretax income of $3.0 million for the three months ended March\u00a031, 2023, which resulted in an effective income tax rate of 38.8%, primarily impacted by state taxes, non-deductible compensation, certain stock-based compensation and other non-deductible expenses. ", "entities": [ { "start_character": 94, "end_character": 97, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3500000.0 }, { "start_character": 463, "end_character": 466, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001287750-24-000028", "filing_date": 1714513249000, "quarter_ending": "20240331", "company_name": "ARES CAPITAL CORP", "text": "Ivy Hill Asset Management,\u00a0L.P. (\u201cIHAM\u201d), a wholly owned portfolio company of the Company, is an asset manager and an SEC-registered investment adviser. As of March\u00a031, 2024,\u00a0IHAM had assets under management of approximately $13.3 billion. As of March\u00a031, 2024, IHAM managed 21 vehicles (the \u201cIHAM Vehicles\u201d). IHAM earns fee income from managing the IHAM Vehicles and has also invested in certain of these vehicles as part of its business strategy. The amortized cost of IHAM\u2019s total investments as of March 31, 2024 and December 31, 2023 was $2,321\u00a0and $2,288, respectively. For the three months ended March 31, 2024 and 2023,\u00a0IHAM had management and incentive fee income of $14 and $14, respectively and investment-related income of $99 and $61, respectively, which included net realized gains or losses on investments and other transactions.", "entities": [ { "start_character": 677, "end_character": 679, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 }, { "start_character": 685, "end_character": 687, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001144980-24-000112", "filing_date": 1714149494000, "quarter_ending": "20240331", "company_name": "ASBURY AUTOMOTIVE GROUP INC", "text": "The Company's consolidated statement of income for the three months ended March 31, 2024 included revenue and net income attributable to the Jim Koons Dealerships of $681.4\u00a0million and $26.5\u00a0million, respectively.", "entities": [ { "start_character": 167, "end_character": 172, "label": "revenues", "start_date_for_period": "2023-12-11", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 681400000.0 }, { "start_character": 186, "end_character": 190, "label": "earnings", "start_date_for_period": "2023-12-11", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 26500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-006606", "filing_date": 1708696453000, "quarter_ending": "20231231", "company_name": "ATI INC", "text": "ATI had a 50% interest in the industrial titanium joint venture known as Uniti LLC (Uniti), with the remaining 50% interest held by VSMPO, a Russian producer of titanium, aluminum, and specialty steel products. On March 9, 2022, the Company announced the termination of Uniti, and this joint venture is expected to be fully dissolved in the first quarter of fiscal year 2024. No impairments were recorded as a result of the decision to terminate the Uniti joint venture. Uniti was accounted for under the equity method of accounting. ATI\u2019s share of Uniti\u2019s income was $0.2 million in fiscal year 2023, $4.4 million in fiscal year 2022, and $1.0 million in fiscal year 2021, which is included in AA&S segment\u2019s operating results, and within other income/expense, net, on the consolidated statements of operations. Sales to Uniti, which are included in ATI\u2019s consolidated statements of operations, were $4.9 million in fiscal year 2023, $45.0 million in fiscal year 2022, and $45.8 million in fiscal year 2021. Accounts receivable from Uniti was $4.5 million at January 1, 2023.", "entities": [ { "start_character": 908, "end_character": 911, "label": "revenues", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4900000.0 }, { "start_character": 942, "end_character": 946, "label": "revenues", "start_date_for_period": "2022-01-03", "end_date_for_period": "2023-01-01", "currency_/_unit": "iso4217:USD", "value": 45000000.0 }, { "start_character": 981, "end_character": 985, "label": "revenues", "start_date_for_period": "2021-01-04", "end_date_for_period": "2022-01-02", "currency_/_unit": "iso4217:USD", "value": 45800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001815849-24-000007", "filing_date": 1709050703000, "quarter_ending": "20231231", "company_name": "ATI Physical Therapy, Inc.", "text": "The Company has negative operating cash flows, operating losses and net losses. For the year ended December 31, 2023, the Company had cash flows used in operating activities of $12.4 million, operating loss of $27.5 million and net loss of $66.1 million. These results are, in part, due to our current capital structure and trends experienced by the Company in recent years including a tight labor market for available physical therapy and other healthcare providers in the workforce, visit volume softness, decreases in rate per visit and increases in interest costs. If results of operations in the coming twelve months do not improve relative to the previous twelve months, the Company is at risk of insufficient funding to meet its obligations as they become due as well as non-compliance with its minimum liquidity financial covenant under its 2022 Credit Agreement.", "entities": [ { "start_character": 211, "end_character": 215, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -27500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001815849-24-000036", "filing_date": 1715012016000, "quarter_ending": "20240331", "company_name": "ATI Physical Therapy, Inc.", "text": "The Company has continued to generate negative operating cash flows, operating losses and net losses. For the three months ended March 31, 2024, the Company had cash flows used in operating activities of $39.1 million, operating loss of $4.8 million and net loss of $13.5 million. These results are, in part, due to our current capital structure, including cash interest costs, and continuation of trends experienced by the Company in recent years including a tight labor market for available physical therapy and other healthcare providers in the workforce. The Company has continued to fund cash used in operations primarily from financing activities and expects to need additional liquidity to continue funding working capital requirements, necessary capital expenditures as well as to be available for general corporate purposes, including interest repayments. The Company is at risk of insufficient funding to meet its obligations as they become due as well as non-compliance with its minimum liquidity financial covenant under its 2022 Credit Agreement. These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ", "entities": [ { "start_character": 238, "end_character": 241, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001377789-24-000019", "filing_date": 1714580017000, "quarter_ending": "20240329", "company_name": "AVIAT NETWORKS, INC.", "text": "Revenue and operating loss associated with the NEC Transaction included in the consolidated statements of operations for the three months ended March\u00a029, 2024 were $22.5 million and $(0.4) million, respectively. Revenue and operating loss associated with the NEC Transaction included in the consolidated statements of operations from the acquisition date to the period ending March\u00a029, 2024 were $29.8 million and $(1.2) million, respectively.", "entities": [ { "start_character": 184, "end_character": 187, "label": "ebit", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": -400000.0 }, { "start_character": 416, "end_character": 419, "label": "ebit", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": -1200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001214816-24-000024", "filing_date": 1709053955000, "quarter_ending": "20231231", "company_name": "AXIS CAPITAL HOLDINGS LTD", "text": "Reinsurance premiums of $119\u00a0million were allocated to the retroactive element of the agreement which was deemed to have met the established criteria for retroactive reinsurance accounting. At the closing date, the Company recognized acquisition costs of $33\u00a0million and a loss expense of $7\u00a0million in the consolidated statement of operations associated with the retroactive element of the agreement. In addition, the Company recognized reinsurance recoverable on unpaid losses of $76\u00a0million and reinsurance recoverable on paid losses of $4\u00a0million in the consolidated balance sheets associated with the retroactive element of the agreement (refer to Note 8 ", "entities": [ { "start_character": 25, "end_character": 28, "label": "revenues", "start_date_for_period": "2023-09-22", "end_date_for_period": "2023-09-22", "currency_/_unit": "iso4217:USD", "value": 119000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-028198", "filing_date": 1718352369000, "quarter_ending": "20240331", "company_name": "AZEK Co Inc.", "text": "The amounts in the \"As Reported\" columns are amounts derived from the Company's previously filed financial statements in its Quarterly Report on Form 10-Q for the interim period ended March 31, 2023, originally filed with the Securities and Exchange Commission on May 5, 2023 (the \u201cOriginal March 31, 2023 Form 10-Q\u201d). The amounts in the \"Investigation Adjustments\" columns present the impact of the adjustments from the independent investigation related to the overstatement of Inventory and the understatement of Cost of Sales. The amounts in the \"Other Adjustments\" columns present the impact of other adjustments primarily related to the reclassification between Accrued interest and Accrued expenses and other liabilities in the condensed consolidated balance sheet, certain reclassifications in the condensed income statements, depreciation misstatement and cash flow misclassifications in previously issued financial statements and were not material, individually or in aggregate, to any of the prior periods financial statements. The amounts in the \"As Restated\" columns are the updated amounts including the impacts from both Investigation Adjustments and Other Adjustments. The only impact of restatement to the Consolidated Statements of Stockholders Equity was $2.0 million and $(1.9) million to Net income (loss) for the three and six months ended March 31, 2023, respectively, and $(13.7) million, $(17.6) million, $(19.3) million and $(19.9) million to opening Accumulated deficit at September 31, 2022, December 31, 2022, September 30, 2023 and December 31, 2023, respectively.", "entities": [ { "start_character": 1274, "end_character": 1277, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 1292, "end_character": 1295, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-010901", "filing_date": 1710346788000, "quarter_ending": "20231231", "company_name": "Aadi Bioscience, Inc.", "text": "The Company has experienced net losses since its inception and expects to continue to incur net losses into the foreseeable future. As of and for the year ended December\u00a031, 2023, the Company had an accumulated deficit of $269.0 million and a net loss of $65.8 million. T", "entities": [ { "start_character": 256, "end_character": 260, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -65800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021657", "filing_date": 1715184351000, "quarter_ending": "20240331", "company_name": "Aadi Bioscience, Inc.", "text": "The Company has experienced net losses since its inception and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit of $287.3 million as of March\u00a031, 2024 and a net loss of $18.3 million and $15.2 million for the three months ended March\u00a031, 2024 and 2023, respectively. To date, these operating losses have been funded primarily from outside sources of invested capital through the issuance of convertible promissory notes, grant funding, the sale of securities, and proceeds from license agreements. ", "entities": [ { "start_character": 229, "end_character": 233, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -18300000.0 }, { "start_character": 247, "end_character": 251, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -15200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001821393-24-000012", "filing_date": 1709223499000, "quarter_ending": "20231231", "company_name": "Aaron's Company, Inc.", "text": "Includes revenues from Canadian operations of $17.2 million, $18.6 million and $22.7 million during the years ended December\u00a031, 2023, 2022, and 2021, which are primarily lease revenues and fees.", "entities": [ { "start_character": 47, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 17200000.0 }, { "start_character": 62, "end_character": 66, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 18600000.0 }, { "start_character": 80, "end_character": 84, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 22700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001821393-24-000012", "filing_date": 1709223499000, "quarter_ending": "20231231", "company_name": "Aaron's Company, Inc.", "text": "Of the franchise royalties and fees, $17.8 million, $18.6 million and $19.8 million during the years ended December\u00a031, 2023, 2022 and 2021 respectively, is related to franchise royalty income that is recognized as the fees become due. The remaining revenue is primarily related to advertising fees charged to franchisees. Franchise royalties and fees are recorded within franchise royalties and other revenues in the accompanying consolidated statements of earnings.", "entities": [ { "start_character": 38, "end_character": 42, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 17800000.0 }, { "start_character": 53, "end_character": 57, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 18600000.0 }, { "start_character": 71, "end_character": 75, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 19800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001821393-24-000012", "filing_date": 1709223499000, "quarter_ending": "20231231", "company_name": "Aaron's Company, Inc.", "text": ", during the years ended December\u00a031, 2023, 2022, and 2021. Included in lease revenues and fees above, the Company had $24.8\u00a0million, $27.2\u00a0million and $27.3\u00a0million of other revenue during the years ended December\u00a031, 2023, 2022, and 2021, respectively, within the scope of ASC 606, ", "entities": [ { "start_character": 120, "end_character": 124, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 24800000.0 }, { "start_character": 135, "end_character": 139, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 27200000.0 }, { "start_character": 153, "end_character": 157, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 27300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001821393-24-000070", "filing_date": 1715012384000, "quarter_ending": "20240331", "company_name": "Aaron's Company, Inc.", "text": "Of the franchise royalties and fees, $4.5 million and $4.8 million during the three months ended March\u00a031, 2024 and 2023, respectively, is related to franchise royalty income that is recognized as the fees become due. The remaining revenue is primarily related to advertising fees charged to franchisees. Franchise royalties and fees are recorded within franchise royalties and other revenues in the accompanying condensed consolidated statements of (loss) earnings.", "entities": [ { "start_character": 38, "end_character": 41, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4500000.0 }, { "start_character": 55, "end_character": 58, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001821393-24-000070", "filing_date": 1715012384000, "quarter_ending": "20240331", "company_name": "Aaron's Company, Inc.", "text": ", during the three months ended March\u00a031, 2024 and 2023. Included in lease revenues and fees above, the Company had $6.2 million and $6.3 million of other revenue during the three months ended March\u00a031, 2024 and 2023, respectively, within the scope of ASC 606, ", "entities": [ { "start_character": 117, "end_character": 120, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6200000.0 }, { "start_character": 134, "end_character": 137, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 6300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-013670", "filing_date": 1711649530000, "quarter_ending": "20231231", "company_name": "Accelerate Diagnostics, Inc", "text": "Since inception, the Company has not achieved profitable operations or positive cash flows from operations. The Company\u2019s accumulated deficit totaled $668.9 million as of December\u00a031, 2023. During the year ended December\u00a031, 2023, the Company had a net loss of $61.6 million and negative cash flows from operations of $40.2 million. The Company had working capital of $12.4 million as of December 31, 2023.", "entities": [ { "start_character": 262, "end_character": 266, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -61600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022710", "filing_date": 1715362916000, "quarter_ending": "20240331", "company_name": "Accelerate Diagnostics, Inc", "text": "For the three months ended March\u00a031, 2024, the Company recorded a no tax expense related to its foreign operations. The Company\u2019s tax expense for the three months ended March\u00a031, 2024 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $14.2 million, as no tax benefits were recorded for current year tax losses generated in the U.S. and other foreign jurisdictions. At March\u00a031, 2024, the Company had deferred tax assets primarily related to U.S. Federal and state tax loss carryforwards and a deferred tax liability related to the Company\u2019s convertible notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.", "entities": [ { "start_character": 299, "end_character": 303, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -14200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022710", "filing_date": 1715362916000, "quarter_ending": "20240331", "company_name": "Accelerate Diagnostics, Inc", "text": "Since inception, the Company has not achieved profitable operations or positive cash flows from operations. The Company\u2019s accumulated deficit totaled $683.1 million as of March\u00a031, 2024. During the three months ended March\u00a031, 2024, the Company had a net loss of $14.2 million and negative cash flows from operations of $8.5 million. The Company had working capital of $8.0 million as of March\u00a031, 2024. ", "entities": [ { "start_character": 266, "end_character": 270, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -14200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020584", "filing_date": 1716199965000, "quarter_ending": "20240331", "company_name": "Accustem Sciences Inc.", "text": "The\ncondensed consolidated financial statements have been prepared on the going concern basis, which contemplates the realization of assets\nand discharge of liabilities in the normal course of business. The Company has financed its activities principally from support from\na related party. The Company has incurred a net loss in every fiscal period since inception. For the three months ended March 31, 2023,\nthe Company incurred a net loss of $526,602. The Company has an accumulated deficit of $7,048,547 as of March 31, 2024. The Company anticipates\noperating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development\nof its technology and products, and expenses related to the commercialization of its products.", "entities": [ { "start_character": 445, "end_character": 452, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -526602.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-014036", "filing_date": 1711988377000, "quarter_ending": "20231231", "company_name": "Acutus Medical, Inc.", "text": "The Company has limited revenue, and has incurred significant operating losses and negative cash flows from operations since its inception, and if it is unable to realize the expected benefits of the Restructuring, anticipates that it could incur significant losses for at least the next several years. As of December\u00a031, 2023 and December\u00a031, 2022, the Company had cash, cash equivalents, restricted cash and marketable securities of $29.4 million and $76.2 million, respectively. For the year ended December\u00a031, 2023, net loss was $11.9 million from continuing operations and net loss was $69.7 million from discontinued operations. For the year ended December 31, 2022, net income was $28.8 million from continuing operations and net loss was $68.4 million from discontinued operations. Net", "entities": [ { "start_character": 535, "end_character": 539, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -11900000.0 }, { "start_character": 690, "end_character": 694, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 28800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011022", "filing_date": 1711128479000, "quarter_ending": "20231231", "company_name": "AgeX Therapeutics, Inc.", "text": "Net\nloss from operations before income taxes for the years ended December 31, 2023 and 2022 was approximately $14.8 million and $10.5 million,\nrespectively.", "entities": [ { "start_character": 111, "end_character": 115, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 14800000.0 }, { "start_character": 129, "end_character": 133, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 10500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-013947", "filing_date": 1712596530000, "quarter_ending": "20231231", "company_name": "AiXin Life International, Inc.", "text": "The\nCompany has suffered net losses of $2,090,694 and $6,369,245 for the years ended December 31, 2023 and 2022, respectively, and used net\ncash in operating activities of $1,392,259 and $1,624,565 for the years ended December 31, 2023 and 2022, respectively, and has an accumulated\ndeficit of $17,220,392 as of December 31, 2023. These facts and conditions raise substantial doubt about the Company\u2019s ability\nto continue as a going concern. From January 1, 2023 through December 31, 2023, the Company\u2019s cash and cash equivalents decreased\nfrom $510,128 to $443,758 mainly due to operating losses, and the use of cash to support operating activities.", "entities": [ { "start_character": 40, "end_character": 49, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -2090694.0 }, { "start_character": 55, "end_character": 64, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -6369245.0 } ] }, { "form_type": "10-Q", "accession_number": "0000002969-24-000010", "filing_date": 1707145285000, "quarter_ending": "20231231", "company_name": "Air Products & Chemicals, Inc.", "text": "Changes in estimates on sale of equipment projects accounted for under the cost incurred input method are recognized as a cumulative adjustment for the inception-to-date effect of such change. We recorded changes to project estimates that unfavorably impacted operating income by approximately $30 and $25 for the three months ended 31 December 2023 and 2022, respectively.", "entities": [ { "start_character": 295, "end_character": 297, "label": "ebit", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -30000000.0 }, { "start_character": 303, "end_character": 305, "label": "ebit", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -25000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000002969-24-000026", "filing_date": 1714474638000, "quarter_ending": "20240331", "company_name": "Air Products & Chemicals, Inc.", "text": "Changes in estimates on sale of equipment projects accounted for under the cost incurred input method are recognized as a cumulative adjustment for the inception-to-date effect of such change. We recorded changes to project cost estimates that unfavorably impacted operating income by approximately $35 and $65 for the three and six months ended 31 March 2024, respectively, and approximately $35 and $60 for the three and six months ended 31 March 2023, respectively.", "entities": [ { "start_character": 300, "end_character": 302, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -35000000.0 }, { "start_character": 308, "end_character": 310, "label": "ebit", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -65000000.0 }, { "start_character": 394, "end_character": 396, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -35000000.0 }, { "start_character": 402, "end_character": 404, "label": "ebit", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -60000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000894081-24-000016", "filing_date": 1709227584000, "quarter_ending": "20231231", "company_name": "Air Transport Services Group, Inc.", "text": "Basic weighted average shares outstanding for purposes of basic earnings per share are less than the shares outstanding due to 288,371 shares, 226,449 shares and 283,139 shares of restricted stock for 2023, 2022 and 2021, respectively, which are accounted for as part of diluted weighted average shares outstanding in diluted earnings per share. ", "entities": [ { "start_character": 127, "end_character": 134, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 288371.0 }, { "start_character": 143, "end_character": 150, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 226449.0 }, { "start_character": 162, "end_character": 169, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 283139.0 } ] }, { "form_type": "10-K", "accession_number": "0000894081-24-000016", "filing_date": 1709227584000, "quarter_ending": "20231231", "company_name": "Air Transport Services Group, Inc.", "text": "CAM's leases do not contain residual guarantees. Approximately 13% of CAM's leases to external customers contain purchase options at projected market values. As of December 31, 2023, minimum future payments from external customers for leased aircraft and equipment were scheduled to be $271.2 million, $248.9 million, $226.6 million, $199.2 million and $164.1 million, respectively, for the next 5 years ending December 31, 2028 and $237.5 million thereafter. CAM's external customer revenues for non-lease activities were $34.3 million and $35.1 million during 2023 and 2022, respectively, for engine services and the sale of spare engine parts. ACMI Services external customer revenues included approximately $5.6 million, $10.1 million and $13.2 million for the years ended December 31, 2023, 2022 and 2021, respectively, for the rental income of specific aircraft included in the consideration paid by customers under certain contracts.", "entities": [ { "start_character": 525, "end_character": 529, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 34300000.0 }, { "start_character": 543, "end_character": 547, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 35100000.0 }, { "start_character": 714, "end_character": 717, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5600000.0 }, { "start_character": 728, "end_character": 732, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 10100000.0 }, { "start_character": 746, "end_character": 750, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 13200000.0 } ] }, { "form_type": "10-K", "accession_number": "0000894081-24-000016", "filing_date": 1709227584000, "quarter_ending": "20231231", "company_name": "Air Transport Services Group, Inc.", "text": "The Company had revenues of approximately $725.6 million, $839.0 million and $701.9 million for 2023, 2022 and 2021, respectively, derived primarily from aircraft leases in foreign countries, routes with flights departing from or arriving in foreign countries or aircraft maintenance and modification services performed in foreign countries. All revenues from the CMI agreement with DHL and the", "entities": [ { "start_character": 43, "end_character": 48, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 725600000.0 }, { "start_character": 59, "end_character": 64, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 839000000.0 }, { "start_character": 78, "end_character": 83, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 701900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001646972-24-000060", "filing_date": 1713774829000, "quarter_ending": "20240224", "company_name": "Albertsons Companies, Inc.", "text": "(1) Fiscal 2023, fiscal 2022 and fiscal 2021 include 3.0 million, 2.8 million and 2.7 million Class A common shares remaining to be issued, respectively. ", "entities": [ { "start_character": 53, "end_character": 56, "label": "eps", "start_date_for_period": "2023-02-26", "end_date_for_period": "2024-02-24", "currency_/_unit": "xbrli:shares", "value": 3000000.0 }, { "start_character": 66, "end_character": 69, "label": "eps", "start_date_for_period": "2022-02-27", "end_date_for_period": "2023-02-25", "currency_/_unit": "xbrli:shares", "value": 2800000.0 }, { "start_character": 82, "end_character": 85, "label": "eps", "start_date_for_period": "2021-02-28", "end_date_for_period": "2022-02-26", "currency_/_unit": "xbrli:shares", "value": 2700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001545654-24-000020", "filing_date": 1714078044000, "quarter_ending": "20240331", "company_name": "Alexander & Baldwin, Inc.", "text": "Related to the Grace Disposal Group, the Company entered into contracts in the ordinary course of business, as a supplier, with affiliate entities that required accounting under the equity method due to the Company's financial interests in such entities and also with affiliate parties that are members in entities in which the Company also was a member and held a controlling financial interest. For the three months ended March 31, 2023, during which such relationships existed, revenues earned and expenses recognized from transactions with affiliates were $3.9 million and $1.4 million, respectively. Due to the sale of the Grace Disposal Group in November 2023, these relationships no longer exist and consequently, for the three months ended March 31, 2024, there were no revenues earned or expenses recognized from transactions with such affiliates.", "entities": [ { "start_character": 561, "end_character": 564, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001579241-24-000006", "filing_date": 1708409078000, "quarter_ending": "20231231", "company_name": "Allegion plc", "text": "Due to a reporting change effective January 1, 2023, results for the Global Portable Security brands (inclusive of the AXA, Kryptonite and Trelock businesses) are now fully reflected within the Allegion International segment. Accordingly, the 2022 and 2021 summary of operations by reportable segment below have been recast to conform with the current year presentation. The impact of this recast was to realign approximately $20.9\u00a0million and $22.2\u00a0million of Net revenues, $2.1\u00a0million and $1.5\u00a0million of Segment operating income and $9.1\u00a0million and $9.2\u00a0million of Segment assets for the years ended December 31, 2022 and 2021, from the Allegion Americas segment to the Allegion International segment. ", "entities": [ { "start_character": 476, "end_character": 479, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 493, "end_character": 496, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001737287-24-000021", "filing_date": 1710435319000, "quarter_ending": "20231231", "company_name": "Allogene Therapeutics, Inc.", "text": "The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company\u2019s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company\u2019s product candidates. The Company had cash, cash equivalents and investments of\u00a0$448.7 million as of December\u00a031, 2023. Since inception through December\u00a031, 2023, the Company has incurred cumulative net losses of $1,562.2 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.", "entities": [ { "start_character": 487, "end_character": 494, "label": "earnings", "start_date_for_period": "2017-11-30", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1562200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000040729-24-000012", "filing_date": 1715012629000, "quarter_ending": "20240331", "company_name": "Ally Financial Inc.", "text": "We recognized operating lease revenue of $356 million for the three months ended March 31, 2024, and $402 million for the three months ended March 31, 2023. Depreciation expense on operating lease assets includes net remarketing gains recognized on the sale of operating lease assets. The following table summarizes the components of depreciation expense on operating lease assets.", "entities": [ { "start_character": 42, "end_character": 45, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 356000000.0 }, { "start_character": 102, "end_character": 105, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 402000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001704715-24-000097", "filing_date": 1714981056000, "quarter_ending": "20240331", "company_name": "Alpha Metallurgical Resources, Inc.", "text": "For the three months ended March 31, 2024, the Company recorded income tax expense of $14,165 on income before income taxes of $141,160. The income tax expense differs from the expected statutory amount primarily due to the permanent impact of percentage depletion, foreign-derived intangible income deductions, and stock compensation, partially offset by the impact of non-deductible compensation and state income taxes, net of federal impact. For the three months ended March 31, 2023, the Company recorded income tax expense of $42,411 on income before income taxes of $313,182. The income tax expense differs from the expected statutory amount primarily due to the permanent impact of percentage depletion and foreign-derived intangible income deductions, partially offset by the impact of state income taxes, net of federal impact.", "entities": [ { "start_character": 128, "end_character": 135, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 141160000.0 }, { "start_character": 573, "end_character": 580, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 313182000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012509", "filing_date": 1711992102000, "quarter_ending": "20231231", "company_name": "Alset Inc.", "text": "We\nhave established a front foot benefit (\u201cFFB\u201d) assessment on all of the NVR lots. This is a 30-year annual assessment allowed\nin Frederick County which requires homeowners to reimburse the developer for the costs of installing public water and sewer to the lots.\nThese assessments become effective as homes are settled, at which time we can sell the collection rights to investors who will pay an\nupfront lump sum, enabling us to more quickly realize the revenue. The selling prices range from $3,000 to $4,500 per home depending\non the type of home. Our total revenue from the front foot benefit assessment is approximately $1 million. To recognize revenue of FFB\nassessment, both our and NVR\u2019s performance obligation have to be satisfied. Our performance obligation is completed once we complete\nthe construction of water and sewer facility and close the lot sales with NVR, which inspects these water and sewer facility prior to\nclose lot sales to ensure all specifications are met. NVR\u2019s performance obligation is to sell homes they build to homeowners. Our\nFFB revenue is recognized on quarterly basis after NVR closes sales of homes to homeowners. The agreement with these FFB investors is\nnot subject to amendment by regulatory agencies and thus our revenue from FFB assessment is not either. During the years ended December\n31, 2023 and 2022, we recognized revenue of $0 and $126,737 from FFB assessment, respectively.", "entities": [ { "start_character": 628, "end_character": 629, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020031", "filing_date": 1714667525000, "quarter_ending": "20240331", "company_name": "Altice USA, Inc.", "text": "For the three months ended March\u00a031, 2024, we recorded tax expense of $2,924 on a pre-tax loss of $9,972, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The higher tax rate was primarily due to the impact of state tax expense, certain non-deductible expenses, and tax deficiencies on share-based compensation.", "entities": [ { "start_character": 99, "end_character": 104, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9972000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020031", "filing_date": 1714667525000, "quarter_ending": "20240331", "company_name": "Altice USA, Inc.", "text": "For the three months ended March\u00a031, 2023, we recorded a tax expense of $30,372 on pre-tax income of $61,542, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The higher tax rate was due to the impact of certain non-deductible expenses, state tax expense, and tax deficiencies on share-based compensation.", "entities": [ { "start_character": 102, "end_character": 108, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 61542000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-022351", "filing_date": 1710397203000, "quarter_ending": "20231231", "company_name": "Alto Ingredients, Inc.", "text": "For\nthe year ended December 31, 2021, net sales attributed to the results of operations for Stockton and Madera were $2.6 million and $0,\nrespectively. For the year ended December 31, 2021, pre-tax loss attributed to the results of operations for Stockton and Madera was\n$2.8 million and $2.0 million, respectively. The above pre-tax results include asset impairments associated with Stockton and Madera\nrecorded for the year ended December 31, 2021 of $0 and $1.2 million, respectively.", "entities": [ { "start_character": 272, "end_character": 275, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2800000.0 }, { "start_character": 289, "end_character": 292, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001488139-24-000014", "filing_date": 1709212160000, "quarter_ending": "20231231", "company_name": "Ameresco, Inc.", "text": "In accordance with specific PPA contract terms, we recognize revenues from the sale and delivery of the energy output from renewable energy plants over time as produced and delivered to the customer. Environmental attributes revenue is recognized at a point in time when the environmental attributes are transferred to the customer in accordance with the transfer protocols of the environmental attributes market that we operate in. In the cases where environmental attributes are sold to the same customer as the energy output, we record revenue monthly for both the energy output and the environmental attribute output, as generated and delivered to the customer. We have determined that certain PPAs contained a lease component in accordance with ASC 840, Leases, prior to the adoption of Topic 842. We recognized $10,687, $10,904 and $11,726 of operating lease revenue under these agreements during the years ended December\u00a031, 2023, 2022, and 2021, respectively.", "entities": [ { "start_character": 818, "end_character": 824, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 10687000.0 }, { "start_character": 827, "end_character": 833, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 10904000.0 }, { "start_character": 839, "end_character": 845, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 11726000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001500217-24-000027", "filing_date": 1714744573000, "quarter_ending": "20240331", "company_name": "American Assets Trust, Inc.", "text": "During the third quarter of 2020, we entered into a lease with American Assets, Inc. (\"AAI\"), an entity owned and controlled by Ernest Rady, our Chief Executive Officer and Chairman of the Board, for office space at Torrey Point to replace a previously existing lease with AAI at Torrey Reserve Campus. Rents commenced on March 1, 2021 for an initial lease term of ten years at an average annual rental rate of $0.2\u00a0million. Rental revenue recognized on the AAI lease of $0.1 million and $0.1 million for the three months ended March 31, 2024 and 2023, respectively, is included in rental income on the statements of comprehensive income.", "entities": [ { "start_character": 412, "end_character": 415, "label": "revenues", "start_date_for_period": "2021-03-01", "end_date_for_period": "2021-03-01", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 472, "end_character": 475, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 489, "end_character": 492, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001632970-24-000057", "filing_date": 1715699673000, "quarter_ending": "20240331", "company_name": "American Healthcare REIT, Inc.", "text": "Basic earnings (loss) per share for all periods presented are computed by dividing net income (loss) applicable to common stock by the weighted average number of shares of our common stock outstanding during the period. Net income (loss) applicable to common stock is calculated as net income (loss) attributable to controlling interest less distributions allocated to participating securities of $1,095,000 and $926,000 for the three months ended March 31, 2024 and 2023, respectively. Diluted earnings (loss) per share are computed based on the weighted average number of shares of our common stock and all potentially dilutive securities, if any. TBUs, nonvested shares of our RSAs and limited partnership units of our operating partnership are participating securities and give rise to potentially dilutive shares of our common stock.", "entities": [ { "start_character": 398, "end_character": 407, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1095000.0 }, { "start_character": 413, "end_character": 420, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 926000.0 } ] }, { "form_type": "10-K", "accession_number": "0001595527-24-000006", "filing_date": 1711990454000, "quarter_ending": "20231231", "company_name": "American Strategic Investment Co.", "text": "In October 2021, the Company signed a termination agreement with the parking garage tenants at its 400 E. 67th Street - Laurel Condominium/200 Riverside Boulevard properties. As discussed above, new tenants have signed lease agreements with the Company for the spaces in July 2022. In addition, the Company recorded a termination fee for a tenant in its 9 Times Square property. These termination agreements required the tenants to pay termination fees aggregating $1.5\u00a0million to the Company, which was all received during the fourth quarter of 2021. The termination fees are recorded in revenue from tenants in the consolidated statements of operations and comprehensive loss.", "entities": [ { "start_character": 466, "end_character": 469, "label": "revenues", "start_date_for_period": "2021-10-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001899287-24-000016", "filing_date": 1711642297000, "quarter_ending": "20231231", "company_name": "Amprius Technologies, Inc.", "text": "Since our inception, we have incurred recurring losses and negative cash flows from operations. During the year ended December\u00a031, 2023, we incurred a net loss of $36.8\u00a0million and at December\u00a031, 2023, the accumulated deficit was $129.7 million. We expect to incur additional losses in the future as we scale our business and increase our operating expenditures, such as increasing our research and development spend and headcount. Additionally, we expect to increase our capital expenditures as we complete the design and build-out of a ", "entities": [ { "start_character": 164, "end_character": 168, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -36800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001899287-24-000048", "filing_date": 1715274441000, "quarter_ending": "20240331", "company_name": "Amprius Technologies, Inc.", "text": "Revenue from the sale of battery products includes bill-and-hold arrangements, which were $0.2\u00a0million during the three months ended March\u00a031, 2024 and none during the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 91, "end_character": 94, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 152, "end_character": 156, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001899287-24-000048", "filing_date": 1715274441000, "quarter_ending": "20240331", "company_name": "Amprius Technologies, Inc.", "text": "Since our inception, we have incurred recurring losses and negative cash flows from operations. During the three months ended March\u00a031, 2024, we incurred a net loss of $9.9 million and at March\u00a031, 2024, our accumulated deficit was $139.5 million. We expect to incur additional losses in the future as we scale our business and increase our operating expenditures, such as increasing our research and development spend and headcount. Additionally, we expect to increase our capital expenditures as we complete the design and build-out of a ", "entities": [ { "start_character": 169, "end_character": 172, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000821026-24-000141", "filing_date": 1715170725000, "quarter_ending": "20240331", "company_name": "Andersons, Inc.", "text": "The difference between the 9.1% effective tax rate and the U.S. federal statutory rate of 21.0% for the three months ended March\u00a031, 2023 is primarily attributable to the tax impact of non-controlling interest, state and local income taxes, and nondeductible compensation. During the three months ended March 31, 2023, a discrete income tax benefit of $12.0\u00a0million was recorded on a loss before income taxes of $94.7\u00a0million from ELEMENT operations, which included an $87.2\u00a0million impairment charge.", "entities": [ { "start_character": 413, "end_character": 417, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 94700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006103", "filing_date": 1707841848000, "quarter_ending": "20231231", "company_name": "Anebulo Pharmaceuticals, Inc.", "text": "Since\ninception, the Company\u2019s activities have consisted primarily of performing research and development to advance its product candidates.\nThe Company is still in the development phase and has not been marketing any developed products to date. Since inception, the Company\nhas incurred losses, including a net loss of approximately $5.2 million for the six-month period ended December 31, 2023. As of December\n31, 2023, the Company had an accumulated deficit of $62.4 million. The Company expects to continue to generate operating losses. The\nCompany expects that its cash, along with access to the Facility Amount under the LSA (as defined below in Note 10), will be sufficient\nto fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial\nstatements. Until such time, if ever, as the Company can generate substantial product revenue from sales of any current or future product\ncandidates, the Company expects to seek additional funding in order to reach its development and commercialization objectives through\nvarious potential sources, such as equity and debt financings or through collaboration, license and development agreements. The Company\nmay not be able to obtain funding or enter into collaboration, license or development agreements on acceptable terms, or at all. The\nterms of any funding may be dilutive to or adversely affect the rights of the Company\u2019s stockholders. If the Company is unable\nto obtain funding on satisfactory terms, or at all, the Company could be forced to delay, scale back or eliminate the development of\nits current or future product candidates or other business.", "entities": [ { "start_character": 335, "end_character": 338, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -5200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019922", "filing_date": 1715790679000, "quarter_ending": "20240331", "company_name": "Anebulo Pharmaceuticals, Inc.", "text": "Since\ninception, the Company\u2019s activities have consisted primarily of performing research and development to advance its product candidates.\nThe Company is still in the development phase and has not been marketing any developed products to date. Since inception, the Company\nhas incurred losses, including a net loss of approximately $6.9 million for the nine-month period ended March 31, 2024. As of March 31,\n2024, the Company had an accumulated deficit of $64.1 million. The Company expects to continue to generate operating losses. The Company\nexpects that its cash, along with access to the Facility Amount under the LSA (as defined below in Note 10), will be sufficient to fund\nits operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial statements.\nUntil such time, if ever, as the Company can generate substantial product revenue from sales of any current or future product candidates,\nthe Company expects to seek additional funding in order to reach its development and commercialization objectives through various potential\nsources, such as equity and debt financings or through collaboration, license and development agreements. The Company may not be able\nto obtain funding or enter into collaboration, license or development agreements on acceptable terms, or at all. The terms of any funding\nmay be dilutive to or adversely affect the rights of the Company\u2019s stockholders. If the Company is unable to obtain funding on\nsatisfactory terms, or at all, the Company could be forced to delay, scale back or eliminate the development of its current or future\nproduct candidates or other business.", "entities": [ { "start_character": 335, "end_character": 338, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019922", "filing_date": 1715790679000, "quarter_ending": "20240331", "company_name": "Anebulo Pharmaceuticals, Inc.", "text": "Other\nassets include loan commitment fees. Total loan commitment fees of approximately $0.7 million are being amortized over three years, the\nterm of the loan (see Note 10). The balance was $0.6 million and zero as of March 31, 2024 and June 30, 2023, respectively. For both\nthe three and nine months ended March 31, 2024, the Company recorded interest expense of $0.1 million related to the amortization of\nthe loan commitment fees.", "entities": [ { "start_character": 88, "end_character": 91, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001304492-24-000077", "filing_date": 1719420391000, "quarter_ending": "20240331", "company_name": "Anterix Inc.", "text": "In October 2022, the Company entered into an agreement with Xcel Energy Services Inc. (\u201cXcel Energy\u201d) providing Xcel Energy dedicated long-term usage of the Company\u2019s 900 MHz Broadband Spectrum for a term of 20 years throughout Xcel Energy\u2019s service territory in eight states (the \u201cXcel Energy Agreement\u201d) for a total of $80.0\u00a0million, of which $8.0\u00a0million was received by the Company in December 2022. In July 2023 and November 2023, the Company delivered the cleared 900 MHz Broadband Spectrum and the associated broadband leases and received milestone payments of $21.2\u00a0million in each period. During the year ended March\u00a031, 2024, the Company delivered the cleared 900 MHz Broadband Spectrum and the associated broadband leases and received a milestone payment of $16.8\u00a0million in January 2024. The revenue recognized for the year ended March\u00a031, 2024, was approximately $1.9\u00a0million.", "entities": [ { "start_character": 877, "end_character": 880, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001398987-24-000091", "filing_date": 1714634826000, "quarter_ending": "20240331", "company_name": "Anywhere Real Estate Inc.", "text": "Transactions between segments are eliminated in consolidation. Revenues for Franchise Group include intercompany royalties and marketing fees paid by Owned Brokerage Group of $64 million and $63 million for the three months ended March\u00a031, 2024 and 2023, respectively. Such amounts are eliminated through the Corporate and Other line.", "entities": [ { "start_character": 176, "end_character": 178, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -64000000.0 }, { "start_character": 192, "end_character": 194, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -63000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001467760-24-000033", "filing_date": 1714407375000, "quarter_ending": "20240331", "company_name": "Apollo Commercial Real Estate Finance, Inc.", "text": "For the three months ended March\u00a031, 2024, 423,784 incremental shares were excluded in the calculation of diluted net income per share because the effect was anti-dilutive. For the three months ended March\u00a031, 2023, 3,221,559 weighted-average unvested RSUs were included in the calculation of diluted net income per share because the effect was dilutive.", "entities": [ { "start_character": 216, "end_character": 225, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 3221559.0 } ] }, { "form_type": "10-Q", "accession_number": "0001801777-23-000059", "filing_date": 1699546099000, "quarter_ending": "20230930", "company_name": "Applied Molecular Transport Inc.", "text": "The Company has incurred net losses in each reporting period since inception, including net losses of $52.2\u00a0million and $103.7\u00a0million for the nine months ended September 30, 2023 and 2022, respectively, and the Company\u2019s accumulated deficit at September\u00a030, 2023 was $418.2 million. The Company\u2019s current operating plan indicates it will continue to incur losses from operations and generate negative cash flows from operating activities, given the Company does not generate any revenue from product sales or otherwise. ", "entities": [ { "start_character": 103, "end_character": 107, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -52200000.0 }, { "start_character": 121, "end_character": 126, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -103700000.0 } ] }, { "form_type": "10-K", "accession_number": "0000719135-24-000016", "filing_date": 1711022922000, "quarter_ending": "20231231", "company_name": "Apyx Medical Corp", "text": "The Company has incurred recurring net losses and cash outflows from operations and it anticipates that losses will continue in the near term. For the year ended December 31, 2023, the Company incurred a loss from operations of $17.3\u00a0million and used $5.2\u00a0million of cash in operations, which is inclusive of the receipt of its tax refund of approximately $8.1\u00a0million. As of December 31, 2023, cash and cash equivalents on-hand were $43.7\u00a0million. The Company plans to continue to fund its operations and capital funding needs through existing cash, sales of our products and if necessary additional equity and/or debt financing. However, it cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders. The sale of additional equity would result in dilution to the Company\u2019s stockholders. Incurring additional debt financing would result in further debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict the Company\u2019s operations. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, it may be required to delay, limit, reduce, or terminate its sales, marketing and product development. Any of these actions could harm the business, results of operations and prospects.", "entities": [ { "start_character": 229, "end_character": 233, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -17300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-009010", "filing_date": 1709658769000, "quarter_ending": "20231231", "company_name": "Aquestive Therapeutics, Inc.", "text": "In consideration of the rights granted to Sunovion under the Sunovion License Agreement, the Company received aggregate payments totaling $22,000 to date. In addition to the upfront payment of $5,000, the Company has also earned an aggregate of $17,000 in connection with specified regulatory and development milestones in the United States and Europe (the \u201cInitial Milestone Payments\u201d), all of which have been received to date. With the Monetization Agreement (defined below) entered into on November 3, 2020 relating to KYNMOBI as described in the paragraph below, the Company is no longer entitled to receive any payments under the Sunovion License Agreement.", "entities": [ { "start_character": 139, "end_character": 145, "label": "revenues", "start_date_for_period": "2023-10-23", "end_date_for_period": "2023-10-23", "currency_/_unit": "iso4217:USD", "value": 22000000.0 }, { "start_character": 194, "end_character": 199, "label": "revenues", "start_date_for_period": "2023-10-23", "end_date_for_period": "2023-10-23", "currency_/_unit": "iso4217:USD", "value": 5000000.0 }, { "start_character": 246, "end_character": 252, "label": "revenues", "start_date_for_period": "2023-10-23", "end_date_for_period": "2023-10-23", "currency_/_unit": "iso4217:USD", "value": 17000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021118", "filing_date": 1715099012000, "quarter_ending": "20240331", "company_name": "Aquestive Therapeutics, Inc.", "text": "The Company\u2019s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items. For the three months ended March\u00a031, 2024, the effective income tax rate was 0%, and the Company recorded no income tax expense from its pretax loss of $12,828. For the three months ended March\u00a031, 2023, the Company recorded no income tax from its pretax income of $8,068.", "entities": [ { "start_character": 296, "end_character": 302, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -12828000.0 }, { "start_character": 409, "end_character": 414, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 8068000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021118", "filing_date": 1715099012000, "quarter_ending": "20240331", "company_name": "Aquestive Therapeutics, Inc.", "text": "In consideration of the rights granted to Sunovion under the Sunovion License Agreement, the Company received aggregate payments totaling $22,000 to date. In addition to the upfront payment of $5,000, the Company has also earned an aggregate of $17,000 in connection with specified regulatory and development milestones in the United States and Europe (the \u201cInitial Milestone Payments\u201d), all of which have been received to date. With the Monetization Agreement (defined below) entered into on November 3, 2020 relating to KYNMOBI as described in the paragraph below, the Company is no longer entitled to receive any payments under the Sunovion License Agreement.", "entities": [ { "start_character": 139, "end_character": 145, "label": "revenues", "start_date_for_period": "2016-04-01", "end_date_for_period": "2016-04-01", "currency_/_unit": "iso4217:USD", "value": 22000000.0 }, { "start_character": 194, "end_character": 199, "label": "revenues", "start_date_for_period": "2016-04-01", "end_date_for_period": "2016-04-01", "currency_/_unit": "iso4217:USD", "value": 5000000.0 }, { "start_character": 246, "end_character": 252, "label": "revenues", "start_date_for_period": "2016-04-01", "end_date_for_period": "2016-04-01", "currency_/_unit": "iso4217:USD", "value": 17000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021118", "filing_date": 1715099012000, "quarter_ending": "20240331", "company_name": "Aquestive Therapeutics, Inc.", "text": "On September 24, 2017, the Company entered into an agreement with Indivior, or the Indivior Supplemental Agreement. Pursuant to the Indivior Supplemental Agreement, the Company conveyed to Indivior all existing and future rights in the settlement of various ongoing patent enforcement legal actions and disputes related to the Suboxone product. The Company also conveyed to Indivior the right to sublicense manufacturing and marketing capabilities to enable an Indivior licensed generic buprenorphine product to be produced and sold by parties unrelated to Indivior or Aquestive. Under the Indivior Supplemental Agreement, the Company was entitled to receive certain payments from Indivior commencing on the date of the Indivior Supplemental Agreement through January 1, 2023. Once paid, all payments made under the Indivior Supplemental Agreement are non-refundable. Through February 20, 2019, the at-risk launch date of the competing generic products of Dr. Reddy\u2019s Labs and Alvogen, the Company received an aggregate of $40,750 from Indivior under the Indivior Supplemental Agreement. Further payments under the Indivior Supplemental Agreement were suspended until adjudication of related patent infringement litigation is finalized. No further payments are due to the Company under the Indivior Supplemental Agreement. See Note 19, ", "entities": [ { "start_character": 1024, "end_character": 1030, "label": "revenues", "start_date_for_period": "2017-09-24", "end_date_for_period": "2019-02-20", "currency_/_unit": "iso4217:USD", "value": 40750000.0 } ] }, { "form_type": "10-K", "accession_number": "0001447028-24-000035", "filing_date": 1709657329000, "quarter_ending": "20231231", "company_name": "Arbutus Biopharma Corp", "text": "The Company recognized $10.7 million of revenue based on labor hours expended by the Company on its Manufacturing Obligations during the twelve months ended December\u00a031, 2023, and $26.0 million during the twelve months ended December\u00a031, 2022.", "entities": [ { "start_character": 24, "end_character": 28, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 10700000.0 }, { "start_character": 181, "end_character": 185, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 26000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001447028-24-000035", "filing_date": 1709657329000, "quarter_ending": "20231231", "company_name": "Arbutus Biopharma Corp", "text": "The Company determined the initial transaction price of the combined performance obligation to be $50.4 million, which includes the $40.0 million upfront fee, $4.4 million of withholding taxes paid by Qilu on behalf of the Company and the premium paid for the Share Transaction of $4.1 million. The Company determined the Milestone Payments to be variable consideration subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. ", "entities": [ { "start_character": 282, "end_character": 285, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4099999.9999999995 } ] }, { "form_type": "10-Q", "accession_number": "0001447028-24-000038", "filing_date": 1714667538000, "quarter_ending": "20240331", "company_name": "Arbutus Biopharma Corp", "text": "The Company recognized $0.2 million of revenue based on labor hours expended by the Company on its Manufacturing Obligations during the three months ended March 31, 2024 and $4.1 million during the three months ended March 31, 2023.", "entities": [ { "start_character": 24, "end_character": 27, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 175, "end_character": 178, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4099999.9999999995 } ] }, { "form_type": "10-K", "accession_number": "0000007084-24-000009", "filing_date": 1710223270000, "quarter_ending": "20231231", "company_name": "Archer-Daniels-Midland Co", "text": "Net sales to unconsolidated affiliates during the years ended December\u00a031, 2023, 2022, and 2021 were $7.0 billion, $7.8 billion, and $6.6 billion, respectively.", "entities": [ { "start_character": 102, "end_character": 105, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 7000000000.0 }, { "start_character": 116, "end_character": 119, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 7800000000.0 }, { "start_character": 134, "end_character": 137, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 6600000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001739445-24-000012", "filing_date": 1708683457000, "quarter_ending": "20231231", "company_name": "Arcosa, Inc.", "text": "In October 2022, the Company completed the sale of its storage tanks business for $275\u00a0million. Net cash proceeds received at closing were approximately $271.6\u00a0million, after transaction closing costs. The sale resulted in a pre-tax gain of $189.0\u00a0million recognized during the year ended December\u00a031, 2022. An additional gain of $6.4\u00a0million was recognized during the year ended December\u00a031, 2023, primarily due to the resolution of certain contingencies from the sale. The storage tanks business, historically reported within the Engineered Structures segment as continuing operations until the date of sale, is a leading manufacturer of steel pressure tanks for the storage and transportation of propane, ammonia, and other gases serving the residential, commercial, energy, and agricultural markets with operations in the U.S. and Mexico. Revenues and operating profit of the storage tanks business prior to the sale were $188.9 million and $41.1\u00a0million, respectively, for the year ended December\u00a031, 2022, and $216.2 million and $36.8\u00a0million, respectively, for the year ended December\u00a031, 2021. As the sale of the storage tanks business was not considered a strategic shift that would have had a major effect on the Company's operations or financial results, it is not reported as a discontinued operation. In October 2022, the Company used $155.0\u00a0million of the cash proceeds from the sale to repay the outstanding loans borrowed under its revolving credit facility. See Note 7 Debt for additional information.", "entities": [ { "start_character": 927, "end_character": 932, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 188900000.0 }, { "start_character": 946, "end_character": 950, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 41100000.0 }, { "start_character": 1017, "end_character": 1022, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 216200000.0 }, { "start_character": 1036, "end_character": 1040, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 36800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001739445-24-000012", "filing_date": 1708683457000, "quarter_ending": "20231231", "company_name": "Arcosa, Inc.", "text": "The goodwill acquired, none of which is tax-deductible, primarily relates to StonePoint's market position and existing workforce. The customer relationships intangible asset was assigned a useful life of 10 years. Revenues and operating profit (loss) included in the Consolidated Statement of Operations from the date of the acquisition were approximately $123.7\u00a0million and $(0.1)\u00a0million during the year ended December 31, 2021, respectively.", "entities": [ { "start_character": 357, "end_character": 362, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 123700000.0 }, { "start_character": 377, "end_character": 380, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020484", "filing_date": 1715966027000, "quarter_ending": "20240331", "company_name": "Arena Group Holdings, Inc.", "text": "For\nthe three months ended March 31, 2024, the Company incurred a net loss from continuing operations of $12,720,\nand as of March 31, 2024, had cash on hand of $4,003\nand a working capital deficit of $225,009.\nThe Company\u2019s net loss from continuing operations and working capital deficit have been evaluated by management to determine\nif the significance of those conditions or events would limit its ability to meet its obligations when due. Also, since the\nCompany\u2019s 2023 Notes (see Note 11), Senior Secured Notes, Delayed Draw Term Notes and 2022 Bridge Notes (see Note 12)\n(collectively its \u201ccurrent debt\u201d) are subject to a forbearance period through the earlier of the following: (a)\nSeptember 30, 2024; (b) the occurrence of the closing of the Business Combination and (c) the termination of the Business\nCombination prior to closing (as further described in Note 18) unless the Company is able to refinance or modify the terms of its\ncurrent debt it runs the risk that its debt could be called, therefore, it may not be able to meet its obligations when\ndue.", "entities": [ { "start_character": 106, "end_character": 112, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -12720000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001897982-24-000011", "filing_date": 1707235649000, "quarter_ending": "20231231", "company_name": "Aspen Technology, Inc.", "text": "Inmation\u2019s revenue included in the Company\u2019s condensed consolidated statements of operations was $0.8\u00a0million and $0.9\u00a0million for the three months ended December\u00a031, 2023 and 2022, respectively, and $1.3\u00a0million and $1.2\u00a0million for the six months ended December\u00a031, 2023 and 2022, respectively. Inmation\u2019s net loss included in the Company\u2019s condensed consolidated statements of operations was $2.2\u00a0million and $0.9\u00a0million for the three months ended December\u00a031, 2023 and ", "entities": [ { "start_character": 396, "end_character": 399, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001897982-24-000011", "filing_date": 1707235649000, "quarter_ending": "20231231", "company_name": "Aspen Technology, Inc.", "text": "2022, respectively, and $2.3\u00a0million and $1.1\u00a0million for the six months ended December\u00a031, 2023 and 2022, respectively. Results included amortization of developed technology and customer relationships of $1.5\u00a0million and $1.4\u00a0million for the three months ended December\u00a031, 2023 and 2022 respectively, and $2.9\u00a0million and $1.9\u00a0million for the six months ended December\u00a031, 2023 and 2022, respectively. ", "entities": [ { "start_character": 25, "end_character": 28, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2300000.0 }, { "start_character": 42, "end_character": 45, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001650372-24-000016", "filing_date": 1714147577000, "quarter_ending": "20240331", "company_name": "Atlassian Corp", "text": "The Company reported an income tax provision of $7.0 million on pretax income of $19.8 million and an income tax provision of $72.3 million on pretax loss of $31.3 million for the three and nine months ended March\u00a031, 2024, respectively, as compared to an income tax provision of $53.6 million on pretax loss of $155.4 million and an income tax provision of $162.1 million on pretax loss of $265.7 million for the three and nine months ended March\u00a031, 2023, respectively. The decrease in the income tax provision for the three and nine months ended March\u00a031, 2024 is primarily attributable to a decrease in the recognition of reserves for uncertain tax positions and the partial release of valuation allowance as a result of Loom acquisition. See Note 7,", "entities": [ { "start_character": 82, "end_character": 86, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 19800000.0 }, { "start_character": 159, "end_character": 163, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -31300000.0 }, { "start_character": 313, "end_character": 318, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -155400000.0 }, { "start_character": 392, "end_character": 397, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -265700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001921963-24-000007", "filing_date": 1707897708000, "quarter_ending": "20231231", "company_name": "Atmus Filtration Technologies Inc.", "text": "Related party sales to Cummins represented 17.4% of net sales in 2023 ($282.5 million), 19.3% of net sales in 2022 ($302.2 million) and 18.5% of net sales in 2021 ($266.8 million). For the\u00a0years ended December\u00a031, 2023, 2022 and 2021, two external customers, PACCAR and the Traton Group, each represented greater than 10% of our annual net sales. These customers represented 15.6% and 11.8% of net sales in 2023, 16.2% and 12.0% of net sales in 2022 and 15.1% and 11.7% of net sales in 2021. No other customers exceeded 10% of net sales in the three years presented.", "entities": [ { "start_character": 72, "end_character": 77, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 282500000.0 }, { "start_character": 117, "end_character": 122, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 302200000.0 }, { "start_character": 165, "end_character": 170, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 266800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000769397-24-000091", "filing_date": 1718036388000, "quarter_ending": "20240430", "company_name": "Autodesk, Inc.", "text": "Autodesk had income tax expense of $57 million, relative to pre-tax income of $309 million for the three months ended April 30, 2024, and income tax expense of $60 million, relative to pre-tax income of $221 million for the three months ended April\u00a030, 2023. Income tax expense for the three months ended April 30, 2024, reflects U.S. and foreign tax expense, including withholding tax, reduced by tax-deductible stock-based compensation and the foreign derived intangibles tax benefit in the U.S.", "entities": [ { "start_character": 79, "end_character": 82, "label": "earnings", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 309000000.0 }, { "start_character": 204, "end_character": 207, "label": "earnings", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 221000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001730463-24-000048", "filing_date": 1711040159000, "quarter_ending": "20231231", "company_name": "Autolus Therapeutics plc", "text": "As of December\u00a031, 2023, the Company held cash and cash equivalents of $239.6 million and a net loss attributable to ordinary shareholders for the year the ended December\u00a031, 2023 of $208.4 million. As of December 31, 2023, the Company had an accumulated deficit of $878.6 million. The Company concluded with its existing cash and cash equivalents of $239.6 million together with the total aggregate gross proceeds received post year end of $600.0\u00a0million ($250.0 million and $350.0 million received from BioNTech SE and an underwritten offering, respectively as further details described in Note 24 - Subsequent events) that it can fund its operations for at least the next twelve months from the date of issuance of these financial statements and as such has prepared the consolidated financial statements on the going concern basis. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. Even if the Company's planned regulatory submissions for its products are approved, and the Company is successful in its commercialization efforts, additional funding will be needed before the Company is expected to reach cash breakeven.", "entities": [ { "start_character": 184, "end_character": 189, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -208400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001730463-24-000064", "filing_date": 1715963940000, "quarter_ending": "20240331", "company_name": "Autolus Therapeutics plc", "text": "The Company has incurred recurring losses since its inception, including net losses of $52.7 million and $39.8 million for the three months ended March 31, 2024 and 2023, respectively. The Company had an accumulated deficit of $931.3 million and $878.6 million as of March 31, 2024 and December 31, 2023, respectively. The Company expects to continue to generate operating losses in the foreseeable future. The Company\u2019s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. As of the date these unaudited condensed consolidated financial statements are issued, the Company expects that its cash and cash equivalents at March 31, 2024 of $758.5 million will be sufficient to fund the Company\u2019s operations for at least twelve\u00a0months from the issuance date of these unaudited condensed consolidated financial statements and accordingly they have been prepared on a going concern basis. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. Even if the ", "entities": [ { "start_character": 88, "end_character": 92, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -52700000.0 }, { "start_character": 106, "end_character": 110, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -39800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-013786", "filing_date": 1711728304000, "quarter_ending": "20231231", "company_name": "Avalo Therapeutics, Inc.", "text": "For the year ended December 31, 2023, Avalo generated a net loss of $31.5 million and negative cash flows from operations of $30.7 million. As of December\u00a031, 2023, Avalo had $7.4 million in cash and cash equivalents. For the year ended December\u00a031, 2023, the Company raised approximately $46.2\u00a0million of net proceeds from equity offerings. Avalo fully retired its debt in 2023, which included principal payments of $21.2\u00a0million, inclusive of the full payoff of the loan in September of 2023.", "entities": [ { "start_character": 69, "end_character": 73, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -31500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022763", "filing_date": 1715585595000, "quarter_ending": "20240331", "company_name": "Avalo Therapeutics, Inc.", "text": "For the three months ended March 31, 2024, Avalo generated a net loss of $121.3\u00a0million and negative cash flows from operations of $6.2 million. As of March 31, 2024, Avalo had $110.2 million in cash and cash equivalents. In March 2024, the Company closed a private placement investment for up to $185\u00a0million in gross proceeds, including an initial upfront gross investment of $115.6\u00a0million. Net proceeds were $108.1\u00a0million after deducting transaction costs. The Company could receive up to an additional $69.4\u00a0million of gross proceeds upon the exercise of warrants issued in the financing. ", "entities": [ { "start_character": 74, "end_character": 79, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -121300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001603756-24-000062", "filing_date": 1714494538000, "quarter_ending": "20240331", "company_name": "Axonics, Inc.", "text": "The Company incurred net losses of $19.1 million and $9.2 million for the three months ended March 31, 2024 and 2023, respectively, and had an accumulated deficit of $399.5 million as of March\u00a031, 2024 compared to $380.4 million at December\u00a031, 2023. The Company expects to continue to spend a significant amount of its existing resources on sales and marketing activities as the Company continues to invest in commercializing and marketing its products in the United States and internationally.", "entities": [ { "start_character": 36, "end_character": 40, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -19100000.0 }, { "start_character": 54, "end_character": 57, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -9200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001701478-24-000005", "filing_date": 1715274202000, "quarter_ending": "20240331", "company_name": "Azitra, Inc.", "text": "Total related party revenue was $0 and $113,300 for the three months ended March 31, 2024 and March 31, 2023, respectively. Accounts receivable due from the related party was $0 and $90,000 at March\u00a031, 2024 and December\u00a031, 2023, respectively. ", "entities": [ { "start_character": 33, "end_character": 34, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 }, { "start_character": 40, "end_character": 47, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 113300.0 }, { "start_character": 86, "end_character": 87, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 } ] }, { "form_type": "10-Q", "accession_number": "0001701478-24-000005", "filing_date": 1715274202000, "quarter_ending": "20240331", "company_name": "Azitra, Inc.", "text": "The unaudited condensed financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, management has identified the following conditions and events that created an uncertainty about the ability of the Company to continue as a going concern. As of and for the three months ended March 31, 2024, the Company has an accumulated deficit of $51.5 million, a loss from operations of $3.0\u00a0million, used $3.0 million to fund operations and had approximately $2.3 million of working capital. These factors among others raise substantial doubt about the Company\u2019s ability to continue as a going concern.", "entities": [ { "start_character": 592, "end_character": 595, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3000000.0 }, { "start_character": 611, "end_character": 614, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-017512", "filing_date": 1713909055000, "quarter_ending": "20231231", "company_name": "B. Riley Financial, Inc.", "text": "$40,383 and the fair value was $25,423 as of December\u00a031, 2022. The total assets and liabilities of bebe as of December\u00a031, 2022 was $94,401 and $45,858, respectively. Total revenues of bebe during the years ended December 31, 2022, and 2021 was $55,452 and $50,745, respectively. Net income of bebe during the years ended December 31, 2022 and 2021 was $17,423 and $8,366, respectively. During the years ended December\u00a031, 2023, 2022, and 2021, the Company received dividends from bebe of $245, $3,197, and $2,136, respectively.", "entities": [ { "start_character": 247, "end_character": 253, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 55452000.0 }, { "start_character": 259, "end_character": 265, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 50745000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-017512", "filing_date": 1713909055000, "quarter_ending": "20231231", "company_name": "B. Riley Financial, Inc.", "text": "On July\u00a019, 2022, BRPM 150 completed a business combination with FaZeClan Holdings, Inc. (\u201cFaze Holdings\u201d) in a reverse merger transaction resulting in BRPM 150 no longer being a VIE of the Company and no longer being included in the consolidated group of the Company. In connection with the de-consolidation of BRPM 150, among other items, prepaid expenses and other assets decreased by $172,584 related to funds held in a trust account and redeemable noncontrolling interests in equity of subsidiaries decreased by $172,500. During the year ended December 31, 2022, the Company recognized incentive fees of $41,885, which is included in services and fees in the consolidated statement of operations. ", "entities": [ { "start_character": 610, "end_character": 616, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 41885000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023642", "filing_date": 1715793548000, "quarter_ending": "20240331", "company_name": "B. Riley Financial, Inc.", "text": "The Company\u2019s effective income tax rate was a benefit of 26.3% for the three months ended March 31, 2024 as compared to a provision of 32.4% for the three months ended March 31, 2023. During the three months ended March\u00a031, 2024, the Company had a loss before income taxes of $65,044 and a benefit from income taxes of $17,090 resulting from the impact of items that are not tax deductible. The change in the effective tax rate compared to the prior year is primarily due to the impact of items that are not tax deductible on the loss of $65,044 before income taxes.", "entities": [ { "start_character": 277, "end_character": 283, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -65044000.0 }, { "start_character": 539, "end_character": 545, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -65044000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007933", "filing_date": 1709220625000, "quarter_ending": "20231231", "company_name": "BANC OF CALIFORNIA, INC.", "text": "The regulatory framework also imposes various restrictions on the ability of the Bank to make capital distributions, which include dividends, stock redemptions or repurchases, and certain other items. For example, taking into account the financial condition of the Bank and other factors, the DFPI may object and therefore prevent the Bank from paying dividends to the Company. Generally, the Bank may declare a dividend without the approval of the DFPI as long as the total dividends declared in a calendar year do not exceed either the retained earnings of the Bank or the total of net earnings of the Bank for three previous fiscal years less any dividend paid during such period. Because substantially all of our business activities, income and cash flow are expected to be generated by the Bank, an inability of the Bank to pay dividends or distribute capital to the Company would adversely affect the Company\u2019s liquidity. Dividends can also be restricted if the capital conservation buffer requirement is not met. In general, the Bank may declare a dividend without the approval of the FRB as long as the total of all dividends declared by the Bank during the calendar year, including the proposed dividend, does not exceed the sum of the Bank\u2019s net income during the current calendar year and the retained net income of the prior two calendar years. The Bank had a cumulative net loss of $0.8 billion during the three fiscal years of 2023, 2022, and 2021, compared to dividends of $357.0 million paid by the Bank during that same period. During 2023, Banc of California, Inc. received $46.0 million in dividends from the Bank. Since the Bank had an accumulated deficit of $3.1 billion at December\u00a031, 2023, for the foreseeable future, dividends from the Bank to Banc of California, Inc. will require DFPI and FRB approval.", "entities": [ { "start_character": 1396, "end_character": 1399, "label": "earnings", "start_date_for_period": "2018-01-01", "end_date_for_period": "2020-12-31", "currency_/_unit": "iso4217:USD", "value": -800000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007933", "filing_date": 1709220625000, "quarter_ending": "20231231", "company_name": "BANC OF CALIFORNIA, INC.", "text": "Stockholders' equity was $3.4\u00a0billion at December\u00a031, 2023, a decrease of $559.8 million compared to December\u00a031, 2022. The decrease was primarily due to a net loss of $1.9\u00a0billion in 2023, partially offset by an increase of $1.0\u00a0billion from the issuance of stock in the Merger and the concurrent $400 million capital raise and a decrease in negative AOCI of $358.8 million. The components of stockholders' equity changed considerably during 2023 primarily due to new shares and new classes of stock issued in conjunction with the Merger. At December\u00a031, 2022, our stockholders' equity consisted of approximately 79 million shares of issued common stock and 513,250 shares of issued Series A Preferred Stock. At December\u00a031, 2023, our stockholders' equity consisted of the following:", "entities": [ { "start_character": 169, "end_character": 172, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1900000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000070858-24-000156", "filing_date": 1714494852000, "quarter_ending": "20240331", "company_name": "BANK OF AMERICA CORP /DE/", "text": "For the three months ended March 31, 2024, 62\u00a0million average dilutive potential common shares associated with the Series L preferred stock were antidilutive, whereas they were included in the diluted share count under the \u201cif-converted\u201d method for the three months ended March 31, 2023.", "entities": [ { "start_character": 43, "end_character": 45, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 62000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000009984-24-000051", "filing_date": 1708966049000, "quarter_ending": "20231231", "company_name": "BARNES GROUP INC", "text": "The operating results of MB Aerospace have been included in the Consolidated Statements of Income since the Acquisition Date. The Company reported $114,469 in net sales and an operating loss of $13,884 from MB Aerospace, included within the Aerospace segment's operating profit, inclusive of $19,192 of short-term purchase accounting adjustments related to inventory step-up and backlog intangible amortization and $8,182 of amortization of other intangible assets acquired, for the period from the Acquisition Date through December 31, 2023.", "entities": [ { "start_character": 148, "end_character": 155, "label": "revenues", "start_date_for_period": "2023-08-31", "end_date_for_period": "2023-08-31", "currency_/_unit": "iso4217:USD", "value": 114469000.0 }, { "start_character": 195, "end_character": 201, "label": "ebit", "start_date_for_period": "2023-08-31", "end_date_for_period": "2023-08-31", "currency_/_unit": "iso4217:USD", "value": 13884000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000010048-24-000005", "filing_date": 1707754484000, "quarter_ending": "20231231", "company_name": "BARNWELL INDUSTRIES INC", "text": "The following table presents certain financial information related to Barnwell\u2019s reporting segments. All revenues reported are from external customers with no intersegment sales or transfers.", "entities": [ { "start_character": 156, "end_character": 158, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0000010048-24-000010", "filing_date": 1715703708000, "quarter_ending": "20240331", "company_name": "BARNWELL INDUSTRIES INC", "text": "The following table presents certain financial information related to Barnwell\u2019s reporting segments. All revenues reported are from external customers with no intersegment sales or transfers.", "entities": [ { "start_character": 156, "end_character": 158, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0000913142-24-000007", "filing_date": 1707841028000, "quarter_ending": "20231231", "company_name": "BELDEN INC.", "text": "Revenues generated in both the Enterprise Solutions and Industrial Automation Solutions segments from our largest customer were approximately $378.1 million (15% of revenues), $387.7 million (15% of revenues), and $374.8 million (16% of revenues) for the years ended December\u00a031, 2023,\u00a02022, and 2021, respectively. At December\u00a031, 2023 and 2022, we had $61.9 million and $28.8 million in accounts receivable outstanding from this customer, which represented approximately 15% and 7% of our total accounts receivable balance as of December\u00a031, 2023 and 2022, respectively.", "entities": [ { "start_character": 143, "end_character": 148, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 378100000.0 }, { "start_character": 177, "end_character": 182, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 387700000.0 }, { "start_character": 215, "end_character": 220, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 374800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001031308-24-000004", "filing_date": 1715098135000, "quarter_ending": "20240331", "company_name": "BENTLEY SYSTEMS INC", "text": "The Company issues certain performance-based RSUs determined to be participating securities because holders of such shares have non-forfeitable dividend rights in the event of the Company\u2019s declaration of a dividend for common shares. As of March\u00a031, 2024 and 2023, there were 343,825 and 387,237 participating securities outstanding, respectively.", "entities": [ { "start_character": 277, "end_character": 284, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 343825.0 }, { "start_character": 289, "end_character": 296, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 387237.0 } ] }, { "form_type": "10-Q", "accession_number": "0000011544-24-000012", "filing_date": 1714752703000, "quarter_ending": "20240331", "company_name": "BERKLEY W R CORP", "text": "The Company presents both basic and diluted net income per share (\u201cEPS\u201d) amounts. Basic EPS is calculated by dividing net income by the weighted average number of common shares outstanding during the period (including 11,663,450 and 11,416,856 common shares held in a grantor trust as of March\u00a031, 2024 and 2023, respectively). The common shares held in the grantor trust are for delivery upon settlement of vested but mandatorily deferred restricted stock units (\"RSUs\"). Shares held by the grantor trust do not affect diluted shares outstanding since the shares deliverable under vested RSUs were already included in diluted shares outstanding. Diluted EPS is based upon the weighted average number of basic and common equivalent shares outstanding during the period and is calculated using the treasury stock method for stock incentive plans. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect. ", "entities": [ { "start_character": 218, "end_character": 228, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 11663450000.0 }, { "start_character": 233, "end_character": 243, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 11416856.0 } ] }, { "form_type": "10-Q", "accession_number": "0000011544-24-000012", "filing_date": 1714752703000, "quarter_ending": "20240331", "company_name": "BERKLEY W R CORP", "text": "(2) Revenues for Insurance from foreign operations for the three months ended March 31, 2024 and 2023 were $393\u00a0million and $274\u00a0million, respectively. Revenues for Reinsurance & Monoline Excess from foreign operations for the three months ended March 31, 2024 and 2023 were $111\u00a0million and $106\u00a0million, respectively.", "entities": [ { "start_character": 108, "end_character": 111, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 393000000.0 }, { "start_character": 125, "end_character": 128, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 274000000.0 }, { "start_character": 276, "end_character": 279, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 111000000.0 }, { "start_character": 293, "end_character": 296, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 106000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001081316-24-000003", "filing_date": 1708711203000, "quarter_ending": "20231231", "company_name": "BERKSHIRE HATHAWAY ENERGY CO", "text": "PacifiCorp has an intercompany administrative services agreement and a mutual assistance agreement with BHE and its subsidiaries. Amounts charged to PacifiCorp by BHE and its subsidiaries under these agreements totaled $168\u00a0million, $123\u00a0million and $70\u00a0million during the years ended December 31, 2023, 2022 and 2021, respectively. Amounts charged to PacifiCorp in 2023 and 2022 were primarily reflected in construction work in progress on the Consolidated Balance Sheets as of December 31, 2023 and 2022. Payables associated with the charges were $15\u00a0million and $16\u00a0million as of December\u00a031, 2023 and 2022, respectively. Amounts charged by PacifiCorp to BHE and its subsidiaries under these agreements totaled $44\u00a0million, $23\u00a0million and $8\u00a0million during the years ended December\u00a031, 2023, 2022 and 2021, respectively. Receivables associated with the charges were $8\u00a0million and $3\u00a0million as of December\u00a031, 2023 and 2022, respectively. Such amounts primarily relate to information technology projects and other costs managed at a consolidated level and allocated or passed through to affiliates.", "entities": [ { "start_character": 715, "end_character": 717, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 44000000.0 }, { "start_character": 728, "end_character": 730, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 23000000.0 }, { "start_character": 744, "end_character": 745, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 8000000.0 }, { "start_character": 871, "end_character": 872, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 8000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001081316-24-000003", "filing_date": 1708711203000, "quarter_ending": "20231231", "company_name": "BERKSHIRE HATHAWAY ENERGY CO", "text": "The effective tax rate for the year ended December 31, 2023, is 54% and results from a $553\u00a0million income tax benefit associated with a $1,021\u00a0million pre-tax loss primarily related to a $1,677\u00a0million increase in wildfire loss accruals, net of expected insurance recoveries as described in Note 14. The $553\u00a0million income tax benefit is primarily comprised of a $214\u00a0million benefit, or 21%, from the application of the federal statutory income tax rate to the pre-tax loss, a $180\u00a0million benefit, or 18%, from federal income tax credits, a $111\u00a0million benefit, or 11%, from effects of ratemaking and a $41\u00a0million benefit, or 4%, from state income tax.", "entities": [ { "start_character": 138, "end_character": 143, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1021000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001081316-24-000010", "filing_date": 1714758926000, "quarter_ending": "20240331", "company_name": "BERKSHIRE HATHAWAY ENERGY CO", "text": "The effective income tax rate for the three-month period ended March 31, 2023 of 48% resulted from a $110\u00a0million income tax benefit associated with a $230\u00a0million pre-tax loss, primarily related to a $359\u00a0million increase in wildfire loss accruals, net of expected insurance recoveries as described in Note 10. The $110\u00a0million income tax benefit is primarily comprised of a $48\u00a0million benefit, or 21%, from the application of the federal statutory income tax rate to the pre-tax loss and a $29\u00a0million benefit, or 13%, from federal income tax credits.", "entities": [ { "start_character": 152, "end_character": 155, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -230000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001655210-24-000025", "filing_date": 1709283038000, "quarter_ending": "20231231", "company_name": "BEYOND MEAT, INC.", "text": "During the first quarter of 2023, the Company completed a reassessment of the useful lives of its large manufacturing and research and development equipment, and determined that the Company should increase the estimated useful lives for certain of its equipment from a range of 5 to 10 years a uniform 10 years. The timing of this reassessment was based on a combination of factors accumulating over time, including historical useful life information and changes in the Company\u2019s planned use of the equipment, that provided the Company with updated information that allowed it to make a better estimate of the economic lives of such equipment. This reassessment was accounted for as a change in accounting estimate and was made on a prospective basis effective January 1, 2023. This change in accounting estimate decreased depreciation expense in 2023 by $21.0 million, impacting cost of goods sold and research and development expenses by $19.0 million and $2.0\u00a0million, respectively, and decreased both basic and diluted net loss per share available to common stockholders by $0.33. ", "entities": [ { "start_character": 1079, "end_character": 1083, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": null, "value": 0.33 } ] }, { "form_type": "10-Q", "accession_number": "0001655210-24-000117", "filing_date": 1715273102000, "quarter_ending": "20240330", "company_name": "BEYOND MEAT, INC.", "text": "Net revenues earned from TPP included in the U.S. retail channel net revenues were $0 and $5.3\u00a0million, including the $2.0\u00a0million non-refundable up-front fee, for the three months ended March\u00a030, 2024 and April\u00a01, 2023, respectively.", "entities": [ { "start_character": 84, "end_character": 85, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 0.0 }, { "start_character": 91, "end_character": 94, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 5300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007951", "filing_date": 1709222501000, "quarter_ending": "20231231", "company_name": "BGC Group, Inc.", "text": "For the years ended December\u00a031, 2023, 2022 and 2021, the Company recognized related party revenues of $16.0 million, $14.7 million and $14.9 million, respectively, for the services provided to Cantor. These revenues are included as part of \u201cFees from related parties\u201d in the Company\u2019s Consolidated Statements of Operations.", "entities": [ { "start_character": 104, "end_character": 108, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 16000000.0 }, { "start_character": 119, "end_character": 123, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 14700000.0 }, { "start_character": 137, "end_character": 141, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 14900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007951", "filing_date": 1709222501000, "quarter_ending": "20231231", "company_name": "BGC Group, Inc.", "text": "The aggregate purchase price paid by the Company to Cantor consisted of approximately $24.2\u00a0million in cash plus a $4.8\u00a0million post-closing adjustment determined after closing based on netting Lucera\u2019s expenses paid by Cantor after May 1, 2016 against accounts receivable owed to Lucera by Cantor for access to Lucera\u2019s business from May 1, 2016 through the closing date. The Company previously had a 20% ownership interest in Lucera and accounted for its investment using the equity method. The purchase has been accounted for as a transaction between entities under common control. During the years ended December\u00a031, 2023, 2022 and 2021, Lucera recognized nil, nil and $0.2 million in related party revenues from Cantor, respectively. These revenues are included in \u201cData, network and post-trade\u201d in the Company\u2019s Consolidated Statements of Operations.", "entities": [ { "start_character": 674, "end_character": 677, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022251", "filing_date": 1715271604000, "quarter_ending": "20240331", "company_name": "BGC Group, Inc.", "text": "For the three months ended March 31, 2024 and 2023, the Company recognized related party revenues of $4.4 million and $4.0 million, respectively, for the services provided to Cantor. These revenues are included as part of \u201cFees from related parties\u201d in the Company\u2019s unaudited Condensed Consolidated Statements of Operations.", "entities": [ { "start_character": 102, "end_character": 105, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4400000.0 }, { "start_character": 119, "end_character": 122, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000875045-24-000009", "filing_date": 1707846044000, "quarter_ending": "20231231", "company_name": "BIOGEN INC.", "text": "For the years ended December 31, 2023, 2022 and 2021, we recognized $13.6 million, $20.6 million and $20.7 million, respectively, as a component of contract manufacturing, royalty and other revenue in our consolidated statements of income related to the license agreement and other services performed under our collaboration with Samsung Bioepis. ", "entities": [ { "start_character": 69, "end_character": 73, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 13600000.0 }, { "start_character": 84, "end_character": 88, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 20600000.0 }, { "start_character": 102, "end_character": 106, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 20700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001061630-24-000064", "filing_date": 1713941103000, "quarter_ending": "20240331", "company_name": "BLACKSTONE MORTGAGE TRUST, INC.", "text": "For the three months ended March\u00a031, 2024, our Convertible Notes were not included in the calculation of diluted earnings per share, as the impact is antidilutive. For the three months ended March\u00a031, 2023, represents 8.3\u00a0million of weighted average shares, using the if-converted method, related to our March 2022 Convertible Notes. Refer to Note 12 for further discussion of our convertible notes.", "entities": [ { "start_character": 70, "end_character": 72, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 }, { "start_character": 218, "end_character": 221, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 8300000.000000001 } ] }, { "form_type": "10-Q", "accession_number": "0001823945-24-000041", "filing_date": 1714754214000, "quarter_ending": "20240331", "company_name": "BLUE OWL CAPITAL INC.", "text": "Included in the weighted-average Class A Shares outstanding are RSUs that have vested but have not been settled in Class A Shares. These RSUs do not participate in dividends until settled in Class A Shares. These vested RSUs totaled 12,098,617 for the three months ended March\u00a031, 2024, and 10,736,476 for the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 233, "end_character": 243, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 12098617.0 }, { "start_character": 291, "end_character": 301, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 10736476.0 } ] }, { "form_type": "10-Q", "accession_number": "0000012927-24-000025", "filing_date": 1713964236000, "quarter_ending": "20240331", "company_name": "BOEING CO", "text": "BCA loss from operations was $1,143 million for the three months ended March 31, 2024 compared with $615 million in the same period in 2023 reflecting lower 737 deliveries and 737-9 customer considerations, partially offset by lower abnormal production costs.", "entities": [ { "start_character": 30, "end_character": 35, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1143000000.0 }, { "start_character": 101, "end_character": 104, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -615000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001328581-24-000018", "filing_date": 1708446249000, "quarter_ending": "20231231", "company_name": "BOISE CASCADE Co", "text": "The facilities acquired in the BROSCO Acquisition expanded our door and millwork business into the Northeast U.S. markets and enhance BMD's general line product mix. Sales and operating income of $43.3\u00a0million and $2.3\u00a0million, respectively, were reported for these facilities as part of the BMD segment for the year ended December\u00a031, 2023. ", "entities": [ { "start_character": 215, "end_character": 218, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001656423-24-000007", "filing_date": 1709049365000, "quarter_ending": "20231231", "company_name": "BOSTON PROPERTIES INC", "text": "Santa Monica Business Park contributed approximately $3.9\u00a0million of revenue and $(0.9)\u00a0million of net income to the Company for the period December 14, 2023 through December 31, 2023.", "entities": [ { "start_character": 54, "end_character": 57, "label": "revenues", "start_date_for_period": "2023-12-14", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3900000.0 }, { "start_character": 83, "end_character": 86, "label": "earnings", "start_date_for_period": "2023-12-14", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001656423-24-000028", "filing_date": 1715338103000, "quarter_ending": "20240331", "company_name": "BOSTON PROPERTIES INC", "text": "901 New York Avenue contributed approximately $7.9\u00a0million of revenue and $2.3\u00a0million of net loss to the Company for the period from January 8, 2024 through March 31, 2024. 901 New York Avenue is a premier workplace consisting of approximately 524,000 net rentable square feet. ", "entities": [ { "start_character": 47, "end_character": 50, "label": "revenues", "start_date_for_period": "2024-01-08", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7900000.0 }, { "start_character": 75, "end_character": 78, "label": "earnings", "start_date_for_period": "2024-01-08", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001078207-24-000019", "filing_date": 1708457405000, "quarter_ending": "20231231", "company_name": "BOWFLEX INC.", "text": "Management has determined that under these circumstances, there is substantial doubt about our ability to continue as a going concern for twelve months from the issuance date of this report. Our assessment of going concern was completed in accordance with FASB ASC Topic 205-40, \u201cBasis of Presentation\u2014Going Concern.\u201d For the three and nine months ended December 31, 2023, we incurred a net loss of $34.3 million and $51.8 million, respectively, and for the three and nine months ended December 31, 2022, we incurred a net loss of $11.1 million and $84.5 million, respectively. As of December 31, 2023, we had $15.9 million of cash, working capital of $31.9 million and $24.4 million available for future borrowings under our ABL Credit Facility.", "entities": [ { "start_character": 400, "end_character": 404, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -34300000.0 }, { "start_character": 418, "end_character": 422, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -51800000.0 }, { "start_character": 532, "end_character": 536, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -11100000.0 }, { "start_character": 550, "end_character": 554, "label": "earnings", "start_date_for_period": "2022-04-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -84500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000733076-24-000010", "filing_date": 1715270760000, "quarter_ending": "20240331", "company_name": "BRIGHTHOUSE LIFE INSURANCE Co", "text": "The related party expense for the Company was commissions paid on the sale of variable products and passed through to the broker-dealer affiliate. The related party revenue for the Company was fee income passed through the broker-dealer affiliate from trusts and mutual funds whose shares serve as investment options of policyholders of the Company. Fee income received related to these transactions and recorded in other revenues was $43\u00a0million and $42\u00a0million for the three months ended March 31, 2024 and 2023, respectively. Commission expenses incurred related to these transactions and recorded in other expenses were $239\u00a0million and $225\u00a0million for the three months ended March 31, 2024 and 2023, respectively. The Company also had related party fee income receivables of $15 million and $14 million at March\u00a031, 2024", "entities": [ { "start_character": 436, "end_character": 438, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 43000000.0 }, { "start_character": 452, "end_character": 454, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 42000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000014272-24-000096", "filing_date": 1714048726000, "quarter_ending": "20240331", "company_name": "BRISTOL MYERS SQUIBB CO", "text": "Provision for income taxes in interim periods is determined based on the estimated annual effective tax rates and the tax impact of discrete items that are reflected immediately. The income tax provision of $392 million during the three months ended March\u00a031, 2024 on a pretax loss of $11.5\u00a0billion resulted in an effective tax rate of (3.4)%, which included the impact of a $12.1\u00a0billion one-time, non-tax deductible charge for the acquisition of Karuna. Additional changes to the effective tax rate may occur in future periods due to various reasons, including changes to the estimated pretax earnings mix and tax reserves and revised interpretations or changes to the tax legislation code. Income tax payments were $187\u00a0million and $149\u00a0million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 286, "end_character": 290, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -11500000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001781755-24-000016", "filing_date": 1709137811000, "quarter_ending": "20231231", "company_name": "BRP Group, Inc.", "text": "Total revenues and expenses of the Company\u2019s consolidated VIEs included in the consolidated statements of comprehensive loss were $2.0 million and $1.1 million, respectively, for the year ended December 31, 2023, $1.7 million and $1.0 million, respectively, for the year ended December 31, 2022, and $1.0 million and $0.6 million, respectively, for the year ended December 31, 2021.", "entities": [ { "start_character": 131, "end_character": 134, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 214, "end_character": 217, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1700000.0 } ] }, { "form_type": "10-K", "accession_number": "0000014930-24-000054", "filing_date": 1708084813000, "quarter_ending": "20231231", "company_name": "BRUNSWICK CORP", "text": "The Boat segment consists of the Brunswick Boat Group (Boat Group), which manufactures and distributes recreational boats, and Business Acceleration. We believe that the Boat segment, which had net sales of $1,989.4 million during 2023, is a world leader in the manufacture and sale of pleasure boats. The Boat segment manages Brunswick's boat brands, evaluates and\u00a0optimizes the Boat segment's boat portfolio, promotes recreational boating services and activities to enhance the consumer experience and dealer profitability, including through its Business Acceleration initiatives, and speeds the introduction of new technologies into boat manufacturing and design processes.", "entities": [ { "start_character": 208, "end_character": 215, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1989400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000014930-24-000054", "filing_date": 1708084813000, "quarter_ending": "20231231", "company_name": "BRUNSWICK CORP", "text": "The Navico Group segment, which had net sales of $914.7 million in 2023, designs, develops, manufactures, and markets products and systems for the marine, RV, specialty vehicle, mobile and industrial markets, as well as aftermarket channels. Navico Group products include marine electronics, sensors, and control systems, digital control and monitoring systems, instruments, fish finders, sonar, radar, trolling motors, fuel systems, batteries, power management, and electrical systems. Navico Group sells its products to aftermarket distributors and retailers as well as original equipment manufacturers. White River Marine Group, LLC, Brunswick's Engine P&A distribution businesses and Brunswick Boat Group are significant customers.", "entities": [ { "start_character": 50, "end_character": 55, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 914700000.0 } ] }, { "form_type": "10-K", "accession_number": "0000014930-24-000054", "filing_date": 1708084813000, "quarter_ending": "20231231", "company_name": "BRUNSWICK CORP", "text": "The Engine P&A segment had net sales of $1,199.8 million in 2023. Engine P&A sells products such as engine parts and consumables including oils and lubricants, electrical products, boat parts and systems, and also includes our marine parts and accessories distribution businesses. ", "entities": [ { "start_character": 41, "end_character": 48, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1199800000.0 } ] }, { "form_type": "10-K", "accession_number": "0000014930-24-000054", "filing_date": 1708084813000, "quarter_ending": "20231231", "company_name": "BRUNSWICK CORP", "text": "The Propulsion segment, which we believe is a world leader in the manufacturing and sale of recreational marine engines and propulsion systems, had net sales of $2,763.8 million in 2023. The Propulsion segment designs, manufactures and sells engines, controls, rigging, and propellers globally to over 860 boat builders (both independent and Brunswick's Boat segment) and a network of more than 8,900 marine dealers and distributors, specialty marine retailers, marine service centers, and various local, state, and federal governmental accounts", "entities": [ { "start_character": 162, "end_character": 169, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2763800000.0 } ] }, { "form_type": "10-K", "accession_number": "0000014930-24-000054", "filing_date": 1708084813000, "quarter_ending": "20231231", "company_name": "BRUNSWICK CORP", "text": ", with Brunswick being the acquiring entity, and reflecting estimates and assumptions deemed appropriate by Company management. Transaction costs related to the acquisition were expensed as incurred within Selling, general and administrative expense and totaled $1.0\u00a0million and $13.8\u00a0million for the years ended December 31, 2022 and 2021, respectively. The net sales and operating loss, respectively, of Navico included in Brunswick's consolidated financial statements since the date of acquisition through December 31, 2021 was $120.4\u00a0million and $7.4\u00a0million, which includes $9.0\u00a0million of expense related to inventory fair value adjustments and $5.8\u00a0million of intangible asset amortization.", "entities": [ { "start_character": 532, "end_character": 537, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 120400000.0 }, { "start_character": 551, "end_character": 554, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -7400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000014930-24-000103", "filing_date": 1714653311000, "quarter_ending": "20240330", "company_name": "BRUNSWICK CORP", "text": "Navico Group segment's operating loss in the first quarter of 2024 was $2.4 million, a decrease from operating earnings of $12.8 million in the first quarter of 2023,", "entities": [ { "start_character": 72, "end_character": 75, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -2400000.0 }, { "start_character": 124, "end_character": 128, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 12800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-032825", "filing_date": 1713180556000, "quarter_ending": "20231231", "company_name": "BTC Digital Ltd.", "text": "Under\nthe current Hong Kong Inland Revenue Ordinance, the Group\u2019s Hong Kong subsidiaries are subject to Hong Kong profits tax on its\ntaxable income generated from the operations in Hong Kong.\u00a0A Two-tiered Profits Tax rates regime was introduced since year 2018\nwhere the first HK$2,000 of assessable profits earned by a company will be taxed at half the current tax rate (8.25%) whilst the remaining\nprofits will continue to be taxed at 16.5%. There is an anti-fragmentation measure where each group will have to nominate only one company\nin the group to benefit from the progressive rates.\u00a0Payments of dividends by the subsidiaries to the Company are not subject to\nwithholding tax in Hong Kong.", "entities": [ { "start_character": 280, "end_character": 285, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:HKD", "value": 2000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001486957-24-000011", "filing_date": 1709051317000, "quarter_ending": "20231231", "company_name": "BWX Technologies, Inc.", "text": "We would be subject to withholding taxes if we were to distribute earnings from certain foreign subsidiaries. As of December\u00a031, 2023, the undistributed earnings of these subsidiaries were approximately $292.3 million, and our unrecognized deferred income tax liabilities of approximately $14.6 million would be payable upon the distribution of these earnings. All of our foreign earnings are considered indefinitely reinvested.", "entities": [ { "start_character": 204, "end_character": 209, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 292300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001630805-24-000014", "filing_date": 1710519931000, "quarter_ending": "20231231", "company_name": "Babcock & Wilcox Enterprises, Inc.", "text": "If we had net income in the years ended December\u00a031, 2023 and 2022, diluted shares would include an additional 0.3 million and 0.7 million shares, respectively.", "entities": [ { "start_character": 111, "end_character": 114, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 300000.0 }, { "start_character": 127, "end_character": 130, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001630805-24-000028", "filing_date": 1715272783000, "quarter_ending": "20240331", "company_name": "Babcock & Wilcox Enterprises, Inc.", "text": "For the three months ended March 31, 2024 if we had net income, we would have had no additional dilutive shares. If we had net income for the three months ended March 31, 2023 we would have included 0.4 million in diluted shares. ", "entities": [ { "start_character": 82, "end_character": 84, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 }, { "start_character": 199, "end_character": 202, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001781755-24-000030", "filing_date": 1715098728000, "quarter_ending": "20240331", "company_name": "Baldwin Insurance Group, Inc.", "text": "Total revenues and expenses of the Company\u2019s consolidated VIEs included in the condensed consolidated statements of comprehensive income (loss) were $0.5 million and $0.3 million, respectively, for the three months ended March 31, 2024 and $0.4 million and $0.3 million, respectively, for the three months ended March 31, 2023.", "entities": [ { "start_character": 150, "end_character": 153, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 }, { "start_character": 241, "end_character": 244, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001747079-24-000055", "filing_date": 1714727562000, "quarter_ending": "20240331", "company_name": "Bally's Corp", "text": "The Company leases its hotel rooms to patrons and records the corresponding lessor revenue in \u201cNon-gaming revenue\u201d within our condensed consolidated statements of operations. The Company had lessor revenues related to the rental of hotel rooms of $41.1\u00a0million and $47.3\u00a0million for the three months ended March\u00a031, 2024 and 2023, respectively. Hotel leasing arrangements vary in duration, but are short-term in nature.", "entities": [ { "start_character": 248, "end_character": 252, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 41100000.0 }, { "start_character": 266, "end_character": 270, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 47300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001514416-24-000083", "filing_date": 1715097908000, "quarter_ending": "20240331", "company_name": "Bandwidth Inc.", "text": "The Company\u2019s effective tax rate was 2.1% and (647.6)% for the three months ended March 31, 2024 and 2023, respectively. The increase in the effective tax rate is primarily due to near breakeven pre-tax income in the first quarter of 2023 of $0.5 million in relation to the tax benefit resulting from operating losses outside of the U.S.", "entities": [ { "start_character": 243, "end_character": 246, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001819574-24-000025", "filing_date": 1717433989000, "quarter_ending": "20240331", "company_name": "Bark, Inc.", "text": "\u2014 Since inception, the Company has funded its operations primarily with cash flows from operations and issuances of preferred stock and convertible notes. The Company recognized net loss of $37.0 million, $61.5 million, and $68.3 million for the years ended March\u00a031, 2024, 2023 and 2022, respectively. The Company expects that the its cash resources will be sufficient to meet our liquidity, capital ", "entities": [ { "start_character": 191, "end_character": 195, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -37000000.0 }, { "start_character": 206, "end_character": 210, "label": "earnings", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -61500000.0 }, { "start_character": 225, "end_character": 229, "label": "earnings", "start_date_for_period": "2021-04-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": -68300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001634117-24-000011", "filing_date": 1710264231000, "quarter_ending": "20240127", "company_name": "Barnes & Noble Education, Inc.", "text": "We recorded an income tax expense of $229 on pre-tax loss of $(9,699) during the 13 weeks ended January\u00a027, 2024, which represented an effective income tax rate of (2.4)% and an income tax expense of $139 on pre-tax loss of $(21,995) during the 13 weeks ended January\u00a028, 2023, which represented an effective income tax rate of (0.6)%. We recorded an income tax expense of $532 on pre-tax loss of $(34,513) during the 39 weeks ended January\u00a027, 2024, which represented an effective income tax rate of (1.5)% and an income tax expense of $603 on pre-tax loss of $(47,685) during the 39 weeks ended January\u00a028, 2023, which represented an effective income tax rate of (1.3)%. The effective tax rate for the 13 weeks ended January\u00a027, 2024 is lower than the prior year comparable period due to immaterial return to provision adjustments recorded in the prior year. The effective tax rate for the 39 weeks ended January\u00a027, 2024 is materially consistent with the prior year comparable period.", "entities": [ { "start_character": 63, "end_character": 68, "label": "earnings", "start_date_for_period": "2023-10-29", "end_date_for_period": "2024-01-27", "currency_/_unit": "iso4217:USD", "value": -9699000.0 }, { "start_character": 226, "end_character": 232, "label": "earnings", "start_date_for_period": "2022-10-30", "end_date_for_period": "2023-01-28", "currency_/_unit": "iso4217:USD", "value": -21995000.0 }, { "start_character": 400, "end_character": 406, "label": "earnings", "start_date_for_period": "2023-04-30", "end_date_for_period": "2024-01-27", "currency_/_unit": "iso4217:USD", "value": -34513000.0 }, { "start_character": 564, "end_character": 570, "label": "earnings", "start_date_for_period": "2022-05-01", "end_date_for_period": "2023-01-28", "currency_/_unit": "iso4217:USD", "value": -47685000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019241", "filing_date": 1715703326000, "quarter_ending": "20240331", "company_name": "Belpointe PREP, LLC", "text": "For\nthe three months ended March 31, 2024 and 2023, the basic and diluted weighted-average units outstanding were 3,631,531 and 3,523,449,\nrespectively. For the three months ended March 31, 2024 and 2023, net loss attributable to Class A units was $4.0 million and $2.8 million,\nrespectively, and the loss per basic and diluted unit was $1.10 and $0.80, respectively.", "entities": [ { "start_character": 249, "end_character": 252, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4000000.0 }, { "start_character": 266, "end_character": 269, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -2800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001830210-24-000025", "filing_date": 1710437528000, "quarter_ending": "20231231", "company_name": "Benson Hill, Inc.", "text": "For the year ended December\u00a031, 2023, our Company incurred a net loss from continuing operations of $111,247, had negative cash flows from operating activities of $73,131 and had capital expenditures of $11,760. As of December\u00a031, 2023, our Company had cash and marketable securities of $48,680 and no restricted cash. Furthermore, as of December\u00a031, 2023, our Company had an accumulated deficit of $523,786 and term debt and notes payable of $60,451, which are subject to repayment terms and covenants further described in ", "entities": [ { "start_character": 101, "end_character": 108, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -111247000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001830210-24-000050", "filing_date": 1715271379000, "quarter_ending": "20240331", "company_name": "Benson Hill, Inc.", "text": "For the three\u00a0months ended March\u00a031, 2024, our Company incurred a net loss from continuing operations of $26,314 and had negative cash flows from operating activities of $15,045 and capital expenditures of $409. As of March\u00a031, 2024, we had cash and marketable securities of ", "entities": [ { "start_character": 106, "end_character": 112, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -26314000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014436", "filing_date": 1712933876000, "quarter_ending": "20231231", "company_name": "Better Choice Co Inc.", "text": "The\nCompany is subject to risks common in the pet wellness consumer market including, but not limited to, dependence on key personnel, competitive\nforces, successful marketing and sale of its products, the successful protection of its proprietary technologies, ability to grow into\nnew markets, and compliance with government regulations. The Company has continually incurred losses and has an accumulated deficit.\nThe Company\u2019s term loan agreement with Alphia imposes certain financial covenants, including minimum liquidity of $3.0 million,\nminimum EBITDA of $(4.5) million, and maximum marketing spend ratio of 30%. The Company was not in compliance with certain covenants\nrelated to the Alphia Term Loan Facility as of December 31, 2023 and the debt is callable by the lender. Our continued operating losses\nalong with our failure to meet the financial covenants create substantial doubt about the Company\u2019s ability to continue as a going\nconcern for a period of twelve months from the date these consolidated financial statements are issued. The Company does not currently\nexpect it will be able to generate sufficient cash flow from operations to maintain sufficient liquidity to meet the required financial\ncovenants in certain periods prior to maturity giving the lender the right to call the debt. The Company will need to either raise additional\ncapital or obtain additional financing, and/or secure future waivers or amendments from its lenders or accomplish some combination of\nthese items to maintain sufficient liquidity. There can be no assurance that the Company will be successful in raising additional capital,\nsecuring future waivers and/or amendments from its lenders, renewing or refinancing its existing debt or securing new financing. If the\nCompany is unsuccessful in doing so, it may need to reduce the scope of its operations, repay amounts owed to its lenders or sell certain\nassets.", "entities": [ { "start_character": 563, "end_character": 566, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -4500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020392", "filing_date": 1715955754000, "quarter_ending": "20240331", "company_name": "Better Choice Co Inc.", "text": "The\nCompany is subject to risks common in the pet wellness consumer market including, but not limited to, dependence on key personnel, competitive\nforces, successful marketing and sale of its products, the successful protection of its proprietary technologies, ability to grow into\nnew markets, and compliance with government regulations. The Company has continually incurred losses and has an accumulated deficit.\nThe Company\u2019s term loan agreement with Alphia imposes certain financial covenants, including minimum liquidity of $3.0 million,\nminimum EBITDA of $(4.5) million, and maximum marketing spend ratio of 30%. The Company was not in compliance with certain covenants\nrelated to the Alphia Term Loan Facility as of March 31, 2024 and the debt is callable by the lender. Our continued operating losses\nalong with our failure to meet the financial covenants create substantial doubt about the Company\u2019s ability to continue as a going\nconcern for a period of twelve months from the date these consolidated financial statements are issued. The Company does not currently\nexpect it will be able to generate sufficient cash flow from operations to maintain sufficient liquidity to meet the required financial\ncovenants in certain periods prior to maturity giving the lender the right to call the debt. The Company will need to either raise additional\ncapital or obtain additional financing, and/or secure future waivers or amendments from its lenders or accomplish some combination of\nthese items to maintain sufficient liquidity. There can be no assurance that the Company will be successful in raising additional capital,\nsecuring future waivers and/or amendments from its lenders, renewing or refinancing its existing debt or securing new financing. If the\nCompany is unsuccessful in doing so, it may need to reduce the scope of its operations, repay amounts owed to its lenders or sell certain\nassets.", "entities": [ { "start_character": 563, "end_character": 566, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-025000", "filing_date": 1719249642000, "quarter_ending": "20240331", "company_name": "Beyond Air, Inc.", "text": "The\ncarrying amount of net assets of the VIE included in the consolidated financial statements, after the elimination of intercompany balances\nand transactions, was $10.7 million (including $10.9 million of cash) at March 31, 2024, compared with $20.6 million (including $20.5\nmillion of cash) at March 31, 2023. Beyond Cancer generated $20.2 million of losses (before elimination of intercompany amounts) for\nthe year ended March 31, 2024 compared with $17.9 million of losses (before elimination of intercompany amounts) for the year ended March\n31, 2023. The Company\u2019s attributed losses as the primary beneficiary was proportional to its equity interest in Beyond Cancer (80%)\nfor the year ended March 31, 2024.", "entities": [ { "start_character": 338, "end_character": 342, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 20200000.0 }, { "start_character": 455, "end_character": 459, "label": "earnings", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 17900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-032898", "filing_date": 1713190766000, "quarter_ending": "20231231", "company_name": "Bio Essence Corp", "text": "The\nCompany incurred net losses of $802,547 and $527,884\u00a0from the company\u2019s continuing operations for the years ended December\n31, 2023 and 2022, respectively. The Company also had an accumulated deficit of $9,140,474 from the company\u2019s continuing operations\nas of December 31, 2023. These conditions raise substantial doubt about the Company\u2019s ability to continue as a going concern. The\nCompany plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing\nand promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans\nfrom banks or others. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to\nraise additional funds on reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue\nas a going concern is dependent upon the Company\u2019s ability to further implement its business plan and generate sufficient revenue\nand its ability to raise additional funds by way of a public or private offering. The financial statements do not include any adjustments\nthat might result from the outcome of this uncertainty.\u00a0", "entities": [ { "start_character": 36, "end_character": 43, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -802547.0 }, { "start_character": 49, "end_character": 56, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -527884.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-044667", "filing_date": 1715957285000, "quarter_ending": "20240331", "company_name": "Bio Essence Corp", "text": "The Company incurred net losses\nof $33,173\u00a0and $23,064\u00a0from the company\u2019s continuing operations for the three months ended March 31, 2024 and 2023, respectively.\nThe Company also had an accumulated deficit of $8,916,722\u00a0from the company\u2019s continuing operations as of March 31, 2024. These\nconditions raise substantial doubt about the Company\u2019s ability to continue as a going concern. The Company plans to increase its\nincome by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities.\nManagement also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.\nWhile the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds\non reasonable terms and conditions, there can be no assurances to that effect. The ability of the Company to continue as a going concern\nis dependent upon the Company\u2019s ability to further implement its business plan and generate sufficient revenue and its ability to\nraise additional funds by way of a public or private offering. The financial statements do not include any adjustments that might result\nfrom the outcome of this uncertainty.\u00a0", "entities": [ { "start_character": 36, "end_character": 42, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -33173.0 }, { "start_character": 48, "end_character": 54, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -23064.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012056", "filing_date": 1711736133000, "quarter_ending": "20231231", "company_name": "BioRestorative Therapies, Inc.", "text": "The\naccompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which\ncontemplates realization of assets and satisfying liabilities in the normal course of business. For the year ended December 31, 2023,\nthe Company had a net loss of $14.4 million (of which, $7.8 million was attributable to non-cash stock-based compensation) and negative\ncash flows from operations of $6.4 million. The Company anticipates that it will continue to incur net losses and negative cash flows\nfrom operations as it executes its development plans for 2024 and beyond, as well as other potential strategic and business development\ninitiatives. The Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments\nin marketable securities and additional infusions of cash from equity and debt financing. Subsequent to December 31, 2023, the Company\nraised gross proceeds of approximately $8.1 million in connection with a warrant exercise program, which is further discussed in Note\n10 \u2013 Subsequent Events.", "entities": [ { "start_character": 305, "end_character": 309, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -14400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019878", "filing_date": 1715789784000, "quarter_ending": "20240331", "company_name": "Biofrontera Inc.", "text": "If\nwe fail to earn $150 million in revenues from Ameluz\u00ae and the\nRhodoLED\u00ae lamp series over the preceding five (5) year period leading to the Ameluz LSA\u2019s termination date\n(either fifteen (15) years from the date of the Amended and Restated License and Supply Agreement, dated June 16, 2021 or any later termination\ndate following the automatic renewal of this Agreement), Biofrontera Pharma has the right to terminate the Ameluz LSA by providing one\n(1) year written notice.", "entities": [ { "start_character": 20, "end_character": 23, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 150000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020846", "filing_date": 1715067399000, "quarter_ending": "20240330", "company_name": "Bioventus Inc.", "text": "The Company\u2019s two reportable segments are U.S. and International. U.S. segment revenues totaled $114,281 and $103,978 for the three months ended March\u00a030, 2024 and April\u00a01, 2023, respectively. International segment revenues totaled $15,176 and $15,081 for the three months ended March\u00a030, 2024 and April\u00a01, 2023, respectively. The Company\u2019s products are primarily sold to orthopedists, musculoskeletal and sports medicine physicians, podiatrists, neurosurgeons and orthopedic spine surgeons, as well as to their patients. The Company does not disclose segment information by asset as the Chief Operating Decision Maker does not review or use it to allocate resources or to assess the operating results and financial performance. Segment Adjusted EBITDA is the segment profitability metric reported to the Company\u2019s Chief Operating Decision Maker for purposes of decisions about allocation of resources to, and assessing performance of, each reportable segment.", "entities": [ { "start_character": 97, "end_character": 104, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 114281000.0 }, { "start_character": 110, "end_character": 117, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 103978000.0 }, { "start_character": 233, "end_character": 239, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 15176000.0 }, { "start_character": 245, "end_character": 251, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 15081000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001753539-24-000063", "filing_date": 1715189936000, "quarter_ending": "20240331", "company_name": "BlackSky Technology Inc.", "text": "The Company recorded revenue from related parties of $2.0\u00a0million and $0 for the three months ended March\u00a031, 2024 and 2023, respectively. Accounts receivable from related parties was $0 as of March\u00a031, 2024 and December 31, 2023. ", "entities": [ { "start_character": 54, "end_character": 57, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 71, "end_character": 72, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 }, { "start_character": 111, "end_character": 112, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 } ] }, { "form_type": "10-K", "accession_number": "0001779128-24-000015", "filing_date": 1710263275000, "quarter_ending": "20231231", "company_name": "Blade Air Mobility, Inc.", "text": "As of December\u00a031, 2023, the Company had net working capital of $170,770, cash and cash equivalents of $27,873 and short-term investments of $138,264. The Company had net losses of $56,076 and $27,260 for the years ended December\u00a031, 2023 and December\u00a031, 2022, respectively. ", "entities": [ { "start_character": 182, "end_character": 188, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -56076000.0 }, { "start_character": 194, "end_character": 200, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -27260000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010214", "filing_date": 1710751853000, "quarter_ending": "20231231", "company_name": "Blink Charging Co.", "text": "The\nconsolidated financial statements of the Company include the results of operations of Envoy from April 18, 2023 to December 31, 2023\nand do not include results of operations for periods prior to April 18, 2023. The results of operations of Envoy from April 18, 2023\nto December 31, 2023 included revenues of $2,743 and a net loss of $2,620.", "entities": [ { "start_character": 338, "end_character": 343, "label": "earnings", "start_date_for_period": "2023-04-17", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2620000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010214", "filing_date": 1710751853000, "quarter_ending": "20231231", "company_name": "Blink Charging Co.", "text": "As\nof December 31, 2023, the Company had cash and cash equivalents of $121,691\nand working capital of $152,033.\nDuring the years ended December 31, 2023, 2022, and 2021, the Company incurred a net loss of $203,693,\n$91,560 and\n$55,119,\nrespectively. During the years ended December 31, 2023, 2022, and 2021, the Company used cash in operating activities of $97,570,\n$82,365,\nand $40,570,\nrespectively.", "entities": [ { "start_character": 206, "end_character": 213, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -203693000.0 }, { "start_character": 216, "end_character": 222, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -91560000.0 }, { "start_character": 228, "end_character": 234, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -55119000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010214", "filing_date": 1710751853000, "quarter_ending": "20231231", "company_name": "Blink Charging Co.", "text": "The\nconsolidated financial statements of the Company include the results of operations from Blue Corner as of May 10, 2021 to December 31,\n2021 and do not include results of operations for the year ended December 31, 2020. The results of operations of Blue Corner from May\n10, 2021 to December 31, 2021 included revenues of $7,553 and a net loss of $2,567.", "entities": [ { "start_character": 350, "end_character": 355, "label": "earnings", "start_date_for_period": "2021-05-09", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2567000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010214", "filing_date": 1710751853000, "quarter_ending": "20231231", "company_name": "Blink Charging Co.", "text": "The\nconsolidated financial statements of the Company include the results of operations of EB from April 22, 2022 to December 31, 2022 and\ndo not include results of operations for periods prior to April 22, 2022. The results of operations of EB from April 22, 2022 to December\n31, 2022 included revenues of $4,601 and a net loss of $4,355.", "entities": [ { "start_character": 332, "end_character": 337, "label": "earnings", "start_date_for_period": "2022-04-21", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 4355000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010214", "filing_date": 1710751853000, "quarter_ending": "20231231", "company_name": "Blink Charging Co.", "text": "The\nconsolidated financial statements of the Company include the results of operations of SemaConnect from June 15, 2022 to December 31,\n2022 and do not include results of operations for periods prior to June 15, 2022. The results of operations of SemaConnect from June\n15, 2022 to December 31,2022 included revenues of $18,411 and a net loss of $3,295.", "entities": [ { "start_character": 347, "end_character": 352, "label": "earnings", "start_date_for_period": "2022-06-15", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3295000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010214", "filing_date": 1710751853000, "quarter_ending": "20231231", "company_name": "Blink Charging Co.", "text": "In\naddition, provided EB reaches specified gross revenue or new EV charger installation targets over the three years post-closing, the Company\nalso agreed to issue up to approximately $6,400 in additional shares of its common stock to EB shareholders (the \u201cContingent Consideration\u201d).\nThe Contingent Consideration was recorded at an estimated fair value of $3,814. As of December 31, 2022, the estimated fair value of\nthe Contingent Consideration was $1,316. The Company uses a probability-weighted discounted cash flow approach as a valuation technique\nto determine the fair value of the contingent consideration liabilities on the acquisition date and at each reporting period. The significant\nunobservable inputs used in the fair value measurements are projections over the earn-out period, and the probability outcome percentages\nthat are assigned to each scenario. Significant increases or decreases to either of these inputs in isolation could result in a significantly\nhigher or lower liability with a higher liability capped by the contractual maximum of the contingent consideration liabilities.", "entities": [ { "start_character": 185, "end_character": 190, "label": "revenues", "start_date_for_period": "2022-04-21", "end_date_for_period": "2022-04-22", "currency_/_unit": "iso4217:USD", "value": 6400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-005035", "filing_date": 1708013062000, "quarter_ending": "20231231", "company_name": "Bloom Energy Corp", "text": "For the year ended December 31, 2023, the Company recognized a provision for income taxes of $1.9\u00a0million on a pre-tax loss of $306.0\u00a0million, for an effective tax rate of (0.6)%. For the year ended December 31, 2022, we recognized a provision for income taxes of $1.1\u00a0million on a pre-tax loss of $314.0\u00a0million, for an effective tax rate of (0.3)%. For the year ended December 31, 2021, we recognized a provision for income taxes of $1.0\u00a0million on a pre-tax loss of $192.3\u00a0million, for an effective tax rate of (0.5)%. The effective tax rate for 2023, 2022 and 2021 is lower than the statutory federal tax rate primarily due to a full valuation allowance against U.S. deferred tax assets.", "entities": [ { "start_character": 128, "end_character": 133, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -306000000.0 }, { "start_character": 299, "end_character": 304, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -314000000.0 }, { "start_character": 470, "end_character": 475, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -192300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-005035", "filing_date": 1708013062000, "quarter_ending": "20231231", "company_name": "Bloom Energy Corp", "text": "In May 2013, we entered into a joint venture with Softbank Corp. (\u201cSoftbank\u201d), which was accounted for as an equity method investment. Under this arrangement, we sold the Energy Servers and provided maintenance services to the joint venture. On July 1, 2021 (the \u201cBEJ Closing Date\u201d), we acquired Softbank\u2019s 50% interest in the joint venture for a cash payment of $2.0\u00a0million and subject to a $3.6\u00a0million earn out. As of the BEJ Closing Date, Bloom Energy Japan Limited (\u201cBloom Energy Japan\u201d) is no longer considered a related party. For the year ended December 31, 2021 we recognized related party revenue of $1.6\u00a0million.", "entities": [ { "start_character": 612, "end_character": 615, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-005035", "filing_date": 1708013062000, "quarter_ending": "20231231", "company_name": "Bloom Energy Corp", "text": ", revenue from electricity sales from these Portfolio Financings with the PPA Entities amounted to $14.3\u00a0million, $25.9\u00a0million and $28.6\u00a0million, respectively.", "entities": [ { "start_character": 100, "end_character": 104, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 14300000.0 }, { "start_character": 115, "end_character": 119, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 25900000.0 }, { "start_character": 133, "end_character": 137, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 28600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-005035", "filing_date": 1708013062000, "quarter_ending": "20231231", "company_name": "Bloom Energy Corp", "text": "Including related party revenue of $487.2\u00a0million, $36.3\u00a0million and $16.0\u00a0million for the years ended December 31, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 36, "end_character": 41, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 487200000.0 }, { "start_character": 52, "end_character": 56, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 36300000.0 }, { "start_character": 70, "end_character": 74, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 16000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022309", "filing_date": 1715274005000, "quarter_ending": "20240331", "company_name": "Bloom Energy Corp", "text": "There have been no changes in related party relationships during the three months ended March 31, 2024. For information on our related party transactions, see Part II, Item 8, Note 12 \u2014", "entities": [ { "start_character": 16, "end_character": 18, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022309", "filing_date": 1715274005000, "quarter_ending": "20240331", "company_name": "Bloom Energy Corp", "text": "For the three months ended March 31, 2024 and 2023, we recorded an income tax (benefit) provisions of $(0.5) million and $0.3 million on pre-tax losses of $57.0 million and $74.7 million for effective tax rates of 0.9% and (0.3)%, respectively.", "entities": [ { "start_character": 156, "end_character": 160, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -57000000.0 }, { "start_character": 174, "end_character": 178, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -74700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022309", "filing_date": 1715274005000, "quarter_ending": "20240331", "company_name": "Bloom Energy Corp", "text": "Including related party revenue of $122.2\u00a0million and $0.8\u00a0million for the three months ended March 31, 2024, and 2023, respectively.", "entities": [ { "start_character": 36, "end_character": 41, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 122200000.0 }, { "start_character": 55, "end_character": 58, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001701114-23-000117", "filing_date": 1699512263000, "quarter_ending": "20230930", "company_name": "Blue Apron Holdings, Inc.", "text": "The Company has a history of significant net losses, including $89.3 million and $87.9 million for the nine months ended September\u00a030, 2023, and 2022, respectively, and operating cash flows of $(16.5) million and $(68.0) million for the nine months ended September\u00a030, 2023, and 2022, respectively. As of September 30, 2023, the Company had a ", "entities": [ { "start_character": 64, "end_character": 68, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -89300000.0 }, { "start_character": 82, "end_character": 86, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -87900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001944366-24-000053", "filing_date": 1715271608000, "quarter_ending": "20240331", "company_name": "Blue Owl Real Estate Net Lease Trust", "text": "The computation of diluted net income per common share for the three months ended March 31, 2024 includes 38,683 dilutive restricted Class I shares and 28,698,892 dilutive NLT OP units. The computation of diluted net income per common share for three months ended March 31, 2023 includes 16,212 dilutive restricted Class I shares and 29,037,051 dilutive NLT OP units.", "entities": [ { "start_character": 106, "end_character": 112, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 38683.0 }, { "start_character": 289, "end_character": 295, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 16212.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-027305", "filing_date": 1711645313000, "quarter_ending": "20231231", "company_name": "Bluejay Diagnostics, Inc.", "text": "In June\n2022, the Company sold five Symphony analyzers to the Company\u2019s business partner, Toray, for $249,040, all of which was paid in\nJune 2022. Future sales to Toray are not currently anticipated.", "entities": [ { "start_character": 102, "end_character": 109, "label": "revenues", "start_date_for_period": "2022-06-01", "end_date_for_period": "2022-06-30", "currency_/_unit": "iso4217:USD", "value": 249040.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-007432", "filing_date": 1708535159000, "quarter_ending": "20231231", "company_name": "Bone Biologics Corp", "text": "The\nCompany has no significant operating history and since inception to December 31, 2023 has incurred accumulated losses of approximately\n$80.9 million. The Company will continue to incur significant expenses for development activities for their lead product NELL-1/DBM.\nOperating expenditures for the next twelve months are estimated at $5.5 million. The accompanying consolidated financial statements for\nthe year ended December 31, 2023 have been prepared assuming the Company will continue as a going concern. As reflected in the financial\nstatements, the Company incurred a net loss of $8.9 million, and used net cash in operating activities of $9.6 million during the year\nended December 31, 2023. These factors raise substantial doubt about the Company\u2019s ability to continue as a going concern within\none year after the date that the financial statements are issued. The consolidated financial statements do not include any adjustments\nrelated to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might\nbe necessary should the Company be unable to continue as a going concern.", "entities": [ { "start_character": 593, "end_character": 596, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019271", "filing_date": 1715704263000, "quarter_ending": "20240331", "company_name": "Bone Biologics Corp", "text": "The\nCompany has not generated revenue from operations and since inception to March 31, 2024 has incurred accumulated losses of\napproximately $81.8\nmillion. The Company will continue to incur significant expenses for development activities for their lead product NELL-1/DBM.\nOperating expenditures for the next twelve months are estimated at $6.9\nmillion. The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2024 have been\nprepared assuming the Company will continue as a going concern. As reflected in the financial statements, the Company incurred a net\nloss of $0.9\nmillion, and used net cash in operating activities of $1.3\nmillion during the three months ended March 31, 2024. These factors raise substantial doubt about the Company\u2019s ability to\ncontinue as a going concern within one year after the date that the financial statements are issued. In addition, our independent\nregistered public accounting firm, in its audit report to the financial statements included in our Annual Report on Form 10-K for\nthe year ended December 31, 2023, expressed substantial doubt about our ability to continue as a going concern. The consolidated\nfinancial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or\nthe amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going\nconcern.", "entities": [ { "start_character": 620, "end_character": 623, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001443646-24-000075", "filing_date": 1716533474000, "quarter_ending": "20240331", "company_name": "Booz Allen Hamilton Holding Corp", "text": "During fiscal 2024, 2023, and 2022, respectively, approximately 1.1 million, 1.1 million, and 0.9 million shares of participating securities were paid dividends totaling $2.1 million, $1.8 million, and $1.4 million, respectively. There were undistributed earnings of $2.9 million, $0.3 million, and $1.7 million allocated to the participating class of securities in both basic and diluted earnings per share of common stock for fiscal 2024, 2023, and 2022, respectively. ", "entities": [ { "start_character": 64, "end_character": 67, "label": "eps", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 1100000.0 }, { "start_character": 77, "end_character": 80, "label": "eps", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 1100000.0 }, { "start_character": 94, "end_character": 97, "label": "eps", "start_date_for_period": "2021-04-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "xbrli:shares", "value": 900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-010652", "filing_date": 1710264458000, "quarter_ending": "20231231", "company_name": "Bowman Consulting Group Ltd.", "text": "For calculating basic earnings per share, for the year ended December\u00a031, 2022, the weighted average number of shares outstanding exclude 2,004,944 non-vested restricted shares and 12,830 unexercised substantive options. The ", "entities": [ { "start_character": 138, "end_character": 147, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 2004944.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-010652", "filing_date": 1710264458000, "quarter_ending": "20231231", "company_name": "Bowman Consulting Group Ltd.", "text": "For calculating basic loss per share, for the year ended December\u00a031, 2023, the weighted average number of shares outstanding exclude 1,796,615 non-vested restricted shares and 7,900 unexercised substantive options. The computation of diluted loss per share for the year ended December\u00a031, 2023 did not assume the effect to all potential dilutive common stock equivalents outstanding for the period. ", "entities": [ { "start_character": 134, "end_character": 143, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 1796615.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021187", "filing_date": 1715102315000, "quarter_ending": "20240331", "company_name": "Bowman Consulting Group Ltd.", "text": "For calculating basic loss per share, for the three months ended March\u00a031, 2024, the weighted average number of shares outstanding exclude 1,431,607 non-vested restricted shares and 4,791 unexercised substantive options. The computation of diluted earnings per share for the three months ended March\u00a031, 2024 did not assume the effect to all potential dilutive common stock equivalents outstanding for the period.", "entities": [ { "start_character": 139, "end_character": 148, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 1431607.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021187", "filing_date": 1715102315000, "quarter_ending": "20240331", "company_name": "Bowman Consulting Group Ltd.", "text": "For calculating basic earnings per share, for the three months ended March\u00a031, 2023, the weighted average number of shares outstanding exclude 1,750,268 non-vested restricted shares and 9,690 unexercised substantive options. The computation of diluted earnings per share for the three months ended March\u00a031, 2023 did not assume the effect of restricted shares or substantive options because the effects were antidilutive. ", "entities": [ { "start_character": 143, "end_character": 152, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 1750268.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019886", "filing_date": 1715790042000, "quarter_ending": "20240331", "company_name": "Boxabl Inc.", "text": "These consolidated financial statements have been prepared under the assumption that the Company will be able to\ncontinue its operations and will be able to realize its assets and discharge its liabilities in the normal course of business for the\nforeseeable future. For the three months ended March 31, 2024, the Company reported a net loss of $12,051K, an operating cash outflow\nof $10,391K, and an accumulated deficit of $679,537K as of March 31, 2024.", "entities": [ { "start_character": 346, "end_character": 352, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -12051000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-012213", "filing_date": 1710951049000, "quarter_ending": "20231231", "company_name": "Bridger Aerospace Group Holdings, Inc.", "text": "For the year ended December 31, 2023, the Company had an operating loss of $57.5 million, net loss of $77.4\u00a0million and cash flow used in operating activities of $26.8\u00a0million. In addition, as of December 31, 2023, the Company had unrestricted cash or investments of $24.0\u00a0million.", "entities": [ { "start_character": 76, "end_character": 80, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -57500000.0 }, { "start_character": 103, "end_character": 107, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -77400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023200", "filing_date": 1715702845000, "quarter_ending": "20240331", "company_name": "Bridger Aerospace Group Holdings, Inc.", "text": "For the three months ended March\u00a031, 2024, the Company had an operating loss of $15.3 million, net loss of $20.1 million and net cash used in operating activities of $19.8 million. In addition, as of March\u00a031, 2024, the Company had unrestricted cash or investments of $6.8 million.", "entities": [ { "start_character": 81, "end_character": 85, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -15300000.0 }, { "start_character": 108, "end_character": 112, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -20100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001685040-24-000007", "filing_date": 1708621312000, "quarter_ending": "20231231", "company_name": "Brighthouse Financial, Inc.", "text": "The aggregated summarized financial data presented below reflects the latest available financial information and is as of and for the years ended December\u00a031, 2023, 2022 and 2021. Aggregate total assets of these entities totaled $799.2\u00a0billion and $880.1\u00a0billion at December\u00a031, 2023 and 2022, respectively. Aggregate total liabilities of these entities totaled $56.8\u00a0billion and $109.3\u00a0billion at December\u00a031, 2023 and 2022, respectively. Aggregate net income (loss) of these entities totaled $24.8\u00a0billion, ($12.8)\u00a0billion and $22.6\u00a0billion for the years ended December\u00a031, 2023, 2022 and 2021, respectively. Aggregate net income\u00a0(loss) from the underlying entities in which the Company invests is primarily comprised of investment income, including recurring investment income and realized and unrealized investment gains\u00a0(losses).", "entities": [ { "start_character": 495, "end_character": 499, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 24800000000.0 }, { "start_character": 511, "end_character": 515, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -12800000000.0 }, { "start_character": 530, "end_character": 534, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 22600000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001525221-24-000039", "filing_date": 1715111926000, "quarter_ending": "20240331", "company_name": "Bristow Group Inc.", "text": "The Company and VIH lease certain aircraft and facilities and from time to time purchase inventory from one another. During the three months ended March\u00a031, 2024 and 2023, the Company made payments of $1.1\u00a0million and $1.5\u00a0million to its related parties, respectively, and also generated total revenues of $7.1\u00a0million and $4.6\u00a0million from its related parties, respectively. ", "entities": [ { "start_character": 307, "end_character": 310, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7100000.0 }, { "start_character": 324, "end_character": 327, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-018527", "filing_date": 1715275904000, "quarter_ending": "20231231", "company_name": "Brownie's Marine Group, Inc", "text": "We\nsell products to Brownie\u2019s Southport Divers, Inc., Brownie\u2019s Palm Beach Divers, and Brownie\u2019s Yacht Toys, companies\nowned by the brother of Robert Carmichael. Combined net revenues from these entities for the years December 31, 2023 and 2022, totaled\n$806,824 and $981,791, respectively. Accounts receivable from Brownie\u2019s SouthPort Diver\u2019s, Inc., Brownie\u2019s Palm Beach\nDivers, and Brownie\u2019s Yacht Toys at December 31, 2023, were $12,766, $11,927 and $6,790, respectively. Accounts receivable from Brownie\u2019s\nSouthPort Diver\u2019s, Inc., Brownie\u2019s Palm Beach Divers, and Brownie\u2019s Yacht Toys at December 31, 2022, were $16,875,\n$6,773 and $15,532, respectively.", "entities": [ { "start_character": 255, "end_character": 262, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 806824.0 }, { "start_character": 268, "end_character": 275, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 981791.0 } ] }, { "form_type": "10-K", "accession_number": "0001723580-24-000009", "filing_date": 1712747004000, "quarter_ending": "20240101", "company_name": "BurgerFi International, Inc.", "text": "The Company\u2019s franchise agreements provide for franchisee contributions of a percentage of gross restaurant sales, which are recognized as royalty income. Amounts collected are required to be used for advertising and related costs, including reasonable costs of administration. For the year ended January\u00a01, 2024 , the Company had brand development royalties of approximately $1.4 million and brand development expenses of approximately $2.7 million. For the year ended January\u00a02, 2023, the Company had brand development royalties of approximately $1.4 million and approximately $1.8 million brand development expenses. ", "entities": [ { "start_character": 377, "end_character": 380, "label": "revenues", "start_date_for_period": "2023-01-03", "end_date_for_period": "2024-01-01", "currency_/_unit": "iso4217:USD", "value": 1400000.0 }, { "start_character": 549, "end_character": 552, "label": "revenues", "start_date_for_period": "2023-01-03", "end_date_for_period": "2024-01-01", "currency_/_unit": "iso4217:USD", "value": 1400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001723580-24-000009", "filing_date": 1712747004000, "quarter_ending": "20240101", "company_name": "BurgerFi International, Inc.", "text": "The Company's South Florida franchises contribute a percentage of gross restaurant sales, which are recognized as royalty income. Amounts collected are required to be used for local advertising and related costs, including reasonable costs of administering the advertising program. For the year ended January\u00a01, 2024, the Company had advertising co-op royalties of approximately $0.4 million and advertising co-op expenses of approximately $0.7 million. For the year ended January\u00a02, 2023, the Company had advertising co-op royalties of approximately $0.4 million and approximately $0.8 million of advertising co-op expenses. ", "entities": [ { "start_character": 380, "end_character": 383, "label": "revenues", "start_date_for_period": "2023-01-03", "end_date_for_period": "2024-01-01", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 552, "end_character": 555, "label": "revenues", "start_date_for_period": "2023-01-03", "end_date_for_period": "2024-01-01", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-006144", "filing_date": 1708586401000, "quarter_ending": "20231231", "company_name": "C4 Therapeutics, Inc.", "text": "The Company has incurred recurring losses since its inception, including net losses of $132.5 million and $128.2 million for the years ended December\u00a031, 2023 and 2022, respectively. In addition, as of December\u00a031, 2023, the Company had an accumulated deficit of $528.4 million. To date, the Company has not generated any revenue from product sales as none of its product candidates has been approved for commercialization. The Company expects to continue to generate operating losses for the foreseeable future. ", "entities": [ { "start_character": 88, "end_character": 93, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -132500000.0 }, { "start_character": 107, "end_character": 112, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -128199999.99999999 } ] }, { "form_type": "10-Q", "accession_number": "0000016058-24-000070", "filing_date": 1713974471000, "quarter_ending": "20240331", "company_name": "CACI INTERNATIONAL INC /DE/", "text": "Aggregate net changes in estimates for the three and nine months ended March\u00a031, 2024 reflected an increase to income before income taxes of $7.5 million ($0.25 per diluted share) and $24.5 million ($0.81 per diluted share), respectively, compared with $5.3 million ($0.17 per diluted share) and $16.8 million ($0.53 per diluted share), for the three and nine months ended March\u00a031, 2023. The Company uses its statutory tax rate when calculating the impact to diluted earnings per share.", "entities": [ { "start_character": 142, "end_character": 145, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7500000.0 }, { "start_character": 185, "end_character": 189, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 24500000.0 }, { "start_character": 254, "end_character": 257, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5300000.0 }, { "start_character": 297, "end_character": 301, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 16800000.0 } ] }, { "form_type": "10-K", "accession_number": "0000790051-24-000058", "filing_date": 1708092416000, "quarter_ending": "20231231", "company_name": "CARLISLE COMPANIES INC", "text": "For the period from February 1, 2022 to December 31, 2022, the related product lines contributed revenues of $12.0 million, and operating income of $0.2 million. The results of operations of MBTech are reported within the CWT segment.", "entities": [ { "start_character": 110, "end_character": 114, "label": "revenues", "start_date_for_period": "2022-02-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 12000000.0 }, { "start_character": 149, "end_character": 152, "label": "ebit", "start_date_for_period": "2022-02-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001690820-24-000165", "filing_date": 1714580197000, "quarter_ending": "20240331", "company_name": "CARVANA CO.", "text": "As of March\u00a031, 2024, the Company is a tenant under various operating leases related to certain of its hubs, vending machines, inspection and reconditioning centers, auction locations, storage, parking and corporate offices. The initial terms expire at various dates between 2024 and 2038. Many of the leases include one or more renewal options ranging from one to twenty years and some contain purchase options. The Company leases and subleases certain of its real estate to third parties. Lease and sublease income for the three months ended March\u00a031, 2024 and 2023 was $2 million and $1 million, respectively, and is included in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations.", "entities": [ { "start_character": 554, "end_character": 555, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 588, "end_character": 589, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000018230-24-000020", "filing_date": 1714557924000, "quarter_ending": "20240331", "company_name": "CATERPILLAR INC", "text": "Includes revenues from Construction Industries, Resource Industries, Energy & Transportation and All Other Segment of $177\u00a0million and $162\u00a0million in the three months ended March\u00a031, 2024 and 2023, respectively. ", "entities": [ { "start_character": 119, "end_character": 122, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 177000000.0 }, { "start_character": 136, "end_character": 139, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 162000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001138118-24-000006", "filing_date": 1708409351000, "quarter_ending": "20231231", "company_name": "CBRE GROUP, INC.", "text": "Our Real Estate Investments segment invests our own capital in certain real estate investment funds with clients. We provided investment management, property management, brokerage and other professional services in connection with these real estate investments and earned revenues from these unconsolidated subsidiaries of $278.8\u00a0million, $268.9\u00a0million and $213.5\u00a0million during the years ended December\u00a031, 2023, 2022 and 2021, respectively. We had receivables of $83.2\u00a0million and $73.2\u00a0million at December\u00a031, 2023 and 2022, respectively, from these entities. Additionally, in our global development business, we earned development and construction management revenues from these unconsolidated subsidiaries of $165.0\u00a0million, $147.8\u00a0million and $104.3\u00a0million during the years ended December\u00a031, 2023, 2022 and 2021. We had receivables of $30.4\u00a0million and $21.1\u00a0million at December\u00a031, 2023 and 2022, respectively, from these entities.", "entities": [ { "start_character": 324, "end_character": 329, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 278800000.0 }, { "start_character": 340, "end_character": 345, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 268900000.0 }, { "start_character": 359, "end_character": 364, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 213500000.0 }, { "start_character": 716, "end_character": 721, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 165000000.0 }, { "start_character": 732, "end_character": 737, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 147800000.0 }, { "start_character": 751, "end_character": 756, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 104300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001138118-24-000014", "filing_date": 1714753143000, "quarter_ending": "20240331", "company_name": "CBRE GROUP, INC.", "text": "The accompanying consolidated statement of operations for the three months ended March\u00a031, 2024 includes revenue, operating loss and net income of $41.4\u00a0million, $0.3\u00a0million and $0.5\u00a0million, respectively, attributable to the J&J acquisition. This does not include the total direct transaction and integration costs of $17.5\u00a0million incurred during the first quarter of 2024 in connection with the J&J acquisition, which are included in the unaudited pro forma results. ", "entities": [ { "start_character": 148, "end_character": 152, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 41400000.0 }, { "start_character": 163, "end_character": 166, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -300000.0 }, { "start_character": 180, "end_character": 183, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001271833-24-000003", "filing_date": 1706857982000, "quarter_ending": "20231231", "company_name": "CCO HOLDINGS LLC", "text": "The Company's government assistance during the years ending December\u00a031, 2023 and 2022 primarily consists of federal subsidies from the Rural Development Opportunity Fund (\u201cRDOF\u201d) and state broadband grants primarily funded by the American Rescue Plan Act of 2021 (\u201cARPA\u201d). The Company was awarded approximately $1.2\u00a0billion in federal subsidies in phase I of the RDOF auction to be received monthly over ten years to deploy and operate broadband services to unserved communities to more than one million estimated passings. For accounting purposes, RDOF subsidies are recorded as other revenue since the primary conditions for the receipt of the subsidies are the build out and operation of the broadband network over the ten years. During the years ended December\u00a031, 2023 and 2022, other revenues included approximately $116\u00a0million and $107\u00a0million of RDOF subsidy revenue, respectively. ", "entities": [ { "start_character": 827, "end_character": 830, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 116000000.0 }, { "start_character": 844, "end_character": 847, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 107000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001065059-24-000031", "filing_date": 1715187717000, "quarter_ending": "20240331", "company_name": "CENTRUS ENERGY CORP", "text": "In the three months ended March 31, 2024, one customer in the LEU segment individually represented $18.9 million of revenue and one customer in the Technical Solutions segment individually represented $19.8 million of revenue. ", "entities": [ { "start_character": 100, "end_character": 104, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 18900000.0 }, { "start_character": 202, "end_character": 206, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 19800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001324404-24-000008", "filing_date": 1708619593000, "quarter_ending": "20231231", "company_name": "CF Industries Holdings, Inc.", "text": "From time to time, we will enter the marketplace to purchase product in order to satisfy the obligations of our customer contracts. When we purchase product for this purpose, we are the principal in the transaction and recognize revenue on a gross basis. As discussed in Note 10\u2014Equity Method Investment, we have transactions in the normal course of business with PLNL, reflecting our obligation to purchase 50% of the ammonia produced by PLNL at current market prices. Other than products purchased from PLNL, products purchased in the marketplace in order to satisfy the obligations of our customers were not material during 2023 and 2022, and $68\u00a0million for 2021.", "entities": [ { "start_character": 647, "end_character": 649, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 68000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001324404-24-000014", "filing_date": 1714653705000, "quarter_ending": "20240331", "company_name": "CF Industries Holdings, Inc.", "text": "For the three months ended March 31, 2024, we recorded an income tax provision of $62 million on pre-tax income of $300 million, or an effective tax rate of 20.7%, compared to an income tax provision of $169 million on pre-tax income of $819\u00a0million, or an effective tax rate of 20.6%, for the three months ended March 31, 2023. ", "entities": [ { "start_character": 116, "end_character": 119, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 300000000.0 }, { "start_character": 238, "end_character": 241, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 819000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-011279", "filing_date": 1710437869000, "quarter_ending": "20240131", "company_name": "CHAMPIONS ONCOLOGY, INC.", "text": "The Company's liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. Recently, the Company has met these cash requirements through cash on hand, working capital management, and sales of products and services. In the past, the Company has also received proceeds from certain private placements and public offerings of its securities. For the nine months ended January\u00a031, 2024, the Company had a net loss of approximately $7.2 million and cash used in operations of approximately $4.3 million. As of January\u00a031, 2024, the Company had an accumulated deficit of approximately $84.5 million and cash on hand of approximately $4.5 million. The Company believes that cash on hand, together with expected cash to be provided from operations during fiscal year 2025, are adequate to fund operations through at least 12 months from the filing of this Quarterly Report on Form 10-Q (this \"Report\"). However, should the Company's revenue expectations not materialize, the Company believes it has cost reduction strategies that could be implemented without disrupting the business or restructuring the Company. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.", "entities": [ { "start_character": 558, "end_character": 561, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -7200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140361-24-024560", "filing_date": 1715014919000, "quarter_ending": "20240331", "company_name": "CHARLES & COLVARD LTD", "text": "The Company\u2019s accompanying condensed consolidated\n financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of obligations in the normal course of business. However, for the nine months ended March 31, 2024, the Company\n had losses of $9.04 million and cash flow used in operations of $6.1 million. These factors and particularly our recent cash burn rate when combined with our existing cash and cash equivalents and availability of our short-term resources raise\n substantial doubt about the Company\u2019s ability to continue as a going concern for one year from the date the financial statements are issued.", "entities": [ { "start_character": 337, "end_character": 341, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9040000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000892553-24-000096", "filing_date": 1714753659000, "quarter_ending": "20240331", "company_name": "CHART INDUSTRIES INC", "text": "The convertible note hedge offsets any dilution upon actual conversion of the 2024 Notes up to a common stock price of\u00a0$71.775 per share. The hedge cannot be taken into account under U.S. GAAP because it is anti-dilutive. If the hedge could have been considered, it would have reduced the diluted shares by 2.48 for the three months ended March 31, 2024. For further information, refer to Note 9, \u201cDebt and Credit Arrangements.\u201d", "entities": [ { "start_character": 309, "end_character": 313, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 2480000.0 } ] }, { "form_type": "10-K", "accession_number": "0001091667-24-000028", "filing_date": 1706857383000, "quarter_ending": "20231231", "company_name": "CHARTER COMMUNICATIONS, INC. /MO/", "text": "The Company's government assistance during the years ending December\u00a031, 2023 and 2022 primarily consists of federal subsidies from the Rural Development Opportunity Fund (\u201cRDOF\u201d) and state broadband grants primarily funded by the American Rescue Plan Act of 2021 (\u201cARPA\u201d). The Company was awarded approximately $1.2\u00a0billion in federal subsidies in phase I of the RDOF auction to be received monthly over ten years to deploy and operate broadband services to unserved communities to more than one million estimated passings. For accounting purposes, RDOF subsidies are recorded as other revenue since the primary conditions for the receipt of the subsidies are the build out and operation of the broadband network over the ten years. During the years ended December\u00a031, 2023 and 2022, other revenues included approximately $116\u00a0million and $107\u00a0million of RDOF subsidy revenue, respectively. ", "entities": [ { "start_character": 827, "end_character": 830, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 116000000.0 }, { "start_character": 844, "end_character": 847, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 107000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021732", "filing_date": 1715186774000, "quarter_ending": "20240331", "company_name": "CHESAPEAKE UTILITIES CORP", "text": "For the three months ended March 31, 2024, the Company\u2019s consolidated results include $35.9 million of operating revenue and net income of $4.2 million attributable to FCG which includes $0.9 million of transaction and transition-related expenses. ", "entities": [ { "start_character": 87, "end_character": 91, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 35900000.0 }, { "start_character": 140, "end_character": 143, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000093410-24-000021", "filing_date": 1714648485000, "quarter_ending": "20240331", "company_name": "CHEVRON CORP", "text": "The income tax expense decreased $543 million between quarterly periods from $2.9 billion in 2023 to $2.4 billion in 2024. The company\u2019s income before income tax expense decreased $1.6 billion from $9.5 billion in 2023 to $7.9 billion in 2024, primarily due to lower downstream margins and natural gas realizations, partly offset by higher upstream sales volumes in the U.S. The company\u2019s effective tax rate decreased slightly between quarterly periods from 31 percent in 2023 to 30 percent in 2024. The change in effective tax rate is primarily due to mix effects resulting from the absolute level of earnings or losses and whether they arose in higher or lower tax rate jurisdictions.", "entities": [ { "start_character": 199, "end_character": 202, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 9500000000.0 }, { "start_character": 223, "end_character": 226, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7900000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001046311-24-000010", "filing_date": 1708447203000, "quarter_ending": "20231231", "company_name": "CHOICE HOTELS INTERNATIONAL INC /DE", "text": "Royalty, licensing and management fees and other revenues from franchised and managed properties are presented net of intersegment revenues of $11.1 million, $5.5\u00a0million, and $2.9\u00a0million for the years ended December 31, 2023, 2022, and 2021, respectively.", "entities": [ { "start_character": 144, "end_character": 148, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -11100000.0 }, { "start_character": 159, "end_character": 162, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -5500000.0 }, { "start_character": 177, "end_character": 180, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -2900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001046311-24-000010", "filing_date": 1708447203000, "quarter_ending": "20231231", "company_name": "CHOICE HOTELS INTERNATIONAL INC /DE", "text": "As presented in Note 20, the Corporate & Other segment revenue amounts were $110.9 million, $108.9 million, and $45.7 million for the years ended December 31, 2023, 2022, and 2021, respectively, which are presented in other revenues and owned hotels revenues in the consolidated statements of income. The remaining revenues relate to the Hotel Franchising & Management reportable segment. ", "entities": [ { "start_character": 77, "end_character": 82, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 110900000.0 }, { "start_character": 93, "end_character": 98, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 108900000.0 }, { "start_character": 113, "end_character": 117, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 45700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001046311-24-000022", "filing_date": 1715176562000, "quarter_ending": "20240331", "company_name": "CHOICE HOTELS INTERNATIONAL INC /DE", "text": "The Company has management fee arrangements with certain of its unconsolidated affiliates. The fees earned and the payroll costs reimbursed under these arrangements totaled $1.6 million and $0.7 million for the three months ended March 31, 2024 and 2023, respectively. ", "entities": [ { "start_character": 174, "end_character": 177, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 }, { "start_character": 191, "end_character": 194, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001046311-24-000022", "filing_date": 1715176562000, "quarter_ending": "20240331", "company_name": "CHOICE HOTELS INTERNATIONAL INC /DE", "text": "Royalty, licensing and management fees and other revenues from franchised and managed properties are presented net of intersegment revenues of $2.5 million and $2.3 million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 144, "end_character": 147, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2500000.0 }, { "start_character": 161, "end_character": 164, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001046311-24-000022", "filing_date": 1715176562000, "quarter_ending": "20240331", "company_name": "CHOICE HOTELS INTERNATIONAL INC /DE", "text": "As presented in Note 11, the Corporate & Other segment revenue amounts were $35.1 million and $26.1 million for the three months ended March 31, 2024 and 2023, respectively, which are presented in other revenues and owned hotels revenues in the consolidated statements of income. The remaining revenues relate to the Hotel Franchising & Management reportable segment.", "entities": [ { "start_character": 77, "end_character": 81, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 35100000.0 }, { "start_character": 95, "end_character": 99, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 26100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000936395-24-000025", "filing_date": 1717684869000, "quarter_ending": "20240427", "company_name": "CIENA CORP", "text": "United States revenue was $1.3 billion and $1.4 billion, respectively. No other country accounted for 10% or more of total revenue for the periods indicated in the above table.", "entities": [ { "start_character": 27, "end_character": 30, "label": "revenues", "start_date_for_period": "2023-10-29", "end_date_for_period": "2024-04-27", "currency_/_unit": "iso4217:USD", "value": 1300000000.0 }, { "start_character": 44, "end_character": 47, "label": "revenues", "start_date_for_period": "2022-10-30", "end_date_for_period": "2023-04-29", "currency_/_unit": "iso4217:USD", "value": 1400000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000858877-24-000003", "filing_date": 1708447051000, "quarter_ending": "20240127", "company_name": "CISCO SYSTEMS, INC.", "text": "Our operating lease income was $15\u00a0million and $31\u00a0million for the second quarter and first six months of fiscal 2024, respectively, and $18\u00a0million and $39\u00a0million for the corresponding periods of fiscal 2023, respectively, and was included in product revenue in the Consolidated Statements of Operations.", "entities": [ { "start_character": 32, "end_character": 34, "label": "revenues", "start_date_for_period": "2023-10-29", "end_date_for_period": "2024-01-27", "currency_/_unit": "iso4217:USD", "value": 15000000.0 }, { "start_character": 48, "end_character": 50, "label": "revenues", "start_date_for_period": "2023-07-30", "end_date_for_period": "2024-01-27", "currency_/_unit": "iso4217:USD", "value": 31000000.0 }, { "start_character": 138, "end_character": 140, "label": "revenues", "start_date_for_period": "2022-10-30", "end_date_for_period": "2023-01-28", "currency_/_unit": "iso4217:USD", "value": 18000000.0 }, { "start_character": 154, "end_character": 156, "label": "revenues", "start_date_for_period": "2022-07-31", "end_date_for_period": "2023-01-28", "currency_/_unit": "iso4217:USD", "value": 39000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000858877-24-000007", "filing_date": 1716309443000, "quarter_ending": "20240427", "company_name": "CISCO SYSTEMS, INC.", "text": "Our operating lease income was $14\u00a0million and $45\u00a0million for the third quarter and first nine months of fiscal 2024, respectively, and $18\u00a0million and $56\u00a0million for the corresponding periods of fiscal 2023, respectively, and was included in product revenue in the Consolidated Statements of Operations.", "entities": [ { "start_character": 32, "end_character": 34, "label": "revenues", "start_date_for_period": "2024-01-28", "end_date_for_period": "2024-04-27", "currency_/_unit": "iso4217:USD", "value": 14000000.0 }, { "start_character": 48, "end_character": 50, "label": "revenues", "start_date_for_period": "2023-07-30", "end_date_for_period": "2024-04-27", "currency_/_unit": "iso4217:USD", "value": 45000000.0 }, { "start_character": 138, "end_character": 140, "label": "revenues", "start_date_for_period": "2023-01-29", "end_date_for_period": "2023-04-29", "currency_/_unit": "iso4217:USD", "value": 18000000.0 }, { "start_character": 154, "end_character": 156, "label": "revenues", "start_date_for_period": "2022-07-31", "end_date_for_period": "2023-04-29", "currency_/_unit": "iso4217:USD", "value": 56000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000831001-24-000033", "filing_date": 1708708234000, "quarter_ending": "20231231", "company_name": "CITIGROUP INC", "text": "(3)\u00a0\u00a0\u00a0\u00a0Total revenues for the U.K. were approximately $7.6\u00a0billion, $9.2\u00a0billion and $7.4\u00a0billion for 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 55, "end_character": 58, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 7600000000.0 }, { "start_character": 69, "end_character": 72, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9200000000.0 }, { "start_character": 86, "end_character": 89, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7400000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000759944-24-000039", "filing_date": 1708099360000, "quarter_ending": "20231231", "company_name": "CITIZENS FINANCIAL GROUP INC/RI", "text": "In addition, the supplemental pro forma financial information includes non-recurring acquisition-related costs of $335 million incurred during the year ended December 31, 2022, as summarized in the following table. These costs, along with the $13 million incurred during 2021, are included in the first quarter of 2021 for the purpose of reporting supplemental pro forma financial information presented above.", "entities": [ { "start_character": 115, "end_character": 118, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 335000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001764046-24-000063", "filing_date": 1715148313000, "quarter_ending": "20240331", "company_name": "CLARIVATE PLC", "text": "During the three months ended March 31, 2024 and 2023, we recognized an income tax provision of $15.0 on loss before income taxes of $60.0 and an income tax benefit of $63.6 on loss before income taxes of $20.1, respectively. The overall change in tax expense is primarily due to the $70.4 tax benefit recorded on the settlement of an open tax dispute during the three months ended March 31, 2023, and due to the change in the mix of taxing jurisdictions in which pre-tax profits and losses were recognized.", "entities": [ { "start_character": 134, "end_character": 138, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -60000000.0 }, { "start_character": 206, "end_character": 210, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -20100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001156375-24-000072", "filing_date": 1714571731000, "quarter_ending": "20240331", "company_name": "CME GROUP INC.", "text": "In the first quarter of 2024 and 2023, earnings from cash performance bond and guaranty fund contributions were $1,036.7\u00a0million and $1,256.3\u00a0million, respectively. In the first quarter of 2024 and 2023, expense related to the distribution of interest earned on collateral reinvestments were $967.4\u00a0million and $1,163.5\u00a0million, respectively. The earnings from cash performance bonds and guaranty fund contributions are included in investment income and the expense related to the distribution of interest earned is included in other non-operating income (expense) on the consolidated statements of income. ", "entities": [ { "start_character": 113, "end_character": 120, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1036700000.0 }, { "start_character": 134, "end_character": 141, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1256300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001070412-24-000027", "filing_date": 1714043042000, "quarter_ending": "20240331", "company_name": "CNX Resources Corp", "text": "(A)\u00a0\u00a0\u00a0\u00a0Included in Natural Gas, NGLs and Oil Revenue are sales of $42,909 to NRG Business Marketing LLC (formerly Direct Energy Business Marketing LLC), which comprises over 10% of revenue from contracts with external customers for the period.", "entities": [ { "start_character": 67, "end_character": 73, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 42909000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001070412-24-000027", "filing_date": 1714043042000, "quarter_ending": "20240331", "company_name": "CNX Resources Corp", "text": "(D)\u00a0\u00a0\u00a0\u00a0Included in Natural Gas, NGLs and Oil Revenue are sales of $55,101 to Direct Energy Business Marketing LLC, which comprises over 10% of revenue from contracts with external customers for the period.", "entities": [ { "start_character": 67, "end_character": 73, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 55101000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007787", "filing_date": 1709189992000, "quarter_ending": "20231231", "company_name": "COMPASS Pathways plc", "text": "The Company has incurred recurring losses since its inception, including net losses of $118.5 million and $91.5 million for the years ended December\u00a031, 2023 and 2022, respectively. In addition, as of December\u00a031, 2023, the Company had an accumulated deficit of $379.6 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of December\u00a031, 2023 of $220.2 million, together with the net proceeds raised to date during the first quarter, will be sufficient to fund its operating expenses and capital expenditure requirements into late 2025. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company\u2019s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company\u2019s business, results of operations, and financial conditions.", "entities": [ { "start_character": 88, "end_character": 93, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -118500000.0 }, { "start_character": 107, "end_character": 111, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -91500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021351", "filing_date": 1715150759000, "quarter_ending": "20240331", "company_name": "COMPASS Pathways plc", "text": "The Company has incurred recurring losses since its inception, including net losses of $35.2 million and $24.2 million for the three months ended March\u00a031, 2024 and 2023, respectively. In addition, as of March\u00a031, 2024, the Company had an accumulated deficit of $414.8 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes the cash and cash equivalents on hand as of March\u00a031, 2024 of $262.9 million, will be sufficient to fund its operating expenses and capital expenditure requirements into 2026. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company\u2019s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company\u2019s business, results of operations, and financial conditions.", "entities": [ { "start_character": 88, "end_character": 92, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -35200000.0 }, { "start_character": 106, "end_character": 110, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -24200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-002325", "filing_date": 1704818375000, "quarter_ending": "20230630", "company_name": "COMSovereign Holding Corp.", "text": "During\nthe three and six months ended June 30, 2023, the Company recorded $184,992 and $369,984, respectively, of dividends paid or payable\nto the holders of the 9.25% Series A Preferred Stock, compared to $184,992 and $308,320 for the three and six months ended June 30, 2022.", "entities": [ { "start_character": 75, "end_character": 82, "label": "eps", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-06-30", "currency_/_unit": "iso4217:USD", "value": 184992.0 }, { "start_character": 88, "end_character": 95, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-06-30", "currency_/_unit": "iso4217:USD", "value": 369984.0 }, { "start_character": 207, "end_character": 214, "label": "eps", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-06-30", "currency_/_unit": "iso4217:USD", "value": 184992.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-002331", "filing_date": 1704818821000, "quarter_ending": "20230930", "company_name": "COMSovereign Holding Corp.", "text": "During\nthe three and nine months ended September 30, 2023, the Company recorded $184,992 and $554,976, respectively, of dividends paid or payable\nto the holders of the 9.25% Series A Preferred Stock, compared to $184,992 and $493,312 for the three and nine months ended September\n30, 2022.", "entities": [ { "start_character": 81, "end_character": 88, "label": "eps", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 184992000.0 }, { "start_character": 94, "end_character": 101, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 554976000.0 }, { "start_character": 213, "end_character": 220, "label": "eps", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 184992000.0 }, { "start_character": 226, "end_character": 233, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 493312000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000023197-24-000080", "filing_date": 1718698409000, "quarter_ending": "20240430", "company_name": "COMTECH TELECOMMUNICATIONS CORP /DE/", "text": "Weighted average stock options, RSUs and restricted stock outstanding of 930,000 and 956,000 shares for the three months ended April 30, 2024 and 2023, respectively, and 1,067,000 and 1,001,000 shares for the nine months ended April 30, 2024 and 2023, respectively, were not included in our diluted EPS calculation because their effect would have been anti-dilutive. Our EPS calculations exclude 469,000 and 429,000 weighted average performance shares outstanding for the three months ended April 30, 2024 and 2023, respectively, and 624,000 and 384,000 for the nine months ended April 30, 2024 and 2023, respectively, as the performance conditions have not yet been satisfied. However, the numerator for EPS calculations for each respective period is reduced by the compensation expense related to these awards.", "entities": [ { "start_character": 396, "end_character": 403, "label": "eps", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "xbrli:shares", "value": 469000.0 }, { "start_character": 408, "end_character": 415, "label": "eps", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "xbrli:shares", "value": 429000.0 }, { "start_character": 534, "end_character": 541, "label": "eps", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "xbrli:shares", "value": 624000.0 }, { "start_character": 546, "end_character": 553, "label": "eps", "start_date_for_period": "2022-08-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "xbrli:shares", "value": 384000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000023197-24-000080", "filing_date": 1718698409000, "quarter_ending": "20240430", "company_name": "COMTECH TELECOMMUNICATIONS CORP /DE/", "text": "Over the past three fiscal years, we incurred operating losses of $14,660,000, $33,752,000, and $68,298,000 in fiscal 2023, 2022 and 2021, respectively. More recently, we recognized an operating loss of $3,470,000 in the three months ended April 30, 2024 and operating income of $1,589,000 in the nine months ended April 30, 2024. In addition, over the past three fiscal years, net cash used in operating activities was $4,433,000 and $40,638,000 in fiscal 2023 and 2021, respectively, and net cash provided by operating activities was $1,997,000 in fiscal 2022. More recently, net cash used in operating activities was $44,998,000 in the nine months ended April 30, 2024.", "entities": [ { "start_character": 67, "end_character": 77, "label": "ebit", "start_date_for_period": "2022-08-01", "end_date_for_period": "2023-07-31", "currency_/_unit": "iso4217:USD", "value": -14660000.0 }, { "start_character": 80, "end_character": 90, "label": "ebit", "start_date_for_period": "2021-08-01", "end_date_for_period": "2022-07-31", "currency_/_unit": "iso4217:USD", "value": -33752000.0 }, { "start_character": 97, "end_character": 107, "label": "ebit", "start_date_for_period": "2020-08-01", "end_date_for_period": "2021-07-31", "currency_/_unit": "iso4217:USD", "value": -68298000.0 }, { "start_character": 204, "end_character": 213, "label": "ebit", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -3470000.0 }, { "start_character": 280, "end_character": 289, "label": "ebit", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 1589000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019230", "filing_date": 1715702754000, "quarter_ending": "20240331", "company_name": "CONDUIT PHARMACEUTICALS INC.", "text": "In\naccordance with Accounting Standards Codification (\u201cASC\u201d) 205-40, Going Concern, the Company has evaluated whether there\nare conditions and events, considered in the aggregate, that raise substantial doubt about the Company\u2019s ability to continue as\na going concern within one year after the date the financial statements are issued. Since its inception, the Company has generated significant\nlosses and as of March 31, 2024, the Company had an accumulated deficit of $14.9 million. For the three months ended March 31, 2024 and\n2023, the Company had net losses of $3.6 million and $1.7 million, respectively, and cash used in operating activities of $2.4 million\nand $2.0 million, respectively.", "entities": [ { "start_character": 568, "end_character": 571, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3600000.0 }, { "start_character": 585, "end_character": 588, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001223389-24-000028", "filing_date": 1713441137000, "quarter_ending": "20240131", "company_name": "CONNS INC", "text": "For the years ended January\u00a031, 2024, 2023 and 2022, the amount of overhead allocated to each segment reflected in SG&A was $32.5 million, $31.7 million and $40.6 million, respectively. For the years ended January\u00a031, 2024, 2023 and 2022, the amount of reimbursement made to the retail segment by the credit segment was $25.0 million, $26.3 million and $28.3 million, respectively.", "entities": [ { "start_character": 322, "end_character": 326, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": 25000000.0 }, { "start_character": 337, "end_character": 341, "label": "revenues", "start_date_for_period": "2022-02-01", "end_date_for_period": "2023-01-31", "currency_/_unit": "iso4217:USD", "value": 26300000.0 }, { "start_character": 355, "end_character": 359, "label": "revenues", "start_date_for_period": "2021-02-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 28300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001163165-24-000010", "filing_date": 1708005675000, "quarter_ending": "20231231", "company_name": "CONOCOPHILLIPS", "text": "From the acquisition date through December 31, 2021, \u201cTotal Revenues and Other Income\u201d and \u201cNet Income (Loss)\u201d associated with the acquired Concho business were approximately $6,571 million and $2,330 million, respectively. The results associated with the Concho business for the same period include a before- and after-tax loss of $305 million and $233 million, respectively, on the acquired derivative contracts. The before-tax loss is recorded within \u201cTotal Revenues and Other Income\u201d on our consolidated income statement. ", "entities": [ { "start_character": 195, "end_character": 200, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2330000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001163165-24-000010", "filing_date": 1708005675000, "quarter_ending": "20231231", "company_name": "CONOCOPHILLIPS", "text": "From the acquisition date through December 31, 2023, \"Total Revenues and Other Income\" and \"Net Income (Loss)\" associated with the acquired assets were $572\u00a0million and $119\u00a0million, respectively.", "entities": [ { "start_character": 170, "end_character": 173, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 119000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001710366-24-000006", "filing_date": 1707497276000, "quarter_ending": "20231231", "company_name": "CONSOL Energy Inc.", "text": "The SPV is a non-guarantor subsidiary of the Revolving Credit Facility, and the SPV holds the assets pledged to the lender in the securitization facility. The SPV had total assets of $147,918 and $158,877, comprised mainly of $147,612 and $158,127 trade receivables, net, at December\u00a031, 2023 and 2022, respectively. For the years ended December\u00a031, 2023, 2022 and 2021, net income (loss) attributable to the SPV was $5,129, $12,330 and $(54), respectively, which primarily reflected intercompany fees related to purchasing the receivables, which are eliminated in the Consolidated Financial Statements contained within this Annual Report on Form 10-K. During the years ended December\u00a031, 2023, 2022 and 2021, there were no borrowings or payments under the accounts receivable securitization facility. See Note 11 - Accounts Receivable Securitization for additional information. ", "entities": [ { "start_character": 418, "end_character": 423, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5129000.0 }, { "start_character": 426, "end_character": 432, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 12330000.0 }, { "start_character": 439, "end_character": 441, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -54000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001710366-24-000012", "filing_date": 1715065012000, "quarter_ending": "20240331", "company_name": "CONSOL Energy Inc.", "text": "The SPV is not a guarantor of the Revolving Credit Facility, and the SPV holds the assets pledged to the lender in the securitization facility. The SPV had total assets of $160,278 and $147,918, comprised mainly of $159,864 and $147,612 trade receivables, net, at March\u00a031, 2024 and December\u00a031, 2023, respectively. Net income attributable to the SPV was $46 and $2,622 for the three months ended March\u00a031, 2024 and 2023, respectively, which primarily reflected intercompany fees related to purchasing the receivables, which are eliminated in the Consolidated Financial Statements contained within this Quarterly Report on Form 10-Q. During the three months ended March\u00a031, 2024 and 2023, there were no borrowings or payments under the accounts receivable securitization facility. See Note 9 - Accounts Receivable Securitization for additional information.", "entities": [ { "start_character": 356, "end_character": 358, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 46000.0 }, { "start_character": 364, "end_character": 369, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2622000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000900075-24-000007", "filing_date": 1709054696000, "quarter_ending": "20240131", "company_name": "COPART INC", "text": "$8.3 million for the six months ended January 31, 2024 and 2023, respectively, and is included within Service revenues on the consolidated statements of income.", "entities": [ { "start_character": 1, "end_character": 4, "label": "revenues", "start_date_for_period": "2022-08-01", "end_date_for_period": "2023-01-31", "currency_/_unit": "iso4217:USD", "value": 8300000.000000001 } ] }, { "form_type": "10-Q", "accession_number": "0000900075-24-000007", "filing_date": 1709054696000, "quarter_ending": "20240131", "company_name": "COPART INC", "text": "The cost of the leased space as of January\u00a031, 2024 and July\u00a031, 2023 was $50.3 million and $51.2 million, respectively.\u00a0The accumulated depreciation associated with the leased assets as of January\u00a031, 2024 and July\u00a031, 2023 was $4.1 million and $3.8 million, respectively. Both the leased assets and accumulated depreciation are included in Property and equipment, net on the consolidated balance sheet. Rental income from these operating leases was $4.2 million and $4.1 million for the three months ended January 31, 2024 and 2023, respectively,", "entities": [ { "start_character": 452, "end_character": 455, "label": "revenues", "start_date_for_period": "2023-11-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": 4200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000900075-24-000014", "filing_date": 1716483732000, "quarter_ending": "20240430", "company_name": "COPART INC", "text": "$12.3 million for the nine months ended April 30, 2024 and 2023, respectively, and is included within Service revenues on the consolidated statements of income.", "entities": [ { "start_character": 1, "end_character": 5, "label": "revenues", "start_date_for_period": "2022-08-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 12300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000900075-24-000014", "filing_date": 1716483732000, "quarter_ending": "20240430", "company_name": "COPART INC", "text": "The cost of the leased space as of April\u00a030, 2024 and July\u00a031, 2023 was $50.3 million and $51.2 million, respectively.\u00a0The accumulated depreciation associated with the leased assets as of April\u00a030, 2024 and July\u00a031, 2023 was $4.4 million and $3.8 million, respectively. Both the leased assets and accumulated depreciation are included in Property and equipment, net on the consolidated balance sheet. Rental income from these operating leases was $4.4 million and $4.0 million for the three months ended April 30, 2024 and 2023, respectively,", "entities": [ { "start_character": 465, "end_character": 468, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001024305-24-000023", "filing_date": 1715098934000, "quarter_ending": "20240331", "company_name": "COTY INC.", "text": "The effective tax rate of (158.8)% for the three months ended March 31, 2024 was primarily due to a benefit of $8.5 on the resolution of foreign uncertain tax positions compared to $3.4 of income in the period.", "entities": [ { "start_character": 182, "end_character": 185, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000025232-24-000004", "filing_date": 1707322659000, "quarter_ending": "20231231", "company_name": "COUSINS PROPERTIES INC", "text": "The Company recognizes contractual revenues from leases on a straight-line basis over the term of the respective lease. Our leases regularly include allowances for tenant improvements. If we determine the improvements are our assets, we capitalize the cost of the improvements and recognize depreciation expense associated with such improvements over the shorter of the estimated useful life or the term of the lease. If the improvements are tenant assets, we defer the cost of improvements funded by us as a lease incentive asset and amortize it as a reduction of rental revenue over the term of the lease. Our determination of whether improvements are our assets or tenant assets also affects when we commence revenue recognition in connection with a lease. The Company records deferred revenue for the portion of company owned tenant improvements funded by or reimbursed by tenants and amortizes this amount on a straight-line basis into rental income over the term of the related lease. As of December\u00a031, 2023 and 2022, the Company had unamortized deferred income related to tenant-funded tenant improvements of $141.0 million and $100.1 million, respectively, included in deferred income on the consolidated balance sheets. During 2023, 2022, and 2021, the Company recognized $20.0\u00a0million, $11.2\u00a0million, and $5.4\u00a0million, respectively, in revenues related to the amortization of tenant-funded tenant improvements.", "entities": [ { "start_character": 1283, "end_character": 1287, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 20000000.0 }, { "start_character": 1298, "end_character": 1302, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 11200000.0 }, { "start_character": 1317, "end_character": 1320, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 5400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000025232-24-000004", "filing_date": 1707322659000, "quarter_ending": "20231231", "company_name": "COUSINS PROPERTIES INC", "text": "Certain leases also provide for percentage rents based upon the level of sales achieved by the lessee. Percentage rents are recognized once the specified sales target is achieved. In addition, leases typically provide for reimbursement of the tenants' share of real estate taxes, insurance, and other operating expenses to the Company. Operating expense reimbursements are recognized as the related expenses are incurred. During 2023, 2022, and 2021, the Company recognized $163.2 million, $160.7 million, and $155.5 million, respectively, in revenues from tenants related to operating expense reimbursements. ", "entities": [ { "start_character": 475, "end_character": 480, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 163200000.0 }, { "start_character": 491, "end_character": 496, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 160700000.0 }, { "start_character": 511, "end_character": 516, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 155500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001624794-24-000032", "filing_date": 1716445787000, "quarter_ending": "20240331", "company_name": "CSW INDUSTRIALS, INC.", "text": "For the year ended March 31, 2024, 2023 and 2022, the Whitmore JV generated net income of $1.8 million, $0.3 million and $1.9 million, respectively. ", "entities": [ { "start_character": 91, "end_character": 94, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1800000.0 }, { "start_character": 105, "end_character": 108, "label": "earnings", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 122, "end_character": 125, "label": "earnings", "start_date_for_period": "2021-04-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001058623-24-000077", "filing_date": 1714723478000, "quarter_ending": "20240331", "company_name": "CUMULUS MEDIA INC", "text": "For the three months ended March\u00a031, 2024, the Company recorded an income tax expense of $1.5\u00a0million on pre-tax book loss of $12.7\u00a0million, resulting in an effective tax rate of approximately (11.8)%. For the three months ended March\u00a031, 2023, the Company recorded an income tax expense of $5.8\u00a0million on pre-tax book loss of $15.7\u00a0million, resulting in an effective tax rate of approximately (37.1)%.", "entities": [ { "start_character": 127, "end_character": 131, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -12700000.0 }, { "start_character": 329, "end_character": 333, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -15700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001108205-24-000010", "filing_date": 1707408077000, "quarter_ending": "20231231", "company_name": "CURIS INC", "text": "The Company will require substantial funds to maintain its research and development program and support operations. The Company has incurred losses and cash outflows from operations since its inception. The Company had an accumulated deficit of approximately $1.2 billion as of December 31, 2023 and incurred a net loss of $47.4 million and used $38.4 million of cash in operations for the year ended December 31, 2023. The Company expects to continue to generate operating losses in the foreseeable future. ", "entities": [ { "start_character": 324, "end_character": 328, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -47400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001108205-24-000033", "filing_date": 1715070621000, "quarter_ending": "20240331", "company_name": "CURIS INC", "text": "The Company will require substantial funds to maintain its research and development programs and support operations. The Company has incurred losses and cash outflows from operations since its inception. The Company had an accumulated deficit of $1.2 billion as of March 31, 2024, and incurred a net loss of $11.9 million and used $13.2 million of cash in operations for the three months ended March 31, 2024. The Company expects to continue to generate operating losses in the foreseeable future. ", "entities": [ { "start_character": 309, "end_character": 313, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -11900000.0 } ] }, { "form_type": "10-K", "accession_number": "0000026324-24-000004", "filing_date": 1708418606000, "quarter_ending": "20231231", "company_name": "CURTISS WRIGHT CORP", "text": "The net impact of the error resulted in an overstatement of previously reported total net sales and net earnings of approximately $5\u00a0million and $4\u00a0million, respectively, for the year ended December 31, 2021 and an overstatement of previously reported total net sales and net earnings of approximately $8\u00a0million and ", "entities": [ { "start_character": 147, "end_character": 148, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -4000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-022628", "filing_date": 1715357753000, "quarter_ending": "20231231", "company_name": "CUTERA INC", "text": "When preparing financial statements, management has the responsibility to evaluate if the Company has adequate liquidity to continue to operate for the next twelve months. In performing this assessment, management considered the Company's current financial condition and liquidity sources, including current funds, forecasted future cash flows and unconditional obligations due over the next twelve months. In addition, management evaluated the history of the Company's financial performance, and determined that the Company has had a historic trend of operating losses, which continues to have an unfavorable impact on the Company's overall liquidity. Most recently, the Company reported net losses of $162.8\u00a0million and $82.3\u00a0million for the years ended December\u00a031, 2023 and 2022.", "entities": [ { "start_character": 705, "end_character": 710, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -162800000.0 }, { "start_character": 724, "end_character": 728, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -82300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022635", "filing_date": 1715358081000, "quarter_ending": "20240331", "company_name": "CUTERA INC", "text": "When preparing financial statements, management has the responsibility to evaluate if the Company has adequate liquidity to continue to operate for the next twelve months. In performing this assessment, management considered the Company's current financial condition and liquidity sources, including current funds, forecasted future cash flows and unconditional obligations due over the next twelve months. In addition, management evaluated the history of the Company's financial performance, and determined that the Company has had a historic trend of operating losses, which continues to have an unfavorable impact on the Company's overall liquidity. Most recently, the Company reported net losses of $22.8 million for the three months ended March\u00a031, 2024 and $162.8\u00a0million for the year ended December\u00a031, 2023.", "entities": [ { "start_character": 704, "end_character": 708, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -22800000.0 }, { "start_character": 764, "end_character": 769, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -162800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011730", "filing_date": 1711641672000, "quarter_ending": "20231231", "company_name": "CVD EQUIPMENT CORP", "text": "Including\nthe loss on disposition of $0.2 million, the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for\nthe year ended December 31, 2023. The total assets and total liabilities of the Tantaline subsidiary were $1.1 million and $0.4 million\nas of December 31, 2022.", "entities": [ { "start_character": 115, "end_character": 118, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001699136-24-000007", "filing_date": 1709224560000, "quarter_ending": "20231231", "company_name": "Cactus, Inc.", "text": "From acquisition date through December 31, 2023, FlexSteel produced revenue of $340.2 million and net income of $61.7 million. The pro forma financial information below represents the combined results of operations for the years ended December 31, 2023 and 2022, as if the acquisition had occurred as of January 1, 2022. The unaudited pro forma combined financial information includes, where applicable, adjustments for additional amortization expense related to the fair value step-up of intangible assets, additional inventory fair value step-up expense, additional depreciation expense associated with adjusting property and equipment to fair value, decreases in interest expense due to modification of borrowings in conjunction with the acquisition and associated tax-related impacts of adjustments. These pro forma adjustments are based on available information as of the date hereof and upon assumptions that we believe are reasonable to reflect the impact of the FlexSteel acquisition on our historical financial information on a supplemental pro forma basis. Adjustments do not include the elimination of transaction-related costs incurred or any costs related to integration activities, cost savings or synergies that have been or may be achieved by the combined business. The unaudited pro forma financial information is presented for informational purposes only and is neither indicative of the results of operations that would have occurred if the acquisition had taken place at the beginning of the period presented nor indicative of future operating results.", "entities": [ { "start_character": 113, "end_character": 117, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 61700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-021133", "filing_date": 1709919588000, "quarter_ending": "20231231", "company_name": "Cadrenal Therapeutics, Inc.", "text": "The\naccompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the\nrealization of assets and settlement of liabilities and commitments in the normal course of business. The financial statements do not\nreflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the\nCompany is unable to continue as a going concern. Since inception, the Company has incurred operating losses, and negative cash flows\nfrom operations. For the year ended December 31, 2023, the Company had a net loss of $8,357,086, which included $4,682,454 of non-cash\nexpenses. Cash used in operations for the year ended December 31, 2023 totaled $3,530,323. As of December 31, 2023, the Company had cash\nand cash equivalents of $8,402,500, net working capital of $7,665,298, and an accumulated deficit of $15,071,415.", "entities": [ { "start_character": 627, "end_character": 636, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8357086.0 } ] }, { "form_type": "10-K", "accession_number": "0001627282-24-000039", "filing_date": 1713217767000, "quarter_ending": "20231231", "company_name": "CaliberCos Inc.", "text": "Consolidated funds \u2013 other revenue includes rental revenue of $4.0\u00a0million and $3.6\u00a0million for the years ended December 31, 2023 and 2022, respectively. Rental revenue includes the revenues generated primarily by the rental operations of the residential (multi-family and single-family) and commercial properties of our consolidated funds. ", "entities": [ { "start_character": 63, "end_character": 66, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 }, { "start_character": 80, "end_character": 83, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001627282-24-000058", "filing_date": 1715277886000, "quarter_ending": "20240331", "company_name": "CaliberCos Inc.", "text": "Consolidated funds \u2013 other revenue includes rental revenue of $0.4\u00a0million and $1.0\u00a0million, for the three months ended March 31, 2024 and 2023, respectively. Rental revenue includes the revenues generated primarily by the rental operations of the residential (multi-family and single-family) and commercial properties of our consolidated funds. ", "entities": [ { "start_character": 63, "end_character": 66, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 80, "end_character": 83, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023563", "filing_date": 1715789930000, "quarter_ending": "20240331", "company_name": "Canoo Inc.", "text": "In connection with the Walmart EV Fleet Purchase Agreement, the Company entered into a Warrant Issuance Agreement with Walmart pursuant to which the Company issued to Walmart a Warrant to purchase an aggregate of 2.7\u00a0million shares of Common Stock, subject to certain anti-dilutive adjustments, at an exercise price of $49.45 per share, which represented approximately 20.0% ownership in the Company on a fully diluted basis as of the issuance date. As a result of the anti-dilution adjustments, as of March\u00a031, 2024, the Warrant is exercisable for an aggregate of 2.9 million shares of Common Stock at a per share exercise price of $44.87. The Warrant has a term of 10 years and is vested with respect to 0.7 million shares of Common Stock. The Warrant will vest quarterly in amounts proportionate with the net revenue realized by the Company from transactions with Walmart or its affiliates under the Walmart EV Fleet Purchase Agreement or enabled by any other agreement between the Company and Walmart, and any net revenue attributable to any products or services offered by Walmart or its affiliates related to the Company, until such net revenue equals $300.0\u00a0million, at which time the Warrant will have vested fully. ", "entities": [ { "start_character": 1159, "end_character": 1164, "label": "revenues", "start_date_for_period": "2022-07-11", "end_date_for_period": "2022-07-11", "currency_/_unit": "iso4217:USD", "value": 300000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010800", "filing_date": 1711040139000, "quarter_ending": "20231231", "company_name": "CareCloud, Inc.", "text": "Liquidity\nand Going Concern \u2014 Primarily due to a decline in revenue associated with our Healthcare IT segment and a goodwill impairment\nof $42 million, the Company generated a net loss of $48.7 million and had a net decrease in cash of $9.0 million for the year ended December\n31, 2023. At December 31, 2023, the Company had negative working capital of $57,000 and cash of $3.3 million. Absent any other action,\nthe Company will require additional liquidity to continue its operations over the next 12 months.", "entities": [ { "start_character": 189, "end_character": 193, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -48700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019276", "filing_date": 1715704283000, "quarter_ending": "20240331", "company_name": "CareCloud, Inc.", "text": "Liquidity\nand Going Concern \u2014 Primarily due to a decline in revenue associated with our Healthcare IT segment and a goodwill impairment\nof $42.0 million for the year ended December 31, 2023, the Company generated a net loss of $48.7 million and had a net decrease in cash\nof $9.0 million. For the three months ended March 31, 2024, the Company had a net loss of $241,000. At December 31, 2023, the Company\nhad negative working capital of $57,000 and cash of $3.3 million. At March 31, 2024, the Company had positive working capital of $474,000\nand cash of $4.1 million. Absent any other action, the Company may require additional liquidity to continue its operations over the next\n12 months.", "entities": [ { "start_character": 228, "end_character": 232, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -48700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001619856-24-000013", "filing_date": 1710174352000, "quarter_ending": "20231231", "company_name": "Caribou Biosciences, Inc.", "text": "We have incurred operating losses and negative cash flows from operations since our inception and we had an accumulated deficit of $299.3 million as of December\u00a031, 2023. During the year ended December\u00a031, 2023, we incurred a net loss of $102.1 million and used $93.3 million of cash in operating activities. We expect to continue to incur substantial losses, and our ability to achieve and sustain profitability will depend on the successful development, regulatory approval, and commercialization of our product candidates and on our generation of sufficient revenue to support our cost structure. We may never achieve profitability and, unless and until we do, we will need to continue to raise additional capital. Our management expects that existing cash, cash equivalents, and marketable securities of $372.4 million as of December\u00a031, 2023, will be sufficient to fund our current operating plan for at least the next 12 months from the date of issuance of our consolidated financial statements.", "entities": [ { "start_character": 239, "end_character": 244, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -102100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001619856-24-000038", "filing_date": 1715098525000, "quarter_ending": "20240331", "company_name": "Caribou Biosciences, Inc.", "text": "During the three months ended March 31, 2023, we recognized $1.6\u00a0million in revenue associated with the now-terminated Collaboration and License Agreement, dated February 9, 2021 (as amended, \u201cAbbVie Agreement\u201d) with AbbVie Manufacturing Management Unlimited Company (\u201cAbbVie\u201d). No revenue was recognized under the AbbVie Agreement during the three months ended March\u00a031, 2024, as the AbbVie Agreement was terminated effective October 25, ", "entities": [ { "start_character": 61, "end_character": 64, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 }, { "start_character": 279, "end_character": 281, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001619856-24-000038", "filing_date": 1715098525000, "quarter_ending": "20240331", "company_name": "Caribou Biosciences, Inc.", "text": "We have incurred operating losses and negative cash flows from operations since our inception and we had an accumulated deficit of $340.5 million as of March\u00a031, 2024. During the three months ended March\u00a031, 2024, we incurred a net loss of $41.2 million and used $37.2 million of cash in operating activities. We expect to continue to incur substantial losses, and our ability to achieve and sustain profitability will depend on the successful development, regulatory approval, and commercialization of our product candidates and on our ability to generate sufficient revenue to support our cost structure. We may never achieve profitability and, unless and until we do, we will need to continue to raise additional capital. Our management expects that existing cash, cash equivalents, and marketable securities of $345.9 million as of March\u00a031, 2024, will be sufficient to fund our current operating plan for at least the next 12 months from the date of issuance of our unaudited condensed consolidated financial statements.", "entities": [ { "start_character": 241, "end_character": 245, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -41200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001596783-23-000186", "filing_date": 1702055199000, "quarter_ending": "20230930", "company_name": "Catalent, Inc.", "text": "The Company recorded a benefit for income taxes for the three months ended September 30, 2023 of $38 million relative to loss before income taxes of $797 million. The Company recorded a provision for income taxes for the three months ended September 30, 2022 of $3 million relative to earnings before income taxes of $3 million. The income tax benefit for the quarter is primarily the result of a deferred tax benefit resulting from the impairment of goodwill during the quarter and certain discrete income tax benefits. This income tax benefit was partially reduced by a $53 million valuation allowance on domestic deferred tax assets and several unfavorable permanent tax adjustments that were fixed and not impacted by the reduced pretax earnings. Discrete items recognized during the quarter include a favorable audit settlement and equity related compensation tax benefits. The quarterly provision was also impacted by the geographic distribution of the Company's pretax income resulting from our business mix, changes in the tax impact of permanent differences, restructuring, special items, certain equity related compensation, and other discrete tax items that may have unique tax implications depending on the nature of the item.", "entities": [ { "start_character": 150, "end_character": 153, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -797000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001596783-24-000020", "filing_date": 1707920635000, "quarter_ending": "20231231", "company_name": "Catalent, Inc.", "text": "The Company recorded a benefit for income taxes for the six months ended December 31, 2023 of $14 million relative to loss before income taxes of $979 million. The Company recorded a provision for income taxes for the six months ended December 31, 2022 of $36 million relative to earnings before income taxes of $117 million. The income tax benefit for the period is primarily the result of income tax expense in select international jurisdictions and the inability to recognize income tax benefit on incremental domestic losses. ", "entities": [ { "start_character": 147, "end_character": 150, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -979000000.0 }, { "start_character": 313, "end_character": 316, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 117000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001596783-24-000020", "filing_date": 1707920635000, "quarter_ending": "20231231", "company_name": "Catalent, Inc.", "text": "The Company recorded a provision for income taxes for the three months ended December 31, 2023 of $24 million relative to loss before income taxes of $182 million. The Company recorded a provision for income taxes for the three months ended December 31, 2022 of $33 million relative to earnings before income taxes of $114 million. The income tax expense for the quarter is primarily the result of income tax expense in select international jurisdictions and the inability to recognize income tax benefit on incremental domestic losses. The quarterly provision was also impacted by the geographic distribution of the Company's pretax loss resulting from our business mix, changes in the tax impact of permanent differences, restructuring, special items, certain equity related compensation, and other discrete tax items that may have unique tax implications depending on the nature of the item.", "entities": [ { "start_character": 151, "end_character": 154, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -182000000.0 }, { "start_character": 319, "end_character": 322, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 114000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001596783-24-000033", "filing_date": 1715185430000, "quarter_ending": "20240331", "company_name": "Catalent, Inc.", "text": "The Company recorded a provision for income taxes for the three months ended March 31, 2024 of $15 million relative to loss before income taxes of $86 million. The Company recorded a benefit for income taxes for the three months ended March 31, 2023 of $55 million relative to loss before income taxes of $282 million. The income tax expense for the quarter is primarily the result of income tax expense in select international jurisdictions and the inability to recognize income tax benefit on incremental domestic losses. The quarterly provision was also impacted by the geographic distribution of the Company's pretax income resulting from our business mix, changes in the tax impact of permanent differences, restructuring, special items, certain equity related compensation, and other discrete tax items that may have unique tax implications depending on the nature of the item.", "entities": [ { "start_character": 148, "end_character": 150, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -86000000.0 }, { "start_character": 306, "end_character": 309, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -282000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001596783-24-000033", "filing_date": 1715185430000, "quarter_ending": "20240331", "company_name": "Catalent, Inc.", "text": "The Company recorded a provision for income taxes for the nine months ended March 31, 2024 of $1 million relative to loss before income taxes of $1.065 billion. The Company recorded a benefit for income taxes for the nine months ended March 31, 2023 of $19 million relative to loss before income taxes of $165 million. The income tax expense for the period is primarily the result of income tax expense in select international jurisdictions and the inability to recognize income tax benefit on incremental domestic losses. ", "entities": [ { "start_character": 146, "end_character": 151, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1065000000.0 }, { "start_character": 306, "end_character": 309, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -165000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001306830-24-000029", "filing_date": 1708705163000, "quarter_ending": "20231231", "company_name": "Celanese Corp", "text": "The amount of M&M Net sales and Earnings (loss) from continuing operations before tax consolidated by the Company since the acquisition date through December\u00a031,\u00a02022 were $430\u00a0million and $(80)\u00a0million, respectively.", "entities": [ { "start_character": 191, "end_character": 193, "label": "earnings", "start_date_for_period": "2022-11-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -80000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001341766-24-000015", "filing_date": 1709153986000, "quarter_ending": "20231231", "company_name": "Celsius Holdings, Inc.", "text": "Revenue to Pepsi amounted to $782.3 million and $142.3 million for the years ended December\u00a031, 2023 and 2022, respectively, and are included in Revenue.", "entities": [ { "start_character": 30, "end_character": 35, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 782300000.0 }, { "start_character": 49, "end_character": 54, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 142300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001341766-24-000015", "filing_date": 1709153986000, "quarter_ending": "20231231", "company_name": "Celsius Holdings, Inc.", "text": "Revenue from Sweden represented the largest foreign portion of total consolidated revenue accounting for approximately $29.3 million, $21.7 million, and $26.9 million for the years ended December\u00a031, 2023, 2022, and 2021, respectively.", "entities": [ { "start_character": 120, "end_character": 124, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 29300000.0 }, { "start_character": 135, "end_character": 139, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 21700000.0 }, { "start_character": 154, "end_character": 158, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 26900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001341766-24-000015", "filing_date": 1709153986000, "quarter_ending": "20231231", "company_name": "Celsius Holdings, Inc.", "text": "The Company recognizes revenue from the agreement over time because Qifeng simultaneously receives and consumes the benefits from the services. The Company uses the passage of time to measure progress towards satisfying its performance obligation because of its ongoing efforts in providing the exclusive license rights including providing continuous access, updates and support, to product development, brand promotion and technical expertise. Total revenue recognized under the agreement was approximately $2.2 million, $2.0 million, and $1.6 million for the years ended December\u00a031, 2023, 2022, and 2021, respectively, which is reflected in the revenues from Asia-Pacific.", "entities": [ { "start_character": 509, "end_character": 512, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2200000.0 }, { "start_character": 523, "end_character": 526, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 541, "end_character": 544, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140859-24-000019", "filing_date": 1706708249000, "quarter_ending": "20231231", "company_name": "Cencora, Inc.", "text": "Revenue from the various agreements and arrangements with WBA was $18.1 billion and $16.2 billion in the three months ended December\u00a031, 2023 and 2022, respectively. The Company\u2019s receivable from WBA, net of incentives, was $7.5 billion and $8.1 billion as of December\u00a031, 2023 and September\u00a030, 2023, respectively.", "entities": [ { "start_character": 67, "end_character": 71, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 18100000000.0 }, { "start_character": 85, "end_character": 89, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 16200000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140859-24-000072", "filing_date": 1714579646000, "quarter_ending": "20240331", "company_name": "Cencora, Inc.", "text": "Revenue from the various agreements and arrangements with WBA was $18.8 billion and $36.9 billion in the three and six months ended March\u00a031, 2024, respectively. Revenue from the various agreements and arrangements with WBA was $16.8 billion and $33.0 billion in the three and six months ended March\u00a031, 2023, respectively. The Company\u2019s receivable from WBA, net of incentives, was $7.8 billion and $8.1 billion as of March\u00a031, 2024 and September\u00a030, 2023, respectively.", "entities": [ { "start_character": 67, "end_character": 71, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 18800000000.0 }, { "start_character": 85, "end_character": 89, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 36900000000.0 }, { "start_character": 229, "end_character": 233, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 16800000000.0 }, { "start_character": 247, "end_character": 251, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 33000000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001498233-24-000021", "filing_date": 1711735192000, "quarter_ending": "20231231", "company_name": "Cepton, Inc.", "text": "The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of December\u00a031, 2023, the Company had cash and cash equivalents of $50.4 million, short-term investment of $6.0 million, and an accumulated deficit of $134.6 million. For the year ended December\u00a031, 2023, the Company incurred an operating loss of $50.7 million and had negative cash flows from operating activities of $35.5 million.", "entities": [ { "start_character": 376, "end_character": 380, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -50700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001498233-24-000035", "filing_date": 1715702777000, "quarter_ending": "20240331", "company_name": "Cepton, Inc.", "text": "Koito is an automotive tier 1 partner and investor of the Company and sales to Koito were $1.3 million and $0.9 million (67% and 58% of our total revenue) for the three months ended March\u00a031, 2024 and 2023, respectively. The accounts receivable balance from Koito was $4.7 million as of March\u00a031, 2024. This balance is inclusive of the receivable balance from realizable gain on GM project cancellation recoveries, as described in Note 17. As of December\u00a031, 2023, the accounts receivable balance from Koito was $2.1 million. ", "entities": [ { "start_character": 91, "end_character": 94, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 }, { "start_character": 108, "end_character": 111, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001498233-24-000035", "filing_date": 1715702777000, "quarter_ending": "20240331", "company_name": "Cepton, Inc.", "text": "The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of March\u00a031, 2024, the Company had cash and cash equivalents of $49.2 million and an accumulated deficit of $141.4 million. During the three months ended March\u00a031, 2024, the Company incurred an operating loss of $11.5\u00a0million and had negative cash flows from operating activities of $7.1 million. ", "entities": [ { "start_character": 351, "end_character": 355, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -11500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001827090-24-000006", "filing_date": 1709224238000, "quarter_ending": "20231231", "company_name": "Certara, Inc.", "text": "The results of operations of the acquired business and the fair value of the acquired assets and liabilities assumed are included in the Company\u2019s consolidated financial statements with effect from the date of the acquisition. The Company\u2019s consolidated statement of operations and comprehensive loss for the year ended December 31, 2021 includes revenues of $6,129 and a net income of $380 which includes the effects of purchase accounting adjustments, primarily changes in amortization of intangible assets.", "entities": [ { "start_character": 387, "end_character": 390, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 380000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-009380", "filing_date": 1709740897000, "quarter_ending": "20231231", "company_name": "ChromaDex Corp.", "text": "In connection with the preparation of these financial statements for the year ended December\u00a031, 2023, management evaluated whether there were conditions and events, considered in the aggregate, that raised substantial doubt about the Company\u2019s ability to meet its obligations as they became due over the next twelve months from the date of issuance of these financial statements for the year ended December\u00a031, 2023. Management assessed that there were such conditions and events, including a history of recurring operating losses, a history of negative cash flows from operating activities and inflationary pressures. For the year ended December\u00a031, 2023, the Company incurred a net loss of approximately $4.9\u00a0million, however, during the same period the Company\u2019s operating activities provided cash of $7.1\u00a0million. As of December\u00a031, 2023, the Company had unrestricted cash and cash equivalents of $27.2\u00a0million which consists of bank deposits and short-term investments, including highly liquid investment-grade debt instruments with an original maturity of three months or less.", "entities": [ { "start_character": 708, "end_character": 711, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -4900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001739940-24-000005", "filing_date": 1709218085000, "quarter_ending": "20231231", "company_name": "Cigna Group", "text": "The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $139 million and an increase to Shareholders' net income for the years ended December 31, 2022 and December 31, 2021 of $36 million and $5 million, respectively. The corresponding impact to diluted earnings per share was an increase of $0.11 and $0.02 for the years ended December 31, 2022 and December 31, 2021, respectively. ", "entities": [ { "start_character": 261, "end_character": 263, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 36000000.0 }, { "start_character": 277, "end_character": 278, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001367859-24-000046", "filing_date": 1709654551000, "quarter_ending": "20231231", "company_name": "Citizens Community Bancorp Inc.", "text": "The Company chose to adopt ASU 2023-02 because it felt that the proportional amortization method more accurately reflects the economic substance of its tax credit investment. Proportional amortization better matches the cost of the investment with the benefits received, and including the amortization of the investment in provision for income taxes better reflects the benefit the Company receives from the transaction. For the twelve months ended December 31, 2023, adopting ASU 2023-02 increased net income $120. ", "entities": [ { "start_character": 511, "end_character": 514, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 120000.0 } ] }, { "form_type": "10-K", "accession_number": "0001334978-24-000006", "filing_date": 1708928317000, "quarter_ending": "20231231", "company_name": "Clear Channel Outdoor Holdings, Inc.", "text": "Europe revenue is comprised of revenue from the Company\u2019s Europe-North segment. Europe total revenue for 2023, 2022 and 2021 includes revenue from the U.K. of $253.8\u00a0million, $229.7\u00a0million and $224.7\u00a0million, respectively. ", "entities": [ { "start_character": 160, "end_character": 165, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 253800000.0 }, { "start_character": 176, "end_character": 181, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 229700000.0 }, { "start_character": 195, "end_character": 200, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 224700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001856314-24-000060", "filing_date": 1715157111000, "quarter_ending": "20240331", "company_name": "Clear Secure, Inc.", "text": "The Company reported a tax expense of $1,965 on a pretax income of $34,053 for the three months ended March 31, 2024 as compared to a tax benefit of $119 on a pretax loss of $8,392 for the three months ended March 31, 2023. This resulted in an effective tax rate of 5.8% for the three months ended March 31, 2024 as compared to 1.4% percent for the three months ended March 31, 2023. The Company's effective tax rate differs from the statutory rate primarily due to the following: (1) the impact of Alclear being a partnership and allocating its taxable results to its non-controlling members, (2) movement in valuation allowance, (3) foreign taxes, and (4) the impact of U.S. federal and state taxes in excess of applicable tax attributes (e.g., net operating losses and general business tax credits). ", "entities": [ { "start_character": 68, "end_character": 74, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 34053000.0 }, { "start_character": 175, "end_character": 180, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -8392000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001285550-24-000051", "filing_date": 1715102264000, "quarter_ending": "20240331", "company_name": "ClearPoint Neuro, Inc.", "text": "During the three months ended March\u00a031, 2024, the Company recognized approximately $1.5 million of revenue, which was previously included in deferred revenue in the accompanying condensed consolidated balance sheet at December\u00a031, 2023.", "entities": [ { "start_character": 84, "end_character": 87, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001637757-24-000003", "filing_date": 1708620069000, "quarter_ending": "20231231", "company_name": "Clearway Energy LLC", "text": "Certain of these PPAs have no minimum lease payments and all of the lease revenue under these PPAs is recorded as contingent rent on an actual basis when the electricity is delivered. The contingent lease revenue recognized in the years ended December\u00a031, 2023, 2022 and 2021 was $780 million, $850 million and $741 million, respectively. See Note 15, ", "entities": [ { "start_character": 282, "end_character": 285, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 780000000.0 }, { "start_character": 296, "end_character": 299, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 850000000.0 }, { "start_character": 313, "end_character": 316, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 741000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001679788-24-000089", "filing_date": 1714666314000, "quarter_ending": "20240331", "company_name": "Coinbase Global, Inc.", "text": "Certain of the Company\u2019s directors, executive officers, and principal owners, including immediate family members, are users of the Company\u2019s platform. The Company recognized revenue from related party customers of $6.9\u00a0million and $3.1\u00a0million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, accounts receivable from related party customers were $4.2\u00a0million and $3.4\u00a0million, respectively.", "entities": [ { "start_character": 215, "end_character": 218, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6900000.0 }, { "start_character": 232, "end_character": 235, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001823144-24-000002", "filing_date": 1710258988000, "quarter_ending": "20231231", "company_name": "CompoSecure, Inc.", "text": "Basic earnings per share for the year ended December 31, 2022 was calculated by dividing net income attributable to Class A Common shareholders of $18,657 divided by 15,372,422 of weighted average Class A common shares outstanding at December 31, 2022. Diluted earnings per share was calculated by dividing net income adjusted for net effects of dilutive equity award and exchangeable notes of $36,674 divided by 32,555,317 of weighted average common shares after adjusting for the net effects of dilutive equity awards and exchangeable notes outstanding at December 31, 2022.", "entities": [ { "start_character": 148, "end_character": 154, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 18657000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001823144-24-000004", "filing_date": 1715012897000, "quarter_ending": "20240331", "company_name": "CompoSecure, Inc.", "text": "Basic earnings per share for the three months ended March\u00a031, 2024 was calculated by dividing net income attributable to Class A Common shareholders of $4,025 divided by 20,566,970 of weighted average Class A common shares outstanding at March\u00a031, 2024. Diluted earnings per share for the three months ended March\u00a031, 2024 was calculated by dividing net income adjusted for the net effect of dilutive equity awards and exchangeable notes of $16,020 divided by 96,235,469 of weighted average common shares after adjusting for the net effect of dilutive equity awards and exchangeable notes outstanding at March\u00a031, 2024.", "entities": [ { "start_character": 153, "end_character": 158, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4025000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001823144-24-000004", "filing_date": 1715012897000, "quarter_ending": "20240331", "company_name": "CompoSecure, Inc.", "text": "Basic earnings per share for the three months ended March\u00a031, 2023 was calculated by dividing net income attributable to Class A Common shareholders of $2,329 divided by 17,632,000 of weighted average Class A common shares outstanding at March\u00a031, 2023. Diluted earnings per share for the three months ended March\u00a031, 2023 was calculated by dividing net income adjusted for the net effect of dilutive equity awards of $10,739, divided by 94,736,000 of weighted average common shares after adjusting for the net effect of dilutive equity awards outstanding at March\u00a031, 2023.", "entities": [ { "start_character": 153, "end_character": 158, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2329000.0 } ] }, { "form_type": "10-K", "accession_number": "0001120970-24-000014", "filing_date": 1709050532000, "quarter_ending": "20231231", "company_name": "Comstock Inc.", "text": "We determined that the lease initiation fee of $1,250,000 should be recognized as revenue ratably over the term of the lease and quarterly lease payments will be recognized as revenue in the period received. For the year ended December\u00a031, 2023, we recorded revenue of $906,250 which includes the quarterly lease payments of $875,000 and amortization of the lease initiation fee of $31,250. As of December\u00a031, 2023, $1,218,750 of deferred revenue for the initiation fee remains, which the Company classified the short and long term deferred revenue of $62,500 and $1,156,250, respectively, in accrued expenses and other liabilities and deferred revenue in our consolidated balance sheet.", "entities": [ { "start_character": 270, "end_character": 277, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 906250.0 } ] }, { "form_type": "10-Q", "accession_number": "0001120970-24-000044", "filing_date": 1714409595000, "quarter_ending": "20240331", "company_name": "Comstock Inc.", "text": "We determined that the Mining Lease initiation fee of $1,250,000 should be recognized as revenue ratably over the term of the Mining Lease and quarterly lease payments will be recognized as revenue in the period received. For the three months ended March\u00a031, 2024, we recorded revenue of $390,625 which includes the quarterly lease payments of $375,000 and amortization of the lease initiation fee of $15,625. No revenue was recorded the first quarter of 2023. As of March\u00a031, 2024, $1,203,125 of deferred revenue for the initiation fee remains, is recorded as current deferred revenue in our condensed consolidated balance sheet.", "entities": [ { "start_character": 289, "end_character": 296, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 390625.0 } ] }, { "form_type": "10-Q", "accession_number": "0001120970-24-000044", "filing_date": 1714409595000, "quarter_ending": "20240331", "company_name": "Comstock Inc.", "text": "The Condensed Consolidated Financial Statements are prepared on the going concern basis of accounting that assumes the realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has cumulative net losses from operations and an accumulated deficit of $289.2 million at March\u00a031, 2024. For the three months ended March\u00a031, 2024, the Company recognized a net loss of $6.9 million and cash and cash equivalents decreased by $3.3 million from $3.8 million at December 31, 2023 to $0.5 million at March\u00a031, 2024. The Company intends to fund our operations over the next twelve months from (i) existing cash and cash equivalents, (ii) lease revenues (iii) sales of engineering services and technology licenses, and (iv) planned sale of investment and other non-strategic assets, including mineral property. Based on these expected funding sources, management believes the Company will have sufficient funds to sustain our operations and meet our contractual and investment commitments during the 12 months following the date of issuance of the Consolidated Financial Statements included herein. While the Company has been successful in the past in obtaining the necessary capital to support our operations, including registered equity financings from our existing shelf registration statement, borrowings, asset sales and other means, there is no assurance the Company will be able to sell additional assets timely and/or obtain additional equity capital or other financing, if needed. Risks to our liquidity include future operating expenditures above management\u2019s expectations, including but not limited to exploration, pre-development, research and development, selling, general and administrative, investment related expenditures, the sale of the Silver Springs Properties, and amounts to be raised from the issuance of equity under our existing shelf registration statement. Declines in the share price of our common stock would also adversely affect our results of operations, financial condition and cash flows and available liquidity. If the Company is unable to obtain any necessary additional funds, this could have an immediate material adverse effect on liquidity and raise substantial doubt about our ability to continue as a going concern. In such case, the Company could be required to limit or discontinue certain business plans, activities or operations, reduce or delay certain capital expenditures or investments, or sell certain assets or businesses. There can be no assurance that the Company would be able to take any such actions on favorable terms, in a timely manner, or at all.", "entities": [ { "start_character": 412, "end_character": 415, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001120970-24-000044", "filing_date": 1714409595000, "quarter_ending": "20240331", "company_name": "Comstock Inc.", "text": "Revenues from operating leases on our land and building leased to others totaled $35,325 and $30,750 for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 82, "end_character": 88, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 35325.0 }, { "start_character": 94, "end_character": 100, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 30750.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-008851", "filing_date": 1709654740000, "quarter_ending": "20240131", "company_name": "Connexa Sports Technologies Inc.", "text": "The\nCompany recognized net sales of $105,400 and $92,887 during the nine months ended January 31, 2024 and 2023, respectively, to related\nparties. As of January 31, 2024 and 2023, related parties had accounts receivable due to the Company of $71,048 and $91,857, respectively.", "entities": [ { "start_character": 37, "end_character": 44, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": 105400.0 }, { "start_character": 50, "end_character": 56, "label": "revenues", "start_date_for_period": "2022-05-01", "end_date_for_period": "2023-01-31", "currency_/_unit": "iso4217:USD", "value": 92887.0 } ] }, { "form_type": "10-K", "accession_number": "0001347652-24-000051", "filing_date": 1715698322000, "quarter_ending": "20231231", "company_name": "CorEnergy Infrastructure Trust, Inc.", "text": "Contemporaneously with the execution of the Contribution Agreement, the Company and Corridor entered into the First Amendment (the \"First Amendment\") to the Management Agreement that had the effect, beginning February\u00a01, 2021, of (i) eliminating the management fee, (ii) providing a one-time, $1.0\u00a0million advance to Corridor to fund bonus payments to its employees in connection with the Internalization and (iii) providing payments to Corridor for actual employee compensation and office related expenses. Further, the First Amendment provided that, beginning April\u00a01, 2021, the Company paid Corridor additional cash fees equivalent to the aggregate amount of all distributions that would accrue, if declared, on and after such date with respect to the securities to be issued as the Internalization Consideration pursuant to the Contribution Agreement (an amount, assuming payment on a cash basis equal to approximately $172\u00a0thousand per quarter). This agreement was in effect until the closing of the Internalization on July\u00a06, 2021. The Company paid $53\u00a0thousand for declared dividends under this agreement.", "entities": [ { "start_character": 1056, "end_character": 1058, "label": "eps", "start_date_for_period": "2021-04-01", "end_date_for_period": "2021-07-06", "currency_/_unit": "iso4217:USD", "value": 53000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-010682", "filing_date": 1710265698000, "quarter_ending": "20231231", "company_name": "Core Scientific, Inc./tx", "text": "For the year ended December\u00a031, 2023, the Company generated a net loss of $246.5 million. The Company had unrestricted cash and cash equivalents of $50.4 million as of December\u00a031, 2023. The Company has historically generated cash primarily from the issuance of common stock and debt, through sales of digital assets received as digital asset mining revenue and from operations through contracts with customers. As of December\u00a031, 2023, the Company had a working capital deficit of $391.4 million and a total stockholders\u2019 deficit of $596.9 million. The Company\u2019s status in bankruptcy along with its historical financial performance resulted in the Company previously concluding and disclosing that there was substantial doubt regarding its ability to continue as a going concern.", "entities": [ { "start_character": 75, "end_character": 80, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -246500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-010682", "filing_date": 1710265698000, "quarter_ending": "20231231", "company_name": "Core Scientific, Inc./tx", "text": "Transaction costs of $1.9\u00a0million are assumed to have occurred on the pro forma close date of January 1, 2020, and are recognized as if incurred in the first quarter of 2020;", "entities": [ { "start_character": 22, "end_character": 25, "label": "earnings", "start_date_for_period": "2020-01-01", "end_date_for_period": "2020-03-31", "currency_/_unit": "iso4217:USD", "value": -1900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021848", "filing_date": 1715196946000, "quarter_ending": "20240331", "company_name": "Core Scientific, Inc./tx", "text": "For the three months ended March\u00a031, 2024, the Company generated net income of $210.7 million. The Company had unrestricted cash and cash equivalents of $98.1 million as of March\u00a031, 2024, compared to $50.4 million as of December\u00a031, 2023. The Company has historically generated cash primarily from the issuance of common stock and debt, through sales of digital assets received as digital asset mining revenue and through revenue from contracts with customers. As of March\u00a031, 2024, the Company had net working capital of $5.2 million and a total stockholders\u2019 deficit of $318.5 million.", "entities": [ { "start_character": 80, "end_character": 85, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 210700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001889539-24-000006", "filing_date": 1708006459000, "quarter_ending": "20231231", "company_name": "Corebridge Financial, Inc.", "text": "Adjustments include Fortitude Re activity of $(590) million, $6,841 million and $2,012 million for the years ended December 31, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 47, "end_character": 50, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -590000000.0 }, { "start_character": 62, "end_character": 67, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 6841000000.0 }, { "start_character": 81, "end_character": 86, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2012000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001889539-24-000022", "filing_date": 1714740818000, "quarter_ending": "20240331", "company_name": "Corebridge Financial, Inc.", "text": "Adjustments include Fortitude Re activity of $190 million and $(611) million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 46, "end_character": 49, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 190000000.0 }, { "start_character": 64, "end_character": 67, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -611000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000883902-24-000011", "filing_date": 1708704103000, "quarter_ending": "20231231", "company_name": "Cornerstone Building Brands, Inc.", "text": "During July 2023, the Company completed measurement period adjustments, which were mainly composed of a $291.5 million increase to property, plant and equipment and a $174.7 million decrease to intangible assets. The effect of measurement period adjustments on the estimated fair value elements were reflected as if the adjustments had been made as of the date of the Merger, including a $66.5 million cumulative catch-up to depreciation and amortization expense recorded during the three months ended July 1, 2023 resulting from the update in the fair market value of property, plant and equipment and intangible assets. The table below presents the Consolidated Statements of (Loss) Income line items impacted by the aforementioned adjustments for previously reported periods.", "entities": [ { "start_character": 389, "end_character": 393, "label": "ebit", "start_date_for_period": "2023-04-02", "end_date_for_period": "2023-07-01", "currency_/_unit": "iso4217:USD", "value": -66500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001755672-24-000013", "filing_date": 1714659860000, "quarter_ending": "20240331", "company_name": "Corteva, Inc.", "text": "Includes a benefit (charge) of $19 million for the three months ended March 31, 2023, relating to the sale of seeds already under production in Russia when the decision to exit the country was made and that the company was contractually required to purchase. It consists of $41 million of net sales and $22 million of cost of goods sold for the three months ended March 31, 2023. ", "entities": [ { "start_character": 275, "end_character": 277, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 41000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001692951-24-000052", "filing_date": 1711645852000, "quarter_ending": "20231231", "company_name": "Cottonwood Communities, Inc.", "text": "Distributions on our common stock are determined by the board of directors based on our financial condition and other relevant factors. Common stockholders may choose to receive cash distributions or purchase additional shares through our distribution reinvestment plan. For the year ended December 31, 2023, we paid aggregate distributions of $24.2 million, including $21.9 million distributions paid in cash and $2.4 million of distributions reinvested through our distribution reinvestment plan. For the year ended December 31, 2022, we paid aggregate distributions of $20.0 million, including $17.8 million distributions paid in cash and $2.2 million of distributions reinvested through our distribution reinvestment plan.", "entities": [ { "start_character": 345, "end_character": 349, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 24200000.0 }, { "start_character": 573, "end_character": 577, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 20000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001692951-24-000080", "filing_date": 1715359918000, "quarter_ending": "20240331", "company_name": "Cottonwood Communities, Inc.", "text": "Distributions on our common stock are determined by the board of directors based on our financial condition and other relevant factors. Common stockholders may choose to receive cash distributions or purchase additional shares through our distribution reinvestment plan. For the three months ended March 31, 2024, we paid aggregate distributions of $5.7 million, including $0.7 million of distributions reinvested through our distribution reinvestment plan.", "entities": [ { "start_character": 350, "end_character": 353, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 5700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001828962-24-000014", "filing_date": 1709671161000, "quarter_ending": "20231231", "company_name": "Cricut, Inc.", "text": "The Company\u2019s income before income taxes of $79.8\u00a0million, $82.0\u00a0million, and $192.4\u00a0million during the years ended December\u00a031, 2023, 2022, and 2021, respectively, consisted of $78.4\u00a0million, $81.0\u00a0million, and $191.5\u00a0million of income earned in the United States. The remaining amount was earned in foreign jurisdictions.", "entities": [ { "start_character": 45, "end_character": 49, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 79800000.0 }, { "start_character": 60, "end_character": 64, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 82000000.0 }, { "start_character": 79, "end_character": 84, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 192400000.0 }, { "start_character": 179, "end_character": 183, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 78400000.0 }, { "start_character": 194, "end_character": 198, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 81000000.0 }, { "start_character": 213, "end_character": 218, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 191500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001761696-24-000018", "filing_date": 1716222612000, "quarter_ending": "20240331", "company_name": "Crown Electrokinetics Corp.", "text": "Revenue recognized during the three months ended March\u00a031, 2024 was generated by the Company\u2019s wholly-owned subsidiary, Crown Fiber Optics Corporation, and was $0.7 million. During the three months ended March\u00a031, 2023, revenue generated was approximately $22,000.", "entities": [ { "start_character": 161, "end_character": 164, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 700000.0 }, { "start_character": 257, "end_character": 263, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 22000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001761696-24-000018", "filing_date": 1716222612000, "quarter_ending": "20240331", "company_name": "Crown Electrokinetics Corp.", "text": "The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As reflected in the condensed consolidated financial statements, the Company had an accumulated deficit of approximately $121.6 million and cash of approximately $0.3 million as of March\u00a031, 2024, a net loss of approximately $4.6 million, and approximately $2.7 million of net cash used in operating activities for the three months ended March\u00a031, 2024.", "entities": [ { "start_character": 422, "end_character": 425, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001709682-24-000010", "filing_date": 1709828397000, "quarter_ending": "20231231", "company_name": "Custom Truck One Source, Inc.", "text": "Rental revenue is primarily comprised of revenues from rental agreements and freight charges billed to customers. Equipment sales recognized pursuant to sales-type leases are recorded within equipment sales revenue. Charges to customers for damaged rental equipment are recorded within parts and services revenue. Parts and services revenue includes $30.0 million, $26.1 million and $21.5 million related to services provided to customers for the years ended December\u00a031, 2023, 2022, and 2021, respectively. ", "entities": [ { "start_character": 351, "end_character": 355, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 30000000.0 }, { "start_character": 366, "end_character": 370, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 26100000.0 }, { "start_character": 384, "end_character": 388, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 21500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001907982-24-000049", "filing_date": 1711722173000, "quarter_ending": "20231231", "company_name": "D-Wave Quantum Inc.", "text": "For the years ended December 31, 2023 and 2022, the Company incurred a net loss of $82.7 million and $53.7 million, respectively, and the Company had net cash outflows from operating activities of $60.6 million and $45.2 million, respectively. As of December\u00a031, 2023, the Company had cash of $41.3 million ", "entities": [ { "start_character": 84, "end_character": 88, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -82700000.0 }, { "start_character": 102, "end_character": 106, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -53700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001907982-24-000061", "filing_date": 1715617674000, "quarter_ending": "20240331", "company_name": "D-Wave Quantum Inc.", "text": "For the three months ended March 31, 2024 and 2023, the Company incurred a net loss of $17.3 million and $24.4 million, respectively, and the Company had net cash outflows from operating activities of $12.1 million and $13.6 million, respectively. As of March\u00a031, 2024, the Company had cash of $27.3 million ", "entities": [ { "start_character": 88, "end_character": 92, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -17300000.0 }, { "start_character": 106, "end_character": 110, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -24400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000916540-24-000009", "filing_date": 1709133494000, "quarter_ending": "20231230", "company_name": "DARLING INGREDIENTS INC.", "text": "The amount of net sales and net income (loss) from the Gelnex Acquisition included in the Company\u2019s consolidated statement of operations for the year ended December 30, 2023 was $267.1 million and $(26.2) million, respectively. The Company incurred acquisition costs related to the Gelnex Acquisition for the year ended December 30, 2023 of approximately $6.7 million.", "entities": [ { "start_character": 199, "end_character": 203, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": -26200000.0 } ] }, { "form_type": "10-K", "accession_number": "0000916540-24-000009", "filing_date": 1709133494000, "quarter_ending": "20231230", "company_name": "DARLING INGREDIENTS INC.", "text": "The amount of net sales and net income from the FASA Acquisition included in the Company\u2019s consolidated statement of operations for the twelve months ended December\u00a030, 2023 were $362.7 million and $3.5 million, respectively. ", "entities": [ { "start_character": 199, "end_character": 202, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 3500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000916540-24-000009", "filing_date": 1709133494000, "quarter_ending": "20231230", "company_name": "DARLING INGREDIENTS INC.", "text": "The amount of net sales and net income from the Valley Acquisition included in the Company\u2019s consolidated statement of operations for the twelve months ended December\u00a030, 2023 were $780.9 million and $9.0 million, respectively.", "entities": [ { "start_character": 201, "end_character": 204, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 9000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000916540-24-000014", "filing_date": 1715098883000, "quarter_ending": "20240330", "company_name": "DARLING INGREDIENTS INC.", "text": "$246.7 million and $338.6 million, respectively. At March\u00a030, 2024 and December 30, 2023, the Company had zero and $172.3 million in outstanding receivables due from the DGD Joint Venture, respectively. At March\u00a030, 2024 and December 30, 2023, the Company had $0.7 million and zero in deferred revenue with the DGD Joint Venture, respectively. In addition, the Company has eliminated approximately $62.1 million and $63.4 million of additional sales for the three months ended March\u00a030, 2024 and April\u00a01, 2023, respectively to defer the Company's portion of profit of approximately $10.0 million and $15.6\u00a0million on those sales relating to inventory assets remaining on the DGD Joint Venture's balance sheet at March\u00a030, 2024 and April\u00a01, 2023, respectively. ", "entities": [ { "start_character": 1, "end_character": 6, "label": "revenues", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 246700000.0 }, { "start_character": 20, "end_character": 25, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 338600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000916540-24-000014", "filing_date": 1715098883000, "quarter_ending": "20240330", "company_name": "DARLING INGREDIENTS INC.", "text": "The amount of net sales and net income (loss) from the Gelnex Acquisition included in the Company's consolidated statement of operations for the three months ended March 30, 2024 was $65.9 million and $(36.1) million, respectively.", "entities": [ { "start_character": 203, "end_character": 207, "label": "earnings", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -36100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-042345", "filing_date": 1715617854000, "quarter_ending": "20240331", "company_name": "DATASEA INC.", "text": "The accompanying consolidated\nfinancial statements (\u201cCFS\u201d) were prepared\u00a0assuming the Company will continue as a going concern, which contemplates\ncontinuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. For the three months\nended March 31, 2024 and 2023, the Company had a net loss of approximately $4.14\u00a0million\u00a0and $1.30\u00a0million, respectively.\nFor the nine months ended March 31, 2024 and 2023, the Company had a net loss of approximately $6.00\u00a0million and $3.92\u00a0million,\nrespectively. The Company had an accumulated deficit of approximately $34.06\u00a0million as of March 31, 2024, and negative cash flow\nfrom operating activities of approximately $5.95\u00a0million and $2.33\u00a0million for the nine months ended March 31, 2024 and 2023,\nrespectively. The historical operating results including recurring losses from operations raise substantial doubt about the Company\u2019s\nability to continue as a going concern.", "entities": [ { "start_character": 358, "end_character": 362, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4139999.9999999995 }, { "start_character": 376, "end_character": 380, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 }, { "start_character": 500, "end_character": 504, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6000000.0 }, { "start_character": 518, "end_character": 522, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3920000.0 } ] }, { "form_type": "10-K", "accession_number": "0000027996-24-000065", "filing_date": 1708607514000, "quarter_ending": "20231231", "company_name": "DELUXE CORP", "text": "\u2013 In June 2023, we completed the sale of our North American web hosting and logo design businesses for net cash proceeds of $31,230, and we recognized a pretax gain of $17,486. These businesses generated annual revenue of approximately $66,000 during 2022, primarily in our Data Solutions segment. The assets and liabilities sold were not material to our consolidated balance sheet.", "entities": [ { "start_character": 237, "end_character": 243, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 66000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000027996-24-000065", "filing_date": 1708607514000, "quarter_ending": "20231231", "company_name": "DELUXE CORP", "text": "In September and December 2023, we executed agreements allowing for the conversion of our U.S. and Canadian payroll and human resources services customers to other service providers. During 2023, we received initial cash consideration of $15,669 under these agreements, which is included in proceeds from sale of businesses and long-lived assets on the consolidated statement of cash flows. We recognized related income of $10,700 during the fourth quarter of 2023, which is included in gain on sale of businesses and long-lived assets on the consolidated statement of income. Recognition of the remaining income will be based on actual customer conversion and retention activity, which we expect will be completed during 2024. These businesses generated annual revenue of approximately $27,000 in the Payments segment during 2023. Our U.S. and Canadian payroll and human resources businesses comprise a reporting unit that had a goodwill balance of $7,743 as of December 31, 2023. We evaluated this goodwill for impairment as of December 31, 2023, and, based on our quantitative analysis, we concluded that it was not impaired as of that date. In conjunction with our phased transition out of these businesses, we expect that this goodwill will be fully impaired in 2024, at the point when the remaining cash flows generated by these businesses in 2024 no longer support the carrying value of the reporting unit.", "entities": [ { "start_character": 788, "end_character": 794, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 27000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000027996-24-000065", "filing_date": 1708607514000, "quarter_ending": "20231231", "company_name": "DELUXE CORP", "text": "During 2022, we also sold the assets of our Promotional Solutions strategic sourcing and retail packaging businesses. These businesses generated annual revenue of approximately $29,000 during 2021. Neither the gain on these sales nor the assets and liabilities sold were material to our consolidated financial statements.", "entities": [ { "start_character": 178, "end_character": 184, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 29000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000027996-24-000065", "filing_date": 1708607514000, "quarter_ending": "20231231", "company_name": "DELUXE CORP", "text": "\u2013 In May 2022, we completed the sale of our Australian web hosting business for net cash proceeds of $17,620, and we recognized a pretax gain of $15,166.This business generated annual revenue in our Data Solutions segment of $23,766 during 2021. The assets and liabilities sold were not material to our consolidated balance sheet.", "entities": [ { "start_character": 226, "end_character": 232, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 23766000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000027996-24-000120", "filing_date": 1714732697000, "quarter_ending": "20240331", "company_name": "DELUXE CORP", "text": "In June 2023, we completed the sale of our North American web hosting and logo design businesses. These businesses generated revenue of approximately $28,000 during 2023, through the sale date. Further information regarding this sale can be found under the caption \"Note 6: Acquisition and Divestitures\" in the Notes to Consolidated Financial Statements appearing in the 2023 Form 10-K.", "entities": [ { "start_character": 151, "end_character": 157, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 28000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000027996-24-000120", "filing_date": 1714732697000, "quarter_ending": "20240331", "company_name": "DELUXE CORP", "text": "In September and December 2023, we executed agreements allowing for the conversion of our U.S. and Canadian payroll and human resources services customers to other service providers. During the quarter ended March 31, 2024, we recognized related income of $7,581, which is included in gain on sale of businesses and long-lived assets on the consolidated statement of comprehensive income. Recognition of the remaining income will be based on actual customer conversion and retention activity, which we expect to be completed during 2024. These businesses generated annual revenue of approximately $27,000 during 2023. Our U.S. and Canadian payroll and human resources businesses comprise a reporting unit that had a goodwill balance of $7,743 as of March 31, 2024. We evaluated this goodwill for impairment as of March 31, 2024, and, based on our quantitative analysis, we concluded that it was not impaired as of that date. In conjunction with our phased transition out of these businesses, we expect that this goodwill will be fully impaired during 2024, at the point when the remaining cash flows generated by these businesses in 2024 no longer support the carrying value of the reporting unit. During the quarter ended March 31, 2024, we also recognized a gain of $1,000 on the sale of a small business distributor customer list.", "entities": [ { "start_character": 598, "end_character": 604, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 27000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012365", "filing_date": 1711987872000, "quarter_ending": "20231231", "company_name": "DIGITAL ALLY, INC.", "text": "The\naccompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of\nassets and the satisfaction of liabilities in the normal course of business. The Company incurred substantial operating losses in\nthe years ended December 31, 2023 and December 31, 2022 primarily due to reduced gross margins caused by a combination of\ncompetitors\u2019 introduction of newer products with more advanced features together with significant price cutting of their\nproducts and the recent acquisitions with much smaller margins than the video solutions segment, historically. The Company incurred\noperating losses of approximately $22.2\nmillion for the year ended December 31, 2023 and $29.7\nmillion during the year ended December 31, 2022 and it had an accumulated deficit of $117.7\nmillion as of December 31, 2023. These matters raise substantial doubt about Company\u2019s ability to continue as a going\nconcern. In recent years the Company has accessed the public and private capital markets to raise funding through the issuance of\ndebt and equity. In that regard, the Company raised approximately $66.6 million\nin the year ended December 31, 2021 through two underwritten public offerings. These equity raises were utilized to fund its\noperations and acquisitions. Management expects to continue this pattern until it achieves positive cash flows from operations,\nalthough it can offer no assurance in this regard.", "entities": [ { "start_character": 674, "end_character": 678, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -22200000.0 }, { "start_character": 729, "end_character": 733, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -29700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000029644-24-000067", "filing_date": 1717494508000, "quarter_ending": "20240430", "company_name": "DONALDSON Co INC", "text": "During the third quarter of fiscal 2024, the Company announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A. (Medica). Medica is a leader in hollow fiber membrane filtration technology for medical applications and water purification. Headquartered in Medolla, Italy, the Company has over 700 employees globally and generated \u20ac80\u00a0million of revenue in calendar 2023. The transaction is subject, among other things, to the acceptance of the tender offer on the ordinary shares of Medica, which was formally announced to the market on April 29, 2024. Upon acceptance of the tender offer, Donaldson would acquire a 49% stake of Medica with the option to acquire the remaining 51% stake in the future", "entities": [ { "start_character": 385, "end_character": 387, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:EUR", "value": 80000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000029905-24-000008", "filing_date": 1707496306000, "quarter_ending": "20231231", "company_name": "DOVER Corp", "text": "The following unaudited pro forma results of operations reflect the 2021 acquisitions of RegO and Acme Cryogenics as if they had occurred on January 1, 2021. The pro forma information is not necessarily indicative of the results that actually would have occurred, nor does it indicate future operating results of the combined companies. The pro forma earnings are adjusted to reflect the comparable impact of additional depreciation and amortization expense, net of tax, resulting from the fair value measurement of tangible and intangible assets; nonrecurring acquisition-related costs, net of tax, of $5,855; and inventory step-up charges, net of tax, of $15,082. These unaudited pro forma adjustments are based upon purchase price allocations. The actual revenues and earnings for RegO and Acme Cryogenics from the date of acquisition on December 28, 2021 and December 16, 2021, respectively, to December 31, 2021 were not material.", "entities": [ { "start_character": 604, "end_character": 609, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 5855000.0 }, { "start_character": 658, "end_character": 664, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 15082000.0 } ] }, { "form_type": "10-K", "accession_number": "0001842022-24-000003", "filing_date": 1708091290000, "quarter_ending": "20231231", "company_name": "DT Midstream, Inc.", "text": "Includes revenues outside the scope of ASC 606 primarily related to contracts accounted for as leases of $7 million, $10 million and $9 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 106, "end_character": 107, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 7000000.0 }, { "start_character": 118, "end_character": 120, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 10000000.0 }, { "start_character": 134, "end_character": 135, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 9000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001842022-24-000007", "filing_date": 1714475766000, "quarter_ending": "20240331", "company_name": "DT Midstream, Inc.", "text": "Includes revenues outside the scope of ASC 606 primarily related to contracts accounted for as leases of $2 million and $1 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 106, "end_character": 107, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 121, "end_character": 122, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001401914-24-000016", "filing_date": 1711641719000, "quarter_ending": "20231231", "company_name": "Dare Bioscience, Inc.", "text": "At December\u00a031, 2023, the Company had an accumulated deficit of approximately $171.2 million, cash and cash equivalents of approximately $10.5 million, deferred grant funding liabilities under the Company's grant agreements related to DARE-LARC1 and DARE-LBT of approximately $13.7 million, and a working capital deficit of approximately $2.9 million. The Company's cash and cash equivalents at December\u00a031, 2023 represented grant funds received under such grant agreements that may be applied solely toward direct costs for the development of DARE-LARC1 and DARE-LBT, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support the entire operations of the Company. For the year ended December\u00a031, 2023, the Company incurred a net loss of $30.2 million and had negative cash flow from operations of approximately $38.9 million. ", "entities": [ { "start_character": 811, "end_character": 815, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -30200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001401914-24-000033", "filing_date": 1715702518000, "quarter_ending": "20240331", "company_name": "Dare Bioscience, Inc.", "text": "As of March\u00a031, 2024, the Company had an accumulated deficit of approximately $178.0 million, cash and cash equivalents of approximately $3.6 million, deferred grant funding liabilities under the Company's grant agreements related to DARE-LARC1, DARE-LBT and its bacteria-based live biotherapeutic product of approximately $11.8 million, and a working capital deficit of approximately $7.7 million. The Company's cash and cash equivalents at March\u00a031, 2024 represented grant funds received under such agreements that may be applied solely toward direct costs for the development of DARE-LARC1, DARE-LBT and its bacteria-based live biotherapeutic product, other than approximately 10% of such funds, which may be applied toward general overhead and administration expenses that support the entire operations of the Company. For the three months ended March\u00a031, 2024, the Company incurred a net loss of approximately $6.8 million and had negative cash flow from operations of approximately $6.8 million. ", "entities": [ { "start_character": 916, "end_character": 919, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6800000.0 }, { "start_character": 989, "end_character": 992, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-041172", "filing_date": 1699979438000, "quarter_ending": "20230930", "company_name": "Decentral Life, Inc.", "text": "The\nCompany\u2019s related party revenue for three months ended September 30, 2023 and 2022, were $173,187 and $-0-, respectively.", "entities": [ { "start_character": 94, "end_character": 101, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 173187.0 }, { "start_character": 108, "end_character": 109, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 0.0 } ] }, { "form_type": "10-K", "accession_number": "0001654151-24-000004", "filing_date": 1707289912000, "quarter_ending": "20231231", "company_name": "Deciphera Pharmaceuticals, Inc.", "text": "The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has incurred recurring losses including net losses of $194.9 million, $178.9 million, and $300.0 million for the years ended December\u00a031, 2023, 2022, and 2021, respectively. As of December\u00a031, 2023, the Company had an accumulated deficit of $1.4 billion. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities of $352.9 million as of December\u00a031, 2023, together with anticipated product, royalty, and supply revenues, but excluding any potential future milestones received under its collaboration or license agreements will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to fund its operations.", "entities": [ { "start_character": 306, "end_character": 311, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -194900000.0 }, { "start_character": 322, "end_character": 327, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -178900000.0 }, { "start_character": 342, "end_character": 347, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -300000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001654151-24-000018", "filing_date": 1715326026000, "quarter_ending": "20240331", "company_name": "Deciphera Pharmaceuticals, Inc.", "text": "The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has incurred recurring losses, including net losses of $45.1 million and $194.9 million for the three months ended March\u00a031, 2024 and the year ended December\u00a031, 2023, respectively. As of March\u00a031, 2024, the Company had an accumulated deficit of $1.5 billion. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities of $299.3 million as of March\u00a031, 2024, together with anticipated product, royalty, and supply revenues, but excluding any potential future milestones received under its collaboration or license agreements will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements. ", "entities": [ { "start_character": 308, "end_character": 312, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -45100000.0 }, { "start_character": 326, "end_character": 331, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -194900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001651944-24-000014", "filing_date": 1709225618000, "quarter_ending": "20231231", "company_name": "DermTech, Inc.", "text": "The Company has incurred operating losses since inception and has an accumulated deficit of $423.9 million as of December\u00a031, 2023. As of December\u00a031, 2023, cash and cash equivalents totaled approximately $36.7 million and short-term marketable securities totaled approximately $19.1 million. For the year ended December\u00a031, 2023, The Company reported a net loss of $100.9 million and cash used in operating activities of $77.0 million. The Company's transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The timing and amount of the Company's actual expenditures will be based on many factors, including cash flows from operations and the potential growth of its business, and may vary from current estimates. The Company's management expects that based on its currently planned business operations and considering the restructuring activities (Note 5) implemented in June 2023, currently available resources will not provide sufficient funds to meet its anticipated operating costs within the Evaluation Period. The Company currently anticipates that it will need to raise additional capital, increase average selling prices and revenues and may need to further reduce operating costs following the Evaluation Period. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of issuance of the consolidated financial statements for the year ended December\u00a031, 2023. If we are unable to obtain additional funding on acceptable terms when and as needed, we may be forced to delay or reduce the scope of our commercial and sales activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in our financial statements, further curtail planned operations or cease operations entirely and wind down our business. Any of these could materially and adversely affect the Company's liquidity, financial condition and business prospects and, as a result, our stockholders may not receive full value, or may receive no value, for their investment. In light of our existing cash and cash equivalents and our current obligations, such a liquidation or disposition process may occur subject to bankruptcy protections, which may further reduce the value that we may receive for our assets. ", "entities": [ { "start_character": 367, "end_character": 372, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -100900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001651944-24-000047", "filing_date": 1715712124000, "quarter_ending": "20240331", "company_name": "DermTech, Inc.", "text": "The Company has incurred operating losses since inception and has an accumulated deficit of $443.9 million as of March\u00a031, 2024. As of March\u00a031, 2024, cash and cash equivalents totaled approximately $27.6 million and short-term marketable securities totaled approximately $11.4 million. For the three months ended March\u00a031, 2024, the Company reported a net loss of $20.0 million and cash used in operating activities of $17.1 million. The Company's transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The timing and amount of the Company's actual expenditures will be based on many factors, including cash flows from operations and the potential growth of its business, and may vary from current estimates. The Company's management expects that based on its currently planned business operations and considering the restructuring activities implemented in June 2023, January 2024 (Note 5) and April 2024 (Note 7) currently available resources will not provide sufficient funds to meet its anticipated operating costs within the Evaluation Period. The Company currently anticipates that it will need to complete a strategic transaction and/or raise additional capital, increase average selling prices and revenues and may need to further reduce operating costs following or prior to the expiration of the Evaluation Period. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of issuance of the unaudited condensed consolidated financial statements for the quarter ended March\u00a031, 2024. If the Company is unable to obtain additional funding on acceptable terms when and as needed or otherwise successfully complete a strategic transaction, it may be forced to delay or further reduce the scope of its commercial and sales activities, extend payment terms with suppliers, liquidate assets where possible at a potentially lower amount than as recorded in its financial statements, further curtail planned operations or cease operations entirely and wind down its business. Any of these could materially and adversely affect the Company's liquidity, financial condition and business prospects and, as a result, the Company\u2019s stockholders may not receive full value, or may receive no value, for their investment. In light of the Company\u2019s existing cash and cash equivalents and our current obligations, such a liquidation or disposition process may occur subject to bankruptcy protections, which may further reduce the value that the Company may receive for its assets. ", "entities": [ { "start_character": 366, "end_character": 370, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -20000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001319947-24-000035", "filing_date": 1717517304000, "quarter_ending": "20240504", "company_name": "Designer Brands Inc.", "text": ", of our condensed consolidated financial statements for the Quarterly Reports on Forms 10-Q for the first and second quarters of 2023. The above table for the three months ended April 29, 2023 has been corrected to reflect the reduction of $8.3 million of U.S. Retail segment net sales from accessories and other and increases of $4.0 million and $4.3 million of U.S. Retail segment net sales to women\u2019s footwear and men\u2019s footwear, respectively, representing the impact of the error for the first quarter of 2023. This immaterial correction did not impact the condensed consolidated statements of operations, comprehensive income (loss), or balance sheets.", "entities": [ { "start_character": 242, "end_character": 245, "label": "revenues", "start_date_for_period": "2023-01-29", "end_date_for_period": "2023-04-29", "currency_/_unit": "iso4217:USD", "value": -8300000.000000001 }, { "start_character": 332, "end_character": 335, "label": "revenues", "start_date_for_period": "2023-01-29", "end_date_for_period": "2023-04-29", "currency_/_unit": "iso4217:USD", "value": 4000000.0 }, { "start_character": 349, "end_character": 352, "label": "revenues", "start_date_for_period": "2023-01-29", "end_date_for_period": "2023-04-29", "currency_/_unit": "iso4217:USD", "value": 4300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001822359-24-000016", "filing_date": 1709137427000, "quarter_ending": "20231231", "company_name": "DocGo Inc.", "text": "Net loss for the Company\u2019s VIEs were $235,976, $373,456 and $122,982 for the years ended December\u00a031, 2023, 2022 and 2021, respectively. The total assets amounted to $4,364,274 and $610,553 on December\u00a031, 2023 and 2022, respectively. Total liabilities were $4,811,857 and $320,424 on December\u00a031, 2023 and 2022, respectively. The Company\u2019s VIEs total stockholders\u2019 deficit were $447,583 and $290,130 on December\u00a031, 2023 and 2022, respectively. ", "entities": [ { "start_character": 38, "end_character": 45, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 235976.0 }, { "start_character": 48, "end_character": 55, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 373456.0 }, { "start_character": 61, "end_character": 68, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 122982.0 } ] }, { "form_type": "10-Q", "accession_number": "0001822359-24-000045", "filing_date": 1715186171000, "quarter_ending": "20240331", "company_name": "DocGo Inc.", "text": "Net loss for the Company's VIEs was $275,905 and $186,637 for the three months ended March\u00a031, 2024 and 2023, respectively. The total assets amounted to $5,364,950 and $4,364,274 as of March\u00a031, 2024 and December\u00a031, 2023, respectively. Total liabilities were $6,088,439 and $4,811,857 as of March\u00a031, 2024 and December\u00a031, 2023, respectively. The Company's VIEs' total stockholders\u2019 deficit was $723,489 and $447,583 as of March\u00a031, 2024 and December\u00a031, 2023, respectively.", "entities": [ { "start_character": 37, "end_character": 44, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -275905.0 }, { "start_character": 50, "end_character": 57, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -186637.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-002964", "filing_date": 1706809729000, "quarter_ending": "20231229", "company_name": "Dolby Laboratories, Inc.", "text": "Other investments as of December\u00a029, 2023 is primarily comprised of an equity method investment of $6.5\u00a0million and an equity security without a readily determinable fair value, valued at $5.0\u00a0million. The equity method investment is measured at cost minus impairment, if any, adjusted for our proportionate share of the investee's net income or loss. Our share of the equity method investee's net income or loss is included in other income/(expense), net on the unaudited interim condensed consolidated statements of operations. Our share of the equity method investee's net income was $3.3\u00a0million in the first quarter of fiscal 2024 and was not material in the first quarter of fiscal 2023. ", "entities": [ { "start_character": 588, "end_character": 591, "label": "earnings", "start_date_for_period": "2023-09-30", "end_date_for_period": "2023-12-29", "currency_/_unit": "iso4217:USD", "value": 3300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020061", "filing_date": 1714669373000, "quarter_ending": "20240329", "company_name": "Dolby Laboratories, Inc.", "text": "Other investments as of March\u00a029, 2024 is primarily comprised of an equity method investment of $6.9\u00a0million and an equity security without a readily determinable fair value, valued at $5.0\u00a0million. The equity method investment is measured at cost minus impairment, if any, adjusted for our proportionate share of the investee's net income or loss. Our share of the equity method investee's net income or loss is included in other income/(expense), net on the unaudited interim condensed consolidated statements of operations. Our share of the equity method investee's net income was $3.6\u00a0million in the second quarter of fiscal 2024 and was not material in the second quarter of fiscal 2023. Our share of the equity method investee's net income was $6.9\u00a0million in the fiscal year-to-date period ended March\u00a029, 2024 and was $1.7\u00a0million in the fiscal year-to-date period ended March 31, 2023.", "entities": [ { "start_character": 585, "end_character": 588, "label": "earnings", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 3600000.0 }, { "start_character": 827, "end_character": 830, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001364250-24-000012", "filing_date": 1708099776000, "quarter_ending": "20231231", "company_name": "Douglas Emmett Inc", "text": "Estimated tenant recoveries for real estate taxes, common area maintenance and other recoverable operating expenses, which are included in Rental revenues and tenant recoveries on our consolidated statements of operations, are recognized as revenue on a gross basis in the period that the recoverable expenses are incurred. Subsequent to year-end, in accordance with our policy, we perform reconciliations on a lease-by-lease basis and bill or credit each tenant for any differences between the estimated expenses we billed to the tenant and the actual expenses incurred. Tenant recoveries were $61.6\u00a0million, $58.2\u00a0million and $56.5\u00a0million in 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 598, "end_character": 602, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 61600000.0 }, { "start_character": 613, "end_character": 617, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 58200000.0 }, { "start_character": 631, "end_character": 635, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 56500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001364250-24-000012", "filing_date": 1708099776000, "quarter_ending": "20231231", "company_name": "Douglas Emmett Inc", "text": "Tenant improvements constructed, and owned by us, and reimbursed by tenants are recorded as our assets, and the related revenue, which are included in Rental revenues and tenant recoveries on our consolidated statements of operations, is recognized over the related lease term. We recognized revenue for reimbursement of tenant improvements of $5.8 million, $4.8\u00a0million and $5.8 million during 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 346, "end_character": 349, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5800000.0 }, { "start_character": 360, "end_character": 363, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 4800000.0 }, { "start_character": 377, "end_character": 380, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001364250-24-000012", "filing_date": 1708099776000, "quarter_ending": "20231231", "company_name": "Douglas Emmett Inc", "text": "Our lease contracts generally make a specified number of parking spaces available to the tenant, and we bill and recognize parking revenues on a monthly basis in accordance with the lease agreements, generally using the monthly parking rates in effect at the time of billing. Office parking revenues were $92.2\u00a0million, $84.9\u00a0million and $69.0 million in 2023, 2022 and 2021, respectively, and are included in office Parking and other income on our consolidated statements of operations. Office parking receivables were $0.8\u00a0million and $0.9 million as of December\u00a031, 2023 and 2022, respectively, and are included in Tenant receivables on our consolidated balance sheets.", "entities": [ { "start_character": 307, "end_character": 311, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 92200000.0 }, { "start_character": 322, "end_character": 326, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 84900000.0 }, { "start_character": 340, "end_character": 344, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 69000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001364250-24-000012", "filing_date": 1708099776000, "quarter_ending": "20231231", "company_name": "Douglas Emmett Inc", "text": "We own two parcels of land from which we receive rent under ground leases. We account for our ground lease revenues as operating leases in accordance with Topic 842. Ground lease revenues were $7.9\u00a0million, $2.1\u00a0million and $0.3\u00a0million in 2023, 2022 and 2021, respectively, and are included in office Parking and other income on our consolidated statements of operations.", "entities": [ { "start_character": 196, "end_character": 199, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 7900000.0 }, { "start_character": 210, "end_character": 213, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 227, "end_character": 230, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001364250-24-000028", "filing_date": 1715283572000, "quarter_ending": "20240331", "company_name": "Douglas Emmett Inc", "text": "We account for our rental revenues, and variable lease payments such as tenant recoveries and parking revenues, in accordance with Topic 842. We adopted a practical expedient which allows us to account for our rental revenues, tenant recoveries and parking revenues on a combined basis. Rental revenues and tenant recoveries from tenant leases are included in Rental revenues and tenant recoveries on our consolidated statements of operations. Tenant recoveries were $9.1\u00a0million and $13.1\u00a0million ", "entities": [ { "start_character": 470, "end_character": 473, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 9100000.0 }, { "start_character": 487, "end_character": 491, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 13100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001804745-24-000015", "filing_date": 1715184294000, "quarter_ending": "20240330", "company_name": "Driven Brands Holdings Inc.", "text": "The Company has 2,067,468 and 5,351,252 shares of performance awards that are contingent on performance conditions which have not yet been met and therefore have been excluded from the computation of weighted average shares for the three months ended March\u00a030, 2024 and April\u00a01, 2023, respectively.", "entities": [ { "start_character": 16, "end_character": 25, "label": "eps", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "xbrli:shares", "value": 2067468.0 }, { "start_character": 30, "end_character": 39, "label": "eps", "start_date_for_period": "2021-12-26", "end_date_for_period": "2022-03-26", "currency_/_unit": "xbrli:shares", "value": 5351252.0 } ] }, { "form_type": "10-K", "accession_number": "0001326160-24-000037", "filing_date": 1708694836000, "quarter_ending": "20231231", "company_name": "Duke Energy CORP", "text": "(a)\u00a0\u00a0\u00a0\u00a0EU&I includes $160\u00a0million of expense recorded within Impairment of assets and other charges, $77\u00a0million of income within Other Income and expenses, $5\u00a0million of expense within Operations, maintenance and other, $13\u00a0million of income within regulated operating revenues, $3\u00a0million of expense within interest expense and $6\u00a0million of expense within Depreciation and amortization on the Duke Energy Carolinas' Consolidated Statement of Operations related to the South Carolina Supreme Court decision on coal ash and insurance proceeds; it also includes $42\u00a0million of expense recorded within Impairment of assets and other charges, $34\u00a0million of income within Other Income and expenses, $7\u00a0million of expense within Operations, maintenance, and other, $15\u00a0million of income within Regulated electric operating revenues, $5\u00a0million of expense within interest expense and $1\u00a0million of expense within Depreciation and amortization on the Duke Energy Progress' Consolidated Statement of Operations.", "entities": [ { "start_character": 102, "end_character": 104, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 77000000.0 }, { "start_character": 642, "end_character": 644, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 34000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001799208-24-000024", "filing_date": 1714665873000, "quarter_ending": "20240331", "company_name": "Dun & Bradstreet Holdings, Inc.", "text": "The effective tax rate for the three months ended March\u00a031, 2024 was 66.0%, reflecting a tax benefit of $44.2\u00a0million on pre-tax loss of $67.0\u00a0million, compared to 26.0% for the three months ended March\u00a031, 2023, which reflected a tax benefit of $11.8\u00a0million on pre-tax loss of $45.4\u00a0million. The change in the effective tax rate for the three months ended March 31, 2024 compared to the prior year quarter was primarily a result of a decrease to our uncertain tax positions as a result of an audit settlement and a reduction to the Global Intangible Low-Taxed Income (\"GILTI\") inclusion in the U.S. due to an election allowing for the exclusion of certain income, partially offset by the impact of the Global Anti-Base Erosion and Profit Shifting (\"BEPS\") - Pillar Two Global Minimum Tax introduced by The Organization for Economic Co-operation and Development (\"OECD\").", "entities": [ { "start_character": 138, "end_character": 142, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -67000000.0 }, { "start_character": 280, "end_character": 284, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -45400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012285", "filing_date": 1711983621000, "quarter_ending": "20231231", "company_name": "Dynamic Shares Trust", "text": "The\nTrust is an \u201cemerging growth company,\u201d as defined in the Jumpstart Our Business Startups (\u201cJOBS\u201d) Act of 2012.\nIt will remain an emerging growth company until the earlier of (1) the beginning of the first fiscal year following the fifth anniversary\nof its initial public offering, (2) the beginning of the first fiscal year after annual gross revenue is $1.235 billion (subject to adjustment\nfor inflation) or more, (3) the date on which the Fund has, during the previous three-year period, issued more than $1.0 billion in non-convertible\ndebt securities and (4) as of the end of any fiscal year in which the market value of common equity held by non-affiliates exceeded $700\nmillion as of the end of the second quarter of that fiscal year.", "entities": [ { "start_character": 359, "end_character": 364, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1235000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018863", "filing_date": 1715614048000, "quarter_ending": "20240331", "company_name": "Dynamic Shares Trust", "text": "The\nTrust is an \u201cemerging growth company,\u201d as defined in the Jumpstart Our Business Startups (\u201cJOBS\u201d) Act of 2012.\nIt will remain an emerging growth company until the earlier of (1) the beginning of the first fiscal year following the fifth anniversary\nof its initial public offering, (2) the beginning of the first fiscal year after annual gross revenue is $1.07 billion (subject to adjustment\nfor inflation) or more, (3) the date on which the Fund has, during the previous three-year period, issued more than $1.0 billion in non-convertible\ndebt securities and (4) as of the end of any fiscal year in which the market value of common equity held by non-affiliates exceeded $700\nmillion as of the end of the second quarter of that fiscal year.", "entities": [ { "start_character": 359, "end_character": 363, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1070000000.0000001 } ] }, { "form_type": "10-Q", "accession_number": "0000832428-24-000023", "filing_date": 1715348889000, "quarter_ending": "20240331", "company_name": "E.W. SCRIPPS Co", "text": "The dilutive effects of performance-based stock awards are included in the computation of diluted earnings per share to the extent the related performance criteria are met through the respective balance sheet reporting date. As of March\u00a031, 2024, potential dilutive securities representing 420,000 shares were excluded from the computation of diluted earnings per share as the related performance criteria were not yet met, although the Company expects to meet various levels of criteria in the future. ", "entities": [ { "start_character": 290, "end_character": 297, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 420000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001065088-24-000076", "filing_date": 1714668758000, "quarter_ending": "20240331", "company_name": "EBAY INC", "text": "We review the useful lives of equipment on an ongoing basis, and effective January 1, 2024 we changed our estimate of the useful lives for our servers and networking equipment from three years to four years. The longer useful lives are due to continuous improvements in our hardware, software, and data center designs. The effect of this change in estimate for the three months ended March\u00a031, 2024, based on servers and network equipment that were included in \u201cProperty and equipment, net\u201d as of December\u00a031, 2023 and those acquired during the three months ended March\u00a031, 2024, was a reduction in depreciation expense of $26\u00a0million and an increase to net income of $21\u00a0million, or $0.04 per basic share and $0.04 per diluted share.", "entities": [ { "start_character": 669, "end_character": 671, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 21000000.0 }, { "start_character": 685, "end_character": 689, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": null, "value": 0.04 }, { "start_character": 711, "end_character": 715, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": null, "value": 0.04 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-003698", "filing_date": 1707322167000, "quarter_ending": "20231231", "company_name": "EDGEWELL PERSONAL CARE Co", "text": "For the three months ended December 31, 2022, the Company had income tax expense of $4.6 on Earnings before income taxes of $17.0. The effective tax rate for the three months ended December 31, 2022 was 27.0%. The difference between the federal statutory rate and the effective rate was primarily due to an unfavorable mix of earnings in higher tax rate jurisdictions.", "entities": [ { "start_character": 125, "end_character": 129, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 17000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-003698", "filing_date": 1707322167000, "quarter_ending": "20231231", "company_name": "EDGEWELL PERSONAL CARE Co", "text": "For the three months ended December 31, 2023, the Company had income tax expense of $1.2, on Earnings before income taxes of $6.0. The effective tax rate for the three months ended December 31, 2023 w", "entities": [ { "start_character": 126, "end_character": 129, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 6000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021700", "filing_date": 1715185265000, "quarter_ending": "20240331", "company_name": "EDGEWELL PERSONAL CARE Co", "text": ", respectively, on Earnings before income taxes of $26.6 and $43.6, respectively. The effective tax rate for the three and six months ended March 31, 2023 was 27.0% and 26.9%, respectively. The difference between the federal statutory rate and the effective rate was primarily due to an unfavorable mix of earnings in higher tax rate jurisdictions.", "entities": [ { "start_character": 52, "end_character": 56, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 26600000.0 }, { "start_character": 62, "end_character": 66, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 43600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021700", "filing_date": 1715185265000, "quarter_ending": "20240331", "company_name": "EDGEWELL PERSONAL CARE Co", "text": "For the three and six months ended March 31, 2024, the Company had income tax expense of $11.0 and $12.2, respectively, on Earnings before income taxes of $47.0 and $53.0, respectively. The effective tax rate for the three and six months ended March 31, 2024 w", "entities": [ { "start_character": 156, "end_character": 160, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 47000000.0 }, { "start_character": 166, "end_character": 170, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 53000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000712515-24-000023", "filing_date": 1716394339000, "quarter_ending": "20240331", "company_name": "ELECTRONIC ARTS INC.", "text": "We attribute net revenue from external customers to individual countries based on the location of the legal entity that sells the products and/or services. Note that revenue attributed to the legal entity that makes the sale is often not the country where the consumer resides. For example, revenue generated by our Swiss legal entity includes digital revenue from consumers who reside outside of Switzerland, including consumers who reside outside of Europe. Revenue generated by our Swiss legal entity during fiscal years 2024, 2023, and 2022 represents $4,374 million, $4,085 million and $3,423 million or 58 percent, 55 percent and 49 percent of our total net revenue, respectively. Revenue generated in the United States represents over 99 percent of our total North America net revenue. There were no other countries with net revenue greater than 10 percent.", "entities": [ { "start_character": 557, "end_character": 562, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4374000000.0 }, { "start_character": 573, "end_character": 578, "label": "revenues", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4085000000.0 }, { "start_character": 592, "end_character": 597, "label": "revenues", "start_date_for_period": "2021-04-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": 3423000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000059478-24-000065", "filing_date": 1708515877000, "quarter_ending": "20231231", "company_name": "ELI LILLY & Co", "text": "Collaboration and other revenue associated with prior period transfers of intellectual property was $191.6 million, $163.4 million, and $175.0 million during the years ended December 31, 2023, 2022, and 2021, respectively.", "entities": [ { "start_character": 101, "end_character": 106, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 191600000.0 }, { "start_character": 117, "end_character": 122, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 163400000.0 }, { "start_character": 137, "end_character": 142, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 175000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000059478-24-000065", "filing_date": 1708515877000, "quarter_ending": "20231231", "company_name": "ELI LILLY & Co", "text": "Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $2.02\u00a0billion and $2.24\u00a0billion during the years ended December\u00a031, 2022 and 2021, respectively. We had no sales of our COVID-19 antibodies during the year ended December\u00a031, 2023.", "entities": [ { "start_character": 146, "end_character": 150, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2020000000.0 }, { "start_character": 164, "end_character": 168, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2240000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000808326-24-000010", "filing_date": 1707754149000, "quarter_ending": "20231231", "company_name": "EMCORE CORP", "text": "We have recently experienced losses from our operations and used a significant amount of cash, amounting to a net loss of $5.7 million and net cash outflows from operations of $1.8 million for the three months ended December 31, 2023, and we expect to continue to incur losses and use cash in our operations in the near term. As a result of our recent cash outflows, we have taken actions to manage our liquidity and plan to continue to do so. As of December\u00a031, 2023, our cash and cash equivalents totaled $21.2 million, including restricted cash of $0.5\u00a0million and we had $7.2\u00a0million available under our Credit Agreement (as defined in ", "entities": [ { "start_character": 123, "end_character": 126, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -5700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000808326-24-000021", "filing_date": 1715628674000, "quarter_ending": "20240331", "company_name": "EMCORE CORP", "text": "We have recently experienced losses from our operations and used a significant amount of cash, amounting to a net loss of $8.5 million and $14.2 million for the three and six months ended March 31, 2024, respectively, and net cash outflows from continuing operations of $9.7 million for the six months ended March 31, 2024. We expect to continue to incur losses and use cash in our operations in the near term. As a result of our recent cash outflows, we have taken actions to manage our liquidity and plan to continue to do so. As of March\u00a031, 2024, our cash and cash equivalents totaled $12.0 million, including restricted cash of $0.5\u00a0million.", "entities": [ { "start_character": 123, "end_character": 126, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -8500000.0 }, { "start_character": 140, "end_character": 144, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -14200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000032604-24-000008", "filing_date": 1707321923000, "quarter_ending": "20231231", "company_name": "EMERSON ELECTRIC CO", "text": "On October 11, 2023, the Company completed the acquisition of National Instruments Corporation (\u201cNI\u201d). NI, which provides software-connected automated test and measurement systems that enable enterprises to bring products to market faster and at a lower cost, had revenues of approximately $1.7\u00a0billion and pretax earnings of approximately $170 for the 12 months ended September 30, 2023. NI is now referred to as Test & Measurement and reported as a new segment in the Software and Control business group, see Note 14.", "entities": [ { "start_character": 291, "end_character": 294, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1700000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000032604-24-000024", "filing_date": 1715184993000, "quarter_ending": "20240331", "company_name": "EMERSON ELECTRIC CO", "text": "On October 11, 2023, the Company completed the acquisition of National Instruments Corporation (\u201cNI\u201d). NI, which provides software-connected automated test and measurement systems that enable enterprises to bring products to market faster and at a lower cost, had revenues of approximately $1.7\u00a0billion and pretax earnings of approximately $170 for the 12 months ended September 30, 2023. NI is now referred to as Test & Measurement and reported as a new segment in the Software and Control business group, see Note 14.", "entities": [ { "start_character": 291, "end_character": 294, "label": "revenues", "start_date_for_period": "2023-10-11", "end_date_for_period": "2023-10-11", "currency_/_unit": "iso4217:USD", "value": 1700000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000895728-24-000013", "filing_date": 1715324680000, "quarter_ending": "20240331", "company_name": "ENBRIDGE INC", "text": "Includes operating revenues and commodity costs from our natural gas and power marketing subsidiaries for the three months ended March 31, 2024 of $332 million (2023 - $520 million) and $322 million (2023 - $499 million), respectively.", "entities": [ { "start_character": 148, "end_character": 151, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:CAD", "value": 332000000.0 }, { "start_character": 169, "end_character": 172, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:CAD", "value": 520000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000895728-24-000013", "filing_date": 1715324680000, "quarter_ending": "20240331", "company_name": "ENBRIDGE INC", "text": "Includes revenues from lease contracts for the three months ended March\u00a031, 2024 and 2023 of $140 million and $144 million, respectively.", "entities": [ { "start_character": 94, "end_character": 97, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:CAD", "value": 140000000.0 }, { "start_character": 111, "end_character": 114, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:CAD", "value": 144000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-012713", "filing_date": 1711121071000, "quarter_ending": "20231231", "company_name": "ENERGY FOCUS, INC/DE", "text": "Due to our financial performance as of December 31, 2023 and 2022, including net losses of $4.3 million and $10.3 million for the twelve months ended December 31, 2023 and 2022, respectively, and total cash used in operating activities of $2.4 million and $6.7 million for the twelve months ended December 31, 2023 and 2022, respectively, we determined that substantial doubt about our ability to continue as a going concern continues to exist at December 31, 2023. As a result of restructuring actions and initiatives, we have tailored our operating expenses to be more in line with our expected sales volumes; however, we continue to incur losses and have a substantial accumulated deficit.", "entities": [ { "start_character": 92, "end_character": 95, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -4300000.0 }, { "start_character": 109, "end_character": 113, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -10300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022861", "filing_date": 1715614303000, "quarter_ending": "20240331", "company_name": "ENERGY FOCUS, INC/DE", "text": "Due to our financial performance as of March\u00a031, 2024 and December\u00a031, 2023, including net losses of $0.4 million for the three months ended March\u00a031, 2024 and $4.3\u00a0million for the twelve months ended December\u00a031, 2023, and total cash used in operating activities of $0.1 million for the three months ended March\u00a031, 2024 and $2.4 million for the twelve months ended December\u00a031, 2023, we determined that substantial doubt about our ability to continue as a going concern continues to exist at March\u00a031, 2024. As a result of restructuring actions and initiatives, we have tailored our operating expenses to be more in line with our expected sales volumes; however, we continue to incur losses and have a substantial accumulated deficit.", "entities": [ { "start_character": 102, "end_character": 105, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -400000.0 }, { "start_character": 161, "end_character": 164, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001385849-24-000029", "filing_date": 1714753931000, "quarter_ending": "20240331", "company_name": "ENERGY FUELS INC", "text": "For the three months ended March 31, 2024 and 2023, the Company did not record income tax benefit on income before tax of $3.64 million and $114.26 million, respectively. The effective tax rate was 0% for each of the three months ended March 31, 2024 and 2023, which was a result of the full valuation allowance on net deferred tax assets.", "entities": [ { "start_character": 123, "end_character": 127, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3640000.0 }, { "start_character": 141, "end_character": 147, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 114260000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001385849-24-000029", "filing_date": 1714753931000, "quarter_ending": "20240331", "company_name": "ENERGY FUELS INC", "text": "On October 27, 2021, after closing on the sale of certain conventional uranium assets to CUR, the Company began providing services to CUR under a mine operating agreement. Pursuant to that agreement, the Company earned $0.02\u00a0million and $0.27\u00a0million for the three months ended March 31, 2024 and 2023, respectively. As of March\u00a031, 2024 and December 31, 2023, $0.07\u00a0million and $0.05\u00a0million was due from CUR, respectively. Additionally, the Company accrued $1.50\u00a0million and $1.53\u00a0million as of March\u00a031, 2024 and December\u00a031, 2023, respectively, in Other long-term receivables related to deferred cash payments for production thresholds pursuant to the terms of the asset purchase agreement with CUR.", "entities": [ { "start_character": 220, "end_character": 224, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 20000.0 }, { "start_character": 238, "end_character": 242, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 270000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001125376-24-000064", "filing_date": 1714579366000, "quarter_ending": "20240331", "company_name": "ENSIGN GROUP, INC", "text": "Certain of the Company's independent subsidiaries and 80 Standard Bearer independent real estate subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the independent subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from Ensign affiliated operations for the three months ended March 31, 2024 and 2023 was $18,006 and $15,931, respectively.", "entities": [ { "start_character": 1352, "end_character": 1358, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 18006000.0 }, { "start_character": 1364, "end_character": 1370, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 15931000.0 } ] }, { "form_type": "10-K", "accession_number": "0000835357-24-000003", "filing_date": 1710783033000, "quarter_ending": "20231231", "company_name": "EQUITABLE FINANCIAL LIFE INSURANCE CO OF AMERICA", "text": "The net impact of assumption changes during 2023 increased remeasurement of liability for future policy benefits by $12 million, decreased policyholders\u2019 benefits by $1 million, decreased market risk benefits and purchased market risk benefits by $8 million, and decreased other operating costs and expenses by $42 million. This resulted in an increase in income (loss) from operations, before income taxes of $39 million and an increase to net income (loss) by $31 million.", "entities": [ { "start_character": 411, "end_character": 413, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 39000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000835357-24-000003", "filing_date": 1710783033000, "quarter_ending": "20231231", "company_name": "EQUITABLE FINANCIAL LIFE INSURANCE CO OF AMERICA", "text": "The net impact of assumption changes during 2021 decreased remeasurement of liability for future policy benefits by $4\u00a0million, increased policyholders\u2019 benefits by $14\u00a0million, and increased change in market risk benefits and purchased market risk benefits by$1\u00a0million . This resulted in a decrease in income (loss) from operations, before income taxes of $11\u00a0million and decreased net income (loss) by $9\u00a0million.", "entities": [ { "start_character": 359, "end_character": 361, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -11000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001877322-24-000088", "filing_date": 1714545175000, "quarter_ending": "20240329", "company_name": "ESAB Corp", "text": "The invasion of Ukraine by Russia and the sanctions imposed in response have increased the level of economic and political uncertainty. While ESAB continues to closely monitor the situation and evaluate options, the Company is meeting current contractual obligations while addressing applicable laws and regulations. For the three months ended March 29, 2024, Russia represented approximately 5% of the Company\u2019s total revenue, and approximately $4\u00a0million of its Net income. Russia also has approximately 3% of the Company\u2019s total net assets excluding any goodwill allocation as of March\u00a029, 2024. In case of a disposition of the Russia business, a portion of goodwill would need to be allocated and disposed of at the relative fair value attributable to the Russia business. Russia has a cumulative translation loss of approximately $118\u00a0million as of March\u00a029, 2024, which could be realized upon a transition out. The Company is closely monitoring developments in Ukraine and Russia. Changes in laws and regulations or other factors impacting the Company\u2019s ability to fulfill contractual obligations could have an adverse effect on the results of operations.", "entities": [ { "start_character": 447, "end_character": 448, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001877322-24-000088", "filing_date": 1714545175000, "quarter_ending": "20240329", "company_name": "ESAB Corp", "text": "During the three months ended March 31, 2023, Income from continuing operations before income taxes was $71.2 million, while Income tax expense was $37.0 million. The effective tax rate was 52.0% for the three months ended March 31, 2023. The effective tax rate differed from the 2023 U.S. federal statutory rate of 21.0% primarily due to discrete tax expenses in 2023 for dividend withholding taxes and an increase in the liability for uncertain tax positions as discussed below, that do not recur in 2024.", "entities": [ { "start_character": 105, "end_character": 109, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 71200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001877322-24-000088", "filing_date": 1714545175000, "quarter_ending": "20240329", "company_name": "ESAB Corp", "text": "During the three months ended March 29, 2024, Income from continuing operations before income taxes was $81.4 million, while Income tax expense was $18.5 million. The effective tax rate was 22.7% for the three months ended March 29, 2024. The effective tax rate differed from the 2024 U.S. federal statutory rate of 21.0% primarily due to withholding taxes.", "entities": [ { "start_character": 105, "end_character": 109, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 81400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000920522-24-000045", "filing_date": 1714581969000, "quarter_ending": "20240331", "company_name": "ESSEX PROPERTY TRUST, INC.", "text": "Includes the Company's share of equity income from joint ventures and preferred equity investments, gain on sales of co-investments, co-investment promote income and income from early redemption of preferred equity investments. Includes related party income of $1.1 million and $2.0 million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 262, "end_character": 265, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1100000.0 }, { "start_character": 279, "end_character": 282, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001370637-24-000013", "filing_date": 1708539505000, "quarter_ending": "20231231", "company_name": "ETSY INC", "text": "Revenue and net loss were $36.7\u00a0million and $59.1\u00a0million, respectively, for Depop and Elo7, in the aggregate, from their respective dates of acquisition through December 31, 2021. Acquisition-related expenses are expensed as incurred and were recorded in general and administrative expenses. They were $1.2\u00a0million, $2.8\u00a0million, and $36.7\u00a0million for the years ended December 31, 2023, 2022, and 2021, respectively. The 2021 acquisition-related expenses primarily related to advisory, legal, valuation, and other professional fees.", "entities": [ { "start_character": 45, "end_character": 49, "label": "earnings", "start_date_for_period": "2021-07-02", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -59100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-016204", "filing_date": 1708621877000, "quarter_ending": "20231231", "company_name": "EURONET WORLDWIDE, INC.", "text": "We issued Convertible Senior Notes (\"Convertible Notes\") due March 2049 on March 18, 2019. Our Convertible Notes currently have a settlement feature requiring us upon conversion to settle the principal amount of the debt and any conversion value in excess of the principal value (\"conversion premium\"), for cash or shares of our common stock or a combination thereof, at our option. We have stated our intent to settle any conversion of these notes by paying cash for the principal value and issuing common stock for any conversion premium; however, after adopting ASU 2020-06, 2.8 million incremental shares assumed for conversion of convertible notes shall be included in the dilutive earnings per share calculation, if dilutive, regardless of whether the market price trigger has been met. Therefore, our Convertible Notes were included in the calculation of diluted earnings (loss) per share if their inclusion was dilutive. The dilutive effect increases the more the market price exceeds the conversion price of\u00a0$188.73\u00a0per share.\u00a0", "entities": [ { "start_character": 578, "end_character": 581, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 2800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-016204", "filing_date": 1708621877000, "quarter_ending": "20231231", "company_name": "EURONET WORLDWIDE, INC.", "text": "In August 2020, the FASB issued ASU 2020-06,\u00a0\"Accounting for Convertible Instruments and Contracts in an Entity's Own Equity\"\u00a0which simplifies the accounting for convertible instruments by eliminating certain accounting models when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in-capital. Under this ASU, certain debt instruments with embedded conversion features will be accounted for as a single liability measured at its amortized cost. Additionally, this ASU eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments. We adopted this standard on January 1, 2022 using the modified retrospective approach, which resulted in our Convertible Senior Notes due 2049\u00a0being recognized as a single liability. As a result of the adoption of this standard we recorded a $99.7\u00a0million decrease to additional paid-in capital, a $56.8\u00a0million decrease in debt discounts and a $42.9\u00a0million increase in retained earnings. The adoption of this standard also impacted our deferred tax liability by decreasing our deferred tax liability by $15.0\u00a0million, decreasing retained earnings by $10.6\u00a0million, and increasing additional paid-in capital by $25.6\u00a0million. Additionally, the elimination of the treasury stock method will increase the number of dilutive shares used in the diluted earnings per share calculation, if dilutive, by 2.8\u00a0million shares.\u00a0\u00a0", "entities": [ { "start_character": 1508, "end_character": 1511, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 2800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-039798", "filing_date": 1714759383000, "quarter_ending": "20240331", "company_name": "EURONET WORLDWIDE, INC.", "text": "Euronet issued Convertible Senior Notes (\"Convertible Notes\") due March 2049 on March 18, 2019. The Convertible Notes currently have a settlement feature requiring us upon conversion to settle the principal amount of the debt and any conversion value in excess of the principal value (\"conversion premium\"), for cash or shares of Euronet's common stock or a combination thereof, at the Company's option. The Company has stated its intent to settle any conversion of these notes by paying cash for the principal value and issuing common stock for any conversion premium; however, after adopting ASU 2020-06, 2.8 million incremental shares assumed for conversion of convertible notes is required to be included in the dilutive earnings per share calculation, if dilutive, regardless of whether the market price trigger has been met. Therefore, the Convertible Notes were included in the calculation of diluted earnings per share if their inclusion was dilutive. The dilutive effect increases the more the market price exceeds the conversion price of $188.73\u00a0per share. See Note 10, Debt Obligations, to the consolidated financial statements for more information about the Convertible Notes.", "entities": [ { "start_character": 607, "end_character": 610, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 2800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-039798", "filing_date": 1714759383000, "quarter_ending": "20240331", "company_name": "EURONET WORLDWIDE, INC.", "text": "Euronet issued Convertible Senior Notes (\"Convertible Notes\") due March 2049 on March 18, 2019. The Convertible Notes currently have a settlement feature requiring us upon conversion to settle the principal amount of the debt and any conversion value in excess of the principal value (\"conversion premium\"), for cash or shares of Euronet's common stock or a combination thereof, at the Company's option. The Company has stated its intent to settle any conversion of these notes by paying cash for the principal value and issuing common stock for any conversion premium; however, after adopting ASU 2020-06, 2.8 million incremental shares assumed for conversion of convertible notes is required to be included in the dilutive earnings per share calculation, if dilutive, regardless of whether the market price trigger has been met. Therefore, the Convertible Notes were included in the calculation of diluted earnings per share if their inclusion was dilutive. The dilutive effect increases the more the market price exceeds the conversion price of $188.73\u00a0per share. ", "entities": [ { "start_character": 607, "end_character": 610, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 2800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Biodex has generated $18,341,613 of revenue and has generated a loss before tax of $1,100,960. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Biodex's revenue would have been $22,888,022 and loss before tax would have been $1,979,753. If the combination had taken place at the beginning of the year, consolidated revenues would have been $67,173,860 and consolidated losses before tax would have been $17,576,801. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. The pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 41, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 18341613.0 }, { "start_character": 103, "end_character": 112, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 1100960.0 }, { "start_character": 309, "end_character": 319, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 22888022.0 }, { "start_character": 357, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 1979753.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 67173860.0 }, { "start_character": 535, "end_character": 545, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": -17576801.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Biodex has generated $18,341,613 of revenue and has generated a loss before tax of $1,100,960. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Biodex's revenue would have been $22,888,022 and loss before tax would have been $1,979,753. If the combination had taken place at the beginning of the year, consolidated revenues would have been $67,173,860 and consolidated losses before tax would have been $17,576,801. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. The pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 41, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 18341613.0 }, { "start_character": 103, "end_character": 112, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 1100960.0 }, { "start_character": 309, "end_character": 319, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 22888022.0 }, { "start_character": 357, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 1979753.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 67173860.0 }, { "start_character": 535, "end_character": 545, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": -17576801.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Biodex has generated $18,341,613 of revenue and has generated a loss before tax of $1,100,960. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Biodex's revenue would have been $22,888,022 and loss before tax would have been $1,979,753. If the combination had taken place at the beginning of the year, consolidated revenues would have been $67,173,860 and consolidated losses before tax would have been $17,576,801. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. The pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 41, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 18341613.0 }, { "start_character": 103, "end_character": 112, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 1100960.0 }, { "start_character": 309, "end_character": 319, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 22888022.0 }, { "start_character": 357, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 1979753.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 67173860.0 }, { "start_character": 535, "end_character": 545, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": -17576801.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Biodex has generated $18,341,613 of revenue and has generated a loss before tax of $1,100,960. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Biodex's revenue would have been $22,888,022 and loss before tax would have been $1,979,753. If the combination had taken place at the beginning of the year, consolidated revenues would have been $67,173,860 and consolidated losses before tax would have been $17,576,801. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. The pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 41, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 18341613.0 }, { "start_character": 103, "end_character": 112, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 1100960.0 }, { "start_character": 309, "end_character": 319, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 22888022.0 }, { "start_character": 357, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 1979753.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": 67173860.0 }, { "start_character": 535, "end_character": 545, "label": "earnings", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-03-15", "currency_/_unit": "iso4217:CAD", "value": -17576801.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Arrowhead has generated $3,348,342 of revenue and has generated a loss before tax of $73,423. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Arrowhead's revenue would have been $4,719,741 and a loss before tax would have been $80,075. If the combination had taken place at the beginning of the year, consolidated revenues would have been $63,998,850 and consolidated net earnings before tax would have been $16,704,660. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 44, "end_character": 53, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 3348342.0 }, { "start_character": 105, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 73423.0 }, { "start_character": 311, "end_character": 320, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 4719741.0 }, { "start_character": 360, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 80075.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 63998850.0 }, { "start_character": 541, "end_character": 551, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": -16704660.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Arrowhead has generated $3,348,342 of revenue and has generated a loss before tax of $73,423. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Arrowhead's revenue would have been $4,719,741 and a loss before tax would have been $80,075. If the combination had taken place at the beginning of the year, consolidated revenues would have been $63,998,850 and consolidated net earnings before tax would have been $16,704,660. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 44, "end_character": 53, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 3348342.0 }, { "start_character": 105, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 73423.0 }, { "start_character": 311, "end_character": 320, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 4719741.0 }, { "start_character": 360, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 80075.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 63998850.0 }, { "start_character": 541, "end_character": 551, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": -16704660.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Arrowhead has generated $3,348,342 of revenue and has generated a loss before tax of $73,423. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Arrowhead's revenue would have been $4,719,741 and a loss before tax would have been $80,075. If the combination had taken place at the beginning of the year, consolidated revenues would have been $63,998,850 and consolidated net earnings before tax would have been $16,704,660. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 44, "end_character": 53, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 3348342.0 }, { "start_character": 105, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 73423.0 }, { "start_character": 311, "end_character": 320, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 4719741.0 }, { "start_character": 360, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 80075.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 63998850.0 }, { "start_character": 541, "end_character": 551, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": -16704660.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-008449", "filing_date": 1713287801000, "quarter_ending": "20231231", "company_name": "EVOME MEDICAL TECHNOLOGIES INC.", "text": "Since acquisition, Arrowhead has generated $3,348,342 of revenue and has generated a loss before tax of $73,423. These amounts are included in the consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Arrowhead's revenue would have been $4,719,741 and a loss before tax would have been $80,075. If the combination had taken place at the beginning of the year, consolidated revenues would have been $63,998,850 and consolidated net earnings before tax would have been $16,704,660. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 44, "end_character": 53, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 3348342.0 }, { "start_character": 105, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:CAD", "value": 73423.0 }, { "start_character": 311, "end_character": 320, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 4719741.0 }, { "start_character": 360, "end_character": 366, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 80075.0 }, { "start_character": 472, "end_character": 482, "label": "revenues", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": 63998850.0 }, { "start_character": 541, "end_character": 551, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-05-15", "currency_/_unit": "iso4217:CAD", "value": -16704660.0 } ] }, { "form_type": "10-Q", "accession_number": "0001483510-23-000066", "filing_date": 1701966056000, "quarter_ending": "20231028", "company_name": "EXPRESS, INC.", "text": "The Company\u2019s revenues, results of operations and cash flows have been materially adversely impacted by negative macroeconomic factors beginning in the third and fourth quarters of 2022 and throughout 2023. The persistently challenging macroeconomic and retail apparel environments, including reduced consumer spending and increased price sensitivity in discretionary categories, have significantly impacted the Company's performance. Net sales during the thirty-nine weeks ended October 28, 2023 decreased approximately $77.2 million compared to the thirty-nine weeks ended October 29, 2022, despite the addition of $93.0 million of Bonobos net sales. This decline, coupled with aggressive promotional activity, drove gross margin and operating loss below the Company's expectations. For the thirty-nine weeks ended October 28, 2023, the Company reported a net operating loss of $138.4 million and negative operating cash flows of $131.4 million.", "entities": [ { "start_character": 881, "end_character": 886, "label": "ebit", "start_date_for_period": "2023-01-29", "end_date_for_period": "2023-10-28", "currency_/_unit": "iso4217:USD", "value": -138400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012410", "filing_date": 1711989079000, "quarter_ending": "20231231", "company_name": "Eastside Distilling, Inc.", "text": "The\nCompany had an accumulated deficit of $82.7 million as of December 31, 2023, having incurred a net loss of $7.5 million during the year\nended December 31, 2023.", "entities": [ { "start_character": 112, "end_character": 115, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -7500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018888", "filing_date": 1715616954000, "quarter_ending": "20240331", "company_name": "Eastside Distilling, Inc.", "text": "The\nSeries B Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on the last day of December of each year. Dividends\nshall accrue from day to day, whether or not declared, and shall be cumulative. Dividends are payable at the Company\u2019s option either\nin cash or \u201cin kind\u201d in shares of common stock; provided, however that dividends may only be paid in cash following the fiscal\nyear in which the Company has net income (as shown in its audited financial statements contained in its Annual Report on Form 10-K for\nsuch year) of at least $0.5 million. For \u201cin-kind\u201d dividends, holders will receive that number of shares of common stock\nequal to (i) the amount of the dividend payment due such stockholder divided by (ii) the volume weighted average price of the common\nstock for the 90 trading days immediately preceding a dividend date (\u201cVWAP\u201d). For the the year ended December 31, 2023, the\nCompany issued dividends of 92,957 shares of common stock at a VWAP of $1.61 per share to its Series B Preferred stockholders. For both\nthe three months ended March 31, 2024 and 2023, the Company accrued $37,500 of preferred dividends.", "entities": [ { "start_character": 562, "end_character": 565, "label": "earnings", "start_date_for_period": "2021-10-18", "end_date_for_period": "2021-10-19", "currency_/_unit": "iso4217:USD", "value": 500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018888", "filing_date": 1715616954000, "quarter_ending": "20240331", "company_name": "Eastside Distilling, Inc.", "text": "The\nCompany had an accumulated deficit of $84.0 million as of March 31, 2024, having incurred a net loss of $1.3 million during the three\nmonths ended March 31, 2024.", "entities": [ { "start_character": 109, "end_character": 112, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001708035-24-000070", "filing_date": 1709222561000, "quarter_ending": "20231231", "company_name": "Ecovyst Inc.", "text": "Net income attributable to the noncontrolling interest related to the Performance Chemicals business, net of tax was $333 for the year ended December 31, 2021. Net loss attributable to Ecovyst Inc., related to the Performance Chemicals business, net of tax was $(144,137) for the year ended December 31, 2021.", "entities": [ { "start_character": 263, "end_character": 270, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -144137000.0 } ] }, { "form_type": "10-K", "accession_number": "0001708035-24-000070", "filing_date": 1709222561000, "quarter_ending": "20231231", "company_name": "Ecovyst Inc.", "text": "Net income for the year ended December 31, 2023 increased by $1,390 from adjustments for the Company\u2019s interest rate cap agreements related to prior year interest expense amortization, $840 from adjustments related to prior year sales rebate reserves and $2,776 from adjustments for the Company\u2019s equity in net income of affiliated companies related to revised Zeolyst International historical results offset by $1,301 from other adjustments. The $3,705 total net impact of these adjustment was not material to the consolidated financial statements for any prior quarterly or annual periods or the current annual period.", "entities": [ { "start_character": 448, "end_character": 453, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3705000.0 } ] }, { "form_type": "10-K", "accession_number": "0001708035-24-000070", "filing_date": 1709222561000, "quarter_ending": "20231231", "company_name": "Ecovyst Inc.", "text": "Sales to affiliates were $2,457, $5,915 and $3,643 for the years ended December 31, 2023, 2022 and 2021, respectively. Purchases from affiliates were immaterial during the years ended December 31, 2023, 2022 and 2021.", "entities": [ { "start_character": 26, "end_character": 31, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2457000.0 }, { "start_character": 34, "end_character": 39, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 5915000.0 }, { "start_character": 45, "end_character": 50, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 3643000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001708035-24-000083", "filing_date": 1714752534000, "quarter_ending": "20240331", "company_name": "Ecovyst Inc.", "text": "From time to time, the Company makes sales to and purchases raw materials from portfolio companies of funds that are affiliated with INEOS Capital Partners. The Company had sales of $1,249 and $595 to companies affiliated with INEOS Capital Partners for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 183, "end_character": 188, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1249000.0 }, { "start_character": 194, "end_character": 197, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 595000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001708035-24-000083", "filing_date": 1714752534000, "quarter_ending": "20240331", "company_name": "Ecovyst Inc.", "text": "The Partnership purchases certain of its raw materials from the Company and is charged for various manufacturing costs incurred at the Company\u2019s Kansas City production facility. The amount of these costs charged to the Partnership were $4,034 and $5,841 for the three months ended March 31, 2024 and 2023, respectively. Certain administrative, marketing, engineering, management-related, and research and development services are provided to the Partnership by the Company. The Partnership was charged $4,300 and $3,634 for the three months ended March 31, 2024 and 2023, respectively, for these services. In addition, the Partnership was charged certain product demonstration costs of $357 and $500 for the three months ended March 31, 2024 and 2023, respectively. These charges to the Partnership are recorded as reductions in either cost of goods sold or selling, general and administrative expenses in the consolidated statements of income, depending on the nature of the expenditures.", "entities": [ { "start_character": 237, "end_character": 242, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4034000.0 }, { "start_character": 248, "end_character": 253, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5841000.0 }, { "start_character": 503, "end_character": 508, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4300000.0 }, { "start_character": 514, "end_character": 519, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3634000.0 }, { "start_character": 687, "end_character": 690, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 357000.0 }, { "start_character": 696, "end_character": 699, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001708035-24-000083", "filing_date": 1714752534000, "quarter_ending": "20240331", "company_name": "Ecovyst Inc.", "text": "There were no sales to affiliates for the three months ended March 31, 2024 and $1,700 for the three months ended March 31, 2023, respectively. There were no purchases from affiliates for the three months ended March 31, 2024 and immaterial for the three months ended March 31, 2023, respectively.", "entities": [ { "start_character": 11, "end_character": 13, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 }, { "start_character": 81, "end_character": 86, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1700000.0 }, { "start_character": 155, "end_character": 157, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001391127-23-000058", "filing_date": 1700150521000, "quarter_ending": "20230930", "company_name": "Edgio, Inc.", "text": "In accordance with its accounting policies, the company reviews the estimated useful lives of its property and equipment on an ongoing basis. In January 2023, we completed an assessment of the useful lives of our network equipment and concluded to adjust our estimate of the useful life of our network equipment from three to five years due to advances in technology and improvements in how we operate our network equipment. The effect of this change in estimate, effective January 1, 2023, was a reduction of $2,692 and $9,826, primarily in depreciation - network expense in cost of services within our consolidated statement of operations, a decrease in net loss by approximately $2,622 and $9,472, and a decrease in basic and diluted loss per share by $0.01 and $0.04, for the three and nine months ended September 30, 2023, respectively.", "entities": [ { "start_character": 683, "end_character": 688, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 2622000.0 }, { "start_character": 694, "end_character": 699, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 9472000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-015297", "filing_date": 1712596760000, "quarter_ending": "20231231", "company_name": "Eiger BioPharmaceuticals, Inc.", "text": "The Company\u2019s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in the United States in January 2021 and in Europe in November 2022. Prior to 2021, the Company had no product revenue. In the United States, the Company sells Zokinvy to a single specialty pharmacy provider that subsequently dispenses the product directly to patients. The Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue.", "entities": [ { "start_character": 235, "end_character": 237, "label": "revenues", "start_date_for_period": "2020-01-01", "end_date_for_period": "2020-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-015297", "filing_date": 1712596760000, "quarter_ending": "20231231", "company_name": "Eiger BioPharmaceuticals, Inc.", "text": "In June 2021, the French National Agency for Medicines and Health Products Safety (ANSM) granted Zokinvy (lonafarnib) a Temporary Authorizations for Use (Autorisation Temporaire d'Utilisation or ATU) for an early access program for a term of one year. The Company has received a one year extension of the ATU program and expects the program to continue until commercial reimbursement of Zokinvy is approved in France. In the context of this program, the Company sells product to a distributor who in turn ships product to pharmacies after receiving requests from physicians for patients in France. In November 2021, the Company began distributing and recognizing revenue from sales of Zokinvy (lonafarnib) through a reimbursed early access program in France. The Company recorded revenue of $2.4\u00a0million and $0.2\u00a0million from sales of product under the ATU program for the years ended December\u00a031, 2023 and 2022, respectively.", "entities": [ { "start_character": 792, "end_character": 795, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2400000.0 }, { "start_character": 809, "end_character": 812, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001156039-24-000015", "filing_date": 1708533031000, "quarter_ending": "20231231", "company_name": "Elevance Health, Inc.", "text": ", which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year to our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not have an overall material impact, our prior period financial statements presented in this Annual Report on Form 10-K have been restated to reflect the impacts of our adoption as required by the new standard. Adjustments of $(131) and $54, respectively, were made to shareholders\u2019 net income for the years ended December 31, 2022 and 2021, which include adjustments to benefit expense of $155 and $(74), respectively. In addition, the following balance sheet adjustments were made at years ended December 31, 2022 and 2021: $(17) and $(4), respectively, to total assets; $47 and $(39), respectively, to total liabilities; $13 and $(19), respectively, to accumulated other comprehensive loss; and $(64) and $35, respectively to shareholders\u2019 equity and total equity. ", "entities": [ { "start_character": 1349, "end_character": 1352, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -131000000.0 }, { "start_character": 1359, "end_character": 1361, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 54000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021140", "filing_date": 1715099713000, "quarter_ending": "20240331", "company_name": "Empire State Realty OP, L.P.", "text": "Since we became a public company, we have earned supervisory fees from entities affiliated with Anthony E. Malkin, our Chairman and Chief Executive Officer. These fees were $0.2 million and $0.2 million for the three months ended March\u00a031, 2024 and 2023, respectively. These fees are included within third-party management and other fees.", "entities": [ { "start_character": 174, "end_character": 177, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 191, "end_character": 194, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021140", "filing_date": 1715099713000, "quarter_ending": "20240331", "company_name": "Empire State Realty OP, L.P.", "text": "Since we became a public company, we have earned property management fees from entities affiliated with Anthony E. Malkin. These fees were $0.1 million and $0.1 million for the three months ended March\u00a031, 2024 and 2023, respectively. These fees are included within third-party management and other fees.", "entities": [ { "start_character": 140, "end_character": 143, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 157, "end_character": 160, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021140", "filing_date": 1715099713000, "quarter_ending": "20240331", "company_name": "Empire State Realty OP, L.P.", "text": "We receive rent generally at the market rental rate for 5,447 square feet of leased space from an entity affiliated with Anthony E. Malkin at one of our properties. Under the lease, the tenant has the right to cancel such lease without special payment on 90 days\u2019 notice. We also have a shared use agreement with such tenant, to occupy a portion of the leased premises as the office location for Peter L. Malkin, our chairman emeritus, utilizing approximately 15% of the space, for which we pay to such tenant an allocable pro rata share of the cost. We also have agreements with these entities and excluded properties and businesses to provide them with general computer-related support services. Total aggregate revenue was $0.1 million and $0.1 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 727, "end_character": 730, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 744, "end_character": 747, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021106", "filing_date": 1715098719000, "quarter_ending": "20240331", "company_name": "Empire State Realty Trust, Inc.", "text": "We receive rent generally at the market rental rate for 5,447 square feet of leased space from an entity affiliated with Anthony E. Malkin at one of our properties. Under the lease, the tenant has the right to cancel such lease without special payment on 90 days\u2019 notice. We also have a shared use agreement with such tenant, to occupy a portion of the leased premises as the office location for Peter L. Malkin, our chairman emeritus, utilizing approximately 15% of the space, for which we pay to such tenant an allocable pro rata share of the cost. We also have agreements with these entities and excluded properties and businesses to provide them with general computer-related support services. Total aggregate revenue was $0.1 million and $0.1 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 727, "end_character": 730, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 744, "end_character": 747, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021106", "filing_date": 1715098719000, "quarter_ending": "20240331", "company_name": "Empire State Realty Trust, Inc.", "text": "Since we became a public company, we have earned supervisory fees from entities affiliated with Anthony E. Malkin, our Chairman and Chief Executive Officer. These fees were $0.2 million and $0.2 million for the three months ended March\u00a031, 2024 and 2023, respectively. These fees are included within third-party management and other fees.", "entities": [ { "start_character": 174, "end_character": 177, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 191, "end_character": 194, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021106", "filing_date": 1715098719000, "quarter_ending": "20240331", "company_name": "Empire State Realty Trust, Inc.", "text": "Since we became a public company, we have earned property management fees from entities affiliated with Anthony E. Malkin. These fees were $0.1 million and $0.1 million for the three months ended March\u00a031, 2024 and 2023, respectively. These fees are included within third-party management and other fees.", "entities": [ { "start_character": 140, "end_character": 143, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 157, "end_character": 160, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001379041-24-000042", "filing_date": 1708967087000, "quarter_ending": "20231231", "company_name": "Employers Holdings, Inc.", "text": "The LPT Reserve Adjustments for the years ended December\u00a031, 2023 and 2021 decreased GAAP net income by $0.9 million, and increased net income by $2.6 million, respectively, but did not affect taxable income. The LPT Contingent Commission Adjustments increased net income by $0.3 million, and $0.5 million during 2023 and 2021, respectively, but did not increase taxable income.", "entities": [ { "start_character": 105, "end_character": 108, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -900000.0 }, { "start_character": 147, "end_character": 150, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2600000.0 }, { "start_character": 276, "end_character": 279, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 294, "end_character": 297, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001823529-24-000036", "filing_date": 1709188810000, "quarter_ending": "20231231", "company_name": "Enact Holdings, Inc.", "text": "We have a broad customer base of mortgage lenders diversified by size, type and geography that includes large money center banks, non-bank lenders, national and local mortgage bankers, community banks and credit unions. Our largest customer accounted for approximately $118\u00a0million, or 10% of our ", "entities": [ { "start_character": 270, "end_character": 273, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 118000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001823529-24-000036", "filing_date": 1709188810000, "quarter_ending": "20231231", "company_name": "Enact Holdings, Inc.", "text": "The difference of $53.4 million between written premiums of $903.7 million and earned premiums of $957.1 million represents the decrease in unearned premiums for the year ended December\u00a031, 2023. The decrease in unearned premiums was mainly the result of premiums recognized via the earnings curve and low originations related to our single-premium product. Assumed premium as a percentage of net premium earned is 0.2% for the year ended December 31, 2023 and 0.0% for the years ended December 31, 2022 and 2021. ", "entities": [ { "start_character": 99, "end_character": 104, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 957100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001823529-24-000105", "filing_date": 1714718391000, "quarter_ending": "20240331", "company_name": "Enact Holdings, Inc.", "text": "In prior periods, we provided certain information technology and administrative services (such as facilities and maintenance) to Genworth. We charged Genworth $0.1 million for these services for the three months ended March 31, 2023. ", "entities": [ { "start_character": 160, "end_character": 163, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001823529-24-000105", "filing_date": 1714718391000, "quarter_ending": "20240331", "company_name": "Enact Holdings, Inc.", "text": "The difference between written premiums of $230.3 million and earned premiums of $240.7 million represents the decrease in unearned premiums for the three months ended March 31, 2024. The difference between written premiums of $221.1 million and earned premiums of $235.1 million represents the decrease in unearned premiums for the three months ended March 31, 2023. In both periods, the decrease in unearned premiums was primarily the result of premiums earned over time coupled with low originations of our single premium mortgage insurance product. ", "entities": [ { "start_character": 82, "end_character": 87, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 240700000.0 }, { "start_character": 266, "end_character": 271, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 235100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001276187-24-000024", "filing_date": 1708086462000, "quarter_ending": "20231231", "company_name": "Energy Transfer LP", "text": "The Partnership regularly enters into related party transactions with several of its unconsolidated affiliates. In addition to commercial transactions, these transactions include the provision of certain management services and leases of certain assets. While the Partnership believes that such related party transactions generally reflect market rates, the pricing under such agreements may not be comparable to similar transactions with unaffiliated third parties. For the years ended December\u00a031, 2023, 2022 and 2021, the Partnership\u2019s consolidated income statements reflect revenues from related parties of $626\u00a0million, $391\u00a0million and $410\u00a0million, respectively. ", "entities": [ { "start_character": 612, "end_character": 615, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 626000000.0 }, { "start_character": 626, "end_character": 629, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 391000000.0 }, { "start_character": 643, "end_character": 646, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 410000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001463101-24-000071", "filing_date": 1713889727000, "quarter_ending": "20240331", "company_name": "Enphase Energy, Inc.", "text": "For the three months ended March\u00a031, 2024 and 2023, the Company\u2019s income tax provision totaled $4.6\u00a0million and $32.1\u00a0million, respectively, on a net loss before income taxes of $11.5\u00a0million and a net income before income taxes of $179.0\u00a0million, respectively. For the three months ended March\u00a031, 2024, the income tax provision was calculated using the annualized effective tax rate method and was primarily due to tax expense from equity compensation shortfalls, offset by tax benefit from year-to-date loss before income taxes. For the three months ended March 31, 2023, the income tax provision was calculated using the annualized effective tax rate method and was primarily due to projected tax expense in the U.S. and foreign jurisdictions that are profitable, partially offset by a tax deduction from employee stock compensation reported as a discrete event.", "entities": [ { "start_character": 179, "end_character": 183, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -11500000.0 }, { "start_character": 233, "end_character": 238, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 179000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001689375-24-000016", "filing_date": 1710314670000, "quarter_ending": "20231231", "company_name": "Entrada Therapeutics, Inc.", "text": "In July 2023, the Company and Pierrepont Therapeutics, Inc. (Pierrepont) entered into a license agreement (the Pierrepont Agreement) to advance the development of ENTR-501, the Company\u2019s intracellular thymidine phosphorylase enzyme replacement therapy in development for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). The Company recognized no revenue related to this agreement for the year ended ", "entities": [ { "start_character": 374, "end_character": 376, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001805077-24-000013", "filing_date": 1709573353000, "quarter_ending": "20231231", "company_name": "Eos Energy Enterprises, Inc.", "text": "Since its inception, the Company has incurred significant losses and negative cash from operations in order to fund its development. During the year ended December\u00a031, 2023, the Company incurred a net loss of $229,506, incurred negative cash flows from operations of $145,018, and had an accumulated deficit of $875,846 as of December\u00a031, 2023.", "entities": [ { "start_character": 210, "end_character": 217, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -229506000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001805077-24-000051", "filing_date": 1715703486000, "quarter_ending": "20240331", "company_name": "Eos Energy Enterprises, Inc.", "text": "Since its inception, the Company has incurred significant losses and negative cash from operations in order to fund its development. During the three months ended March\u00a031, 2024, the Company incurred a net loss of $46,708, incurred negative cash flows from operations of $40,474 and had an accumulated deficit of $922,554 as of March\u00a031, 2024.", "entities": [ { "start_character": 215, "end_character": 221, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -46708000.0 } ] }, { "form_type": "10-K", "accession_number": "0000727920-24-000005", "filing_date": 1710782956000, "quarter_ending": "20231231", "company_name": "Equitable Financial Life Insurance Co", "text": "The net impact of assumption changes during 2021 increased remeasurement of liability for future policy benefits by $37\u00a0million, decreased policyholders\u2019 benefits by $30\u00a0million, decreased change in market risk benefits and purchased market risk benefits by $414\u00a0million, increased interest credited to policyholder\u2019s account balances by $1\u00a0million and increased amortization of DAC by $2\u00a0million. This resulted in an increase in income (loss) from operations, before income taxes of $404\u00a0million and increased net income (loss) by $319\u00a0million.", "entities": [ { "start_character": 485, "end_character": 488, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 404000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000727920-24-000005", "filing_date": 1710782956000, "quarter_ending": "20231231", "company_name": "Equitable Financial Life Insurance Co", "text": "The net impact of assumption changes during 2022 increased remeasurement of liability for future policy benefits by $8\u00a0million, decreased policyholders\u2019 benefits by $2\u00a0million, increased change in market risk benefits and purchased market risk benefits by $206\u00a0million and increased interest credited to policyholder\u2019s account balances by $1\u00a0million. This resulted in a decrease in income (loss) from operations, before income taxes of $213\u00a0million and a decrease in net income (loss) by $168\u00a0million.", "entities": [ { "start_character": 437, "end_character": 440, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -213000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000727920-24-000005", "filing_date": 1710782956000, "quarter_ending": "20231231", "company_name": "Equitable Financial Life Insurance Co", "text": "The net impact of assumption changes during 2023 decreased other income by $51\u00a0million, increased remeasurement of liability for future policy benefits by $36\u00a0million, increased policyholders\u2019 benefits by $10\u00a0million and decreased change in market risk benefits and purchased market risk benefits by $50\u00a0million. This resulted in a decrease in income (loss) from operations, before income taxes of $47\u00a0million and a decrease in net income (loss) by $37\u00a0million.", "entities": [ { "start_character": 399, "end_character": 401, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -47000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001333986-24-000009", "filing_date": 1708964361000, "quarter_ending": "20231231", "company_name": "Equitable Holdings, Inc.", "text": "The net impact of this assumption update during 2022 increased remeasurement of liability for future policy benefits by $14\u00a0million, decreased policyholders\u2019 benefits by $13\u00a0million, increased change in market risk benefits and purchased market risk benefits by $204\u00a0million and increased interest credited to policyholder\u2019s account balances by $1\u00a0million. This resulted in a decrease in income (loss) from operations, before income taxes of $206\u00a0million and decreased net income (loss) by $163\u00a0million.", "entities": [ { "start_character": 443, "end_character": 446, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -206000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001333986-24-000009", "filing_date": 1708964361000, "quarter_ending": "20231231", "company_name": "Equitable Holdings, Inc.", "text": "The net impact of this assumption update during 2021 increased remeasurement of liability for future policy benefits by $33\u00a0million, increased policyholders\u2019 benefits by $11\u00a0million, decreased change in market risk benefits and purchased market risk benefits by $446\u00a0million, increased interest credited to policyholder\u2019s account balances by $1\u00a0million and increased amortization of DAC by $1\u00a0million. This resulted in an increase in income (loss) from operations, before income taxes of $400\u00a0million and increased net income (loss) by $316\u00a0million.", "entities": [ { "start_character": 489, "end_character": 492, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 400000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001333986-24-000009", "filing_date": 1708964361000, "quarter_ending": "20231231", "company_name": "Equitable Holdings, Inc.", "text": "The net impact of assumption changes during 2023 decreased other income by $9\u00a0million, increased remeasurement of liability for future policy benefits by $51\u00a0million, decreased policy benefits by $2\u00a0million, and decreased the change in market risk benefits and purchased market risk benefits by $53\u00a0million. This resulted in a decrease in income (loss) from operations, before income taxes of $5\u00a0million and decreased net income (loss) by $4\u00a0million.", "entities": [ { "start_character": 394, "end_character": 395, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -5000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140361-24-026010", "filing_date": 1715706898000, "quarter_ending": "20240331", "company_name": "Eterna Therapeutics Inc.", "text": "The Company has incurred significant operating losses and has an accumulated deficit as a result of its efforts to develop product candidates, including conducting clinical trials and providing general and\n administrative support for operations. As of March 31, 2024, the Company had an unrestricted cash balance of approximately $5.1\n million and an accumulated deficit of approximately $193.6 million. For the three months ended March 31, 2024, the Company incurred a net loss of $6.6 million, and the Company used cash of $3.7\n million in operating activities.", "entities": [ { "start_character": 509, "end_character": 512, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001853145-24-000035", "filing_date": 1715274628000, "quarter_ending": "20240331", "company_name": "EverCommerce Inc.", "text": "The Swap Agreements are accounted for as derivatives whereby the fair value of each contract is reported within the unaudited condensed consolidated balance sheets, and related gains or losses resulting from changes in the fair value are reported in interest and other expense, net, in the unaudited condensed consolidated statements of operations and comprehensive loss. As of March\u00a031, 2024 the fair value of the Initial Swap was a liability of $0.6 million while the fair value of the Second Swap was an asset of $0.6 million and are reported in other non-current liabilities and other non-current assets, respectively, on the unaudited condensed consolidated balance sheet. During the three months ended March 31, 2024 and 2023, the related gains and losses resulting from changes in fair value was a gain of $4.8 million and a loss of $4.2 million, respectively.", "entities": [ { "start_character": 814, "end_character": 817, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4800000.0 }, { "start_character": 841, "end_character": 844, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -4200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628908-24-000017", "filing_date": 1708625384000, "quarter_ending": "20231231", "company_name": "Evolent Health, Inc.", "text": "We have included the financial results of NIA in our consolidated financial statements from January 20, 2023. The consolidated statements of operations and comprehensive income (loss) include $242.1\u00a0million of revenues and $0.1\u00a0million of net income attributable to NIA for the year ended December 31, 2023.", "entities": [ { "start_character": 224, "end_character": 227, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001570562-24-000041", "filing_date": 1709829740000, "quarter_ending": "20231231", "company_name": "Evolus, Inc.", "text": "Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next twelve months. The Company recorded net loss from operations of $49,233 and a total net loss of $61,685 for the twelve months ended December 31, 2023. The Company used cash of $34,008 from operations during the twelve months ended December 31, 2023, which included the final lump sum settlement payment of $5,000 to Medytox and Allergan, Inc. and Allergan Limited (together, \u201cAllergan\u201d) and an upfront payment of $4,441 to Symatese S.A.S. (\u201cSymatese\u201d). As of December\u00a031, 2023, the Company had $62,838 in cash and cash equivalents and an accumulated deficit of $558,979. ", "entities": [ { "start_character": 286, "end_character": 292, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -49233000.0 }, { "start_character": 318, "end_character": 324, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -61685000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001570562-24-000080", "filing_date": 1715101241000, "quarter_ending": "20240331", "company_name": "Evolus, Inc.", "text": "Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities and management expects operating losses and negative cash flows to continue for at least the next twelve months. The Company recorded net loss from operations of $8,922 and a total net loss of $13,109 for the three months ended March 31, 2024. The Company used cash of $10,615 from operations during the three months ended March 31, 2024. As of March 31, 2024, the Company had $96,958 in cash and cash equivalents and an accumulated deficit of $572,088. ", "entities": [ { "start_character": 286, "end_character": 291, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -8922000.0 }, { "start_character": 317, "end_character": 323, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -13109000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-008053", "filing_date": 1709226468000, "quarter_ending": "20231231", "company_name": "Evolv Technologies Holdings, Inc.", "text": "Includes related party revenue of $11.3\u00a0million and $13.5\u00a0million for the years ended December\u00a031, 2023 and 2022, respectively.", "entities": [ { "start_character": 35, "end_character": 39, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 11300000.0 }, { "start_character": 53, "end_character": 57, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 13500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-008053", "filing_date": 1709226468000, "quarter_ending": "20231231", "company_name": "Evolv Technologies Holdings, Inc.", "text": "For the year ended December 31, 2022, the reclassifications resulted in an increase in license fee and other revenue of $1.3 million and a corresponding decrease in service revenue, as well as in increase in cost of license fee and other revenue of $2.2 million and a corresponding decrease in cost of service revenue.", "entities": [ { "start_character": 121, "end_character": 124, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022282", "filing_date": 1715272616000, "quarter_ending": "20240331", "company_name": "Evolv Technologies Holdings, Inc.", "text": "Includes related party revenue of $1.9 million and $3.6 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 35, "end_character": 38, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 }, { "start_character": 52, "end_character": 55, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022282", "filing_date": 1715272616000, "quarter_ending": "20240331", "company_name": "Evolv Technologies Holdings, Inc.", "text": "For the three months ended March 31, 2023, the reclassifications resulted in an increase in license fee and other revenue of $0.6 million and a corresponding decrease in service revenue, as well as in increase in cost of license fee and other revenue of $0.3 million and a corresponding decrease in cost of service revenue.", "entities": [ { "start_character": 126, "end_character": 129, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019633", "filing_date": 1715774814000, "quarter_ending": "20240331", "company_name": "Ezagoo Ltd", "text": "As\nof March 31, 2024, the Company had working capital deficit of $3,185,649 and accumulated deficit of $4,833,579,\nand had incurred a net loss of $94,665\nand negative operating cashflows of $148,436 for the three months ended March 31, 2024. The continuation of the Company as a going\nconcern through March 31, 2024 is dependent upon improving profitability and the continuing financial support from its stockholders.\nManagement believes the existing shareholders or external financing will provide additional cash to meet the Company\u2019s\nobligations as they become due.", "entities": [ { "start_character": 147, "end_character": 153, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -94665.0 } ] }, { "form_type": "10-Q", "accession_number": "0000917491-24-000011", "filing_date": 1714581564000, "quarter_ending": "20240331", "company_name": "FARO TECHNOLOGIES INC", "text": "As of March\u00a031, 2024, there were approximately 1,754,711 shares issuable upon the exercise of options, the vesting of time-based restricted stock and the contingent vesting of market-based restricted stock units that were excluded from the dilutive calculations, as they were anti-dilutive. For the three months ended March\u00a031, 2023, there were approximately 1,077,583 issuable upon the exercise of options that were excluded from the dilutive calculations, as they were anti-dilutive. In addition, the Company issued $75 million aggregate principal amount of the Notes on January 24, 2023, which, if converted, would result in the issuance of a maximum of 2,124,645 shares of common stock. These shares were excluded from the dilutive calculations, as their effect would have been anti-dilutive. ", "entities": [ { "start_character": 657, "end_character": 666, "label": "eps", "start_date_for_period": "2023-01-24", "end_date_for_period": "2023-01-24", "currency_/_unit": "xbrli:shares", "value": 2124645.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-040093", "filing_date": 1699549116000, "quarter_ending": "20230930", "company_name": "FDCTECH, INC.", "text": "During\nthe nine months ended September 30, 2023, and 2022, the Company incurred a net income and net loss of $1,366,777 and $974,984.", "entities": [ { "start_character": 110, "end_character": 119, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1366777.0 }, { "start_character": 125, "end_character": 132, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -974984.0 } ] }, { "form_type": "10-K", "accession_number": "0000277509-24-000005", "filing_date": 1709045908000, "quarter_ending": "20231231", "company_name": "FEDERAL SIGNAL CORP /DE/", "text": "In the period between the January\u00a03, 2023 closing date and December\u00a031, 2023, Blasters generated $20.6 million of net sales and $1.5 million of operating income. ", "entities": [ { "start_character": 98, "end_character": 102, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 20600000.0 }, { "start_character": 129, "end_character": 132, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000277509-24-000005", "filing_date": 1709045908000, "quarter_ending": "20231231", "company_name": "FEDERAL SIGNAL CORP /DE/", "text": "In the period between the April\u00a03, 2023 closing date and December\u00a031, 2023, Trackless generated $28.1 million of net sales and $5.1 million of operating income, before elimination of intercompany transactions.", "entities": [ { "start_character": 97, "end_character": 101, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 28100000.0 }, { "start_character": 128, "end_character": 131, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140361-24-025068", "filing_date": 1715244044000, "quarter_ending": "20240331", "company_name": "FEMASYS INC", "text": "$3,599,510. The Company expects such losses to increase over the next few years as\n the Company advances FemBloc through clinical development until FDA approval is received and is available to be marketed.", "entities": [ { "start_character": 1, "end_character": 10, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3599510.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-040055", "filing_date": 1699546090000, "quarter_ending": "20230930", "company_name": "FG Financial Group, Inc.", "text": "For\nthe three months ended September 30, 2023, the Company recorded equity method gains from FGMP of approximately $1.2 million. No\ncapital contributions were made to FGMP during the quarter. For the nine months ended September 30, 2023, the Company contributed\n$0.1\nmillion into FGMP and has recorded equity method gains of approximately $4.1\nmillion. The carrying value of our investment in FGMP as of September 30, 2023 was approximately $9.9\nmillion compared to $5.7\nmillion as of December 31, 2022. Of the $9.9\nmillion carrying value of our investment in FGMP at September 30, 2023 the Company may allocate up to approximately $0.4\nmillion to incentivize and compensate individuals and entities for the successful merger of SPACs launched under our\nplatform.", "entities": [ { "start_character": 442, "end_character": 445, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 9900000.0 }, { "start_character": 467, "end_character": 470, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 5700000.0 }, { "start_character": 512, "end_character": 515, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 9900000.0 } ] }, { "form_type": "10-K", "accession_number": "0000035527-24-000088", "filing_date": 1709053873000, "quarter_ending": "20231231", "company_name": "FIFTH THIRD BANCORP", "text": "Operating lease equipment was $459 million and $627 million at December\u00a031, 2023 and 2022, respectively, net of accumulated depreciation of $355\u00a0million and $338\u00a0million at December\u00a031, 2023 and 2022, respectively. The Bancorp recorded lease income of $135\u00a0million, $146\u00a0million and $152\u00a0million relating to lease payments for operating leases in leasing business revenue in the Consolidated Statements of Income for the years ended December\u00a031, 2023, 2022 and 2021, respectively. Depreciation expense related to operating lease equipment was $110\u00a0million, $121\u00a0million and $124\u00a0million for the years ended December\u00a031, 2023, 2022 and 2021, respectively. The Bancorp received payments of $140\u00a0million and $147\u00a0million related to operating leases during the years ended December\u00a031, 2023 and 2022, respectively.", "entities": [ { "start_character": 253, "end_character": 256, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 135000000.0 }, { "start_character": 267, "end_character": 270, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 146000000.0 }, { "start_character": 284, "end_character": 287, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 152000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000035527-24-000166", "filing_date": 1715102592000, "quarter_ending": "20240331", "company_name": "FIFTH THIRD BANCORP", "text": "Operating lease equipment was $427 million and $459 million at March\u00a031, 2024 and December\u00a031, 2023, respectively, net of accumulated depreciation of $361 million and $355 million at March\u00a031, 2024 and December\u00a031, 2023, respectively. The Bancorp recorded lease income of $28 million and $37 million relating to lease payments for operating leases in leasing business revenue in the Condensed Consolidated Statements of Income during the three months ended March\u00a031, 2024 and 2023, respectively. Depreciation expense related to operating lease equipment was $23 million and $31 million for the three months ended March\u00a031, 2024 and 2023, respectively. The Bancorp received payments of $27 million and $41\u00a0million related to operating leases during the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 273, "end_character": 275, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 28000000.0 }, { "start_character": 289, "end_character": 291, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 37000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000947559-24-000024", "filing_date": 1715348335000, "quarter_ending": "20240331", "company_name": "FIRST BANCSHARES INC /MS/", "text": "At March\u00a031, 2024, the Company had approximately $7.964 billion in assets, $5.086 billion in net loans held for investment (\u201cLHFI\u201d), $6.710 billion in deposits, and $959.9 million in shareholders' equity. For the three months ended March\u00a031, 2024, the Company reported net income of $20.6 million.", "entities": [ { "start_character": 284, "end_character": 288, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 20600000.0 } ] }, { "form_type": "10-K", "accession_number": "0000798941-24-000018", "filing_date": 1708705220000, "quarter_ending": "20231231", "company_name": "FIRST CITIZENS BANCSHARES INC /DE/", "text": "Net interest income, noninterest income and net income of $1.95\u00a0billion, $478\u00a0million and $530\u00a0million, respectively, from the SVB segment (see Note 23\u2014Business Segment Information) were included in BancShares\u2019 Consolidated Statement of Income from the SVBB Acquisition Date through December 31, 2023. ", "entities": [ { "start_character": 91, "end_character": 94, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 530000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000798941-24-000018", "filing_date": 1708705220000, "quarter_ending": "20231231", "company_name": "FIRST CITIZENS BANCSHARES INC /DE/", "text": "The amount of interest income, noninterest income and net income of $1.75\u00a0billion, $1.24\u00a0billion and $587\u00a0million, respectively, attributable to the acquisition of CIT were included in BancShares\u2019 Consolidated Statement of Income for the year ended December 31, 2022. CIT\u2019s interest income, noninterest income and net income noted above reflect management\u2019s best estimates, based on information available at the reporting date.", "entities": [ { "start_character": 102, "end_character": 105, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 587000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000798941-24-000018", "filing_date": 1708705220000, "quarter_ending": "20231231", "company_name": "FIRST CITIZENS BANCSHARES INC /DE/", "text": "The following table presents certain unaudited pro forma financial information for illustrative purposes only, for the year ended December 31, 2022 and 2021 as if CIT had been acquired on January 1, 2021. The unaudited estimated pro forma information combines the historical results of CIT and BancShares and includes certain pro forma adjustments.\u00a0The key pro forma adjustments relate to the following items that were recognized in BancShares Consolidated Statement of Income for the year ended December 31, 2022, but were reflected in 2021 for the pro forma financial information: (i) provision for credit losses of $513 million related to the Non-PCD loans and leases and unfunded commitments; (ii) acquisition-related expenses of $231 million; (iii) estimated purchase accounting adjustment accretion and amortization related to fair value adjustments and intangibles associated with the CIT Merger; and (iv) $431 million gain on acquisition. BancShares expects to achieve operating cost savings and other business synergies as a result of the acquisition that are not reflected in the pro forma amounts that follow. The pro forma information should not be relied upon as being indicative of the historical results of operations that would have occurred had the acquisition taken place on January 1, 2021. Actual results may differ from the unaudited pro forma information presented below and the differences could be significant.", "entities": [ { "start_character": 619, "end_character": 622, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 513000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000798941-24-000031", "filing_date": 1715246407000, "quarter_ending": "20240331", "company_name": "FIRST CITIZENS BANCSHARES INC /DE/", "text": "Net interest income, noninterest income and net income of $65\u00a0million, $14\u00a0million and $35\u00a0million, respectively, attributable to the SVBB Acquisition were included in BancShares\u2019 Consolidated Statement of Income for the three months ended March 31, 2023.", "entities": [ { "start_character": 88, "end_character": 90, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 35000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000921825-24-000018", "filing_date": 1707930212000, "quarter_ending": "20231231", "company_name": "FIRST INDUSTRIAL REALTY TRUST INC", "text": "Net income of the Joint Ventures for the years ended December 31, 2023, 2022 and 2021 was $46,664, $171,511 and $14,905, respectively. Included in net income during the year ended December 31, 2023 was $4,907 of lease revenue as well as gain on sale of real estate of $40,616 related to the sale of approximately 31 acres of land. Our economic share of the lease revenue and gain on sale was $2,404 and $19,902, respectively. Included in net income during the year ended December 31, 2022 is gain on sale of real estate of $171,671 related to the sale of approximately 391 acres of land for which our economic share of the gain on sale was $84,119. Included in net income during the year ended December 31, 2021 is gain on sale of real estate of $15,160 related to the sale of 138 net acres of land from the Former Joint Venture for which our economic share of the gain on sale was $7,142. However, since the Company was the purchaser of the 138 net acres, we netted our portion of gain on sale against the basis of the land acquired. ", "entities": [ { "start_character": 203, "end_character": 208, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4907000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000921825-24-000044", "filing_date": 1713536525000, "quarter_ending": "20240331", "company_name": "FIRST INDUSTRIAL REALTY TRUST INC", "text": "Net income of the Joint Venture for the three months ended March 31, 2024 and 2023 was $2,032 and $40,045, respectively. Included in net income during the three months ended March 31, 2024 was $1,624 of lease revenue as well as gain on sale of real estate of $191. The gain on sale of real estate recognized during the three months ended March 31, 2024 relates to gain that was deferred on land sales during the years ended December 31, 2023 and 2022. An allocable portion of this gain on sale was deferred because the Joint Venture was required to complete infrastructure work for the purchasers of the land. The deferred gain is being recognized under the percentage of completion method. Our economic share of the Joint Venture's lease revenue and gain on sale was $796 and $94, respectively. Included in net income of the Joint Venture during the three months ended March 31, 2023 is gain on sale of real estate of $40,041 related to the sale of approximately 31 acres of land for which our economic share was $19,620. For the three months ended March 31, 2024 and 2023, we earned incentive fees of $406 and $8,045, respectively, from the Joint Venture, which is reflected in the ", "entities": [ { "start_character": 194, "end_character": 199, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1624000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000860413-24-000066", "filing_date": 1714742941000, "quarter_ending": "20240331", "company_name": "FIRST INTERSTATE BANCSYSTEM INC", "text": "Net income increased $2.1 million to $58.4 million, or $0.57 per share, during the three months ended March\u00a031, 2024, as compared to net income of $56.3 million, or $0.54 per share, for the same period in 2023. The increase during the quarter ended March\u00a031, 2024 when compared to the same period in 2023 was primarily attributable to an increase in non-interest income as a result of a $23.4 million loss on the disposition of available-for-sale investment securities during the 2023 period. This increase was partially offset by lower net interest income as a result of higher interest expense on deposits and other borrowed funds. ", "entities": [ { "start_character": 38, "end_character": 42, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 58400000.0 }, { "start_character": 56, "end_character": 60, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": null, "value": 0.57 }, { "start_character": 148, "end_character": 152, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 56300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001274494-24-000022", "filing_date": 1714580551000, "quarter_ending": "20240331", "company_name": "FIRST SOLAR, INC.", "text": "During the three months ended March 31, 2024, we received advance payments of $21.4\u00a0million from this subsidiary for future module sales and recognized $6.1 million of revenue therefrom on module sales of 24 megawatts.", "entities": [ { "start_character": 153, "end_character": 156, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6100000.0 } ] }, { "form_type": "10-K", "accession_number": "0000798354-24-000037", "filing_date": 1708584755000, "quarter_ending": "20231231", "company_name": "FISERV INC", "text": "Includes processing and other fees charged to related party investments accounted for under the equity method of $178 million, $201 million and $203 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively (see Note 19).", "entities": [ { "start_character": 114, "end_character": 117, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 178000000.0 }, { "start_character": 128, "end_character": 131, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 201000000.0 }, { "start_character": 145, "end_character": 148, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 203000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000798354-24-000100", "filing_date": 1713943160000, "quarter_ending": "20240331", "company_name": "FISERV INC", "text": "Includes processing and other fees charged to related party investments accounted for under the equity method of $40 million and $46 million for the three months ended March 31, 2024 and 2023, respectively (see Note 19). ", "entities": [ { "start_character": 114, "end_character": 116, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 40000000.0 }, { "start_character": 130, "end_character": 132, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 46000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000798354-24-000100", "filing_date": 1713943160000, "quarter_ending": "20240331", "company_name": "FISERV INC", "text": "To the extent the Company maintains a controlling financial interest in an alliance, the alliance\u2019s financial statements are consolidated with those of the Company and the related processing fees are treated as an intercompany transaction and eliminated in consolidation. To the extent the Company has significant influence in, but not control of, an alliance, the Company uses the equity method to account for its investment in the alliance. As a result, the processing and other service fees charged to merchant alliances accounted for under the equity method are recognized in the Company\u2019s consolidated statements of income primarily as processing and services revenue. Such fees totaled $40 million and $46 million for the three months ended March 31, 2024 and 2023, respectively. No directors or officers of the Company have ownership interests in any of the alliances. The formation of each of these alliances generally involves the Company and the financial institution contributing contracts with merchants to the alliance and a cash payment from one owner to the other to achieve the desired ownership percentage for each. The Company and the financial institution enter into a long-term processing service agreement, which governs the Company\u2019s provision of transaction processing services to the alliance. The Company had approximately $38 million of amounts due from unconsolidated merchant alliances included within trade accounts receivable, net in the Company\u2019s consolidated balance sheets at both March\u00a031, 2024 and December\u00a031, 2023.", "entities": [ { "start_character": 693, "end_character": 695, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 40000000.0 }, { "start_character": 709, "end_character": 711, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 46000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000928054-24-000023", "filing_date": 1710483422000, "quarter_ending": "20231231", "company_name": "FLOTEK INDUSTRIES INC/CN/", "text": "The Company currently funds its operations with cash on hand, availability under the ABL (see Note 9, \u201cDebt and Convertible Notes Payable\u201d) and other liquid assets. Although the Company has a history of negative cash flows from operations and losses, the Company recognized $24.3\u00a0million and $24.7\u00a0million of gross profit and net income, respectively, during the year ended December 31, 2023. While we believe that our cash, liquid assets, and availability under the ABL will provide us with sufficient financial resources to fund operations to meet our capital requirements and anticipated obligations as they become due, uncertainty surrounding the long term stability and strength of the oil and gas markets could have a negative impact on our liquidity. ", "entities": [ { "start_character": 294, "end_character": 298, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 24700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000928054-24-000053", "filing_date": 1715270859000, "quarter_ending": "20240331", "company_name": "FLOTEK INDUSTRIES INC/CN/", "text": "The Company currently funds its operations with cash on hand, availability under the ABL (see Note 9, \u201cDebt and Convertible Notes Payable\u201d) and other liquid assets. The Company recognized $8.8 million and $1.6 million of gross profit and net income, respectively, during the three months ended March 31, 2024. While we believe that our cash, liquid assets, and availability under the ABL will provide us with sufficient financial resources to fund operations to meet our capital requirements and anticipated obligations as they become due, uncertainty surrounding the long-term stability and strength of the oil and gas markets could have a negative impact on our liquidity. The availability of capital is dependent on the Company\u2019s operating cash flow, which is currently expected to be principally derived from the ProFrac Agreement (see Note 9, \u201cDebt and Convertible Notes Payable\u201d and Note 16, \u201cRelated Party Transactions\u201d). Related party revenues for the three months ended March 31, 2024 included Contract Shortfall Fees of $8.7 million. Related party receivables as of March 31, 2024 included accrued Contract Shortfall Fees of $13.7\u00a0million comprised of the remaining 2023 Contract Shortfall Fees payment of $5.0\u00a0million, which was collected in April 2024, and $8.7\u00a0million of accrued 2024 Contract Shortfall Fees, which will be due in the first quarter of 2025 under the terms of the ProFrac Agreement. ", "entities": [ { "start_character": 207, "end_character": 210, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 } ] }, { "form_type": "10-K", "accession_number": "0000038009-24-000016", "filing_date": 1707248182000, "quarter_ending": "20231231", "company_name": "FORD MOTOR CREDIT CO LLC", "text": "The Unallocated Other was a $173 million loss for full year 2023, a $340 million deterioration from 2022, primarily reflecting negative derivative market valuation adjustments in 2023, and non-recurrence of positive derivative market valuation adjustments in prior year.", "entities": [ { "start_character": 29, "end_character": 32, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -173000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000881453-24-000006", "filing_date": 1710420076000, "quarter_ending": "20231231", "company_name": "FORTITUDE LIFE INSURANCE & ANNUITY CO", "text": "Company\u2019s products. Commissions and fees were paid by PAD to broker-dealers who sold the Predecessor Company\u2019s products. Commissions and fees paid by the Predecessor Company to PAD were $29 million for the three months ended March 31, 2022 and $467 million for the year ended December 31, 2021.", "entities": [ { "start_character": 187, "end_character": 189, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": 29000000.0 }, { "start_character": 245, "end_character": 248, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 467000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000881453-24-000006", "filing_date": 1710420076000, "quarter_ending": "20231231", "company_name": "FORTITUDE LIFE INSURANCE & ANNUITY CO", "text": "As part of the recapture transaction, the Predecessor Company sent invested assets of $6.8 billion, net of $2.0 billion ceding commissions as consideration to Pruco Life, which is equivalent to the amount of statutory reserve credit taken as of June 30, 2021. The company released living benefit liabilities of $8.3 billion as well as variable annuity base contracts of $3.0 billion and benefit and payout reserves of $0.9 billion. ", "entities": [ { "start_character": 108, "end_character": 111, "label": "revenues", "start_date_for_period": "2021-07-01", "end_date_for_period": "2021-07-01", "currency_/_unit": "iso4217:USD", "value": 2000000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000352825-24-000108", "filing_date": 1715086936000, "quarter_ending": "20240331", "company_name": "FOSTER L B CO", "text": "For the three months ended March 31, 2024 and 2023, the Company recorded an income tax expense of $289 on pre-tax income of $4,694 and an income tax benefit of $541 on pre-tax losses of $2,712, respectively, for an effective income tax rate of 6.2% and 19.9%, respectively. The Company's effective income tax rate for the three months ended March 31, 2024 differed from the federal statutory rate of 21% primarily due to the realization of a portion of its U.S. deferred tax assets previously offset by a valuation allowance. The Company continues to maintain a full valuation allowance against its U.S. deferred tax assets, which is likely to result in significant variability of the effective tax rate in the current year. Changes in pre-tax income projections, combined with the seasonal nature of our businesses, could also impact the effective income tax rate each quarter.", "entities": [ { "start_character": 125, "end_character": 130, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4694000.0 }, { "start_character": 187, "end_character": 192, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -2712000.0 } ] }, { "form_type": "10-K", "accession_number": "0000831259-24-000011", "filing_date": 1708020031000, "quarter_ending": "20231231", "company_name": "FREEPORT-MCMORAN INC", "text": "2021. Consolidated revenues also include PT-FI\u2019s sales to PT Smelting totaling $27 million in 2023 (reflecting adjustments to prior period provisionally priced concentrate sales), $3.0 billion in 2022 and $3.1 billion in 2021 as well as sales to PT-FI\u2019s partner in PT Smelting, MMC, totaling $2.0\u00a0billion in 2023, $0.6\u00a0billion in 2022 and $0.4\u00a0billion in 2021. ", "entities": [ { "start_character": 80, "end_character": 82, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 27000000.0 }, { "start_character": 181, "end_character": 184, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3000000000.0 }, { "start_character": 206, "end_character": 209, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 3100000000.0 }, { "start_character": 293, "end_character": 296, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2000000000.0 }, { "start_character": 315, "end_character": 318, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 600000000.0 }, { "start_character": 340, "end_character": 343, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 400000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000831259-24-000011", "filing_date": 1708020031000, "quarter_ending": "20231231", "company_name": "FREEPORT-MCMORAN INC", "text": "Outstanding stock options with exercise prices greater than the average market price of FCX\u2019s common stock during the year are excluded from the computation of diluted net income per share of common stock. Excluded shares of common stock associated with outstanding stock options totaled less than 1 million shares in 2023, 1 million shares in 2022 and 5 million shares in 2021.", "entities": [ { "start_character": 298, "end_character": 299, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 1000000.0 }, { "start_character": 324, "end_character": 325, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 1000000.0 }, { "start_character": 353, "end_character": 354, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 5000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000831259-24-000011", "filing_date": 1708020031000, "quarter_ending": "20231231", "company_name": "FREEPORT-MCMORAN INC", "text": "FCX concluded that the attribution of PT-FI\u2019s net income or loss from December 21, 2018 (the date of the divestment transaction), through December 31, 2022 (the Initial Period), should be based on the economics replacement agreement included in the PT-FI Shareholders Agreement, as previously discussed. The economics replacement agreement entitled FCX to approximately 81% of PT-FI dividends paid during the Initial Period, with the remaining 19% paid to the noncontrolling interests. PT-FI\u2019s cumulative net income during the Initial Period totaled $6.0 billion, of which $4.9 billion was attributed to FCX. In addition, because PT-FI did not achieve the Gold Target (as defined in the PT-FI Shareholders Agreement) during the Initial Period, PT-FI\u2019s net income and cash dividends associated with the sale of approximately 190,000 ounces of gold during 2023 were attributed approximately 81% to FCX and 19% to MIND ID.", "entities": [ { "start_character": 574, "end_character": 577, "label": "earnings", "start_date_for_period": "2018-12-22", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 4900000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-011529", "filing_date": 1710523020000, "quarter_ending": "20231231", "company_name": "FS Specialty Lending Fund", "text": "Loan origination fees, original issue discount and market discount are capitalized and the Company accretes such amounts as interest income over the respective term of the loan or security. Upon the prepayment of a loan or security, any unamortized loan origination fees and original issue discount are recorded as interest income. Structuring and other non-recurring upfront fees are recorded as fee income when earned. The Company records prepayment premiums on loans and securities as fee income when it earns such amounts. For the year ended December 31, 2023, the Company recognized $591 in structuring or other upfront fee revenue. For the years ended December 31, 2022 and 2021, the Company did not recognize any structuring or other upfront fee revenue. ", "entities": [ { "start_character": 589, "end_character": 592, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 591000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020074", "filing_date": 1714670601000, "quarter_ending": "20240331", "company_name": "Fat Brands, Inc", "text": "The Company recognized loss from operations of $1.4 million during the thirteen weeks ended March\u00a031, 2024 and income from operations of $0.4 million during the thirteen weeks ended March\u00a026, 2023. The Company has a history of net losses and an accumulated deficit of $307.1 million as of March\u00a031, 2024. Additionally, the Company had negative working capital of $142.5 million. Of this amount, $91.8 million represents redeemable preferred stock as discussed in Note 9. Since the Company did not deliver the applicable cash proceeds at the related due dates, the amount accrues interest until the payments are completed. The Company had $39.9 million of unrestricted cash at March\u00a031, 2024 and plans on the combination of cash flows from operations, cash on hand, $87.0 million of issued but not sold aggregate principal amount of fixed rate secured notes and $105.2 million aggregate principal amount of repurchased but not re-sold fixed rate secured notes (see Note 8) to be sufficient to cover any working capital requirements for the next twelve months from the date of this report. If the Company does not achieve its operating plan, additional forms of financing may be required through the issuance of debt or equity. Although management believes it will have access to financing, no assurances can be given that such financing will be available on acceptable terms, in a timely manner or at all.", "entities": [ { "start_character": 48, "end_character": 51, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1400000.0 }, { "start_character": 138, "end_character": 141, "label": "ebit", "start_date_for_period": "2022-12-26", "end_date_for_period": "2023-03-26", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-011953", "filing_date": 1710869001000, "quarter_ending": "20231231", "company_name": "Fathom Holdings Inc.", "text": "\u2014 The Company has a history of negative cash flows from operations and operating losses. The Company generated net losses of approximately $24.0 million and $27.6 million, for the years ended December\u00a031, 2023 and 2022, respectively. Additionally, the Company anticipates further expenditures associated with the process of expanding its business organically and via acquisitions. The Company had cash and cash equivalents of $7.4 million and $8.3 million as of December\u00a031, 2023 and 2022, respectively. Management believes that existing cash along with its planned budget, which includes an increase in agent fees implemented in January 2024, growth from increasing attach rates across the Company\u2019s businesses from internal referrals, reduction of certain expenses given initiatives implemented throughout 2023, and the expected ability to achieve sales volumes necessary to cover forecasted expenses, provide sufficient funding to continue as a going concern for a period of at least one year from the date of the issuance of these consolidated financial statements.", "entities": [ { "start_character": 140, "end_character": 144, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -24000000.0 }, { "start_character": 158, "end_character": 162, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -27600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022767", "filing_date": 1715587721000, "quarter_ending": "20240331", "company_name": "Fathom Holdings Inc.", "text": "\u2014 The Company has a history of negative cash flows from operations and operating losses. The Company generated net losses of approximately $5.9 million and $5.7 million for the three months ended March\u00a031, 2024 and 2023, respectively. Additionally, the Company anticipates further expenditures associated with the process of expanding its business organically and via acquisitions. The Company received net proceeds of $3.3 million in April 2023 from the issuance of convertible notes. The Company had cash and cash equivalents of $5.7 million and $7.4 million as of March\u00a031, 2024 and December\u00a031, 2023, respectively. ", "entities": [ { "start_character": 140, "end_character": 143, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -5900000.0 }, { "start_character": 157, "end_character": 160, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -5700000.0 }, { "start_character": 532, "end_character": 535, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -5700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001520138-24-000013", "filing_date": 1705384923000, "quarter_ending": "20231130", "company_name": "FingerMotion, Inc.", "text": "We\nrecorded $27,588,403 and $21,241,015 in revenue, respectively, for the nine months ended November 30, 2023 and 2022.", "entities": [ { "start_character": 13, "end_character": 23, "label": "revenues", "start_date_for_period": "2023-03-01", "end_date_for_period": "2023-11-30", "currency_/_unit": "iso4217:USD", "value": 27588403.0 }, { "start_character": 29, "end_character": 39, "label": "revenues", "start_date_for_period": "2022-03-01", "end_date_for_period": "2022-11-30", "currency_/_unit": "iso4217:USD", "value": 21241015.0 } ] }, { "form_type": "10-K", "accession_number": "0001856365-24-000013", "filing_date": 1711386983000, "quarter_ending": "20231231", "company_name": "Finwise Bancorp", "text": "During the third quarter of 2022, the Company identified an error in the calculation of the Company\u2019s tax provision which understated income tax expense for previously reported financial statements. The error was related to an incorrect application of Section 162(m) of the Internal Revenue Code, which limits tax deductions relating to executive compensation of certain executives of publicly held companies. The Company recorded an out-of-period adjustment during the third quarter of 2022 to correct the previously understated income tax expense. The adjustment resulted in a decrease to after-tax income of $(0.9)\u00a0million for the year ended December 31, 2022. The impact associated with this correction was not considered material to the interim unaudited consolidated financial statements for the three months ended September 30, 2022, year ended December 31, 2022, or the financial statements of any previously filed interim or annual periods.", "entities": [ { "start_character": 613, "end_character": 616, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001574197-24-000018", "filing_date": 1709323832000, "quarter_ending": "20231231", "company_name": "Five Point Holdings, LLC", "text": "The Company and a subsidiary of Lennar Corporation separately lease portions of the building under the ownership of the Gateway Commercial Venture, and during the years ended December\u00a031, 2023, 2022 and 2021, the Gateway Commercial Venture recognized $8.5\u00a0million, $8.4\u00a0million and $8.5\u00a0million, respectively, in rental revenues from those leasing arrangements.", "entities": [ { "start_character": 252, "end_character": 255, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 8500000.0 }, { "start_character": 266, "end_character": 269, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 8400000.0 }, { "start_character": 283, "end_character": 286, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 8500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001574197-24-000063", "filing_date": 1713549745000, "quarter_ending": "20240331", "company_name": "Five Point Holdings, LLC", "text": "At March\u00a031, 2024 and December\u00a031, 2023, included in contract assets in the table above is $64.5 million and $66.1 million, respectively, attributed to incentive compensation revenue recognized but not yet due (see Note 3). Management fee revenues under the A&R DMA are included in management services\u2014related party in the accompanying condensed consolidated statements of operations and are included in the Great Park segment. Management fee revenues under the A&R DMA were $8.6 million and $4.1 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 476, "end_character": 479, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 8600000.0 }, { "start_character": 493, "end_character": 496, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4099999.9999999995 } ] }, { "form_type": "10-Q", "accession_number": "0001574197-24-000063", "filing_date": 1713549745000, "quarter_ending": "20240331", "company_name": "Five Point Holdings, LLC", "text": "During the three months ended March\u00a031, 2024, the Company recorded a $1.0 million provision for income taxes on pre-tax income of $7.0 million. In the three months ended March\u00a031, 2023, the Company recorded no provision or benefit for income taxes (after application of an increase in the Company\u2019s valuation allowance) on pre-tax loss of $9.7 million. The effective tax rate for the three months ended March\u00a031, 2024 was higher than in the three months ended March\u00a031, 2023 primarily due to the Company\u2019s valuation allowance, which was released during the year ended December 31, 2023. The effective tax rates for both the three months ended March\u00a031, 2024 and 2023 differ from the 21% federal statutory rate and applicable state statutory rates primarily due to the disallowance of executive compensation expenses not deductible for tax and to the pre-tax portion of income and losses that are passed through to the other partners of the Operating Company and the San Francisco Venture.", "entities": [ { "start_character": 131, "end_character": 134, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7000000.0 }, { "start_character": 340, "end_character": 343, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -9700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001574197-24-000063", "filing_date": 1713549745000, "quarter_ending": "20240331", "company_name": "Five Point Holdings, LLC", "text": "The Gateway Commercial Venture owns one commercial office building and approximately 50 acres of commercial land with additional development rights at a 73 acre office, medical, research and development campus located within the Great Park Neighborhoods (the \u201cFive Point Gateway Campus\u201d). The Five Point Gateway Campus consists of four buildings totaling approximately one million square feet. The Company and a subsidiary of Lennar lease portions of the building owned by the Gateway Commercial Venture, and during the three months ended March\u00a031, 2024 and 2023, the Gateway Commercial Venture recognized $2.5\u00a0million and $2.2\u00a0million, respectively, in rental revenues from those leasing arrangements.", "entities": [ { "start_character": 607, "end_character": 610, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2500000.0 }, { "start_character": 624, "end_character": 627, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "Since the acquisition date through December 31, 2023, Original Hemp revenue was $0.2 million with net income and comprehensive income of $0.1 million.", "entities": [ { "start_character": 81, "end_character": 84, "label": "revenues", "start_date_for_period": "2023-02-28", "end_date_for_period": "2023-03-01", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "Since the acquisition date through December 31, 2023, Original Hemp revenue was $0.2 million with net income and comprehensive income of $0.1 million.", "entities": [ { "start_character": 81, "end_character": 84, "label": "revenues", "start_date_for_period": "2023-02-28", "end_date_for_period": "2023-03-01", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "If FGH was acquired at January 1, 2022, the combined revenue and net loss of FGH and the Company would have increased approximately $40.3 million and $19.0 million, respectively (unaudited).", "entities": [ { "start_character": 133, "end_character": 137, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 40300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "If FGH was acquired at January 1, 2022, the combined revenue and net loss of FGH and the Company would have increased approximately $40.3 million and $19.0 million, respectively (unaudited).", "entities": [ { "start_character": 133, "end_character": 137, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 40300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "If JustCBD was acquired at January 1, 2022, the combined revenue and net loss of JustCBD and the Company would have increased approximately $5.2 million and $1.6 million, respectively (unaudited).", "entities": [ { "start_character": 141, "end_character": 144, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 5200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "If JustCBD was acquired at January 1, 2022, the combined revenue and net loss of JustCBD and the Company would have increased approximately $5.2 million and $1.6 million, respectively (unaudited).", "entities": [ { "start_character": 141, "end_character": 144, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 5200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "If No Cap was acquired at January 1, 2022, the combined revenue of No Cap and the Company would have increased approximately $1.9 million, and the combined net loss would have decreased by $1.0 million (unaudited). ", "entities": [ { "start_character": 126, "end_character": 129, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "If No Cap was acquired at January 1, 2022, the combined revenue of No Cap and the Company would have increased approximately $1.9 million, and the combined net loss would have decreased by $1.0 million (unaudited). ", "entities": [ { "start_character": 126, "end_character": 129, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "The fair value of the trade receivables reflects a $0.2 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, No Cap revenue was $0.6 million with net income and comprehensive loss of $0.1 million.", "entities": [ { "start_character": 232, "end_character": 235, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-007367", "filing_date": 1711644287000, "quarter_ending": "20231231", "company_name": "Flora Growth Corp.", "text": "The fair value of the trade receivables reflects a $0.2 million discount to the gross contractual amounts as allowance for potentially uncollectible amounts. Since the acquisition date through December 31, 2022, No Cap revenue was $0.6 million with net income and comprehensive loss of $0.1 million.", "entities": [ { "start_character": 232, "end_character": 235, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-009539", "filing_date": 1709795342000, "quarter_ending": "20231231", "company_name": "Foghorn Therapeutics Inc.", "text": "(\u201cLilly\u201d) (see Note 8). In the third quarter of 2022, the Company achieved a research milestone related to a collaboration agreement (the \u201cMerck Collaboration Agreement\u201d) with Merck Sharp & Dohme Corp. (\u201cMerck\u201d) and received a $5.0\u00a0million milestone payment. The Company has incurred recurring losses, including net losses of $98.4 million and $108.9 million for the years ended December\u00a031, 2023 and 2022, respectively. As of December\u00a031, 2023, the Company had an accumulated deficit of $471.6 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.", "entities": [ { "start_character": 327, "end_character": 331, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -98400000.0 }, { "start_character": 345, "end_character": 350, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -108900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020455", "filing_date": 1714979037000, "quarter_ending": "20240331", "company_name": "Foghorn Therapeutics Inc.", "text": "The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of preferred stock, upfront and milestone payments from collaboration agreements, a public offering and a stock purchase agreement. The Company has incurred recurring losses, including net losses of $25.0\u00a0million and $30.5\u00a0million for the three months ended March\u00a031, 2024 and 2023, respectively. As of March\u00a031, 2024, the Company had an accumulated deficit of $496.6 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these interim condensed consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.", "entities": [ { "start_character": 522, "end_character": 526, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -25000000.0 }, { "start_character": 540, "end_character": 544, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -30500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001965040-24-000036", "filing_date": 1716534094000, "quarter_ending": "20240331", "company_name": "Fortrea Holdings Inc.", "text": "During the three months ended March 31, 2023, there were reductions of approximately $11 from performance obligations which were partially satisfied in previous periods; such amounts were primarily related to changes in estimate and to a much lesser extent, changes in scope. The change in estimate resulted in an estimated reduction to revenue of $10, and a decrease in income from continuing operations of $8 and in income per share of $0.09.", "entities": [ { "start_character": 409, "end_character": 410, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -8000000.0 }, { "start_character": 439, "end_character": 443, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": null, "value": -0.09 } ] }, { "form_type": "10-Q", "accession_number": "0001965040-24-000036", "filing_date": 1716534094000, "quarter_ending": "20240331", "company_name": "Fortrea Holdings Inc.", "text": "During the three months ended March 31, 2024, there were reductions of approximately $34 in revenue related to performance obligations partially satisfied in previous periods. Of this reduction, approximately half was associated with changes in scope or price, and approximately half was related to changes in estimated effort to complete customer contract obligations. The change in estimate resulted in an estimated reduction to revenue of $17, and an increase in loss from continuing operations of $16 and in loss per share of $0.18. ", "entities": [ { "start_character": 502, "end_character": 504, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -16000000.0 }, { "start_character": 531, "end_character": 535, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": null, "value": -0.18 } ] }, { "form_type": "10-K", "accession_number": "0001562528-24-000008", "filing_date": 1708965333000, "quarter_ending": "20231231", "company_name": "Franklin BSP Realty Trust, Inc.", "text": "Rental income for the years ended December\u00a031, 2023 and 2022 totaled $17.9\u00a0million and $9.6\u00a0million, respectively. Rental income is included in ", "entities": [ { "start_character": 70, "end_character": 74, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 17900000.0 }, { "start_character": 88, "end_character": 91, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001562528-24-000016", "filing_date": 1714407857000, "quarter_ending": "20240331", "company_name": "Franklin BSP Realty Trust, Inc.", "text": "Rental income for the three months ended March\u00a031, 2024 and 2023 totaled $4.7\u00a0million and $3.1\u00a0million, respectively. Rental income is included in ", "entities": [ { "start_character": 74, "end_character": 77, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4700000.0 }, { "start_character": 91, "end_character": 94, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-011460", "filing_date": 1710518941000, "quarter_ending": "20231231", "company_name": "Fresh Tracks Therapeutics, Inc.", "text": "The Company has incurred significant operating losses and has an accumulated deficit as a result of in-licensing and development of product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the year ended December\u00a031, 2023, the Company had a net loss of $5.7\u00a0million and net cash used in operating activities of $4.3\u00a0million. As of\u00a0December\u00a031, 2023, the Company had cash and cash equivalents of $10.9\u00a0million\u00a0and an accumulated deficit of $172.2\u00a0million. The Company expects to continue to incur additional losses for the foreseeable future as it implements the Plan of Dissolution.", "entities": [ { "start_character": 345, "end_character": 348, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -5700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-009759", "filing_date": 1710311497000, "quarter_ending": "20231231", "company_name": "GAN Ltd", "text": "The\naccompanying consolidated financial statements have been prepared on the going concern basis. As of December 31, 2023, the Company had\nan accumulated deficit of $309.3 million, with cash of $38.6 million and liabilities to users of $10.2 million. During the year ended\nDecember 31, 2023, the Company incurred a net loss of $34.4 million. The Company used $3.6 million of cash in operations during the year\nended December 31, 2023. In April 2022, a subsidiary of the Company entered into a $30.0 million term credit facility with net proceeds\nof $27.6 million (the \u201cCredit Facility\u201d).", "entities": [ { "start_character": 328, "end_character": 332, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -34400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018495", "filing_date": 1715274073000, "quarter_ending": "20240331", "company_name": "GAN Ltd", "text": "The\naccompanying condensed consolidated financial statements have been prepared on a going concern basis. As of March 31, 2024, the Company\nhad an accumulated deficit of $313.5 million, with cash of $36.6 million and liabilities to users of $10.2 million. During the three\nmonths ended March 31, 2024, the Company incurred a net loss of $4.2 million. The Company used $0.3 million of cash in operations during\nthe three months ended March 31, 2024. In April 2022, a subsidiary of the Company entered into a $30.0 million term credit facility with\nnet proceeds of $27.6 million (the \u201cCredit Facility\u201d).", "entities": [ { "start_character": 338, "end_character": 341, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018495", "filing_date": 1715274073000, "quarter_ending": "20240331", "company_name": "GAN Ltd", "text": "On\nNovember 7, 2023, the Company entered into the Merger Agreement at a share price of $1.97.\nThe close of the merger is also predicated upon receipt of approval of the Merger and change in control of the Company by all\nrelevant gaming authorities and other conditions. The Company anticipates that securing such regulatory approvals will take some\ntime, and that the closing of the Merger may not occur until late 2024 or early 2025. Refer to Note 1. As the Company entered into,\nand announced, the Merger Agreement prior to the revenue conditions being met, and the share price would be less than $2.00\nper share threshold, there would be no liability. A 75% probability was applied to the sale\nscenario resulting in $0\nvalue and 25% to the year-end Monte Carlo value which assumes a sale in the future with potential revenue thresholds being met. As\nof December 31, 2023, the fair value was determined to be approximately $0.3\nmillion. On March 31, 2024, the fair value was determined to be approximately $0.3\nmillion. The recurring value is not sensitive to significant changes in inputs due primarily to the weighting of the sale scenario. Changes to probability could result in increases or decreases\nto the valuation of the liability in the future.", "entities": [ { "start_character": 720, "end_character": 721, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 } ] }, { "form_type": "10-Q", "accession_number": "0000749251-24-000024", "filing_date": 1714457119000, "quarter_ending": "20240331", "company_name": "GARTNER INC", "text": "The Company evaluates segment performance and allocates resources based on gross contribution margin. Gross contribution, as presented in the tables below, is defined as operating income or loss excluding certain Cost of services and product development expenses, Selling, general and administrative expenses, Depreciation, Amortization of intangibles, Acquisition and integration charges and Gain from sale of divested operation. Certain bonus and fringe benefit costs included in consolidated Cost of services and product development are not allocated to segment expense. The accounting policies used by the reportable segments are the same as those used by the Company. There are no intersegment revenues. The Company does ", "entities": [ { "start_character": 540, "end_character": 542, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011946", "filing_date": 1711724467000, "quarter_ending": "20231231", "company_name": "GENELUX Corp", "text": "The\naccompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement\nof liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, the Company has\nexperienced recurring losses from operations since inception and incurred a net loss of $28,297 and used cash in operations of $20,275\nduring the year ended December 31, 2023. These factors raise substantial doubt about the Company\u2019s ability to continue as a going\nconcern. The ability of the Company to continue as a going concern is dependent upon the Company\u2019s ability to raise additional\nfunds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is\nunable to continue as a going concern.", "entities": [ { "start_character": 372, "end_character": 378, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -28297000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018436", "filing_date": 1715271358000, "quarter_ending": "20240331", "company_name": "GENELUX Corp", "text": "The\naccompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets\nand the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements,\nthe Company has experienced recurring losses from operations since inception and incurred a net loss of $7,850 and used cash in operations\nof $4,354 during the three months ended March 31, 2024, and had an accumulated deficit of $229,374 as of March 31, 2024. These factors raise substantial doubt about the Company\u2019s ability to continue\nas a going concern. The ability of the Company to continue as a going concern is dependent upon the Company\u2019s ability to raise\nadditional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the\nCompany is unable to continue as a going concern.", "entities": [ { "start_character": 382, "end_character": 387, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -7850000.0 } ] }, { "form_type": "10-K", "accession_number": "0001022321-24-000018", "filing_date": 1708696351000, "quarter_ending": "20231231", "company_name": "GENESIS ENERGY LP", "text": "During the years ended December 31, 2023, 2022, and 2021, we acted as a lessor in our revenue contracts associated with our 330,00 barrel-capacity ocean going tanker, the M/T American Phoenix, included in our marine transportation segment. Our lease revenues for this arrangement were $23.6\u00a0million, $16.4\u00a0million and $15.0\u00a0million for the years ended December 31, 2023, 2022 and 2021, respectively. ", "entities": [ { "start_character": 287, "end_character": 291, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 23600000.0 }, { "start_character": 302, "end_character": 306, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 16399999.999999998 }, { "start_character": 320, "end_character": 324, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 15000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001022321-24-000051", "filing_date": 1714653239000, "quarter_ending": "20240331", "company_name": "GENESIS ENERGY LP", "text": "During the three months ended March 31, 2024 and 2023, we acted as a lessor in a revenue contract associated with our 330,000 barrel-capacity ocean gong tanker, the M/T American Phoenix, included in our marine transportation segment. Our lease revenues for this arrangement were $6.8 million and $5.8 million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 280, "end_character": 283, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6800000.0 }, { "start_character": 297, "end_character": 300, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001143513-24-000006", "filing_date": 1714580574000, "quarter_ending": "20240331", "company_name": "GLADSTONE CAPITAL CORP", "text": "Gladstone Securities, LLC (\u201cGladstone Securities\u201d), a privately-held broker-dealer registered with the Financial Industry Regulatory Authority and insured by the Securities Investor Protection Corporation, which is 100% indirectly owned and controlled by Mr. Gladstone, our chairman and chief executive officer, has provided other services, such as investment banking and due diligence services, to certain of our portfolio companies, for which Gladstone Securities receives a fee. Any such fees paid by portfolio companies to Gladstone Securities do not impact the fees we pay to the Adviser or the non-contractual, unconditional and irrevocable credits against the base management fee or incentive fee. Gladstone Securities received fees from portfolio companies totaling $0.1 million during each of the three and six months ended March\u00a031, 2024, respectively, and $0.2 million and $0.3 million during the three and six months ended March\u00a031, 2023, respectively.", "entities": [ { "start_character": 868, "end_character": 871, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 885, "end_character": 888, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001321741-24-000005", "filing_date": 1707235646000, "quarter_ending": "20231231", "company_name": "GLADSTONE INVESTMENT CORPORATION\\DE", "text": "In October 2023, we exited our investment in Counsel Press, Inc., which resulted in success fee income of $1.4 million, a realized gain of $43.5 million and the repayment of our debt investment of $27.5 million at par.", "entities": [ { "start_character": 107, "end_character": 110, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-10-31", "currency_/_unit": "iso4217:USD", "value": 1400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001321741-24-000005", "filing_date": 1707235646000, "quarter_ending": "20231231", "company_name": "GLADSTONE INVESTMENT CORPORATION\\DE", "text": "From time to time, Gladstone Securities provides services, such as investment banking and due diligence services, to certain of our portfolio companies, for which it receives a fee. Any such fees paid by portfolio companies to Gladstone Securities do not impact the fees we pay to the Adviser or the non-contractual, unconditional, and irrevocable credits against the base management fee. No fees were received by Gladstone Securities from our portfolio companies during the three months ended December 31, 2023. During the nine months ended December\u00a031, 2023, the fees received by Gladstone Securities from our portfolio companies totaled $0.3 million. During the three and nine months ended December\u00a031, 2022, the fees received by Gladstone Securities from our portfolio companies totaled $0.3 million and $1.6 million, respectively.", "entities": [ { "start_character": 641, "end_character": 644, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 793, "end_character": 796, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 810, "end_character": 813, "label": "revenues", "start_date_for_period": "2022-04-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001321741-24-000009", "filing_date": 1715184474000, "quarter_ending": "20240331", "company_name": "GLADSTONE INVESTMENT CORPORATION\\DE", "text": "Securities do not impact the fees we pay to the Adviser or the non-contractual, unconditional, and irrevocable credits against the base management fee. During the years ended March\u00a031, 2024, 2023, and 2022, the fees received by Gladstone Securities from portfolio companies totaled $0.3 million, $1.6 million, and $3.2 million, respectively.", "entities": [ { "start_character": 283, "end_character": 286, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 297, "end_character": 300, "label": "revenues", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 }, { "start_character": 315, "end_character": 318, "label": "revenues", "start_date_for_period": "2021-04-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": 3200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001321741-24-000009", "filing_date": 1715184474000, "quarter_ending": "20240331", "company_name": "GLADSTONE INVESTMENT CORPORATION\\DE", "text": "In October 2023, we exited our investment in Counsel Press, Inc., which resulted in success fee income of $1.4 million, a realized gain of $43.5 million and the repayment of our debt investment of $27.5 million at par.", "entities": [ { "start_character": 107, "end_character": 110, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-10-31", "currency_/_unit": "iso4217:USD", "value": 1400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014777", "filing_date": 1713271691000, "quarter_ending": "20231231", "company_name": "GLOBAL TECH INDUSTRIES GROUP, INC.", "text": "On\nSeptember 14, 2022, the Company entered into a Share Exchange Agreement with Wildfire Media Corp. (\u201cWildfire Media\u201d) and\nthe shareholders of Wildfire Media Corp. (collectively, the \u201cWildfire Shareholders\u201d). Wildfire Media is a legal marketing\ncompany in the business of supporting law firms with client acquisition research, data-driven marketing, media planning and analysis\nand client retention services. Under the terms of the agreement, GTII will, at the closing, issue to the Wildfire Shareholders 100 million\nrestricted common shares (the \u201cAcquisition Shares\u201d) in exchange for all outstanding shares of Wildfire Media. The closing\nof the transaction is subject to customary conditions to closing, as well as certain conditions specific to the transaction, including,\nwithout limitation, Wildfire Media providing GTII with audited financial statements and GTII concluding a due diligence review that is\nsatisfactory in all respects to GTII. The Wildfire Shareholders have a post-closing \u201cearn-out\u201d opportunity for 100 million\nadditional restricted GTII common shares (the \u201cEarn-Out Shares\u201d) if Wildfire Media achieves $25 million in gross revenue.\nCurrently, Wildfire Media has $85 million in receivables. The Acquisition Shares and the Earn-Out Shares shall be subject to a lock-up\nagreement pursuant to which the Wildfire Shareholders agree not to sell or transfer the shares until the expiration of the 1-year buy-back\nperiod, except as may be otherwise provided in the lock-up agreement. On October 18, 2022, Wildfire Media Corp retained the services\nof a PCAOB approved auditing firm to undertake the requisite two-year audit as part of the agreed due diligence process.", "entities": [ { "start_character": 1127, "end_character": 1129, "label": "revenues", "start_date_for_period": "2022-09-13", "end_date_for_period": "2022-09-14", "currency_/_unit": "iso4217:USD", "value": 25000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000320335-24-000006", "filing_date": 1709140646000, "quarter_ending": "20231231", "company_name": "GLOBE LIFE INC.", "text": "Premium income for traditional long-duration life and health insurance products is recognized evenly over the contract period and when due from the policyholder. Premiums for short-duration health contracts are recognized as revenue over the contract period in proportion to the insurance protection provided. Premiums for universal life-type and annuity contracts are added to the policy account value, and revenues for such products are recognized as charges to the policy account value for mortality, administration, and surrenders (retrospective deposit method). Life premium includes policy charges of $12.9 million, $13.5 million, and $14.2 million for the years ended December 31, 2023, 2022, and 2021, respectively. Other premium consists of annuity policy charges in each year. For most insurance products, the related benefits and expenses are matched with revenues by means of the provision of future policy benefits and the amortization of DAC in a manner which recognizes profits as they are earned over the revenue recognition period. For limited-payment life insurance products, the profits are recognized over the contract period.", "entities": [ { "start_character": 608, "end_character": 612, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 12900000.0 }, { "start_character": 623, "end_character": 627, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 13500000.0 }, { "start_character": 642, "end_character": 646, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 14200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-029139", "filing_date": 1718902000000, "quarter_ending": "20240430", "company_name": "GMS Inc.", "text": "The Company accounts for business combinations by recognizing the assets acquired and liabilities assumed at the acquisition date fair value. In valuing certain acquired assets and liabilities, fair value estimates use Level 3 inputs, including future expected cash flows and discount rates.\u00a0Goodwill is measured as the excess of consideration transferred over the fair values of the assets acquired and the liabilities assumed. While the Company uses its best estimates and assumptions to value assets acquired and liabilities assumed at the acquisition date, the Company\u2019s estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one\u00a0year from the acquisition date, the Company records adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments arising from new facts and circumstances are recorded to the Consolidated Statements of Operations and Comprehensive Income. The results of operations of acquisitions are reflected in the Company\u2019s Consolidated Financial Statements from the date of acquisition. The Company's Consolidated Statement of Operations and Comprehensive Income for the year ended April\u00a030, 2024 included $71.5 million of net sales and $5.4 million of net loss from acquisitions made in fiscal 2024. The Company recorded transaction costs of $4.9 million, $2.0 million and $3.5 million during the years ended April\u00a030, 2024, 2023 and 2022, respectively.", "entities": [ { "start_character": 1346, "end_character": 1349, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -5400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000931148-24-000065", "filing_date": 1714134345000, "quarter_ending": "20240331", "company_name": "GRAFTECH INTERNATIONAL LTD", "text": "Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding, which included 462,847 and 341,570 shares of participating securities in the three months ended March\u00a031, 2024 and 2023, respectively. Diluted loss per share is calculated by dividing net loss by the sum of the weighted average number of common shares outstanding plus the additional common shares that would have been outstanding if potentially dilutive securities had been issued.", "entities": [ { "start_character": 132, "end_character": 139, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 462847.0 }, { "start_character": 144, "end_character": 151, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 341570.0 } ] }, { "form_type": "10-K", "accession_number": "0001408075-24-000012", "filing_date": 1708533661000, "quarter_ending": "20231231", "company_name": "GRAPHIC PACKAGING HOLDING CO", "text": "The Consolidated Statements of Operations include $1,135\u00a0million of Net Sales and $17\u00a0million of Loss from Operations for AR Packaging for the year ended December 31, 2022 and $176\u00a0million of Net Sales and $8\u00a0million of Loss from Operations for the year ended December 31, 2021. The year ended December 31, 2022 included $96\u00a0million of impairment charges related to the divestiture of its two packaging facilities in Russia. See \u201c", "entities": [ { "start_character": 51, "end_character": 56, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1135000000.0 }, { "start_character": 83, "end_character": 85, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 17000000.0 }, { "start_character": 177, "end_character": 180, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 176000000.0 }, { "start_character": 207, "end_character": 208, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 8000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001408075-24-000020", "filing_date": 1714494119000, "quarter_ending": "20240331", "company_name": "GRAPHIC PACKAGING HOLDING CO", "text": "During the three months ended March\u00a031, 2024, the Company recognized Income Tax Expense of $53 million on Income before Income Taxes of $218 million. The effective tax rate for the three months ended March\u00a031, 2024 is different from the statutory rate primarily due to discrete tax adjustments including a tax benefit of $3\u00a0million related to excess tax benefits on restricted stock units that vested during the period in addition to the mix of earnings between foreign and domestic jurisdictions, including those with and without valuation allowances. ", "entities": [ { "start_character": 137, "end_character": 140, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 218000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001408075-24-000020", "filing_date": 1714494119000, "quarter_ending": "20240331", "company_name": "GRAPHIC PACKAGING HOLDING CO", "text": "During the three months ended March\u00a031, 2023, the Company recognized Income Tax Expense of $64 million on Income before Income Taxes of $271 million. The effective tax rate for the three months ended March\u00a031, 2023 is different from the statutory rate primarily due to discrete tax adjustments including a tax benefit of $2\u00a0million related to excess tax benefits on restricted stock units that vested during the period in addition to the mix of earnings between foreign and domestic jurisdictions, including those with and without valuation allowances.", "entities": [ { "start_character": 137, "end_character": 140, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 271000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000050725-24-000010", "filing_date": 1707326906000, "quarter_ending": "20231231", "company_name": "GRIFFON CORP", "text": "During the quarter ended December\u00a031, 2023, the Company recognized a tax provision of $17,965 on income before taxes of $60,142, compared to $19,318 on income before taxes of $68,020 in the prior year quarter. The current year quarter results included strategic review costs - retention and other of $4,658 ($3,500, net of tax), restructuring charges of $12,400 ($9,213, net of tax), gain on sale of building of $547 ($406, net of tax); and discrete and certain other tax provisions, net, that affect comparability of $783. The prior year quarter results included strategic review - retention and other of $8,232 ($6,222, net of tax); proxy costs of $1,503 ($1,153, net of tax); gain on the sale of building $10,852 ($8,323, net of tax); and discrete and certain other tax benefits, net, that affect comparability of $333. Excluding these items, the effective tax rates for the quarters ended December\u00a031, 2023 and 2022 were 27.9% and 29.1%, respectively.", "entities": [ { "start_character": 121, "end_character": 127, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 60142000.0 }, { "start_character": 176, "end_character": 182, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 68020000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000050725-24-000071", "filing_date": 1715188931000, "quarter_ending": "20240331", "company_name": "GRIFFON CORP", "text": "During the six months ended March\u00a031, 2024, the Company recognized a tax provision of $42,395 on income before taxes of $148,715, compared to a tax benefit of $8,586 on a loss before taxes of $22,139 in the comparable prior year period. The six month period ended March\u00a031, 2024 included restructuring charges of $14,801 ($10,982, net of tax); strategic review - retention and other of $7,334 ($5,497, net of tax); gain on sale of building of $558 ($415, net of tax); and discrete and certain other tax provisions, net, that affect comparability of $393. ", "entities": [ { "start_character": 121, "end_character": 128, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 148715000.0 }, { "start_character": 193, "end_character": 199, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -22139000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000050725-24-000071", "filing_date": 1715188931000, "quarter_ending": "20240331", "company_name": "GRIFFON CORP", "text": "During the quarter ended March\u00a031, 2024, the Company recognized a tax provision of $24,430 on income before taxes of $88,573, compared to a tax benefit of $27,904 on a loss before taxes of $90,159 in the prior year quarter. The current year quarter results included strategic review costs - retention and other of $2,676 ($1,997, net of tax); restructuring charges of $2,401 ($1,769, net of tax); gain on sale of building of $11 ($9, net of tax); and discrete and certain other tax benefits, net, that affect comparability of $390. The prior year quarter results included strategic review - retention and other of $6,190 ($4,658, net of tax); restructuring charges of $78,334 ($58,529, net of tax); intangible asset impairment charges of $100,000 ($74,256, net of tax); proxy expenses of $614 ($471, net of tax); and discrete and certain other tax benefits, net, that affect comparability of $8,723. Excluding these items, the effective tax rates for the quarters ended March\u00a031, 2024 and 2023 were 27.9% and 29.5%, respectively.", "entities": [ { "start_character": 118, "end_character": 124, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 88573000.0 }, { "start_character": 190, "end_character": 196, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -90159000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019970", "filing_date": 1715792440000, "quarter_ending": "20240331", "company_name": "GT Biopharma, Inc.", "text": "The\naccompanying condensed consolidated financial statements have been prepared under the assumption that the Company will continue as a\ngoing concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of\nbusiness. For the three months ended March 31, 2024, the Company recorded a net loss of $2.3\nmillion and used cash in operations of $4.2\nmillion. As of March 31, 2024, the Company had a cash and short-term investments balance of $9.8\nmillion, working capital of $5.3\nmillion and stockholders\u2019 equity of $5.3\nmillion. Management anticipates that the $9.8\nmillion of cash and cash equivalents and short-term investments are adequate to satisfy the liquidity needs of the Company for at\nleast one year from the date the Company\u2019s condensed consolidated financial statements for the three months ended March 31,\n2024 were issued.", "entities": [ { "start_character": 352, "end_character": 355, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007527", "filing_date": 1709132411000, "quarter_ending": "20231231", "company_name": "GULFPORT ENERGY CORP", "text": "There were 0.3 million and 0.2 million shares of restricted stock that were considered dilutive for the years ended December\u00a031, 2023 and December\u00a031, 2022, respectively. There were no shares of restricted stock that were considered dilutive for the Prior Successor Period or Prior Predecessor Period. There were 3.2 million, 3.7 million and 4.1 million potential shares of common stock issuable due to the Company's convertible Preferred Stock for the years ended December\u00a031, 2023, December\u00a031, 2022 and Prior Successor Period, respectively. There were 0.1 million shares of restricted stock that were considered anti-dilutive during the Prior Successor Period. ", "entities": [ { "start_character": 11, "end_character": 14, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 300000.0 }, { "start_character": 27, "end_character": 30, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001852244-24-000007", "filing_date": 1708017407000, "quarter_ending": "20231231", "company_name": "GXO Logistics, Inc.", "text": "For the year ended December 31, 2023, PFS generated revenues of $82\u00a0million and income before income taxes was not material. Pro forma results of operations for this acquisition have not been presented as they are not material to the Consolidated Financial Statements.", "entities": [ { "start_character": 65, "end_character": 67, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 82000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020697", "filing_date": 1716222094000, "quarter_ending": "20240331", "company_name": "GameSquare Holdings, Inc.", "text": "The\nCompany incurred transaction costs of $1.4 million associated with the Merger. All such costs were expensed as incurred. The loss attributed\nto FaZe\u2019s operations from the acquisition date to March 31, 2024, was $210 thousand, with revenue of $2.6 million.", "entities": [ { "start_character": 216, "end_character": 219, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 210000.0 }, { "start_character": 247, "end_character": 250, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001718512-24-000036", "filing_date": 1714582281000, "quarter_ending": "20240330", "company_name": "Gates Industrial Corp plc", "text": "For the three months ended March\u00a030, 2024, we had an income tax expense of $34.5\u00a0million on pre-tax income of $80.7\u00a0million, which resulted in an effective tax rate of 42.8%, compared to an income tax expense of $15.3\u00a0million on pre-tax income of $46.2\u00a0million, which resulted in an effective tax rate of 33.1% for the three months ended April\u00a01, 2023. ", "entities": [ { "start_character": 111, "end_character": 115, "label": "earnings", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 80700000.0 }, { "start_character": 248, "end_character": 252, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 46200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-005761", "filing_date": 1708466116000, "quarter_ending": "20231231", "company_name": "Gatos Silver, Inc.", "text": "Under the Unanimous Omnibus Partner Agreement, the Company provides certain management and administrative services to the LGJV. The Company earned $6,000 and $5,000 under this agreement for the years ended December 31, 2023 and 2022, respectively, which have been recorded on the statement of income under other income. The Company received $6,417 and $5,417 in cash from the LGJV under this agreement for the years ended December 31, 2023 and 2022, respectively. The Company had receivables under this ", "entities": [ { "start_character": 148, "end_character": 153, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 6000000.0 }, { "start_character": 159, "end_character": 164, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020650", "filing_date": 1715012644000, "quarter_ending": "20240331", "company_name": "Gatos Silver, Inc.", "text": "Under the Unanimous Omnibus Partner Agreement, the Company provides certain management and administrative services to the LGJV. The Company earned $1,500 and $1,250 under this agreement for the three months ended March 31, 2024 and 2023, respectively, which has been recorded on the statement of income and comprehensive income under other income. The Company received $1,500 and $1,250 in cash from the LGJV under this agree", "entities": [ { "start_character": 148, "end_character": 153, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 }, { "start_character": 159, "end_character": 164, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1250000.0 }, { "start_character": 370, "end_character": 375, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 }, { "start_character": 381, "end_character": 386, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1250000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000804269-24-000009", "filing_date": 1713884983000, "quarter_ending": "20240331", "company_name": "General Motors Financial Company, Inc.", "text": "Under subvention programs, GM makes cash payments to us for offering incentivized rates and structures on retail loan and lease finance products. In addition, GM makes cash payments to us to cover interest payments on certain commercial loans we make to GM-franchised dealers. We received subvention payments from GM of $777 million and $749 million for the three months ended March 31, 2024 and 2023. Subvention due from GM is recorded as a related party receivable.", "entities": [ { "start_character": 321, "end_character": 324, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 777000000.0 }, { "start_character": 338, "end_character": 341, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 749000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-026458", "filing_date": 1717442346000, "quarter_ending": "20240430", "company_name": "Gitlab Inc.", "text": "For the three months ended April 30, 2024, the Company recorded income tax expense of $12.7 million on pretax loss of $42.2 million. The income tax expense for the three months ended April 30, 2024 was primarily related to an increase in tax expense for unrecognized tax benefits and the Company's foreign and domestic operations.", "entities": [ { "start_character": 119, "end_character": 123, "label": "earnings", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -42200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-041055", "filing_date": 1699977937000, "quarter_ending": "20230930", "company_name": "GlassBridge Enterprises, Inc.", "text": "On\nSeptember 29, 2023, GlassBridge purchased MSRs and assumed related obligations from Greenway. Under the transaction, GlassBridge acquired\nthe MSRs and title to 2,009 fixed rate residential Mortgage Loans with an aggregate value of approximately $435 Million, for a total\npurchase price of $6.1\n", "entities": [ { "start_character": 293, "end_character": 296, "label": "revenues", "start_date_for_period": "2023-09-28", "end_date_for_period": "2023-09-29", "currency_/_unit": "iso4217:USD", "value": 6100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000041719-24-000018", "filing_date": 1715270648000, "quarter_ending": "20240331", "company_name": "Glatfelter Corp", "text": "For the three months ended March 31, 2024, we had a pretax loss from continuing operations of $21.0\u00a0million and income tax expense of $5.2\u00a0million. The effective income tax rate for the three months ended March 31, 2024 was unfavorably impacted by the jurisdictional mix of pretax results among the Company and its subsidiaries and losses which generated no tax benefit in domestic and certain foreign jurisdictions.", "entities": [ { "start_character": 95, "end_character": 99, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -21000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006634", "filing_date": 1707926769000, "quarter_ending": "20231231", "company_name": "Glimpse Group, Inc.", "text": "The\nCompany has incurred recurring losses since its inception, including a net loss of approximately $0.7\nmillion for the three months ended December 31, 2023. In addition, as of December 31, 2023, the Company had an accumulated deficit\nof $57.5\nmillion. The Company expects to continue to generate negative cash flow for the foreseeable future. The Company expects that its\ncash and cash equivalents as of December 31, 2023 may not be sufficient to fund operations for at least the next twelve months from\nthe date of issuance of these condensed consolidated financial statements and the Company will need to obtain additional funding.\nAccordingly, the Company has concluded that substantial doubt exists about the Company\u2019s ability to continue as a going\nconcern for a period of at least 12 months from the date of issuance of these condensed consolidated financial\nstatements.", "entities": [ { "start_character": 102, "end_character": 105, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006634", "filing_date": 1707926769000, "quarter_ending": "20231231", "company_name": "Glimpse Group, Inc.", "text": "For\nthe three and six months ended December 31, 2022, Pulpo had revenue of 0.04\nmillion and $0.12\nmillion, respectively, and net losses of $0.34\nmillion and $0.59\nmillion, respectively, reported in the condensed consolidated statements of operations for the periods.", "entities": [ { "start_character": 140, "end_character": 144, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 340000.0 }, { "start_character": 158, "end_character": 162, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 590000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006634", "filing_date": 1707926769000, "quarter_ending": "20231231", "company_name": "Glimpse Group, Inc.", "text": "For\nthe three and six months ended December 31, 2023, Pulpo had revenue of zero\nand $0.07\nmillion, respectively, and net losses of $0.17\nmillion and $0.43\nmillion, respectively (exclusive of the intangible asset impairment write-off), reported in the condensed consolidated statements of\noperations for the periods.", "entities": [ { "start_character": 132, "end_character": 136, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 170000.0 }, { "start_character": 150, "end_character": 154, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 430000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019832", "filing_date": 1715789171000, "quarter_ending": "20240331", "company_name": "Glimpse Group, Inc.", "text": "For\nthe three and nine months ended March 31, 2024, Pulpo had revenue of zero\nand $0.07\nmillion, respectively, and net losses of zero and $0.43\nmillion, respectively (exclusive of the goodwill and intangible asset impairment write-off), reported in the condensed consolidated\nstatements of operations for the periods.", "entities": [ { "start_character": 139, "end_character": 143, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 430000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019832", "filing_date": 1715789171000, "quarter_ending": "20240331", "company_name": "Glimpse Group, Inc.", "text": "The\nCompany has incurred recurring losses since its inception, including a net loss of approximately $1.5 million for the three months ended\nMarch 31, 2024. In addition, as of March 31, 2024, the Company had an accumulated deficit of $59.0 million. The Company expects to continue\nto generate negative cash flow for the foreseeable future. The Company expects that its cash and cash equivalents as of March 31, 2024\nmay not be sufficient to fund operations for at least the next twelve months from the date of issuance of these consolidated financial\nstatements and the Company will need to obtain additional funding. Accordingly, the Company has concluded that substantial doubt exists\nabout the Company\u2019s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these\nconsolidated financial statements.", "entities": [ { "start_character": 102, "end_character": 105, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019832", "filing_date": 1715789171000, "quarter_ending": "20240331", "company_name": "Glimpse Group, Inc.", "text": "For\nthe three and nine months ended March 31, 2023, Pulpo had revenue of $0.23\nmillion and $0.35\nmillion, respectively, and net losses of $0.14\nmillion and $0.73\nmillion, respectively, reported in the condensed consolidated statements of operations for the periods.", "entities": [ { "start_character": 139, "end_character": 143, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 140000.0 }, { "start_character": 157, "end_character": 161, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 730000.0 } ] }, { "form_type": "10-K", "accession_number": "0001820872-24-000005", "filing_date": 1710347091000, "quarter_ending": "20231231", "company_name": "Global Business Travel Group, Inc.", "text": "The amount of revenue and net loss of Ovation since the acquisition date included in the consolidated statements of operations for the year ended December 31 2021 was $23 million and $16 million, respectively. Assuming an acquisition date of January 1, 2021, the unaudited pro forma revenue and net loss of the Company for the year ended December 31, 2021 would not have been materially different to the amount of revenue and net loss presented in the consolidated statements of operations. ", "entities": [ { "start_character": 168, "end_character": 170, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 23000000.0 }, { "start_character": 184, "end_character": 186, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -16000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-016428", "filing_date": 1713286182000, "quarter_ending": "20231231", "company_name": "Global Clean Energy Holdings, Inc.", "text": "The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. As shown in the accompanying consolidated financial statements, the Company has incurred a net loss applicable to its common stockholders of $89.9 million during the twelve months ended December\u00a031, 2023, and had an accumulated deficit of $261.7 million at December\u00a031, 2023. At December\u00a031, 2023, the Company had working capital deficit of $217.5 million and a stockholders' deficit of $129.2 million. Our Facility is still under construction, and we do not expect to generate any revenue from our Facility until the commencement of commercial operations at the Facility. ", "entities": [ { "start_character": 276, "end_character": 280, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 89900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023631", "filing_date": 1715792474000, "quarter_ending": "20240331", "company_name": "Global Clean Energy Holdings, Inc.", "text": "The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. As shown in the accompanying condensed consolidated financial statements, the Company has incurred a net loss applicable to its common stockholders of $28.0 million during the three months ended March\u00a031, 2024, and had an accumulated deficit of $289.6 million at March\u00a031, 2024. At March\u00a031, 2024, the Company had negative working capital of $306.7 million and a stockholders\u2019 deficit of $163.2 million. The conversion project at our Facility is still ongoing, and we do not expect to generate any revenue from our Facility until the commencement of commercial operations. ", "entities": [ { "start_character": 296, "end_character": 300, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -28000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001526113-24-000014", "filing_date": 1715184979000, "quarter_ending": "20240331", "company_name": "Global Net Lease, Inc.", "text": "No GNL LTIP Unit share equivalents were included in the computation for the three months ended March\u00a031, 2024 since the performance period ended on September 11, 2023 and they were not included in three and three months ended March\u00a031, 2023 since their impact was anti-dilutive.", "entities": [ { "start_character": 0, "end_character": 2, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001526113-24-000014", "filing_date": 1715184979000, "quarter_ending": "20240331", "company_name": "Global Net Lease, Inc.", "text": "No PSU share equivalents were included in the computation for the three months ended March\u00a031, 2024 since their impact was anti-dilutive, and none were included for the three months ended March 31, 2023 since they hadn\u2019t been issued yet.", "entities": [ { "start_character": 0, "end_character": 2, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 }, { "start_character": 142, "end_character": 146, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001434728-24-000153", "filing_date": 1715190624000, "quarter_ending": "20240331", "company_name": "Global Water Resources, Inc.", "text": "For the three months ended March 31, 2024, tax expense of $0.3\u00a0million was recorded on pre-tax income of $0.9\u00a0million, compared to tax expense of $0.9\u00a0million recorded on pre-tax income of $3.3\u00a0million for the three months ended March 31, 2023.", "entities": [ { "start_character": 106, "end_character": 109, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 900000.0 }, { "start_character": 147, "end_character": 150, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 900000.0 }, { "start_character": 190, "end_character": 193, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001500435-24-000080", "filing_date": 1715101466000, "quarter_ending": "20240331", "company_name": "GoPro, Inc.", "text": "The Company recorded an income tax expense of $298.2 million for the three months ended March 31, 2024, on pre-tax net loss of $40.9 million. The Company\u2019s income tax expense for the three months ended March 31, 2024 primarily resulted from a tax expense of $1.4 million on pre-tax book income in certain tax jurisdictions, and discrete items that included $294.9 million of net tax expense from the establishment of a valuation allowance on United States federal and state net deferred tax assets, and $2.5 million of nondeductible equity tax expense for employee stock-based compensation, partially offset by $0.4 million of restructuring charges. ", "entities": [ { "start_character": 128, "end_character": 132, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -40900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001500435-24-000080", "filing_date": 1715101466000, "quarter_ending": "20240331", "company_name": "GoPro, Inc.", "text": "For the three months ended March 31, 2023 the Company recorded an income tax benefit of $8.3\u00a0million\u00a0on pre-tax net loss of $38.1\u00a0million. The Company\u2019s income tax benefit for the three months ended March\u00a031, 2023 was composed of $8.8 million of tax benefit incurred on pre-tax loss, and discrete items that primarily included $0.3 million of nondeductible equity tax expense for employee stock-based compensation, and $0.1 million of tax expense related to the foreign provision to income tax return adjustments.", "entities": [ { "start_character": 125, "end_character": 129, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -38100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001500435-24-000080", "filing_date": 1715101466000, "quarter_ending": "20240331", "company_name": "GoPro, Inc.", "text": "Revenue from the United States, which is included in the Americas geographic region, was $56.3 million and $75.6 million, for the three months ended March 31, 2024 and 2023, respectively. No other individual country exceeded 10% of total revenue for any period presented. The Company does not disclose revenue by product category as it does not track sales incentives and other revenue adjustments by product category to report such data.", "entities": [ { "start_character": 90, "end_character": 94, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 56300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001876945-24-000033", "filing_date": 1712301755000, "quarter_ending": "20231231", "company_name": "Gold Flora Corp.", "text": "Historically, the Company\u2019s primary source of liquidity has been its operations, capital contributions made by members and debt financing. The Company is currently meeting its current operational obligations as they become due from its current working capital and from operations. However, the Company has sustained annual losses since inception and may require additional capital in the future. As of December\u00a031, 2023 and 2022, the Company had a total shareholders\u2019 deficit attributable to the Company of $7,248 and $23,579, respectively, a net loss attributable to the Company of $42,620 and $21,324 for the year ended December\u00a031, 2023 and 2022, respectively and net cash used in operating activities of $31,182 and $15,143, for the year ended December\u00a031, 2023 and 2022. Because of these factors, there is substantial doubt about the Company\u2019s ability to continue as a going concern. ", "entities": [ { "start_character": 584, "end_character": 590, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -42620000.0 }, { "start_character": 596, "end_character": 602, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -21324000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001876945-24-000044", "filing_date": 1715753239000, "quarter_ending": "20240331", "company_name": "Gold Flora Corp.", "text": "Historically, the Company\u2019s primary source of liquidity has been its operations, capital contributions made by members and debt financing. The Company is currently meeting its current operational obligations as they become due from its current working capital and from operations. However, the Company has sustained annual losses since inception and may require additional capital in the future. As of March\u00a031, 2024 and December\u00a031, 2023, the Company had a total shareholders\u2019 deficit attributable to the Company of $20,765 and $7,248 and for the three months ended March\u00a031, 2024 and 2023 a net loss attributable to the Company of $13,635 and $9,322, and net cash used in operating activities of $4,359 and $1,057, respectively. Because of these factors, there is substantial doubt about the Company\u2019s ability to continue as a going concern. ", "entities": [ { "start_character": 634, "end_character": 640, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -13635000.0 }, { "start_character": 646, "end_character": 651, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -9322000.0 } ] }, { "form_type": "10-K", "accession_number": "0000104889-24-000010", "filing_date": 1708705035000, "quarter_ending": "20231231", "company_name": "Graham Holdings Co", "text": "As of December\u00a031, 2023, the Company also held investments in several other affiliates; GHG held a 40% interest in Residential Home Health Illinois, a 40% interest in Residential Hospice Illinois, a 40% interest in the joint venture formed between GHG and a Michigan hospital, and a 40% interest in the joint venture formed between GHG and Allegheny Health Network (AHN). During the first quarter of 2022, GHG invested an additional $18.5 million in the Residential Home Health Illinois and Residential Hospice Illinois affiliates to fund their acquisition of certain home health and hospice assets of the NorthShore University HealthSystem. The transaction diluted GHG\u2019s interest in Residential Hospice Illinois resulting in a $0.6 million gain on sale of investment in affiliate (see Note 16). For the years ended December\u00a031, 2023, 2022 and 2021, GHG recorded $15.6 million, $13.9 million and $10.9 million, respectively, in revenue for services provided to its affiliates. ", "entities": [ { "start_character": 864, "end_character": 868, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 15600000.0 }, { "start_character": 879, "end_character": 883, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 13900000.0 }, { "start_character": 897, "end_character": 901, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 10900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000104889-24-000016", "filing_date": 1714552077000, "quarter_ending": "20240331", "company_name": "Graham Holdings Co", "text": "As of March\u00a031, 2024, the Company also held investments in several other affiliates; GHG held a 40% interest in each of the following affiliates: Residential Home Health Illinois, Residential Hospice Illinois, Mary Free Bed at Home, and Allegheny Health Network (AHN) Healthcare at Home. For the three months ended March\u00a031, 2024 and 2023, the Company recorded $4.1 million and $3.5 million, respectively, in revenue for services provided to the affiliates of GHG.", "entities": [ { "start_character": 362, "end_character": 365, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4099999.9999999995 }, { "start_character": 379, "end_character": 382, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001703644-24-000032", "filing_date": 1709309193000, "quarter_ending": "20231231", "company_name": "Granite Point Mortgage Trust Inc.", "text": "For the year ended December 31, 2022, and 2021, excluded from the calculation of diluted earnings per share is the effect of adding back $17.5 million and $18.2 million, respectively, of interest expense related to the Company\u2019s convertible senior notes. For the years ended December 31, 2022, and 2021, 13,431,000 and 14,065,946, respectively, of weighted average common share equivalents related to the assumed conversion of the Company\u2019s convertible senior notes were also excluded from the calculation of diluted earnings per share, as their inclusion would be antidilutive. As of December\u00a031, 2023, the convertible notes have been redeemed and no notes remain outstanding.", "entities": [ { "start_character": 138, "end_character": 142, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 17500000.0 }, { "start_character": 156, "end_character": 160, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 18200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001703644-24-000071", "filing_date": 1715102078000, "quarter_ending": "20240331", "company_name": "Granite Point Mortgage Trust Inc.", "text": "For the three months ended March 31, 2023, excluded from the calculation of diluted earnings per share is the effect of adding back $2.3 million of interest expense related to the Company\u2019s convertible senior notes. For the three months ended March 31, 2023, 6,591,765 of weighted average common share equivalents related to the assumed conversion of the Company\u2019s convertible senior notes were also excluded from the calculation of diluted earnings per share, as their inclusion would be antidilutive. As of March\u00a031, 2024, the convertible notes have been redeemed and no notes remain outstanding.", "entities": [ { "start_character": 133, "end_character": 136, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001635650-23-000071", "filing_date": 1698770579000, "quarter_ending": "20230930", "company_name": "Green Plains Partners LP", "text": "Revenue from Green Plains Trade Group was $19.2 million and $58.3 million for the three and nine months ended September\u00a030, 2023, respectively, and $19.0 million and $55.9 million for the three and nine months ended September\u00a030, 2022, respectively, which exceeds 10% of the partnership\u2019s total revenue. ", "entities": [ { "start_character": 43, "end_character": 47, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 19200000.0 }, { "start_character": 61, "end_character": 65, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 58300000.0 }, { "start_character": 149, "end_character": 153, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 19000000.0 }, { "start_character": 167, "end_character": 171, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 55900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001563922-24-000004", "filing_date": 1715604219000, "quarter_ending": "20240331", "company_name": "Greenbacker Renewable Energy Co LLC", "text": "Base management fees under GCM\u2019s advisory fee agreements with GDEV I, dated March 3, 2022, are calculated as described herein. For the period from March 3, 2022 through the date on which the commitment period ends (as defined in the GDEV I amended and restated limited partnership agreements), the management fee is calculated at an annual rate of 1.75% to 2.00%, depending on the limited partner, of the aggregate capital commitments to GDEV I. Beginning on the date following the date on which the commitment period terminates, the management fee is calculated at an annual rate of 1.75% to 2.00%, depending on the limited partner, of the aggregate cost basis of all portfolio securities of GDEV I. The management fees earned are payable quarterly in advance. During the three months ended March\u00a031, 2024 and 2023, the Company earned $0.6 million and $0.6 million in management fees from GDEV I, which is included in Investment Management revenue on the Consolidated Statements of Operations. As of March\u00a031, 2024 and December\u00a031, 2023, the Company was not owed any management fees from GDEV I. As of March\u00a031, 2024 and December\u00a031, 2023, GDEV I prepaid the Company management fees of nil, which is included in Other current liabilities on the Consolidated Balance Sheets.", "entities": [ { "start_character": 837, "end_character": 840, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 600000.0 }, { "start_character": 854, "end_character": 857, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001563922-24-000004", "filing_date": 1715604219000, "quarter_ending": "20240331", "company_name": "Greenbacker Renewable Energy Co LLC", "text": "During the three months ended March\u00a031, 2024 and 2023, the Company earned $1.3 million and $0.5 million, respectively, in management fees from GREC II, which is included in Investment Management revenue on the Consolidated Statements of Operations. As of March\u00a031, 2024 and December\u00a031, 2023, the Company was owed $1.3\u00a0million and $2.3 million, respectively, in management fees from GREC II, which is included in Accounts receivable, net on the Consolidated Balance Sheets.", "entities": [ { "start_character": 75, "end_character": 78, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 }, { "start_character": 92, "end_character": 95, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 }, { "start_character": 315, "end_character": 318, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001563922-24-000004", "filing_date": 1715604219000, "quarter_ending": "20240331", "company_name": "Greenbacker Renewable Energy Co LLC", "text": "Base management fees under GCM\u2019s advisory agreement with GDEV II, dated November 11, 2022, are calculated as described herein. For the period from November 11, 2022 through the date on which the commitment period ends (as defined in the GDEV II amended and restated limited partnership agreement), the management fee is calculated at an annual rate of 1.50% to 2.00%, depending on the limited partner, of the aggregate capital commitments to GDEV II. Beginning on the date following the date on which the commitment period terminates, the management fee will be calculated at an annual rate of 1.50% to 2.00%, depending on the limited partner, of the aggregate cost basis of all portfolio securities of GDEV II. The management fees earned are payable quarterly in advance. During the three months ended March\u00a031, 2024 and 2023, the Company earned $0.4 million and $0.3\u00a0million, respectively, in management fees from GDEV II, which is included in Investment Management revenue on the Consolidated Statements of Operations. As of March\u00a031, 2024 and December\u00a031, 2023, the Company was owed $0.2 million and $0.8 million, respectively, in management fees from GDEV II, which is included in Accounts receivable, net on the Consolidated Balance Sheets.", "entities": [ { "start_character": 848, "end_character": 851, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 865, "end_character": 868, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001563922-24-000004", "filing_date": 1715604219000, "quarter_ending": "20240331", "company_name": "Greenbacker Renewable Energy Co LLC", "text": "Base management fees under GCM\u2019s advisory fee agreement with GROZ are calculated at a monthly rate of 0.125% (1.50% annually) of the average gross invested capital for GROZ. During the three months ended March\u00a031, 2024 and 2023, the Company earned $0.1 million and $0.1 million, respectively, in management fees from GROZ. Management fees from GROZ are included in Investment Management revenue on the Consolidated Statements of Operations. The management fees earned are payable monthly, in arrears. As of March\u00a031, 2024 and December\u00a031, 2023, the Company was owed $0.3\u00a0million and $0.2\u00a0million, respectively, in management fees from GROZ, which is included in Accounts receivable, net on the Consolidated Balance Sheets.", "entities": [ { "start_character": 249, "end_character": 252, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 266, "end_character": 269, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001563922-24-000004", "filing_date": 1715604219000, "quarter_ending": "20240331", "company_name": "Greenbacker Renewable Energy Co LLC", "text": "In addition, the Company earns administrative fee revenue for certain technical, financial, legal, accounting, tax and operational asset management services performed by Greenbacker Administration. Pursuant to the administration agreement between GREC II and Greenbacker Administration, GREC II will reimburse Greenbacker Administration for the costs and expenses incurred by Greenbacker Administration and any sub-administrators in performing their obligations and providing personnel and facilities to GREC II. During the three months ended March\u00a031, 2024 and 2023, the Company earned $1.3 million and $0.4 million, respectively, in administrative fee revenue, which is included in Investment Management revenue on the Consolidated Statements of Operations. As of March\u00a031, 2024 and December\u00a031, 2023, the Company was owed $1.3\u00a0million and $2.4 million, respectively, in administrative fees from GREC II, which is included in Accounts receivable, net on the Consolidated Balance Sheets.", "entities": [ { "start_character": 588, "end_character": 591, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 }, { "start_character": 605, "end_character": 608, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 826, "end_character": 829, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001563922-24-000004", "filing_date": 1715604219000, "quarter_ending": "20240331", "company_name": "Greenbacker Renewable Energy Co LLC", "text": "The Company entered into secured loans to finance the purchase and installation of energy-efficient lighting with AEC Companies. Certain of the loans with LED Funding LLC, an AEC Company, converted to a lease on the day the energy efficiency upgrades became operational. AEC Companies are considered related parties as the members of these entities own a direct, noncontrolling ownership interest in the Company. The loans between the AEC Companies and the Company, and the subsequent leases, were negotiated at arm\u2019s length and contain standard terms and conditions that would be included in third-party lending agreements, including required security and collateral, interest rates based upon risk of the specific loan, and term of the loan. As of March\u00a031, 2024 and December\u00a031, 2023, the Company was owed $0.1\u00a0million and $0.1\u00a0million, respectively, in lease payments from AEC Companies, which is included in Accounts receivable, net on the Consolidated Balance Sheets. As of March\u00a031, 2024 and December\u00a031, 2023, the principal balance of the loan receivable was $0.2\u00a0million and $0.2\u00a0million, respectively, which is included in Other noncurrent assets on the Consolidated Balance Sheets. The interest receivable as of March\u00a031, 2024 and December\u00a031, 2023 was not material. The Company received payments of $35.2\u00a0thousand and $0.1\u00a0million on the operating leases and the loan receivable, respectively, for the three months ended March\u00a031, 2024. There were no payments received on the operating leases and the loan receivable for the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 1312, "end_character": 1316, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 35200.0 } ] }, { "form_type": "10-K", "accession_number": "0001437749-24-010107", "filing_date": 1711731656000, "quarter_ending": "20231231", "company_name": "Guerrilla RF, Inc.", "text": ", the Company incurred a net loss of\u00a0$16.0\u00a0million and used $13.4\u00a0million in cash to fund operations.\u00a0 As a result, the Company had an accumulated deficit of $43.0 million as of ", "entities": [ { "start_character": 38, "end_character": 42, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -16000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001437749-24-016686", "filing_date": 1715705718000, "quarter_ending": "20240331", "company_name": "Guerrilla RF, Inc.", "text": "The Company has incurred substantial negative cash flows from operations in nearly every fiscal period since inception,\u00a0including a net loss\u00a0of $3.4\u00a0million for the three months ended March 31, 2024.\u00a0\u00a0As of March\u00a031, 2024, the Company had an accumulated deficit of $46.4\u00a0million and a cash balance of $3.6 million.\u00a0\u00a0We expect losses and negative cash flows to continue in the near term, primarily due to continued investment in research and development, sales and marketing efforts, and increased administration expenses as our Company grows.\u00a0 We plan to continue to invest in the implementation of our long-term strategic plan and we anticipate that we will require additional funding in fiscal\u00a02024.\u00a0 There is\u00a0no\u00a0assurance that appropriate funding\u00a0will be available on terms, which are acceptable to us, or at all.\u00a0 This requirement for additional funding raises substantial doubt about our ability to continue as a going concern.", "entities": [ { "start_character": 145, "end_character": 148, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000045012-24-000015", "filing_date": 1713958350000, "quarter_ending": "20240331", "company_name": "HALLIBURTON CO", "text": "During the three months ended March\u00a031, 2024, we recorded a total income tax provision of $178 million on a pre-tax income of $787 million, resulting in an effective tax rate of 22.6% for the quarter. During the three months ended March\u00a031, 2023, we recorded a total income tax provision of $174 million on a pre-tax income of $829 million, resulting in an effective tax rate of 21.0% for the quarter. ", "entities": [ { "start_character": 127, "end_character": 130, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 787000000.0 }, { "start_character": 328, "end_character": 331, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 829000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000874766-24-000016", "filing_date": 1708705954000, "quarter_ending": "20231231", "company_name": "HARTFORD FINANCIAL SERVICES GROUP, INC.", "text": "Company\u2019s before tax consolidated net income. Accordingly, the Company is disclosing aggregated, summarized financial data for the Company\u2019s investments accounted for under the equity method based on the most recently available information. This aggregated, summarized financial data does not represent the Company\u2019s proportionate share of investees' assets or earnings. Aggregate total assets of the investees totaled $308.3 billion and $289.9 billion as of December\u00a031, 2023 and 2022, respectively. Aggregate total liabilities of the investees totaled $44.0 billion and $46.8 billion as of December\u00a031, 2023 and 2022, respectively. Aggregate net investment loss\u00a0of the investees totaled $1.2\u00a0billion for the period ended December\u00a031, 2023. Aggregate total investment income of the investees totaled $1.6\u00a0billion, and $2.1\u00a0billion for the periods ended December 31, 2022 and 2021, respectively. Aggregate net income excluding net investment income\u00a0of the investees totaled $13.0 billion, $11.9 billion and $46.7 billion for the periods ended December\u00a031, 2023, 2022 and 2021, respectively. As of, and for the period ended, December\u00a031, 2023, the aggregated summarized financial data reflects the latest available financial information.", "entities": [ { "start_character": 975, "end_character": 979, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 13000000000.0 }, { "start_character": 990, "end_character": 994, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 11900000000.0 }, { "start_character": 1008, "end_character": 1012, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 46700000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-018706", "filing_date": 1714149819000, "quarter_ending": "20240331", "company_name": "HEALTHPEAK PROPERTIES, INC.", "text": "On October 26, 2023, the Company amended its lease with Graphite Bio, Inc. (\u201cGraphite Bio\u201d) at one of its lab buildings in South San Francisco, California. Under the terms of the amended lease agreement, Graphite Bio\u2019s lease expiration date was accelerated from April 2033 to December 2024 in exchange for an upfront cash payment of $37\u00a0million, comprised of a $21\u00a0million termination fee and $16\u00a0million prepayment of Graphite Bio\u2019s contractual rent through the amended term. The $37\u00a0million is being recognized as rental and related revenues on the Consolidated Statements of Operations on a straight-line basis through the amended term of the lease.", "entities": [ { "start_character": 334, "end_character": 336, "label": "revenues", "start_date_for_period": "2023-10-26", "end_date_for_period": "2023-10-26", "currency_/_unit": "iso4217:USD", "value": 37000000.0 }, { "start_character": 482, "end_character": 484, "label": "revenues", "start_date_for_period": "2023-10-26", "end_date_for_period": "2023-10-26", "currency_/_unit": "iso4217:USD", "value": 37000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000799233-24-000020", "filing_date": 1715356817000, "quarter_ending": "20240331", "company_name": "HEARTLAND EXPRESS INC", "text": "Total revenues recorded were $270.3 million and $330.9 million for the three months ended March\u00a031, 2024 and 2023, respectively. Fuel surcharge revenues were $36.2 million and $49.6 million for the three months ended March\u00a031, 2024 and 2023, respectively. Accessorial, brokerage and other revenues recorded in the consolidated statements of comprehensive income (loss) collectively represented $20.1 million and $24.6 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 30, "end_character": 35, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 270300000.0 }, { "start_character": 49, "end_character": 54, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 330900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000920112-24-000099", "filing_date": 1715159453000, "quarter_ending": "20240331", "company_name": "HEARTLAND FINANCIAL USA INC", "text": "HTLF has loan interest rate swap relationships with customers to assist them in managing their interest rate risk. Upon entering into these loan swaps, HTLF enters into offsetting positions with counterparties in order to minimize interest rate risk to HTLF. These back-to-back loan swaps qualify as free standing financial derivatives with the fair values reported in other assets and other liabilities on the consolidated balance sheets. Any gains and losses on these back-to-back swaps are recorded in noninterest income on the consolidated statements of income, and for the three months ended March 31, 2024, and March 31, 2023, no gain or loss was recognized. HTLF recognized $891,000 in fee income related to executing back-to-back loan swaps for customers for the three months ended March 31, 2024, compared to $2.0\u00a0million and for the three months ended March 31, 2023. ", "entities": [ { "start_character": 682, "end_character": 689, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 891000.0 }, { "start_character": 819, "end_character": 822, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001066605-24-000018", "filing_date": 1715012244000, "quarter_ending": "20240331", "company_name": "HEIDRICK & STRUGGLES INTERNATIONAL INC", "text": "The Company reported income before taxes of $22.9 million and an income tax provision of $8.9 million for the three months ended March 31, 2024. The Company reported income before taxes of $22.8 million and an income tax provision of $7.2 million for the three months ended March 31, 2023. The effective tax rates for the three months ended March 31, 2024, and 2023, were 38.8% and 31.7%, respectively. The effective tax rate for the three months ended March 31, 2024, was impacted by non-deductible earnout expenses and the mix of income. The effective tax rate for the three months ended March 31, 2023, was impacted by one-time items and the mix of income.", "entities": [ { "start_character": 45, "end_character": 49, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 22900000.0 }, { "start_character": 190, "end_character": 194, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 22800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001017480-24-000070", "filing_date": 1718107534000, "quarter_ending": "20240504", "company_name": "HIBBETT INC", "text": "For the 13-weeks ended April\u00a029, 2023, 88,001 options were excluded from the computation of diluted weighted-average common shares or common share equivalents outstanding because of their anti-dilutive effect. For the 13-weeks ended April\u00a029, 2023, we also excluded 117,037 unvested stock awards granted to certain employees from the computations of diluted weighted-average common shares and common share equivalents outstanding because they are subject to certain performance-based annual vesting conditions which had not been achieved by April\u00a029, 2023, respectively. There would have been 49,203 dilutive impact on shares assuming the performance criteria had been achieved as of April\u00a029, 2023.", "entities": [ { "start_character": 593, "end_character": 599, "label": "eps", "start_date_for_period": "2023-01-29", "end_date_for_period": "2023-04-29", "currency_/_unit": "xbrli:shares", "value": 49203.0 } ] }, { "form_type": "10-K", "accession_number": "0000921082-24-000006", "filing_date": 1707235540000, "quarter_ending": "20231231", "company_name": "HIGHWOODS PROPERTIES, INC.", "text": "We recognized rental and other revenues related to operating lease payments of $819.9 million, $816.3 million and $754.9 million, of which variable lease payments were $72.9 million, $69.8 million and $57.3 million, during the years ended December\u00a031, 2023, 2022 and 2021, respectively. The following table sets forth the undiscounted cash flows for future minimum base rents to be received from customers for leases in effect as of December\u00a031, 2023 for our consolidated properties:", "entities": [ { "start_character": 80, "end_character": 85, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 819900000.0 }, { "start_character": 96, "end_character": 101, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 816300000.0 }, { "start_character": 115, "end_character": 120, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 754900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000921082-24-000020", "filing_date": 1713888282000, "quarter_ending": "20240331", "company_name": "HIGHWOODS PROPERTIES, INC.", "text": "We generally lease our office properties to lessees in exchange for fixed monthly payments that cover rent, property taxes, insurance and certain cost recoveries, primarily common area maintenance. Office properties that are under lease are primarily located in Atlanta, Charlotte, Nashville, Orlando, Pittsburgh, Raleigh, Richmond and Tampa and are leased to a wide variety of lessees across many industries. Our leases are operating leases and mostly range from three to 10 years. We recognized rental and other revenues related to operating lease payments of $207.8 million and $209.4 million during the three months ended March\u00a031, 2024 and 2023, respectively. Included in these amounts were variable lease payments of $22.5 million and $19.4 million during the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 563, "end_character": 568, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 207800000.0 }, { "start_character": 582, "end_character": 587, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 209400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001128361-24-000016", "filing_date": 1715098754000, "quarter_ending": "20240331", "company_name": "HOPE BANCORP INC", "text": "For the three months ended March\u00a031, 2024, the Company recorded an income tax provision totaling $10.0 million on pretax income of $35.9 million, representing an effective tax rate of 27.94%, compared with an income tax provision of $13.7 million on pretax income of $52.8 million, representing an effective tax rate of 25.91% for the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 132, "end_character": 136, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 35900000.0 }, { "start_character": 268, "end_character": 272, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 52800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001501585-24-000013", "filing_date": 1714647316000, "quarter_ending": "20240331", "company_name": "HUNTINGTON INGALLS INDUSTRIES, INC.", "text": "Cumulative catch-up revenue adjustments for the three months ended March 31, 2023, included a favorable adjustment of $15\u00a0million on a contract at the Company's Newport News segment, which increased diluted earnings per share by $0.30. Cumulative catch-up revenue adjustments for the three months ended March 31, 2023, included an unfavorable adjustment of $14\u00a0million on a contract at the Company's Newport News segment, which decreased diluted earnings per share by $0.28. ", "entities": [ { "start_character": 119, "end_character": 121, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 15000000.0 }, { "start_character": 358, "end_character": 360, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -14000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001173514-24-000072", "filing_date": 1715100321000, "quarter_ending": "20240331", "company_name": "HYSTER-YALE MATERIALS HANDLING, INC.", "text": "The Company recognized net income attributable to stockholders of $51.5 million in the first quarter of 2024 compared with $26.6 million in the first quarter of 2023. The improvement was primarily the result of higher operating profit, partially offset by increased income tax expense, mainly from a higher effective income tax rate in the first quarter of 2024 compared with the first quarter of 2023. This higher rate was due to the continued capitalization of research and development expenditures for U.S. tax purposes combined with the Company's inability to record deferred tax assets on its balance sheet given its U.S. valuation allowance position. See Note 5 of the Company's condensed consolidated financial statements for further discussion of the Company's income tax provision. ", "entities": [ { "start_character": 67, "end_character": 71, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 51500000.0 }, { "start_character": 124, "end_character": 128, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 26600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-025569", "filing_date": 1711384621000, "quarter_ending": "20231231", "company_name": "Hall of Fame Resort & Entertainment Co", "text": "As\nservices are provided, the Company is recognizing revenue on a straight-line basis over the expected term of the agreement. During the\nyears ended December 31, 2023 and 2022, the Company recognized $2,819,041 and $2,697,487 of net sponsorship revenue, respectively.", "entities": [ { "start_character": 202, "end_character": 211, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2819041.0 }, { "start_character": 217, "end_character": 226, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2697487.0 } ] }, { "form_type": "10-K", "accession_number": "0001360604-24-000026", "filing_date": 1708065271000, "quarter_ending": "20231231", "company_name": "Healthcare Realty Trust Inc", "text": "The Company's leases typically have escalators that are either based on a stated percentage or an index such as the CPI. In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the years ended December\u00a031, 2023 and 2022 was $1.3 billion and $907.5 million, respectively.", "entities": [ { "start_character": 749, "end_character": 752, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1300000000.0 }, { "start_character": 766, "end_character": 771, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 907500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001360604-24-000045", "filing_date": 1715063805000, "quarter_ending": "20240331", "company_name": "Healthcare Realty Trust Inc", "text": "The Company's leases typically have escalators that are either based on a stated percentage or an index such as the consumer price index (\"CPI\"). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three months ended March\u00a031, 2024 was $318.1 million. Lease income for the Company's operating leases recognized for the three months ended March 31, 2023 was $324.1 million.", "entities": [ { "start_character": 769, "end_character": 774, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 318100000.0 }, { "start_character": 891, "end_character": 896, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 324100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011537", "filing_date": 1711558876000, "quarter_ending": "20231231", "company_name": "Healthier Choices Management Corp.", "text": "Revenue\nand net income for year ended December 31, 2022 were $6.3 million and $0.05 million, respectively, from the date of acquisition through\nDecember 31, 2022. Acquisition-related expenses of $906,000 were expensed as incurred and recorded in selling, general and administrative\nexpenses in the consolidated statements of operations for the year ended December 31, 2022. The expenses primarily related to legal and\nother professional fees.", "entities": [ { "start_character": 79, "end_character": 83, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 50000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011537", "filing_date": 1711558876000, "quarter_ending": "20231231", "company_name": "Healthier Choices Management Corp.", "text": "Revenue\nand net income were $3.1 million and $0.3 million, respectively, from the date of acquisition through December 31, 2023. Acquisition-related\nexpenses of $131,000 were expensed as incurred and recorded in selling, general and administrative expenses in the consolidated statements\nof operations for the year ended December 31, 2023. The expenses primarily related to legal and other professional fees.", "entities": [ { "start_character": 46, "end_character": 49, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011537", "filing_date": 1711558876000, "quarter_ending": "20231231", "company_name": "Healthier Choices Management Corp.", "text": "Revenue\nand net income for year ended December 31, 2022 from date of acquisition were $11.9 million and $0.30 million, respectively. Acquisition-related\nexpenses of $157,000 were expensed as incurred and recorded in selling, general and administrative expenses in the consolidated statements\nof operations for the year ended December 31, 2022. The expenses primarily related to legal and other professional fees.", "entities": [ { "start_character": 105, "end_character": 109, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001840292-24-000010", "filing_date": 1711470206000, "quarter_ending": "20231231", "company_name": "Heliogen, Inc.", "text": "In May\u00a02021, Heliogen sub-leased a portion of its office space in Pasadena, California to Idealab. In March and May 2023, Heliogen entered into amendments to the sub-lease with Idealab. Refer to Note 11\u2014Leases for additional information regarding our Pasadena, California office space lease. The sub-lease has an initial annual base rent of $0.2 million and contains a 3% per annum escalation clause. The sub-lease is subject to termination by either party upon six months prior written notice. Concurrently with the parties\u2019 entering into the sub-lease agreement, Idealab and Heliogen also entered into certain property management and shared facilities staffing agreements, which provide that Heliogen pays Idealab $3 thousand per month for building management services and $13 thousand per month for shared facilities staff and services (with proportional reimbursement of salaries). Such agreements are subject to termination by either party with 90 days prior written notice. The Company recognized rental revenue of $0.2 million and $0.1 million for years ending December\u00a031, 2023 and 2022, respectively, from Idealab included in other income, net on our consolidated statements of operations. ", "entities": [ { "start_character": 1039, "end_character": 1042, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001840292-24-000010", "filing_date": 1711470206000, "quarter_ending": "20231231", "company_name": "Heliogen, Inc.", "text": "As of December\u00a031, 2023, the Company had liquidity of $75.1 million, consisting of $62.7 million of cash and cash equivalents and $12.4 million of investments and no debt. During the year ended December\u00a031, 2023, the Company incurred a net loss of $129.6 million and used cash in operations of $71.6 million. The Company expects to continue to generate operating losses and have significant cash outflows from operating activities for at least the next few years. Based on these factors, the Company anticipates that it may not have sufficient resources to fund its cash obligations for the next 12 months after the issuance date of the consolidated financial statements, which raises substantial doubt about the Company\u2019s ability to continue as a going concern. ", "entities": [ { "start_character": 249, "end_character": 254, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -129600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001840292-24-000022", "filing_date": 1715184703000, "quarter_ending": "20240331", "company_name": "Heliogen, Inc.", "text": "As of March\u00a031, 2024, the Company had liquidity of $60.7 million, consisting of $58.2 million of cash and cash equivalents and $2.5 million of investments and no debt. During the three months ended March\u00a031, 2024, the Company incurred a net loss of $15.2 million and used cash in operations of $14.3 million. The Company expects to continue to generate operating losses and have significant cash outflows from operating activities for at least the next few years. Based on these factors, the Company anticipates that it may not have sufficient resources to fund its cash obligations for the next 12 months after the issuance date of the consolidated financial statements, which raises substantial doubt about the Company\u2019s ability to continue as a going concern. ", "entities": [ { "start_character": 250, "end_character": 254, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -15200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001840292-24-000022", "filing_date": 1715184703000, "quarter_ending": "20240331", "company_name": "Heliogen, Inc.", "text": "On March 24, 2023, Heliogen entered into an agreement with NantG Power, LLC (\u201cNantG\u201d), an affiliated sister-company to Nant Capital LLC, a holder of more than 5% of Heliogen\u2019s outstanding voting stock, to provide front-end concept design and R&D engineering services. During the three months ended March\u00a031, 2024, the Company recognized $86 thousand of services revenue from NantG. The Company did not recognize any revenue from NantG during the three months ended March\u00a031, 2023. As of March\u00a031, 2024 and December\u00a031, 2023, we had outstanding accounts receivable of $0.2 million and $0.1 million, respectively, with NantG.", "entities": [ { "start_character": 338, "end_character": 340, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 86000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000046765-24-000006", "filing_date": 1706545663000, "quarter_ending": "20231231", "company_name": "Helmerich & Payne, Inc.", "text": "We continue to use our captive insurance companies to insure the deductibles for our domestic workers\u2019 compensation, general liability, automobile liability claims programs, and medical stop-loss program and to insure the deductibles from the Company's international casualty and property programs. Our operating subsidiaries are paying premiums to the Captives, typically on a monthly basis, for the estimated losses based on an external actuarial analysis. These premiums are currently held in a restricted cash account, resulting in a transfer of risk from our operating subsidiaries to the Captives. Direct operating costs primarily consisted of adjustments to accruals for estimated losses of $3.5 million and $2.9 million and rig and casualty insurance premiums of $9.1 million and $10.0 million during the three months ended December\u00a031, 2023 and 2022, respectively. These operating costs were recorded within Drilling services operating expenses in our Unaudited Condensed Consolidated Statement of Operations. Intercompany premium revenues recorded by the Captives during the three months ended December\u00a031, 2023 and 2022 amounted to $15.2 million and $16.4 million, respectively, which were eliminated upon consolidation.\u00a0These intercompany insurance premiums are reflected as segment operating expenses within the North America Solutions, Offshore Gulf of Mexico, and International Solutions reportable operating segments and are reflected as intersegment sales within \"Other.\" Our medical stop loss operating expenses for the three months ended December\u00a031, 2023 and 2022 were $4.1\u00a0million and $2.8\u00a0million, respectively.", "entities": [ { "start_character": 1145, "end_character": 1149, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 15200000.0 }, { "start_character": 1163, "end_character": 1167, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 16399999.999999998 } ] }, { "form_type": "10-Q", "accession_number": "0000046765-24-000030", "filing_date": 1713975873000, "quarter_ending": "20240331", "company_name": "Helmerich & Payne, Inc.", "text": "We continue to use our captive insurance companies to insure the deductibles for our domestic workers\u2019 compensation, general liability, automobile liability claims programs, and medical stop-loss program and to insure the deductibles from the Company's international casualty and property programs. Our operating subsidiaries are paying premiums to the Captives, typically on a monthly basis, for the estimated losses based on an external actuarial analysis. These premiums are currently held in a restricted cash account, resulting in a transfer of risk from our operating subsidiaries to the Captives. Direct operating costs primarily consisted of adjustments of $1.6 million and $1.7 million to accruals for estimated losses for the three months ended March\u00a031, 2024 and 2023, respectively, and $5.1 million and $4.7 million for the six months ended March\u00a031, 2024 and 2023, respectively, and rig and casualty insurance premiums of $9.9 million and $10.9 million during the three months ended March\u00a031, 2024 and 2023, respectively, and $19.0 million and $20.9\u00a0million for the six months ended March\u00a031, 2024 and 2023, respectively. These operating costs were recorded within Drilling services operating expenses in our Unaudited Condensed Consolidated Statement of Operations. Intercompany premium revenues recorded by the Captives during the three months ended March\u00a031, 2024 and 2023 amounted to $15.8 million and $17.7 million, respectively, and $31.0 million and $34.1 million during the six months ended March\u00a031, 2024 and 2023, respectively, which were eliminated upon consolidation.\u00a0These intercompany insurance premiums are reflected as segment operating expenses within the North America Solutions, International Solutions, and Offshore Gulf of Mexico reportable operating segments and are reflected as intersegment sales within \"Other.\" Our medical stop loss operating expenses for the three months ended March\u00a031, 2024 and 2023 were $3.2\u00a0million and $2.5\u00a0million, respectively, and $7.3\u00a0million and $5.3 million for the six months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 1403, "end_character": 1407, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 15800000.0 }, { "start_character": 1421, "end_character": 1425, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 17700000.0 }, { "start_character": 1454, "end_character": 1458, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 31000000.0 }, { "start_character": 1472, "end_character": 1476, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 34100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001773751-24-000025", "filing_date": 1708965595000, "quarter_ending": "20231231", "company_name": "Hims & Hers Health, Inc.", "text": "During the year ended December\u00a031, 2023, the Company incurred a net loss of $23.5 million and had positive cash flows from operating activities of $73.5 million. As of December\u00a031, 2023, the Company had an accumulated deficit of $368.2 million, cash and cash equivalents of $96.7 million, and short-term investments of $124.3 million.", "entities": [ { "start_character": 77, "end_character": 81, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -23500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001773751-24-000132", "filing_date": 1715012225000, "quarter_ending": "20240331", "company_name": "Hims & Hers Health, Inc.", "text": "For the three months ended March\u00a031, 2024 and 2023, the VIEs charged $33.1 million and $22.5 million, respectively, for services rendered. For the three months ended March\u00a031, 2024 and 2023, operations of the VIEs generated a net loss of $0.8 million and net income of $2.7 million, respectively, inclusive of administrative expenses.", "entities": [ { "start_character": 239, "end_character": 242, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -800000.0 }, { "start_character": 270, "end_character": 273, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001210708-24-000032", "filing_date": 1715357739000, "quarter_ending": "20240331", "company_name": "Hudson Global, Inc.", "text": "The benefit from income taxes for the three months ended March\u00a031, 2024 was $88 on a pre-tax loss of $2,986, compared to a benefit from income taxes of $139 on pre-tax income of $215 for the same period in 2023. The Company\u2019s effective income tax rate was positive 3% and negative 65% for the three months ended March\u00a031, 2024 and 2023, respectively. For the three months ended March\u00a031, 2024, the effective tax rates differed from the U.S. Federal statutory rate of 21% primarily due to changes in valuation allowances in the U.S. and certain foreign jurisdictions, which reduces or eliminates the effective tax rate on current year profits or losses, foreign tax rate differences, and non-deductible expense. For the three months ended March\u00a031, 2023, the effective tax rates differed from the U.S. Federal statutory rate of 21% primarily due to a discrete tax benefit recognized following the lapse of certain statutes of limitations related to Spain, recognition of a portion of a deferred tax asset in Canada, state income taxes, changes in valuation allowances in the U.S. and certain foreign jurisdictions which reduces or eliminates the effective tax rate on current year profits or losses, foreign tax rate differences, taxes on repatriations or deemed repatriation of foreign profits, and non-deductible expenses.", "entities": [ { "start_character": 102, "end_character": 107, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2986000.0 }, { "start_character": 179, "end_character": 182, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 215000.0 } ] }, { "form_type": "10-K", "accession_number": "0001818382-24-000040", "filing_date": 1711613199000, "quarter_ending": "20231231", "company_name": "Humacyte, Inc.", "text": "Since its inception in 2004, the Company has generated no product revenue and has incurred operating losses and negative cash flows from operations in each year. To date, the Company has financed its operations primarily through the sale of equity securities and convertible debt, proceeds from the Reverse Recapitalization, borrowings under loan facilities, proceeds from a revenue interest purchase agreement and, to a lesser extent, through governmental and other grants. At December\u00a031, 2023 and December\u00a031, 2022, the Company had an accumulated deficit of $537.3 million and $426.5\u00a0million, respectively. The Company\u2019s operating losses were $100.0 million and $84.6 million for the years ended December\u00a031, 2023 and 2022, respectively. Net cash flows used in operating activities were $73.3 million and $71.1 million during the years ended December\u00a031, 2023 and 2022, respectively. Substantially all of the Company\u2019s operating losses resulted from costs incurred in connection with the Company\u2019s research and development programs and from general and administrative costs associated with the Company\u2019s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates.", "entities": [ { "start_character": 647, "end_character": 652, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -100000000.0 }, { "start_character": 666, "end_character": 670, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -84600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001818382-24-000056", "filing_date": 1715616663000, "quarter_ending": "20240331", "company_name": "Humacyte, Inc.", "text": "Since its inception in 2004, the Company has generated no product revenue and has incurred operating losses and negative cash flows from operations in each year. To date, the Company has financed its operations primarily through the sale of equity securities and convertible debt, proceeds from the Reverse Recapitalization, borrowings under loan facilities, proceeds from a revenue interest purchase agreement and, to a lesser extent, through governmental and other grants. At March\u00a031, 2024 and December\u00a031, 2023, the Company had an accumulated deficit of $569.2 million and $537.3 million, respectively. The Company\u2019s operating losses were $26.6\u00a0million and $22.5\u00a0million for the three months ended March\u00a031, 2024 and 2023, respectively. Net cash flows used in operating activities were $27.3\u00a0million and $18.6 million during the three months ended March\u00a031, 2024 and 2023, respectively. Substantially all of the Company\u2019s operating losses resulted from costs incurred in connection with the Company\u2019s research and development programs and from general and administrative costs associated with the Company\u2019s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates.", "entities": [ { "start_character": 644, "end_character": 648, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -26600000.0 }, { "start_character": 662, "end_character": 666, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -22500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001289848-24-000119", "filing_date": 1714494550000, "quarter_ending": "20240331", "company_name": "Huron Consulting Group Inc.", "text": "For the three months ended March\u00a031, 2024, our effective tax rate was (2.5)% as we recognized an income tax benefit of $0.4 million on income of $17.6 million. The effective tax rate of (2.5)% was more favorable than the statutory rate, inclusive of state income taxes, of 26.1%, primarily due to a discrete tax benefit for share-based compensation awards that vested during the quarter.", "entities": [ { "start_character": 146, "end_character": 150, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 17600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001289848-24-000119", "filing_date": 1714494550000, "quarter_ending": "20240331", "company_name": "Huron Consulting Group Inc.", "text": "For the three months ended March\u00a031, 2023, our effective tax rate was 15.3% as we recognized income tax expense of $2.4 million on income of $15.8 million. The effective tax rate of 15.3% was more favorable than the statutory rate, inclusive of state income taxes, of 26.6%, primarily due to a discrete tax benefit for share-based compensation awards that vested during the quarter and a tax benefit related to non-taxable gains on our investments used to fund our deferred compensation liability. These favorable items were partially offset by certain nondeductible expense items.", "entities": [ { "start_character": 142, "end_character": 146, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 15800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001716583-24-000025", "filing_date": 1711095318000, "quarter_ending": "20231231", "company_name": "Hyzon Motors Inc.", "text": "During 2023 the Company entered into contracts with a customer to upfit internal combustion engine vehicles to FCEVs. The Company offered certain trade-in and buyback options of FCEVs to its end customer who purchase upfit services including fuel cell powertrain. Under these arrangements, the Company receives full payment shortly after the upfit FCEV is delivered, and the end customer subsequently has the option to trade-in for credit or sell the FCEV back for cash during an agreed upon period and for a predetermined value. As of December\u00a031, 2023, $1.3 million reported as Unbilled receivable in the Consolidated Balance Sheets represents the amount the Company is entitled to collect upon the delivery of the FCEVs. Those contracts are accounted for as an operating lease when the end customer has a significant economic incentive to exercise the trade-in or buyback option at contract inception. For the year ended December\u00a031, 2023, the Company recognized no operating lease revenue and no operating lease equipment depreciation expense. As of December\u00a031, 2023, the Company had deferred $1.0 million of upfront lease related payments, $0.3\u00a0million of which was recorded in the Contract liabilities and $0.7\u00a0million of which was recorded in the Other liabilities in the Consolidated Balance Sheets. The upfront lease related payments will be recognized on a straight-line basis over the individual lease term. ", "entities": [ { "start_character": 823, "end_character": 825, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 }, { "start_character": 966, "end_character": 968, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0000883984-24-000005", "filing_date": 1709053529000, "quarter_ending": "20231231", "company_name": "ICU MEDICAL INC/DE", "text": "Smiths Medical is included in our consolidated results beginning on January 7, 2022. Total revenues and net loss attributable to Smiths Medical for the period from January 7, 2022 to December 31, 2022 were $950.7\u00a0million and $(74.3)\u00a0million, respectively. The net loss figure is an estimate as the results by company are less identifiable due to integration. The following unaudited pro forma financial information presents the combined results of operations of ICU and Smiths Medical as if the acquisition had occurred on January 1, 2021. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place on the date indicated or of results that may occur in the future. ", "entities": [ { "start_character": 207, "end_character": 212, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 950700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019793", "filing_date": 1715788848000, "quarter_ending": "20240331", "company_name": "IMAC Holdings, Inc.", "text": "The\nCompany\u2019s consolidated financial statements are prepared in accordance with GAAP and includes the assumption of a going concern\nbasis, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, as shown\nin the accompanying consolidated financial statements, the Company has sustained substantial losses from operations since inception and\nhas discontinued its operations as of December 31, 2023 which raises substantial doubt regarding the Company\u2019s ability to continue\nas a going concern for twelve months from the issuance date of this report. The Company had a working capital deficit of approximately\n($1.2) million at March 31, 2024. The Company had a net loss of approximately $0.4 million for the three months ended March 31, 2024,\nand used cash in operations of approximately $0.2 million for the three months ended March 31, 2024. The Company expects to continue\nto incur expenditures for working capital.", "entities": [ { "start_character": 748, "end_character": 751, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001466085-24-000023", "filing_date": 1709136962000, "quarter_ending": "20231231", "company_name": "INDEPENDENCE REALTY TRUST, INC.", "text": "For the period from December 16, 2021 through December 31, 2021, STAR contributed $15,589 of revenues and $18,388 of net loss to our results of operations, inclusive of certain merger and integration costs.", "entities": [ { "start_character": 83, "end_character": 89, "label": "revenues", "start_date_for_period": "2021-12-16", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 15589000.0 } ] }, { "form_type": "10-K", "accession_number": "0001731122-24-000304", "filing_date": 1708698184000, "quarter_ending": "20231031", "company_name": "INNOVATIVE DESIGNS INC", "text": "These\nfinancial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its\nassets and discharge its liabilities in the normal course of business. The Company had net losses of ($301,378) and ($225,489)\nand negative cash flows from operations of ($209,489) and ($99,685) for the fiscal year ended October 31, 2023 and 2022, respectively.\nIn addition, the Company has an accumulated deficit of ($10,636,957). These factors raise substantial doubt regarding the Company\u2019s\nability to continue as a going concern for a period of one year from the issuance of these financial statements. Management\u2019s\nplans include cash receipts through sales, sales of Company stock, and borrowings from private parties. These financial statements\ndo not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities\nthat might be necessary should the Company be unable to continue as a going concern.", "entities": [ { "start_character": 235, "end_character": 242, "label": "earnings", "start_date_for_period": "2022-11-01", "end_date_for_period": "2023-10-31", "currency_/_unit": "iso4217:USD", "value": -301378.0 }, { "start_character": 250, "end_character": 257, "label": "earnings", "start_date_for_period": "2021-11-01", "end_date_for_period": "2022-10-31", "currency_/_unit": "iso4217:USD", "value": -225489.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-024329", "filing_date": 1718731544000, "quarter_ending": "20240430", "company_name": "INNSUITES HOSPITALITY TRUST", "text": "Hotel\nOperation results of the Albuquerque Hotel and the Tucson Hotel both achieved record results for the Fiscal Year ended January 31,\n2024. Increased record revenue and Gross Operating Profit (GOP), results are expected for the two hotels, during the Fiscal Year\n2025, ending January 31, 2025. IHT reported a strong annual improvement of results in Fiscal Year 2024, (February 1, 2023, to\nJanuary 31, 2024), with Net Income Attributable to Controlling Interests of $203,880.\nEarnings Per Share based on this Net Income Attributable to Controlling Interest amount was $0.02.\nTotal Revenues increased to approximately $7.5\nmillion, which is an approximate increase of 5%\nfrom the same prior Fiscal Year total of $7.1\nmillion. Consolidated Net Income before non-cash depreciation expense was $956,333\nfor the Fiscal Year ended January 31, 2024. IHT hotel operations are contributing to a solid start in the current 2025 Fiscal Year\n(February 1, 2024 through January 31, 2025), with both the Tucson Hotel and Albuquerque Hotel achieving record results for the\ncombined months of February, March, April, and May of the current Fiscal Year. Combined Revenue for both hotels surpassed $2.9\nmillion for the first four months of Fiscal 2025, a new combined record level. These are all positive signs for InnSuites, as\nprogress continues heading in the right direction as the Travel Industry, and InnSuites Hospitality Trust (IHT) specifically,\ncontinue to rebound and thrive.", "entities": [ { "start_character": 620, "end_character": 623, "label": "revenues", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 7500000.0 }, { "start_character": 714, "end_character": 717, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": 7100000.0 }, { "start_character": 1182, "end_character": 1185, "label": "revenues", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-05-31", "currency_/_unit": "iso4217:USD", "value": 2900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001055726-24-000011", "filing_date": 1709740909000, "quarter_ending": "20231231", "company_name": "INOVIO PHARMACEUTICALS, INC.", "text": "The Company incurred a net loss of $135.1 million for the year ended December\u00a031, 2023. The Company had working capital of $110.5 million and an accumulated deficit of $1.6 billion as of December\u00a031, 2023. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company\u2019s cash, cash equivalents and short-term investments of $145.3 million as of December 31, 2023 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. ", "entities": [ { "start_character": 36, "end_character": 41, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -135100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001055726-24-000020", "filing_date": 1715616080000, "quarter_ending": "20240331", "company_name": "INOVIO PHARMACEUTICALS, INC.", "text": "The Company incurred a net loss attributable to common stockholders of $30.5 million for the three months ended March 31, 2024. The Company had working capital of $88.3 million and an accumulated deficit of $1.7 billion as of March\u00a031, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. ", "entities": [ { "start_character": 72, "end_character": 76, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -30500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-006391", "filing_date": 1708619888000, "quarter_ending": "20231231", "company_name": "INSIGHT ENTERPRISES INC", "text": "The Company adopted this standard effective January 1, 2022, using the modified retrospective approach. Therefore, financial statements for the year ended December 31, 2022 and forward are presented under the new standard, while the comparative period is not adjusted and is reported in accordance with the Company's previous method of accounting. The adoption of ASU 2020-06 significantly impacted our consolidated statements of operations and consolidated balance sheet as we no longer report accreted interest on the Notes. The cumulative effect adjustment from prior periods that we recognized in our consolidated balance sheet as adjustments to reduce additional paid in capital and increase retained earnings were $44,731,000 and $17,789,000, respectively. Had we followed the prior method of accounting for the year ended December 31, 2022, reported basic and diluted EPS would decrease by $0.24 and $0.22, respectively, from $8.04 and $7.66, respectively, to $7.80 and $7.44, respectively.", "entities": [ { "start_character": 898, "end_character": 902, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": null, "value": 0.24 }, { "start_character": 934, "end_character": 938, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": null, "value": 8.04 }, { "start_character": 968, "end_character": 972, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": null, "value": 7.8 } ] }, { "form_type": "10-Q", "accession_number": "0001104506-24-000016", "filing_date": 1715238030000, "quarter_ending": "20240331", "company_name": "INSMED Inc", "text": "The Company had $595.7 million in cash and cash equivalents as of March\u00a031, 2024 and reported a net loss of $157.1 million for the three months ended March\u00a031, 2024. The Company has funded its operations through public offerings of equity securities, de", "entities": [ { "start_character": 109, "end_character": 114, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -157100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001145197-24-000011", "filing_date": 1708624173000, "quarter_ending": "20231231", "company_name": "INSULET CORP", "text": "In February 2021, the Company entered into a distribution agreement, the terms of which are consistent with those prevailing at arm\u2019s length. The spouse of one of the members of the Company\u2019s Board of Directors is an executive officer of the distributor. The Company recorded $473.7\u00a0million, $249.9\u00a0million and $58.2\u00a0million of net revenues from the distributor for the years ended December 31, 2023, 2022, and 2021, respectively.", "entities": [ { "start_character": 277, "end_character": 282, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 473700000.0 }, { "start_character": 293, "end_character": 298, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 249900000.0 }, { "start_character": 312, "end_character": 316, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 58200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-005569", "filing_date": 1707467461000, "quarter_ending": "20231231", "company_name": "INTELLIGENT BIO SOLUTIONS INC.", "text": "The\nCompany incurred a net loss of $1,969,641 and $4,394,845\u00a0(after losses attributable to non-controlling interest) for the three and\nsix months ended December 31, 2023, respectively (net loss of $420,600 and $1,628,893\u00a0for the three and six months ended December\n31, 2022, respectively). As of December 31, 2023, the Company has shareholders\u2019 equity of $3,154,234, a working capital deficit\nof $2,238,430, and an accumulated deficit of $46,202,418.", "entities": [ { "start_character": 36, "end_character": 45, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1969641.0 }, { "start_character": 51, "end_character": 60, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -4394845.0 }, { "start_character": 198, "end_character": 205, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -420600.0 }, { "start_character": 211, "end_character": 220, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1628893.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018167", "filing_date": 1715157055000, "quarter_ending": "20240331", "company_name": "INTELLIGENT BIO SOLUTIONS INC.", "text": "The\nCompany incurred a net loss of $2,977,667 and $7,372,512 (after losses attributable to non-controlling interest) for the three and nine\nmonths ended March 31, 2024, respectively (net loss of $6,343,906 and $7,972,799 for the three and nine months ended March 31, 2023,\nrespectively). As of March 31, 2024, the Company has shareholders\u2019 equity of $10,997,772, working capital of $5,814,284,\nand an accumulated deficit of $49,180,085.", "entities": [ { "start_character": 36, "end_character": 45, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2977667.0 }, { "start_character": 51, "end_character": 60, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -7372512.0 }, { "start_character": 196, "end_character": 205, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -6343906.0 }, { "start_character": 211, "end_character": 220, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -7972799.0 } ] }, { "form_type": "10-Q", "accession_number": "0001567264-24-000010", "filing_date": 1715270487000, "quarter_ending": "20240331", "company_name": "INTENSITY THERAPEUTICS, INC.", "text": "The Company is a research and development company and has not generated any revenue from its product candidates. The Company has experienced net losses and negative cash flows from operations each year since its inception. Through March\u00a031, 2024, the Company has an accumulated deficit of $55.1 million. The Company\u2019s operations have been financed primarily through the sale of equity securities and convertible notes. The Company\u2019s net loss for the three months ended March\u00a031, 2024 was $4.6 million. The Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. The Company does not expect to receive significant product revenue in the near term. The Company, therefore, expects to continue to incur substantial losses for the foreseeable future.", "entities": [ { "start_character": 489, "end_character": 492, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000715787-24-000019", "filing_date": 1715098861000, "quarter_ending": "20240331", "company_name": "INTERFACE INC", "text": "During the three months ended March\u00a031, 2024, the Company recorded a total income tax provision of $4.8 million on pre-tax income of $19.0 million resulting in an effective tax rate of 25.4%, as compared to a total income tax provision of $0.2 million on pre-tax loss of $0.5 million resulting in a negative effective tax rate of 35.2% during the three months ended April\u00a02, 2023. The year-over-year change in the effective tax rate is primarily due to the tax effects of pre-tax income in the current year quarter compared to pre-tax loss in the prior year quarter and favorable changes related to share-based compensation and the limitation on the deduction for business interest expenses under Internal Revenue Code section 163(j). The pre-tax loss for the three months ended April 2, 2023, included significant unusual or infrequent items that are specifically excluded from the AETR. The tax effects related to these specifically excluded items are recognized discretely. The income tax benefits recognized discretely were at a lower effective tax rate compared to the estimated AETR resulting in an overall negative effective tax rate for the three months ended April 2, 2023.", "entities": [ { "start_character": 134, "end_character": 138, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 19000000.0 }, { "start_character": 272, "end_character": 275, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-04-02", "currency_/_unit": "iso4217:USD", "value": -500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018432", "filing_date": 1715271333000, "quarter_ending": "20240331", "company_name": "INTERPACE BIOSCIENCES, INC.", "text": "For\nthe three months ended March 31, 2024, the Company had operating income from continuing operations of $0.9 million. As of March 31, 2024,\nthe Company had cash and cash equivalents of $2.8 million, total current assets of $9.4 million and current liabilities of $19.0 million.\nAs of May 3, 2024, the Company had approximately $2.8 million of cash and cash equivalents.", "entities": [ { "start_character": 107, "end_character": 110, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014838", "filing_date": 1713286213000, "quarter_ending": "20231231", "company_name": "INVO Bioscience, Inc.", "text": "Historically,\nthe Company has funded its cash and liquidity needs through revenue collection, equity financings, notes, and convertible notes. For\nthe years ended December 31, 2023 and 2022, the Company incurred a net loss of approximately $8.0\nmillion and $10.9\nmillion, respectively, and has an accumulated deficit of approximately $57.8\nmillion as of December 31, 2023. Approximately $2.8\nmillion of the net loss was related to non-cash expenses for the year ended December 31, 2023, compared to $3.0\nmillion for the year ended December 31, 2022.", "entities": [ { "start_character": 241, "end_character": 244, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8000000.0 }, { "start_character": 258, "end_character": 262, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -10900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014838", "filing_date": 1713286213000, "quarter_ending": "20231231", "company_name": "INVO Bioscience, Inc.", "text": "The\nCompany determined the Georgia JV is a VIE, and that the Company is its primary beneficiary because the Company has an obligation to\nabsorb losses that are potentially significant and the Company controls the majority of the activities that impact the Georgia JV\u2019s\neconomic performance, specifically control of the INVOcell and lab services quality management. As a result, the Company consolidated\nthe Georgia JV\u2019s results with its own. As of December 31, 2023, the Company invested $0.9 million in the Georgia JV in the form\nof capital contributions as well as $0.5 million in the form of a note. For the years ended December 31, 2023 and 2022, the Georgia JV\nrecorded net losses of $0.2 million and $0.6 million, respectively. Noncontrolling interest in the Georgia JV was $0.", "entities": [ { "start_character": 690, "end_character": 693, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 707, "end_character": 710, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014838", "filing_date": 1713286213000, "quarter_ending": "20231231", "company_name": "INVO Bioscience, Inc.", "text": "The\nCompany determined the Alabama JV is a VIE, and that there is no primary beneficiary. As a result, the Company uses the equity method\nto account for its interest in the Alabama JV. As of December 31, 2023, the Company invested $1.4 million in the Alabama JV in the form\nof a note. For the years ended December 31, 2023 and 2022, the Alabama JV recorded net losses of $0.03 million and $0.3 million, respectively,\nof which the Company recognized losses from equity method investments of $0.02 million and $0.2 million, respectively.", "entities": [ { "start_character": 372, "end_character": 376, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 30000.0 }, { "start_character": 390, "end_character": 393, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019786", "filing_date": 1715788829000, "quarter_ending": "20240331", "company_name": "INVO Bioscience, Inc.", "text": "The\nCompany determined the Alabama JV is a VIE, and that there is no primary beneficiary. As a result, the Company uses the equity method\nto account for its interest in the Alabama JV. March 31, 2024, the Company invested $1.4 million in the Alabama JV in the form of a note.\nFor the three months ended March 31, 2024, the Alabama JV recorded net income of $0.2 thousand, of which the Company recognized a gain\nfrom equity method investments of $0.1 thousand. For the three months ended March 31, 2023, the Alabama JV recorded a net loss of $37\nthousand, of which the Company recognized a loss from equity method investments of $18 thousand.", "entities": [ { "start_character": 358, "end_character": 361, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200.0 }, { "start_character": 542, "end_character": 544, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 37000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019786", "filing_date": 1715788829000, "quarter_ending": "20240331", "company_name": "INVO Bioscience, Inc.", "text": "The\nCompany determined the Georgia JV is a VIE, and that the Company is its primary beneficiary because the Company has an obligation to\nabsorb losses that are potentially significant and the Company controls the majority of the activities that impact the Georgia JV\u2019s\neconomic performance, specifically control of the INVOcell and lab services quality management. As a result, the Company consolidated\nthe Georgia JV\u2019s results with its own. As of March 31, 2024, the Company invested $0.9 million in the Georgia JV in the form of\ncapital contributions as well as $0.5 million in the form of a note. For the three months ended March 31, 2024 and 2023, the Georgia\nJV recorded net losses of $50 thousand and $32 thousand respectively. Noncontrolling interest in the Georgia JV was $0.", "entities": [ { "start_character": 691, "end_character": 693, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 50000.0 }, { "start_character": 708, "end_character": 710, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 32000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019786", "filing_date": 1715788829000, "quarter_ending": "20240331", "company_name": "INVO Bioscience, Inc.", "text": "Historically,\nthe Company has funded its cash and liquidity needs primarily through revenue collection and debt and equity financings.\nFor the three months ended March 31, 2024, and 2023, the Company incurred a net loss of approximately $1.6\nmillion and $2.6\nmillion, respectively, and has an accumulated deficit of approximately $59.4\nmillion as of March 31, 2024. Approximately $1.0\nmillion of the net loss was related to non-cash expenses for the three months ended March 31, 2024, compared to $0.9\nmillion for the three months ended March 31, 2023.", "entities": [ { "start_character": 238, "end_character": 241, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1600000.0 }, { "start_character": 255, "end_character": 258, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -2600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018877", "filing_date": 1715616346000, "quarter_ending": "20240331", "company_name": "IR-Med, Inc.", "text": "The\nCompany has started the preparations of the commercial launch of its first device, the PressureSafe, but does not expect to generate\nsignificant revenue until such time as the Company shall have completed the design and development of its initial products candidates\nand initiates marketing activities for its commercial product. During the three months ended March 31, 2024, the Company incurred losses\nof $657", "entities": [ { "start_character": 413, "end_character": 416, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -657000.0 } ] }, { "form_type": "10-K", "accession_number": "0001159167-24-000008", "filing_date": 1709050324000, "quarter_ending": "20231230", "company_name": "IROBOT CORP", "text": "In fiscal 2023, the Company's performance continued to be impacted by lower orders from retailers and distributors largely resulting from a decline in consumer sentiment, and resultant spending, as well as increased pricing competition in the market. During fiscal 2023, the Company's revenue declined 25% from fiscal 2022. The lower revenue has resulted in operating losses of $264.1 million and operating cash outflows of $114.8 million for fiscal 2023. On July 24, 2023, the Company entered into the $200.0\u00a0million Term Loan. Total proceeds from the Term Loan were $188.2\u00a0million, net of debt issuance costs, which will be used to fund the Company's ongoing operations. As a result, the Company ended fiscal 2023 with cash and cash equivalents of $185.1\u00a0million compared to $117.9 million as of December 31, 2022. ", "entities": [ { "start_character": 379, "end_character": 384, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": -264100000.00000003 } ] }, { "form_type": "10-Q", "accession_number": "0001159167-24-000039", "filing_date": 1715185421000, "quarter_ending": "20240330", "company_name": "IROBOT CORP", "text": "In first quarter of fiscal 2024, the Company's performance continued to be impacted by lower orders from retailers and distributors largely resulting from a decline in consumer sentiment and increased pricing competition in the market. During the three months ended March\u00a030, 2024, the Company's revenue declined 6.4% compared to the three months ended April\u00a01, 2023. The Company's operating income of $11.9 million and operating cash inflows of $1.4 million for the three months ended March\u00a030, 2024 benefited from the one-time receipt of the Parent Termination Fee net of professional fees paid of $75.2\u00a0million. At March\u00a030, 2024, the Company's cash and cash equivalents were $118.4 million. The Company also had $41.8 million in restricted cash, $40.0 million of which is set aside for future repayment of the Term Loan subject to limited rights for the purchase of inventory in the third quarters of fiscal 2024 and 2025.", "entities": [ { "start_character": 403, "end_character": 407, "label": "ebit", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 11900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014892", "filing_date": 1713288685000, "quarter_ending": "20231231", "company_name": "ISUN, INC.", "text": "As of December\n31, 2023, the Company had a working capital deficiency of $3.9 million. During the years ended December 31, 2023 and 2022, the Company\nincurred net losses of $19.4", "entities": [ { "start_character": 174, "end_character": 178, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -19400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014892", "filing_date": 1713288685000, "quarter_ending": "20231231", "company_name": "ISUN, INC.", "text": "The\nCompany would cease to be an \u201cemerging growth company\u201d upon the earliest to occur of: the last day of the fiscal year in\nwhich it has more than $1.07 billion in annual revenue; the date it qualifies as a \u201clarge accelerated filer,\u201d with at least\n$700 million of equity securities held by non-affiliates; the issuance, in any three-year period, by it of more than $1.0 billion in\nnon-convertible debt or December of 2024.", "entities": [ { "start_character": 149, "end_character": 153, "label": "revenues", "start_date_for_period": "2024-12-01", "end_date_for_period": "2024-12-31", "currency_/_unit": "iso4217:USD", "value": 1070000000.0000001 } ] }, { "form_type": "10-K", "accession_number": "0000216228-24-000020", "filing_date": 1707753282000, "quarter_ending": "20231231", "company_name": "ITT INC.", "text": "Includes revenue of $1,075.8, $978.6, and $842.9 from the United States for 2023, 2022, and 2021, respectively.", "entities": [ { "start_character": 21, "end_character": 28, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1075800000.0 }, { "start_character": 31, "end_character": 36, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 978600000.0 }, { "start_character": 43, "end_character": 48, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 842900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018458", "filing_date": 1715272051000, "quarter_ending": "20240331", "company_name": "Immix Biopharma, Inc.", "text": "On\nDecember 8, 2022, Nexcella entered into a Research and License agreement with HADASIT and BIRAD (collectively, the \u201cLicensors\u201d)\nto acquire intellectual property rights pertaining to CAR-T (the \u201cH&B License\u201d). Pursuant to the H&B License, Nexcella\npaid the Licensors an upfront license fee of $1.5 million in December 2022 (included in research and development expenses on the consolidated\nstatements of operations and comprehensive loss). Additional quarterly payments totaling approximately $13 million related to the Company\u2019s\nongoing support of the CAR-T clinical trials currently ongoing at HADASIT, are due through September 2026, along with an annual license\nfee of $50,000. Future royalty payments of 5% are due on net sales of licensed products, combined with sales milestone payments in the\naggregate amount of up to $20 million when annual net sales reach certain thresholds for each licensed product. The royalties for each\nlicensed product on a country-to-country basis are to be paid through the latter of (a) the expiration of the last-to-expire valid claim\nunder a licensed patent (if any) in such country; (b) the date of expiration of any other Exclusivity Right (as defined in the H&B\nLicense) or data protection period granted by a regulatory or other governmental authority with respect to a licensed product that provides\nexclusivity in the relevant country; or (c) the end of a period of 15 years from the date of the First Commercial Sale (as defined in\nthe H&B License) of the applicable Licensed Product (as defined in the H&B License) in such country.", "entities": [ { "start_character": 830, "end_character": 832, "label": "revenues", "start_date_for_period": "2022-12-07", "end_date_for_period": "2022-12-08", "currency_/_unit": "iso4217:USD", "value": 20000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001326110-24-000037", "filing_date": 1710865913000, "quarter_ending": "20231231", "company_name": "ImmunityBio, Inc.", "text": "The license agreements may include non-refundable upfront payments, event-based milestone payments, sales-based royalty payments, or some combination of these. The event-based milestone payments represent variable consideration and we use the most likely amount method to estimate this variable consideration. Given the high degree of uncertainly around the achievement of these milestones, we do not recognize revenue from these milestone payments until the uncertainty associated with these payments is resolved. We currently estimate variable consideration related to milestone payments to be zero and, as such, no revenue has been recognized for milestone payments. We recognize revenue from sales-based royalty payments when or as sales occur. On a quarterly basis, we re-evaluate our estimate of milestone variable consideration to determine whether any amount should be included in the transaction price and recorded in revenue prospectively.", "entities": [ { "start_character": 596, "end_character": 600, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0.0 }, { "start_character": 615, "end_character": 617, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011616", "filing_date": 1711613446000, "quarter_ending": "20231231", "company_name": "Imunon, Inc.", "text": "Since\ninception, the Company has incurred substantial operating losses, principally from expenses associated with the Company\u2019s research\nand development programs, clinical trials conducted in connection with the Company\u2019s drug candidates, and applications and submissions\nto the FDA. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For\nthe year ended December 31, 2023, the Company had a net loss of $19.5 million and used $19.0 million to fund operations. As of December\n31, 2023, the Company has incurred approximately $388 million of cumulative net losses. As of December 31, 2023, the Company had $15.7\nmillion in cash and cash equivalents, short-term investments, and interest receivable and $1.3 million net proceeds from the sale of\nits New Jersey net operating losses. The Company has substantial future capital requirements to continue its research and development\nactivities and advance its drug candidates through various development stages. The Company believes these expenditures are essential\nfor the commercialization of its drug candidates and technologies.", "entities": [ { "start_character": 473, "end_character": 477, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -19500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018795", "filing_date": 1715587857000, "quarter_ending": "20240331", "company_name": "Imunon, Inc.", "text": "Since\ninception, the Company has incurred substantial operating losses, principally from expenses associated with the Company\u2019s research\nand development programs, clinical trials conducted in connection with the Company\u2019s drug candidates, and applications and submissions\nto the FDA. The Company has not generated significant revenue and has incurred significant net losses in each year since inception. For\nthe quarter ended March 31, 2024, the Company had a net loss of $4.9 million and used $5.9 million to fund operations. As of March\n31, 2024, the Company has incurred approximately $393 million of cumulative net losses. As of March 31, 2024, the Company had $9.8 million\nin cash and cash equivalents, short-term investments, and interest receivable to fund its operations. ", "entities": [ { "start_character": 473, "end_character": 476, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018162", "filing_date": 1715155598000, "quarter_ending": "20240331", "company_name": "Indaptus Therapeutics, Inc.", "text": "The\nCompany has incurred net losses and utilized cash in operations since inception. For the three-month period ended March 31, 2024,\nthe Company incurred a net loss of approximately $3.8\nmillion, and as of March 31, 2024, the Company had an accumulated deficit of approximately $49.2\nmillion. In addition, during the three-month period ended March 31, 2024, the Company used approximately $3.9\nmillion of cash in operations and expects to continue to incur significant cash outflows and incur future additional losses as\nclinical trials and commercialization of the Company\u2019s product candidates will require significant additional financing. The\nCompany believes that, as of the date of the issuance of these unaudited condensed consolidated financial statements, it will not\nhave adequate cash to fund its ongoing activities beyond the third quarter of 2024 based on its current operating plan. The Company\nplans to execute its operating plan by obtaining additional capital, principally through entering into collaborations, strategic\nalliances, or license agreements with third parties and/or additional public or private debt and equity financing. However, there is\nno assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on\nterms acceptable to the Company or in the amounts required. If the Company is unsuccessful in securing sufficient financing, it may\nneed to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects, or\ncease operations.", "entities": [ { "start_character": 184, "end_character": 187, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001138639-24-000153", "filing_date": 1716541207000, "quarter_ending": "20240330", "company_name": "Infinera Corp", "text": "Income taxes for the three-months ended March\u00a030, 2024 represented a tax expense of $4.7\u00a0million on pre-tax losses of $56.7\u00a0million. This compared to a tax expense of $3.6\u00a0million on pre-tax losses of $4.8\u00a0million for the three-months ended April\u00a01, 2023. ", "entities": [ { "start_character": 119, "end_character": 123, "label": "earnings", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -56700000.0 }, { "start_character": 202, "end_character": 205, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": -4800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001868778-24-000021", "filing_date": 1714666836000, "quarter_ending": "20240331", "company_name": "Informatica Inc.", "text": "The Company computes its income tax provision for interim periods by applying the estimated annual effective tax rate to year-to-date pre-tax income or loss from recurring operations and adjusting for discrete tax items arising in that quarter. The Company's income tax benefit was $25.5 million on pretax losses of $16.1 million for the three months ended March\u00a031, 2024, which resulted in a positive effective tax rate of 158%. The Company\u2019s effective tax rate differs from the U.S. statutory rate of 21% primarily due to an increase in its valuation allowance and to a lesser extent from foreign income taxed at different rates and non-deductible stock-based compensation.", "entities": [ { "start_character": 317, "end_character": 321, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -16100000.000000002 } ] }, { "form_type": "10-Q", "accession_number": "0001868778-24-000021", "filing_date": 1714666836000, "quarter_ending": "20240331", "company_name": "Informatica Inc.", "text": "The Company's income tax expense was $59.6 million on pretax losses of $56.8 million for the three months ended March\u00a031, 2023, which resulted in a negative effective tax rate of 105%. The Company\u2019s effective tax rate differs from the U.S. statutory rate of 21% primarily due to an increase in its valuation allowance and to a lesser extent from foreign income taxed at different rates and non-deductible stock-based compensation. ", "entities": [ { "start_character": 72, "end_character": 76, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -56800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022249", "filing_date": 1715271498000, "quarter_ending": "20240331", "company_name": "InfuSystem Holdings, Inc", "text": "During the three months ended March\u00a031, 2024, the Company recorded a benefit from income taxes totaling $0.2 million on pre-tax losses of $1.3 million, representing an effective tax rate of 14.3%. During the three months ended March\u00a031, 2023, the Company recorded a benefit from income taxes totaling $0.3 million on pre-tax losses of $0.6 million, representing an effective tax rate of 48.2%. These rates differed from the U.S. statutory rate mainly due to the effects of local, state and foreign jurisdiction income taxes, limitations on the deductions of certain expenses including meals and entertainment expense and management compensation and differences between expense recognized for book purposes versus tax purposes associated with equity compensation expense. The impact of permanent differences weighs heavier on the effective tax rate when pre-tax earnings are close to break even.", "entities": [ { "start_character": 139, "end_character": 142, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1300000.0 }, { "start_character": 336, "end_character": 339, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014609", "filing_date": 1713196939000, "quarter_ending": "20231231", "company_name": "Inspired Entertainment, Inc.", "text": "As\nof December 31, 2023, the Company\u2019s cash on hand was $40.0 million, and the Company had working capital in addition to cash of\n$11.8 million. The Company recorded net income of $7.6 million and $20.6 million and net losses of $40.6 million for the year ended December\n31, 2023, 2022 and 2021, respectively. Net income/losses include excess capital expenditure, excluding the acquisition of subsidiary\nassets, over depreciation and amortization, of $7.9 million and $6.6 million for the years ended December 31, 2023 and 2022, respectively,\nand excess depreciation and amortization over capital expenditure, excluding the acquisition of subsidiary assets, of $28.8 million for\nthe year ended December 31, 2021, non-cash stock-based compensation of $11.2 million, $10.8 million and $13.0 million for the year ended\nDecember 31, 2023, 2022 and 2021, respectively, and non-cash changes in fair value of warrant liability of $0.9 million gain for the\nyear ended December 31, 2021. Historically, the Company has generally had positive cash flows from operating activities and has relied\non a combination of cash flows provided by operations and the incurrence of debt and/or the refinancing of existing debt to fund its\nobligations. Cash flows provided by operations amounted to $45.5 million, $24.7 million and $2.4 million for the year ended December\n31, 2023, 2022 and 2021 respectively, with the changes year on year due primarily to an improved working capital position with favorable\nmovements in inventory which was expanded in the twelve months ended December 31, 2022 to safeguard future supply for production after\nthe COVID-19 pandemic. Favorable movements were also seen in accounts receivable and accounts payable due to timing and varying levels\nof production activity including the installation of 2,500 machines into Greece during the last few months of 2023. Working capital of\n$51.8 million includes a non-cash settled item of $5.6 million of deferred income. Management currently believes that the Company\u2019s\ncash balances on hand, cash flows expected to be generated from operations, ability to control and defer capital projects and amounts\navailable from the Company\u2019s external borrowings will be sufficient to fund the Company\u2019s net cash requirements through April\n2025.", "entities": [ { "start_character": 181, "end_character": 184, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 7600000.0 }, { "start_character": 198, "end_character": 202, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 20600000.0 }, { "start_character": 230, "end_character": 234, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -40600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018572", "filing_date": 1715326233000, "quarter_ending": "20240331", "company_name": "Inspired Entertainment, Inc.", "text": "As\nof March 31, 2024, the Company\u2019s cash on hand was $35.3 million, and the Company had working capital in addition to cash of $14.7\nmillion. The Company recorded a net loss of $5.7 million and $1.4 million for the three months ended March 31, 2024 and 2023, respectively.\nNet income/losses include non-cash stock-based compensation of $2.3 million and $2.9 million for the three months ended March 31, 2024\nand 2023, respectively. Historically, the Company has generally had positive cash flows from operating activities and has relied on a\ncombination of cash flows provided by operations and the incurrence of debt and/or the refinancing of existing debt to fund its obligations.\nCash flows provided by operations amounted to $3.6 million and $11.6 million for the three months ended March 31, 2024 and 2023, respectively. ", "entities": [ { "start_character": 178, "end_character": 181, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -5700000.0 }, { "start_character": 195, "end_character": 198, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001114483-24-000059", "filing_date": 1714060866000, "quarter_ending": "20240329", "company_name": "Integer Holdings Corp", "text": "The Company\u2019s effective tax rate for the first quarter of 2024 was 17.1% on $24.7 million of income before taxes compared to 18.3% on $16.0 million of income before taxes for the same period in 2023. The difference between the Company\u2019s effective tax rates and the U.S. federal statutory income tax rate of 21% for the first quarter of 2024 and 2023 is due principally to the net impact of the Company\u2019s earnings outside the U.S., which are generally taxed at rates that differ from the U.S. federal rate, the Global Intangible Low-Taxed Income (\u201cGILTI\u201d) tax, the Foreign Derived Intangible Income (\u201cFDII\u201d) deduction, the availability of tax credits and the recognition of certain discrete tax items. For the first quarter of 2024, the Company recorded discrete tax benefits of $0.8\u00a0million, compared to discrete tax expense of $0.1\u00a0million for the first quarter of 2023. The discrete tax benefits for the first quarter of 2024 relate predominately to excess tax benefits, net of deductibility limitations, recognized upon vesting of RSUs. The discrete tax expense for the first quarter of 2023 relates to tax shortfalls recorded for the forfeiture of certain PRSUs, partially offset by excess tax benefits recognized upon vesting of RSUs.", "entities": [ { "start_character": 77, "end_character": 81, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 24700000.0 }, { "start_character": 135, "end_character": 139, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 16000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-013949", "filing_date": 1711976525000, "quarter_ending": "20231231", "company_name": "Intellicheck, Inc.", "text": "For the year ended December\u00a031, 2023, the Company incurred a net loss of $(1,980) and had net cash used in operating activities of $(647). As of December\u00a031, 2023, the Company had cash and cash equivalents of $3,980, short term investments of $5,000, working capital (defined as current assets minus current liabilities) of $7,843 and an accumulated deficit of $133,565. Based on the Company\u2019s business plan and cash resources, Intellicheck expects its existing and future resources and revenues generated from operations to satisfy its working capital requirements for at least the next 12 months from the date of filing.", "entities": [ { "start_character": 75, "end_character": 80, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1980000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023185", "filing_date": 1715702595000, "quarter_ending": "20240331", "company_name": "Intellicheck, Inc.", "text": "For the three months ended March\u00a031, 2024, the Company incurred a net loss of $(442) and generated cash from operations of $869. As of March\u00a031, 2024, the Company had cash and cash equivalents of $9,239, working capital (defined as current assets minus current liabilities) of $7,200 and an accumulated deficit of $(134,007). Based on the Company\u2019s business plan and cash resources, Intellicheck expects its existing and future resources and revenues generated from operations to satisfy its working capital requirements for at least the next 12 months from the date of filing.", "entities": [ { "start_character": 80, "end_character": 83, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -442000.0 } ] }, { "form_type": "10-K", "accession_number": "0001571949-24-000007", "filing_date": 1707381140000, "quarter_ending": "20231231", "company_name": "Intercontinental Exchange, Inc.", "text": "We concluded that Bakkt meets the significance test under Rule 3-09 of Regulation S-X for 2022. Bakkt's total assets and liabilities as of December 31, 2022 were $455\u00a0million and $119\u00a0million, respectively, and Bakkt's net revenues and net loss in 2022 were $55\u00a0million and $2.0\u00a0billion, respectively. We concluded that Bakkt no longer meets the significance test for 2023. In accordance with Rule 3-09 of Regulation S-X, as Bakkt met the significance test for a prior year presented in these financial statements, Bakkt financial statements as of and for the year ended December\u00a031, 2023 will be filed subsequently as an amendment to this Form 10-K.", "entities": [ { "start_character": 275, "end_character": 278, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -2000000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-025481", "filing_date": 1719509337000, "quarter_ending": "20231231", "company_name": "International Land Alliance Inc.", "text": "Management\nevaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the consolidated\nfinancial statements were available to be issued and determined that substantial doubt exists about the Company\u2019s ability to continue\nas a going concern. The Company\u2019s ability to continue as a going concern is dependent on the Company\u2019s ability to generate\nrevenues from its properties, raise capital or issue debt instruments. The Company has faced significant liquidity shortages as shown\nin the accompanying consolidated financial statements. As of December 31, 2023, the Company\u2019s current liabilities exceeded its\ncurrent assets by approximately $26.9 million. The Company has recorded a net loss of $2.1 million for the year ended December 31, 2023,\nand has an accumulated deficit of approximately $27.2 million as of December 31, 2023. Net cash used in operating activities for the\nyear ended December 31, 2023, was approximately $2.2 million. These factors raise substantial doubt about the Company\u2019s ability\nto continue as a going concern.", "entities": [ { "start_character": 761, "end_character": 764, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -2100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001437749-24-014351", "filing_date": 1714665408000, "quarter_ending": "20240331", "company_name": "Investar Holding Corp", "text": "The Bank owns its corporate headquarters building, the first floor of which is occupied by multiple tenants. The Bank, as lessor, also leases a portion of one of its branch locations and a former stand-alone ATM location.\u00a0All tenant leases are operating leases. The Bank, as lessor, recognized lease income of\u00a0$0.1\u00a0million\u00a0for each of the\u00a0", "entities": [ { "start_character": 311, "end_character": 314, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001501134-23-000104", "filing_date": 1699461365000, "quarter_ending": "20230930", "company_name": "Invitae Corp", "text": "The Company has generally incurred net losses since its inception and had an accumulated deficit of $6.2 billion and $4.8 billion as of September 30, 2023 and December 31, 2022, respectively. The Company had net losses of $3.1 billion, $379.0 million and $602.2 million for the years ended December 31, 2022, 2021 and 2020, respectively. The Company used net cash in operating activities of $493.0\u00a0million, $559.8\u00a0million and $298.5\u00a0million during the years ended December 31, 2022, 2021 and 2020, respectively. The Company had net losses of $942.1 million and $301.2 million for the three months ended September 30, 2023 and 2022, respectively, and $1.3 billion and $3.0 billion for the nine months ended September 30, 2023 and 2022, respectively. Included in the Company's net loss for the three months ended September 30, 2023 are non-cash items such as $881.2 million for impairments and losses on disposals of long-lived assets, net. Included in the Company's net loss for the three months ended September 30, 2022 are non-cash items such as $55.5 million for impairments and losses on disposals of long-lived assets, net. Included in the Company\u2019s net loss for the nine months ended September 30, 2023 are non-cash items such as $1.0 billion for impairments and losses on disposals of long-lived assets, net. Included in the Company\u2019s net loss for the nine months ended September 30, 2022 are non-cash items such as a $2.3\u00a0billion loss on ", "entities": [ { "start_character": 223, "end_character": 226, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -3100000000.0 }, { "start_character": 237, "end_character": 242, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -379000000.0 }, { "start_character": 256, "end_character": 261, "label": "earnings", "start_date_for_period": "2020-01-01", "end_date_for_period": "2020-12-31", "currency_/_unit": "iso4217:USD", "value": -602200000.0 }, { "start_character": 543, "end_character": 548, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -942100000.0 }, { "start_character": 562, "end_character": 567, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -301200000.0 }, { "start_character": 651, "end_character": 654, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -1300000000.0 }, { "start_character": 668, "end_character": 671, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -3000000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001418819-24-000023", "filing_date": 1713423710000, "quarter_ending": "20240331", "company_name": "Iridium Communications Inc.", "text": "Income before income taxes and loss on equity method investments was $29.2\u00a0million for the three months ended March\u00a031, 2024, while the income tax expense was $7.9\u00a0million. The effective tax rate was 27.2% for the three months ended March\u00a031, 2024, which differed from the federal statutory rate of 21%, primarily due to the discrete tax expense associated with stock compensation and nondeductible executive compensation partially offset by the deduction for foreign derived intangible income. ", "entities": [ { "start_character": 70, "end_character": 74, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 29200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001418819-24-000023", "filing_date": 1713423710000, "quarter_ending": "20240331", "company_name": "Iridium Communications Inc.", "text": "Additionally, Aireon pays power and data services fees of approximately $23.5 million per year, in the aggregate for the delivery of air traffic surveillance data over the Iridium", "entities": [ { "start_character": 73, "end_character": 77, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 23500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001418819-24-000023", "filing_date": 1713423710000, "quarter_ending": "20240331", "company_name": "Iridium Communications Inc.", "text": "Under the agreements with Aireon, Aireon will pay the Company fees of $200.0 million to host the ADS-B receivers, of which $94.5 million had been paid as of March\u00a031, 2024. These fees are recognized over the estimated useful life of the satellites, which is expected to result in revenue of approximately $9.3 million per year, following the change in estimate of the useful lives of the satellites that occurred in the fourth quarter of 2023. The Company recognized $2.3\u00a0million and $4.0 million of hosting fee revenue under the Hosting Agreement for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 71, "end_character": 76, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000000.0 }, { "start_character": 124, "end_character": 128, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 94500000.0 }, { "start_character": 468, "end_character": 471, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2300000.0 }, { "start_character": 485, "end_character": 488, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001418819-24-000023", "filing_date": 1713423710000, "quarter_ending": "20240331", "company_name": "Iridium Communications Inc.", "text": "Income before income taxes and loss on equity method investments was $5.5\u00a0million for the three months ended March\u00a031, 2023, while the income tax benefit was $5.5\u00a0million. The effective tax rate was (99.6)%, which differed from the federal statutory rate of 21%, primarily due to the discrete tax benefit associated with stock compensation, partially offset by tax expense associated with nondeductible executive compensation.", "entities": [ { "start_character": 70, "end_character": 73, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5500000.0 }, { "start_character": 159, "end_character": 162, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000091419-24-000054", "filing_date": 1718729350000, "quarter_ending": "20240430", "company_name": "J M SMUCKER Co", "text": "The transaction was accounted for under the acquisition method of accounting, and accordingly, the results of Hostess Brands operations, including $637.3 in net sales and $73.4 in operating income, are included within the Sweet Baked Snacks segment for 2024. The operating income for the year ended April 30, 2024, includes the recognition of an unfavorable fair value purchase accounting adjustment of $8.3, attributable to the acquired inventory, and excludes special project costs recognized within the segment.", "entities": [ { "start_character": 172, "end_character": 176, "label": "ebit", "start_date_for_period": "2023-05-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 73400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001612630-24-000006", "filing_date": 1714676716000, "quarter_ending": "20240331", "company_name": "JOINT Corp", "text": "These transactions involved terms no less favorable to us than those that would have been obtained in the absence of such affiliation. Although we have no way of estimating the aggregate amount of franchise fees, royalties, advertising fund fees, IT related income and computer software fees that these franchisees will pay over the life of the franchise licenses, the franchisees affiliated with Mr. Gramm are subject to such fees under the same terms and conditions as all other franchisees. These franchisees affiliated with Mr. Gramm paid $32,864 and $27,724 in the three months ended March 31, 2024 and 2023, respectively, for such royalties and other fees.", "entities": [ { "start_character": 544, "end_character": 550, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 32864.0 }, { "start_character": 556, "end_character": 562, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 27724.0 } ] }, { "form_type": "10-K", "accession_number": "0001822993-24-000009", "filing_date": 1709137148000, "quarter_ending": "20231231", "company_name": "Jackson Financial Inc.", "text": "Intersegment eliminations in the above tables are included in the Corporate and Other segment. These include the elimination of investment income, between Retail Annuities and the Corporate and Other segments, as well as the elimination from fee income and investment income of investment fees paid by Jackson Financial and its subsidiaries to its affiliate PPM, which were $76 million, $74 million, and $69 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 375, "end_character": 377, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 76000000.0 }, { "start_character": 388, "end_character": 390, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 74000000.0 }, { "start_character": 405, "end_character": 407, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 69000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001822993-24-000009", "filing_date": 1709137148000, "quarter_ending": "20231231", "company_name": "Jackson Financial Inc.", "text": "The adoption of LDTI resulted in increases in net income attributable to Jackson Financial of $489 million and $234 million for the years ended December 31, 2022 and 2021, respectively, and also resulted in an increase in total equity of $223 million for the year ended December 31, 2022.", "entities": [ { "start_character": 95, "end_character": 98, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 489000000.0 }, { "start_character": 112, "end_character": 115, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 234000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001822993-24-000020", "filing_date": 1715185413000, "quarter_ending": "20240331", "company_name": "Jackson Financial Inc.", "text": "Intersegment eliminations in the above tables are included in the Corporate and Other segment. These include the elimination of investment income, between Retail Annuities and the Corporate and Other segments, as well as the elimination from fee income and investment income of investment fees paid by Jackson Financial and its subsidiaries to PPM, which were $19 million and $18 million for the three months ended March\u00a031, 2024 and 2023, ", "entities": [ { "start_character": 361, "end_character": 363, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -19000000.0 }, { "start_character": 377, "end_character": 379, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 18000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001620459-24-000022", "filing_date": 1709224539000, "quarter_ending": "20231231", "company_name": "James River Group Holdings, Ltd.", "text": "Other income is principally comprised of fee income earned on policies for which the Company has no exposure to underwriting risk. Fee income of $5.3 million, $3.8 million, and $4.5 million is included in other income for the years ended December\u00a031, 2023, 2022, and 2021, respectively. Fees are earned on a pro rata basis over the service period of the underlying business. Policies are accounted for on an individual basis, with no aggregation by counterparty.", "entities": [ { "start_character": 146, "end_character": 149, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5300000.0 }, { "start_character": 160, "end_character": 163, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3800000.0 }, { "start_character": 178, "end_character": 181, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 4500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001620459-24-000089", "filing_date": 1715271465000, "quarter_ending": "20240331", "company_name": "James River Group Holdings, Ltd.", "text": ") and other operating expenses of the operating segments. Gross fee income of $1.3\u00a0million and $1.1\u00a0million for the Specialty Admitted Insurance segment was included in other income and in underwriting profit (loss) for the three", "entities": [ { "start_character": 79, "end_character": 82, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 }, { "start_character": 96, "end_character": 99, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-015260", "filing_date": 1712593269000, "quarter_ending": "20231230", "company_name": "JanOne Inc.", "text": "The Company currently faces a challenging competitive environment and is focused on improving its overall profitability, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $17.1 million for the year ended December\u00a030, 2023, and net income from continuing operations of approximately $8.0 million for the fiscal year ended December\u00a031, 2022. Additionally, as of December\u00a030, 2023, the Company has total current assets of approximately $346,000 and total current liabilities of approximately $5.9 million resulting in a net negative working capital of approximately $5.2 million. Cash used in continuing operations was approximately $855,000.", "entities": [ { "start_character": 232, "end_character": 236, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": -17100000.0 }, { "start_character": 343, "end_character": 346, "label": "earnings", "start_date_for_period": "2022-01-02", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 8000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020286", "filing_date": 1714752702000, "quarter_ending": "20240330", "company_name": "JanOne Inc.", "text": "The Company currently faces a challenging competitive environment and is focused on improving its overall profitability and liquidity, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $2.1 million for the 13 weeks ended March 30, 2024. Additionally, as of March\u00a030, 2024, the Company has total current assets of approximately $1.2 million and total current liabilities of approximately $8.1 million resulting in a net negative working capital of approximately $6.9 million. Cash used in operations from continuing operations was approximately $544,000. Additionally, stockholders' equity, as of March\u00a030, 2024, is approximately $3.8 million.", "entities": [ { "start_character": 246, "end_character": 249, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -2100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-042805", "filing_date": 1715694813000, "quarter_ending": "20240331", "company_name": "Jasper Therapeutics, Inc.", "text": "The\nCompany has incurred significant losses and negative cash flows from operations since its inception. During the three months ended March\n31, 2024 and 2023, the Company incurred net losses of $13.7 million and $14.3 million, respectively. During the three months ended March\n31, 2024 and 2023, the Company had negative cash flows from operations of $15.7 million and $10.3 million, respectively. As of March\n31, 2024, the Company had an accumulated deficit of $183.3 million. The Company expects to continue to incur substantial losses, and\nits ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product\ncandidates and on the achievement of sufficient revenues to support the Company\u2019s cost structure.", "entities": [ { "start_character": 196, "end_character": 200, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -13700000.0 }, { "start_character": 214, "end_character": 218, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -14300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000096223-24-000015", "filing_date": 1712334146000, "quarter_ending": "20240229", "company_name": "Jefferies Financial Group Inc.", "text": "During the three months ended February 29, 2024, Aircadia Leasing II LLC (\u201cAircadia\u201d), a wholly owned subsidiary, purchased airplanes and simultaneously entered into a lease with the seller to lease the airplanes for a term of 42 months. The transaction was accounted for as a sale leaseback and the airplanes are recognized within Premises and equipment on our Consolidated Statements of Financial Condition at $57.7\u00a0million. During the three months ended February 29, 2024, we recognized $3.8\u00a0million of operating lease income in our Consolidated Statements of Earnings.", "entities": [ { "start_character": 491, "end_character": 494, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 3800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000096223-24-000015", "filing_date": 1712334146000, "quarter_ending": "20240229", "company_name": "Jefferies Financial Group Inc.", "text": "Represents dividends declared during the period on participating securities plus an allocation of undistributed earnings to participating securities. Net losses are not allocated to participating securities.\u00a0Participating securities represent certain preferred stock, restricted stock and RSUs for which requisite service has not yet been rendered and amounted to weighted average shares of 21.2\u00a0million for the three months ended February 29, 2024, compared with 0.7\u00a0million during the three months ended February 28, 2023.\u00a0Dividends paid on participating securities were not material during the three months ended February\u00a029, 2024 and February\u00a028, 2023.\u00a0Undistributed earnings are allocated to participating securities based upon their right to share in earnings if all earnings for the period had been distributed.", "entities": [ { "start_character": 391, "end_character": 395, "label": "eps", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "xbrli:shares", "value": 21200000.0 }, { "start_character": 464, "end_character": 467, "label": "eps", "start_date_for_period": "2022-12-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "xbrli:shares", "value": 700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-014147", "filing_date": 1711992475000, "quarter_ending": "20231231", "company_name": "Jushi Holdings Inc.", "text": "As previously reported in the 2022 consolidated financial statements, the Company incurred a loss from operations of $220,333, including non-cash asset impairment charges of $159,645, and used net cash of $21,416 for operating activities for the year ended December 31, 2022, and as of that date, the Company\u2019s current liabilities exceeded its current assets by $37,577. Since inception, management has focused on building a diverse portfolio of assets in attractive markets to vertically integrate its business. As such, the Company incurred losses as it continued to expand. Management has put in place plans to increase the profitability of the business in fiscal year 2023 and beyond. In order to achieve profitable future operations, management began to commercialize production from its recently expanded grower-processing facilities in Pennsylvania and Virginia, as well as implemented a cost savings and efficiency optimization plan which included, among others, reduction in labor and packaging costs as well as operating efficiencies at the Company\u2019s retail and grower-processing facilities. ", "entities": [ { "start_character": 118, "end_character": 125, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -220333000.0 } ] }, { "form_type": "10-K", "accession_number": "0000054381-24-000005", "filing_date": 1708619751000, "quarter_ending": "20231231", "company_name": "KAMAN Corp", "text": "All outstanding stock awards were excluded in the computation of diluted earnings per share in the year ended December\u00a031, 2022 because their effect was antidilutive due to the net loss. For the year ended December\u00a031, 2022, an additional 64,767 shares, issuable under equity awards, which would have been dilutive if exercised based on the average market price being higher than the exercise price, were excluded from the computation of diluted earnings per share as their effect was antidilutive due to the net loss.", "entities": [ { "start_character": 239, "end_character": 245, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 64767.0 } ] }, { "form_type": "10-K", "accession_number": "0000054381-24-000005", "filing_date": 1708619751000, "quarter_ending": "20231231", "company_name": "KAMAN Corp", "text": "Net sales under contracts with USG agencies (including sales to foreign governments through foreign military sales contracts with USG agencies) totaled $174.8 million, $205.0 million and $230.6 million in 2023, 2022 and 2021, respectively, and represent direct and indirect sales to the USG and related agencies.", "entities": [ { "start_character": 153, "end_character": 158, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 174800000.0 }, { "start_character": 169, "end_character": 174, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 205000000.0 }, { "start_character": 188, "end_character": 193, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 230600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001482430-24-000035", "filing_date": 1715710967000, "quarter_ending": "20240331", "company_name": "KBS Real Estate Investment Trust III, Inc.", "text": "During the three months ended March\u00a031, 2024 and 2023, the Company recognized $83,000 and $83,000 of revenue related to this lease, respectively. ", "entities": [ { "start_character": 79, "end_character": 85, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 83000.0 }, { "start_character": 91, "end_character": 97, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 83000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-005583", "filing_date": 1708446033000, "quarter_ending": "20231230", "company_name": "KELLANOVA", "text": "These suppliers' net sales, totaling $796\u00a0million and $900\u00a0million for the years ended December\u00a030, 2023 and December\u00a031, 2022, respectively, consist primarily of inventory purchases by Multipro.", "entities": [ { "start_character": 38, "end_character": 41, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 796000000.0 }, { "start_character": 55, "end_character": 58, "label": "revenues", "start_date_for_period": "2022-01-02", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 900000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000719733-24-000012", "filing_date": 1707407346000, "quarter_ending": "20231230", "company_name": "KEY TRONIC CORP", "text": "Historically, we have financed operations and met our capital expenditure requirements primarily through cash flows provided by operations and borrowings under our credit facilities. We generated operating and net income of $3.9 million and $1.1 million respectively, during the 3-month period ended December\u00a030, 2023, and have positive working capital of $193.9 million as of December\u00a030, 2023. Due to the timing between the procurement of raw materials, production cycle and payment from our customers, we have relied on borrowings on our credit facilities and cash from operations to fund operations of the Company. Based on current projections, we anticipate generating cash from operations as revenue is expected to remain flat during the third quarter of fiscal year 2024 and decreasing working capital requirements as existing backlog is manufactured and shipped.", "entities": [ { "start_character": 225, "end_character": 228, "label": "ebit", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 3900000.0 }, { "start_character": 242, "end_character": 245, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 1100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000719733-24-000023", "filing_date": 1715691577000, "quarter_ending": "20240330", "company_name": "KEY TRONIC CORP", "text": "Historically, due to the timing between the procurement of raw materials, production cycle and payment from our customers, we have financed operations and met our capital expenditure requirements primarily through cash flows provided by operations and borrowings under our credit facilities. We generated an operating loss and net loss of $(0.6)\u00a0million and $(2.2)\u00a0million, respectively, during the 3-month period ended March\u00a030, 2024, and have positive working capital of $197.5\u00a0million as of March\u00a030, 2024. Based on current projections, we anticipate generating cash from operations as revenue is expected to remain flat during the fourth quarter of fiscal year 2024 and decreasing working capital requirements as existing backlog is manufactured and shipped.", "entities": [ { "start_character": 341, "end_character": 344, "label": "ebit", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -600000.0 }, { "start_character": 360, "end_character": 363, "label": "earnings", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -2200000.0 } ] }, { "form_type": "10-K", "accession_number": "0000930420-24-000019", "filing_date": 1708704391000, "quarter_ending": "20231231", "company_name": "KFORCE INC", "text": "For the years ended December\u00a031, 2023, 2022 and 2021, there were 319\u00a0thousand, 449\u00a0thousand and 633\u00a0thousand common stock equivalents, respectively, included in the diluted WASO. For the years ended December\u00a031, 2023, 2022 and 2021, there were 157\u00a0thousand, 292\u00a0thousand and 9\u00a0thousand, respectively, of anti-dilutive common stock equivalents. ", "entities": [ { "start_character": 65, "end_character": 68, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 319000.0 }, { "start_character": 79, "end_character": 82, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 449000.0 }, { "start_character": 96, "end_character": 99, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 633000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000930420-24-000080", "filing_date": 1714579530000, "quarter_ending": "20240331", "company_name": "KFORCE INC", "text": "For the three months ended March\u00a031, 2024 and 2023, 206 thousand and 212 thousand common stock equivalents were included in the diluted WASO, respectively. For the three months ended\u00a0March\u00a031, 2024 and 2023, there were 1 thousand and 264 thousand anti-dilutive common stock equivalents, respectively.", "entities": [ { "start_character": 52, "end_character": 55, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 206000.0 }, { "start_character": 69, "end_character": 72, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 212000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001372514-24-000053", "filing_date": 1715324435000, "quarter_ending": "20240331", "company_name": "KIORA PHARMACEUTICALS INC", "text": "In April 2024, the Company received grant funding of $20,000 from the Choroideremia Research Foundation (\"CRF\") in support of validating functional vision assessments for patients with profound blindness. This grant ", "entities": [ { "start_character": 54, "end_character": 60, "label": "revenues", "start_date_for_period": "2024-04-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 20000.0 } ] }, { "form_type": "10-K", "accession_number": "0001404912-24-000005", "filing_date": 1709223706000, "quarter_ending": "20231231", "company_name": "KKR & Co. Inc.", "text": "The cumulative impact of the retrospective application of the LDTI adoption increased net income attributable to shareholders by $319.5\u00a0million and $65.9\u00a0million for each of the periods ended December 31, 2022 and 2021, respectively ($385.4\u00a0million cumulatively), and increased other comprehensive income by $589.6\u00a0million and $10.3\u00a0million for each of the periods ended December 31, 2022 and 2021, respectively ($599.9\u00a0million cumulatively). These increases were primarily as a result of an increase in discount rates and Global Atlantic\u2019s instrument-specific credit risk during each of the respective periods.", "entities": [ { "start_character": 130, "end_character": 135, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 319500000.0 }, { "start_character": 149, "end_character": 153, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 65900000.00000001 }, { "start_character": 235, "end_character": 240, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 385400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-009985", "filing_date": 1710436718000, "quarter_ending": "20231230", "company_name": "KOPIN CORP", "text": "The\nCompany has incurred net losses of $19.7 million and $19.3 million for the year ended December 30, 2023, and for the fiscal year ended\nDecember 31, 2022, respectively, and net cash outflows from operations of $15.3 million and $17.7 million for the year ended December\n30, 2023, and for the fiscal year ended December 31, 2022, respectively. The Company\u2019s net cash outflows from operations were partially\na result of funding its ongoing investments in research and development, which management believes will continue, production inefficiencies\nresulting from intermittent supply chain disruptions and litigation costs. Management has implemented certain plans to reduce cash outflows\nincluding operational improvements and the curtailment of certain development programs, both of which are expected to preserve cash.\nThe litigation is discussed in Note 12. In addition, in the first quarter of 2024, the Company sold 3.1 million shares of\ncommon stock for net proceeds of $7.3 million. The Company believes that its existing cash, cash equivalents, along with the net proceeds\nreceived in the first quarter of 2024 will be adequate to satisfy its current operating plans for at least the next twelve months from\nthe issuance of these financial statements. The Company has in the past sold equity securities through at-the-market equity offerings\nand in the traditional fashion of significant equity offerings. Nonetheless, management monitors the capital markets on an ongoing basis\nand may consider raising capital if favorable market conditions develop. If the Company\u2019s actual results are less than projected\nor the Company needs to raise capital for additional liquidity, the Company may be required to do additional equity financings, reduce\nexpenses, or enter into a strategic transaction. However, management can make no assurance that the Company will be able to raise additional\ncapital, reduce expenses sufficiently, or enter into a strategic transaction on terms acceptable to the Company, or at all.", "entities": [ { "start_character": 40, "end_character": 44, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": -19700000.0 }, { "start_character": 58, "end_character": 62, "label": "earnings", "start_date_for_period": "2021-12-26", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -19300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019194", "filing_date": 1715698933000, "quarter_ending": "20240330", "company_name": "KOPIN CORP", "text": "The\naccompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of\nassets and the satisfaction of liabilities in the normal course of business. The Company incurred a net loss of $19.6\nmillion and net cash outflows from operations of $15.3\nmillion for the fiscal year ended 2023. The Company incurred a net loss of $32.5\nmillion for the three months ended March 30, 2024 and net cash outflows from operations of $3.1\nmillion. This net loss of $32.5 million includes an estimated $24.8 million of possible damages related to a jury verdict which is\nexplained below. In addition, the Company has experienced a significant decline in its cash and cash equivalents and marketable debt\nsecurities over the last several years, which was primarily a result of funding operating losses. As described in Note 14\nLitigation, on April 22, 2024, a jury verdict was entered against the Company awarding approximately $5.1\nmillion in damages as well as recommending $19.7\nmillion in disgorgement and exemplary damages. While no final judgment has been issued by the Court, the Court will take that\nrecommendation under advisement and will rule in its final judgment on the final amount after briefing on the issues. The Company\nplans to argue that the damages, disgorgement and exemplary damages should be reduced or eliminated. The Company is also considering\nthe appeal of any award in a final judgment. The Company had $21.8\nmillion of cash and cash equivalents, restricted cash, and marketable debt securities at March 30, 2024.", "entities": [ { "start_character": 247, "end_character": 251, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": -19600000.0 }, { "start_character": 383, "end_character": 387, "label": "earnings", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -32500000.0 }, { "start_character": 511, "end_character": 515, "label": "earnings", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -32500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001069258-24-000036", "filing_date": 1715098610000, "quarter_ending": "20240331", "company_name": "KRATOS DEFENSE & SECURITY SOLUTIONS, INC.", "text": "Revenue from the U.S. Government, which includes foreign military sales contracted through the U.S. Government, includes revenue from contracts for which the Company is the prime contractor as well as those for which the Company is a subcontractor and the ultimate customer is the U.S. Government. The KGS and US segments have substantial revenue from the U.S. Government. Sales to the U.S. Government amounted to approximately $190.9 million and $160.3 million, or 69% and 69% of total Kratos revenue, for the three months ended March\u00a031, 2024 and March\u00a026, 2023, respectively.", "entities": [ { "start_character": 429, "end_character": 434, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 190900000.0 }, { "start_character": 448, "end_character": 453, "label": "revenues", "start_date_for_period": "2022-12-26", "end_date_for_period": "2023-03-26", "currency_/_unit": "iso4217:USD", "value": 160300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001007587-24-000003", "filing_date": 1710517754000, "quarter_ending": "20231231", "company_name": "KVH INDUSTRIES INC \\DE\\", "text": "Lease revenue recognized was $553 and $537 for the year ended December 31, 2023 and 2022, respectively, in service sales in the statements of operations.", "entities": [ { "start_character": 30, "end_character": 33, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 553000.0 }, { "start_character": 39, "end_character": 42, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 537000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001007587-24-000005", "filing_date": 1715015739000, "quarter_ending": "20240331", "company_name": "KVH INDUSTRIES INC \\DE\\", "text": "Lease revenue recognized was $125 for the three months ended March 31, 2024, respectively, in service sales in the consolidated statements of operations.", "entities": [ { "start_character": 30, "end_character": 33, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 125000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-017691", "filing_date": 1713977551000, "quarter_ending": "20231231", "company_name": "Katapult Holdings, Inc.", "text": "Consolidated statement of operations and comprehensive loss for the year ended December 31, 2022 is a decrease to rental revenue of $2,492", "entities": [ { "start_character": 133, "end_character": 138, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -2492000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-017691", "filing_date": 1713977551000, "quarter_ending": "20231231", "company_name": "Katapult Holdings, Inc.", "text": "Correction to increase deferred revenue by $2,631 on our consolidated balance sheet and decrease rental revenue by $116 related to recognition of deferred revenue. The impact to the beginning balance of accumulated deficit in our consolidated statement of stockholders' (deficit) equity for the deferred revenue impact as of December 31, 2021 is an increase of accumulated deficit as of December 31, 2021 of $2,515.", "entities": [ { "start_character": 116, "end_character": 119, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -116000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023376", "filing_date": 1715756800000, "quarter_ending": "20240331", "company_name": "Katapult Holdings, Inc.", "text": "Condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2023 is a decrease to rental revenue of $593", "entities": [ { "start_character": 148, "end_character": 151, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -593000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-043598", "filing_date": 1715789179000, "quarter_ending": "20240331", "company_name": "Keen Vision Acquisition Corp.", "text": "At\nMarch 31, 2024, the Company had working capital surplus of $585,190\u00a0and net income of $3,266,193 for the three months ended March\n31, 2024. The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans.\nThe Company initially had nine months from the consummation of the Initial Public Offering to consummate the initial Business Combination.\nIf the Company does not complete a Business Combination within nine months from the consummation of the Initial Public Offering, the\nCompany will trigger an automatic winding up, dissolution and liquidation pursuant to the terms of the Amended and Restated Memorandum\nand Articles of Association. As a result, this has the same effect as if the Company had formally gone through a voluntary liquidation\nprocedure under the Companies Act (As Revised) of the British Virgin Islands. Accordingly, no vote would be required from our shareholders\nto commence such a voluntary winding up, dissolution and liquidation. However, the Company may extend the period of time to consummate\na Business Combination two times (for a total of up to 21 months from the consummation of the Initial Public Offering to complete a Business\nCombination, including Automatic Extension Period). If the Company is unable to consummate the Company\u2019s Initial Business Combination\nby October 27, 2024 (unless further extended), the Company will, as promptly as possible but not more than ten business days thereafter,\nredeem\u00a0100% of the Company\u2019s outstanding public shares for a pro rata portion of the funds held in the Trust Account, including\na pro rata portion of any interest earned on the funds held in the Trust Account and not necessary to pay taxes, and then seek to liquidate\nand dissolve. However, the Company may not be able to distribute such amounts as a result of claims of creditors which may take priority\nover the claims of the Company\u2019s public shareholders. In the event of dissolution and liquidation, the Company\u2019s warrants\nwill expire and will be worthless.", "entities": [ { "start_character": 90, "end_character": 99, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3266193.0 } ] }, { "form_type": "10-Q", "accession_number": "0001408100-24-000091", "filing_date": 1715272224000, "quarter_ending": "20240331", "company_name": "Kennedy-Wilson Holdings, Inc.", "text": "During the three months ended March\u00a031, 2024, the Company generated pre-tax book income of $64.4\u00a0million related to its global operations and recorded a tax provision of $26.7 million. The tax expense for the period is above the U.S. statutory tax rate. Significant items impacting the quarterly tax provision include: increase in valuation allowance against the Company\u2019s deferred tax asset on the outside basis difference of its investment in KWE and tax charges associated with non-deductible executive compensation under IRC Section 162(m). During the period, the Company's net deferred tax asset (and associated valuation allowance) related to its excess tax basis in legacy European real estate assets increased as a result of KWE realizing higher taxable income than book income on the disposition of real estate and impairment losses not recognized for tax.", "entities": [ { "start_character": 92, "end_character": 96, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 64400000.00000001 } ] }, { "form_type": "10-K", "accession_number": "0001944048-24-000057", "filing_date": 1709308999000, "quarter_ending": "20231231", "company_name": "Kenvue Inc.", "text": "Diluted net income per share is computed by giving effect to all potentially dilutive equity instruments or equity awards that are outstanding during the period. There were no equity awards of the Company outstanding prior to the Kenvue IPO and no dilutive equity instruments of the Company outstanding prior to the Exchange Offer. During the fiscal twelve months ended December 31, 2023, 44,745,842 shares were determined to be anti-dilutive under the treasury stock method and therefore were excluded from the diluted net income per share calculation.", "entities": [ { "start_character": 173, "end_character": 175, "label": "eps", "start_date_for_period": "2023-05-08", "end_date_for_period": "2023-05-08", "currency_/_unit": "xbrli:shares", "value": 0 }, { "start_character": 245, "end_character": 247, "label": "eps", "start_date_for_period": "2023-05-08", "end_date_for_period": "2023-05-08", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001944048-24-000057", "filing_date": 1709308999000, "quarter_ending": "20231231", "company_name": "Kenvue Inc.", "text": "In relations to the net economic benefit arrangements, the Company recognized a receivable of $10\u00a0million and a payable of $49\u00a0million to J&J as of December 31, 2023 on the Company\u2019s Consolidated Balance Sheets and $36\u00a0million of net income for the fiscal twelve months ended December 31, 2023 in the Company\u2019s Consolidated Statements of Operations.", "entities": [ { "start_character": 216, "end_character": 218, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 36000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001944048-24-000057", "filing_date": 1709308999000, "quarter_ending": "20231231", "company_name": "Kenvue Inc.", "text": "The Company recognized net income of $85\u00a0million related to the Deferred Legal Entities for the fiscal twelve months ended December 31, 2023 in the Company\u2019s Consolidated Statements of Operations.", "entities": [ { "start_character": 38, "end_character": 40, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 85000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001944048-24-000100", "filing_date": 1715270570000, "quarter_ending": "20240331", "company_name": "Kenvue Inc.", "text": "Diluted net income per share is computed by giving effect to all potentially dilutive equity instruments or equity awards that are outstanding during the period. During the fiscal three months ended March 31, 2024, 57,601,000 shares were determined to be anti-dilutive under the treasury stock method and therefore were excluded from the diluted net income per share calculation. There were no equity awards of the Company outstanding prior to the Kenvue IPO and no dilutive equity instruments of the Company outstanding prior to the Exchange Offer.", "entities": [ { "start_character": 391, "end_character": 393, "label": "eps", "start_date_for_period": "2023-05-08", "end_date_for_period": "2023-05-08", "currency_/_unit": "xbrli:shares", "value": 0 }, { "start_character": 463, "end_character": 465, "label": "eps", "start_date_for_period": "2023-05-08", "end_date_for_period": "2023-05-08", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001944048-24-000100", "filing_date": 1715270570000, "quarter_ending": "20240331", "company_name": "Kenvue Inc.", "text": "The Company recognized Net income of $2\u00a0million and $0\u00a0million related to the Deferred Legal Entities for the fiscal three months ended March 31, 2024 and April 2, 2023, respectively, in the Condensed Consolidated Statements of Operations.", "entities": [ { "start_character": 38, "end_character": 39, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001944048-24-000100", "filing_date": 1715270570000, "quarter_ending": "20240331", "company_name": "Kenvue Inc.", "text": "The Company recognized a net payable to J&J of $32\u00a0million in relation to the net economic benefit arrangements as of March 31, 2024 on the Condensed Consolidated Balance Sheet. The Company recognized $14\u00a0million and $0\u00a0million of Net income in relation to the net economic benefit arrangements for the fiscal three months ended March 31, 2024 and April 2, 2023, respectively, in the Condensed Consolidated Statements of Operations.", "entities": [ { "start_character": 202, "end_character": 204, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001669162-24-000020", "filing_date": 1714061564000, "quarter_ending": "20240331", "company_name": "Kinsale Capital Group, Inc.", "text": "The Company presented $8.1\u00a0million as fee income for the three months ended March 31, 2024, in the consolidated statements of income and comprehensive income. The Company reclassified $6.2\u00a0million to fee income from underwriting, acquisition and insurance expenses in the previously issued financial statements on Form 10-Q for the three months ended March 31, 2023, to correct prior periods\u2019 presentation. The Company considered the qualitative and quantitative impacts and determined that the correction was not material to the Company's previously issued consolidated financial statements.", "entities": [ { "start_character": 23, "end_character": 26, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 8100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001955520-24-000007", "filing_date": 1709052674000, "quarter_ending": "20231231", "company_name": "Knife River Corp", "text": "For those joint ventures accounted for using proportionate consolidation, the Company recorded in its Consolidated Statements of Operations $4.9\u00a0million, $9.1\u00a0million, and $10.1\u00a0million of revenue for the years ended December\u00a031, 2023, 2022 and 2021, respectively. The Company also reported an operating loss of $1.9\u00a0million for the year ended December\u00a031, 2023, and operating income of $823,000 and $1.3\u00a0million for the years ended December 31, 2022 and 2021, respectively. As of December\u00a031, 2023, 2022 and 2021, the Company had interest in assets from these joint ventures of $45,000, $912,000 and $643,000, respectively.", "entities": [ { "start_character": 141, "end_character": 144, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4900000.0 }, { "start_character": 155, "end_character": 158, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9100000.0 }, { "start_character": 173, "end_character": 177, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 10100000.0 }, { "start_character": 313, "end_character": 316, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1900000.0 }, { "start_character": 388, "end_character": 395, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 823000.0 }, { "start_character": 401, "end_character": 404, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001492691-24-000015", "filing_date": 1708604982000, "quarter_ending": "20231231", "company_name": "Knight-Swift Transportation Holdings Inc.", "text": "During 2023, the Company's consolidated operating results included U.S. Xpress' total revenue of $916.2\u00a0million and a net loss of $11.7\u00a0million. U.S. Xpress' net loss during 2023 included $4.6\u00a0million related to the amortization of intangible assets acquired in the U.S. Xpress Acquisition. ", "entities": [ { "start_character": 98, "end_character": 103, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 916200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001492691-24-000064", "filing_date": 1714568548000, "quarter_ending": "20240331", "company_name": "Knight-Swift Transportation Holdings Inc.", "text": "The $20.4 million operating loss within our All Other Segments is primarily driven by the $19.5\u00a0million operating loss in the third-party insurance business.", "entities": [ { "start_character": 5, "end_character": 9, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -20400000.0 }, { "start_character": 91, "end_character": 95, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -19500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001767042-24-000011", "filing_date": 1709829173000, "quarter_ending": "20231231", "company_name": "Kodiak Gas Services, Inc.", "text": "Basic earnings per share is computed by dividing net income attributable to common shareholders by the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the Basic Weighted Average Shares Outstanding plus all potential dilutive common shares outstanding during the period. For the year ended December 31, 2023, the Company had 268,388 dilutive common shares outstanding. The Company did not have any dilutive common shares outstanding during the years ended December 31, 2022 and 2021, respectively.", "entities": [ { "start_character": 440, "end_character": 447, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 268388.0 } ] }, { "form_type": "10-Q", "accession_number": "0000202058-24-000103", "filing_date": 1714133790000, "quarter_ending": "20240329", "company_name": "L3HARRIS TECHNOLOGIES, INC. /DE/", "text": "Revenue and income before income taxes of AR included in our Condensed Consolidated Statement of Operations for the quarter ended March\u00a029, 2024 were $542 million and $72 million, respectively. Unaudited pro forma financial results of the operations acquired with AJRD for the quarter ended March\u00a031, 2023 were $566 million of revenue and $60 million of income before income taxes, which were prepared as if the acquisition was completed on the first day of our fiscal 2023, December 31, 2022. The proforma results include adjustments to remove costs directly attributable to the acquisition, such as transaction-related costs and the impact of purchase price adjustments, and certain corporate expenses such as pension, interest, and amortization. The pro forma results do not include any integration synergies and are not necessarily indicative of our results of operations that actually would have been obtained had the acquisition of AJRD been completed for the period presented, or which may be realized in the future. ", "entities": [ { "start_character": 168, "end_character": 170, "label": "earnings", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 72000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000202058-24-000103", "filing_date": 1714133790000, "quarter_ending": "20240329", "company_name": "L3HARRIS TECHNOLOGIES, INC. /DE/", "text": "During the quarter ended December\u00a029, 2023, we entered into a definitive agreement to sell our CAS Disposal Group for a cash purchase price of $700 million, with additional contingent consideration of up to $100\u00a0million, subject to customary purchase price adjustments and closing conditions as set forth in the agreement. As of March\u00a029, 2024, the fair value less costs to sell of the CAS Disposal Group was $891\u00a0million, inclusive of consideration related to noncontrolling interest and accumulated other comprehensive income. Income before income taxes for the quarters ended March\u00a031, 2023 and March\u00a029, 2024 were $17\u00a0million and $21\u00a0million, respectively. The CAS Disposal Group, which is part of our IMS segment, provides integrated aircraft avionics, pilot training and data analytics services for the commercial aviation industry. The transaction is expected to close in fiscal 2024. ", "entities": [ { "start_character": 619, "end_character": 621, "label": "earnings", "start_date_for_period": "2022-12-31", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 17000000.0 }, { "start_character": 635, "end_character": 637, "label": "earnings", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 21000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000920148-24-000014", "filing_date": 1708961703000, "quarter_ending": "20231231", "company_name": "LABORATORY CORP OF AMERICA HOLDINGS", "text": "During 2023, the BLS segment generated $2,774.2 million in total revenue and $396.3 million in segment operating income, resulting in an operating margin of 14.3%.", "entities": [ { "start_character": 40, "end_character": 47, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2774200000.0 }, { "start_character": 78, "end_character": 83, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 396300000.0 } ] }, { "form_type": "10-K", "accession_number": "0000920148-24-000014", "filing_date": 1708961703000, "quarter_ending": "20231231", "company_name": "LABORATORY CORP OF AMERICA HOLDINGS", "text": "During 2023, the Dx segment generated $9,415.1 million in total revenues and $1,591.3 million in segment operating income, resulting in an operating margin of 16.9%. ", "entities": [ { "start_character": 39, "end_character": 46, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 9415100000.0 }, { "start_character": 78, "end_character": 85, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1591300000.0 } ] }, { "form_type": "10-K", "accession_number": "0000920148-24-000014", "filing_date": 1708961703000, "quarter_ending": "20231231", "company_name": "LABORATORY CORP OF AMERICA HOLDINGS", "text": "Revenues in the U.S. were $10,177.7 (83.7%), $9,930.3 (83.7%) and $10,981.2 (83.6%) for the years ended December\u00a031, 2023, 2022, and 2021.", "entities": [ { "start_character": 27, "end_character": 35, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 10177700000.0 }, { "start_character": 46, "end_character": 53, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9930300000.0 }, { "start_character": 67, "end_character": 75, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 10981200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000920148-24-000032", "filing_date": 1714479501000, "quarter_ending": "20240331", "company_name": "LABORATORY CORP OF AMERICA HOLDINGS", "text": "Revenues in the U.S. were $2,654.6 (83.6%) and $2,557.4 (84.2%) for the three months ended March 31, 2024, and 2023, respectively.", "entities": [ { "start_character": 27, "end_character": 34, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2654600000.0 }, { "start_character": 48, "end_character": 55, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2557400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-019876", "filing_date": 1714652406000, "quarter_ending": "20240331", "company_name": "LAMAR ADVERTISING CO/NEW", "text": "Revenues from external customers attributable to foreign countries totaled $7,704 and $6,076 for the three months ended March\u00a031, 2024 and 2023, respectively. Net carrying value of long-lived assets located in foreign countries totaled $13,065 and $13,930 as of March\u00a031, 2024 and December\u00a031, 2023, respectively. All other revenues from external customers and long-lived assets relate to domestic operations.", "entities": [ { "start_character": 76, "end_character": 81, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7704000.0 }, { "start_character": 87, "end_character": 92, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 6076000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-003010", "filing_date": 1706878396000, "quarter_ending": "20231224", "company_name": "LEE ENTERPRISES, Inc", "text": "We recorded an income tax expense of $0.2 million related to income before taxes of $1.5 million for the three months ended December\u00a024, 2023. We recorded an income tax expense of $0.4 million related to income before taxes of $2.3 million for the three months ended December\u00a025, 2022. The effective income tax rate for the three months ended December\u00a024, 2023, was 16.7%. The effective income tax rate for the three months ended December\u00a025, 2022, was 19.4%.", "entities": [ { "start_character": 85, "end_character": 88, "label": "earnings", "start_date_for_period": "2023-09-25", "end_date_for_period": "2023-12-24", "currency_/_unit": "iso4217:USD", "value": 1500000.0 }, { "start_character": 228, "end_character": 231, "label": "earnings", "start_date_for_period": "2022-09-26", "end_date_for_period": "2022-12-25", "currency_/_unit": "iso4217:USD", "value": 2300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020172", "filing_date": 1714731151000, "quarter_ending": "20240324", "company_name": "LEE ENTERPRISES, Inc", "text": "We recorded an income tax benefit of $2.8 million related to loss before taxes of $14.5 million for the three months ended March\u00a024, 2024, and an income tax benefit of $2.6 million related to loss before income taxes of $13.0 million for the six months ended March\u00a024, 2024. We recorded an income tax benefit of $2.1 million related to loss before taxes of $7.4 million for the three months ended March\u00a026, 2023, and an income tax benefit of $1.6 million related to a loss before income taxes of $5.2 million for the six months ended March 26, 2023. The effective income tax rate for the three and six months ended March\u00a024, 2024, was 19.6% and 19.9%, respectively. The effective income tax rate for the three and six months ended March\u00a026, 2023, were 27.8% and 31.5%, respectively.", "entities": [ { "start_character": 83, "end_character": 87, "label": "earnings", "start_date_for_period": "2023-12-25", "end_date_for_period": "2024-03-24", "currency_/_unit": "iso4217:USD", "value": -14500000.0 }, { "start_character": 221, "end_character": 225, "label": "earnings", "start_date_for_period": "2023-09-25", "end_date_for_period": "2024-03-24", "currency_/_unit": "iso4217:USD", "value": -13000000.0 }, { "start_character": 358, "end_character": 361, "label": "earnings", "start_date_for_period": "2022-12-26", "end_date_for_period": "2023-03-26", "currency_/_unit": "iso4217:USD", "value": -7400000.0 }, { "start_character": 497, "end_character": 500, "label": "earnings", "start_date_for_period": "2022-09-26", "end_date_for_period": "2023-03-26", "currency_/_unit": "iso4217:USD", "value": -5200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000094845-24-000045", "filing_date": 1719418125000, "quarter_ending": "20240526", "company_name": "LEVI STRAUSS & CO", "text": "The Company\u2019s effective income tax rate was (49.4)% for the three months ended May\u00a026, 2024, compared to 78.4% for the same prior-year period. The decrease in the effective tax rate in the current quarter is primarily driven by a tax benefit of $7.5\u00a0million related to a favorable resolution of a state audit in the current year and the inclusion of discrete tax benefits recognized on $7.2\u00a0million of loss before income tax in the prior year.", "entities": [ { "start_character": 387, "end_character": 390, "label": "earnings", "start_date_for_period": "2023-02-27", "end_date_for_period": "2023-05-28", "currency_/_unit": "iso4217:USD", "value": -7200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001580670-24-000029", "filing_date": 1714495105000, "quarter_ending": "20240331", "company_name": "LGI Homes, Inc.", "text": "In determining the most appropriate reportable segments, we consider operating segments\u2019 economic and other characteristics, including home floor plans, average selling prices, gross margin percentage, geographical proximity, production construction processes, suppliers, subcontractors, regulatory environments, customer type and underlying demand and supply. Each operating segment follows the same accounting policies and is managed by our management team. We have no inter-segment sales, as all sales are to external customers. Operating results for each segment may not be indicative of the results for such segment had it been an independent, stand-alone entity for the periods presented.", "entities": [ { "start_character": 92, "end_character": 94, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001065696-24-000009", "filing_date": 1708609966000, "quarter_ending": "20231231", "company_name": "LKQ CORP", "text": "$546\u00a0million and an operating loss of $17\u00a0million, including $25\u00a0million of restructuring and transaction related expenses and", "entities": [ { "start_character": 39, "end_character": 41, "label": "ebit", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -17000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001065696-24-000009", "filing_date": 1708609966000, "quarter_ending": "20231231", "company_name": "LKQ CORP", "text": "In the period between the acquisition dates and December\u00a031, 2023, these acquisitions generated revenue of $156\u00a0million, including $69\u00a0million within our Specialty segment, $67\u00a0million within our Europe segment, and the remaining amount within our Wholesale - North America segment, and operating income of $11\u00a0million, primarily within our Europe segment.", "entities": [ { "start_character": 308, "end_character": 310, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 11000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001397911-24-000011", "filing_date": 1708531848000, "quarter_ending": "20231231", "company_name": "LPL Financial Holdings Inc.", "text": "The Company recognized revenue for services provided to these related parties of $19.7 million, $5.7 million and $6.1 million during the years ended December\u00a031, 2023, 2022 and 2021, respectively. The Company incurred expense for services provided by these related parties of $3.6 million, $3.4 million and $2.2 million during the years ended December\u00a031, 2023, 2022 and 2021, respectively. As of December\u00a031, 2023, receivables from and payables to related parties were $5.0\u00a0million and $0.4\u00a0million, respectively. As of December 31, 2022, receivables from and payables to related parties were not material.", "entities": [ { "start_character": 82, "end_character": 86, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 19700000.0 }, { "start_character": 97, "end_character": 100, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 5700000.0 }, { "start_character": 114, "end_character": 117, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 6100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-028934", "filing_date": 1711992464000, "quarter_ending": "20231231", "company_name": "LQR House Inc.", "text": "The\naccompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets\nand the satisfaction of liabilities in the normal course of business. The Company sustained net losses of $15,747,724 and $1,842,175\nduring the years ended December 31, 2023 and 2022, respectively, and had cash used in operations of $9,113,855\u00a0during the year ended\nDecember 31, 2023. The Company requires additional capital to operate and expects losses to continue for the foreseeable future. These\nfactors raise substantial doubts about the Company\u2019s ability to continue as a going concern.", "entities": [ { "start_character": 248, "end_character": 258, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -15747724.0 }, { "start_character": 264, "end_character": 273, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1842175.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-028934", "filing_date": 1711992464000, "quarter_ending": "20231231", "company_name": "LQR House Inc.", "text": "Vault\nis the exclusive membership program for CWS Platform customers. Through the CWS Platform, users can sign up for membership where they\nwill have access to all products available through CWS combined with special membership benefits including discounted products, free\nshipping and promotional offers.\u00a0Prior to the acquisition of the CWS Platform, the Company marketed this membership program on the\nCWS Platform and was entitled to 50% of the revenue from the subscriptions as the agent of the transaction. Upon the acquisition of the\nCWS Platform, the Company records gross revenue as it is the principal in the transaction. The Company records a reserve for chargebacks\nand cancellations at the time of the transaction based on historical experience.\u00a0During the years ended December 31, 2023 and 2022,\nrevenue from Vault memberships totaled $31,386 and $20,524, respectively.", "entities": [ { "start_character": 849, "end_character": 855, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 31386.0 }, { "start_character": 861, "end_character": 867, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 20524.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011377", "filing_date": 1711519422000, "quarter_ending": "20231231", "company_name": "LadRx Corp", "text": "The\nCompany\u2019s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates\nthe realization of assets and satisfaction of liabilities in the normal course of business. During the year ended December 31, 2023,\nalthough we realized a net income of $0.4 million, we had a loss from operations of $3.8 million, and incurred a net loss of $4.2 million\nfor the year ended December 31, 2022, and had total stockholders\u2019 equity as of December 31, 2023 of $0.1 million. The Company has\nno recurring revenue, and we are likely to continue to incur losses unless and until we conclude a successful strategic partnership or\nfinancing for our LADR\u2122 technology. As a result, management has concluded that there is substantial doubt about the Company\u2019s\nability to continue as a going concern. The Company\u2019s consolidated financial statements do not include any adjustments that might\nresult from the outcome of this uncertainty.", "entities": [ { "start_character": 313, "end_character": 316, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 360, "end_character": 363, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -3800000.0 }, { "start_character": 401, "end_character": 404, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -4200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019407", "filing_date": 1715754128000, "quarter_ending": "20240331", "company_name": "LadRx Corp", "text": "The\nCompany\u2019s condensed financial statements have been presented on the basis that it will continue as a going concern, which contemplates\nthe realization of assets and satisfaction of liabilities in the normal course of business. During the three-month period ended March\n31, 2024, although we realized a net income of $0.2 million, we had a loss from operations of $0.8 million, and incurred a net loss from\noperations of $3.8 million for the year ended December 31, 2023, and had total stockholders\u2019 equity as of March 31, 2024 of $0.3\nmillion. The Company has no recurring revenue, and we are likely to continue to incur losses unless and until we conclude a successful\nstrategic partnership or financing for our LADR\u2122 technology. As a result, management has concluded that there is substantial doubt\nabout the Company\u2019s ability to continue as a going concern. The Company\u2019s financial statements do not include any adjustments\nthat might result from the outcome of this uncertainty. The Company\u2019s independent registered public accounting firm, in its report\non the Company\u2019s consolidated financial statements for the year ended December 31, 2023, has also expressed doubt about the Company\u2019s\nability to continue as a going concern.", "entities": [ { "start_character": 321, "end_character": 324, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 368, "end_character": 371, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -800000.0 }, { "start_character": 425, "end_character": 428, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -3800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001721386-24-000012", "filing_date": 1714600283000, "quarter_ending": "20240331", "company_name": "Landsea Homes Corp", "text": "In December 2021, the Company sold model homes to a related party for total consideration of $15.2 million. As part of this transaction, the Company leased back these models. The total amount of rent payments made during the three months ended March 31, 2024, and 2023, were $0.2 million and $0.2 million, respectively. The right-of-use asset and lease liability balances associated with these leases is $0.4 million and $0.4 million, respectively, as of March\u00a031, 2024 and $0.5 million and $0.5 million, respectively, as of December\u00a031, 2023. ", "entities": [ { "start_character": 94, "end_character": 98, "label": "revenues", "start_date_for_period": "2021-12-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 15200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-008069", "filing_date": 1709227350000, "quarter_ending": "20231231", "company_name": "LanzaTech Global, Inc.", "text": "The accompanying consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash and cash equivalents of $75,585, short and long-term held-to-maturity debt investments of $45,159 and an accumulated deficit of $(831,872) as of December\u00a031, 2023 and cash outflows from operations of $(97,296) and a net loss of $(134,098) for the twelve months ended December\u00a031, 2023. As a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,285, which represents the proceeds from the Business Combination received net of (1) transaction expenses, (2) the PIPE investment and (3) the amount paid to ACM ARRT H LLC (\u201cACM\u201d) and Vellar Opportunity Fund SPV LLC - Series 10 (\u201cVellar\u201d) in relation to the Forward Purchase Agreement (see below).", "entities": [ { "start_character": 695, "end_character": 702, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -134098000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-008069", "filing_date": 1709227350000, "quarter_ending": "20231231", "company_name": "LanzaTech Global, Inc.", "text": "On May 13, 2020, the Company contributed $15,000 in intellectual property in exchange for a 37.5% interest (\u201cOriginal Interest\u201d) of LanzaJet, Inc. (\u201cLanzaJet\u201d) in connection with an investment agreement (\u201cInvestment Agreement\u201d). The Company accounts for the transaction as a revenue transaction with a customer under ASC 606. The licensing and technical support services provided are recognized as a single combined performance obligation satisfied over the expected period of those services, beginning May 2020 through December 2025. During the years ended December\u00a031, 2023 and December\u00a031, 2022, the Company recognized revenue from this arrangement of $2,249 and $2,160 respectively, net of intra-entity profit elimination and has associated deferred revenue of $5,375 and $8,062, as of December\u00a031, 2023 and December\u00a031, 2022, respectively. Intra-entity profits related to this arrangement are $437 and $527 for the years ended December\u00a031, 2023 and 2022, respectively. Intra-entity profits are amortized over a 15-year period through 2034.", "entities": [ { "start_character": 667, "end_character": 672, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2160000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021946", "filing_date": 1715238323000, "quarter_ending": "20240331", "company_name": "LanzaTech Global, Inc.", "text": ", for more information. The transition services agreement generally sets out the respective rights, responsibilities and obligations of the Company and LanzaJet with respect to R&D services, access to office and laboratory space, business development and other administrative support services. The transition services agreement may be terminated by mutual consent of the Company and LanzaJet, by LanzaJet at any time, and by the Company upon breach or non-payment by LanzaJet. There are no substantive termination penalties in the event the Company terminates. For the three months ended March\u00a031, 2024 and 2023, the Company recognized revenue from related parties of approximately $31 and $45, respectively, under the transition services agreement. ", "entities": [ { "start_character": 594, "end_character": 596, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 31000.0 }, { "start_character": 691, "end_character": 693, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 45000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021946", "filing_date": 1715238323000, "quarter_ending": "20240331", "company_name": "LanzaTech Global, Inc.", "text": "The Company supplies SGLT with certain water-soluble organic compounds required in the Company's proprietary gas fermentation process, small-size equipment and consulting services. For the three months ended March\u00a031, 2024 and 2023, the Company recognized revenue of approximately $51 and $0, respectively. The Company also provided engineering services and incurred costs of $185 and $249 for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 282, "end_character": 284, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 51000.0 }, { "start_character": 290, "end_character": 291, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021946", "filing_date": 1715238323000, "quarter_ending": "20240331", "company_name": "LanzaTech Global, Inc.", "text": "The accompanying consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash and cash equivalents of $56,747, short-term held-to-maturity debt investments of $34,819 and an accumulated deficit of $(857,380) as of March\u00a031, 2024 and cash outflows from operations of $(28,289) and a net loss of $(25,508) for the three months ended March\u00a031, 2024. As a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,285, which represents the proceeds from the Business Combination received net of (1) transaction expenses, (2) the PIPE investment and (3) the amount paid to ACM ARRT H LLC (\u201cACM\u201d) and Vellar Opportunity Fund SPV LLC - Series 10 (\u201cVellar\u201d) in relation to the Forward Purchase Agreement (see below).", "entities": [ { "start_character": 683, "end_character": 689, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -25508000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-006304", "filing_date": 1710317919000, "quarter_ending": "20231231", "company_name": "Leatt Corp", "text": "Concentration of Credit Risk (continued) - 31, 2023 and 2022, annual revenues associated with international customers were $33,271,920 and $59,020,266, or 70% and 77% of total revenue, respectively.", "entities": [ { "start_character": 124, "end_character": 134, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 33271920.0 }, { "start_character": 140, "end_character": 150, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 59020266.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-006304", "filing_date": 1710317919000, "quarter_ending": "20231231", "company_name": "Leatt Corp", "text": "Concentration of Credit Risk (continued) - 31, 2023 and 2022, annual revenues associated with international customers were $33,271,920 and $59,020,266, or 70% and 77% of total revenue, respectively.", "entities": [ { "start_character": 124, "end_character": 134, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 33271920.0 }, { "start_character": 140, "end_character": 150, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 59020266.0 } ] }, { "form_type": "10-Q", "accession_number": "0000794323-24-000006", "filing_date": 1714496861000, "quarter_ending": "20240331", "company_name": "Level 3 Parent, LLC", "text": "For the three months ended March 31, 2024 and 2023, our gross rental income was $146\u00a0million and $181\u00a0million, which represents approximately 9% and 10% of our operating revenue, respectively.", "entities": [ { "start_character": 81, "end_character": 84, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 146000000.0 }, { "start_character": 98, "end_character": 101, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 181000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-015139", "filing_date": 1713439233000, "quarter_ending": "20231231", "company_name": "Lever Global Corp", "text": "For\nthe fiscal year ended December 31, 2023, and 2022, the Company incurred a net loss of $2,784,844 and $1,932,194. From March 24, 2022 (\u201cInception\u201d)\nand December 31, 2023, the Company did not generate any significant revenue.", "entities": [ { "start_character": 91, "end_character": 100, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -2784844.0 }, { "start_character": 106, "end_character": 115, "label": "earnings", "start_date_for_period": "2022-03-24", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1932194.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022455", "filing_date": 1715322928000, "quarter_ending": "20240331", "company_name": "Li-Cycle Holdings Corp.", "text": "The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company\u2019s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated interim financial statements are issued. Based on its recurring losses from operations since inception, which included losses from operations of $44.2 million for the quarter ended March 31, 2024 ($39.1 million for the quarter ended March 31, 2023), net cash used in operating activities of $29.1 million during the three months ended March 31, 2024 ($22.4 million for the quarter ended March 31, 2023), and the pause on construction of the Rochester Hub project (as described below), the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these unaudited condensed consolidated interim financial statements were issued.", "entities": [ { "start_character": 411, "end_character": 415, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -44200000.0 }, { "start_character": 463, "end_character": 467, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -39100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001694028-24-000031", "filing_date": 1713459195000, "quarter_ending": "20240331", "company_name": "Liberty Energy Inc.", "text": "A member of the board of directors of the Company, Audrey Robertson, serves as Executive Vice President of Finance of Franklin Mountain Energy, LLC (\u201cFranklin Mountain\u201d). During the three months ended March 31, 2024 and March 31, 2023, the Company performed hydraulic fracturing services for Franklin Mountain in the amount of $11.5 million and $23.3 million, respectively. ", "entities": [ { "start_character": 328, "end_character": 332, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 11500000.0 }, { "start_character": 346, "end_character": 350, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 23300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001694028-24-000031", "filing_date": 1713459195000, "quarter_ending": "20240331", "company_name": "Liberty Energy Inc.", "text": "Liberty Resources LLC, an oil and gas exploration and production company, and its successor entity (collectively, the \u201cAffiliate\u201d) had certain common ownership and management with the Company. Effective March 14, 2024, the Affiliate is no longer a related party, following its acquisition by an unaffiliated party. The amounts of the Company\u2019s revenue related to hydraulic fracturing services provided to the Affiliate for the period January 1, 2024 through March 13, 2024, and the three months ended March 31, 2023, were $11.1 million and $6.5 million, respectively.", "entities": [ { "start_character": 523, "end_character": 527, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 11100000.0 }, { "start_character": 541, "end_character": 544, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 6500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001694028-24-000031", "filing_date": 1713459195000, "quarter_ending": "20240331", "company_name": "Liberty Energy Inc.", "text": "Revenues from operating leases for the three months ended March 31, 2024 and 2023 were $9.1 million and $8.6 million, respectively.", "entities": [ { "start_character": 88, "end_character": 91, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 9100000.0 }, { "start_character": 105, "end_character": 108, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 8600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001712184-24-000030", "filing_date": 1708620138000, "quarter_ending": "20231231", "company_name": "Liberty Latin America Ltd.", "text": "Our consolidated statements of operations include earnings (losses) before income taxes attributable to the Chile JV Entities of ($26\u00a0million) and $271\u00a0million for the years ended December 31, 2022 and 2021, respectively. ", "entities": [ { "start_character": 131, "end_character": 133, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 26000000.0 }, { "start_character": 148, "end_character": 151, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 271000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-009581", "filing_date": 1710174656000, "quarter_ending": "20231231", "company_name": "LifeMD, Inc.", "text": "Total\nrevenue for LifeMD PC was approximately $4.3 million and $499 thousand for the year ended December 31, 2023 and 2022, respectively. Total\nnet loss for LifeMD PC was approximately $1.2 million and $5.8 million for the year ended December 31, 2023 and 2022, respectively.", "entities": [ { "start_character": 47, "end_character": 50, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4300000.0 }, { "start_character": 64, "end_character": 67, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 499000.0 }, { "start_character": 186, "end_character": 189, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1200000.0 }, { "start_character": 203, "end_character": 206, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 5800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018250", "filing_date": 1715186756000, "quarter_ending": "20240331", "company_name": "LifeMD, Inc.", "text": "Total\nrevenue for LifeMD PC was approximately $7.6 million and $358 thousand for the three months ended March 31, 2024 and 2023, respectively.\nTotal net income for LifeMD PC was approximately $5.2 million for the three months ended March 31, 2024 and net loss for LifeMD PC was\napproximately $1.0 million for the three months ended March 31, 2023.", "entities": [ { "start_character": 47, "end_character": 50, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7600000.0 }, { "start_character": 64, "end_character": 67, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 358000.0 }, { "start_character": 193, "end_character": 196, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 5200000.0 }, { "start_character": 293, "end_character": 296, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000750004-24-000028", "filing_date": 1715186442000, "quarter_ending": "20240331", "company_name": "Light & Wonder, Inc.", "text": "The amount of rental income revenue that is outside the scope of ASC 606 was $127\u00a0million and $117\u00a0million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 78, "end_character": 81, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 127000000.0 }, { "start_character": 95, "end_character": 98, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 117000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001802749-23-000135", "filing_date": 1700497604000, "quarter_ending": "20230930", "company_name": "Lightning eMotors, Inc.", "text": "As of September\u00a030, 2023, the Company had $6,022 in cash and cash equivalents. For the nine months ended September\u00a030, 2023, the Company incurred a net loss of $95,555 and cash used in operating activities was $49,886. The Company had negative working capital of $30,601 as of September\u00a030, 2023. The current and historical operating cash flows, current cash and working capital balances, and forecasted obligations of the Company were considered in connection with management\u2019s evaluation of the Company\u2019s ongoing liquidity. ", "entities": [ { "start_character": 161, "end_character": 167, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -95555000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021719", "filing_date": 1715185995000, "quarter_ending": "20240331", "company_name": "Limbach Holdings, Inc.", "text": "In addition, during the first quarter of 2022, the Company entered into an amendment to the aforementioned sublease agreement, which, among other things, expanded the sublease premises to include the entire second floor of its leased space in Southern California, consisting of 16,720 square feet. Under the terms of the amended sublease agreement, the sublessee is obligated to pay the Company base rent of approximately $0.8\u00a0million per year, which is subject to a 3.0% annual rent increase, plus certain operating expenses and other costs. The amended sublease term commenced in March 2022 and continues through April 30, 2027. For both the three months ended March\u00a031, 2024 and 2023, the Company recorded approximately $0.3\u00a0million of income in selling, general and administrative expenses related to this sublease agreement. ", "entities": [ { "start_character": 724, "end_character": 727, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-015181", "filing_date": 1713455249000, "quarter_ending": "20231231", "company_name": "Limitless X Holdings Inc.", "text": "The accompanying\nconsolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among\nother things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated\ndeficit of $26.1 million\u00a0at December 31, 2023, and had a net loss of $16.1 million\u00a0for the year ended December 31, 2023 and\nnet cash used in operating activities of $6.9 million\u00a0for the year ended December 31, 2023. These matters raise substantial doubt\nabout the Company\u2019s ability to continue as a going concern.", "entities": [ { "start_character": 358, "end_character": 362, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -16100000.000000002 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020645", "filing_date": 1716218628000, "quarter_ending": "20240331", "company_name": "Limitless X Holdings Inc.", "text": "The\naccompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates,\namong other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated\ndeficit of $27.2 million at March 31, 2024, and had a net loss of $1.1 million for the three months ended March 31, 2024 and net cash\nused in operating activities of $0.6 million for the three months ended March 31, 2024. These matters raise substantial doubt about the\nCompany\u2019s ability to continue as a going concern.", "entities": [ { "start_character": 355, "end_character": 358, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012376", "filing_date": 1711988141000, "quarter_ending": "20231231", "company_name": "LiquidValue Development Inc.", "text": "In\nlate 2022 and early 2023, the Company entered into three contracts with builders to sell multiple lots from its Lakes at Black Oak\nproject. The sales contemplated by these contracts are contingent on certain conditions which the parties to such contracts will\nneed to meet and are expected to generate approximately $22\nmillion of funds from operations, not including certain expenses that the Company will be required to pay. In addition, the Company\nwill be entitled to receive certain reimbursements in the year ended December 31, 2024. The sale of 335 lots closed in the first six\nmonths of 2023 generating approximately $18.1\nmillion revenue. The sale of remaining lots closed on January 4, 2024.", "entities": [ { "start_character": 629, "end_character": 633, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 18100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018232", "filing_date": 1715184657000, "quarter_ending": "20240331", "company_name": "LiquidValue Development Inc.", "text": "In\nlate 2022 and early 2023, the Company entered into three contracts with builders to sell multiple lots from its Lakes at Black Oak project.\nThe sales contemplated by these contracts were contingent on certain conditions which the parties to such contracts had to meet and generated approximately $23 million of funds from operations, not including certain expenses that the Company was required\nto pay. In addition, the Company is entitled to receive certain reimbursements in the year ended December 31, 2024. The sale of 335 lots\nclosed in the first six months of 2023 generating approximately $18.1 million revenue. The sale of remaining lots closed on January 4,\n2024 generating approximately $5.0 million in revenue.", "entities": [ { "start_character": 601, "end_character": 605, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-06-30", "currency_/_unit": "iso4217:USD", "value": 18100000.0 }, { "start_character": 702, "end_character": 705, "label": "revenues", "start_date_for_period": "2024-01-04", "end_date_for_period": "2024-01-04", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018800", "filing_date": 1715588516000, "quarter_ending": "20240331", "company_name": "Lucid Diagnostics Inc.", "text": "The\nCompany incurred a net loss attributable to Lucid Diagnostics Inc common stockholders of approximately $18.1 million and had net cash\nflows used in operating activities of approximately $12.6 million for the three month period ended March 31, 2024. As of March 31, 2024,\nthe Company had working capital of approximately $7.6 million, with such working capital inclusive of the Senior Secured Convertible\nNote classified as a current liability of approximately $13.1 million and approximately $24.8 million of cash.", "entities": [ { "start_character": 108, "end_character": 112, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -18100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018800", "filing_date": 1715588516000, "quarter_ending": "20240331", "company_name": "Lucid Diagnostics Inc.", "text": "The\nCompany has financed its operations principally through public and private issuances of its common stock, preferred stock, and debt.\nThe Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially\nall of their efforts to the commercialization of their initial product and services and ongoing research and development activities and\nconducting clinical trials. The Company generated $1.0 million of revenues for the three month period ended March 31, 2024, however the\nCompany does not expect to generate positive cash flows from operating activities in the near future.", "entities": [ { "start_character": 470, "end_character": 473, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007209", "filing_date": 1709050162000, "quarter_ending": "20231231", "company_name": "Lucid Group, Inc.", "text": "The Company provides an RVG to its commercial banking partner in connection with its vehicle leasing program. Under the vehicle leasing program, the Company generally receives full payment for the vehicle sales price at the time of delivery or shortly after delivery, does not bear casualty and credit risks during the lease term, and is contractually obligated (or entitled) to share a portion of the shortfall (or excess) between the resale value realized by the commercial banking partner and a predetermined resale value. During the years ended December\u00a031, 2023 and 2022, vehicle sales with RVG totaled $190.9\u00a0million and $31.1\u00a0million, respectively. At the lease inception, the Company is required to deposit cash collateral equal to a contractual percentage of the residual value of the leased vehicles with the commercial banking partner. The cash collateral is held in a restricted bank account owned by the commercial banking partner until it is used, as applicable, in settlement of the RVG at the end of the lease term. Cash collateral is recorded in other noncurrent assets, subject to asset impairment review at each reporting period. ", "entities": [ { "start_character": 609, "end_character": 614, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 190900000.0 }, { "start_character": 628, "end_character": 632, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 31100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007209", "filing_date": 1709050162000, "quarter_ending": "20231231", "company_name": "Lucid Group, Inc.", "text": "From inception through December\u00a031, 2023, the Company has incurred operating losses and negative cash flows from operating activities. For the years ended December\u00a031, 2023, 2022 and 2021, the Company has incurred net losses of $2.8\u00a0billion, $1.3\u00a0billion and $2.6\u00a0billion, respectively. The Company had an accumulated deficit of $10.2\u00a0billion as of December\u00a031, 2023. ", "entities": [ { "start_character": 229, "end_character": 232, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -2800000000.0 }, { "start_character": 243, "end_character": 246, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1300000000.0 }, { "start_character": 260, "end_character": 263, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -2600000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020633", "filing_date": 1715012066000, "quarter_ending": "20240331", "company_name": "Lucid Group, Inc.", "text": "From inception through March\u00a031, 2024, the Company has incurred operating losses and negative cash flows from operating activities. For the three months ended March\u00a031, 2024 and 2023, the Company has incurred net losses of $680.9\u00a0million and $779.5\u00a0million, respectively. The Company had an accumulated deficit of $10.9\u00a0billion as of March\u00a031, 2024. ", "entities": [ { "start_character": 224, "end_character": 229, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -680900000.0 }, { "start_character": 243, "end_character": 248, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -779500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020633", "filing_date": 1715012066000, "quarter_ending": "20240331", "company_name": "Lucid Group, Inc.", "text": "In August 2023, Lucid LLC entered into the EV Purchase Agreement with the Government of Saudi Arabia, a related party of PIF, which is an affiliate of Ayar, as represented by the Ministry of Finance. The EV Purchase Agreement supersedes the letter of undertaking that Lucid LLC entered into in April 2022. Pursuant to the terms of the EV Purchase Agreement, the Government of Saudi Arabia and its entities and corporate subsidiaries and other beneficiaries (collectively, the \u201cPurchaser\u201d) may purchase up to 100,000 vehicles, with a minimum purchase quantity of 50,000 vehicles and an option to purchase up to an additional 50,000 vehicles during a ten-year period. Under the EV Purchase Agreement, the Purchaser may reduce the minimum vehicle purchase quantity by the number of vehicles set out in any purchase order not accepted by us or by the number of vehicles that Lucid LLC fails to deliver within six months from the date of the applicable purchase order. The Purchaser also has absolute discretion to decide whether to exercise the option to purchase the additional 50,000 vehicles. The Company recognized net vehicle sales amount of SAR 192.6 million (approximately $51.4\u00a0million) during the three months ended March\u00a031, 2024. The Company recorded amounts due from the Purchaser of SAR 318.4 million (approximately $84.9 million) and SAR 133.2 million (approximately $35.5 million) in accounts receivable, net in the condensed consolidated balance sheets as of March\u00a031, 2024 and December\u00a031, 2023, respectively. See \u201cVehicle Sales without Residual Value Guarantee\u201d section under Note 2 \u201cSignificant Accounting Policies\u201d for the revenue recognition policies. ", "entities": [ { "start_character": 1147, "end_character": 1152, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:SAR", "value": 192600000.0 }, { "start_character": 1177, "end_character": 1181, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 51400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000018926-24-000016", "filing_date": 1708618051000, "quarter_ending": "20231231", "company_name": "Lumen Technologies, Inc.", "text": "For the years ended December 31, 2023, 2022 and 2021, our gross rental income was $1.0 billion, $1.2 billion and $1.2 billion, respectively, which represents 7%, 7% and 6% respectively, of our operating revenue for the years ended December 31, 2023, 2022 and 2021.", "entities": [ { "start_character": 83, "end_character": 86, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1000000000.0 }, { "start_character": 97, "end_character": 100, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1200000000.0 }, { "start_character": 114, "end_character": 117, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1200000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000018926-24-000054", "filing_date": 1714496808000, "quarter_ending": "20240331", "company_name": "Lumen Technologies, Inc.", "text": "For the three months ended March 31, 2024 and 2023, our gross rental income was $221 million and $269\u00a0million, respectively, which represents approximately 7% of our operating revenue for both the three months ended March 31, 2024 and 2023.", "entities": [ { "start_character": 81, "end_character": 84, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 221000000.0 }, { "start_character": 98, "end_character": 101, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 269000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007592", "filing_date": 1709136831000, "quarter_ending": "20231231", "company_name": "Lyell Immunopharma, Inc.", "text": "In June 2022, the Company recorded adjustments to revenue related to a change in estimate in connection with the Collaboration and License Agreement, entered into in 2019 and amended in June 2020 and December 2021 (\u201cGSK\u00a0Agreement\u201d) with GlaxoSmithKline Intellectual Property (No. 5) Limited and Glaxo Group Limited (together,\u00a0\u201cGSK\u201d). The Company and GSK mutually agreed to conclude research activities on an undisclosed target for hematological cancers in June 2022. As a result, the Company decreased the related estimated project costs, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $83.6\u00a0million, decreased net loss by $83.6 million and resulted in a $0.34 reduction in the Company\u2019s basic and diluted net loss per common share for the year ended ", "entities": [ { "start_character": 665, "end_character": 669, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 83600000.0 }, { "start_character": 702, "end_character": 706, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 83600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001759509-24-000019", "filing_date": 1708409023000, "quarter_ending": "20231231", "company_name": "Lyft, Inc.", "text": "For the years ended December\u00a031, 2023, 2022 and 2021, in relation to the driver, rider and Light Vehicle riders incentive programs, the Company recorded $1.1\u00a0billion, $1.4\u00a0billion and $1.3\u00a0billion as a reduction to revenue and $142.5\u00a0million, $109.8\u00a0million and $64.7\u00a0million as sales and marketing expense, respectively.", "entities": [ { "start_character": 154, "end_character": 157, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1100000000.0 }, { "start_character": 168, "end_character": 171, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1400000000.0 }, { "start_character": 185, "end_character": 188, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -1300000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001759509-24-000069", "filing_date": 1715270849000, "quarter_ending": "20240331", "company_name": "Lyft, Inc.", "text": "For the three months ended March\u00a031, 2024, in relation to the driver, rider and Light Vehicle riders incentive programs, the Company recorded $225.1 million as a reduction to revenue and $68.0 million as sales and marketing expense. For the three months ended March\u00a031, 2023, in relation to the driver, rider and Light Vehicle riders incentive programs, the Company recorded $303.7 million as a reduction to revenue and $23.3 million as sales and marketing expense.", "entities": [ { "start_character": 143, "end_character": 148, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -225100000.0 }, { "start_character": 376, "end_character": 381, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -303700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001125345-24-000060", "filing_date": 1709827420000, "quarter_ending": "20231231", "company_name": "MACROGENICS INC", "text": "The Company recognized de minimis revenue during the year ended December\u00a031, 2023 under the Provention Manufacturing and Clinical Supply Agreement. During the year ended 2022, the Company recognized revenue of $5.3\u00a0million under the Provention Manufacturing and Clinical Supply Agreement.", "entities": [ { "start_character": 211, "end_character": 214, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001125345-24-000060", "filing_date": 1709827420000, "quarter_ending": "20231231", "company_name": "MACROGENICS INC", "text": "2022, and 2021 the Company recognized revenue of $4.2 million, $0.3\u00a0million and $7.8\u00a0million, respectively, for services performed under this agreement. ", "entities": [ { "start_character": 50, "end_character": 53, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4200000.0 }, { "start_character": 64, "end_character": 67, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 81, "end_character": 84, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001125345-24-000060", "filing_date": 1709827420000, "quarter_ending": "20231231", "company_name": "MACROGENICS INC", "text": ", 2022 and 2021, the Company recognized revenue of $1.9 million, $0.7 million and $1.5 million, respectively, for services performed under this agreement. ", "entities": [ { "start_character": 52, "end_character": 55, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 }, { "start_character": 66, "end_character": 69, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 700000.0 }, { "start_character": 83, "end_character": 86, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001125345-24-000088", "filing_date": 1715270558000, "quarter_ending": "20240331", "company_name": "MACROGENICS INC", "text": "During the three months ended March 31, 2024 and 2023, the Company recorded revenue of $0.3\u00a0million and $0.4\u00a0million, respectively, ", "entities": [ { "start_character": 88, "end_character": 91, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 106, "end_character": 109, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001125345-24-000088", "filing_date": 1715270558000, "quarter_ending": "20240331", "company_name": "MACROGENICS INC", "text": "Since the inception of the NIAID Contract, NIAID has exercised the two options contemplated in the original contract and executed modifications such that the total funded contract value as of March\u00a031, 2024 is $25.1\u00a0million. In addition, the most recent modification changed the period of performance under the NIAID Contract to end in September 2024. During the three months ended March 31, 2024 and 2023, the Company recognized revenue under the NIAID Contract of $0.4 million and $0.3 million, respectively.", "entities": [ { "start_character": 467, "end_character": 470, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 484, "end_character": 487, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001125345-24-000088", "filing_date": 1715270558000, "quarter_ending": "20240331", "company_name": "MACROGENICS INC", "text": "$3.6\u00a0million, respectively, under the Incyte Manufacturing and Clinical Supply Agreement. As of March\u00a031, 2024, $6.1\u00a0million in revenue was deferred under this agreement, all of which was current. As of December 31, 2023, $7.0\u00a0million", "entities": [ { "start_character": 1, "end_character": 4, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001125345-24-000088", "filing_date": 1715270558000, "quarter_ending": "20240331", "company_name": "MACROGENICS INC", "text": "In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte\u2019s obligation to pay royalties under the Incyte License Agreement. The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the three months ended March 31, 2024, the Company recognized revenue of $0.4\u00a0million for services performed under the Incyte Commercial Supply Agreement. No revenue was recognized for the three months ended March 31, 2023 under the Incyte Commercial Supply Agreement. ", "entities": [ { "start_character": 1206, "end_character": 1209, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 1287, "end_character": 1289, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001125345-24-000088", "filing_date": 1715270558000, "quarter_ending": "20240331", "company_name": "MACROGENICS INC", "text": "In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte\u2019s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the three months ended March 31, 2024 and 2023, the Company recognized revenue of $0.1 million and $1.3 million, respectively, for services performed under the Incyte Clinical Supply Agreement. ", "entities": [ { "start_character": 1083, "end_character": 1086, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 1100, "end_character": 1103, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001125345-24-000088", "filing_date": 1715270558000, "quarter_ending": "20240331", "company_name": "MACROGENICS INC", "text": "The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized $0.2 million and $15.0\u00a0million in revenue under the Incyte License Agreement during the three months ended March 31, 2024 and 2023, respectively. ", "entities": [ { "start_character": 28, "end_character": 33, "label": "revenues", "start_date_for_period": "2019-01-01", "end_date_for_period": "2019-06-30", "currency_/_unit": "iso4217:USD", "value": 150000000.0 }, { "start_character": 309, "end_character": 312, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020865", "filing_date": 1715072437000, "quarter_ending": "20240331", "company_name": "MADRIGAL PHARMACEUTICALS, INC.", "text": "The agreement requires future milestone payments to Roche. In March 2024, upon receiving FDA approval of Rezdiffra, a milestone was achieved and $5.0 million became due to Roche. Remaining milestones under the agreement total $3.0 million and are payable upon the Company achieving specified objectives related to future regulatory approval in Europe of resmetirom or a product developed from resmetirom. Furthermore, a tiered single-digit royalty is payable on net sales of resmetirom or a product developed from resmetirom, subject to certain reductions. The Company achieved the U.S. regulatory approval milestone but had no Licensed Product sales for the three months ended March\u00a031, 2024. The company did not achieve any product development or regulatory milestones for the three months ended March 31, 2023. ", "entities": [ { "start_character": 625, "end_character": 627, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 }, { "start_character": 710, "end_character": 712, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020865", "filing_date": 1715072437000, "quarter_ending": "20240331", "company_name": "MADRIGAL PHARMACEUTICALS, INC.", "text": "The Company has incurred losses since inception, including approximately $147.5 million for the three months ended March\u00a031, 2024, resulting in an accumulated deficit of approximately $1,483.8 million as of March\u00a031, 2024. To date, the Company has funded its operations primarily through proceeds from sales of the Company\u2019s capital stock and debt financings. In March 2024, the FDA approved Rezdiffra in the U.S. for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Rezdiffra became available in the U.S. in April 2024. In March 2024, the Company completed a public offering and received approximately $574.0\u00a0million net cash proceeds. In April 2024, underwriters exercised in full their option to purchase additional shares as part of the public offering, resulting in additional net cash proceeds of approximately $85.9\u00a0million. Please see \u201cNote 11 \u2013 Subsequent Events\u201d to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for ", "entities": [ { "start_character": 74, "end_character": 79, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -147500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000101778-24-000023", "filing_date": 1708619611000, "quarter_ending": "20231231", "company_name": "MARATHON OIL CORP", "text": "Revenues from related parties were $23 million, $28 million and $30 million in 2023, 2022 and 2021, respectively, with the majority related to EGHoldings in all years. ", "entities": [ { "start_character": 36, "end_character": 38, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 23000000.0 }, { "start_character": 49, "end_character": 51, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 28000000.0 }, { "start_character": 65, "end_character": 67, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 30000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000101778-24-000099", "filing_date": 1714666350000, "quarter_ending": "20240331", "company_name": "MARATHON OIL CORP", "text": "Revenues from related parties were $2 million for the three months ended March\u00a031, 2024, which primarily related to Alba Plant LLC and AMPCO. Revenues from related parties were $6 million for the three months ended March\u00a031, 2023, with the majority related to EG LNG. As a result of the agreement that took effect on January 1, 2024, related party shipping, handling and other operating expense presented on the face of the consolidated statements of income represents compensation to EG LNG for liquefaction, storage and product handling services.", "entities": [ { "start_character": 36, "end_character": 37, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 }, { "start_character": 178, "end_character": 179, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 6000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000015615-24-000021", "filing_date": 1709243937000, "quarter_ending": "20231231", "company_name": "MASTEC INC", "text": "MasTec operates primarily in the United States and Canada, and, to a far lesser extent, the Caribbean, India and Mexico. Revenue derived from U.S. operations totaled $11.9 billion, $9.6 billion and $7.8 billion for the years ended December\u00a031, 2023, 2022 and 2021, respectively, and revenue derived from foreign operations totaled $95.1 million, $149.9 million and $165.2 million for the respective periods. Revenue from foreign operations was derived primarily from the Company\u2019s Canadian operations in its Oil and Gas segment. Long-lived assets held in the United States included property and equipment, net, of $1.6 billion, $1.7 billion and $1.4 billion as of December\u00a031, 2023, 2022 and 2021, respectively, and for the Company\u2019s businesses in foreign countries, totaled $17.5 million, $21.0 million and $24.5 million for the respective periods. Intangible assets and goodwill, net, related to the Company\u2019s U.S. operations totaled approximately $2.9 billion, $3.0 billion and $2.1 billion as of December\u00a031, 2023, 2022 and 2021, respectively. For the Company\u2019s businesses in foreign countries, intangible assets and goodwill, net, totaled approximately $32.6 million, $35.5 million and $43.8 million as of December\u00a031, 2023, 2022 and 2021, respectively. Substantially all of the Company\u2019s long-lived and intangible assets and goodwill in foreign countries relate to its Canadian operations. As of both December\u00a031, 2023 and 2022, amounts due from customers from which foreign revenue was derived accounted for approximately 1% of the Company\u2019s consolidated net accounts receivable position, which is calculated as accounts receivable, net, less deferred revenue. As of December\u00a031, 2021, such amounts accounted for approximately 2% of the Company\u2019s consolidated net accounts receivable position. Revenue from governmental entities for the years ended December\u00a031, 2023, 2022 and 2021 totaled approximately 11%, 7% and 5% of total revenue, respectively, substantially all of which was derived from the Company\u2019s U.S. operations.", "entities": [ { "start_character": 168, "end_character": 172, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 11900000000.0 }, { "start_character": 183, "end_character": 186, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9600000000.0 }, { "start_character": 200, "end_character": 203, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7800000000.0 }, { "start_character": 333, "end_character": 337, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 95100000.0 }, { "start_character": 348, "end_character": 353, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 149900000.0 }, { "start_character": 367, "end_character": 372, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 165200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000015615-24-000045", "filing_date": 1714669554000, "quarter_ending": "20240331", "company_name": "MASTEC INC", "text": "MasTec operates primarily within the United States and Canada, and, to a far lesser extent, the Caribbean, India and Mexico. Revenue derived from U.S. operations totaled $2.7 billion and $2.6 billion for the ", "entities": [ { "start_character": 172, "end_character": 175, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2700000000.0 }, { "start_character": 189, "end_character": 192, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2600000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000015615-24-000045", "filing_date": 1714669554000, "quarter_ending": "20240331", "company_name": "MASTEC INC", "text": "MasTec purchases, rents and leases equipment and purchases various types of supplies and services used in its business, including ancillary construction services, project-related site restoration and marketing, business development and administrative activities, from a number of different vendors on a non-exclusive basis, and from time to time, rents equipment to, sells certain supplies, or performs construction services on behalf of, entities in which members of subsidiary management have ownership or commercial interests. For the three month periods ended March\u00a031, 2024 and 2023, such payments to related party entities totaled approximately $10.3 million and $16.1 million, respectively. Payables associated with such arrangements totaled approximately $1.2 million and $2.7 million as of March\u00a031, 2024 and December\u00a031, 2023, respectively. Revenue from such related party arrangements totaled approximately $4.4 million and $2.2 million for the three month periods ended March\u00a031, 2024 and 2023, respectively. As of March\u00a031, 2024, accounts receivable, net, less deferred revenue related to these arrangements totaled a receivable of approximately $3.2 million, and as of December\u00a031, 2023, totaled a liability of approximately $0.4 million.", "entities": [ { "start_character": 922, "end_character": 925, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4400000.0 }, { "start_character": 939, "end_character": 942, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2200000.0 } ] }, { "form_type": "10-K", "accession_number": "0000063908-24-000072", "filing_date": 1708605075000, "quarter_ending": "20231231", "company_name": "MCDONALDS CORP", "text": "Diluted earnings per common share is calculated using net income divided by diluted weighted-average shares. Diluted weighted-average shares include weighted-average shares outstanding plus the dilutive effect of share-based compensation calculated using the treasury stock method, of (in millions of shares): 2023\u20134.4; 2022\u20134.8; 2021\u20135.5. Share-based compensation awards that were not included in diluted weighted-average shares because they would have been antidilutive were (in millions of shares): 2023\u20132.0; 2022\u20131.5; 2021\u20132.2.", "entities": [ { "start_character": 315, "end_character": 318, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 4400000.0 }, { "start_character": 325, "end_character": 328, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 4800000.0 }, { "start_character": 335, "end_character": 338, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 5500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000067716-24-000017", "filing_date": 1708622883000, "quarter_ending": "20231231", "company_name": "MDU RESOURCES GROUP INC", "text": "For those joint ventures accounted for using proportionate consolidation, the Company recorded in its Consolidated Statements of Income $7.8\u00a0million, $14.8\u00a0million, and $14.7\u00a0million of revenue for the years ended December\u00a031, 2023, 2022 and 2021, respectively, and $2.1\u00a0million, $3.0\u00a0million and $4.7\u00a0million of operating income for the years ended December\u00a031, 2023, 2022 and 2021, respectively. At December\u00a031, 2023 and 2022, the Company had interest in assets from these joint ventures of $1.8\u00a0million and $2.4\u00a0million, respectively.", "entities": [ { "start_character": 137, "end_character": 140, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 7800000.0 }, { "start_character": 151, "end_character": 155, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 14800000.0 }, { "start_character": 170, "end_character": 174, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 14700000.0 }, { "start_character": 267, "end_character": 270, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 281, "end_character": 284, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3000000.0 }, { "start_character": 298, "end_character": 301, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 4700000.0 } ] }, { "form_type": "10-K", "accession_number": "0000067716-24-000017", "filing_date": 1708622883000, "quarter_ending": "20231231", "company_name": "MDU RESOURCES GROUP INC", "text": "The Company leases certain equipment to third parties through its utility and construction services businesses, which are considered short-term operating leases with terms of less than 12 months. The Company recognized revenue from operating leases of $46.0\u00a0million, $47.9 million and $50.1\u00a0million for the years ended December\u00a031, 2023, 2022 and 2021, respectively. At December\u00a031, 2023, the Company had $9.4\u00a0million of lease receivables with a majority due within 12 months or less.", "entities": [ { "start_character": 253, "end_character": 257, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 46000000.0 }, { "start_character": 268, "end_character": 272, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 47900000.0 }, { "start_character": 286, "end_character": 290, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 50100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000067716-24-000055", "filing_date": 1714639253000, "quarter_ending": "20240331", "company_name": "MDU RESOURCES GROUP INC", "text": "The Company recognized revenue from operating leases of $9.5 million and $12.2 million for the three months ended March\u00a031, 2024 and 2023, respectively. At March\u00a031, 2024, the Company had $8.5 million of lease receivables with a majority due within 12 months.", "entities": [ { "start_character": 57, "end_character": 60, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 9500000.0 }, { "start_character": 74, "end_character": 78, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 12200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001049521-24-000009", "filing_date": 1707236661000, "quarter_ending": "20231229", "company_name": "MERCURY SYSTEMS INC", "text": "The Company recorded an income tax benefit of $18,141 and $2,151 on a loss before income taxes of $63,722 and $13,071 for the second quarters ended December 29, 2023 and December 30, 2022, respectively. The Company recorded an income tax benefit of $31,168 and $3,173 on a loss before income taxes of $113,457 and $28,428 for the six months ended December 29, 2023 and December 30, 2022, respectively.", "entities": [ { "start_character": 99, "end_character": 105, "label": "earnings", "start_date_for_period": "2023-09-30", "end_date_for_period": "2023-12-29", "currency_/_unit": "iso4217:USD", "value": -63722000.0 }, { "start_character": 111, "end_character": 117, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-30", "currency_/_unit": "iso4217:USD", "value": -13071000.0 }, { "start_character": 302, "end_character": 309, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-29", "currency_/_unit": "iso4217:USD", "value": -113457000.0 }, { "start_character": 315, "end_character": 321, "label": "earnings", "start_date_for_period": "2021-07-03", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -28428000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001049521-24-000017", "filing_date": 1715100464000, "quarter_ending": "20240329", "company_name": "MERCURY SYSTEMS INC", "text": "The Company recorded an income tax benefit of $12,643 and $10,446 on a loss before income taxes of $57,217 and $5,290 for the third quarters ended March 29, 2024 and March 31, 2023, respectively. The Company recorded an income tax benefit of $43,811 and $13,619 on a loss before income taxes of $170,674 and $33,718 for the nine months ended March 29, 2024 and March 31, 2023, respectively.", "entities": [ { "start_character": 100, "end_character": 106, "label": "earnings", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": -57217000.0 }, { "start_character": 112, "end_character": 117, "label": "earnings", "start_date_for_period": "2022-12-31", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -5290000.0 }, { "start_character": 296, "end_character": 303, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": -170674000.0 }, { "start_character": 309, "end_character": 315, "label": "earnings", "start_date_for_period": "2021-07-03", "end_date_for_period": "2022-04-01", "currency_/_unit": "iso4217:USD", "value": -33718000.0 } ] }, { "form_type": "10-K", "accession_number": "0001099219-24-000035", "filing_date": 1708022563000, "quarter_ending": "20231231", "company_name": "METLIFE INC", "text": "MetLife P&C income (loss) before provision for income tax as reflected in the consolidated statement of operation was $121\u00a0million for the year ended December 31, 2021.", "entities": [ { "start_character": 119, "end_character": 122, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 121000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001099219-24-000035", "filing_date": 1708022563000, "quarter_ending": "20231231", "company_name": "METLIFE INC", "text": "MetLife Poland and Greece income (loss) before provision for income tax as reflected in the consolidated statements of operations was $19\u00a0million and $50\u00a0million for the years ended December 31, 2022 and 2021, respectively.", "entities": [ { "start_character": 135, "end_character": 137, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 19000000.0 }, { "start_character": 151, "end_character": 153, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 50000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001099219-24-000035", "filing_date": 1708022563000, "quarter_ending": "20231231", "company_name": "METLIFE INC", "text": "Revenues derived from one RIS customer were $8.1\u00a0billion for the year ended December\u00a031, 2022, which represented 14% of consolidated premiums, universal life and investment-type product policy fees and other revenues. The revenue was from a single premium received for a pension risk transfer. Revenues derived from any single customer did not exceed 10% of consolidated premiums, universal life and investment-type product policy fees and other revenues for the years ended December 31,", "entities": [ { "start_character": 45, "end_character": 48, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 8100000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000937834-24-000004", "filing_date": 1709749237000, "quarter_ending": "20231231", "company_name": "METROPOLITAN LIFE INSURANCE CO", "text": "Revenues derived from one RIS customer were $8.1 billion for the year ended December 31, 2022, which represented 23%, of consolidated premiums, universal life and investment-type product policy fees and other revenues. The revenue was from a single premium received for a pension risk transfer. Revenues derived from one Group Benefits customer were $3.6\u00a0billion, $3.8\u00a0billion and $3.9\u00a0billion for the years ended December 31, 2023, 2022 and 2021, respectively, which represented 13%, 11% and 13% of the consolidated premiums, universal life and investment-type product policy fees and other revenues, respectively. Revenues derived from any other customer did not exceed 10% of consolidated premiums, universal life and investment-type product policy fees and other revenues for the years ended December\u00a031, 2023, 2022 or 2021.", "entities": [ { "start_character": 45, "end_character": 48, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 8100000000.0 }, { "start_character": 351, "end_character": 354, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3600000000.0 }, { "start_character": 365, "end_character": 368, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3800000000.0 }, { "start_character": 382, "end_character": 385, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 3900000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000937834-24-000008", "filing_date": 1715099531000, "quarter_ending": "20240331", "company_name": "METROPOLITAN LIFE INSURANCE CO", "text": "The Company has entered into various agreements with affiliates for services necessary to conduct its activities. Typical services provided under these agreements include personnel, policy administrative functions and distribution services. The bases for such charges are modified and adjusted by management when necessary or appropriate to reflect fairly and equitably the actual cost incurred by the Company and/or its affiliates. Expenses and fees incurred with affiliates related to these agreements, recorded in other expenses, were $722 million and $715\u00a0million for the three months ended March\u00a031, 2024 and 2023, respectively. Total revenues received from affiliates related to these agreements were $11 million and $14\u00a0million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 708, "end_character": 710, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 11000000.0 }, { "start_character": 724, "end_character": 726, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001037646-24-000007", "filing_date": 1707483996000, "quarter_ending": "20231231", "company_name": "METTLER TOLEDO INTERNATIONAL INC/", "text": "In accordance with the treasury stock method, the Company has included 123,406, 226,500, and 327,768 common equivalent shares in the calculation of diluted weighted average number of common shares for the years ended December\u00a031, 2023, 2022, and 2021, respectively, relating to outstanding stock options and restricted stock units. ", "entities": [ { "start_character": 71, "end_character": 78, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 123406.0 }, { "start_character": 80, "end_character": 87, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 226500.0 }, { "start_character": 93, "end_character": 100, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 327768.0 } ] }, { "form_type": "10-Q", "accession_number": "0001037646-24-000012", "filing_date": 1715338952000, "quarter_ending": "20240331", "company_name": "METTLER TOLEDO INTERNATIONAL INC/", "text": "In accordance with the treasury stock method, the Company has included 105,640 and 169,979 common equivalent shares in the calculation of diluted weighted average number of common shares outstanding for the three months ended March\u00a031, 2024 and 2023, respectively, relating to outstanding stock options and restricted stock units.", "entities": [ { "start_character": 71, "end_character": 78, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 105640.0 }, { "start_character": 83, "end_character": 90, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 169979.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-019790", "filing_date": 1714635261000, "quarter_ending": "20240331", "company_name": "MGP INGREDIENTS INC", "text": "Participating securities included 260,651 and 227,810 unvested restricted stock units (\u201cRSUs\u201d) at March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 34, "end_character": 41, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 260651.0 }, { "start_character": 46, "end_character": 53, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 227810.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014891", "filing_date": 1713288659000, "quarter_ending": "20231231", "company_name": "MGT CAPITAL INVESTMENTS, INC.", "text": "We\nreceive revenues from third parties renting capacity at our facility and from hosting miners owned by others. The Company recognized\n$324 and $640 from these sources during the years ended December 31, 2023 and 2022, respectively. During the years ended December 31,\n2023 and 2022, two customers accounted for 99% and 83%, respectively, of hosting revenue.", "entities": [ { "start_character": 137, "end_character": 140, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 324000.0 }, { "start_character": 146, "end_character": 149, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 640000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-008335", "filing_date": 1709224191000, "quarter_ending": "20231231", "company_name": "MICROVISION, INC.", "text": "In\n2023, one commercial customer (\u201cCustomer A\u201d) accounted for $4.6\nmillion in revenue, representing 63%\nof our total revenue, a second commercial customer accounted for $0.8\nmillion in revenue, representing 11%\nof our total revenue and a third commercial customer accounted for $0.4\nmillion in revenue, representing 5%\nof our total revenue. In 2022, Customer A accounted for $0.7\nmillion in revenue, representing 100%\nof our total revenue. No revenue was recognized from Customer A during the second half of 2022 or the first three quarters of 2023\nas no shipments of our components were reported by the customer during that period. In 2021, Customer A accounted for $2.5\nmillion in revenue, representing 100%\nof our total revenue. Subsequent to fiscal year 2023, we do not expect to recognize further revenue from Customer A, which will negatively affect our\nfuture revenue.", "entities": [ { "start_character": 63, "end_character": 66, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4600000.0 }, { "start_character": 170, "end_character": 173, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 800000.0 }, { "start_character": 279, "end_character": 282, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 376, "end_character": 379, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 700000.0 }, { "start_character": 668, "end_character": 671, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018637", "filing_date": 1715357173000, "quarter_ending": "20240331", "company_name": "MICROVISION, INC.", "text": "For\nthe three months ended March 31, 2024, a major global commercial trucking OEM accounted for $0.5 million in revenue, representing 52%\nof our total revenue, and a leading supplier of agricultural equipment manufacturer accounted for $0.3 million in revenue, representing\n33% of our total revenue. For the three months ended March 31, 2023, one commercial customer accounted for $0.4 million in revenue, representing\n46% of our total revenue, a second commercial customer accounted for $0.2 million in revenue, representing 24% of our total revenue,\nand a third commercial customer accounted for $0.08 million in revenue, representing 10% of our total revenue.", "entities": [ { "start_character": 97, "end_character": 100, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 500000.0 }, { "start_character": 237, "end_character": 240, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 382, "end_character": 385, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 489, "end_character": 492, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 599, "end_character": 603, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 80000.0 } ] }, { "form_type": "10-K", "accession_number": "0000769520-24-000004", "filing_date": 1709138479000, "quarter_ending": "20231230", "company_name": "MIDDLEBY Corp", "text": "The company\u2019s potentially dilutive securities amounted to 509,000, 852,000 and 1,449,000 for fiscal 2023, 2022 and 2021, respectively. The company's potentially dilutive securities consist of shares issuable on vesting of restricted stock units computed using the treasury method and amounted to approximately 67,000, 73,000 and 56,000 for fiscal 2023, 2022 and 2021, respectively. During fiscal 2023 2022 and 2021, the average market price of the company's common stock exceeded the exercise price of the Convertible Notes (as defined below) resulting in approximately 442,000, 779,000 and 1,393,000 diluted common stock equivalents to be included in the diluted net earnings per share, respectively. There have been no material conversions to date. See Note 5, Financing Arrangements, in these Notes to the Consolidated Financial Statements for further details on the Convertible Notes. There were no anti-dilutive equity awards excluded from common stock equivalents for 2023, 2022 or 2021.", "entities": [ { "start_character": 310, "end_character": 316, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "xbrli:shares", "value": 67000.0 }, { "start_character": 318, "end_character": 324, "label": "eps", "start_date_for_period": "2022-01-02", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 73000.0 }, { "start_character": 329, "end_character": 335, "label": "eps", "start_date_for_period": "2021-01-03", "end_date_for_period": "2022-01-01", "currency_/_unit": "xbrli:shares", "value": 56000.0 }, { "start_character": 570, "end_character": 577, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "xbrli:shares", "value": 442000.0 }, { "start_character": 579, "end_character": 586, "label": "eps", "start_date_for_period": "2022-01-02", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 779000.0 }, { "start_character": 591, "end_character": 600, "label": "eps", "start_date_for_period": "2021-01-03", "end_date_for_period": "2022-01-01", "currency_/_unit": "xbrli:shares", "value": 1393000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000769520-24-000018", "filing_date": 1715273611000, "quarter_ending": "20240330", "company_name": "MIDDLEBY Corp", "text": "The company\u2019s potentially dilutive securities consist of shares issuable on vesting of restricted stock grants computed using the treasury method and amounted to 3,000 and 2,000 for the three months ended March\u00a030, 2024 and April\u00a01, 2023, respectively. For the three months ended March\u00a030, 2024 and April\u00a01, 2023, the average market price of the company's common stock exceeded the exercise price of the Convertible Notes (as defined below) resulting in 737,000 and 781,000 diluted common stock equivalents to be included in the diluted net earnings per share, respectively.", "entities": [ { "start_character": 162, "end_character": 167, "label": "eps", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "xbrli:shares", "value": 3000.0 }, { "start_character": 172, "end_character": 177, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "xbrli:shares", "value": 2000.0 }, { "start_character": 454, "end_character": 461, "label": "eps", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "xbrli:shares", "value": 737000.0 }, { "start_character": 466, "end_character": 473, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "xbrli:shares", "value": 781000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-001659", "filing_date": 1704699032000, "quarter_ending": "20230930", "company_name": "MINIM, INC.", "text": "The\nCompany\u2019s operations have historically been financed through the issuance of common stock and borrowings. Since inception, the\nCompany has incurred significant losses and negative cash flows from operations. During the nine months ended September 30, 2023, the\nCompany incurred a net loss of $16.5 million and had positive cash flows from operating activities of $3.7 million. As of September 30,\n2023, the Company had an accumulated deficit of $91.3 million and cash and cash equivalents of $0.5 million. The Company implemented\ncost reduction plans to align its cost structure to its sales and increase its liquidity. The Company will continue to monitor its cost\nin relation to its sales and adjust its cost structure accordingly. The Company\u2019s financial position and operating results raise\nsubstantial doubt about the Company\u2019s ability to continue as a going concern. The Company believes it does not have sufficient\nresources through its cash and cash equivalents, other working capital and borrowings under its SVB line-of-credit to continue as a going\nconcern through at least one year from the issuance of these financial statements.", "entities": [ { "start_character": 297, "end_character": 301, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -16500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000807863-24-000045", "filing_date": 1713201388000, "quarter_ending": "20231231", "company_name": "MITEK SYSTEMS INC", "text": "As a result of the Warrant Transactions, the Company is required to recognize incremental dilution of earnings per share to the extent the average share price is over $26.53 for any fiscal quarter. During the three months ended December 31, 2023, there was no dilution of earnings per share. The Warrant Transactions expire over a period of 80 trading days commencing on May 1, 2026 and may be settled in net shares of Common Stock or net cash at the Company\u2019s election. Upon initial sale, the Warrant Transactions were recorded as an increase in additional paid-in capital within stockholders\u2019 equity of $23.9\u00a0million. As of December 31, 2023, the Warrant Transactions had not been exercised and remained outstanding.", "entities": [ { "start_character": 257, "end_character": 259, "label": "eps", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 0 }, { "start_character": 674, "end_character": 676, "label": "eps", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0000807863-24-000053", "filing_date": 1715357985000, "quarter_ending": "20240331", "company_name": "MITEK SYSTEMS INC", "text": "As a result of the Warrant Transactions, the Company is required to recognize incremental dilution of earnings per share to the extent the average share price is over $26.53 for any fiscal quarter. During the three months ended March 31, 2024, there was no dilution of earnings per share. The Warrant Transactions expire over a period of 80 trading days commencing on May 1, 2026 and may be settled in net shares of Common Stock or net cash at the Company\u2019s election. Upon initial sale, the Warrant Transactions were recorded as an increase in additional paid-in capital within stockholders\u2019 equity of $23.9\u00a0million. As of March 31, 2024, the Warrant Transactions had not been exercised and remained outstanding.", "entities": [ { "start_character": 254, "end_character": 256, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 }, { "start_character": 668, "end_character": 670, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014966", "filing_date": 1713304779000, "quarter_ending": "20231231", "company_name": "MOBIVITY HOLDINGS CORP.", "text": "We\nhave $416,395 of cash as of December 31, 2023. We had a net loss of $12.1 million for the year ended 2023, and we used $8.1 million of\ncash in our operating activities during 2023. In addition, we raised $5.2 million during two warrant conversion fundings during 2023.\nWe raised $3.0 million in cash Convertible Notes issued during 2023. We raised an additional $2.5 million from the issuance of convertible\nnotes in 2024. There is substantial doubt that our additional cash from our warrant conversion along with our expected cash flow from\noperations, will be sufficient to fund our 12-month plan of operations, there can be no assurance that we will not require significant\nadditional capital within 12 months.", "entities": [ { "start_character": 72, "end_character": 76, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -12100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-043589", "filing_date": 1715789174000, "quarter_ending": "20240331", "company_name": "MOBIX LABS, INC", "text": "The\ncondensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. Since inception,\nthe Company has incurred operating losses and negative cash flows from operations, primarily as a result of its ongoing investment in\nproduct development. For the six months ended March 31, 2024 and 2023, the Company incurred losses from operations of $25,831 and $21,065,\nrespectively, and as of March 31, 2024 the Company had an accumulated deficit of $85,241. The Company has historically financed its operations\nthrough the issuance and sale of equity securities and the issuance of debt. The Company expects to continue to incur operating losses\nand negative cash flows from operations for the foreseeable future and will need to raise additional debt or equity financing to fund\nits operations and satisfy its obligations. While the Company recently entered into a committed equity facility to raise additional capital,\nthe amount and timing of the proceeds, if any, the Company may receive from the sale of shares of Class A Common Stock thereunder will\ndepend on a number of factors, including the numbers of shares the Company may elect to sell, the timing of such sales, the future market\nprice of the Company\u2019s Class A Common stock and the payment of the cash commitment fee (see Note 16\u2014Equity). Management\nbelieves that there is substantial doubt concerning the Company\u2019s ability to continue as a going concern as the Company currently\ndoes not have adequate liquidity to meet its operating needs and satisfy its obligations beyond the next approximately ninety days.", "entities": [ { "start_character": 392, "end_character": 398, "label": "ebit", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -25831000.0 }, { "start_character": 404, "end_character": 410, "label": "ebit", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -21065000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000851968-24-000082", "filing_date": 1714133333000, "quarter_ending": "20240330", "company_name": "MOHAWK INDUSTRIES INC", "text": "For the three months ended March\u00a030, 2024, the Company recorded income tax expense of $27.8 million on earnings before income taxes of $132.8 million for an effective tax rate of 21.0%. For the three months ended April\u00a01, 2023, the Company recorded income tax expense of $28.9 million on earnings before income taxes of $109.2 million, for an effective tax rate of 26.5%. The decrease in the effective tax rate was primarily driven by the Company\u2019s geographic dispersion of profits and losses for the respective periods and the write-off of an income tax receivable no longer expected in the three months ended April 1, 2023.", "entities": [ { "start_character": 136, "end_character": 141, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 132800000.00000001 }, { "start_character": 321, "end_character": 326, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 109200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001059556-24-000017", "filing_date": 1707928440000, "quarter_ending": "20231231", "company_name": "MOODYS CORP /DE/", "text": "The unaudited pro forma results do not include any anticipated cost savings or other effects of the planned integration of RMS. Accordingly, the pro forma results above are not necessarily indicative of the results that would have been reported if the acquisition had occurred on the dates indicated, nor are the pro forma results indicative of results which may occur in the future. The RMS results included in the above have been converted to GAAP from IFRS as issued by the IASB and have been translated to USD at rates in effect for the periods presented. The RMS amounts in the pro forma results include an addition to revenue of approximately $18\u00a0million relating to a fair value adjustment to deferred revenue required as part of acquisition accounting for the year ended December 31, 2021.", "entities": [ { "start_character": 650, "end_character": 652, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 18000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001618034-24-000006", "filing_date": 1714653393000, "quarter_ending": "20240331", "company_name": "MOSAIC CO", "text": "As part of the MWSPC joint venture, we market approximately 25% of MWSPC production. Marketing fees of approximately $3.3\u00a0million and $5.7\u00a0million are included in revenue for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 118, "end_character": 121, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3300000.0 }, { "start_character": 135, "end_character": 138, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001618034-24-000006", "filing_date": 1714653393000, "quarter_ending": "20240331", "company_name": "MOSAIC CO", "text": "The \u201cCorporate, Eliminations and Other\u201d category includes the results of our ancillary distribution operations in India and China. For the three months ended March\u00a031, 2024, distribution operations in India and China collectively had revenue of $129.3\u00a0million, and gross margin of $7.6 million. For the three months ended March\u00a031, 2023, distribution operations in India and China collectively had revenue of $266.8 million, and gross margin of $(10.8) million.", "entities": [ { "start_character": 246, "end_character": 251, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 129300000.00000001 }, { "start_character": 410, "end_character": 415, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 266800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-010008", "filing_date": 1710483070000, "quarter_ending": "20240131", "company_name": "MU GLOBAL HOLDING Ltd", "text": "For\nthe period ended January 31, 2024, the Company incurred a net loss of $44,239. As of January 31, 2024, the Company suffered an accumulated\ndeficit of $2,502,247, capital deficiency of $628,789 and negative operating cash flows of $54,294. The Company\u2019s ability to continue\nas a going concern is dependent upon improving the profitability and the continuing financial support from its shareholders and director.\nManagement believes the existing shareholders, director or external financing will provide the additional cash to meet the Company\u2019s\nobligations as they become due.", "entities": [ { "start_character": 75, "end_character": 81, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -44239.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-023630", "filing_date": 1718263931000, "quarter_ending": "20240430", "company_name": "MU GLOBAL HOLDING Ltd", "text": "For\nthe period ended April 30, 2024, the Company incurred a net loss of $75,074. As of April 30, 2024, the Company suffered an accumulated\ndeficit of $2,533,082, capital deficiency of $654,474 and negative operating cash flows of $90,558. The Company\u2019s ability to continue\nas a going concern is dependent upon improving the profitability and the continuing financial support from its shareholders and director.\nManagement believes the existing shareholders, director or external financing will provide the additional cash to meet the Company\u2019s\nobligations as they become due.", "entities": [ { "start_character": 73, "end_character": 79, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -75074.0 } ] }, { "form_type": "10-Q", "accession_number": "0000700923-24-000029", "filing_date": 1714580713000, "quarter_ending": "20240331", "company_name": "MYR GROUP INC.", "text": "The cost-to-cost method of accounting requires the Company to make estimates about the expected revenue and gross profit on each of its contracts in process. During the three\u00a0months ended March\u00a031, 2024, changes in estimates pertaining to certain projects decreased consolidated gross margin by 1.2%, which resulted in decreases in operating income of $9.8 million, net income of $6.9 million and diluted earnings per common share of $0.41. Additional discussion on the impact of these estimate changes can be found in Item 2, \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations - Consolidated Results of Operations.\u201d", "entities": [ { "start_character": 353, "end_character": 356, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9800000.0 }, { "start_character": 381, "end_character": 384, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140361-23-053260", "filing_date": 1699978981000, "quarter_ending": "20230930", "company_name": "MachTen, Inc.", "text": "The\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Company receives Alternative Connect America Cost Model (\u201cACAM\u201d) funding which is included in Revenues in the Condensed Consolidated Statements of Income at an amount of $2.2 million for each of the three months ended September 30, 2023 and 2022. ACAM revenue for each of the nine months ended September 30, 2023 and 2022 was $6.5 million. The Company also receives Connect America Fund \u2013 Intercarrier Compensation (\u201cCAF-ICC\u201d) funding which is included in Revenues in the\n Condensed Consolidated Statement of Income at an amount of $0.3 million for each of the three months ended September 30, 2023 and\n 2022. CAF-ICC revenues for the nine months ended September 30, 2023 and 2022 were $0.9 million and $0.8 million, respectively.", "entities": [ { "start_character": 735, "end_character": 738, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 900000.0 }, { "start_character": 752, "end_character": 755, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001952073-24-000015", "filing_date": 1715270556000, "quarter_ending": "20240331", "company_name": "Madison Square Garden Entertainment Corp.", "text": ", weighted-average shares used in the calculation for diluted earnings per share (\u201cEPS\u201d) consisted of 48,447 and 48,883 shares of Class A Common Stock for basic EPS, respectively, and the dilutive effect of 338 and 208 shares of Class A Common Stock issuable, respectively, under share-based compensation plans. For the three and nine months ended ", "entities": [ { "start_character": 207, "end_character": 210, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 338.0 }, { "start_character": 215, "end_character": 218, "label": "eps", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 208.0 } ] }, { "form_type": "10-K", "accession_number": "0001412100-24-000014", "filing_date": 1710259628000, "quarter_ending": "20231231", "company_name": "Maiden Holdings, Ltd.", "text": "During the year ended December 31, 2023, net premiums earned from AmTrust accounted for $14,930 or 34.0% of total net premiums earned (2022 \u2013\u00a0$9,749 or 25.8%). ", "entities": [ { "start_character": 89, "end_character": 95, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 14930000.0 }, { "start_character": 143, "end_character": 148, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9749000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001567892-24-000017", "filing_date": 1715237250000, "quarter_ending": "20240329", "company_name": "Mallinckrodt plc", "text": "The Company recognized an income tax benefit of $30.8 million on a loss from continuing operations before income taxes of $280.1 million for the three months ended March\u00a031, 2023 (Predecessor). This resulted in an effective tax rate of 11.0%. The effective tax rate is lower than the Irish statutory tax rate of 12.5% primarily due to the impact of valuation allowances recorded for current year interest limitations, permanent non-deductible tax items, and the mix of pretax earnings in various jurisdictions. ", "entities": [ { "start_character": 123, "end_character": 128, "label": "earnings", "start_date_for_period": "2022-12-31", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -280100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001567892-24-000017", "filing_date": 1715237250000, "quarter_ending": "20240329", "company_name": "Mallinckrodt plc", "text": "The Company recognized an income tax benefit of $0.7\u00a0million on a loss from continuing operations before income taxes of $66.3 million for the three months ended March\u00a029, 2024 (Successor). This resulted in an effective tax rate of 1.1%. The effective tax rate is lower than the Irish statutory tax rate of 12.5% primarily due to the impact of valuation allowances recorded for current year interest limitations, the mix of pretax earnings in various jurisdictions, and remaining effects of adoption of fresh-start accounting as a result of emergence from the 2023 Bankruptcy Proceedings.", "entities": [ { "start_character": 122, "end_character": 126, "label": "earnings", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": -66300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007663", "filing_date": 1709140351000, "quarter_ending": "20231231", "company_name": "Marqeta, Inc.", "text": "The Company had an equity method investment in a private company, which was a related party up until the investment was sold in October 2022. During the years ended December\u00a031, 2022 and 2021, the Company earned net revenue of $2.7 million and $2.8\u00a0million from the private company, respectively. ", "entities": [ { "start_character": 228, "end_character": 231, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2700000.0 }, { "start_character": 245, "end_character": 248, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007663", "filing_date": 1709140351000, "quarter_ending": "20231231", "company_name": "Marqeta, Inc.", "text": "The Company has incurred net losses since its inception. For the year ended December\u00a031, 2023, the Company incurred a net loss of $223.0\u00a0million and had an accumulated deficit of $825.2\u00a0million as of December\u00a031, 2023. The Company expects losses from operations to continue for the foreseeable future as it incurs costs and expenses related to creating new products for customers, acquiring new customers, developing its brand, expanding into new geographies and developing the existing platform infrastructure. The Company believes that its cash and cash equivalents of $981.0 million and short-term investments of $268.7 million as of December\u00a031, 2023 are sufficient to fund its operations through at least the next twelve months from the issuance of these financial statements.", "entities": [ { "start_character": 131, "end_character": 136, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -223000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021181", "filing_date": 1715101918000, "quarter_ending": "20240331", "company_name": "Marqeta, Inc.", "text": "The Company has incurred net losses since its inception. For the three months ended March 31, 2024, the Company incurred net losses of $36.1\u00a0million and had an accumulated deficit of $861.3\u00a0million as of March\u00a031, 2024. The Company expects to incur net losses from operations for the foreseeable future as it incurs costs and expenses related to creating new products for customers, acquiring new customers, developing its brand, expanding into new geographies and developing the existing platform infrastructure. The Company believes that its cash and cash equivalents of $970.4 million and short-term investments of $228.3 million as of March\u00a031, 2024 are sufficient to fund its operations through at least the next twelve months from the issuance of these financial statements.", "entities": [ { "start_character": 136, "end_character": 140, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -36100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006611", "filing_date": 1707926753000, "quarter_ending": "20231231", "company_name": "Marygold Companies, Inc.", "text": "The\nFunds managed by USCF and USCF Advisers are deemed by management to be related parties. The Company\u2019s USCF Investments\nrevenues earned from related parties were $5.0 ", "entities": [ { "start_character": 166, "end_character": 169, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018895", "filing_date": 1715617304000, "quarter_ending": "20240331", "company_name": "Marygold Companies, Inc.", "text": "The\nFunds managed by USCF and USCF Advisers are deemed by management to be related parties. The Company\u2019s USCF Investments revenues\nearned from related parties were $4.4 million and $5.0 million for the three months ended March 31, 2024 and 2023, respectively, and\n$14.5 million and $15.7 million for the nine months ended March 31, 2024 and 2023, respectively. Accounts receivable due from related\nparties were $1.5 million and $1.7 million as of March 31, 2024 and June 30, 2023, respectively. USCF Investments, from time to time,\nprovides initial investments in the creation of ETP and ETF funds that USCF Advisers manages. Such investments included USG, ZSB, USE\nand ZSC, related party funds managed by USCF Advisers, and as of March 31, 2024 the investments totaled $1.3 million, $0.4 million, $3.2\nmillion and $2.3 million, respectively. As of June 30, 2023 the investments totaled $1.3 million, $1.9 million, $2.6 million and $0,\nrespectively. The Company owns 62% and 68% of the outstanding shares of these investments as of March 31, 2024 and June 30, 2023, respectively.", "entities": [ { "start_character": 166, "end_character": 169, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4400000.0 }, { "start_character": 183, "end_character": 186, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 }, { "start_character": 266, "end_character": 270, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 14500000.0 }, { "start_character": 284, "end_character": 288, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 15700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011493", "filing_date": 1711555322000, "quarter_ending": "20231231", "company_name": "Matinas BioPharma Holdings, Inc.", "text": "The\nCompany has experienced net losses and negative cash flows from operations each period since its inception. Through December 31, 2023,\nthe Company had an accumulated deficit of $175,573. The Company\u2019s net loss for the years ended December 31, 2023 and 2022 was $22,942\nand $20,997, respectively.", "entities": [ { "start_character": 266, "end_character": 272, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -22942000.0 }, { "start_character": 278, "end_character": 284, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -20997000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018417", "filing_date": 1715270512000, "quarter_ending": "20240331", "company_name": "Matinas BioPharma Holdings, Inc.", "text": "The\nCompany has experienced net losses and negative cash flows from operations each period since its inception. Through March 31, 2024, the\nCompany had an accumulated deficit of $181,397. The Company\u2019s net loss was $5,824 for the three months ended March 31, 2024.", "entities": [ { "start_character": 216, "end_character": 221, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -5824000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-006850", "filing_date": 1708963615000, "quarter_ending": "20231231", "company_name": "Merck & Co., Inc.", "text": "The amounts included in the consolidated statement of income for the above MSAs include sales of $394\u00a0million, $383\u00a0million and $219\u00a0million in 2023, 2022 and 2021, respectively, and related cost of sales of $422\u00a0million, $404\u00a0million and $195\u00a0million in 2023, 2022 and 2021, respectively. Amounts included in the consolidated statement of income for the TSAs were immaterial in 2023, 2022 and 2021. The amounts due from Organon under all of the above agreements were $632\u00a0million and $511\u00a0million at December\u00a031, 2023 and 2022, respectively, and are reflected in ", "entities": [ { "start_character": 98, "end_character": 101, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 394000000.0 }, { "start_character": 112, "end_character": 115, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 383000000.0 }, { "start_character": 129, "end_character": 132, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 219000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020283", "filing_date": 1714752643000, "quarter_ending": "20240331", "company_name": "Merck & Co., Inc.", "text": "In connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of March\u00a031, 2024, only one jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $107\u00a0million and $94\u00a0million and related cost of sales of $110\u00a0million and $107\u00a0million for the first quarter of 2024 and 2023, respectively. The amounts due from Organon for all spin-off related agreements were $462\u00a0million and $632\u00a0million at March\u00a031, 2024 and December\u00a031, 2023, respectively, and are reflected in ", "entities": [ { "start_character": 927, "end_character": 930, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 107000000.0 }, { "start_character": 944, "end_character": 946, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 94000000.0 }, { "start_character": 1002, "end_character": 1005, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 107000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007407", "filing_date": 1709110140000, "quarter_ending": "20231231", "company_name": "Mersana Therapeutics, Inc.", "text": "The Company has incurred cumulative net losses since inception. The Company\u2019s net loss was $171.7 million, $204.2 million and $170.1 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively. The Company expects to continue to incur operating losses for at least the next several years.\u00a0As of December\u00a031, 2023, the Company had an accumulated deficit of $826.4 million. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company\u2019s stockholders\u2019 equity and working capital.", "entities": [ { "start_character": 92, "end_character": 97, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -171700000.0 }, { "start_character": 108, "end_character": 113, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -204200000.0 }, { "start_character": 127, "end_character": 132, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -170100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021985", "filing_date": 1715245209000, "quarter_ending": "20240331", "company_name": "Mersana Therapeutics, Inc.", "text": "The Company has incurred cumulative net losses since inception. For the three months ended March\u00a031, 2024, the net loss was $19.3 million, compared to $56.2 million in the three months ended March\u00a031, 2023. The Company expects to continue to incur operating losses for at least the next several years. As of March\u00a031, 2024, the Company had an accumulated deficit of $845.7 million. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company\u2019s stockholders\u2019 equity and working capital.", "entities": [ { "start_character": 125, "end_character": 129, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -19300000.0 }, { "start_character": 152, "end_character": 156, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -56200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001760689-24-000007", "filing_date": 1711991798000, "quarter_ending": "20231231", "company_name": "Microvast Holdings, Inc.", "text": "For the years ended December\u00a031, 2023, 2022 and 2021, the Group generated revenues of $306,617, $204,495 and $151,976, gross profit /(loss) of $57,227, $9,073 and $(42,743), and incurred net losses of $106,412, $158,200 and $206,483, respectively.", "entities": [ { "start_character": 87, "end_character": 94, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 306617000.0 }, { "start_character": 97, "end_character": 104, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 204495000.0 }, { "start_character": 110, "end_character": 117, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 151976000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001760689-24-000016", "filing_date": 1715274474000, "quarter_ending": "20240331", "company_name": "Microvast Holdings, Inc.", "text": "For the three months ended March\u00a031, 2023 and 2024, the Group generated revenues of $46,973 and $81,351, gross profit of $4,858 and $17,225, respectively.", "entities": [ { "start_character": 85, "end_character": 91, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 46973000.0 }, { "start_character": 97, "end_character": 103, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 81351000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-012358", "filing_date": 1711005288000, "quarter_ending": "20231231", "company_name": "Mineralys Therapeutics, Inc.", "text": "Since its inception, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations. The Company\u2019s primary uses of cash to date have been to fund research and development activities, business planning, establishing and maintaining the Company\u2019s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. As of December\u00a031, 2023, the Company had an accumulated deficit of $124.7\u00a0million and cash, cash equivalents, and investments of $239.0 million. For the year ended December\u00a031, 2023, the Company had a net loss of $71.9\u00a0million and net cash used in operating activities of $81.2\u00a0million.", "entities": [ { "start_character": 699, "end_character": 703, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -71900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001933414-24-000016", "filing_date": 1715238605000, "quarter_ending": "20240331", "company_name": "Mineralys Therapeutics, Inc.", "text": "Since its inception, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations. The Company\u2019s primary uses of cash to date have been to fund research and development activities, business planning, establishing and maintaining the Company\u2019s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. As of March\u00a031, 2024, the Company had an accumulated deficit of $156.2\u00a0million and cash, cash equivalents, and investments of $338.6 million. For the three months ended March\u00a031, 2024, the Company had a net loss of $31.5\u00a0million and net cash used in operating activities of $19.1\u00a0million.", "entities": [ { "start_character": 701, "end_character": 705, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -31500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001436126-24-000025", "filing_date": 1710175252000, "quarter_ending": "20231231", "company_name": "Mistras Group, Inc.", "text": "The Company became the primary beneficiary in July 2020 of a VIE in which the Company has a 49% interest in a limited partnership, and a 49% stockholder in the corporate general partner of the limited partnership. The Company consolidated the financial statements of the VIE with the financial statements of the Company. As of and for the year ended December\u00a031, 2023, the VIE had immaterial assets and had approximately $3.0\u00a0million of revenue. The Company is the primary sub-contractor of the VIE.", "entities": [ { "start_character": 422, "end_character": 425, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001645873-24-000030", "filing_date": 1709827310000, "quarter_ending": "20231231", "company_name": "Modiv Industrial, Inc.", "text": "During the first quarter of 2023, management determined that its prior treatment of property taxes in those instances where the Company was responsible for paying property taxes and subsequently seeking tenant reimbursement should be treated differently than those instances where property taxes were paid directly by tenants to taxing authorities. Management determined that property taxes paid directly by tenants to taxing authorities should not have been recorded in the Company\u2019s accompanying consolidated statements of operations for the prior year periods in accordance with ASU 2018-20 \u201cLeases (Topic 842) - Narrow-Scope Improvements for Lessors.\u201d Accordingly, the Company\u2019s accompanying consolidated statement of operations for the year ended December\u00a031, 2022 reflects an adjustment to reduce rental income and a corresponding reduction in property expenses of $2,352,235 for such property taxes and the Company's consolidated balance sheet as of December\u00a031, 2022 reflects a reduction in tenant receivables with a corresponding reduction in accounts payable, accrued and other liabilities of $1,596,127. The corrections did not affect net loss, net loss per share or equity for the year ended December\u00a031, 2022 in the accompanying consolidated statement of operations.", "entities": [ { "start_character": 872, "end_character": 881, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2352235.0 } ] }, { "form_type": "10-K", "accession_number": "0001220754-24-000014", "filing_date": 1708717418000, "quarter_ending": "20231231", "company_name": "ModivCare Inc", "text": "The Company's gross share of Matrix's operations for the years ended December\u00a031, 2023, 2022 and 2021 was a loss of $1.1 million, $41.0 million and $53.1 million, respectively, which is presented net of tax on the consolidated statements of operations for a loss of $0.8 million, $30.0 million and $38.3 million, respectively.", "entities": [ { "start_character": 117, "end_character": 120, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1100000.0 }, { "start_character": 131, "end_character": 135, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -41000000.0 }, { "start_character": 149, "end_character": 153, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -53100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001220754-24-000035", "filing_date": 1714674711000, "quarter_ending": "20240331", "company_name": "ModivCare Inc", "text": "The Company's gross share of its Matrix's operations for the three months ended March 31, 2024 and March 31, 2023 was a loss of $1.0 million and income of $1.9\u00a0million, respectively, which is presented net of tax on the unaudited condensed consolidated statements of operations for a loss of $0.7 million and income of $1.4 million, respectively.", "entities": [ { "start_character": 129, "end_character": 132, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1000000.0 }, { "start_character": 156, "end_character": 159, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-026929", "filing_date": 1717614208000, "quarter_ending": "20231231", "company_name": "Momentus Inc.", "text": "The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company\u2019s ability to continue as a going concern is dependent on the Company\u2019s ability to successfully raise capital to fund its business operations and execute on its business plan. To date the Company remains heavily focused on growth and continued development of its proprietary technology, and as a result, it has not generated sufficient revenues to provide cash flows that enable the Company to finance its operations internally and the Company\u2019s financial position and operating results raise substantial doubt about the Company\u2019s ability to continue as a going concern. This is reflected by the Company\u2019s incurred a net loss of $68.9 million for the year ended December\u00a031, 2023, and accumulated deficit of $373.0 million as of December\u00a031, 2023. Additionally, the Company used net cash of $61.8 million to fund its ", "entities": [ { "start_character": 1058, "end_character": 1062, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -68900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001289419-24-000028", "filing_date": 1714134897000, "quarter_ending": "20240331", "company_name": "Morningstar, Inc.", "text": "(1) Corporate and All Other provides a reconciliation between revenue from our Total Reportable Segments and consolidated revenue amounts. Corporate and All Other includes Morningstar Sustainalytics and Morningstar Indexes as sources of revenues. Revenue from Morningstar Sustainalytics was $30.8 million and $27.3 million for the three months ended March\u00a031, 2024 and 2023, respectively. Revenue from Morningstar Indexes was $20.0 million and $14.6 million for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 292, "end_character": 296, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 30800000.0 }, { "start_character": 310, "end_character": 314, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 27300000.0 }, { "start_character": 427, "end_character": 431, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 20000000.0 }, { "start_character": 445, "end_character": 449, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 14600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010314", "filing_date": 1710778267000, "quarter_ending": "20231231", "company_name": "Motus GI Holdings, Inc.", "text": "We\nhave generated limited revenues to date from the sale of products. We have never been profitable and have incurred significant net losses\neach year since our inception, including a loss of $12.9 million for the year ended December 31, 2023, and we expect to continue to incur\nnet operating losses for the foreseeable future. As of December 31, 2023, we had $5.0 million in cash and cash equivalents and an accumulated\ndeficit of $154.2 million. We expect our current spend level to continue in connection with ongoing operating activities, including expenditures\nin R&D, sales and marketing, clinical affairs and manufacturing. In order to continue to operate as a standalone company, we will\nneed additional financing to support our continuing operations. We also have significant debt under our Loan Agreement with Kreos which\ncould negatively impact our ability to operate or consummate a strategic transaction.", "entities": [ { "start_character": 193, "end_character": 197, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -12900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010314", "filing_date": 1710778267000, "quarter_ending": "20231231", "company_name": "Motus GI Holdings, Inc.", "text": "During\nthe year ended December 31, 2023, the Company recognized revenue of $319, which consisted of $295 in accordance with ASC 606 and $24\nin accordance with ASC 842. During the year ended December 31, 2022, the Company recognized revenue of $592, which consisted of $540\nin accordance with ASC 606 and $52 in accordance with ASC 842.", "entities": [ { "start_character": 76, "end_character": 79, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 319000.0 }, { "start_character": 244, "end_character": 247, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 592000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010314", "filing_date": 1710778267000, "quarter_ending": "20231231", "company_name": "Motus GI Holdings, Inc.", "text": "During\nthe year ended December 31, 2023, the Company recognized revenue at a point in time of $281\nand recognized revenue over time of $38.\nDuring the year ended December 31, 2022, the Company recognized revenue at a point in time of $529\nand recognized revenue over time of $63.\nDeferred revenue was $67\nand $39 as of December\n31, 2023 and 2022, respectively.", "entities": [ { "start_character": 95, "end_character": 98, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 281000.0 }, { "start_character": 136, "end_character": 138, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 38000.0 }, { "start_character": 235, "end_character": 238, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 529000.0 }, { "start_character": 276, "end_character": 278, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 63000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019257", "filing_date": 1715703785000, "quarter_ending": "20240331", "company_name": "Motus GI Holdings, Inc.", "text": "The\nCompany has generated limited revenues to date from the sale of products. The Company has never been profitable and has incurred significant\nnet losses each year since its inception, including a loss of $2.1 million for the three months ended March 31, 2024. The Company expects\nto continue to incur net operating losses for the foreseeable future. Net cash used in operating activities for the three months ended\nMarch 31, 2024 was $2.0 million. As of March 31, 2024, the Company had cash and cash equivalents of $4.9 million and an accumulated deficit\nof $156.3 million.", "entities": [ { "start_character": 208, "end_character": 211, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001793229-24-000012", "filing_date": 1709190178000, "quarter_ending": "20231231", "company_name": "MultiPlan Corp", "text": "The following represents pro forma effects of the BST acquisition as if it had occurred on January 1, 2022. The pro forma net loss includes: (1) an increase in amortization of intangible assets of $3.0\u00a0million related to added amortization expense associated with intangible assets acquired in the acquisition; and (2) the addition of $11.3\u00a0million of transaction costs incurred, together with the income tax effects on (1) through (2). These pro forma results are not necessarily indicative of the results that would have occurred if the acquisition occurred on the first day of the period presented, nor does the pro forma financial information purport to present the results of operations for future periods. The following information for the year ended December 31, 2022 is presented in thousands:", "entities": [ { "start_character": 198, "end_character": 201, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2023-05-08", "currency_/_unit": "iso4217:USD", "value": -3000000.0 }, { "start_character": 336, "end_character": 340, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2023-05-08", "currency_/_unit": "iso4217:USD", "value": -11300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001999371-24-005984", "filing_date": 1715617796000, "quarter_ending": "20240331", "company_name": "NANOPHASE TECHNOLOGIES Corp", "text": "Revenue\nfrom international sources approximated $288 and $1,435 for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 49, "end_character": 52, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 288000.0 }, { "start_character": 58, "end_character": 63, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1435000.0 } ] }, { "form_type": "10-K", "accession_number": "0001120193-24-000006", "filing_date": 1708534981000, "quarter_ending": "20231231", "company_name": "NASDAQ, INC.", "text": "From the date of acquisition through December 31, 2023, Adenza revenues of $149 million were included in Financial Technology revenues in the Consolidated Statement of Income and Adenza operating income of $55 million was included in our operating income in the Consolidated Statement of Income", "entities": [ { "start_character": 207, "end_character": 209, "label": "ebit", "start_date_for_period": "2023-11-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 55000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001258602-24-000039", "filing_date": 1715271525000, "quarter_ending": "20240331", "company_name": "NELNET INC", "text": "The Company accounts for its solar investments using the HLBV method of accounting. For the majority of the Company\u2019s solar investments, the HLBV method of accounting results in accelerated losses in the initial years of investment. The Company recognized net gains of $3.0 million and net losses of $1.9 million on its solar investments during the three months ended March 31, 2024 and 2023, respectively. These amounts, which include net losses attributable to third-party noncontrolling interest investors (syndication partners), are included in \u201cother, net\u201d in \"other income (expense)\" on the consolidated statements of income. Solar net losses attributed to noncontrolling interest investors was $1.2 million and $2.7 million for the three months ended March 31, 2024 and 2023, respectively, and is reflected in \u201cnet loss attributable to noncontrolling interests\u201d in the consolidated statements of income. Excluding net losses attributed to noncontrolling interest investors, the Company recognized net gains on its solar investments of $4.2 million and $0.8 million during the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 1043, "end_character": 1046, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4200000.0 }, { "start_character": 1060, "end_character": 1063, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001065280-24-000128", "filing_date": 1713801713000, "quarter_ending": "20240331", "company_name": "NETFLIX INC", "text": "Total U.S. revenues were $3.9 billion and $3.3\u00a0billion for the three months ended March\u00a031, 2024 and 2023, respectively. See Note 2 ", "entities": [ { "start_character": 26, "end_character": 29, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3900000000.0 }, { "start_character": 43, "end_character": 46, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3300000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001072613-24-000334", "filing_date": 1709916434000, "quarter_ending": "20231231", "company_name": "NETWORK-1 TECHNOLOGIES, INC.", "text": "The\nCompany performed an assessment to determine significance of its equity investee using the investment, asset and income tests. The Company\nconcluded the income test threshold was met for the year ended December 31, 2023. The following table provides certain summarized financial\ninformation for the Company\u2019s equity method investee for the periods presented and has been compiled from the equity investee\u2019s\nfinancial statement, reported on one quarter lag. As a result of the Company receiving audited financial statements from ILiAD for its\nyear ended December 31, 2022 (See Note B[2] hereof), the table below includes an additional comprehensive loss of $621,000. For the year\nended December 31, 2023, with respect to such additional comprehensive loss of ILiAD, the Company recorded an additional allocated net\nloss of $42,000.", "entities": [ { "start_character": 827, "end_character": 833, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 42000.0 } ] }, { "form_type": "10-K", "accession_number": "0001273685-24-000033", "filing_date": 1708707578000, "quarter_ending": "20231231", "company_name": "NEW YORK MORTGAGE TRUST INC", "text": "During the year ended December\u00a031, 2023, five of the joint ventures in which the Company held a common equity investment sold their multi-family apartment communities for approximately $219.2 million, subject to certain prorations and adjustments typical in such real estate transactions, and repaid the related mortgages payable in the amount of approximately $173.6 million. The sales generated net gains of approximately $6.0 million and losses on extinguishment of debt of approximately $2.0 million, both of which are primarily included in other income on the accompanying consolidated statements of operations. The sales also generated net income attributable to non-controlling interest of approximately $2.2 million, resulting in net gains attributable to the Company's common shareholders of approximately $1.7 million.", "entities": [ { "start_character": 817, "end_character": 820, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001273685-24-000053", "filing_date": 1714755450000, "quarter_ending": "20240331", "company_name": "NEW YORK MORTGAGE TRUST INC", "text": "In March 2023, the Board of Directors approved a $100.0 million preferred stock repurchase program. The program, which expires March\u00a031, 2025, allows the Company to make repurchases of shares of Preferred Stock, from time to time, in open market transactions, through privately negotiated transactions or block trades or other means, in accordance with applicable securities laws and the rules and regulations of Nasdaq. The Company did not repurchase any shares of its preferred stock during the three months ended March 31, 2024. During the three months ended March 31, 2023, the Company repurchased 19,177 shares of Series G Preferred Stock pursuant to the preferred stock repurchase program for a total cost of approximately $0.3 million, including fees and commissions paid to the broker, representing an average repurchase price of $16.64 per preferred share. The difference between the consideration transferred and the carrying value of the preferred stock resulted in a gain attributable to common stockholders of approximately $0.1 million during the three months ended March 31, 2023. As of March\u00a031, 2024, $97.6 million of the approved amount remained available for the repurchase of shares of Preferred Stock under the preferred stock repurchase program. ", "entities": [ { "start_character": 1039, "end_character": 1042, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001564708-24-000249", "filing_date": 1715237973000, "quarter_ending": "20240331", "company_name": "NEWS CORP", "text": "For the three months ended March 31, 2024, the Company recorded income tax expense\u00a0of $22 million on\u00a0pre-tax\u00a0income of $64 million, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The tax rate was impacted by foreign operations which are subject to higher tax rates and by valuation allowances recorded against tax benefits in certain businesses.", "entities": [ { "start_character": 120, "end_character": 122, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 64000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001564708-24-000249", "filing_date": 1715237973000, "quarter_ending": "20240331", "company_name": "NEWS CORP", "text": "For the nine months ended March\u00a031, 2024, the Company recorded income tax expense\u00a0of $153 million on\u00a0pre-tax\u00a0income of $436 million, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The tax rate was impacted by foreign operations which are subject to higher tax rates and by valuation allowances recorded against tax benefits in certain businesses.", "entities": [ { "start_character": 120, "end_character": 123, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 436000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001564708-24-000249", "filing_date": 1715237973000, "quarter_ending": "20240331", "company_name": "NEWS CORP", "text": "For the three months ended March 31, 2023, the Company recorded income tax expense of $32 million on pre-tax\u00a0income of $91 million, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The tax rate was impacted by foreign operations which are subject to higher tax rates and by valuation allowances recorded against tax benefits in certain businesses.", "entities": [ { "start_character": 120, "end_character": 122, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 91000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001564708-24-000249", "filing_date": 1715237973000, "quarter_ending": "20240331", "company_name": "NEWS CORP", "text": "For the nine months ended March\u00a031, 2023, the Company recorded income tax expense of $128 million on pre-tax\u00a0income of $347 million, resulting in an effective tax rate that was higher than the U.S. statutory tax rate. The tax rate was impacted by foreign operations which are subject to higher tax rates and by valuation allowances recorded against tax benefits in certain businesses.", "entities": [ { "start_character": 120, "end_character": 123, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 347000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018950", "filing_date": 1715620160000, "quarter_ending": "20240331", "company_name": "NEXGEL, INC.", "text": "As\nof March 31, 2024, the Company had a cash balance of $2.4 million. For the three months ended March 31, 2024, the Company incurred a\nnet loss of\u2009$0.9 million and had a net usage of cash in operating activities of $1.1 million. In addition, the Company had a working\ncapital of $2.4 million as of March 31, 2024. Additionally, we believe we have sufficient cash and marketable securities to operate our\nbusiness plan into 2025.", "entities": [ { "start_character": 149, "end_character": 152, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001356115-24-000007", "filing_date": 1710351294000, "quarter_ending": "20231231", "company_name": "NEXPOINT DIVERSIFIED REAL ESTATE TRUST", "text": "As a REIT for U.S. federal income tax purposes, the Company may deduct earnings distributed to stockholders against the income generated by our REIT operations. The Company continues to be subject to income taxes on the income of its taxable REIT subsidiaries. Our consolidated net loss before income taxes was $114.5\u00a0million and $71.6\u00a0million for the year ended December\u00a031, 2023 and the six months ended December 31, 2022, respectively. The Company\u2019s consolidated balance sheet as of December\u00a031, 2023 consists of a $4.5\u00a0million net deferred tax asset at NHF TRS, LLC and a $1.6\u00a0million net deferred tax liability at NREO TRS, Inc. for a consolidated net Deferred Tax asset of $2.9\u00a0million. The Company's consolidated balance sheet as of December 31, 2022 consisted of a $3.4\u00a0million net deferred tax asset at NHF TRS, LLC and a $1.2\u00a0million net deferred tax liability at NREO TRS, Inc. for a consolidated net Deferred Tax asset of $2.2\u00a0million.", "entities": [ { "start_character": 312, "end_character": 317, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -114500000.0 }, { "start_character": 331, "end_character": 335, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -71600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001356115-24-000012", "filing_date": 1715360164000, "quarter_ending": "20240331", "company_name": "NEXPOINT DIVERSIFIED REAL ESTATE TRUST", "text": "As a REIT for U.S. federal income tax purposes, the Company may deduct earnings distributed to shareholders against the income generated by our REIT operations. The Company continues to be subject to income taxes on the income of its taxable REIT subsidiaries. Our consolidated net loss before income taxes was $21.0 million and $18.7 million for the three months ended March\u00a031, 2024 and 2023, respectively. The Company\u2019s consolidated balance sheet as of March\u00a031, 2024 consists of a $4.5\u00a0million net deferred tax asset at NHF TRS, LLC and a $1.6\u00a0million net deferred tax liability at NREO TRS, Inc. for a consolidated net Deferred Tax asset of $2.9\u00a0million. The Company's consolidated balance sheet as of December 31, 2023 consisted of a $4.5\u00a0million net deferred tax asset at NHF TRS, LLC and a $1.6\u00a0million net deferred tax liability at NREO TRS, Inc. for a consolidated net Deferred Tax asset of $2.9\u00a0million.", "entities": [ { "start_character": 312, "end_character": 316, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -21000000.0 }, { "start_character": 330, "end_character": 334, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -18700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001603145-24-000005", "filing_date": 1708465509000, "quarter_ending": "20231231", "company_name": "NEXTERA ENERGY PARTNERS, LP", "text": "(a)\u00a0\u00a0\u00a0\u00a0Represents service revenues earned under gas transportation agreements. Includes related party revenues of approximately $32\u00a0million, $23\u00a0million and $40\u00a0million for 2023, 2022 and 2021, respectively. Includes revenues attributable to foreign countries related to NEP's contract with a Mexican counterparty of approximately $144\u00a0million, $155\u00a0million and $141\u00a0million for 2023, 2022 and 2021, respectively. ", "entities": [ { "start_character": 129, "end_character": 131, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 32000000.0 }, { "start_character": 142, "end_character": 144, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 23000000.0 }, { "start_character": 158, "end_character": 160, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 40000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001603145-24-000010", "filing_date": 1713891416000, "quarter_ending": "20240331", "company_name": "NEXTERA ENERGY PARTNERS, LP", "text": "In connection with the Texas pipelines (see Note 2), a subsidiary of NEP assigned to a subsidiary of NEER certain gas commodity agreements in exchange for entering into transportation agreements and a fuel management agreement whereby the benefits of the gas commodity agreements (net of transportation paid to the NEP subsidiary) were passed back to the NEP subsidiary. During the three months ended March 31, 2023, NEP recognized approximately $2 million in revenues related to the transportation and fuel management agreements which are reflected in income from discontinued operations on the condensed consolidated statements of income. ", "entities": [ { "start_character": 49, "end_character": 50, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001603145-24-000010", "filing_date": 1713891416000, "quarter_ending": "20240331", "company_name": "NEXTERA ENERGY PARTNERS, LP", "text": "(a)\u00a0\u00a0\u00a0\u00a0Represents service revenues earned under gas transportation agreements. Includes related party revenues of approximately $7\u00a0million.", "entities": [ { "start_character": 129, "end_character": 130, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-022183", "filing_date": 1710347406000, "quarter_ending": "20231231", "company_name": "NEXTNAV INC.", "text": "During the years ended December 31, 2023 and 2022, the Company incurred net losses of $71.7 million and $40.1 million, respectively. During the years ended December 31, 2023 and 2022, net cash used in operating activities was $35.4 million and $37.1 million, respectively. As of December 31, 2023, cash and cash equivalents and marketable securities was $85.8 million.\u00a0The Company\u2019s primary use of cash is to fund operations as NextNav continues to grow. The Company expects to incur additional losses and higher operating expenses for the foreseeable future, specifically as NextNav invests in ongoing research and development and the expansion of the TerraPoiNT network.", "entities": [ { "start_character": 87, "end_character": 91, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -71700000.0 }, { "start_character": 105, "end_character": 109, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -40100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-040871", "filing_date": 1715184727000, "quarter_ending": "20240331", "company_name": "NEXTNAV INC.", "text": "Since its inception, NextNav has incurred recurring\nlosses and generated negative cash flows from operations and has primarily\nrelied upon debt and equity financings to fund its cash requirements.\u00a0During the three\u00a0months ended March 31, 2024 and 2023, the Company incurred net losses of $31.6\u00a0million and $16.3\u00a0million, respectively. During the three\u00a0months\u00a0ended March 31, 2024 and\u00a02023, net cash used in operating activities was $7.0\u00a0million and $7.4 million, respectively. As of March 31, 2024, cash and cash equivalents and marketable securities was $79.2\u00a0million.\u00a0 The Company\u2019s primary use of cash is to fund\noperations as NextNav continues to grow. The Company expects to incur\nadditional losses and higher operating expenses for the foreseeable future,\nspecifically as NextNav invests in ongoing research and development and our PNT networks. ", "entities": [ { "start_character": 288, "end_character": 292, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -31600000.0 }, { "start_character": 306, "end_character": 310, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -16300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-040871", "filing_date": 1715184727000, "quarter_ending": "20240331", "company_name": "NEXTNAV INC.", "text": "Since its inception, NextNav has incurred recurring\nlosses and generated negative cash flows from operations and has primarily\nrelied upon debt and equity financings to fund its cash requirements.\u00a0During the three\u00a0months ended March 31, 2024 and 2023, the Company incurred net losses of $31.6\u00a0million and $16.3\u00a0million, respectively. During the three\u00a0months\u00a0ended March 31, 2024 and\u00a02023, net cash used in operating activities was $7.0\u00a0million and $7.4 million, respectively. As of March 31, 2024, cash and cash equivalents and marketable securities was $79.2\u00a0million.\u00a0 The Company\u2019s primary use of cash is to fund\noperations as NextNav continues to grow. The Company expects to incur\nadditional losses and higher operating expenses for the foreseeable future,\nspecifically as NextNav invests in ongoing research and development and our PNT networks. ", "entities": [ { "start_character": 288, "end_character": 292, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -31600000.0 }, { "start_character": 306, "end_character": 310, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -16300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-040871", "filing_date": 1715184727000, "quarter_ending": "20240331", "company_name": "NEXTNAV INC.", "text": "During the three\u00a0months ended March 31, 2024 and 2023, the Company incurred net losses of $31.6\u00a0million and $16.3\u00a0million, respectively. During the three\u00a0months\u00a0ended March 31, 2024 and\u00a02023, net cash used in operating activities was $7.0\u00a0million and $7.4 million, respectively. As of March 31, 2024, cash and cash equivalents and marketable securities was $79.2\u00a0million.\u00a0 The Company\u2019s primary use of cash is to fund\noperations as NextNav continues to grow. The Company expects to incur\nadditional losses and higher operating expenses for the foreseeable future,\nspecifically as NextNav invests in ongoing research and development and our PNT networks. ", "entities": [ { "start_character": 91, "end_character": 95, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -31600000.0 }, { "start_character": 109, "end_character": 113, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -16300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-040871", "filing_date": 1715184727000, "quarter_ending": "20240331", "company_name": "NEXTNAV INC.", "text": "The Company computes its year-to-date provision for income taxes by applying the estimated annual effective tax rate to year-to-date pretax income or loss and adjusts the provision for discrete tax items recorded in the period. A valuation allowance has been established against the Company\u2019s U.S. federal and state deferred tax assets, which results in an annualized effective tax rate for the Company\u2019s U.S. operations of 0.0%.\u00a0During Q2 of 2023 a valuation allowance was established against the\u00a0Company\u2019s French deferred tax asset.\u00a0For the three months ended March 31, 2024, the Company recorded an income tax provision of $44\u00a0thousand related to foreign tax activity in India on a pretax loss of $31.6 million, resulting in an effective tax rate of (0.14)%.\u00a0For the\u00a0three months ended March 31, 2023, the Company recorded an income tax benefit of $13\u00a0thousand related to foreign tax activity on a pretax loss of $16.4\u00a0million, resulting in an effective tax rate of 0.08%. These effective tax rates differ from the U.S. federal statutory rate primarily due to the valuation allowance against the Company\u2019s domestic and French deferred tax assets.", "entities": [ { "start_character": 701, "end_character": 705, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -31600000.0 }, { "start_character": 917, "end_character": 921, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -16399999.999999998 } ] }, { "form_type": "10-K", "accession_number": "0001504461-24-000013", "filing_date": 1717691157000, "quarter_ending": "20240331", "company_name": "NGL Energy Partners LP", "text": "Our lessor arrangements include storage and railcar contracts, of which certain agreements contain renewal options for periods of between one year and five years. We determine if an agreement contains a lease at the inception of the arrangement. If an arrangement is determined to contain a lease, we classify the lease as operating, sales-type or direct financing. Lessor accounting under ASC 842 is substantially unchanged and all of our leases will continue to be classified as operating leases. We also, from time to time, sublease certain of our storage capacity and railcars to third-parties. Fixed rental revenue is recognized on a straight-line basis over the lease term. During the years ended March\u00a031, 2024, 2023 and 2022, fixed rental revenue was $17.8 million, $13.9 million and $14.4\u00a0million, which includes $6.2 million, $3.8 million and $1.4\u00a0million of sublease revenue, respectively.", "entities": [ { "start_character": 760, "end_character": 764, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 17800000.0 }, { "start_character": 775, "end_character": 779, "label": "revenues", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 13900000.0 }, { "start_character": 793, "end_character": 797, "label": "revenues", "start_date_for_period": "2021-04-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": 14400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-010232", "filing_date": 1710173703000, "quarter_ending": "20231231", "company_name": "NGM BIOPHARMACEUTICALS INC", "text": "Since inception, the Company has incurred net losses and negative cash flow from operations. During the years ended December\u00a031, 2023, 2022 and 2021, the Company incurred net losses of $142.4 million, $162.7 million and $120.3 million, respectively. As of December\u00a031, 2023, the Company had an accumulated deficit of $724.0 million.\u00a0The Company expects its accumulated deficit will continue to increase over time and does not expect to experience positive cash flows from operations in the near future.", "entities": [ { "start_character": 186, "end_character": 191, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -142400000.0 }, { "start_character": 202, "end_character": 207, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -162700000.0 }, { "start_character": 221, "end_character": 226, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -120300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001133421-24-000006", "filing_date": 1706198571000, "quarter_ending": "20231231", "company_name": "NORTHROP GRUMMAN CORP /DE/", "text": "The projected loss across the five LRIP lots, which we recognized during the fourth quarter of 2023, is $1.56\u00a0billion. The loss comprises a $143\u00a0million unfavorable EAC adjustment for the first LRIP lot and a $1.37\u00a0billion loss contingency accrual and $45\u00a0million reduction of inventoried costs for the unexercised LRIP lots. As of December 31, 2023, $631\u00a0million of the loss contingency accrual is included in Other current liabilities and $740\u00a0million is included in Other non-current liabilities in the consolidated statement of financial position. ", "entities": [ { "start_character": 141, "end_character": 144, "label": "ebit", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -143000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001133421-24-000006", "filing_date": 1706198571000, "quarter_ending": "20231231", "company_name": "NORTHROP GRUMMAN CORP /DE/", "text": "At the request of the National Aeronautics and Space Administration (NASA), Space Systems submitted an engineering change proposal (ECP) during the fourth quarter of 2023 for scope increases and other aspects of the Habitation and Logistics Outpost (HALO) contract largely stemming from evolving Lunar Gateway architecture and mission requirements. The ECP addresses both work performed and work expected to be performed by the company resulting from scope changes previously approved by NASA, as well as changes NASA has requested the company to propose but has not yet directed the company to perform. The company has begun negotiating with NASA on these various changes and other aspects of the HALO contract. The company\u2019s 2023 results include $100\u00a0million of unfavorable EAC adjustments on the HALO contract and reflect our current best estimate of the outcome of the ECP negotiations assuming the terms of the current contract; however, if the outcome is less favorable than what we have assumed, it could have an adverse effect on our financial position, results of operations and/or cash flows. ", "entities": [ { "start_character": 749, "end_character": 752, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -100000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001133421-24-000006", "filing_date": 1706198571000, "quarter_ending": "20231231", "company_name": "NORTHROP GRUMMAN CORP /DE/", "text": "EAC adjustments on a single performance obligation can have a significant effect on the company\u2019s financial statements. When such adjustments occur, we generally disclose the nature, underlying conditions and financial impact of the adjustments. During the fourth quarter of 2023, we recorded a $143\u00a0million unfavorable EAC adjustment on the first LRIP lot of the B-21 program at Aeronautics Systems as described above. During 2023, we recorded $100\u00a0million of unfavorable EAC adjustments on the HALO program at Space Systems largely due to cost growth stemming from evolving Lunar Gateway architecture and mission requirements combined with macroeconomic challenges. During 2022, we recorded $133\u00a0million of favorable EAC adjustments on the EMD phase of the B-21 program at Aeronautics Systems. During 2021, we recorded $135\u00a0million of unfavorable EAC adjustments on the F-35 program at Aeronautics Systems. No other such adjustments were significant to the financial statements during the years ended December 31, 2023, 2022 and 2021. ", "entities": [ { "start_character": 296, "end_character": 299, "label": "ebit", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -143000000.0 }, { "start_character": 446, "end_character": 449, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -100000000.0 }, { "start_character": 694, "end_character": 697, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 133000000.0 }, { "start_character": 822, "end_character": 825, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -135000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001133421-24-000006", "filing_date": 1706198571000, "quarter_ending": "20231231", "company_name": "NORTHROP GRUMMAN CORP /DE/", "text": "Diluted earnings per share include the dilutive effect of awards granted to employees under stock-based compensation plans. The dilutive effect of these securities totaled 0.5 million, 0.7 million and 0.6 million shares for the years ended December 31, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 172, "end_character": 175, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 500000.0 }, { "start_character": 185, "end_character": 188, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 700000.0 }, { "start_character": 201, "end_character": 204, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001133421-24-000026", "filing_date": 1714060968000, "quarter_ending": "20240331", "company_name": "NORTHROP GRUMMAN CORP /DE/", "text": "Diluted earnings per share include the dilutive effect of awards granted to employees under stock-based compensation plans. The dilutive effect of these securities totaled 0.4 million shares and 0.6 million shares for the three months ended March 31, 2024 and 2023, respectively. ", "entities": [ { "start_character": 172, "end_character": 175, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 400000.0 }, { "start_character": 195, "end_character": 198, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001000694-24-000007", "filing_date": 1709105455000, "quarter_ending": "20231231", "company_name": "NOVAVAX INC", "text": "As of December\u00a031, 2023, the Company had $568.5 million in cash and cash equivalents and had a working capital deficiency. In January 2024, pursuant to the June 2023 Amendment to the advance purchase agreement between the Company and the Canadian government (the \u201cCanada APA\u201d), the Company received the second installment of $174.8\u00a0million from the Canadian government that was contingent and payable upon the Company\u2019s delivery of vaccine doses (see Note 3). During the year ended December\u00a031, 2023, the Company incurred a net loss of $545.1 million and had net cash flows used in operating activities of $714.0\u00a0million.", "entities": [ { "start_character": 537, "end_character": 542, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -545100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001000694-24-000007", "filing_date": 1709105455000, "quarter_ending": "20231231", "company_name": "NOVAVAX INC", "text": "The Company has a collaboration and license agreement with Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) under which the Company granted Takeda an exclusive license to develop, manufacture, and commercialize the Company\u2019s COVID-19 Vaccine in Japan. Under the agreement, Takeda purchases Matrix-M\u2122 adjuvant from the Company to manufacture doses of COVID-19 Vaccine, and the Company is entitled to receive milestone and sales-based royalty payments from Takeda based on the achievement of certain development and commercial milestones, as well as a portion of net profits from the sale of COVID-19 Vaccine. In September 2021, Takeda finalized an agreement with the Government of Japan\u2019s Ministry of Health, Labour and Welfare (\"MHLW\") for the purchase of 150\u00a0million doses of its prototype vaccine. In February 2023, MHLW canceled the remainder of doses under its agreement with Takeda. As a result, it is uncertain whether the Company will receive future sales-based royalty payments from Takeda under the terms and conditions of their current collaboration and licensing agreement. For the year ended December\u00a031, 2023, the Company recognized $6.0\u00a0million of revenue as consideration for changes to certain terms of the license agreement which is included in Royalties and other revenue on the consolidated statements of operations. For the year ended December 31, 2022, the Company recognized $20.0\u00a0million, upon the sale of prototype vaccine in Japan", "entities": [ { "start_character": 1147, "end_character": 1150, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 6000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001000694-24-000007", "filing_date": 1709105455000, "quarter_ending": "20231231", "company_name": "NOVAVAX INC", "text": "During the year ended December\u00a031, 2022, the Company recognized $9.0\u00a0million in revenue related to sales-based royalties, $20.0\u00a0million related to milestone payments, and $15.0\u00a0million in revenue related to a Matrix-M\u2122 adjuvant sales.", "entities": [ { "start_character": 65, "end_character": 68, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9000000.0 }, { "start_character": 123, "end_character": 127, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 20000000.0 }, { "start_character": 172, "end_character": 176, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 15000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001000694-24-000007", "filing_date": 1709105455000, "quarter_ending": "20231231", "company_name": "NOVAVAX INC", "text": "During the year ended December\u00a031, 2023, the Company recognized $8.5\u00a0million in revenue related to license fees, and $16.5\u00a0million in revenue related to a Matrix-M\u2122 adjuvant sales. During the year ended December\u00a031, 2023, the Company did not recognize revenue related to milestone payments.", "entities": [ { "start_character": 65, "end_character": 68, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 8500000.0 }, { "start_character": 118, "end_character": 122, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 16500000.0 }, { "start_character": 238, "end_character": 240, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001000694-24-000031", "filing_date": 1715328326000, "quarter_ending": "20240331", "company_name": "NOVAVAX INC", "text": "As of March\u00a031, 2024, the Company had $480.6 million in cash and cash equivalents and had a working capital deficiency. During the three months ended March\u00a031, 2024, the Company incurred a net loss of $147.6 million and had net cash flows used in operating activities of $83.6 million.", "entities": [ { "start_character": 202, "end_character": 207, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -147600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001000694-24-000031", "filing_date": 1715328326000, "quarter_ending": "20240331", "company_name": "NOVAVAX INC", "text": "During the three months ended March\u00a031, 2024, the Company recognized $4.0\u00a0million in revenue related to license fees and $7.5\u00a0million in revenue related to a Matrix-M\u2122 adjuvant sales. During the three months ended March\u00a031, 2024, the Company did not recognize revenue related to milestone payments.", "entities": [ { "start_character": 70, "end_character": 73, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 }, { "start_character": 122, "end_character": 125, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001000694-24-000031", "filing_date": 1715328326000, "quarter_ending": "20240331", "company_name": "NOVAVAX INC", "text": "During the three months ended March\u00a031, 2023, the Company recognized $1.0\u00a0million in revenue related to a Matrix-M\u2122 adjuvant sales. During the three months ended March\u00a031, 2023, the Company did not recognize revenue related to license fees or milestone payments. ", "entities": [ { "start_character": 70, "end_character": 73, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001000694-24-000031", "filing_date": 1715328326000, "quarter_ending": "20240331", "company_name": "NOVAVAX INC", "text": "Product sales in the U.S. are primarily made through large pharmaceutical wholesale distributors at the wholesale acquisition cost (\u201cWAC\u201d). Product sales in the U.S. are recorded net of gross-to-net deductions. During the three months ended March\u00a031, 2024, product sales in North America includes $6.4\u00a0million of gross-to-net deductions in excess of the WAC, primarily due to wholesale distributor fees for shipments expected to be returned and adjustments made to estimated returns of prior period product sales. Product sales for the rest of the world includes a $3.6\u00a0million reduction to revenue recognized pursuant to the Gavi Settlement Agreement as discussed above. ", "entities": [ { "start_character": 298, "end_character": 301, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001013871-24-000005", "filing_date": 1709137244000, "quarter_ending": "20231231", "company_name": "NRG ENERGY, INC.", "text": "As discussed in Note 3 to the consolidated financial statements, the Company had $28,823 million of revenues. Revenue is derived from various revenue streams in different geographic markets and the Company\u2019s processes and related information technology (IT) systems used to record revenue differ for each of these revenue streams.", "entities": [ { "start_character": 82, "end_character": 88, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 28823000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001013871-24-000010", "filing_date": 1715094377000, "quarter_ending": "20240331", "company_name": "NRG ENERGY, INC.", "text": "Basic income/(loss) per common share is computed by dividing net income/(loss) less cumulative dividends attributable to preferred stock by the weighted average number of common shares outstanding. Shares issued and treasury shares repurchased during the period are weighted for the portion of the period that they were outstanding. Diluted income/(loss) per share is computed in a manner consistent with that of basic income/(loss) per share while giving effect to all potentially dilutive common shares that were outstanding during the period when there is net income. The performance stock units and non-vested restricted stock units are not considered outstanding for purposes of computing basic income/(loss) per share. However, these instruments are included in the denominator for purposes of computing diluted income per share under the treasury stock method for periods when there is net income. The Convertible Senior Notes are convertible, under certain circumstances, into cash or combination of cash and Company\u2019s common stock. The Company is including the potential share settlements, if any, in the denominator for purposes of computing diluted income per share under the if converted method for periods when there is net income. The potential shares settlements are calculated as the excess of the Company's conversion obligation over the aggregate principal amount (which will be settled in cash), divided by the average share price for the period. For the three months ended March\u00a031, 2023, there was no dilutive effect for the Convertible Senior Notes as the Company recorded a net loss.", "entities": [ { "start_character": 603, "end_character": 605, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001045810-24-000029", "filing_date": 1708533417000, "quarter_ending": "20240128", "company_name": "NVIDIA CORP", "text": "In February 2023, we assessed the useful lives of our property, plant, and equipment. Based on advances in technology and usage rate, we increased the estimated useful life of most of our server, storage, and network equipment from three to four or five years, and our assembly and test equipment from five to seven years. The effect of this change for the fiscal year ended January\u00a028, 2024 was a benefit of $33\u00a0million and $102\u00a0million for cost of revenue and operating expenses, respectively, which resulted in an increase in operating income of $135\u00a0million and net income of $114\u00a0million after tax, or $0.05 per both basic and diluted share.", "entities": [ { "start_character": 550, "end_character": 553, "label": "ebit", "start_date_for_period": "2023-10-30", "end_date_for_period": "2024-01-28", "currency_/_unit": "iso4217:USD", "value": 135000000.0 }, { "start_character": 581, "end_character": 584, "label": "earnings", "start_date_for_period": "2023-10-30", "end_date_for_period": "2024-01-28", "currency_/_unit": "iso4217:USD", "value": 114000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001413447-24-000013", "filing_date": 1708582053000, "quarter_ending": "20231231", "company_name": "NXP Semiconductors N.V.", "text": "In 2023, NXP generated income before income taxes of $3,352 million (2022: income of $3,363 million; 2021: income of $2,180 million). The components of income (loss) before income taxes are as follows:\u00a0", "entities": [ { "start_character": 54, "end_character": 59, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3352000000.0 }, { "start_character": 86, "end_character": 91, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3363000000.0 }, { "start_character": 118, "end_character": 123, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2180000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001401708-23-000235", "filing_date": 1699291382000, "quarter_ending": "20230930", "company_name": "NanoString Technologies Inc", "text": "Total revenue in the United States was $30.0 million, $19.0 million, $79.9 million and $60.9 million for the three and nine month periods ended September\u00a030, 2023 and 2022, respectively. The Company\u2019s assets are primarily located in the United States and therefore are not allocated to any specific geographic region.", "entities": [ { "start_character": 40, "end_character": 44, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 30000000.0 }, { "start_character": 55, "end_character": 59, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 19000000.0 }, { "start_character": 70, "end_character": 74, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 79900000.0 }, { "start_character": 88, "end_character": 92, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 60900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001566469-23-000075", "filing_date": 1700670705000, "quarter_ending": "20230930", "company_name": "NantHealth, Inc.", "text": "The Company has incurred significant losses and negative cash flows from operations. As of September\u00a030, 2023, the Company had cash and cash equivalents of $5,822 and an accumulated deficit of $1,165,389. The Company had a net loss of $44,714 and used cash of $20,594 for operating activities for the nine month period ended September\u00a030, 2023. In accordance with Accounting Standards Update (\"ASU\") 2014-15, Presentation of Financial Statements\u2014Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity\u2019s Ability to Continue as a Going Concern, management is required to perform a two-step analysis over the Company\u2019s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company\u2019s ability to continue as a going concern for a period of 12 months from the date the financial statements are issued. If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt. ", "entities": [ { "start_character": 236, "end_character": 242, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -44714000.0 } ] }, { "form_type": "10-K", "accession_number": "0001377630-24-000042", "filing_date": 1710778992000, "quarter_ending": "20231228", "company_name": "National CineMedia, Inc.", "text": "The Company\u2019s Consolidated Statements of Operations include total net revenues and net loss attributable to NCM LLC of $155.1 million and $42.0 million, respectively, for the total of the consolidated periods of December 30, 2022 through April 11, 2023 and August 7, 2023 through December 28, 2023.", "entities": [ { "start_character": 139, "end_character": 143, "label": "earnings", "start_date_for_period": "2022-12-30", "end_date_for_period": "2023-12-28", "currency_/_unit": "iso4217:USD", "value": 42.0 } ] }, { "form_type": "10-K", "accession_number": "0001635984-24-000010", "filing_date": 1709226102000, "quarter_ending": "20231231", "company_name": "National Western Life Group, Inc.", "text": ").\u00a0The Company currently has no share-based compensation awards outstanding that could be redeemed for shares of common stock.", "entities": [ { "start_character": 29, "end_character": 31, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001635984-24-000015", "filing_date": 1715274460000, "quarter_ending": "20240331", "company_name": "National Western Life Group, Inc.", "text": "). The Company currently has no share-based compensation awards outstanding that could be redeemed for shares of common stock.", "entities": [ { "start_character": 29, "end_character": 31, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006697", "filing_date": 1707928262000, "quarter_ending": "20231231", "company_name": "NaturalShrimp Inc", "text": "The\naccompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted\nin the United States of America (\u201cGAAP\u201d), assuming the Company will continue as a going concern, which contemplates the realization\nof assets and satisfaction of liabilities in the normal course of business. For the nine months ended December\n31, 2023, the Company had a net loss available for common stockholders of approximately $10,821,000. As of December 31, 2023, the Company\nhad an accumulated deficit of approximately $178,426,000 and a working capital deficit of approximately $10,406,000. These factors raise\nsubstantial doubt about the Company\u2019s ability to continue as a going concern, within one year from the issuance date of this filing.\nThe Company\u2019s ability to continue as a going concern is dependent on its ability to raise the required additional capital or debt\nfinancing to meet short and long-term operating requirements. During the nine months ended December 31, 2023, the Company received net\ncash proceeds of approximately $2,323,000 from the sale of common shares (See Note 8), $150,000 from the sale of Series E Preferred stock,\n$97,000 from the sale of Series G Preferred stock and the Company received $140,000 proceeds from the issuance of promissory notes, related\nparties. Subsequent to period end, the Company received approximately $248,000 for the sale of common shares and $97,000 from the sale\nof Series G Preferred stock (See Note 12).", "entities": [ { "start_character": 472, "end_character": 482, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -10821000.0 } ] }, { "form_type": "10-K", "accession_number": "0001819404-24-000019", "filing_date": 1709049777000, "quarter_ending": "20231231", "company_name": "Nerdy Inc.", "text": "For the year ended December\u00a031, 2021, $3,779 of the consolidated net loss of Nerdy LLC was attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders\u2019 absorption of a portion of the consolidated net loss of Nerdy LLC for the period of September 21, 2021 through December 31, 2021. For the year ended December\u00a031, 2021, $3,354 of the consolidated net loss of Nerdy LLC was attributable to the NCI, and reflects the Legacy Nerdy Holders\u2019 absorption of a portion of the consolidated net loss of Nerdy LLC for the period of September 21, 2021 through December 31, 2021. For the year ended December\u00a031, 2021, $23,546 of the consolidated net loss of Nerdy LLC was attributable to the Legacy Nerdy Holders to reflect their absorption of 100% of the consolidated net loss of Nerdy LLC pertaining to the period of January 1, 2021 through September 20, 2021, the Closing Date of the Reverse Recapitalization.", "entities": [ { "start_character": 39, "end_character": 44, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -3779000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023431", "filing_date": 1715771967000, "quarter_ending": "20240331", "company_name": "NeuroMetrix, Inc.", "text": "For the quarter ended March\u00a031, 2024, the Company had comprehensive income of $7,006 for net unrealized gains on AFS, in addition to net loss of $3,029,574 in the statements of operations. The Company had comprehensive income of $65,874 for net unrealized gains on AFS, in addition to net loss of $1,574,174 in the statements of operations for the quarter ended March 31, 2023.", "entities": [ { "start_character": 146, "end_character": 155, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3029574.0 }, { "start_character": 299, "end_character": 308, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1574174.0 } ] }, { "form_type": "10-K", "accession_number": "0001404644-24-000020", "filing_date": 1710777878000, "quarter_ending": "20231231", "company_name": "Neurogene Inc.", "text": "Since its inception, the Company has funded its operations primarily with proceeds from the sales of equity securities and has incurred significant recurring losses, including net losses of $36.3 million and $55.2 million for the years ended December\u00a031, 2023 and 2022, respectively. In addition, the Company used cash in operations of $51.4 million and $52.8 million for the years ended December\u00a031, 2023 and 2022, respectively, and had an accumulated deficit of $187.2 million as of December\u00a031, 2023. Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.", "entities": [ { "start_character": 191, "end_character": 195, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -36300000.0 }, { "start_character": 209, "end_character": 213, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -55200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001404644-24-000057", "filing_date": 1715357650000, "quarter_ending": "20240331", "company_name": "Neurogene Inc.", "text": "Since its inception, the Company has funded its operations primarily with proceeds from the sales of equity securities and has incurred significant recurring losses, including net losses of $16.9 million and $12.3 million for the three months ended March\u00a031, 2024 and 2023, respectively. In addition, the Company used cash in operations of $21.7 million and $13.6 million for the three months ended March\u00a031, 2024 and 2023, respectively, and had an accumulated deficit of $204.1 million as of March\u00a031, 2024. Management expects to incur substantial and increasing losses in future periods as the Company advances its products through its clinical and regulatory process and will rely on outside capital to fund its operations for the foreseeable future. The Company has not generated positive cash flows from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.", "entities": [ { "start_character": 191, "end_character": 195, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -16900000.0 }, { "start_character": 209, "end_character": 213, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -12300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001749723-24-000011", "filing_date": 1709223313000, "quarter_ending": "20231231", "company_name": "New Fortress Energy Inc.", "text": "Pro forma net income (loss) for the year ended December 31, 2020 includes non-recurring expenses associated with the Mergers of $37,885; such non-recurring expenses have been removed from the pro forma financial information for the year ended December 31, 2021. Transaction costs incurred and the elimination of a pre-existing lease relationship between the Company and GMLP are considered to be non-recurring. The unaudited pro forma financial information does not give effect to any synergies, operating efficiencies or cost savings that may result from the Mergers.", "entities": [ { "start_character": 129, "end_character": 135, "label": "earnings", "start_date_for_period": "2020-01-01", "end_date_for_period": "2020-12-31", "currency_/_unit": "iso4217:USD", "value": 37885000.0 } ] }, { "form_type": "10-K", "accession_number": "0001749723-24-000011", "filing_date": 1709223313000, "quarter_ending": "20231231", "company_name": "New Fortress Energy Inc.", "text": "The Company\u2019s results of operations for the year ended December\u00a031, 2023 include GMLP\u2019s result of operations from the entire period. Revenue and net loss attributable to GMLP during this period was $0 and $33,148, respectively, which excludes revenue generated from the acquired vessels after the Energos Formation Transaction on August 15, 2022.", "entities": [ { "start_character": 206, "end_character": 212, "label": "earnings", "start_date_for_period": "2021-04-16", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -33148000.0 } ] }, { "form_type": "10-K", "accession_number": "0001749723-24-000011", "filing_date": 1709223313000, "quarter_ending": "20231231", "company_name": "New Fortress Energy Inc.", "text": "The Company\u2019s results of operations for the year ended December\u00a031, 2023 include Hygo\u2019s result of operations for the entire period. Revenue and net loss attributable to Hygo during the period was $5,465 and $11,389, respectively, which excludes revenue generated from the acquired vessels after the Energos Formation Transaction on August 15, 2022.", "entities": [ { "start_character": 208, "end_character": 214, "label": "earnings", "start_date_for_period": "2021-04-15", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -11389000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001749723-24-000052", "filing_date": 1715191780000, "quarter_ending": "20240331", "company_name": "New Fortress Energy Inc.", "text": "The components of lease income from vessel operating leases for the three months ended March\u00a031, 2024 and 2023 are shown below. As the Company has not recognized the sale of all of the vessels included in the Energos Formation Transaction (defined below), the operating lease income for the three months ended March\u00a031, 2024 and March\u00a031, 2023 includes revenue of $42,584 and $76,524 from third-party charters of vessels included in the Energos Formation Transaction. ", "entities": [ { "start_character": 377, "end_character": 383, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 76524000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001829126-23-007325", "filing_date": 1699893505000, "quarter_ending": "20230930", "company_name": "Nexalin Technology, Inc.", "text": "The\n accompanying unaudited condensed consolidated financial statements have been prepared on the basis that we will continue as a going\n concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At\n September\u00a030, 2023, we had a significant accumulated deficit of $76.3 76,257,380\n million. For the three and nine months ended September\u00a030, 2023, we had a loss from operations of $2.4 2,415,537\n million and $4.1 4,071,823\n million, respectively and negative cash flows used in operations of approximately $2.8 2,831,354 million for the nine months ended\n September\u00a030, 2023. While we had a working capital surplus as of September\u00a030, 2023 of approximately $3.1 million our\n operating activities consume most of our cash resources.", "entities": [ { "start_character": 467, "end_character": 476, "label": "ebit", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -2415537.0 }, { "start_character": 500, "end_character": 509, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -4071823.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-23-089471", "filing_date": 1700656146000, "quarter_ending": "20230930", "company_name": "Nogin, Inc.", "text": "For\nthe nine months ended September 30, 2023, revenue from our top three customers amounted to $7.4\u00a0million (or 18% of total revenue),\n$4.2 million (or 10% of total revenue), and $2.1 million (or 5% of total revenue), respectively. For the nine months ended September\n30, 2022, revenue from our top three customers amounted to $21.3 million (or 32% of total revenue), $9.6\u00a0million (or 14% of total\nrevenue), and $6.2 million (or 9% of total revenue), respectively.", "entities": [ { "start_character": 96, "end_character": 99, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 7400000.0 }, { "start_character": 136, "end_character": 139, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 4200000.0 }, { "start_character": 180, "end_character": 183, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 328, "end_character": 332, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 21300000.0 }, { "start_character": 369, "end_character": 372, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 9600000.0 }, { "start_character": 413, "end_character": 416, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 6200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493225-24-000059", "filing_date": 1709223222000, "quarter_ending": "20231231", "company_name": "Northfield Bancorp, Inc.", "text": "At December\u00a031, 2023, 2022, and 2021, there were 77,772, 203,997, and 337,768 dilutive shares outstanding, respectively. \u00a0 \u00a0", "entities": [ { "start_character": 49, "end_character": 55, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 77772.0 }, { "start_character": 57, "end_character": 64, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 203997.0 }, { "start_character": 70, "end_character": 77, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 337768.0 } ] }, { "form_type": "10-K", "accession_number": "0001110805-24-000007", "filing_date": 1708608104000, "quarter_ending": "20231231", "company_name": "NuStar Energy L.P.", "text": "We have entered into certain revenue arrangements where we are considered to be the lessor. Under the largest of these arrangements, we lease certain of our storage tanks in exchange for a fixed fee, subject to an annual CPI adjustment. The operating leases commenced on January 1, 2017, and have initial terms of ten years with successive automatic renewal terms. We recognized lease revenues from these leases of $45.3 million, $43.1 million, and $41.5 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively, which are included in \u201cService revenues\u201d in the consolidated statements of income. As of December\u00a031, 2023, we expect to receive minimum lease payments totaling $117.4 million, based upon the CPI as of the adoption date. We will recognize these payments ratably over the remaining initial lease term.", "entities": [ { "start_character": 416, "end_character": 420, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 45300000.0 }, { "start_character": 431, "end_character": 435, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 43100000.0 }, { "start_character": 450, "end_character": 454, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 41500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001549595-24-000025", "filing_date": 1708013070000, "quarter_ending": "20231130", "company_name": "Nurix Therapeutics, Inc.", "text": "For the year ended November\u00a030, 2023, the Company recognized collaboration revenue related to the Gilead Agreement of $29.9 million, of which $20.3 million was included in deferred revenue as of November\u00a030, 2022, and $7.9\u00a0million was related to performance obligations satisfied in previous periods. For the year ended November\u00a030, 2022, the Company recognized collaboration revenue related to the Gilead Agreement of $23.7 million, of which $18.4\u00a0million was included in deferred revenue as of November\u00a030, 2021, and $4.0 million was related to performance obligations satisfied in previous periods. As of November\u00a030, 2023, deferred revenue related to the Gilead Agreement was $10.0\u00a0million, all of which was current. As of November\u00a030, 2022, deferred revenue related to the Gilead Agreement was $27.4\u00a0million, of which $18.2\u00a0million was current. ", "entities": [ { "start_character": 119, "end_character": 123, "label": "revenues", "start_date_for_period": "2022-12-01", "end_date_for_period": "2023-11-30", "currency_/_unit": "iso4217:USD", "value": 29900000.0 }, { "start_character": 420, "end_character": 424, "label": "revenues", "start_date_for_period": "2021-12-01", "end_date_for_period": "2022-11-30", "currency_/_unit": "iso4217:USD", "value": 23700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001549595-24-000049", "filing_date": 1712732768000, "quarter_ending": "20240229", "company_name": "Nurix Therapeutics, Inc.", "text": "For the three months ended February\u00a029, 2024, the Company recognized collaboration revenue related to the Pfizer Agreement of $3.7 million, all of which was included in deferred revenue as of November\u00a030, 2023. As of February\u00a029, 2024, deferred revenue related to the Pfizer Agreement was $54.7\u00a0million, of which $21.2\u00a0million was included as deferred revenue, current. As of November\u00a030, 2023, deferred revenue related to the Pfizer Agreement was $58.3\u00a0million, of which $17.9\u00a0million was included as deferred revenue, current.", "entities": [ { "start_character": 127, "end_character": 130, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 3700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001549595-24-000049", "filing_date": 1712732768000, "quarter_ending": "20240229", "company_name": "Nurix Therapeutics, Inc.", "text": "For the three months ended February\u00a029, 2024, the Company recognized collaboration revenue related to the Sanofi Agreement of $8.3 million, of which $6.8 million was included in deferred revenue as of November\u00a030, 2023, and $1.3 million was related to activities satisfied in previous periods. For the three months ended February\u00a028, 2023, the Company recognized collaboration revenue related to the Sanofi Agreement of $5.3 million, of which $4.9\u00a0million was included in deferred revenue as of November\u00a030, 2022 and $0.4 million was related to activities satisfied in previous periods. As of February\u00a029, 2024, deferred revenue related to the Sanofi Agreement was $22.5\u00a0million, of which $21.5\u00a0million was included as deferred revenue, current, and included $2.0 million in contract assets representing the unbilled amount related to the research milestone achieved in February 2024. As of November\u00a030, 2023, deferred revenue related to the Sanofi Agreement was $24.9\u00a0million, of which $20.3\u00a0million was included as deferred revenue, current, and included $4.0\u00a0million in contract assets representing the unbilled amount related to the research milestone achieved in November 2023.", "entities": [ { "start_character": 127, "end_character": 130, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 8300000.000000001 }, { "start_character": 421, "end_character": 424, "label": "revenues", "start_date_for_period": "2022-12-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "iso4217:USD", "value": 5300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001549595-24-000049", "filing_date": 1712732768000, "quarter_ending": "20240229", "company_name": "Nurix Therapeutics, Inc.", "text": "For the three months ended February\u00a029, 2024, the Company recognized collaboration revenue related to the Gilead Agreement of $4.6 million, all of which was included in deferred revenue as of November\u00a030, 2023. For the three months ended February\u00a028, 2023, the Company recognized collaboration revenue related to the Gilead Agreement of $7.4\u00a0million, of which $2.8\u00a0million was included in deferred revenue as of November\u00a030, 2022, and $4.1\u00a0million was related to activities satisfied in previous periods. As of February\u00a029, 2024, deferred revenue related to the Gilead Agreement was $5.3\u00a0million, all of which was current. As of November\u00a030, 2023, deferred revenue related to the Gilead Agreement was $10.0 million, all of which was current.", "entities": [ { "start_character": 127, "end_character": 130, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 4600000.0 }, { "start_character": 338, "end_character": 341, "label": "revenues", "start_date_for_period": "2022-12-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "iso4217:USD", "value": 7400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001549595-24-000049", "filing_date": 1712732768000, "quarter_ending": "20240229", "company_name": "Nurix Therapeutics, Inc.", "text": "Upon signing the Gilead Agreement, Gilead paid the Company an upfront payment of $45.0\u00a0million plus $3.0\u00a0million in additional fees. In addition, from the signing of the Gilead Agreement to February\u00a029, 2024, the Company has received payments of $47.0 million for research milestones and additional payments and $20.0\u00a0million for a license option exercise payment. As of February\u00a029, 2024, the Company is eligible to receive up to approximately $1.8 billion in total additional payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones. The Company also is eligible to receive mid-single digit to low tens percentage tiered royalties on annual net sales from any commercial products directed to the optioned collaboration targets, subject to certain reductions and excluding sales in the United States of any products for which the Company exercises its option to co-develop and co-promote, for which the parties share profits and losses evenly.", "entities": [ { "start_character": 313, "end_character": 317, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 20000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001549595-24-000049", "filing_date": 1712732768000, "quarter_ending": "20240229", "company_name": "Nurix Therapeutics, Inc.", "text": "Under the Gilead Agreement, Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration and is responsible for the clinical development and commercialization of drug candidates resulting from the collaboration. The Company retains the option to co-develop and co-promote, under a profit share structure, up to two drug candidates in the United States, provided that the Company may only exercise such option once per licensed product and Gilead retains the right to veto the Company\u2019s option selection for any one drug candidate of its choice. The collaboration excludes the Company\u2019s current internal protein degradation programs for which the Company retains all rights, and also excludes the Company\u2019s future internal programs, provided that the Company has distinguished future programs as excluded from the scope of the collaboration. In March 2023, Gilead exercised the option, which did not represent a material right at contract inception, since it was not offered for free or at a discount, to exclusively license one target (Gilead License Option Exercise), the first development candidate resulting from the Gilead Agreement. Pursuant to the Gilead Agreement, the Company received a license option exercise payment of $20.0\u00a0million in April 2023 for the Gilead License Option Exercise. The license to the functional intellectual property and all goods and services related to the Gilead License Option Exercise were transferred during the second quarter of fiscal year 2023.", "entities": [ { "start_character": 1283, "end_character": 1287, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 20000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022496", "filing_date": 1715335289000, "quarter_ending": "20240331", "company_name": "Nuveen Global Cities REIT, Inc.", "text": "Rental income is recognized on a straight-line basis. The leases do not have material variable payments, material residual value guarantees or material restrictive covenants. Rental income for the three months ended March\u00a031, 2024 and 2023 was $44.7\u00a0million and $42.3\u00a0million, respectively.", "entities": [ { "start_character": 245, "end_character": 249, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 44700000.0 }, { "start_character": 263, "end_character": 267, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 42300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001121484-24-000038", "filing_date": 1714144041000, "quarter_ending": "20240331", "company_name": "OIL STATES INTERNATIONAL, INC", "text": "For the three months ended March\u00a031, 2024, the Company\u2019s income tax expense was $24\u00a0thousand on a pre-tax loss of $13.4\u00a0million, which included a $10.0\u00a0million goodwill impairment charge (approximately $7.7\u00a0million of which was non-deductible) and other non-deductible expenses. This compares to an income tax expense of $1.6\u00a0million on pre-tax income of $3.8\u00a0million, which included certain non-deductible expenses and discrete tax items, for the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 115, "end_character": 119, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -13400000.0 }, { "start_character": 356, "end_character": 359, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000029989-24-000014", "filing_date": 1713294625000, "quarter_ending": "20240331", "company_name": "OMNICOM GROUP INC.", "text": "The Americas is comprised of North America, which includes the United States, Canada and Puerto Rico, and Latin America, which includes South America and Mexico. EMEA is comprised of Europe, the Middle East and Africa. Asia-Pacific includes Australia, Greater China, India, Japan, Korea, New Zealand, Singapore and other Asian countries. Revenue in the United States for the three months ended March\u00a031, 2024, and 2023 was $1,925.9 million and $1,812.2 million, respectively.", "entities": [ { "start_character": 424, "end_character": 431, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1925900000.0 }, { "start_character": 445, "end_character": 452, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1812200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001842279-24-000012", "filing_date": 1710520571000, "quarter_ending": "20231231", "company_name": "OPAL Fuels Inc.", "text": "Included in Renewable Power revenues are $1,016 and $1,364 related to the lease element of the PPAs for the years ended December\u00a031, 2023 and 2022, respectively.", "entities": [ { "start_character": 42, "end_character": 47, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1016000.0 }, { "start_character": 53, "end_character": 58, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1364000.0 } ] }, { "form_type": "10-K", "accession_number": "0001842279-24-000012", "filing_date": 1710520571000, "quarter_ending": "20231231", "company_name": "OPAL Fuels Inc.", "text": "On November 29, 2021, the Company entered into a purchase and sale agreement with NextEra, a related party, for the environmental attributes generated by the RNG Fuels business. Under this agreement, the Company is committed to sell a minimum of 90% of the environmental attributes generated and will receive net proceeds based on the agreed upon price less a specified discount. A specified volume of environmental attributes sold per quarter will incur a discount fee per environmental attribute in addition to the specified discount. The agreement was effective beginning January 1, 2022. For the years ended December\u00a031, 2023 and 2022, the Company earned net revenues after discount and fees of $56,069 and $58,185, respectively, under this contract which was recorded as part of Revenues - RNG Fuel. For the years ended December\u00a031, 2023 and 2022, the Company earned net revenues after discount and fees of $28,468 and $18,735, respectively, which was recorded as part of Revenues - Fuel Station Services. ", "entities": [ { "start_character": 700, "end_character": 706, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 56069000.0 }, { "start_character": 712, "end_character": 718, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 58185000.0 }, { "start_character": 914, "end_character": 920, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 28468000.0 }, { "start_character": 926, "end_character": 932, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 18735000.0 } ] }, { "form_type": "10-K", "accession_number": "0001842279-24-000012", "filing_date": 1710520571000, "quarter_ending": "20231231", "company_name": "OPAL Fuels Inc.", "text": "During third and fourth quarter of 2022, two of the wholly-owned subsidiaries from our Renewable Power portfolio entered into a purchase and sale agreement with an environmental attribute marketing firm to sell environmental attributes associated with renewable biomethane (\"ISCC Carbon Credits\") and purchase brown gas back at contracted fixed prices per million British thermal units (\"MMbtu\"). One of these contracts has a term of 3-years from the date of certification of the facility with an auto-renewal option. The other contract was terminated in August 2023. During the third quarter of 2023, three additional Renewable Power facilities entered into purchase and sale agreements with 3 year terms and similar terms and conditions as the previous contracts. For the years ended December\u00a031, 2023 and 2022, the Company earned net revenues of $16,325 and $3,114, respectively under this contract which were recorded as part of Revenues - Renewable Power in the consolidated statement of operations. ", "entities": [ { "start_character": 851, "end_character": 857, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 16325000.0 }, { "start_character": 863, "end_character": 868, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3114000.0 } ] }, { "form_type": "10-K", "accession_number": "0001842279-24-000012", "filing_date": 1710520571000, "quarter_ending": "20231231", "company_name": "OPAL Fuels Inc.", "text": "Included in Fuel Station Services revenues are $3,943 and $3,510 related to the lease portion of the FPAs for the years ended December\u00a031, 2023 and 2022, respectively. ", "entities": [ { "start_character": 49, "end_character": 54, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3943000.0 }, { "start_character": 60, "end_character": 65, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3510000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001842279-24-000032", "filing_date": 1715358741000, "quarter_ending": "20240331", "company_name": "OPAL Fuels Inc.", "text": "On November 29, 2021, the Company entered into a purchase and sale agreement with NextEra for the Environmental Attributes generated by the RNG Fuels business. Under this agreement, the Company plans to sell a minimum of 90% of the Environmental Attributes generated and will receive net proceeds based on the agreed upon price less a specified discount. A specified volume of Environmental Attributes sold per quarter will incur a fee per Environmental Attribute in addition to the specified discount. The agreement was effective beginning January 1, 2022. For the three months ended March\u00a031, 2024 and 2023, the Company earned net revenues after discount and fees of $15,495 and $4,715 for RNG fuel and $7,741 and $1,493 for Fuel Station Services, respectively, under this contract which was recorded as part of Revenues - RNG fuel and Fuel Station Services. Please see Note 2. ", "entities": [ { "start_character": 670, "end_character": 676, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 15495000.0 }, { "start_character": 682, "end_character": 687, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4715000.0 }, { "start_character": 706, "end_character": 711, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7741000.0 }, { "start_character": 717, "end_character": 722, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1493000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001842279-24-000032", "filing_date": 1715358741000, "quarter_ending": "20240331", "company_name": "OPAL Fuels Inc.", "text": "During third and fourth quarter of 2022, two of the wholly-owned subsidiaries from our Renewable Power portfolio entered into a purchase and sale agreement with an Environmental Attribute marketing firm to sell Environmental Attributes associated with renewable biomethane (\"ISCC Carbon Credits\") and purchase brown gas back at contracted fixed prices per million British thermal units (\"MMbtu\"). One of these contracts has a term of 3-years from the date of certification of the facility with an auto-renewal option. The other contract was terminated in August 2023. During the third quarter of 2023, three additional Renewable Power facilities entered into purchase and sale agreements with 3-year terms and similar terms and conditions as the previous contracts. For the three months ended March\u00a031, 2024 and 2023, the Company earned net revenues of $3,788 and $5,445, respectively under the contracts which were recorded as part of Revenues - Renewable Power in the condensed consolidated statement of operations. ", "entities": [ { "start_character": 855, "end_character": 860, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3788000.0 }, { "start_character": 866, "end_character": 871, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5445000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001842279-24-000032", "filing_date": 1715358741000, "quarter_ending": "20240331", "company_name": "OPAL Fuels Inc.", "text": "On November 29, 2021, the Company entered into a purchase and sale agreement with NextEra, a related party, for the Environmental Attributes generated by the RNG Fuels business. Under this agreement, the Company is committed to sell a minimum of 90% of the Environmental Attributes generated and will receive net proceeds based on the agreed upon price less a specified discount. A specified volume of Environmental Attributes sold per quarter will incur a discount fee per Environmental Attribute in addition to the specified discount. The agreement was effective beginning January 1, 2022. For the three months ended March\u00a031, 2024 and 2023, the Company earned net revenues after discount and fees of $15,495 and $4,715, respectively, under this contract which was recorded as part of Revenues - RNG Fuel. For the three months ended March\u00a031, 2024 and 2023, the Company earned net revenues after discount and fees of $7,741 and $1,493, respectively, which was recorded as part of Revenues - Fuel Station Services. ", "entities": [ { "start_character": 704, "end_character": 710, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 15495000.0 }, { "start_character": 716, "end_character": 721, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4715000.0 }, { "start_character": 921, "end_character": 926, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7741000.0 }, { "start_character": 932, "end_character": 937, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1493000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001842279-24-000032", "filing_date": 1715358741000, "quarter_ending": "20240331", "company_name": "OPAL Fuels Inc.", "text": "Included in Renewable Power revenues are $219 and $331 related to the lease element of the PPAs for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 42, "end_character": 45, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 219000.0 }, { "start_character": 51, "end_character": 54, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 331000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001842279-24-000032", "filing_date": 1715358741000, "quarter_ending": "20240331", "company_name": "OPAL Fuels Inc.", "text": "Included in Fuel Station Services revenues are $772 and $570 related to the lease portion of the FPAs for the three months ended March\u00a031, 2024 and 2023, respectively. ", "entities": [ { "start_character": 48, "end_character": 51, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 772000.0 }, { "start_character": 57, "end_character": 60, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 570000.0 } ] }, { "form_type": "10-K", "accession_number": "0001579877-24-000015", "filing_date": 1708617839000, "quarter_ending": "20231231", "company_name": "OUTFRONT Media Inc.", "text": "We recorded rental income of $1,349.3 million in 2023, $1,321.1 million in 2022 and $1,141.1 million in 2021 in ", "entities": [ { "start_character": 30, "end_character": 37, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1349300000.0 }, { "start_character": 56, "end_character": 63, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1321100000.0 }, { "start_character": 85, "end_character": 92, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1141100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001579877-24-000047", "filing_date": 1714752211000, "quarter_ending": "20240331", "company_name": "OUTFRONT Media Inc.", "text": "Rental income was $304.1 million in the three months ended March 31, 2024, and $298.4 million in the three months ended March 31, 2023, and is recorded in ", "entities": [ { "start_character": 19, "end_character": 24, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 304100000.0 }, { "start_character": 80, "end_character": 85, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 298400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001579877-24-000047", "filing_date": 1714752211000, "quarter_ending": "20240331", "company_name": "OUTFRONT Media Inc.", "text": "We recorded rental income of $304.1 million for the three months ended March 31, 2024, and $298.4 million for the three months ended March 31, 2023, in ", "entities": [ { "start_character": 30, "end_character": 35, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 304100000.0 }, { "start_character": 92, "end_character": 97, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 298400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018632", "filing_date": 1715357168000, "quarter_ending": "20240331", "company_name": "OVERSEAS SHIPHOLDING GROUP INC", "text": "The\nCompany is the lessor under its time charter contracts. Total time charter revenue for the three months ended March 31, 2024 was\nequal to income from lease payments of $95,566\nplus straight-line adjustments of $365.\nFor the three months ended March 31, 2023, total time charter revenue was equal to income from lease payments of $84,434\nless straight-line adjustments of $294. The net book value of owned vessels on noncancelable time charters was equal to $450,907 and $448,663 at March 31,\n2024 and 2023, respectively.", "entities": [ { "start_character": 173, "end_character": 179, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 95566000.0 }, { "start_character": 334, "end_character": 340, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 84434000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001974793-24-000004", "filing_date": 1707768529000, "quarter_ending": "20231231", "company_name": "Oaktree Gardens OLP, LLC", "text": "For the three months ended December\u00a031, 2023, the Company recorded total fee income of $3, all of which was recurring in nature. Recurring fee income consisted of servicing fees.", "entities": [ { "start_character": 36, "end_character": 37, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001974793-24-000011", "filing_date": 1715625647000, "quarter_ending": "20240331", "company_name": "Oaktree Gardens OLP, LLC", "text": "For the three and six months ended March\u00a031, 2024, the Company recorded total fee income of $660 and $663, respectively, of which $3 and $6, respectively, was recurring in nature. Recurring fee income consisted of servicing fees.", "entities": [ { "start_character": 93, "end_character": 96, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 660000.0 }, { "start_character": 102, "end_character": 105, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 663000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001414932-24-000004", "filing_date": 1706723871000, "quarter_ending": "20231231", "company_name": "Oaktree Specialty Lending Corp", "text": "For the three months ended December\u00a031, 2023 and 2022, the Company recorded total fee income of $1.3 million and $2.0\u00a0million, respectively, of which $0.2 million and $0.2\u00a0million, respectively, was recurring in nature. Recurring fee income primarily consisted of servicing fees.", "entities": [ { "start_character": 97, "end_character": 100, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 }, { "start_character": 114, "end_character": 117, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001414932-24-000008", "filing_date": 1714416079000, "quarter_ending": "20240331", "company_name": "Oaktree Specialty Lending Corp", "text": "For the three and six months ended March\u00a031, 2024, the Company recorded total fee income of $2.5 million and $3.9 million, respectively, of which $0.1 million and $0.3 million, respectively, was recurring in nature. For the three and six months ended March\u00a031, 2023, the Company recorded total fee income of $2.4\u00a0million and $4.4\u00a0million, respectively, of which $0.3\u00a0million and $0.6\u00a0million, respectively, was recurring in nature. Recurring fee income primarily consisted of servicing fees.", "entities": [ { "start_character": 93, "end_character": 96, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2500000.0 }, { "start_character": 110, "end_character": 113, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3900000.0 }, { "start_character": 309, "end_character": 312, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2400000.0 }, { "start_character": 326, "end_character": 329, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001872371-24-000004", "filing_date": 1707767853000, "quarter_ending": "20231231", "company_name": "Oaktree Strategic Credit Fund", "text": "For the three months ended December\u00a031, 2023, the Company recorded total fee income of $401, of which $32 was recurring in nature. For the three months ended December 31, 2022, the Company recorded total fee income of $87, of which $62 was recurring in nature. Recurring fee income consisted of servicing fees.", "entities": [ { "start_character": 88, "end_character": 91, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 401000.0 }, { "start_character": 219, "end_character": 221, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 87000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001872371-24-000008", "filing_date": 1715624605000, "quarter_ending": "20240331", "company_name": "Oaktree Strategic Credit Fund", "text": "For the three and six months ended March\u00a031, 2024, the Company recorded total fee income of $1,250 and $1,651, respectively, of which $26 and $58, respectively, was recurring in nature. For the three and six months ended March\u00a031, 2023, the Company recorded total fee income of $141 and $228, respectively, of which $99 and $161, respectively, was recurring in nature. Recurring fee income consisted of servicing fees.", "entities": [ { "start_character": 93, "end_character": 98, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1250000.0 }, { "start_character": 104, "end_character": 109, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1651000.0 }, { "start_character": 279, "end_character": 282, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 141000.0 }, { "start_character": 288, "end_character": 291, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 228000.0 } ] }, { "form_type": "10-K", "accession_number": "0000746210-24-000009", "filing_date": 1710864236000, "quarter_ending": "20231231", "company_name": "Oblong, Inc.", "text": "For the years ended December\u00a031, 2023 and 2022, we incurred net losses of $4,384,000 and $21,941,000, respectively, and net cash used in operating activities was $2,993,000 and $5,934,000, respectively. ", "entities": [ { "start_character": 75, "end_character": 84, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -4384000.0 }, { "start_character": 90, "end_character": 100, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -21941000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000746210-24-000019", "filing_date": 1715184205000, "quarter_ending": "20240331", "company_name": "Oblong, Inc.", "text": "Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares of common stock outstanding does not include any potentially dilutive securities or unvested Restricted Stock. Unvested Restricted Stock, although classified as issued and outstanding at March\u00a031, 2023, was considered contingently returnable until the restrictions lapsed and was not included in the basic net loss per share calculation for the three months ended March 31, 2023. Unvested Restricted Stock does not contain non-forfeitable rights to dividends and dividend equivalents. ", "entities": [ { "start_character": 253, "end_character": 255, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0000746210-24-000019", "filing_date": 1715184205000, "quarter_ending": "20240331", "company_name": "Oblong, Inc.", "text": "As of March\u00a031, 2024, we had $5,360,000 in cash and working capital of $4,436,000. For the three months ended March 31, 2024, we incurred a net loss of $1,136,000 and used $630,000 of net cash in operating activities. ", "entities": [ { "start_character": 153, "end_character": 162, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1136000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-009817", "filing_date": 1710346543000, "quarter_ending": "20240131", "company_name": "Ocean Power Technologies, Inc.", "text": "For\nthe nine months ended January 31, 2024, the Company incurred net losses of approximately $20.8\nmillion, and used cash in operations of approximately $24.7\nmillion. Cash used in operations includes cash payments of the MAR earnout payable of $0.5\nmillion and payment of the fiscal 2023 bonus for all employees. In addition, the Company has continued to make investments to build\ninventory, support order backlog and future growth.", "entities": [ { "start_character": 94, "end_character": 98, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -20800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-016378", "filing_date": 1713282348000, "quarter_ending": "20231231", "company_name": "Ocugen, Inc.", "text": "The Company has incurred recurring net losses since inception and has funded its operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes and debt, and grant proceeds. The Company incurred net losses of approximately $63.1 million and $86.8 million for the years ended December 31, 2023 and 2022, respectively. As of December\u00a031, 2023, the Company had an accumulated deficit of $286.2 million and cash and cash equivalents totaling $39.5\u00a0million. This amount will not meet the Company's capital requirements over the next 12 months after the date that the consolidated financial statements are issued. The Company believes that its cash and cash equivalents will enable it to fund its operations into the fourth quarter of 2024. Due to the inherent uncertainty involved in making estimates and the risks associated with the research, development, and commercialization of biotechnology products, the Company may have based this estimate on assumptions that may prove to be wrong, and the Company's operating plan may change as a result of many factors currently unknown to the Company.", "entities": [ { "start_character": 283, "end_character": 287, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -63100000.0 }, { "start_character": 301, "end_character": 305, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -86800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023038", "filing_date": 1715668322000, "quarter_ending": "20240331", "company_name": "Ocugen, Inc.", "text": "The Company has incurred recurring net losses since inception and has funded its operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes and debt, and grant proceeds. The Company incurred net losses of approximately $11.9 and $17.3 for the three months ended March 31, 2024 and 2023, respectively. As of March\u00a031, 2024, the Company had an accumulated deficit of $298.1 million and cash and cash equivalents totaling $26.4 million. This amount will not meet the Company's capital requirements over the next 12 months after the date that the condensed consolidated financial statements are issued. The Company believes that its cash and cash equivalents will enable it to fund its operations into the fourth quarter of 2024. Due to the inherent uncertainty involved in making estimates and the risks associated with the research, development, and commercialization of biotechnology products, the Company may have ", "entities": [ { "start_character": 283, "end_character": 287, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -11900000.0 }, { "start_character": 293, "end_character": 297, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -17300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001660134-24-000088", "filing_date": 1717006603000, "quarter_ending": "20240430", "company_name": "Okta, Inc.", "text": "For the three months ended April 30, 2023, the Company recorded a tax provision of $4 million on a pretax loss of $115 million. The effective tax rate for the three months ended April 30, 2023 was approximately (3.6)%. The effective tax rate differs from the statutory rate primarily as a result of a full valuation allowance against U.S. deferred tax assets, the tax effect of foreign operations, and U.S. federal and state taxes.", "entities": [ { "start_character": 115, "end_character": 118, "label": "earnings", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": -115000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001660134-24-000088", "filing_date": 1717006603000, "quarter_ending": "20240430", "company_name": "Okta, Inc.", "text": "For the three months ended April\u00a030, 2024, the Company recorded a tax provision of $18 million on a pretax loss of $22 million. The effective tax rate for the three months ended April\u00a030, 2024 was approximately (84.9)%. The effective tax rate differs from the statutory rate primarily as a result of a full valuation allowance against the U.S. deferred tax assets, the tax effect of foreign operations, and U.S. federal and state taxes.", "entities": [ { "start_character": 116, "end_character": 118, "label": "earnings", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -22000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014475", "filing_date": 1712941257000, "quarter_ending": "20231231", "company_name": "Oncotelic Therapeutics, Inc.", "text": "The\naccompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The\nCompany has incurred net losses of approximately $33.5\nmillion since inception of Oncotelic Inc. as the Company\u2019s historical financial statements before the Merger have been\nreplaced with the historical financial statements of Oncotelic Inc. prior to the Merger in the financial statements and filings. The\nCompany also has a negative working capital of approximately $16.2\nmillion at December 31, 2023, of which approximately $1.3\nmillion is attributable to assumed negative working capital of the Company and approximately $2.6\nmillion contingent liability of issuance of common shares of the Company to PointR shareholders upon achievement of certain\nmilestones in accordance with the PointR Merger Agreement. The Company has negative cash flows from operations for the year ended\nDecember 31, 2023 of approximately $1.3\nmillion. These conditions raise substantial doubt about the Company\u2019s ability to continue as a going concern for a period of\none year from the date of this filing. Management expects to incur significantly lower costs and losses in the foreseeable future,\nas a majority of the costs related with the development of OT-101 will be incurred by the JV, but the Company also recognizes the\nneed to raise capital to remain viable. The accompanying consolidated financial statements do not include any adjustments that might\nbe necessary should the Company be unable to continue as a going concern.", "entities": [ { "start_character": 184, "end_character": 188, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 33500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019332", "filing_date": 1715708693000, "quarter_ending": "20240331", "company_name": "Oncotelic Therapeutics, Inc.", "text": "The\naccompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company\nhas incurred net accumulated losses of approximately $34 million since inception of Oncotelic Inc., as the Company\u2019s historical\nfinancial statements before the Merger have been replaced with the historical financial statements of Oncotelic Inc. The Company also\nhas a negative working capital of approximately $16.3 million at March 31, 2024, of which approximately $2.6 million contingent liability\nof issuance of common shares of the Company to PointR shareholders upon achievement of certain milestones in accordance with the PointR\nMerger Agreement. The Company has negative cash flows from operations for the three months ended March 31, 2024 of approximately $0.2\nmillion. These conditions raise substantial doubt about the Company\u2019s ability to continue as a going concern for a period of one\nyear from the date of this filing Management expects to incur significantly lower costs and losses in the foreseeable future, as a majority\nof the costs related with the development of OT-101 will be incurred by the JV, but the Company also recognizes the need to raise capital\nto remain viable. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the\nCompany be unable to continue as a going concern.", "entities": [ { "start_character": 196, "end_character": 198, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 34000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-016456", "filing_date": 1713287981000, "quarter_ending": "20231231", "company_name": "Ontrak, Inc.", "text": "Included in the weighted-average shares of common stock outstanding for the year ended December 31, 2023 is a total of 22,365,731 common shares issuable upon the exercise of Public Offering Pre-funded Warrants and Private Placement Pre-funded Warrants (described in Note 9 below), which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.", "entities": [ { "start_character": 119, "end_character": 129, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 22365731.0 } ] }, { "form_type": "10-K", "accession_number": "0001818502-24-000005", "filing_date": 1711560511000, "quarter_ending": "20231231", "company_name": "OppFi Inc.", "text": "For the year ended December\u00a031, 2023, OppFi recorded an income tax expense of $2.3 million and reported consolidated income before taxes of $41.8 million, resulting in a 5.6% effective income tax rate. For the year ended December\u00a031, 2022, OppFi recorded an income tax benefit of $0.3 million and reported consolidated income before taxes of 3.1 million, resulting in a negative 9.0% effective income tax rate. For the year ended December 31, 2021, OppFi recorded an income tax expense of $0.3\u00a0million and reported consolidated income before taxes of 90.1\u00a0million, resulting in a 0.3% effective income tax rate. Prior to the Closing Date, OppFi-LLC was classified as a partnership for income tax purposes, and was therefore not subject to federal income tax and did not record an expense for income taxes. ", "entities": [ { "start_character": 141, "end_character": 145, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 41800000.0 }, { "start_character": 342, "end_character": 345, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3100000.0 }, { "start_character": 551, "end_character": 555, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 90100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001818502-24-000009", "filing_date": 1715275116000, "quarter_ending": "20240331", "company_name": "OppFi Inc.", "text": "For the three months ended March 31, 2024, OppFi recorded an income tax expense of $0.4 million and reported consolidated income before income taxes of $10.5 million, resulting in a 3.8% effective income tax rate. For the three months ended March 31, 2023, OppFi recorded an income tax expense of $0.1 million and reported consolidated income before income taxes of $4.1 million, resulting in a 3.6% effective income tax rate. ", "entities": [ { "start_character": 153, "end_character": 157, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 10500000.0 }, { "start_character": 367, "end_character": 370, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4099999.9999999995 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-033000", "filing_date": 1713199295000, "quarter_ending": "20231231", "company_name": "OptimizeRx Corp", "text": "The\ncomputation of basic (loss) earnings per common share is computed using the weighted average number of common shares outstanding during\nthe year. The computation of diluted (loss) earnings per common share is based on the basic weighted average number of shares outstanding\nduring the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury\nstock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise\nof certain awards that were excluded from the diluted loss per common share calculation in 2023 and 2022 was 31,727 and 93,626 related\nto options, and 52,607 and 170,859 related to restricted stock units, for a total of 84,334 and 264,485, respectively, because they are\nanti-dilutive, as a result of the net losses incurred in each of the years ended December\u00a031, 2023 and 2022.", "entities": [ { "start_character": 703, "end_character": 709, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 52607.0 }, { "start_character": 714, "end_character": 721, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 170859.0 }, { "start_character": 772, "end_character": 778, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 84334.0 }, { "start_character": 783, "end_character": 790, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 264485.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-006733", "filing_date": 1708935046000, "quarter_ending": "20231231", "company_name": "Organon & Co.", "text": "Discontinued operations include related party sales of $12 million for the year ended December 31, 2021. Costs for inventory purchases from related parties were $53 million for the year ended December 31, 2021.", "entities": [ { "start_character": 56, "end_character": 58, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 12000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014652", "filing_date": 1713200688000, "quarter_ending": "20231231", "company_name": "Orgenesis Inc.", "text": "The\nCompany has received $215 from Sub-licensee as an advance on account of future license fees. No milestones have been completed to date.", "entities": [ { "start_character": 26, "end_character": 29, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 215000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-009809", "filing_date": 1709886259000, "quarter_ending": "20231231", "company_name": "Ovid Therapeutics Inc.", "text": "The Company recorded a net loss of $52.3 million during the year ended December\u00a031, 2023 and expects to incur losses in subsequent periods for at least the next several years. The Company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company\u2019s existing cash, cash equivalents and marketable securities as of December\u00a031, 2023 will be sufficient to fund its current operating plans through at least 12 months from the date of filing of the Company\u2019s Annual Report on Form 10-K. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company\u2019s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently. ", "entities": [ { "start_character": 36, "end_character": 40, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -52300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023067", "filing_date": 1715674303000, "quarter_ending": "20240331", "company_name": "Ovid Therapeutics Inc.", "text": "The Company recorded a net loss of $11.7 million during the three months ended March\u00a031, 2024, and expects to incur losses in subsequent periods for at least the next several years. The Company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company\u2019s existing cash, cash equivalents and marketable securities as of March\u00a031, 2024 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company\u2019s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company\u2019s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.", "entities": [ { "start_character": 36, "end_character": 40, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -11700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-013625", "filing_date": 1711643117000, "quarter_ending": "20231231", "company_name": "P3 Health Partners Inc.", "text": "Capitated revenue is recognized based on a PMPM transaction price to transfer the service for a distinct increment of the series (e.g., month), net of projected acuity adjustments and performance incentives or penalties. The Company recognizes revenue in the month in which eligible members are entitled to receive healthcare benefits during the contract term. The capitation amount is subject to possible retroactive premium risk adjustments based on the member\u2019s individual acuity. Premium risk adjustments recorded in 2023 which relate to prior years were $20.3 million. Premium risk adjustments recorded in 2022 related to prior years were $3.3 million. In the fourth quarter of 2023, the Company released a portion of the constraint applied in previous periods with respect to risk adjustment revenue for dates of service in 2022, which resulted in an increase to capitation revenue in the amount of $27.7\u00a0million for the year ended December 31, 2023. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient not to adjust for the effects of a significant financing component.", "entities": [ { "start_character": 906, "end_character": 910, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 27700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019320", "filing_date": 1715706956000, "quarter_ending": "20240331", "company_name": "PARKS AMERICA, INC", "text": "For\nthe six months ended March 31, 2024, the Company reported a pre-tax loss of $1.82 million and recorded an income tax benefit of $449,600,\ncomprised of a federal benefit of $363,900 and a net state benefit of $85,700. For the six months ended April 2, 2023, the Company reported\nincome pre-tax loss of $1.31 million, and recorded a tax benefit of $310,400, comprised of a federal benefit of $265,300 and a state\nexpense of $45,100.", "entities": [ { "start_character": 81, "end_character": 85, "label": "earnings", "start_date_for_period": "2023-10-02", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1820000.0 }, { "start_character": 306, "end_character": 310, "label": "earnings", "start_date_for_period": "2022-10-03", "end_date_for_period": "2023-04-02", "currency_/_unit": "iso4217:USD", "value": -1310000.0 } ] }, { "form_type": "10-K", "accession_number": "0000076605-24-000078", "filing_date": 1709193671000, "quarter_ending": "20231231", "company_name": "PATRICK INDUSTRIES INC", "text": "For the years ended December\u00a031, 2023, 2022 and 2021, operating income of approximately $1.0 million, $19.4 million and $25.0 million, respectively, was included in the Company\u2019s consolidated statements of income pertaining to the businesses acquired in each such respective year. Acquisition-related costs associated with the businesses acquired in 2023, 2022 and 2021 were immaterial in each respective year.", "entities": [ { "start_character": 89, "end_character": 92, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 }, { "start_character": 103, "end_character": 107, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 19400000.0 }, { "start_character": 121, "end_character": 125, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 25000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000076605-24-000109", "filing_date": 1715243498000, "quarter_ending": "20240331", "company_name": "PATRICK INDUSTRIES INC", "text": "The Company completed four acquisitions in the first three months of 2024 (the \"2024 Acquisitions\"). For the first quarter ended March\u00a031, 2024, net sales included in the Company's condensed consolidated statements of income related to the 2024 Acquisitions were $58.1\u00a0million, and operating income was $11.0\u00a0million. Acquisition-related costs associated with the 2024 Acquisitions were $5.0\u00a0million. Assets acquired and liabilities assumed in the acquisitions were recorded on the Company's condensed consolidated balance sheet at their estimated fair values as of the respective dates of acquisition. For each acquisition, the Company completes its allocation of the purchase price to the fair value of acquired assets and liabilities within a one year measurement period. The Company completed no acquisitions in the first quarter of 2023. ", "entities": [ { "start_character": 304, "end_character": 308, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 11000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000891024-24-000008", "filing_date": 1718720037000, "quarter_ending": "20240427", "company_name": "PATTERSON COMPANIES, INC.", "text": "We have interests in a number of entities that are accounted for using the equity method. During fiscal 2024, 2023 and 2022, we made purchases of $195,048, $198,712 and $193,625 from these entities, respectively. During fiscal 2024, 2023 and 2022, we recorded net sales of $150,892, $123,271 and $117,347 to these entities, respectively. ", "entities": [ { "start_character": 274, "end_character": 281, "label": "revenues", "start_date_for_period": "2023-04-30", "end_date_for_period": "2024-04-27", "currency_/_unit": "iso4217:USD", "value": 150892000.0 }, { "start_character": 284, "end_character": 291, "label": "revenues", "start_date_for_period": "2022-05-01", "end_date_for_period": "2023-04-29", "currency_/_unit": "iso4217:USD", "value": 123271000.0 }, { "start_character": 297, "end_character": 304, "label": "revenues", "start_date_for_period": "2021-04-25", "end_date_for_period": "2022-04-30", "currency_/_unit": "iso4217:USD", "value": 117347000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018913", "filing_date": 1715618127000, "quarter_ending": "20240331", "company_name": "PAVmed Inc.", "text": "The\nCompany has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock\npurchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic\ncompanies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research\nand development activities and conducting clinical trials. The Company generated $1.0 million of revenues for the three month period\nended March 31, 2024, however the Company does not expect to generate positive cash flows from operating activities in the near future.", "entities": [ { "start_character": 502, "end_character": 505, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018913", "filing_date": 1715618127000, "quarter_ending": "20240331", "company_name": "PAVmed Inc.", "text": "The\nCompany incurred a net loss attributable to PAVmed Inc. common stockholders of approximately $22.8 million and had net cash flows used\nin operating activities of approximately $13.1 million for the three month period ended March 31, 2024. As of March 31, 2024, the Company\nhad negative working capital of approximately $25.4 million, with such working capital inclusive of the Senior Secured Convertible Notes\nclassified as a current liability of an aggregate of approximately $45.5 million and approximately $25.5 million of cash.", "entities": [ { "start_character": 98, "end_character": 102, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -22800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001534504-24-000011", "filing_date": 1707980459000, "quarter_ending": "20231231", "company_name": "PBF Energy Inc.", "text": "As of December\u00a031, 2023 and December\u00a031, 2022, there was no LCM inventory adjustment recorded as the replacement value of inventories exceeded the LIFO carrying value. During the year ended December\u00a031, 2021, the Company recorded an adjustment to value its inventories to the lower of cost or market which increased income from operations by $669.6 million, reflecting no LCM inventory reserve at December\u00a031, 2021.", "entities": [ { "start_character": 343, "end_character": 348, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 669600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001566011-24-000003", "filing_date": 1709303179000, "quarter_ending": "20231231", "company_name": "PBF Holding Co LLC", "text": "As of December\u00a031, 2023 and December\u00a031, 2022, there was no LCM inventory adjustment recorded as the replacement value of inventories exceeded the LIFO carrying value. During the year ended December\u00a031, 2021, the Company recorded an adjustment to value its inventories to the lower of cost or market which increased income from operations by $669.6 million, reflecting no LCM inventory reserve at December\u00a031, 2021.", "entities": [ { "start_character": 343, "end_character": 348, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 669600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001064728-24-000021", "filing_date": 1708669299000, "quarter_ending": "20231231", "company_name": "PEABODY ENERGY CORP", "text": "During the years ended December\u00a031, 2023, 2022 and 2021, respectively, Middlemount generated revenue of approximately $219 million, $441 million and $265 million (on a 50% basis). ", "entities": [ { "start_character": 119, "end_character": 122, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 219000000.0 }, { "start_character": 133, "end_character": 136, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 441000000.0 }, { "start_character": 150, "end_character": 153, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 265000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000716605-24-000013", "filing_date": 1715778491000, "quarter_ending": "20240331", "company_name": "PENNS WOODS BANCORP INC", "text": "There are no convertible securities which would affect the denominator in calculating basic and dilutive earnings per share. There were a total of 1,097,000 stock options, with an average exercise price of $25.13, outstanding on March\u00a031, 2024. These options were excluded, on a weighted average basis, in the computation of diluted earnings per share for the period due to the average market price of common shares of $20.20 for the period being less than the strike price. A portion of these options were included, on a weighted average basis, in the computation of diluted earnings per share for the period due to the average market price of common shares of $25.96 for the quarter being greater than the strike price for the period ending March 31, 2023. ", "entities": [ { "start_character": 10, "end_character": 12, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-009464", "filing_date": 1710137147000, "quarter_ending": "20231231", "company_name": "PHI GROUP INC", "text": "As\nshown in the accompanying consolidated financial statements, the Company has accumulated deficit of $as of December 31, 2023 and total\nstockholders\u2019 deficit of $8,546,330. For the quarter ended December 31, 2023, the Company incurred a net loss of $1,711,938 as\ncompared to a net loss of $616,942 during the same period ended December 31, 2022. These factors as well as the uncertain conditions\nthat the Company faces in its day-to-day operations with respect to cash flows create an uncertainty as to the Company\u2019s ability\nto continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be\nunable to continue as a going concern. Management has taken action to strengthen the Company\u2019s working capital position and generate\nsufficient cash to meet its operating needs through June 30, 2024 and beyond.", "entities": [ { "start_character": 252, "end_character": 261, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1711938.0 }, { "start_character": 292, "end_character": 299, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -616942.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020764", "filing_date": 1716225331000, "quarter_ending": "20240331", "company_name": "PHI GROUP INC", "text": "As\nshown in the accompanying consolidated financial statements, the Company has accumulated deficit of $as of March 31, 2024 and total stockholders\u2019\ndeficit of $8,936,653. For the quarter ended March 31, 2024, the Company incurred a net loss of $1,690,405 as compared to a net loss\nof $1,778,712 during the same period ended March 31, 2023. These factors as well as the uncertain conditions that the Company faces in\nits day-to-day operations with respect to cash flows create an uncertainty as to the Company\u2019s ability to continue as a going concern.\nThe financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.\nManagement has taken action to strengthen the Company\u2019s working capital position and generate sufficient cash to meet its operating\nneeds through June 30, 2024 and beyond.", "entities": [ { "start_character": 246, "end_character": 255, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1690405.0 }, { "start_character": 286, "end_character": 295, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1778712.0 } ] }, { "form_type": "10-K", "accession_number": "0001115055-24-000029", "filing_date": 1708967142000, "quarter_ending": "20231231", "company_name": "PINNACLE FINANCIAL PARTNERS INC", "text": "As of December 31, 2023, there were no stock options outstanding to purchase common shares. For the years ended December 31, 2023, 2022 and 2021, respectively, 631,173,\u00a0398,461 and 458,808\u00a0of dilutive stock options, dilutive restricted shares and dilutive restricted share units, including those with performance-based vesting provisions, were included in the diluted earnings per common share calculation under the treasury stock method. For the years ended December 31, 2023, 2022 and 2021, there were a combined 484,871, 263,573 and 32,684 respectively, of restricted shares, restricted stock units and performance stock units excluded from the calculation because they were deemed to be antidilutive. ", "entities": [ { "start_character": 160, "end_character": 167, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 631173.0 }, { "start_character": 169, "end_character": 176, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 398461.0 }, { "start_character": 181, "end_character": 188, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 458808.0 } ] }, { "form_type": "10-K", "accession_number": "0000078814-24-000004", "filing_date": 1708434740000, "quarter_ending": "20231231", "company_name": "PITNEY BOWES INC /DE/", "text": "Due to the net loss from continuing operations for the year ended December 31, 2023, an additional 4.0\u00a0million of common stock equivalents were also excluded from the calculation of diluted earnings per share.", "entities": [ { "start_character": 99, "end_character": 102, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 4000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000078814-24-000026", "filing_date": 1714648533000, "quarter_ending": "20240331", "company_name": "PITNEY BOWES INC /DE/", "text": "(1)\u00a0\u00a0\u00a0\u00a0Due to the net loss for the three months ended March 31, 2024 and 2023, an additional 4.5 million and 4.7\u00a0million, respectively, of common stock equivalents were also excluded from the calculation of diluted earnings per share.", "entities": [ { "start_character": 93, "end_character": 96, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 4500000.0 }, { "start_character": 109, "end_character": 112, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 4700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000078814-24-000026", "filing_date": 1714648533000, "quarter_ending": "20240331", "company_name": "PITNEY BOWES INC /DE/", "text": "During the three months ended March 31, 2024, the Company identified an error and recorded an out of period adjustment of $5\u00a0million to correct the understatement of revenue in prior periods, of which $4\u00a0million originated in 2020 and prior. The impact of the adjustment is not material to the consolidated financial statements for any prior interim or annual periods and is not expected to be material to the 2024 annual period.", "entities": [ { "start_character": 123, "end_character": 124, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 }, { "start_character": 202, "end_character": 203, "label": "earnings", "start_date_for_period": "2020-01-01", "end_date_for_period": "2020-12-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001803914-24-000022", "filing_date": 1711725881000, "quarter_ending": "20231231", "company_name": "PLBY Group, Inc.", "text": "Our revenues, results of operations and cash flows have been materially adversely impacted by negative macroeconomic factors beginning in the second quarter of 2022 and continuing through 2023. The persistently challenging macroeconomic and retail environments, including reduced consumer spending and increased price sensitivity in discretionary categories, has significantly impacted our licensees\u2019 performance. Our net revenues from continuing operations for the year ended December\u00a031, 2023 decreased by $42.6 million, compared to the year ended December\u00a031, 2022, and this decline, coupled with investments into our creator platform, drove our impairment charge, operating loss and net loss. For the year ended December\u00a031, 2023, we reported an operating loss from continuing operations of $190.4 million, and negative operating cash flows from continuing operations of $42.8 million. As of December\u00a031, 2023, we had approximately $28.1 million in unrestricted cash and cash equivalents. ", "entities": [ { "start_character": 796, "end_character": 801, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -190400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001746473-24-000043", "filing_date": 1709050446000, "quarter_ending": "20231231", "company_name": "PLIANT THERAPEUTICS, INC.", "text": "Revenues associated with the Novartis Agreement for the years ended December\u00a031, 2023, 2022 and 2021, were $1.6\u00a0million, $9.7\u00a0million and $7.6\u00a0million, respectively, which consisted of revenue generated from research and development services and a $4.0\u00a0million contingent payment received in 2022 associated with the integrin research target program.", "entities": [ { "start_character": 108, "end_character": 111, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1600000.0 }, { "start_character": 122, "end_character": 125, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9700000.0 }, { "start_character": 139, "end_character": 142, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7600000.0 }, { "start_character": 249, "end_character": 252, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001108426-24-000041", "filing_date": 1714753270000, "quarter_ending": "20240331", "company_name": "PNM RESOURCES INC", "text": "In the year ended December 31, 2023, PNM evaluated the outcome of the NMPRC final order in the 2024 Rate Change and recorded a regulatory disallowance of $55.5\u00a0million on the Consolidated Statement of Earnings and a corresponding reduction to Utility Plant, after accounting for previous impairments, to reflect the remedy adopted in the Final Order for Four Corners. In addition, PNM recorded a reduction to electric operating revenues of $38.4\u00a0million with a corresponding current regulatory liability of $19.2\u00a0million and a deferred regulatory liability of $19.2\u00a0million for the PVNGS rate refunds that will be returned to customers over a two-year period. PNM also recorded a regulatory disallowance of $8.2\u00a0million on the Consolidated Statement of Earnings and a corresponding reduction to Utility Plant for the disallowance of CWIP from PVNGS.", "entities": [ { "start_character": 442, "end_character": 446, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -38400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000945841-24-000089", "filing_date": 1714392259000, "quarter_ending": "20240331", "company_name": "POOL CORP", "text": "We calculate basic and diluted earnings per share using the two-class method. Earnings per share under the two-class method is calculated using net income attributable to common stockholders, which is net income reduced by the earnings allocated to participating securities. Our participating securities include share-based payment awards that contain a non-forfeitable right to receive dividends and are considered to participate in undistributed earnings with common shareholders. Participating securities excluded from weighted average common shares outstanding were 205,000 for the three months ended March 31, 2024 and 213,000 for the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 573, "end_character": 580, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 205000000.0 }, { "start_character": 627, "end_character": 634, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 213000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-018248", "filing_date": 1715186650000, "quarter_ending": "20231231", "company_name": "POWERDYNE INTERNATIONAL, INC.", "text": "Since\nits inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management\nand technical staff, acquiring operating assets and raising capital. The Company has not generated significant revenues from its principal\noperations until March 6, 2022, with the acquisition of CM Tech that will generate between $1.4 to $2.0M in revenues annually. As of\nDecember 31, 2023, the Company had an accumulated deficit of $5,077,401 (December 31, 2022 - $4,993,228). The Company\u2019s continuation\nas a going concern is dependent on its ability to generate sufficient cash flows from operations to meet its obligations and/or obtaining\nadditional financing from its members or other sources, as may be required. For the year ended December 31, 2023, CM Tech has negative\ncash flow from operations in prior year but has turned positive in 2023. The Company is working towards consistently generating positive\ncash flow from operations by increasing revenues and by analyzing potential acquisition targets.", "entities": [ { "start_character": 379, "end_character": 382, "label": "revenues", "start_date_for_period": "2022-03-06", "end_date_for_period": "2022-03-06", "currency_/_unit": "iso4217:USD", "value": 1400000.0 }, { "start_character": 387, "end_character": 390, "label": "revenues", "start_date_for_period": "2022-03-06", "end_date_for_period": "2022-03-06", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000922224-24-000008", "filing_date": 1708084494000, "quarter_ending": "20231231", "company_name": "PPL Corp", "text": "PPL includes $1,851\u00a0million and $1,038\u00a0million for the twelve months ended December 31, 2023 and 2022 of revenues from external customers reported by the Rhode Island Regulated segment. PPL Electric represents revenues from external customers reported by the Pennsylvania Regulated segment and LG&E and KU, net of intercompany power sales and transmission revenues, represent revenues from external customers reported by the Kentucky Regulated segment. See Note 2 for additional information.", "entities": [ { "start_character": 14, "end_character": 19, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1851000000.0 }, { "start_character": 33, "end_character": 38, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1038000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000922224-24-000014", "filing_date": 1714563472000, "quarter_ending": "20240331", "company_name": "PPL Corp", "text": "PPL includes $549\u00a0million for the three months ended March 31, 2024 and $565\u00a0million for the three months ended March 31, 2023", "entities": [ { "start_character": 14, "end_character": 17, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 549000000.0 }, { "start_character": 73, "end_character": 76, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 565000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001356090-24-000007", "filing_date": 1710866927000, "quarter_ending": "20231231", "company_name": "PRECIGEN, INC.", "text": "For the years ended December 31, 2023, 2022, and 2021, 74.6%, 59.6%, and 61.5% of total Exemplar segment revenue was attributable to four customers in 2023 and one for 2022 and 2021, respectively. The Company recognized revenues derived in foreign countries totaling $0, $233, and $378 for the years ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 169, "end_character": 170, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0.0 }, { "start_character": 272, "end_character": 275, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 233000.0 }, { "start_character": 282, "end_character": 285, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 378000.0 } ] }, { "form_type": "10-K", "accession_number": "0001356090-24-000007", "filing_date": 1710866927000, "quarter_ending": "20231231", "company_name": "PRECIGEN, INC.", "text": "During the twelve months ended December\u00a031, 2023, we incurred a loss from continuing operations of $95.9 million and used $66.9 million of cash in our operations, and as of December\u00a031, 2023, had an accumulated deficit of $1,964.5 million. The Company has incurred operating losses since its inception and management expects operating losses and negative cash flows from operations to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In addition, as of", "entities": [ { "start_character": 100, "end_character": 104, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -95900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001356090-24-000010", "filing_date": 1715707425000, "quarter_ending": "20240331", "company_name": "PRECIGEN, INC.", "text": "During the three months ended March 31, 2024, the Company incurred a net loss of $23,738 and used $14,090 of cash in our operations, and as of March\u00a031, 2024, had an accumulated deficit of $1,988,209. The Company has incurred operating losses since its inception and management expects operating losses and negative cash flows from operations to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In addition, as of March\u00a031, 2024, the Company had $44,758 in cash, cash equivalents and short-term investments, and had no committed source of additional funding from either debt or equity financings. The Company\u2019s current cash and investments position is not sufficient to fund the Company's planned operations through one year after the date the interim financial statements are issued and accordingly, there is substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern does not include cash sources outside of the Company's direct control that management expects to be available within the next twelve months.", "entities": [ { "start_character": 82, "end_character": 88, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -23738000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-023201", "filing_date": 1717781287000, "quarter_ending": "20231231", "company_name": "PRESSURE BIOSCIENCES INC", "text": "We\nhave net operating loss carry-forwards for federal income tax purposes of approximately $129,304,842 as of December 31, 2023. Included in these\nnumbers are loss carry-forwards that were obtained through the acquisition of BioSeq, Inc. and are subject to Section 382 NOL limitations.\nThese net operating loss carry-forwards expire at various dates from 2024 through 2038 Under the Tax Reform Act, NOL\u2019s generated\nafter December 31, 2017 can offset only 80% of a corporation\u2019s taxable income in any year. With limited exceptions, NOL\u2019s\ngenerated after 2017, $91,016,166 cannot be carried back, but they can be carried forward indefinitely.", "entities": [ { "start_character": 560, "end_character": 570, "label": "ebit", "start_date_for_period": "2017-01-01", "end_date_for_period": "2017-12-31", "currency_/_unit": "iso4217:USD", "value": 91016166.0 } ] }, { "form_type": "10-Q", "accession_number": "0001287032-24-000152", "filing_date": 1715185463000, "quarter_ending": "20240331", "company_name": "PROSPECT CAPITAL CORP", "text": "During the three months ended March 31, 2024 and March 31, 2023, we received payments of $3,167, and $2,316, respectively, from our portfolio companies for managerial assistance and subsequently remitted these amounts to Prospect Administration. During the nine months ended March 31, 2024 and March 31, 2023, we received payments of $7,667 and $7,008, respectively, from our portfolio companies for managerial assistance and subsequently remitted these amounts to Prospect Administration.", "entities": [ { "start_character": 90, "end_character": 95, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3167000.0 }, { "start_character": 102, "end_character": 107, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2316000.0 }, { "start_character": 335, "end_character": 340, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7667000.0 }, { "start_character": 346, "end_character": 351, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 7008000.0 } ] }, { "form_type": "10-K", "accession_number": "0000777917-24-000025", "filing_date": 1710950634000, "quarter_ending": "20231231", "company_name": "PRUCO LIFE INSURANCE CO", "text": "The Company pays commissions and certain other fees to Prudential Annuities Distributors, Inc. (\u201cPAD\u201d) in consideration for PAD\u2019s marketing and underwriting of the Company\u2019s annuity products. Commissions and fees are paid by PAD to broker-dealers who sell the Company\u2019s annuity products. Commissions and fees paid by the Company to PAD were $587 million, $611 million and $379 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 342, "end_character": 345, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 587000000.0 }, { "start_character": 356, "end_character": 359, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 611000000.0 }, { "start_character": 373, "end_character": 376, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 379000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000777917-24-000025", "filing_date": 1710950634000, "quarter_ending": "20231231", "company_name": "PRUCO LIFE INSURANCE CO", "text": "As part of the recapture transaction, the Company received invested assets of $6.8 billion, net of $2 billion ceding commissions as consideration from PALAC, which is equivalent to the amount of statutory reserve credit taken as of June 30, 2021. The Company released a reinsurance recoverable of $11.6 billion.", "entities": [ { "start_character": 100, "end_character": 101, "label": "revenues", "start_date_for_period": "2021-07-01", "end_date_for_period": "2021-07-01", "currency_/_unit": "iso4217:USD", "value": -2000000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000777917-24-000034", "filing_date": 1715620645000, "quarter_ending": "20240331", "company_name": "PRUCO LIFE INSURANCE CO", "text": "The Company has a YRT reinsurance agreement with Prudential Insurance and reinsures the majority of all mortality risks not otherwise reinsured. This agreement was terminated for new business effective January 1, 2020, with certain new business (primarily universal life policies) terminated as early as 2017. The Company now reinsures a portion of the mortality risk directly to third-party reinsurers and retains all of the non-reinsured portion of the mortality risk. Effective July 1, 2019, certain term life insurance policies were recaptured and subsequently reinsured to PARCC and PAR Term as noted above. As of January 1, 2022, most of the variable life insurance policies were recaptured resulting in a $305\u00a0million loss recorded through \"Policy charges and fee income.\" Those policies were then reinsured to Lotus Re as mentioned below. Effective January 1, 2024, the Company recaptured all GUL policies with Prudential Insurance and subsequently entered into a YRT reinsurance agreement with Prudential Insurance to reinsure the mortality risk for the totality of GUL policies reinsured to PURE.", "entities": [ { "start_character": 713, "end_character": 716, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-01-01", "currency_/_unit": "iso4217:USD", "value": 305000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000777917-24-000034", "filing_date": 1715620645000, "quarter_ending": "20240331", "company_name": "PRUCO LIFE INSURANCE CO", "text": "The Company pays commissions and certain other fees to Prudential Annuities Distributors, Inc. (\u201cPAD\u201d) in consideration for PAD\u2019s marketing and underwriting of the Company\u2019s annuity products. Commissions and fees are paid by PAD to broker-dealers who sell the Company\u2019s annuity products. Commissions and fees paid by the Company to PAD were $178 million and ", "entities": [ { "start_character": 342, "end_character": 345, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 178000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001038509-24-000009", "filing_date": 1710950797000, "quarter_ending": "20231231", "company_name": "PRUCO LIFE INSURANCE OF NEW JERSEY", "text": "During the three and twelve months ended December\u00a031, 2023, the Company recorded out of period adjustments resulting in an aggregate net charge of $6\u00a0million and $11\u00a0million, respectively, to \u201cIncome (loss) from operations before income taxes\u201d. These adjustments primarily relate to ceded reserves from certain affiliated reinsurance activity.", "entities": [ { "start_character": 148, "end_character": 149, "label": "earnings", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -6000000.0 }, { "start_character": 163, "end_character": 165, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -11000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001038509-24-000015", "filing_date": 1715621146000, "quarter_ending": "20240331", "company_name": "PRUCO LIFE INSURANCE OF NEW JERSEY", "text": "The Company pays commissions and certain other fees to Prudential Annuities Distributors, Inc. (\u201cPAD\u201d) in consideration for PAD\u2019s marketing and underwriting of the Company\u2019s annuity products. Commissions and fees are paid by PAD to broker-dealers who sell the Company\u2019s annuity products. Commissions and fees paid by the Company to PAD were $14 million and $8 million for the ", "entities": [ { "start_character": 342, "end_character": 344, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 }, { "start_character": 358, "end_character": 359, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 8000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001137774-24-000045", "filing_date": 1708512326000, "quarter_ending": "20231231", "company_name": "PRUDENTIAL FINANCIAL INC", "text": "Excluding the gain on sale recognized in 2022, the Full Service Retirement business generated pre-tax income/(loss) of approximately $(220)\u00a0million and $180\u00a0million for the years ended December 31, 2022 and 2021, respectively. These amounts exclude the impact of overhead costs retained in the Company\u2019s Corporate and Other operations and ", "entities": [ { "start_character": 135, "end_character": 138, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -220000000.0 }, { "start_character": 153, "end_character": 156, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 180000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001137774-24-000068", "filing_date": 1714666906000, "quarter_ending": "20240331", "company_name": "PRUDENTIAL FINANCIAL INC", "text": "Unvested share-based payment awards that contain nonforfeitable rights to dividends are participating securities and included in the computation of earnings per share pursuant to the two-class method. Under this method, earnings attributable to Prudential Financial are allocated between Common Stock and the participating awards, as if the awards were a second class of stock. During periods of net income available to holders of Common Stock, the calculation of earnings per share excludes the income attributable to participating securities in the numerator and the dilutive impact of these securities from the denominator. In the event of a net loss available to holders of Common Stock, undistributed earnings are not allocated to participating securities and the denominator excludes the dilutive impact of these securities as they do not share in the losses of the Company. Undistributed earnings allocated to participating unvested share-based payment awards for the three months ended March\u00a031, 2024 and 2023, as applicable, were based on 4.1 million and 4.2 million of such awards, respectively, weighted for the period they were outstanding.", "entities": [ { "start_character": 1048, "end_character": 1051, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 4099999.9999999995 }, { "start_character": 1064, "end_character": 1067, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 4200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-010313", "filing_date": 1710778257000, "quarter_ending": "20240131", "company_name": "PURE BIOSCIENCE, INC.", "text": "We\nhave a history of recurring losses, and as of January 31, 2024 we have a stockholders deficiency of $1,321,000. During the six months\nended January 31, 2024, we recorded a net loss of $1,737,000 on recorded net revenue of $1,048,000. In addition, during the six months\nended January 31, 2024 we used $1,323,000 in operating activities resulting in a cash balance of $557,000 as of January 31, 2024. Our\nhistory of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our\nability to continue as a going concern. The Company\u2019s independent registered public accounting firm, in its report on the Company\u2019s\nconsolidated financial statements for the year ended July 31, 2023, has also expressed substantial doubt about the Company\u2019s ability\nto continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the\nrecoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability\nto continue as a going concern.", "entities": [ { "start_character": 188, "end_character": 197, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -1737000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-023869", "filing_date": 1718381437000, "quarter_ending": "20240430", "company_name": "PURE BIOSCIENCE, INC.", "text": "We\nhave a history of recurring losses, and as of April 30, 2024 we have a stockholders deficiency of $2,146,000. During the nine months\nended April 30, 2024, we recorded a net loss of $2,594,000 on recorded net revenue of $1,489,000. In addition, during the nine months\nended April 30, 2024 we used $1,938,000 in operating activities resulting in a cash balance of $442,000 as of April 30, 2024. Our history\nof recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability\nto continue as a going concern. The Company\u2019s independent registered public accounting firm, in its report on the Company\u2019s\nconsolidated financial statements for the year ended July 31, 2023, has also expressed substantial doubt about the Company\u2019s ability\nto continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the\nrecoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability\nto continue as a going concern.", "entities": [ { "start_character": 185, "end_character": 194, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -2594000.0 } ] }, { "form_type": "10-K", "accession_number": "0001568100-24-000013", "filing_date": 1710523227000, "quarter_ending": "20240131", "company_name": "PagerDuty, Inc.", "text": "Certain members of the Company\u2019s Board of Directors serve as directors of, or are executive officers of, and in some cases are investors in, companies that are customers or vendors of the Company. The Company recognized revenue from the sales of its product to related parties of $3.3 million, $1.3\u00a0million, and $2.5\u00a0million in the fiscal years ended January\u00a031, 2024, 2023, and 2022, respectively, and billings of $3.8\u00a0million, $1.8\u00a0million, and $2.2\u00a0million in the fiscal years ended January\u00a031, 2024, 2023, and 2022, respectively.", "entities": [ { "start_character": 281, "end_character": 284, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": 3300000.0 }, { "start_character": 295, "end_character": 298, "label": "revenues", "start_date_for_period": "2022-02-01", "end_date_for_period": "2023-01-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 }, { "start_character": 313, "end_character": 316, "label": "revenues", "start_date_for_period": "2021-02-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 2500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001568100-24-000058", "filing_date": 1717174195000, "quarter_ending": "20240430", "company_name": "PagerDuty, Inc.", "text": "Additionally, as of April 30, 2023, using the conversion rate of 24.9507 shares of common stock per $1,000 principal amount of notes, the potentially dilutive shares that were not included in the diluted per share calculations related to the 2025 Notes was 7.2\u00a0million. ", "entities": [ { "start_character": 257, "end_character": 260, "label": "eps", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "xbrli:shares", "value": 7200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001568100-24-000058", "filing_date": 1717174195000, "quarter_ending": "20240430", "company_name": "PagerDuty, Inc.", "text": "Certain members of the Company\u2019s Board of Directors serve as directors of, or are executive officers of, and in some cases are investors in, companies that are customers or vendors of the Company. The Company billed $4.0\u00a0million and $3.8\u00a0million to entities associated with related parties in the three months ended April 30, 2024 and 2023, respectively. The Company recognized $4.0\u00a0million and $3.2\u00a0million in accounts receivable associated with related parties as of April\u00a030, 2024 and 2023, respectively. Other related party transactions were not material for the three months ended April 30, 2024 and 2023.", "entities": [ { "start_character": 396, "end_character": 399, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 3200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000813828-24-000020", "filing_date": 1714411225000, "quarter_ending": "20240331", "company_name": "Paramount Global", "text": "We enter into operating leases for the use of our owned production facilities and office buildings. Lease payments received under these agreements consist of fixed payments for the rental of space and certain building operating costs, as well as variable payments based on usage of production facilities and services, and escalating costs of building operations. We recorded total lease income, including both fixed and variable amounts, of $6 million and $14 million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 442, "end_character": 443, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6000000.0 }, { "start_character": 457, "end_character": 459, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001600626-24-000023", "filing_date": 1708622973000, "quarter_ending": "20231231", "company_name": "Peakstone Realty Trust", "text": "The Company recognized $219.6 million, $343.3 million and $378.3 million of lease income related to operating lease payments for the year ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 24, "end_character": 29, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 219600000.0 }, { "start_character": 40, "end_character": 45, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 343300000.0 }, { "start_character": 59, "end_character": 64, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 378300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001600626-24-000074", "filing_date": 1715098294000, "quarter_ending": "20240331", "company_name": "Peakstone Realty Trust", "text": "The Company recognized $51.6 million and $58.3 million of lease income related to operating lease payments for the three months ended March 31, 2024 and March\u00a031, 2023, respectively.", "entities": [ { "start_character": 24, "end_character": 28, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 51600000.0 }, { "start_character": 42, "end_character": 46, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 58300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001766400-24-000022", "filing_date": 1709136995000, "quarter_ending": "20231231", "company_name": "Pennant Group, Inc.", "text": "(\u201cASC 805\u201d). The purchase price for the business combinations was $21,376, which primarily consisted of goodwill of $11,517, indefinite-lived intangible assets of $8,914 related to Medicare and Medicaid licenses, and equipment, other assets and accounts receivable of $1,026, less assumed liabilities of $81. The acquisitions contributed $10,549 in revenue and operating income of $280 during the year ended December 31, 2023. The Company anticipates that the total goodwill recognized will be fully deductible for tax purposes. ", "entities": [ { "start_character": 339, "end_character": 345, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 10549000.0 }, { "start_character": 382, "end_character": 385, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 280000.0 } ] }, { "form_type": "10-K", "accession_number": "0001412408-24-000043", "filing_date": 1710518648000, "quarter_ending": "20240131", "company_name": "Phreesia, Inc.", "text": "For the years ended January\u00a031, 2024 and 2023, the Company recognized revenue totaling $1,174 and $775, respectively, for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of January\u00a031, 2024 and 2023, accounts receivable from the pharmaceutical company totaled $416 and $339, respectively.", "entities": [ { "start_character": 88, "end_character": 93, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": 1174000.0 }, { "start_character": 99, "end_character": 102, "label": "revenues", "start_date_for_period": "2022-02-01", "end_date_for_period": "2023-01-31", "currency_/_unit": "iso4217:USD", "value": 775000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001412408-24-000121", "filing_date": 1717171389000, "quarter_ending": "20240430", "company_name": "Phreesia, Inc.", "text": "For the three months ended April\u00a030, 2024 and 2023, the Company recognized revenue totaling $328 and $288, respectively, for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of April\u00a030, 2024 and January\u00a031, 2024, accounts receivable from the pharmaceutical company totaled approximately $208 and $416, respectively.", "entities": [ { "start_character": 93, "end_character": 96, "label": "revenues", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 328000.0 }, { "start_character": 102, "end_character": 105, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 288000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-011484", "filing_date": 1710520247000, "quarter_ending": "20231231", "company_name": "Phunware, Inc.", "text": "For the years ended December\u00a031, 2023 and 2022, we had net losses from continuing operations before income taxes of $41,915 and $45,421, respectively. We had net losses from a discontinued operation of $10,841 and $5,469 for the years ended December\u00a031, 2023 and 2022, respectively.", "entities": [ { "start_character": 117, "end_character": 123, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -41915000.0 }, { "start_character": 129, "end_character": 135, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -45421000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-011484", "filing_date": 1710520247000, "quarter_ending": "20231231", "company_name": "Phunware, Inc.", "text": "We have a history of losses since inception. For the year ended, December\u00a031, 2023, we incurred a net loss of $52,785, used $18,435 in cash for operations and had a working capital deficiency. However, subsequent to December\u00a031, 2023, through a series of offerings of our common stock, we raised aggregate net proceeds of approximately $20.8 million. In addition, the holder of our 2022 Promissory Note, as amended, elected to convert the balance of the 2022 Promissory Note and the 2022 Promissory Note is paid in full. See Note 16 for further discussion on financing activities that occurred subsequent to December\u00a031, 2023.", "entities": [ { "start_character": 111, "end_character": 117, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -52785000.0 } ] }, { "form_type": "10-K", "accession_number": "0001574540-24-000041", "filing_date": 1708618273000, "quarter_ending": "20231231", "company_name": "Physicians Realty Trust", "text": "For 2022, the Company recorded revenues and net loss of $3.6 million and $0.2 million, respectively, from its 2022 acquisitions.", "entities": [ { "start_character": 57, "end_character": 60, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001574540-24-000041", "filing_date": 1708618273000, "quarter_ending": "20231231", "company_name": "Physicians Realty Trust", "text": "The Company recognized rental revenues totaling $8.7 million in 2023, $8.3 million in 2022, and $7.9 million in 2021 from Baylor Scott and White Health, a health care system affiliated with a member of the Trust\u2019s Board of Trustees. ", "entities": [ { "start_character": 49, "end_character": 52, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 8700000.0 }, { "start_character": 71, "end_character": 74, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 8300000.000000001 }, { "start_character": 97, "end_character": 100, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001574540-24-000041", "filing_date": 1708618273000, "quarter_ending": "20231231", "company_name": "Physicians Realty Trust", "text": "During 2023, the Company recorded revenues and net income of $2.7 million and $0.5 million, respectively, from its 2023 acquisitions. ", "entities": [ { "start_character": 62, "end_character": 65, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001728205-24-000062", "filing_date": 1715273216000, "quarter_ending": "20240331", "company_name": "Piedmont Lithium Inc.", "text": "We recorded an income tax benefit of $3.1 million on a loss before taxes of $26.7 million and a provision of $0.5 million on a loss before taxes of $8.1 million in the three months ended March\u00a031, 2024 and 2023, respectively. The effective tax rates were 11.6% and (6.1)% in the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 77, "end_character": 81, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -26700000.0 }, { "start_character": 149, "end_character": 152, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -8100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012355", "filing_date": 1711987555000, "quarter_ending": "20231231", "company_name": "Polar Power, Inc.", "text": "The\naccompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. In accordance\nwith Accounting Standards Codification (\u201cASC\u201d) 205-40, Going Concern, the Company\u2019s management has evaluated\nwhether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company\u2019s ability\nto continue as a going concern within one year after the date the accompanying financial statements were issued. For the year ended December\n31, 2023, the Company recorded a net loss of $6,548\n", "entities": [ { "start_character": 566, "end_character": 571, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -6548000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019861", "filing_date": 1715789748000, "quarter_ending": "20240331", "company_name": "Polar Power, Inc.", "text": "The\naccompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. For the\nthree months ended March 31, 2024, the Company recorded a net loss of $2,142 and used cash in operations of $989. These factors raise substantial doubt about the Company\u2019s ability\nto continue as a going concern within one year after the date that the financial statements are issued. In addition, our independent registered\npublic accounting firm, in its audit report to the financial statements included in our Annual Report on Form 10-K for the year ended\nDecember 31, 2023, expressed substantial doubt about our ability to continue as a going concern. The financial statements\ndo not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification\nof liabilities that might be necessary should the Company be unable to continue as a going concern.", "entities": [ { "start_character": 208, "end_character": 213, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2142000.0 } ] }, { "form_type": "10-K", "accession_number": "0001784535-24-000019", "filing_date": 1710514035000, "quarter_ending": "20231231", "company_name": "Porch Group, Inc.", "text": "In connection with the September 16, 2021, issuance of the 2026 Notes, we used a portion of the proceeds to pay for the capped call transactions, which are expected to generally reduce the potential dilution to our common stock. The capped call transactions impact the number of shares that may be issued by effectively increasing our conversion price from $25 per share to approximately $37.74 per share, which would result in approximately 6\u00a0million potentially dilutive shares instead of the shares reported in this table as of December\u00a031, 2023.", "entities": [ { "start_character": 442, "end_character": 443, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 6000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001530950-23-000350", "filing_date": 1700223426000, "quarter_ending": "20230930", "company_name": "Post Holdings, Inc.", "text": "Based upon the purchase price allocation, the Company recorded $235.0 of trademarks and licensing agreements and $391.0 of customer relationships, both of which are being amortized over a weighted-average useful life of 18 years. Net sales included in the Consolidated Statements of Operations attributable to Pet Food was $679.8 for the year ended September\u00a030, 2023. Due to the level of integration of Pet Food within the Post Consumer Brands segment, it is impracticable to separately present net earnings included in the Consolidated Statements of Operations attributable to Pet Food. The goodwill generated by the Company\u2019s Pet Food acquisition is expected to be deductible for U.S. income tax purposes. ", "entities": [ { "start_character": 324, "end_character": 329, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 679800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001530950-24-000054", "filing_date": 1706871276000, "quarter_ending": "20231231", "company_name": "Post Holdings, Inc.", "text": "Also on December 1, 2023, the Company completed its acquisition of Deeside Cereals I Ltd (\u201cDeeside\u201d) for \u00a311.3 (approximately $14.3). The acquisition was completed using cash on hand. Deeside is a producer of private label cereals in the United Kingdom (the \u201cU.K.\u201d) and is reported in the Weetabix segment. Based upon the preliminary purchase price allocation at December 31, 2023, the Company identified and recorded $20.5 of net assets, which exceeded the purchase price paid for Deeside. As a result, the Company recorded a gain of $6.2, which was included in \u201cOther operating income, net\u201d in the Condensed Consolidated Statements of Operations for the three months ended December 31, 2023. Net sales and operating loss included in the Condensed Consolidated Statements of Operations attributable to Deeside were $2.3 and $0.2, respectively, for the three months ended December\u00a031, 2023. Preliminary values of Deeside are measured as of the date of the acquisition, are not yet finalized pending the final purchase price allocation and are subject to change.", "entities": [ { "start_character": 817, "end_character": 820, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001530950-24-000054", "filing_date": 1706871276000, "quarter_ending": "20231231", "company_name": "Post Holdings, Inc.", "text": "During the three months ended December\u00a031, 2023 and 2022, the Company had net sales to 8th Avenue of $1.7 and $2.4, respectively, and purchases from and royalties paid to 8th Avenue of $19.9 and $23.3, respectively. Sales and purchases between the Company and 8th Avenue were all made at arm\u2019s-length. ", "entities": [ { "start_character": 102, "end_character": 105, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1700000.0 }, { "start_character": 111, "end_character": 114, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001530950-24-000054", "filing_date": 1706871276000, "quarter_ending": "20231231", "company_name": "Post Holdings, Inc.", "text": "Based upon the preliminary purchase price allocation, the Company recorded $79.0 of customer relationships, which is being amortized over a weighted-average useful life of 16 years. Net sales and operating profit included in the Condensed Consolidated Statements of Operations attributable to Perfection were $19.5 and $0.1, respectively, for the three months ended December\u00a031, 2023. The Company recorded $1.8 of acquisition-related costs related to Perfection, which were included in \u201cSelling, general and administrative expenses\u201d in the Condensed Consolidated Statements of Operations during the three months ended December\u00a031, 2023. ", "entities": [ { "start_character": 310, "end_character": 314, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 19500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001530950-24-000144", "filing_date": 1714742478000, "quarter_ending": "20240331", "company_name": "Post Holdings, Inc.", "text": "$3.1 and $5.5, respectively, and purchases from and royalties paid to 8th Avenue of $25.1 and $48.4, respectively. Sales and purchases between the Company and 8th Avenue were all made at arm\u2019s-length. ", "entities": [ { "start_character": 1, "end_character": 4, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3100000.0 }, { "start_character": 10, "end_character": 13, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001530950-24-000144", "filing_date": 1714742478000, "quarter_ending": "20240331", "company_name": "Post Holdings, Inc.", "text": "Based upon the preliminary purchase price allocation, the Company recorded $81.0 of customer relationships, which is being amortized over a weighted-average useful life of 16 years. Net sales and operating profit included in the Condensed Consolidated Statements of Operations attributable to Perfection were $65.1 and $4.8, respectively, for the three months ended March\u00a031, 2024 and $84.6 and $4.9, respectively, for the six months ended March\u00a031, 2024. During the three and six months ended March\u00a031, 2024, the Company recorded acquisition-related costs related to Perfection of $0.1 and $1.9, respectively, which were included in \u201cSelling, general and administrative expenses\u201d in the Condensed Consolidated Statements of Operations. ", "entities": [ { "start_character": 310, "end_character": 314, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 65099999.99999999 }, { "start_character": 386, "end_character": 390, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 84600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001530950-24-000144", "filing_date": 1714742478000, "quarter_ending": "20240331", "company_name": "Post Holdings, Inc.", "text": "Also on December 1, 2023, the Company completed its acquisition of Deeside Cereals I Ltd (\u201cDeeside\u201d) for \u00a311.3 (approximately $14.3). The acquisition was completed using cash on hand. Deeside is a producer of private label cereals in the United Kingdom (the \u201cU.K.\u201d) and is reported in the Weetabix segment. Based upon the preliminary purchase price allocation at March\u00a031, 2024, the Company identified and recorded $20.5 of net assets, which exceeded the purchase price paid for Deeside. As a result, the Company recorded a gain of $6.2, which was included in \u201cOther operating expense (income), net\u201d in the Condensed Consolidated Statements of Operations for the six months ended March\u00a031, 2024. Net sales and operating loss included in the Condensed Consolidated Statements of Operations attributable to Deeside were $7.2 and $0.7, respectively, for the three months ended March\u00a031, 2024 and $9.5 and $0.9, respectively, for the six months ended March\u00a031, 2024. Preliminary values of Deeside are measured as of the date of the acquisition, are not yet finalized pending the final purchase price allocation and are subject to change.", "entities": [ { "start_character": 819, "end_character": 822, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7200000.0 }, { "start_character": 894, "end_character": 897, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 9500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001530950-24-000144", "filing_date": 1714742478000, "quarter_ending": "20240331", "company_name": "Post Holdings, Inc.", "text": "During the three and six months ended March\u00a031, 2024, the Company had net sales to 8th Avenue of $2.1 and $3.8, respectively, and purchases from and royalties paid to 8th Avenue of $19.7 and $39.6, respectively. During the three and six months ended March\u00a031, 2023, the Company had net sales to 8th Avenue of", "entities": [ { "start_character": 98, "end_character": 101, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 107, "end_character": 110, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021182", "filing_date": 1715101994000, "quarter_ending": "20240331", "company_name": "Postal Realty Trust, Inc.", "text": "As of March\u00a031, 2024, the Company\u2019s properties were leased primarily to a single tenant, the USPS. For the three months ended March 31, 2024, approximately 12.4% of the Company\u2019s total rental income, or $2.1 million, was concentrated in Pennsylvania. For the three months ended March 31, 2023, approximately 13.7% of the Company's total rental income, or $2.0 million, was concentrated in Pennsylvania. The ability of the USPS to honor the terms of its leases is dependent upon regulatory, economic, environmental or competitive conditions in Pennsylvania or other regions where the Company operates in and could have a material effect on the Company\u2019s overall business results.", "entities": [ { "start_character": 204, "end_character": 207, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 356, "end_character": 359, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012040", "filing_date": 1711733121000, "quarter_ending": "20231231", "company_name": "Power REIT", "text": "The\nTrust has elected to be treated for tax purposes as a REIT, which means that it is exempt from U.S. federal income tax if a sufficient\nportion of its annual income is distributed to its shareholders, and if certain other requirements are met. In order for the Trust to\nmaintain its REIT qualification, at least 90% of its ordinary taxable annual income must be distributed to shareholders. As of December\n31, 2022, the last tax return completed to date, the Trust has a net operating loss of $24.5 million, which may reduce or eliminate this\nrequirement.", "entities": [ { "start_character": 497, "end_character": 501, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 24500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018671", "filing_date": 1715359265000, "quarter_ending": "20240331", "company_name": "Power REIT", "text": "The\nTrust has elected to be treated for tax purposes as a REIT, which means that it is exempt from U.S. federal income tax if a sufficient\nportion of its annual income is distributed to its shareholders, and if certain other requirements are met. In order for the Trust to\nmaintain its REIT qualification, at least 90% of its ordinary taxable annual income must be distributed to shareholders. As of December\n31, 2022, the last tax return completed to date, the Trust has a net operating loss of $24.5 million, which may reduce or eliminate this\nrequirement.", "entities": [ { "start_character": 497, "end_character": 501, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 24500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018911", "filing_date": 1715617979000, "quarter_ending": "20240331", "company_name": "Prairie Operating Co.", "text": "The\nCompany had a net loss of $9.0 million for the three months ended March 31, 2024. We cannot predict if we will be profitable. We may\ncontinue to incur losses for an indeterminate period of time and may be unable to achieve profitability. An extended period of losses\nand negative cash flow may prevent us from successfully operating and expanding our business. We may be unable to achieve or sustain\nprofitability on a quarterly or annual basis. At March 31, 2024, we had cash and cash equivalents of $4.0 million, a working capital\ndeficit of $2.5 million, and an accumulated deficit of $87.9 million.", "entities": [ { "start_character": 31, "end_character": 34, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001689548-24-000034", "filing_date": 1709622751000, "quarter_ending": "20231231", "company_name": "Praxis Precision Medicines, Inc.", "text": "The Company has incurred recurring losses since its inception, including a net loss of $123.3 million for the year ended December\u00a031, 2023. In addition, as of December\u00a031, 2023, the Company had an accumulated deficit of $653.9 million. The Company expects to continue to generate operating losses for the foreseeable future. ", "entities": [ { "start_character": 88, "end_character": 93, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -123300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001689548-24-000034", "filing_date": 1709622751000, "quarter_ending": "20231231", "company_name": "Praxis Precision Medicines, Inc.", "text": "The Company recognizes revenue for its research services performance obligation using an input method over the duration of the research services. During the year ended December\u00a031, 2023, the Company recognized $2.4 million in collaboration revenue related to the Collaboration Agreement in the consolidated statement of operations. As of December\u00a031, 2023, $2.6 million was included in deferred revenue in the consolidated balance sheet, of which $1.4 million was classified as current.", "entities": [ { "start_character": 211, "end_character": 214, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001689548-24-000060", "filing_date": 1715588465000, "quarter_ending": "20240331", "company_name": "Praxis Precision Medicines, Inc.", "text": "The Company has incurred recurring losses since its inception, including a net loss of $39.6 million for the three months ended March 31, 2024. In addition, as of March\u00a031, 2024, the Company had an accumulated deficit of $693.5\u00a0million. The Company expects to continue to generate operating losses for the foreseeable future.", "entities": [ { "start_character": 88, "end_character": 92, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -39600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001689548-24-000060", "filing_date": 1715588465000, "quarter_ending": "20240331", "company_name": "Praxis Precision Medicines, Inc.", "text": "The Company recognizes revenue for its research services performance obligation over time using an input method over the duration of the research services. During the three months ended March\u00a031, 2024, the Company recognized $0.4 million in collaboration revenue related to the Collaboration Agreement in the condensed consolidated statement of operations. As of March\u00a031, 2024, $2.1 million was included in deferred revenue in the condensed consolidated balance sheet, of which $1.3 million was classified as current. ", "entities": [ { "start_character": 226, "end_character": 229, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000884713-24-000028", "filing_date": 1715255938000, "quarter_ending": "20240330", "company_name": "Primo Water Corp /CN/", "text": "Income tax expense was $9.5\u00a0million on pre-tax income of $28.2\u00a0million for the three months ended March 30, 2024, as compared to income tax expense of $0.3 million on pre-tax income of $3.5 million in the comparable prior year period. The effective income tax rate for the three months ended March 30, 2024 was 33.7% compared to 8.6% in the comparable prior year period.", "entities": [ { "start_character": 58, "end_character": 62, "label": "earnings", "start_date_for_period": "2023-12-31", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 28200000.0 }, { "start_character": 186, "end_character": 189, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 3500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001680247-24-000051", "filing_date": 1710347747000, "quarter_ending": "20231231", "company_name": "ProPetro Holding Corp.", "text": "\u2014\u00a0Current trends in hydraulic fracturing equipment operating conditions such as larger pads, changes to job design and increased pumping hours per day have resulted in shorter useful lives for certain critical components that are included in our property and equipment assets. These recent trends necessitated a review of useful lives of our critical components like fluid ends, power ends, hydraulic fracturing units and other components in the first quarter of 2023. We determined that the estimated useful life of fluid ends is now less than one year, resulting in our determination that costs associated with the replacement of these components will no longer be capitalized, but instead recorded in inventories and amortized to cost of services over their estimated useful life. We have also shortened the estimated useful lives of power ends to two years from five years and hydraulic fracturing units to ten years from fifteen years. This change in accounting estimates was made effective January 1, 2023 and accounted for prospectively. The net effect of this change for the year ended December\u00a031, 2023, was a $19.1 million decrease in net income, or $0.17 per basic and diluted share, respectively.", "entities": [ { "start_character": 1120, "end_character": 1124, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -19100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011976", "filing_date": 1711728360000, "quarter_ending": "20231231", "company_name": "Processa Pharmaceuticals, Inc.", "text": "Our\nconsolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization\nof assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception,\ncurrently devoting substantially all of our efforts toward research and development of our next generation chemotherapy drug product\ncandidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated\ndeficit of $75.4 million at December 31, 2023. During the year ended December 31, 2023, we generated a net loss of $11.1 million and\nused $8.1 million in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved\nfor sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable\nfuture.", "entities": [ { "start_character": 676, "end_character": 680, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -11100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-007191", "filing_date": 1708439958000, "quarter_ending": "20231231", "company_name": "Propanc Biopharma, Inc.", "text": "The\naccompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation\nof the Company as a going concern. For the six months ended December 31, 2023, the Company had no revenues, had a net loss of $935,250,\nand had net cash used in operations of $572,342. Additionally, As of December 31, 2023, the Company had a working capital deficit, stockholders\u2019\ndeficit and accumulated deficit of $3,551,427, $3,563,599, and $65,797,142, respectively. It is management\u2019s opinion that these\nconditions raise substantial doubt about the Company\u2019s ability to continue as a going concern for a period of at least twelve months\nfrom the issue date of this Quarterly Report.", "entities": [ { "start_character": 276, "end_character": 283, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -935250.0 } ] }, { "form_type": "10-Q", "accession_number": "0001844505-24-000013", "filing_date": 1715377436000, "quarter_ending": "20240331", "company_name": "QT IMAGING HOLDINGS, INC.", "text": "The Company has incurred net operating losses and negative cash flows from operations since its inception and had an accumulated deficit of $22,068,735 as of March\u00a031, 2024. During the three months ended March\u00a031, 2024, the Company incurred a net loss of $4,298,590 and used $5,975,515 of cash in operating activities, which includes repayment of net liabilities assumed from the business combination. The Company expects to continue to incur losses, and its ability to achieve and sustain profitability will depend on the achievement of sufficient revenues to ", "entities": [ { "start_character": 256, "end_character": 265, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4298590.0 } ] }, { "form_type": "10-K", "accession_number": "0000068622-24-000005", "filing_date": 1708618293000, "quarter_ending": "20231231", "company_name": "QWEST CORP", "text": "2022 and 2021, our gross rental income was $304 million, $346 million and $324 million, respectively which represents 5% of our operating revenue for the years ended December 31, 2023, 2022 and 2021.", "entities": [ { "start_character": 44, "end_character": 47, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 304000000.0 }, { "start_character": 58, "end_character": 61, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 346000000.0 }, { "start_character": 75, "end_character": 78, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 324000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000068622-24-000007", "filing_date": 1714496922000, "quarter_ending": "20240331", "company_name": "QWEST CORP", "text": "For the three months ended March 31, 2024 and 2023, our gross rental income was $71\u00a0million and $80\u00a0million, respectively, which represents approximately 5% of our operating revenue for both periods.", "entities": [ { "start_character": 81, "end_character": 83, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 71000000.0 }, { "start_character": 97, "end_character": 99, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 80000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001906324-24-000011", "filing_date": 1709220599000, "quarter_ending": "20231231", "company_name": "QuidelOrtho Corp", "text": "2023. The impact from this change in estimate is approximately $0.3 million and is not material to the Company\u2019s Consolidated Financial Statements. ", "entities": [ { "start_character": 64, "end_character": 67, "label": "revenues", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001906324-24-000011", "filing_date": 1709220599000, "quarter_ending": "20231231", "company_name": "QuidelOrtho Corp", "text": "From the acquisition date through January 1, 2023, the acquired results of operations of Ortho contributed total revenues of $1,165.2\u00a0million and net loss of $126.2\u00a0million to the Company\u2019s consolidated results, which included amortization of acquired intangible assets of $104.7\u00a0million and recognition in Cost of sales, excluding amortization of intangibles of the fair value step-up of inventory of $60.6\u00a0million.", "entities": [ { "start_character": 126, "end_character": 133, "label": "revenues", "start_date_for_period": "2022-05-27", "end_date_for_period": "2023-01-01", "currency_/_unit": "iso4217:USD", "value": 1165200000.0 }, { "start_character": 159, "end_character": 164, "label": "earnings", "start_date_for_period": "2022-05-27", "end_date_for_period": "2023-01-01", "currency_/_unit": "iso4217:USD", "value": 126200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001906324-24-000011", "filing_date": 1709220599000, "quarter_ending": "20231231", "company_name": "QuidelOrtho Corp", "text": "In connection with the Combinations, the Company acquired the Joint Business between Ortho and Grifols, under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho\u2019s Hepatitis and HIV diagnostics business. The governance of the Joint Business is shared through a supervisory board made up of equal representation by Ortho and Grifols, which is responsible for all significant decisions relating to the Joint Business that are not exclusively assigned to either Ortho or Grifols, as defined in the Joint Business agreement. The Company\u2019s portion of the pre-tax net profit shared under the Joint Business was $47.3 million and $18.6 million during fiscal years 2023 and 2022, respectively. These amounts included the Company\u2019s portion of the pre-tax net profit of $21.4 million and $11.1 million during fiscal years 2023 and 2022, respectively, on sales transactions with third parties where the Company is the principal. The Company recognized revenues, cost of sales, excluding amortization of intangibles, and operating expenses, on a gross basis on these sales transactions in their respective lines in the Consolidated Statements of (Loss) Income. The Company\u2019s portion of the pre-tax net profit also included revenue from collaboration and royalty agreements of $26.0 million and $7.5 million during fiscal years 2023 and 2022, respectively, which is presented on a net basis within Total revenues.", "entities": [ { "start_character": 629, "end_character": 633, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 47300000.0 }, { "start_character": 647, "end_character": 651, "label": "earnings", "start_date_for_period": "2022-01-03", "end_date_for_period": "2023-01-01", "currency_/_unit": "iso4217:USD", "value": 18600000.0 }, { "start_character": 784, "end_character": 788, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 21400000.0 }, { "start_character": 802, "end_character": 806, "label": "earnings", "start_date_for_period": "2022-01-03", "end_date_for_period": "2023-01-01", "currency_/_unit": "iso4217:USD", "value": 11100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001906324-24-000032", "filing_date": 1715191463000, "quarter_ending": "20240331", "company_name": "QuidelOrtho Corp", "text": "For the three months ended March 31, 2024, the Company recognized an income tax benefit of $92.9 million in relation to loss before income taxes of $1,798.9 million, resulting in an effective tax rate of 5.2%. For the three months ended April 2, 2023, the Company recognized a provision for income taxes of $11.2 million in relation to income before income taxes of $60.0 million, resulting in an effective tax rate of 18.7%. For the three months ended March 31, 2024, the effective tax rate differed from the U.S. federal statutory rate primarily due to goodwill impairment charges that are nondeductible for tax purposes. For the three months ended April 2, 2023, the effective tax rate was impacted by income tax benefits related to non-U.S. earnings being taxed at rates that are different than the U.S. statutory rate, R&D credits, foreign tax credits, and foreign exchange losses, partially offset by income taxes owed in certain U.S. states and Global Intangible Low-Tax Income.", "entities": [ { "start_character": 149, "end_character": 156, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1798900000.0 }, { "start_character": 367, "end_character": 371, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-04-02", "currency_/_unit": "iso4217:USD", "value": 60000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001037038-24-000014", "filing_date": 1716481586000, "quarter_ending": "20240330", "company_name": "RALPH LAUREN CORP", "text": ", $3.055 billion, and $3.039 billion in Fiscal 2024, Fiscal 2023, and Fiscal 2022, respectively. Long-lived assets located in the U.S. were $1.024 billion and $1.106 billion as of March\u00a030, 2024 and April\u00a01, 2023, respectively.", "entities": [ { "start_character": 3, "end_character": 8, "label": "revenues", "start_date_for_period": "2022-04-03", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 3055000000.0 }, { "start_character": 23, "end_character": 28, "label": "revenues", "start_date_for_period": "2021-03-28", "end_date_for_period": "2022-04-02", "currency_/_unit": "iso4217:USD", "value": 3039000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001597672-24-000014", "filing_date": 1715175490000, "quarter_ending": "20240330", "company_name": "RAYONIER ADVANCED MATERIALS INC.", "text": "From 2021 through 2023, average maintenance capital expenditures for the Temiscaming High Purity Cellulose plant was $15\u00a0million. In 2023, the High Purity Cellulose plant incurred an operating loss of $60\u00a0million, including a non-cash asset impairment of $25\u00a0million. Working capital for the High Purity Cellulose plant was $31\u00a0million at the end of 2023. ", "entities": [ { "start_character": 202, "end_character": 204, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -60000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000052827-24-000014", "filing_date": 1708706866000, "quarter_ending": "20231231", "company_name": "RAYONIER INC", "text": "The years ended December\u00a031, 2023, 2022 and 2021 include $105.1\u00a0million, $16.6\u00a0million and $44.8\u00a0million, respectively, from Large Dispositions. The year ended December\u00a031, 2022 includes an $11.5 million gain associated with the multi-family apartment complex sale attributable to noncontrolling interests (\u201cNCI\u201d). The gain associated with the multi-family apartment complex sale attributable to noncontrolling interests is recorded within the Consolidated Statements of Income and Comprehensive Income under the caption \u201cOther operating (expense) income, net.\u201d", "entities": [ { "start_character": 58, "end_character": 63, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 105100000.0 }, { "start_character": 74, "end_character": 78, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 16600000.000000002 }, { "start_character": 92, "end_character": 96, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 44800000.0 } ] }, { "form_type": "10-K", "accession_number": "0000052827-24-000014", "filing_date": 1708706866000, "quarter_ending": "20231231", "company_name": "RAYONIER INC", "text": "The year ended December\u00a031, 2021 includes $45.6\u00a0million of operating income attributable to noncontrolling interests in Timber Funds. Included in operating income attributable to noncontrolling interests in Timber Funds for the year ended December\u00a031, 2021 is $41.2\u00a0million of income from Fund II Timberland Dispositions. The year ended December\u00a031, 2021 also includes $10.3\u00a0million of income on Fund II Timberland Dispositions attributable to Rayonier and a $7.5\u00a0million gain on investment in Timber Funds. ", "entities": [ { "start_character": 43, "end_character": 47, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 45600000.0 } ] }, { "form_type": "10-K", "accession_number": "0000082811-24-000035", "filing_date": 1708966597000, "quarter_ending": "20231231", "company_name": "REGAL REXNORD CORP", "text": "(1) 2023 excludes 0.4\u00a0million of share based compensation awards as the Company had a net loss during the year.", "entities": [ { "start_character": 18, "end_character": 21, "label": "eps", "start_date_for_period": "2022-01-02", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000082811-24-000035", "filing_date": 1708966597000, "quarter_ending": "20231231", "company_name": "REGAL REXNORD CORP", "text": "The following unaudited supplemental pro forma financial information presents the Company's financial results for the fiscal years ended December\u00a031, 2023 and December\u00a031, 2022, respectively, as if the Altra Transaction had occurred on January 2, 2022, the first day of the Company's fiscal year ended December 31, 2022. The pro forma financial information includes, where applicable, adjustments for: (i) additional amortization expense that would have been recognized related to the acquired intangible assets, (ii) additional interest expense on transaction related borrowings less interest income earned on the investment of proceeds from borrowings prior to the close of the Altra Transaction, (iii) additional depreciation expense that would have been recognized related to the acquired property, plant, and equipment, (iv) transaction costs and other one-time non-recurring costs, including share-based compensation expense related to the accelerated vesting of awards for certain former Altra employees, which reduced expenses by $102.6\u00a0million and increased expenses by $102.6\u00a0million for the fiscal years ended December\u00a031, 2023 and December\u00a031, 2022, respectively, (v) additional cost of sales related to the inventory valuation and lease ROU assets valuation adjustments which reduced expenses by $54.5\u00a0million and increased expenses by $54.5\u00a0million for the fiscal years ended December\u00a031, 2023 and December\u00a031, 2022, respectively and (vi) the estimated income tax effect on the pro forma adjustments.", "entities": [ { "start_character": 1039, "end_character": 1044, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 102600000.0 }, { "start_character": 1080, "end_character": 1085, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 102600000.0 }, { "start_character": 1310, "end_character": 1314, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 54500000.0 }, { "start_character": 1350, "end_character": 1354, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 54500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000082811-24-000035", "filing_date": 1708966597000, "quarter_ending": "20231231", "company_name": "REGAL REXNORD CORP", "text": "The following unaudited supplemental pro forma financial information presents the financial results for fiscal year 2021 as if the Rexnord Transaction had occurred on December 29, 2019. The pro forma financial information includes, where applicable, adjustments for: (i) additional amortization expense that would have been recognized related to the acquired intangible assets, (ii) additional interest expense on transaction related borrowings, (iii) additional depreciation expense that would have been recognized related to the acquired property, plant, and equipment, (iv) transaction costs and other one-time non-recurring costs which reduced expenses by $64.4\u00a0million for the year ended January 1, 2022, (v) cost of sales adjustments related to the inventory valuation adjustment which reduced expenses by $24.1\u00a0million for the year ended January 1, 2022, and (vi) the estimated income tax effect on the pro forma adjustments. The pro forma financial information excludes adjustments for estimated cost synergies or other effects of the integration of the Rexnord Transaction and the retrospective effect of changing accounting methods for valuing certain inventories to the FIFO cost method from the LIFO cost method.", "entities": [ { "start_character": 661, "end_character": 665, "label": "revenues", "start_date_for_period": "2021-01-03", "end_date_for_period": "2022-01-01", "currency_/_unit": "iso4217:USD", "value": 64400000.00000001 }, { "start_character": 813, "end_character": 817, "label": "revenues", "start_date_for_period": "2021-01-03", "end_date_for_period": "2022-01-01", "currency_/_unit": "iso4217:USD", "value": 24100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000082811-24-000088", "filing_date": 1715094007000, "quarter_ending": "20240331", "company_name": "REGAL REXNORD CORP", "text": "The following unaudited supplemental pro forma financial information presents the Company's financial results for the three months ended March 31, 2023. The March 31, 2023 information is presented as if the Altra Transaction had occurred on January 2, 2022, the first day of the Company's fiscal year ended December 31, 2022. The pro forma financial information includes, where applicable, adjustments for: (i) additional amortization expense that would have been recognized related to the acquired intangible assets, (ii) additional interest expense on transaction related borrowings less interest income earned on the investment of proceeds from borrowings prior to the close of the Altra Transaction, (iii) additional depreciation expense that would have been recognized related to the acquired property, plant, and equipment, (iv) transaction costs and other one-time non-recurring costs, including share-based compensation expense related to the accelerated vesting of awards for certain former Altra employees, which reduced expenses by $81.3\u00a0million for the three months ended March 31, 2023, and (v) the estimated income tax effect on the pro forma adjustments.", "entities": [ { "start_character": 1044, "end_character": 1048, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 81300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012490", "filing_date": 1711991595000, "quarter_ending": "20231231", "company_name": "RELIABILITY INC", "text": "Although\nthe Company has experienced net losses before taxes in the years ended December 31, 2023 and 2022 of $726 and $569, respectively,\nmanagement believes it has the ability to continue as a going concern and meet its financial obligation as they become due in 2024 and\nbeyond. The factors impacting this view include, but are not limited to, the following:", "entities": [ { "start_character": 111, "end_character": 114, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -726000.0 }, { "start_character": 120, "end_character": 123, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -569000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019582", "filing_date": 1715765813000, "quarter_ending": "20240331", "company_name": "RELIABILITY INC", "text": "Although\nthe Company experienced net losses before taxes for the three months ended March 31, 2024 and in the years ended December 31, 2023\nand 2022 of $262, $726, and $569, respectively, management believes it has the ability to continue as a going concern and meet its financial\nobligation as they become due in 2024 and beyond. The factors impacting this view include, but are not limited to, the following:", "entities": [ { "start_character": 153, "end_character": 156, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -262000.0 }, { "start_character": 159, "end_character": 162, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -726000.0 }, { "start_character": 169, "end_character": 172, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -569000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000083350-24-000013", "filing_date": 1715785318000, "quarter_ending": "20240331", "company_name": "RESERVE PETROLEUM CO", "text": "TWS is accounted for as a consolidated VIE. The Company entered into a Joint Venture Agreement (\"the Agreement\") with TWS South, LLC, a Texas limited liability company, on March 19, 2021, to form a water well drilling company where the Company would provide funding for equipment and operations, with TWS South, LLC providing industry expertise for operations and securing customers in the central Texas region. Equipment and vehicles totaling $330,000 were purchased by the Company and operating cash of $70,000 was made available to begin operations. The Agreement provided that the Company receive all net profits until a total of $300,000 plus 1.2 times any additional funding was reached. Since the effective date of the Agreement, the Company has contributed $1,160,000 toward the joint venture with losses totaling $315,269 as of March\u00a031, 2024.", "entities": [ { "start_character": 823, "end_character": 830, "label": "earnings", "start_date_for_period": "2021-03-19", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 315269.0 } ] }, { "form_type": "10-Q", "accession_number": "0000943819-24-000008", "filing_date": 1714072726000, "quarter_ending": "20240331", "company_name": "RESMED INC", "text": "We lease Sleep and Respiratory Care medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $24.1 million and $69.8 million for the three and nine months ended March\u00a031, 2024 and $22.1 million and $66.2 million for the three and nine months ended March\u00a031, 2023.", "entities": [ { "start_character": 567, "end_character": 571, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 24100000.0 }, { "start_character": 585, "end_character": 589, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 69800000.0 }, { "start_character": 654, "end_character": 658, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 22100000.0 }, { "start_character": 672, "end_character": 676, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 66200000.0 } ] }, { "form_type": "10-K", "accession_number": "0000085961-24-000030", "filing_date": 1708416216000, "quarter_ending": "20231231", "company_name": "RYDER SYSTEM INC", "text": "The non-lease revenue from maintenance services related to our ChoiceLease product is recognized in \"Lease & related maintenance and rental revenue\" in the Consolidated Statements of Earnings. We recognized $963\u00a0million in 2023, and $1.0 billion in both 2022 and 2021.", "entities": [ { "start_character": 209, "end_character": 212, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 963000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001739410-24-000035", "filing_date": 1710260763000, "quarter_ending": "20231231", "company_name": "Rallybio Corp", "text": "During the years ended December\u00a031, 2023 and 2022, the Company incurred a net loss of $74.6\u00a0million and $66.7 million, respectively. In addition, as of December\u00a031, 2023, the Company had an accumulated deficit of ", "entities": [ { "start_character": 87, "end_character": 91, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -74600000.0 }, { "start_character": 105, "end_character": 109, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -66700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001178913-24-000730", "filing_date": 1709025346000, "quarter_ending": "20231231", "company_name": "ReWalk Robotics Ltd.", "text": "The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.", "entities": [ { "start_character": 156, "end_character": 161, "label": "revenues", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-08-08", "currency_/_unit": "iso4217:USD", "value": 7658000.0 }, { "start_character": 175, "end_character": 178, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 249000.0 } ] }, { "form_type": "10-K", "accession_number": "0001178913-24-000730", "filing_date": 1709025346000, "quarter_ending": "20231231", "company_name": "ReWalk Robotics Ltd.", "text": "The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.", "entities": [ { "start_character": 156, "end_character": 161, "label": "revenues", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-08-08", "currency_/_unit": "iso4217:USD", "value": 7658000.0 }, { "start_character": 175, "end_character": 178, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 249000.0 } ] }, { "form_type": "10-K", "accession_number": "0001178913-24-000730", "filing_date": 1709025346000, "quarter_ending": "20231231", "company_name": "ReWalk Robotics Ltd.", "text": "The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.", "entities": [ { "start_character": 156, "end_character": 161, "label": "revenues", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-08-08", "currency_/_unit": "iso4217:USD", "value": 7658000.0 }, { "start_character": 175, "end_character": 178, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 249000.0 } ] }, { "form_type": "10-K", "accession_number": "0001178913-24-000730", "filing_date": 1709025346000, "quarter_ending": "20231231", "company_name": "ReWalk Robotics Ltd.", "text": "The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.", "entities": [ { "start_character": 156, "end_character": 161, "label": "revenues", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-08-08", "currency_/_unit": "iso4217:USD", "value": 7658000.0 }, { "start_character": 175, "end_character": 178, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 249000.0 } ] }, { "form_type": "10-K", "accession_number": "0001178913-24-000730", "filing_date": 1709025346000, "quarter_ending": "20231231", "company_name": "ReWalk Robotics Ltd.", "text": "The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.", "entities": [ { "start_character": 156, "end_character": 161, "label": "revenues", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-08-08", "currency_/_unit": "iso4217:USD", "value": 7658000.0 }, { "start_character": 175, "end_character": 178, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 249000.0 } ] }, { "form_type": "10-K", "accession_number": "0001178913-24-000730", "filing_date": 1709025346000, "quarter_ending": "20231231", "company_name": "ReWalk Robotics Ltd.", "text": "The total revenues and net loss of AlterG, included in the consolidated income statement, since the acquisition date through December 31, 2023, amounted to 7,658 thousand and 249 thousand, respectively.", "entities": [ { "start_character": 156, "end_character": 161, "label": "revenues", "start_date_for_period": "2023-08-01", "end_date_for_period": "2023-08-08", "currency_/_unit": "iso4217:USD", "value": 7658000.0 }, { "start_character": 175, "end_character": 178, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 249000.0 } ] }, { "form_type": "10-K", "accession_number": "0001653653-24-000004", "filing_date": 1708525687000, "quarter_ending": "20231231", "company_name": "Red Rock Resorts, Inc.", "text": "Non-gaming revenue also includes the portion of the transaction price from gaming or non-gaming contracts allocated to discretionary complimentaries and the value of loyalty points redeemed for food, beverage, room and other amenities. Discretionary complimentaries are classified in the departmental revenue category fulfilling the complimentary with a corresponding reduction in the departmental revenues that provided the complimentary, which is primarily casino revenue. Included in non-gaming revenues are discretionary complimentaries and loyalty point redemptions of $171.4 million, $157.5 million and $144.3 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 575, "end_character": 580, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 171400000.0 }, { "start_character": 591, "end_character": 596, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 157500000.0 }, { "start_character": 610, "end_character": 615, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 144300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001653653-24-000004", "filing_date": 1708525687000, "quarter_ending": "20231231", "company_name": "Red Rock Resorts, Inc.", "text": "Management fee revenue represents fees earned from the Company\u2019s three 50%-owned smaller properties, as well as management fees earned from the Company\u2019s previous management agreement with Graton Resort\u00a0& Casino (\u201cGraton Resort\u201d) which it managed on behalf of the Federated Indians of Graton Rancheria through February\u00a05, 2021. There were no management fees from Graton Resort for the year ended December\u00a031, 2023. For the years ended December\u00a031, 2022 and 2021, management fees from Graton Resort totaled $2.2 million and $7.8 million, respectively.", "entities": [ { "start_character": 209, "end_character": 211, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 }, { "start_character": 508, "end_character": 511, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2200000.0 }, { "start_character": 525, "end_character": 528, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 7800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001653653-24-000009", "filing_date": 1715260436000, "quarter_ending": "20240331", "company_name": "Red Rock Resorts, Inc.", "text": "Includes tenant lease revenue of $7.7 million and $5.8 million for the three months ended March\u00a031, 2024 and 2023, respectively. Revenue from tenant leases is accounted for under the lease accounting guidance and included in Other revenues in the Company\u2019s Condensed Consolidated Statements of Income.", "entities": [ { "start_character": 34, "end_character": 37, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7700000.0 }, { "start_character": 51, "end_character": 54, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-041175", "filing_date": 1699979452000, "quarter_ending": "20230930", "company_name": "Rennova Health, Inc.", "text": "During\nthe three months ended September 30, 2023 and 2022, estimated contractual allowances of $9.5 million and $10.2 million, respectively,\nand estimated implicit price concessions of $2.0 million and $1.6 million, respectively, have been recorded as reductions to our revenues\nand accounts receivable balances to enable us to record our revenues and accounts receivable at the estimated amounts we expect to collect.\nAs required by Topic 606, after estimated implicit price concessions and contractual and related allowance adjustments to revenues of\n$11.5 million and $11.8 million, respectively, for the three months ended September 30, 2023 and 2022, we reported net revenues of $3.5\nmillion and $2.8 million, respectively.", "entities": [ { "start_character": 685, "end_character": 688, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 3500000.0 }, { "start_character": 702, "end_character": 705, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 2800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-041175", "filing_date": 1699979452000, "quarter_ending": "20230930", "company_name": "Rennova Health, Inc.", "text": "During\nthe nine months ended September 30, 2023 and 2022, estimated contractual allowances of $29.1 million and $23.4 million, respectively,\nand estimated implicit price concessions of $4.3 million and $5.7 million, respectively, have been recorded as reductions to our revenues\nand accounts receivable balances to enable us to record our revenues and accounts receivable at the estimated amounts we expect to collect.\nAs required by Topic 606, after estimated implicit price concessions and contractual and related allowance adjustments to revenues of\n$33.4 million and $29.1 million, respectively, for the nine months ended September 30, 2023 and 2022, we reported net revenues of $14.8\nmillion and $7.6 million, respectively.", "entities": [ { "start_character": 684, "end_character": 688, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 14800000.0 }, { "start_character": 702, "end_character": 705, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 7600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-041175", "filing_date": 1699979452000, "quarter_ending": "20230930", "company_name": "Rennova Health, Inc.", "text": "At\nSeptember 30, 2023, the Company had a working capital deficit and a stockholders\u2019 deficit of $41.5\nmillion and $27.6\nmillion, respectively. While the Company had net income of $1.5\nmillion for the nine months ended September 30, 2023, it incurred a net loss of $0.5 million and $3.3\nmillion for the three months ended September 30, 2023 and the year ended December 31, 2022, respectively. As of the date of this report, its cash\nis deficient and payments for its operations in the ordinary course are not being made. Losses in prior years and other related\nfactors, including past due accounts payable and payroll taxes, as well as payment defaults under the terms of outstanding notes\npayable and debentures, raise substantial doubt about the Company\u2019s ability to continue as a going concern for 12 months from\nthe filing date of this report.", "entities": [ { "start_character": 180, "end_character": 183, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1500000.0 }, { "start_character": 265, "end_character": 268, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-041175", "filing_date": 1699979452000, "quarter_ending": "20230930", "company_name": "Rennova Health, Inc.", "text": "The\nCompany received HHS Provider Relief Funds, which were provided to eligible healthcare providers out of the $100\nbillion Public Health and Social Services Emergency Fund provided for in the Coronavirus Aid, Relief and Economic Security Act (the\n\u201cCARES Act\u201d). The funds were allocated to eligible healthcare providers for expenses and lost revenue attributable to\nthe COVID-19 pandemic. As of September 30, 2023, our facilities have received approximately $13.6\nmillion in relief funds. The fund payments are grants, not loans, and HHS will not require repayment, but the funds must be used\nonly for grant approved purposes. Based on an analysis of the compliance and reporting requirements of the Provider Relief Funds and\nthe impact of the pandemic on our operating results through September 30, 2023, we have recognized a net of $13.3\nmillion of these funds as income of which $0.3\nmillion was recognized in the three and nine months ended September 30, 2023, and $0.6\nmillion, $4.4\nmillion and $8.0\nmillion were recognized as income during the years ended December 31, 2022, 2021 and 2020, respectively. Accordingly, approximately\n$0.3\nmillion of relief funds received as of September 30, 2023 are included on our balance sheets in accrued expenses \u2013 see Note\n5.", "entities": [ { "start_character": 836, "end_character": 840, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 13300000.0 }, { "start_character": 884, "end_character": 887, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 1139, "end_character": 1142, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012357", "filing_date": 1711987552000, "quarter_ending": "20231231", "company_name": "RenovoRx, Inc.", "text": "The\nCompany has incurred significant losses and negative cash flows from operations since its inception. For the year ended December 31,\n2023, the Company reported a net loss of $10.2 million and an accumulated deficit of $41.4 million and does not expect to generate positive\ncash flows from operations in the foreseeable future. The Company expects to incur significant and increasing losses until regulatory\napproval is granted for its first product candidate, RenovoGem\u2122. Regulatory approval is not guaranteed and may never be obtained.\nThe Company believes it will be able to raise additional capital through debt financings, private or public equity financings, license\nagreements, collaborative agreements or other arrangements with other companies, or other sources of financing. There can be no assurance\nthat such financing will be available or will be at terms acceptable to the Company. The inability to raise capital as and when needed\nwould have a negative impact on the Company\u2019s liquidity financial condition and its ability to pursue its business strategy. The\nCompany will need to generate significant revenue to achieve profitability, and it may never do so.", "entities": [ { "start_character": 179, "end_character": 183, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -10200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018704", "filing_date": 1715361688000, "quarter_ending": "20240331", "company_name": "RenovoRx, Inc.", "text": "The\nCompany is in the pre-revenue stage and therefore has incurred significant losses and negative cash flows from operations since its inception.\nFor the three months ended March 31, 2024, the Company reported a net loss of $1.1\n", "entities": [ { "start_character": 226, "end_character": 229, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001737953-24-000008", "filing_date": 1715847259000, "quarter_ending": "20240331", "company_name": "Replimune Group, Inc.", "text": "The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $215.8 million and $174.3 million for the\u00a0years ended March\u00a031, 2024 and 2023, respectively. In addition, as of March\u00a031, 2024, the Company had an accumulated deficit of $701.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12\u00a0months from the issuance of the consolidated financial statements.", "entities": [ { "start_character": 310, "end_character": 315, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -215800000.0 }, { "start_character": 329, "end_character": 334, "label": "earnings", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -174300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001479290-24-000038", "filing_date": 1709138017000, "quarter_ending": "20231231", "company_name": "Revance Therapeutics, Inc.", "text": "We are not profitable and have incurred losses in each year since our inception. For the year ended December 31, 2023, we had a net loss of $324.0 million and an accumulated deficit of $2.1 billion. Although we began generating revenue from the sale of our Products and Services during the three months ended September 30, 2020, we expect to continue to incur GAAP operating losses for the foreseeable future. As of December 31, 2023, we had a working capital surplus of $249.6 million and capital resources of $253.9 million consisting of cash, cash equivalents, and short-term investments. To date, we have funded our operations primarily through the sale of common stock, convertible senior notes, sales of Products, proceeds from notes issued pursuant to the Note Purchase Agreement, and payments received from collaboration arrangements. We also have a remaining capacity to sell up to $47.2 million of our common stock under the 2022 ATM Agreement as of December 31, 2023.", "entities": [ { "start_character": 141, "end_character": 146, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -324000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001479290-24-000038", "filing_date": 1709138017000, "quarter_ending": "20231231", "company_name": "Revance Therapeutics, Inc.", "text": "We recognize revenue and estimate deferred revenue based on the cost of development service incurred over the total estimated cost of development services to be provided for the development period. For revenue recognition purposes, the development period has an estimated accounting program end date of 2026. It is possible that this period will change and is assessed at each reporting date. ASC Topic 606, Revenue from Contracts with Customers (ASC 606) requires that an entity include a constraint on the amount of variable consideration included in the transaction price. Variable consideration is considered \u201cconstrained\u201d if there is a potential for significant reversal of cumulative revenue recognized. As part of the constraint evaluation, we considered numerous factors, including a shift in certain responsibilities between the two parties which would result in changes to the net cost sharing payments and the total project budget, for which outcomes are difficult to predict as of the date of this Report. We will continue to evaluate the variable transaction price and related revenue recognition in each reporting period and as the above uncertainties are resolved or other changes in circumstances occur. For the years ended December 31, 2023, 2022, and 2021, we recognized revenue related to development services under the Viatris Agreement of $9.0\u00a0million, $7.1 million and $5.7 million, respectively.", "entities": [ { "start_character": 1361, "end_character": 1364, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 9000000.0 }, { "start_character": 1375, "end_character": 1378, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 7100000.0 }, { "start_character": 1392, "end_character": 1395, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 5700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001479290-24-000100", "filing_date": 1715272388000, "quarter_ending": "20240331", "company_name": "Revance Therapeutics, Inc.", "text": "We are not profitable and have incurred losses in each year since our inception. For the three months ended March 31, 2024, we had a total net loss of $53.2 million and an accumulated deficit of $2.1 billion. Although we generate revenue from the sale of our Products, we expect to continue to incur GAAP operating losses for the foreseeable future.", "entities": [ { "start_character": 152, "end_character": 156, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -53200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001571283-24-000022", "filing_date": 1713562184000, "quarter_ending": "20240331", "company_name": "Rexford Industrial Realty, Inc.", "text": "We engage in transactions with Howard Schwimmer, our Co-Chief Executive Officer, earning management fees and leasing commissions from\u00a0entities controlled individually by Mr.\u00a0Schwimmer. Fees and commissions earned from these entities are included in \u201cManagement and leasing services\u201d in the consolidated statements of operations.\u00a0We recorded $0.1 million and $0.2 million for the three months ended March\u00a031, 2024 and 2023, respectively, in management and leasing services revenue.", "entities": [ { "start_character": 342, "end_character": 345, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 359, "end_character": 362, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001635282-24-000030", "filing_date": 1709103653000, "quarter_ending": "20231231", "company_name": "Rimini Street, Inc.", "text": "As of December\u00a031, 2023, the Company\u2019s current liabilities exceeded its current assets by $47.7 million, and the Company recorded net income of $26.1 million for the year ended December\u00a031, 2023.\u00a0As of December\u00a031, 2023, the Company had available cash, cash equivalents and restricted cash of $115.9 million. As of December\u00a031, 2023, the Company\u2019s current liabilities included $263.1 million of deferred revenue whereby the historical costs of fulfilling the Company\u2019s commitments to provide services to its customers was approximately 38% of the related deferred revenue for the year ended December\u00a031, 2023.", "entities": [ { "start_character": 145, "end_character": 149, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 26100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001635282-24-000107", "filing_date": 1714633265000, "quarter_ending": "20240331", "company_name": "Rimini Street, Inc.", "text": "As of March 31, 2024, the Company\u2019s current liabilities exceeded its current assets by $44.5 million, and the Company recorded net income of $1.3 million for the three months ended March 31, 2024. As of March 31, 2024, the Company had available cash, cash equivalents and restricted cash of $129.4 million. As of March 31, 2024, the Company\u2019s current liabilities included $230.0 million of deferred revenue whereby the historical costs of fulfilling the Company's commitments to provide services to its clients was approximately 40% of the related deferred revenue for the three months ended March 31, 2024. ", "entities": [ { "start_character": 142, "end_character": 145, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-24-006630", "filing_date": 1710778306000, "quarter_ending": "20240131", "company_name": "Rise Gold Corp.", "text": "The Company is in the early stages of exploration and as is common with any exploration company, it raises financing for its acquisition activities. The accompanying consolidated financial statements have been prepared on the going concern basis, which presumes that the Company will continue operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred a loss of $1,975,911 for the six-month period ended January 31, 2024 and has accumulated a deficit of $28,644,897. The ability of the Company to continue as a going concern is dependent on the Company's ability to maintain continued support from its shareholders and creditors and to raise additional capital and implement its business plan. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. These events and conditions cast substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.", "entities": [ { "start_character": 470, "end_character": 479, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -1975911.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-24-006630", "filing_date": 1710778306000, "quarter_ending": "20240131", "company_name": "Rise Gold Corp.", "text": "The Company is in the early stages of exploration and as is common with any exploration company, it raises financing for its acquisition activities. The accompanying consolidated financial statements have been prepared on the going concern basis, which presumes that the Company will continue operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred a loss of $1,975,911 for the six-month period ended January 31, 2024 and has accumulated a deficit of $28,644,897. The ability of the Company to continue as a going concern is dependent on the Company's ability to maintain continued support from its shareholders and creditors and to raise additional capital and implement its business plan. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. These events and conditions cast substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.", "entities": [ { "start_character": 470, "end_character": 479, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -1975911.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-24-012652", "filing_date": 1718381136000, "quarter_ending": "20240430", "company_name": "Rise Gold Corp.", "text": "The Company is in the early stages of exploration and as is common with any exploration company, it raises financing for its acquisition activities. The accompanying consolidated financial statements have been prepared on the going concern basis, which presumes that the Company will continue operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred a loss of $2,868,722 for the nine-month period ended April 30, 2024 and has accumulated a deficit of $29,537,708. The ability of the Company to continue as a going concern is dependent on the Company's ability to maintain continued support from its shareholders and creditors and to raise additional capital and implement its business plan. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. These events and conditions cast substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.", "entities": [ { "start_character": 470, "end_character": 479, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -2868722.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-24-012652", "filing_date": 1718381136000, "quarter_ending": "20240430", "company_name": "Rise Gold Corp.", "text": "The Company is in the early stages of exploration and as is common with any exploration company, it raises financing for its acquisition activities. The accompanying consolidated financial statements have been prepared on the going concern basis, which presumes that the Company will continue operations for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred a loss of $2,868,722 for the nine-month period ended April 30, 2024 and has accumulated a deficit of $29,537,708. The ability of the Company to continue as a going concern is dependent on the Company's ability to maintain continued support from its shareholders and creditors and to raise additional capital and implement its business plan. There is no assurance that the Company will be able to obtain adequate financing in the future or that such financing will be on terms advantageous to the Company. These events and conditions cast substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.", "entities": [ { "start_character": 470, "end_character": 479, "label": "earnings", "start_date_for_period": "2023-08-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -2868722.0 } ] }, { "form_type": "10-Q", "accession_number": "0001805284-24-000067", "filing_date": 1715101849000, "quarter_ending": "20240331", "company_name": "Rocket Companies, Inc.", "text": "The Company had income tax expense of $7,656 on Income before income taxes of $298,370 for the three months ended March\u00a031, 2024. The Company had an income tax benefit of $4,504 on Loss before income taxes of $415,987 for the three months ended March 31, 2023.", "entities": [ { "start_character": 79, "end_character": 86, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 298370000.0 }, { "start_character": 210, "end_character": 217, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -415987000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001805284-24-000067", "filing_date": 1715101849000, "quarter_ending": "20240331", "company_name": "Rocket Companies, Inc.", "text": "(3)\u00a0\u00a0\u00a0\u00a0Dilutive impact of share-based compensation awards for the three months ended March\u00a031, 2024 and 2023 comprised of 5,991,171 and 969,848 related to restricted stock units, 63,150 and zero related to performance stock units, 11,125 and zero related to stock options and 46,008 and 47,755 related to TMSPP, respectively.", "entities": [ { "start_character": 122, "end_character": 131, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 5991171.0 }, { "start_character": 136, "end_character": 143, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 969848.0 }, { "start_character": 179, "end_character": 185, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 63150.0 }, { "start_character": 190, "end_character": 194, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 0.0 }, { "start_character": 231, "end_character": 237, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 11125.0 }, { "start_character": 242, "end_character": 246, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 0.0 }, { "start_character": 276, "end_character": 282, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 46008.0 }, { "start_character": 287, "end_character": 293, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 47755.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007271", "filing_date": 1709052218000, "quarter_ending": "20231231", "company_name": "SEALED AIR CORP/DE", "text": "U.S. net sales were $2,913.6 million, $3,073.0 million and $2,925.4 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively. No non-U.S. country accounted for net sales in excess of 10% of consolidated net sales for the years ended December\u00a031, 2023, 2022 or 2021. Sales are allocated to the country/region based on where each sale originated.", "entities": [ { "start_character": 21, "end_character": 28, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2913600000.0 }, { "start_character": 39, "end_character": 46, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3073000000.0 }, { "start_character": 60, "end_character": 67, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 2925400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001390478-24-000004", "filing_date": 1711641706000, "quarter_ending": "20231231", "company_name": "SELLAS Life Sciences Group, Inc.", "text": "Since inception, the Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit of $217.2 million as of December 31, 2023. During the year ended December 31, 2023, the Company incurred a net loss of $37.3 million and used $31.4 million of cash in operations. The Company continues to expect to generate operating losses and negative cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure. As of December 31, 2023, the Company had cash and cash equivalents of $2.5\u00a0million. The Company expects its cash and cash equivalents, together with the net proceeds from a public offering completed on January 8, 2024 (the \"January 2024 Offering\") and the registered direct offering completed on March 19, 2024 (the \"March 2024 Registered Direct Offering\"), will not be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions give rise to a substantial doubt over the Company\u2019s ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. ", "entities": [ { "start_character": 250, "end_character": 254, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -37300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001390478-24-000010", "filing_date": 1715702500000, "quarter_ending": "20240331", "company_name": "SELLAS Life Sciences Group, Inc.", "text": "Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of March\u00a031, 2024, has an accumulated deficit of $226.8\u00a0million. During the three months ended March\u00a031, 2024, the Company incurred a net loss of $9.6\u00a0million, and used $10.8\u00a0million of cash in operations. The Company expects to continue to generate operating losses and negative cash flows from operations for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure.", "entities": [ { "start_character": 254, "end_character": 257, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001032208-24-000015", "filing_date": 1715099355000, "quarter_ending": "20240331", "company_name": "SEMPRA", "text": "Revenues for reportable segments include intersegment revenues of $5 and $14 for the three months ended March 31, 2024 and $5 and $46 for the three months ended March 31, 2023 for Sempra California and Sempra Infrastructure, respectively.", "entities": [ { "start_character": 67, "end_character": 68, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 }, { "start_character": 74, "end_character": 76, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 14000000.0 }, { "start_character": 124, "end_character": 125, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 }, { "start_character": 131, "end_character": 133, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 46000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-006526", "filing_date": 1707922430000, "quarter_ending": "20231231", "company_name": "SHARING SERVICES GLOBAL Corp", "text": "The\naccompanying unaudited condensed consolidated financial statements as of December 31, 2023 have been prepared using generally\naccepted accounting principles in the United States of America (\u201cGAAP\u201d) applicable to a going concern, which\ncontemplates the realization of assets and the liquidation of liabilities in the ordinary course of business. During the nine months\nended December 31, 2023 and 2022, the Company had a net loss was approximately $4.8", "entities": [ { "start_character": 452, "end_character": 455, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -4800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022329", "filing_date": 1715274646000, "quarter_ending": "20240331", "company_name": "SHORE BANCSHARES INC", "text": "Total gross rental income was $0.3 million and $0.4 million for the three months ended March 31, 2024 and 2023, respectively. ", "entities": [ { "start_character": 31, "end_character": 34, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 48, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000832988-24-000083", "filing_date": 1711004747000, "quarter_ending": "20240203", "company_name": "SIGNET JEWELERS LTD", "text": "For Fiscal 2024, Fiscal 2023 and Fiscal 2022, the estimated dilutive effect of share awards includes 0.4\u00a0million, 0.9\u00a0million and 2.0\u00a0million of contingently issuable PSUs, respectively.", "entities": [ { "start_character": 101, "end_character": 104, "label": "eps", "start_date_for_period": "2023-01-29", "end_date_for_period": "2024-02-03", "currency_/_unit": "xbrli:shares", "value": 400000.0 }, { "start_character": 114, "end_character": 117, "label": "eps", "start_date_for_period": "2022-01-30", "end_date_for_period": "2023-01-28", "currency_/_unit": "xbrli:shares", "value": 900000.0 }, { "start_character": 130, "end_character": 133, "label": "eps", "start_date_for_period": "2021-01-31", "end_date_for_period": "2022-01-29", "currency_/_unit": "xbrli:shares", "value": 2000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000351817-24-000016", "filing_date": 1709222781000, "quarter_ending": "20231231", "company_name": "SILVERBOW RESOURCES, INC.", "text": "We recorded an income tax provision of $83.6 million, $9.6 million and $6.4 million for the years ended December 31, 2023, 2022 and 2021. We continually monitor all positive and negative evidence related to our determination on the need for a valuation allowance. During the fourth quarter of 2022, the Company's overall deferred tax position moved from a net deferred tax asset position into a net deferred tax liability position, exclusive of a valuation allowance. In addition, the Company determined it had a significant history of earnings over the prior three years and also considered the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods) and projected future taxable income in making this assessment. As such, during the fourth quarter of 2022, the Company's management determined there was sufficient positive evidence that indicated the Company would more likely that not be able to fully utilize its deferred tax assets and as a result, removed the full valuation allowance. Our effective tax rate for 2022 differs from the statutory rate primarily due to the removal of the full valuation allowance. We recorded an income tax provision of $83.6 million which was primarily attributable to deferred federal and current and deferred state income tax expense of $82.9\u00a0million on income before taxes of $381.3 million and $0.7\u00a0million of non-deductible expenses for the year ended December 31, 2023. While the ", "entities": [ { "start_character": 1380, "end_character": 1385, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 381300000.0 } ] }, { "form_type": "10-K", "accession_number": "0000766829-24-000023", "filing_date": 1708632938000, "quarter_ending": "20231231", "company_name": "SJW GROUP", "text": "The following table reconciles income tax expense to the amount computed by applying the federal statutory rate to income before income taxes of $90,943, $82,324 and $68,847 in 2023, 2022 and 2021, respectively:", "entities": [ { "start_character": 146, "end_character": 152, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 90943000.0 }, { "start_character": 155, "end_character": 161, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 82324000.0 }, { "start_character": 167, "end_character": 173, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 68847000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001663577-24-000137", "filing_date": 1715791585000, "quarter_ending": "20240331", "company_name": "SKINVISIBLE, INC.", "text": "The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization\nof assets and the satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2024, the Company\nhad a net loss of $290,372. The Company has also incurred cumulative net losses of $39,670,860 since its inception and requires capital\nfor its contemplated operational and marketing activities to take place. These factors, among others, raises substantial doubt about\nthe Company\u2019s ability to continue as a going concern within one year from the date of filing. ", "entities": [ { "start_character": 272, "end_character": 279, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -290372.0 }, { "start_character": 337, "end_character": 347, "label": "earnings", "start_date_for_period": "1999-06-06", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -39670860.0 } ] }, { "form_type": "10-Q", "accession_number": "0000004127-24-000007", "filing_date": 1706639016000, "quarter_ending": "20231229", "company_name": "SKYWORKS SOLUTIONS, INC.", "text": "During the three months ended December\u00a029, 2023, the Company changed its accounting estimate for the expected useful lives of certain machinery and equipment. The Company evaluated its current asset base and reassessed the estimated useful lives of certain machinery and equipment in connection with its recent usage of older equipment, including considering the technological and physical obsolescence of such machinery and equipment. Based on its ability to re-use equipment across generations of process technologies and historical usage trends, the Company determined that the expected useful lives for certain machinery and equipment should be increased by up to two years to reflect more closely the estimated economic lives of those assets. This change in estimate was applied prospectively effective for the first quarter of fiscal 2024 and resulted in a decrease in depreciation expense of $22.9\u00a0million for the three months ended December 29, 2023. This benefit increased income from operations by $2.6\u00a0million and decreased ending inventory by $20.3\u00a0million as of December 29, 2023. As a result of this change in accounting estimate, net income increased by $2.6\u00a0million and diluted earnings per share increased by $0.02 for the three months ended December 29, 2023.", "entities": [ { "start_character": 1009, "end_character": 1012, "label": "ebit", "start_date_for_period": "2023-09-30", "end_date_for_period": "2023-12-29", "currency_/_unit": "iso4217:USD", "value": 2600000.0 }, { "start_character": 1170, "end_character": 1173, "label": "ebit", "start_date_for_period": "2023-09-30", "end_date_for_period": "2023-12-29", "currency_/_unit": "iso4217:USD", "value": 2600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000004127-24-000019", "filing_date": 1714500449000, "quarter_ending": "20240329", "company_name": "SKYWORKS SOLUTIONS, INC.", "text": "During the six months ended March 29, 2024, the Company changed its accounting estimate for the expected useful lives of certain machinery and equipment. The Company evaluated its current asset base and reassessed the estimated useful lives of certain machinery and equipment in connection with its recent usage of older equipment, including considering the technological and physical obsolescence of such machinery and equipment. Based on its ability to re-use equipment across generations of process technologies and historical usage trends, the Company determined that the expected useful lives for certain machinery and equipment should be increased by up to two years to reflect more closely the estimated economic lives of those assets. This change in estimate was applied prospectively effective during the first quarter of fiscal 2024 and resulted in a decrease in depreciation expense of $18.9\u00a0million and $37.7 million for the three and six months ended March 29, 2024, respectively. This benefit decreased cost of goods sold by $1.8\u00a0million for each of the three and six months ended March 29, 2024, respectively, decreased research and development expenses by $2.5\u00a0million and $4.9\u00a0million for the three and six months ended March 29, 2024, respectively, and decreased ending inventory by $31.0\u00a0million as of March\u00a029, 2024. As a result of this change in accounting estimate, net income increased by $4.3\u00a0million and $6.7 million and diluted earnings per share increased by $0.03 and $0.04 for the three and six months ended March 29, 2024, respectively.", "entities": [ { "start_character": 1413, "end_character": 1416, "label": "earnings", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 4300000.0 }, { "start_character": 1430, "end_character": 1433, "label": "earnings", "start_date_for_period": "2023-09-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 6700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001040971-24-000010", "filing_date": 1708704400000, "quarter_ending": "20231231", "company_name": "SL GREEN REALTY CORP", "text": "We are entitled to receive fees for providing management, leasing, construction supervision and asset management services to certain of our joint ventures. We earned $21.1 million, $24.0 million and $19.6 million from these services, net of our ownership share of the joint ventures, for the years ended December\u00a031, 2023, 2022, and 2021, respectively. In addition, we have the ability to earn incentive fees based on the ultimate financial performance of certain of the joint venture properties.", "entities": [ { "start_character": 167, "end_character": 171, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 21100000.0 }, { "start_character": 182, "end_character": 186, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 24000000.0 }, { "start_character": 200, "end_character": 204, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 19600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001040971-24-000018", "filing_date": 1714761181000, "quarter_ending": "20240331", "company_name": "SL GREEN REALTY CORP", "text": "We are entitled to receive fees for providing management, leasing, construction supervision and asset management services to certain of our joint ventures. We earned $4.9 million and $4.9 million from these services, net of our ownership share of the joint ventures, for the three months ended March 31, 2024 and 2023, respectively. In addition, we have the ability to earn incentive fees based on the ultimate financial performance of certain of the joint venture properties.", "entities": [ { "start_character": 167, "end_character": 170, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4900000.0 }, { "start_character": 184, "end_character": 187, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001840856-24-000013", "filing_date": 1709284105000, "quarter_ending": "20231231", "company_name": "SOUNDHOUND AI, INC.", "text": "Since inception, the Company has generated recurring losses as well as negative operating cash flows and reported a net loss of $88.9 million for the year ended December\u00a031, 2023. As of December\u00a031, 2023, the Company had an accumulated deficit of $592.4 million. Management expects to continue to incur additional substantial losses in the foreseeable future. The Company has historically funded its operations primarily through equity or debt financings.", "entities": [ { "start_character": 129, "end_character": 133, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -88900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001840856-24-000019", "filing_date": 1715356477000, "quarter_ending": "20240331", "company_name": "SOUNDHOUND AI, INC.", "text": "Since inception, the Company has generated recurring losses as well as negative operating cash flows and reported a net loss of $33.0 million for the three months ended March\u00a031, 2024. As of March\u00a031, 2024, the Company had an accumulated deficit of $625.4 million. Management expects to continue to incur additional substantial losses in the foreseeable future. The Company has historically funded its operations primarily through equity or debt financings.", "entities": [ { "start_character": 129, "end_character": 133, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -33000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001163609-24-000010", "filing_date": 1715783144000, "quarter_ending": "20240331", "company_name": "SOUTH DAKOTA SOYBEAN PROCESSORS LLC", "text": "The Company has equity investments in Prairie AquaTech, LLC, Prairie AquaTech Manufacturing, LLC and Prairie AquaTech Investments, LLC. The Company sold soybean products to Prairie AquaTech, LLC and Prairie AquaTech Manufacturing, LLC totaling $4,021,936 and $2,947,866 during the three months ended March\u00a031, 2024 and 2023, respectively. As of March\u00a031, 2024 and December\u00a031, 2023, Prairie AquaTech, LLC and Prairie AquaTech Manufacturing, LLC owed the Company $1,947,289 and $1,216,699, respectively.", "entities": [ { "start_character": 245, "end_character": 254, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4021936.0 }, { "start_character": 260, "end_character": 269, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2947866.0 } ] }, { "form_type": "10-K", "accession_number": "0000092122-24-000009", "filing_date": 1707932696000, "quarter_ending": "20231231", "company_name": "SOUTHERN CO", "text": "The tariffs for the natural gas distribution utilities include provisions which allow for the recognition of certain revenues prior to the time such revenues are billed to customers.\u00a0These provisions are referred to as alternative revenue programs and provide for the recognition of certain revenues prior to billing, as long as the amounts recognized will be collected from customers within 24 months of recognition.\u00a0Revenue related to alternative revenue programs was $20 million, $(5) million, and $11 million in 2023, 2022, and 2021, respectively. These programs are as follows:", "entities": [ { "start_character": 471, "end_character": 473, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 20000000.0 }, { "start_character": 485, "end_character": 486, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -5000000.0 }, { "start_character": 502, "end_character": 504, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 11000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000092122-24-000009", "filing_date": 1707932696000, "quarter_ending": "20231231", "company_name": "SOUTHERN CO", "text": "On June 15, 2023, the Illinois Commission concluded its review of the Qualifying Infrastructure Plant (QIP) capital investments by Nicor Gas for calendar year 2019 under the QIP rider, also referred to as Investing in Illinois program. The Illinois Commission disallowed $32\u00a0million of the $415\u00a0million of capital investments commissioned in 2019, together with the related return on investment. Nicor Gas recorded a pre-tax charge to income in the second quarter 2023 of $38\u00a0million ($28\u00a0million after tax) associated with the disallowance of capital investments placed in service in 2019. The disallowance is reflected on the statement of income as an $8\u00a0million reduction to revenues and $30\u00a0million in estimated loss on regulatory disallowance. On August 3, 2023, the Illinois Commission denied a rehearing request filed by Nicor Gas. On August 24, 2023, Nicor Gas filed a notice of appeal with the Illinois Appellate Court. Nicor Gas defends these investments in infrastructure as prudently incurred.", "entities": [ { "start_character": 655, "end_character": 656, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-06-30", "currency_/_unit": "iso4217:USD", "value": -8000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000088205-24-000008", "filing_date": 1708624003000, "quarter_ending": "20231231", "company_name": "SPX Technologies, Inc.", "text": "We recognized revenues and net income for ASPEQ of $63.9 and $3.6, respectively, for the year ended December 31, 2023 with the net income impacted by charges during the year ended December 31, 2023 of (i) $13.2 associated with amortization of the various intangible assets mentioned above and (ii) $3.6 associated with the excess fair value (over historical cost) of inventory acquired which has been subsequently sold. During the year ended December 31, 2023, we incurred acquisition-related costs for ASPEQ of $5.4, which have been recorded to \u201cSelling, general and administrative\u201d within our consolidated statements of operations and \u201cCorporate expense\u201d within consolidated operating income in Note 7. ", "entities": [ { "start_character": 52, "end_character": 56, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 63900000.0 }, { "start_character": 62, "end_character": 65, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3600000.0 }, { "start_character": 299, "end_character": 302, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000088205-24-000039", "filing_date": 1714671766000, "quarter_ending": "20240330", "company_name": "SPX Technologies, Inc.", "text": "For the three months ended March\u00a030, 2024, we recorded an income tax provision of $1.9 on $51.1 of pre-tax income from continuing operations, resulting in an effective rate of 3.7%. This compares to an income tax provision for the three months ended April\u00a01, 2023 of $11.3 on $50.4 of pre-tax income from continuing operations, resulting in an effective rate of 22.4%. The most significant item impacting the income tax provision for the first quarters of 2024 and 2023 was $10.9 and $0.9, respectively, of excess tax benefits resulting from stock-based compensation awards that vested and/or were exercised during the periods. ", "entities": [ { "start_character": 91, "end_character": 95, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 51100000.0 }, { "start_character": 277, "end_character": 281, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-04-01", "currency_/_unit": "iso4217:USD", "value": 50400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000088205-24-000039", "filing_date": 1714671766000, "quarter_ending": "20240330", "company_name": "SPX Technologies, Inc.", "text": "We recognized revenues and net income for Ing\u00e9nia of $12.5 and $0.6, respectively, for the three months ended March 30, 2024 with the net income impacted by charges during the three months ended March 30, 2024 of $3.3 associated with amortization of the various intangible assets mentioned above and $0.9 associated with the excess fair value (over historical cost) of inventory acquired which was subsequently sold. ", "entities": [ { "start_character": 54, "end_character": 58, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 12500000.0 }, { "start_character": 64, "end_character": 67, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001479094-24-000016", "filing_date": 1714493342000, "quarter_ending": "20240331", "company_name": "STAG Industrial, Inc.", "text": "During the three months ended March\u00a031, 2024 and 2023, there were\u00a0123,595 and 139,340 of unvested restricted shares of common stock (on a weighted average basis), respectively, that were considered participating securities for the purposes of computing earnings per share.", "entities": [ { "start_character": 66, "end_character": 73, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 123595.0 }, { "start_character": 78, "end_character": 85, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 139340.0 } ] }, { "form_type": "10-Q", "accession_number": "0000093676-24-000010", "filing_date": 1715616056000, "quarter_ending": "20240331", "company_name": "STARRETT L S CO", "text": "Tax expense for the nine month period ended March 31, 2024 was $2.6\u00a0million on profit before tax of $4.8\u00a0million (an effective tax rate of 51%). During the nine month period ended March 31, 2024, the Company recorded a discrete tax expense of $1.3\u00a0million related to IRS Notice 2023-55 released in July 2023 which grants taxpayers temporary relief from applying these final foreign tax credit regulations for tax years beginning on or after December 28, 2021 and ending on or before December 31, 2023 and IRS Notice 2023-80 released in December 2023 which modifies the temporary relief period from applying the final foreign tax credit regulations to tax years beginning on or after December 28, 2021 and ending before the date that notice or guidance withdrawing or modifying the temporary relief is issued. Other than this discrete tax expense recorded, the effective rate for the nine months ended March 31, 2024 was higher than the U.S. statutory tax rate of 21% primarily due to the jurisdictional mix of earnings, particularly Brazil with a statutory rate of 34%, offset by tax credits and permanent deductions generated from research expenses.", "entities": [ { "start_character": 101, "end_character": 104, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000093676-24-000010", "filing_date": 1715616056000, "quarter_ending": "20240331", "company_name": "STARRETT L S CO", "text": "Tax expense for the three month period ended March 31, 2024 was $0.1\u00a0million on profit before tax of $0.7\u00a0million (an effective tax rate of 14%). The effective rate for the three months ended March 31, 2024 was lower than the U.S. statutory tax rate of 21% due in part to a discrete tax benefit of $0.1\u00a0million related to the reversal of uncertain tax positions due to the lapse in the statute of limitations and tax credits and permanent deductions generated from research expenses, offset by the jurisdictional mix of earnings, particularly Brazil with a statutory rate of 34% and foreign losses not benefited.", "entities": [ { "start_character": 102, "end_character": 105, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000093676-24-000010", "filing_date": 1715616056000, "quarter_ending": "20240331", "company_name": "STARRETT L S CO", "text": "Tax expense for the nine months ended March 31, 2023 was a benefit of $1.3\u00a0million on profit before tax of $11.4\u00a0million (an effective tax rate of 11%). During the nine months ended March 31, 2023, the Company recorded a discrete tax benefit of $5.0\u00a0million related to the Company\u2019s partial release of its valuation allowance against its U.S. foreign tax credits and state net operating losses carryforwards, which are expected to be utilized based on demonstrated profitability and current and future forecast income. In addition the Company used current forecasts of future taxable income. Excluding the tax benefit related to the partial release of valuation allowance of 44%, the effective tax rate for the nine months ended March 31, 2023 was higher than the U.S. statutory tax rate of 21% primarily due to the GILTI provisions and the jurisdictional mix of earnings, particularly Brazil with a statutory rate of 34%, and non-creditable foreign withholding tax.", "entities": [ { "start_character": 108, "end_character": 112, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 11400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001452857-24-000008", "filing_date": 1709884457000, "quarter_ending": "20231231", "company_name": "STEEL PARTNERS HOLDINGS L.P.", "text": "On April 25, 2022, the Company completed the sale of its subsidiary, SL Power Electronics Corporation (\"SLPE\"), to AEI US Subsidiary LLC, a subsidiary of Advanced Energy Industries, Inc. for a sales price of $144,500, consisting entirely of cash, subject to customary closing net working capital adjustments. The Company recognized a pre-tax gain from operations of $86,507 which is presented in Gains from sales of businesses in the consolidated statement of operations for the year ended December 31, 2022. SLPE designed, manufactured, and marketed power conversion solutions for original equipment manufacturers in the medical, lighting, audio-visual, controls, and industrial sectors and comprised the Company's Electrical Products business in the Diversified Industrial segment. SLPE recognized net sales of $19,408 and income before taxes of $72 for the year ended December 31, 2022.", "entities": [ { "start_character": 849, "end_character": 851, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 72000.0 } ] }, { "form_type": "10-K", "accession_number": "0001757898-24-000008", "filing_date": 1717000552000, "quarter_ending": "20240331", "company_name": "STERIS plc", "text": "On April 1, 2024, we completed the sale of the Controlled Environment Certification Services business. In fiscal 2025, we recorded net proceeds of $41,546. The business generated approximately $35,000 in revenues during fiscal 2024.", "entities": [ { "start_character": 194, "end_character": 200, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 35000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001757898-24-000008", "filing_date": 1717000552000, "quarter_ending": "20240331", "company_name": "STERIS plc", "text": "In April 2022, we entered into an Asset Purchase Agreement to sell certain assets of our Animal Health business to Veterinary Orthopedic Implants, LLC. We recorded net proceeds of $5,228 and recognized a pre-tax loss on the sale of $4,852 in the Selling, general, and administrative expenses line of the Consolidated Statements of Income. The business generated annual revenues of approximately $12,000.", "entities": [ { "start_character": 396, "end_character": 402, "label": "revenues", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 12000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001757898-24-000008", "filing_date": 1717000552000, "quarter_ending": "20240331", "company_name": "STERIS plc", "text": "In December 2021, we entered into an Asset Purchase Agreement to sell our Renal Care business to Evoqua Water Technologies Corp., for cash consideration of approximately $196,000, subject to certain potential adjustments, including a customary working capital adjustment and contingent consideration of $12,300. We recognized a pre-tax gain on the sale of $4,919. The transaction closed on January 3, 2022. We acquired the Renal Care business as part of the Cantel transaction, which closed on June 2, 2021, and had been integrated into STERIS's Healthcare segment. The Renal Care business generated annual revenues of approximately $180,000. The proceeds from the sale received at closing were used to repay outstanding debt. During the third quarter of fiscal 2023, we received an additional $1,396 in working capital settlements related to the sale of this business. During the second quarter of fiscal 2024, we received an additional $9,458 out of escrow.", "entities": [ { "start_character": 634, "end_character": 641, "label": "revenues", "start_date_for_period": "2022-01-03", "end_date_for_period": "2022-01-03", "currency_/_unit": "iso4217:USD", "value": 180000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000310764-24-000024", "filing_date": 1707908150000, "quarter_ending": "20231231", "company_name": "STRYKER CORP", "text": "Beginning in the first quarter 2023 we consolidated Other MedSurg and Neurotechnology into Endoscopy as Other MedSurg and Neurotechnology (primarily Sustainability Solutions) has been fully integrated into our Endoscopy business. Endoscopy includes sales related to Other of $343, $302 and $277 for 2023, 2022 and 2021. We have reflected these changes in all historical periods presented.", "entities": [ { "start_character": 276, "end_character": 279, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 343000000.0 }, { "start_character": 282, "end_character": 285, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 302000000.0 }, { "start_character": 291, "end_character": 294, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 277000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-013335", "filing_date": 1707841900000, "quarter_ending": "20231231", "company_name": "SUNHYDROGEN, INC.", "text": "On\nJanuary 27, 2022, the Company adopted the 2022 Equity Incentive Plan, to enable the Company to attract and retain the types of employees,\nconsultants, and directors who will contribute to the Company\u2019s long-range success. The maximum number of shares of common stock\nthat may be issued under the 2022 Plan is initially 400,000,000. The number of shares will automatically be increased on the first\u00a0day\nof the Company\u2019s fiscal year beginning in 2023 so that the total number of shares issuable will at all times equal fifteen percent\n(15%) of the Company\u2019s fully diluted capitalization on the first\u00a0day of the Company\u2019s fiscal year, unless the Board\nadopts a resolution providing that the number of shares issuable under the 2022 Plan shall not be so increased. During the year ended\nJune 30, 2023, the Company granted restricted stock in the amount of 120,600,000 shares of which 110,600,000 vested in the period. Ten\nMillion shares will vest on January 1, 2024. As of December 31, 2023, there were 279,400,000 in the reserve. As of July 1, 2023, the\nplan increased to 723,194,742 shares.", "entities": [ { "start_character": 855, "end_character": 866, "label": "eps", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-06-30", "currency_/_unit": "xbrli:shares", "value": 120600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001356576-24-000013", "filing_date": 1709050499000, "quarter_ending": "20231231", "company_name": "SUPERNUS PHARMACEUTICALS, INC.", "text": "The Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition. ASU 2020-06 requires the application of the if-converted method for calculating diluted EPS, whereas the Company previously calculated diluted EPS under the treasury stock method. As a result of the adoption of ASU 2020-06, the 6.8 million in dilutive shares associated with the conversion of the 2023 Notes were included in the calculation of diluted EPS for the year ended December\u00a031, 2022 because their inclusion would be dilutive. For the year ended December\u00a031, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.", "entities": [ { "start_character": 334, "end_character": 337, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "xbrli:shares", "value": 6800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001701756-24-000095", "filing_date": 1715789134000, "quarter_ending": "20240331", "company_name": "Sadot Group Inc.", "text": "The Company's primary source of liquidity is cash on hand. As of March\u00a031, 2024, the Company had a cash balance, a working capital surplus and an accumulated deficit of $1.2 million, $13.2 million, and $87.4 million, respectively. During the three months ended March 31, 2024, the Company incurred a Pre-tax net loss of $0.3 million. The Company had Net ", "entities": [ { "start_character": 321, "end_character": 324, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001108524-24-000009", "filing_date": 1717008500000, "quarter_ending": "20240430", "company_name": "Salesforce, Inc.", "text": "The Company computes its year-to-date provision for income taxes by applying the estimated annual effective tax rate to year-to-date pretax income or loss and adjusts the provision for discrete tax items recorded in the period. For the three months ended April 30, 2024, the Company reported a tax provision of $334\u00a0million on pretax income of $1.9\u00a0billion, which resulted in an effective tax rate of 18 percent. The Company\u2019s effective tax rate differed from the U.S. statutory rate of 21 percent primarily due to research and development credits and excess tax benefits from stock-based compensation.", "entities": [ { "start_character": 345, "end_character": 348, "label": "earnings", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 1900000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001108524-24-000009", "filing_date": 1717008500000, "quarter_ending": "20240430", "company_name": "Salesforce, Inc.", "text": "For the three months ended April 30, 2023, the Company reported a tax provision of $127\u00a0million on pretax income of $326\u00a0million, which resulted in an effective tax rate of 39 percent. The Company\u2019s effective tax rate differed from the U.S. statutory rate of 21 percent primarily due to profitable jurisdictions outside of the United States subject to tax rates greater than 21 percent and withholding taxes.", "entities": [ { "start_character": 117, "end_character": 120, "label": "earnings", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 326000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-23-020819", "filing_date": 1699981254000, "quarter_ending": "20230930", "company_name": "Salona Global Medical Device Corp", "text": "Since acquisition, Biodex has generated $13,328,263 of revenue and has generated a loss before tax of $939,044. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Biodex's revenue would have been $17,874,672 and loss before tax would have been $1,817,837. If the combination had taken place at the beginning of the year, consolidated revenues would have been $51,452,202 and consolidated losses before tax would have been $620,807. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. The pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 41, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 13328263.0 }, { "start_character": 103, "end_character": 110, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 939044.0 }, { "start_character": 335, "end_character": 345, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 17874672.0 }, { "start_character": 383, "end_character": 392, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 1817837.0 }, { "start_character": 498, "end_character": 508, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 51452202.0 }, { "start_character": 561, "end_character": 568, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 620807.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-23-020819", "filing_date": 1699981254000, "quarter_ending": "20230930", "company_name": "Salona Global Medical Device Corp", "text": "Since acquisition, Biodex has generated $13,328,263 of revenue and has generated a loss before tax of $939,044. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Biodex's revenue would have been $17,874,672 and loss before tax would have been $1,817,837. If the combination had taken place at the beginning of the year, consolidated revenues would have been $51,452,202 and consolidated losses before tax would have been $620,807. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. The pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 41, "end_character": 51, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 13328263.0 }, { "start_character": 103, "end_character": 110, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 939044.0 }, { "start_character": 335, "end_character": 345, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 17874672.0 }, { "start_character": 383, "end_character": 392, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 1817837.0 }, { "start_character": 498, "end_character": 508, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 51452202.0 }, { "start_character": 561, "end_character": 568, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 620807.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-23-020819", "filing_date": 1699981254000, "quarter_ending": "20230930", "company_name": "Salona Global Medical Device Corp", "text": "Since acquisition, Arrowhead has generated $1,950,861 of revenue and has generated a loss before tax of $15,498. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Arrowhead's revenue would have been $3,322,260 and a loss before tax would have been $22,150. If the combination had taken place at the beginning of the year, consolidated revenues would have been $48,277,192 and consolidated net earnings before tax would have been $251,334. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 44, "end_character": 53, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 1950861.0 }, { "start_character": 105, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 15498.0 }, { "start_character": 339, "end_character": 348, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 3322260.0 }, { "start_character": 388, "end_character": 394, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 22150.0 }, { "start_character": 500, "end_character": 510, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 48277192.0 }, { "start_character": 569, "end_character": 576, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 251334.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-23-020819", "filing_date": 1699981254000, "quarter_ending": "20230930", "company_name": "Salona Global Medical Device Corp", "text": "Since acquisition, Arrowhead has generated $1,950,861 of revenue and has generated a loss before tax of $15,498. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Arrowhead's revenue would have been $3,322,260 and a loss before tax would have been $22,150. If the combination had taken place at the beginning of the year, consolidated revenues would have been $48,277,192 and consolidated net earnings before tax would have been $251,334. The pro forma unaudited results include estimates and assumptions which management believes are reasonable. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.", "entities": [ { "start_character": 44, "end_character": 53, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 1950861.0 }, { "start_character": 105, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 15498.0 }, { "start_character": 339, "end_character": 348, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 3322260.0 }, { "start_character": 388, "end_character": 394, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 22150.0 }, { "start_character": 500, "end_character": 510, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 48277192.0 }, { "start_character": 569, "end_character": 576, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:CAD", "value": 251334.0 } ] }, { "form_type": "10-Q", "accession_number": "0000811830-24-000020", "filing_date": 1715005030000, "quarter_ending": "20240331", "company_name": "Santander Holdings USA, Inc.", "text": "As discussed in Note 1 to these Condensed Consolidated Financial Statements, in December 2023 SBNA acquired a 20 percent interest in the Structured LLC for approximately $1.1\u00a0billion. The Company did not transfer any assets to the VIE and does not control nor consolidate it. SBNA's 20 percent interest is reported as an AFS debt security that has a fair value of approximately $1.1\u00a0billion and $1.1\u00a0billion at March\u00a031, 2024 and December\u00a031, 2023, respectively. As of March\u00a031, 2024 SBNA serviced approximately $8.9\u00a0billion in multi-family loans for the Structured LLC and receives a market rate servicing fee. For the three months ended March\u00a031, 2024, SBNA recognized $9.9\u00a0million in servicing fee income from the servicing of these assets which is recorded in Miscellaneous income, net, in the accompanying Condensed Consolidated Statements of Operations.", "entities": [ { "start_character": 673, "end_character": 676, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 9900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001883313-24-000013", "filing_date": 1709914566000, "quarter_ending": "20231230", "company_name": "Savers Value Village, Inc.", "text": "In fiscal year 2021, the Company recorded $1.8\u00a0million of transaction costs in selling, general and administrative expense in the Consolidated Statements of Operations and Comprehensive Income related to the 2nd Ave. Acquisition. Following the 2nd Ave. Acquisition, the Company recognized an incremental $15.5\u00a0million of net sales and $1.2\u00a0million of net income attributable to the 2nd Ave. business during fiscal year 2021.", "entities": [ { "start_character": 336, "end_character": 339, "label": "earnings", "start_date_for_period": "2021-01-03", "end_date_for_period": "2022-01-01", "currency_/_unit": "iso4217:USD", "value": 1200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001692063-24-000100", "filing_date": 1714667557000, "quarter_ending": "20240331", "company_name": "Schneider National, Inc.", "text": "The following tables summarize our segment information. Inter-segment revenues within Other include revenues from insurance premiums charged to other segments for workers\u2019 compensation, auto, and other types of insurance. Inter-segment revenues included in Other revenues below were $25.1 million and $18.2 million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 284, "end_character": 288, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 25100000.0 }, { "start_character": 302, "end_character": 306, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 18200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001914496-24-000042", "filing_date": 1711748950000, "quarter_ending": "20231231", "company_name": "Sculptor Diversified Real Estate Income Trust, Inc.", "text": "For the 2023 Successor Period, the Company recognized $5.0 million of rental revenue for the amortization of aggregate below-market leases in excess of above-market leases resulting from the allocation of the purchase price of the applicable properties. Amortization of the in-place leases and leasing commissions during the 2023 Successor Period aggregating to $5.7M is included in depreciation and amortization of the statements of operations. The recognition of these items were not applicable to the 2023 Predecessor Period, or 2022 Predecessor Period.", "entities": [ { "start_character": 55, "end_character": 58, "label": "revenues", "start_date_for_period": "2023-01-04", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001914496-24-000066", "filing_date": 1715803081000, "quarter_ending": "20240331", "company_name": "Sculptor Diversified Real Estate Income Trust, Inc.", "text": "For the 2024 Successor Interim Period and 2023 Successor Interim Period, the Company recognized $1.0 million and $1.3 million, respectively, of rental revenue for the amortization of aggregate below-market leases in excess of above-market leases resulting from the allocation of the purchase price of the applicable properties. Amortization of the in-place leases and leasing commissions during the 2024 Successor Interim Period and 2023 Successor Interim Period aggregating to $3.0 million and $0.9 million, respectively is included in depreciation and amortization of the condensed statements of operations. The recognition of these items were not applicable to the 2023 Predecessor Interim Period.", "entities": [ { "start_character": 97, "end_character": 100, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 }, { "start_character": 114, "end_character": 117, "label": "revenues", "start_date_for_period": "2023-01-04", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001137789-24-000034", "filing_date": 1714148410000, "quarter_ending": "20240329", "company_name": "Seagate Technology Holdings plc", "text": "$70\u00a0million for three and nine months ended March\u00a029, 2024, respectively. Earnings per share for the three months ended March\u00a029, 2024 increased by ", "entities": [ { "start_character": 1, "end_character": 3, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 70000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001854270-24-000052", "filing_date": 1715271314000, "quarter_ending": "20240331", "company_name": "Senti Biosciences, Inc.", "text": "The Company earned no revenue in the three months ended March 31, 2024 and during the three months ended March 31, 2023, Customers A and B accounted for 81% and 19% of revenue, respectively. All revenues were generated in the United States.", "entities": [ { "start_character": 19, "end_character": 21, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001854270-24-000052", "filing_date": 1715271314000, "quarter_ending": "20240331", "company_name": "Senti Biosciences, Inc.", "text": "The Company also subleased its manufacturing facility in Alameda to GeneFab and recorded sublease income of $1.5 million including variable costs charged for the three months ended March\u00a031, 2024. ", "entities": [ { "start_character": 109, "end_character": 112, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001854270-24-000052", "filing_date": 1715271314000, "quarter_ending": "20240331", "company_name": "Senti Biosciences, Inc.", "text": "The Company\u2019s revenue consists of amounts received related to research services provided to customers. The Company earned no revenue in the three months ended March 31, 2024.", "entities": [ { "start_character": 122, "end_character": 124, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001373715-24-000169", "filing_date": 1715013956000, "quarter_ending": "20240331", "company_name": "ServiceNow, Inc.", "text": "In January 2024, we completed an assessment of the useful life of our data center equipment and determined we should increase the estimated useful life of data center equipment from four years to five years. This change in accounting estimate was effective beginning fiscal year 2024. Based on the carrying amount of data center equipment included in property and equipment, net as of December\u00a031, 2023, the effect of this change in estimate for the three months ended March 31, 2024, was a reduction in depreciation expense of $29 million and an increase in net income of $23 million, or $0.11 per share basic and diluted.", "entities": [ { "start_character": 574, "end_character": 576, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 23000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001662991-24-000052", "filing_date": 1709222625000, "quarter_ending": "20231231", "company_name": "Sezzle Inc.", "text": "Total income was $159,356,772 and $125,570,441 for the years ended December 31, 2023 and 2022, respectively. Total income in the fourth quarter has historically been strongest for us, in line with consumer spending habits during the holiday shopping season. Our total income is classified into three categories: transaction income, subscription revenue, and income from other services.", "entities": [ { "start_character": 18, "end_character": 29, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 159356772.0 }, { "start_character": 35, "end_character": 46, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 125570441.0 } ] }, { "form_type": "10-K", "accession_number": "0001662991-24-000052", "filing_date": 1709222625000, "quarter_ending": "20231231", "company_name": "Sezzle Inc.", "text": "We earn income from fees paid by merchants in exchange for our payment processing services. These merchant processing fees are applied to the underlying sales of consumers passing through our platform and are predominantly based on a percentage of the consumer order value plus a fixed fee per transaction. For orders that result in a financing receivable, merchant processing fees are recognized over the underlying order\u2019s duration using the effective interest method. For orders that do not result in a financing receivable, merchant processing fees are recognized at the time the sale is completed. Merchant processing fees totaled $75,249,247 and $92,101,949 for the years ended December 31, 2023 and 2022, respectively.", "entities": [ { "start_character": 637, "end_character": 647, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 75249247.0 }, { "start_character": 653, "end_character": 663, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 92101949.0 } ] }, { "form_type": "10-K", "accession_number": "0001662991-24-000052", "filing_date": 1709222625000, "quarter_ending": "20231231", "company_name": "Sezzle Inc.", "text": "We also earn income from partners on consumer transactions. This income includes interchange fees earned through our virtual card solution and promotional incentives with third parties. Virtual card interchange income is recognized over the underlying order\u2019s duration using the effective interest method and promotional incentives are recognized as they are earned during the promotional period. Partner income totaled $15,336,902 and $7,662,960 for the years ended December 31, 2023 and 2022, respectively.", "entities": [ { "start_character": 421, "end_character": 431, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 15336902.0 }, { "start_character": 437, "end_character": 446, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 7662960.0 } ] }, { "form_type": "10-K", "accession_number": "0001662991-24-000052", "filing_date": 1709222625000, "quarter_ending": "20231231", "company_name": "Sezzle Inc.", "text": "Transaction income also includes income from consumers when they choose to make an installment payment, excluding the first installment, using a card pursuant to state law. These fees are recognized at the time a payment is processed and totaled $19,152,908 and $2,834,287 for the years ended December 31, 2023 and 2022, respectively.", "entities": [ { "start_character": 247, "end_character": 257, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 19152908.0 }, { "start_character": 263, "end_character": 272, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2834287.0 } ] }, { "form_type": "10-K", "accession_number": "0001662991-24-000052", "filing_date": 1709222625000, "quarter_ending": "20231231", "company_name": "Sezzle Inc.", "text": "Income from other services includes all other incomes earned from merchants, consumers, and other third parties not included in transaction income or subscription revenue. This includes late payment fees, gateway fees, and marketing revenue earned from affiliates. Late payment fees are assessed to consumers who fail to make a timely payment and are applied to principal installments that are delinquent for more than 48 hours (or longer depending on the regulations within a specific state jurisdiction) after the scheduled installment payment date. Late payment fees are recognized at the time the fee is charged to the consumer to the extent the fee is reasonably collectible. Late payment fees totaled $9,742,652 and $12,559,835 for the years ended December 31, 2023 and 2022, respectively.", "entities": [ { "start_character": 708, "end_character": 717, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 9742652.0 }, { "start_character": 723, "end_character": 733, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 12559835.0 } ] }, { "form_type": "10-Q", "accession_number": "0001662991-24-000143", "filing_date": 1715191428000, "quarter_ending": "20240331", "company_name": "Sezzle Inc.", "text": "Income from other services includes all other incomes earned from merchants, consumers, and other third parties not included in transaction income or subscription revenue. This includes late payment fees, gateway fees, and marketing revenue earned from affiliates. Late payment fees are assessed to consumers who fail to make a timely payment and are applied to principal installments that are delinquent for more than 48 hours (or longer depending on the regulations within a specific state jurisdiction) after the scheduled installment payment date. Late payment fees are recognized at the time the fee is charged to the consumer to the extent the fee is reasonably collectible. Late payment fees totaled $2,712,682 and $2,419,069 for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 708, "end_character": 717, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2712682.0 }, { "start_character": 723, "end_character": 732, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2419069.0 } ] }, { "form_type": "10-Q", "accession_number": "0001662991-24-000143", "filing_date": 1715191428000, "quarter_ending": "20240331", "company_name": "Sezzle Inc.", "text": "Transaction income also includes income from consumers when they choose to make an installment payment, excluding the first installment, using a card pursuant to state law. These fees are recognized at the time a payment is processed and totaled $7,387,258 and $3,654,746 for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 247, "end_character": 256, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 7387258.0 }, { "start_character": 262, "end_character": 271, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3654746.0 } ] }, { "form_type": "10-Q", "accession_number": "0001662991-24-000143", "filing_date": 1715191428000, "quarter_ending": "20240331", "company_name": "Sezzle Inc.", "text": "We also earn income from partners on consumer transactions. This income includes interchange fees earned through our virtual card solution and promotional incentives with third parties. Virtual card interchange income is recognized over the underlying order\u2019s duration using the effective interest method and promotional incentives are recognized as they are earned during the promotional period. Partner income totaled $4,709,116 and $2,259,786 for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 421, "end_character": 430, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4709116.0 }, { "start_character": 436, "end_character": 445, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2259786.0 } ] }, { "form_type": "10-Q", "accession_number": "0001662991-24-000143", "filing_date": 1715191428000, "quarter_ending": "20240331", "company_name": "Sezzle Inc.", "text": "We earn income from fees paid by merchants in exchange for our payment processing services. These merchant processing fees are applied to the underlying sales of consumers passing through our platform and are predominantly based on a percentage of the consumer order value plus a fixed fee per transaction. For orders that result in a financing receivable, merchant processing fees are recognized over the underlying order\u2019s duration using the effective interest method. For orders that do not result in a financing receivable, merchant processing fees are recognized at the time the sale is completed. Merchant processing fees totaled $14,521,569 and $19,951,436 for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 637, "end_character": 647, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 14521569.0 }, { "start_character": 653, "end_character": 663, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 19951436.0 } ] }, { "form_type": "10-Q", "accession_number": "0001662991-24-000143", "filing_date": 1715191428000, "quarter_ending": "20240331", "company_name": "Sezzle Inc.", "text": "Total income was $46,978,634 and $34,673,431 for the three months ended March 31, 2024 and 2023, respectively. Total income in the fourth quarter has historically been strongest for us, in line with consumer spending habits during the holiday shopping season. Our total income is classified into three categories: transaction income, subscription revenue, and income from other services.", "entities": [ { "start_character": 18, "end_character": 28, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 46978634.0 }, { "start_character": 34, "end_character": 44, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 34673431.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010822", "filing_date": 1711042128000, "quarter_ending": "20231231", "company_name": "Shuttle Pharmaceuticals Holdings, Inc.", "text": "Our\nconsolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction\nof liabilities and commitments in the normal course of business. The Company has incurred losses since inception and has a net loss of\napproximately $6.6 million and no revenues for the year ended December 31, 2023 and working capital of approximately $4.6 million as\nof December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and certain cash\npayment requirements. These conditions, and the Company\u2019s ability to comply with such conditions, raise substantial doubt about the Company\u2019s ability to continue as a going concern within\none year after the date that the consolidated financial statements are issued.", "entities": [ { "start_character": 293, "end_character": 296, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -6600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018944", "filing_date": 1715619719000, "quarter_ending": "20240331", "company_name": "Shuttle Pharmaceuticals Holdings, Inc.", "text": "Our condensed consolidated financial statements are prepared on a going\nconcern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of\nbusiness. The Company has incurred losses since inception and has a net loss of approximately $1.7 million and no revenues for the three months ended March 31, 2024 and has\nworking capital of approximately $2.9 million as of March 31, 2024. In addition, the convertible note payable\noutstanding at March 31, 2024 includes covenants and certain cash payment requirements. These conditions, and the Company\u2019s ability\nto comply with such conditions, raise substantial doubt about the Company\u2019s ability to continue as a going concern within one year\nafter the date that the condensed consolidated financial statements are issued.", "entities": [ { "start_character": 303, "end_character": 306, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-043648", "filing_date": 1715790285000, "quarter_ending": "20240331", "company_name": "Signing Day Sports, Inc.", "text": "Our\nfinancial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of\nliabilities and commitments in the normal course of business. We sustained significant losses and negative cash flows from operations\nand are dependent on debt and equity financing to fund operations. We incurred a net loss of approximately $2.498 million for the three\nmonths ended March 31, 2024 and $0.865 million for the three months ended March 31, 2023. We had cash used in operating activities of\napproximately $1.847 million and $0.216 million for the three months ended March 31, 2024 and 2023, respectively, and an accumulated\ndeficit of approximately $19.5 million and $17.0 million as of March 31, 2024 and December 31, 2023, respectively. These conditions raise\nsubstantial doubt about our ability to continue as a going concern.", "entities": [ { "start_character": 379, "end_character": 384, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2498000.0 }, { "start_character": 440, "end_character": 445, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -865000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-23-086214", "filing_date": 1699894834000, "quarter_ending": "20230930", "company_name": "Silo Pharma, Inc.", "text": "As\nreflected in the accompanying unaudited consolidated financial statements, the Company generated a net loss of $2,579,507 and used cash\nin operations of $2,314,486 during the nine months ended September 30, 2023. Additionally, the Company has an accumulated deficit of\n$9,750,635 on September 30, 2023. As of September 30, 2023, the Company had working capital of $8,241,824.", "entities": [ { "start_character": 115, "end_character": 124, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -2579507.0 } ] }, { "form_type": "10-Q", "accession_number": "0001023459-24-000048", "filing_date": 1712306677000, "quarter_ending": "20240229", "company_name": "Simulations Plus, Inc.", "text": "$0.3 million. Cost of revenues increased $0.5 million, or 60%, primarily due to $0.2\u00a0million from the acquisition of Immunetrics, and gross profit increased by $0.6 million, or 6%, primarily due to the increase in revenues.", "entities": [ { "start_character": 1, "end_character": 4, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001023459-24-000048", "filing_date": 1712306677000, "quarter_ending": "20240229", "company_name": "Simulations Plus, Inc.", "text": "For the three months ended February\u00a029, 2024, the revenue increase of $1.4 million, or 27%, compared to the three months ended February\u00a028, 2023, was primarily due to higher revenues from QSP services of $0.8 million, PBPK services of $0.5 million, higher revenues from PKPD services of $0.3 million, offset by lower revenues from REG services of $0.1 million. Cost of revenues increased by $2.0 million, or 110% primarily driven by $1.3\u00a0million from the reorganization of our internal structure from divisions based on prior acquisitions to business units organized around key product and service offerings and $0.4\u00a0million from the acquisition of Immunetrics, which contributed to our services headcount. Our new business unit structure is designed to optimize the utilization of our scientific talent in support of our revenue growth objectives. Gross profit decreased by $0.5 million, or 15%, for the same periods.", "entities": [ { "start_character": 205, "end_character": 208, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 800000.0 }, { "start_character": 236, "end_character": 239, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 500000.0 }, { "start_character": 288, "end_character": 291, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 348, "end_character": 351, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": -100000.0 }, { "start_character": 876, "end_character": 879, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001023459-24-000048", "filing_date": 1712306677000, "quarter_ending": "20240229", "company_name": "Simulations Plus, Inc.", "text": "$0.3 million. Cost of revenues increased by $0.6 million, or 35%, primarily due to $0.4\u00a0million from the acquisition of Immunetrics, and gross profit increased by $2.0 million, or 14%, primarily due to increase in revenues, for the six months ended February\u00a029, 2024, compared to the six months ended February\u00a028, 2023.", "entities": [ { "start_character": 1, "end_character": 4, "label": "revenues", "start_date_for_period": "2023-09-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001971213-24-000011", "filing_date": 1709219926000, "quarter_ending": "20231231", "company_name": "Sinclair, Inc.", "text": "As we consolidate the licensees as VIEs, the amounts we earn or pay under the arrangements are eliminated in consolidation and the gross revenues of the stations are reported in our consolidated statements of operations. Our consolidated revenues include $140 million, $159 million, and $144 million for the years ended December\u00a031, 2023, 2022, and 2021, respectively, related to the Cunningham Stations.", "entities": [ { "start_character": 256, "end_character": 259, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 140000000.0 }, { "start_character": 270, "end_character": 273, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 159000000.0 }, { "start_character": 288, "end_character": 291, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 144000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001971213-24-000011", "filing_date": 1709219926000, "quarter_ending": "20231231", "company_name": "Sinclair, Inc.", "text": "We sell advertising time to certain operating subsidiaries of MileOne Autogroup, Inc. (\"MileOne\"), including automobile dealerships, body shops, and an automobile leasing company. David Smith, our Executive Chairman, has a controlling interest in, and is a member of the Board of Directors of, MileOne. We received payments for advertising totaling less than $0.1\u00a0million for each of the years ended December\u00a031, 2023 and 2022 and $0.1 million for the year December 31, 2021.", "entities": [ { "start_character": 360, "end_character": 363, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 }, { "start_character": 432, "end_character": 435, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001971213-24-000011", "filing_date": 1709219926000, "quarter_ending": "20231231", "company_name": "Sinclair, Inc.", "text": "In 2019, we entered into a management services agreement with DSG, a wholly-owned subsidiary of DSIH, in which we provide DSG with affiliate sales and marketing services and general and administrative services. The contractual annual amount due from DSG for these services during the fiscal year ended December\u00a031, 2023 is $78 million, which is subject to increases on an annual basis.\u00a0Additionally, the agreement contains an incentive fee payable to us calculated based on certain terms contained within new or renewed distribution agreements with Distributors. As a condition to the Transaction, DSG will defer the cash payment of a portion of its management fee payable to the Company over the next four years. Pursuant to this agreement, excluding the amounts deferred as part of the Transaction, the local media segment recorded $49 million and $60 million of revenue for the years ended December\u00a031, 2023 and 2022 related to both the contractual and incentive fees, of which $24 million was eliminated in consolidation prior to the Deconsolidation for the year ended December 31, 2022. We will not recognize the portion of deferred management fees as revenue until such fees are determined to be collectible. The terms of this agreement are subject to change depending upon the outcome of the settlement with DSG discussed in ", "entities": [ { "start_character": 835, "end_character": 837, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 49000000.0 }, { "start_character": 851, "end_character": 853, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 60000000.0 }, { "start_character": 982, "end_character": 984, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 24000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001971213-24-000011", "filing_date": 1709219926000, "quarter_ending": "20231231", "company_name": "Sinclair, Inc.", "text": "We recorded revenue of $19 million and $15 million for the years ended December\u00a031, 2023 and 2022, respectively, within other related to certain other transactions between DSIH and the Company.", "entities": [ { "start_character": 24, "end_character": 26, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 19000000.0 }, { "start_character": 40, "end_character": 42, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 15000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001971213-24-000011", "filing_date": 1709219926000, "quarter_ending": "20231231", "company_name": "Sinclair, Inc.", "text": "Includes $52 million and $39 million for the year ended December\u00a031, 2023 and 2022, respectively, of revenue for services provided by local media under management services agreements after the Deconsolidation, which is not eliminated in consolidation.", "entities": [ { "start_character": 10, "end_character": 12, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 52000000.0 }, { "start_character": 26, "end_character": 28, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 39000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001971213-24-000011", "filing_date": 1709219926000, "quarter_ending": "20231231", "company_name": "Sinclair, Inc.", "text": "In August 2019, YES Network, which was accounted for as an equity method investment prior to the Deconsolidation, entered into a management services agreement with the Company, in which the Company provides certain services for an initial term that expires on August 29, 2025. The agreement will automatically renew for two 2-year renewal terms, with a final expiration on August 29, 2029. Pursuant to the terms of the agreement, the YES Network paid us a management services fee of $1 million and $6 million for the years ended December 31, 2022 and 2021, respectively.", "entities": [ { "start_character": 484, "end_character": 485, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 }, { "start_character": 499, "end_character": 500, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 6000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001971213-24-000037", "filing_date": 1715341354000, "quarter_ending": "20240331", "company_name": "Sinclair, Inc.", "text": "SBG recorded revenue of $1 million during the three months ended March 31, 2024 and $5 million during the three months ended March 31, 2023 within the local media segment and other related to certain other transactions between DSIH and SBG.", "entities": [ { "start_character": 25, "end_character": 26, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 }, { "start_character": 85, "end_character": 86, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001971213-24-000037", "filing_date": 1715341354000, "quarter_ending": "20240331", "company_name": "Sinclair, Inc.", "text": "SBG has a management services agreement with DSG, a wholly-owned subsidiary of DSIH, in which SBG provides DSG with affiliate sales and marketing services and general and administrative services. Pursuant to this agreement, SBG recorded $13 million of revenue for the three months ended March 31, 2024 and $9 million of revenue for the three months ended March 31, 2023. ", "entities": [ { "start_character": 239, "end_character": 241, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 13000000.0 }, { "start_character": 308, "end_character": 309, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 9000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001971213-24-000037", "filing_date": 1715341354000, "quarter_ending": "20240331", "company_name": "Sinclair, Inc.", "text": "SBG recorded revenue of $2 million during the three months ended March 31, 2024, within the local media segment related to sales services provided by SBG to Sinclair, and certain of its direct and indirect subsidiaries.", "entities": [ { "start_character": 25, "end_character": 26, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001971213-24-000037", "filing_date": 1715341354000, "quarter_ending": "20240331", "company_name": "Sinclair, Inc.", "text": "As SBG consolidates the licensees as VIEs, the amounts SBG earns or pays under the arrangements are eliminated in consolidation and the gross revenues of the stations are reported in SBG's consolidated statements of operations. SBG's consolidated revenues include $34 million for the three months ended March 31, 2024 and $36 million for the three months ended March 31, 2023, related to the Cunningham Stations.", "entities": [ { "start_character": 265, "end_character": 267, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 34000000.0 }, { "start_character": 323, "end_character": 325, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 36000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001971213-24-000037", "filing_date": 1715341354000, "quarter_ending": "20240331", "company_name": "Sinclair, Inc.", "text": "We have a management services agreement with DSG, a wholly-owned subsidiary of DSIH, in which we provide DSG with affiliate sales and marketing services and general and administrative services. Pursuant to this agreement, the local media segment recorded $13\u00a0million and $9\u00a0million of revenue for the three months ended March 31, 2024 and 2023, respectively. ", "entities": [ { "start_character": 256, "end_character": 258, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 13000000.0 }, { "start_character": 272, "end_character": 273, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 9000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001971213-24-000037", "filing_date": 1715341354000, "quarter_ending": "20240331", "company_name": "Sinclair, Inc.", "text": "As we consolidate the licensees as VIEs, the amounts we earn or pay under the arrangements are eliminated in consolidation and the gross revenues of the stations are reported in our consolidated statements of operations. Our consolidated revenues include $34\u00a0million for the three months ended March 31, 2024 and $36\u00a0million for the three months ended March 31, 2023 related to the Cunningham Stations.", "entities": [ { "start_character": 256, "end_character": 258, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 34000000.0 }, { "start_character": 314, "end_character": 316, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 36000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001971213-24-000037", "filing_date": 1715341354000, "quarter_ending": "20240331", "company_name": "Sinclair, Inc.", "text": "We recorded revenue of $4\u00a0million and $5\u00a0million during the three months ended March 31, 2024 and 2023, respectively, related to certain other transactions between DSIH and the Company.", "entities": [ { "start_character": 24, "end_character": 25, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 }, { "start_character": 39, "end_character": 40, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011546", "filing_date": 1711559445000, "quarter_ending": "20231231", "company_name": "Sintx Technologies, Inc.", "text": "For\nthe years ended December 31, 2023 and 2022, the Company incurred a net loss of $8.3 million and $12.0 million, respectively, and used\ncash in operations of $14.1 million and $10.3 million, respectively. The Company had an accumulated deficit of $270.7 million and $262.5\nmillion as of December 31, 2023 and 2022, respectively. To date, the Company\u2019s operations have been principally financed from proceeds\nfrom the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the\nCompany will continue to generate operating losses and use cash in operations. The Company\u2019s continuation as a going concern is\ndependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company\ncan attain profitability and positive cash flows from operations or obtain additional financing is uncertain.", "entities": [ { "start_character": 84, "end_character": 87, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8300000.000000001 }, { "start_character": 101, "end_character": 105, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -12000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018961", "filing_date": 1715620834000, "quarter_ending": "20240331", "company_name": "Sintx Technologies, Inc.", "text": "For\nthe three months ended March 31, 2024, and 2023, the Company incurred a net loss of $0.9 million and $0.3 million, respectively, and\nused cash in operating activities of $2.7 million and $4.9 million, respectively. The Company had an accumulated deficit of $271.6 million\nand $270.7 million as of March 31, 2024, and December 31, 2023, respectively. To date, the Company\u2019s operations have been principally\nfinanced from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It\nis anticipated that the Company will continue to generate operating losses and use cash in operations. The Company\u2019s continuation\nas a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether\nand when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.", "entities": [ { "start_character": 89, "end_character": 92, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -900000.0 }, { "start_character": 106, "end_character": 109, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001819974-24-000008", "filing_date": 1710522794000, "quarter_ending": "20231231", "company_name": "SkyWater Technology, Inc", "text": "For the fiscal years ended December\u00a031, 2023, January\u00a01, 2023, and January\u00a02, 2022, the Company incurred net losses attributable to SkyWater Technology, Inc. of $30,756, $39,593, and $50,696, respectively. As of December\u00a031, 2023 and January\u00a01, 2023, the Company held cash and cash equivalents of $18,382 and $30,025, respectively.", "entities": [ { "start_character": 162, "end_character": 168, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -30756000.0 }, { "start_character": 171, "end_character": 177, "label": "earnings", "start_date_for_period": "2022-01-03", "end_date_for_period": "2023-01-01", "currency_/_unit": "iso4217:USD", "value": -39593000.0 }, { "start_character": 184, "end_character": 190, "label": "earnings", "start_date_for_period": "2021-01-04", "end_date_for_period": "2022-01-02", "currency_/_unit": "iso4217:USD", "value": -50696000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001819974-24-000014", "filing_date": 1715348258000, "quarter_ending": "20240331", "company_name": "SkyWater Technology, Inc", "text": "For the three-month periods ended March\u00a031, 2024 and April\u00a02, 2023, the Company incurred net losses attributable to SkyWater Technology, Inc. of $5,729 and $4,273, respectively. As of March\u00a031, 2024 and December\u00a031, 2023, the Company had cash and cash equivalents of $20,002 and $18,382, respectively.", "entities": [ { "start_character": 146, "end_character": 151, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -5729000.0 }, { "start_character": 157, "end_character": 162, "label": "earnings", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-04-02", "currency_/_unit": "iso4217:USD", "value": -4273000.0 } ] }, { "form_type": "10-K", "accession_number": "0001516551-24-000048", "filing_date": 1711053697000, "quarter_ending": "20231231", "company_name": "Skye Bioscience, Inc.", "text": "The Company has incurred operating losses and negative cash flows from operations since inception and as of December\u00a031, 2023, had a working capital deficit of $2,250,156 and an accumulated deficit of $104,382,549. As of December\u00a031, 2023, the Company had unrestricted cash in the amount of $1,256,453. For the years ended December\u00a031, 2023 and 2022, the Company incurred losses from operations of $34,735,173 and $18,311,732, respectively. For the years ended December\u00a031, 2023 and 2022, the Company incurred net losses of $37,644,784 and $19,481,602, respectively. The Company expects to continue to incur significant losses and negative cash flows from operations through 2024 and in the future. ", "entities": [ { "start_character": 399, "end_character": 409, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -34735173.0 }, { "start_character": 415, "end_character": 425, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -18311732.0 }, { "start_character": 525, "end_character": 535, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -37644784.0 }, { "start_character": 541, "end_character": 551, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -19481602.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-031988", "filing_date": 1712816304000, "quarter_ending": "20231231", "company_name": "Smart Powerr Corp.", "text": "For the years ended December\n31, 2023 and 2022, the Company had a net loss of $746,786\u00a0and $4,457,327, respectively. The Company had an accumulated deficit of\n$60.50\u00a0million as of December 31, 2023. The Company disposed all of its systems and currently holds five power generating systems\nthrough Erdos TCH, the five power generating systems are currently not producing any electricity. The Company is in the process of transforming\nand expanding into an energy storage integrated solution provider business. The Company plans to pursue disciplined and targeted expansion\nstrategies for market areas the Company currently does not serve. The Company actively seeks and explores opportunities to apply energy\nstorage technologies to new industries or segments with high growth potential, including industrial and commercial complexes, large scale\nphotovoltaic (PV) and wind power stations,\u00a0remote islands without electricity,\u00a0and smart energy cities with multi-energy supplies.\u00a0\nThe Company\u2019s cash flow forecast indicates it will have sufficient cash to fund its operations for the next 12 months from the date\nof issuance of these CFS.", "entities": [ { "start_character": 79, "end_character": 86, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -746786.0 }, { "start_character": 92, "end_character": 101, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -4457327.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-042702", "filing_date": 1715687039000, "quarter_ending": "20240331", "company_name": "Smart Powerr Corp.", "text": "For the\nthree months ended March 31, 2024 and 2023, the Company had a net loss of $279,797\u00a0and $89,504, respectively. The Company had an\naccumulated deficit of $60.78\u00a0million as of March 31, 2024. The Company disposed all of its systems and currently holds five power\ngenerating systems through Erdos TCH, the five power generating systems are currently not producing any electricity. The Company is in\nthe process of transforming and expanding into an energy storage integrated solution provider business. The Company plans to pursue disciplined\nand targeted expansion strategies for market areas the Company currently does not serve. The Company actively seeks and explores opportunities\nto apply energy storage technologies to new industries or segments with high growth potential, including industrial and commercial complexes,\nlarge scale photovoltaic (PV) and wind power stations,\u00a0remote islands without electricity,\u00a0and smart energy cities with multi-energy\nsupplies.\u00a0 The Company\u2019s cash flow forecast indicates it will have sufficient cash to fund its operations for the next 12 months\nfrom the date of issuance of these CFS.", "entities": [ { "start_character": 83, "end_character": 90, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -279797.0 }, { "start_character": 96, "end_character": 102, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -89504.0 } ] }, { "form_type": "10-K", "accession_number": "0000091440-24-000005", "filing_date": 1708018611000, "quarter_ending": "20231230", "company_name": "Snap-on Inc", "text": "In general, it is Snap-on\u2019s practice and intention to reinvest certain earnings of its non-U.S. subsidiaries in those operations. As of 2023 year end, the company has not made a provision for incremental U.S. income taxes or additional foreign withholding taxes on approximately $471.9 million of such undistributed earnings that is deemed indefinitely reinvested. Determination of the amount of unrecognized deferred tax liability related to these earnings is not practicable. As a result of the Tax Act, which subjected the majority of the company\u2019s undistributed foreign earnings to taxation for the 2017 tax year, the company can now repatriate non-U.S. cash in a tax efficient manner. Accordingly, the company does not have an indefinitely reinvested assertion on the majority of undistributed earnings for its non-U.S. subsidiaries and has recorded a deferred tax liability of $3.9 million for the incremental tax costs associated with the future potential repatriation of such earnings.", "entities": [ { "start_character": 280, "end_character": 285, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 471900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001640147-24-000101", "filing_date": 1711469791000, "quarter_ending": "20240131", "company_name": "Snowflake Inc.", "text": "A member of the Company\u2019s board of directors currently serves as the Chief Executive Officer of a privately-held company (the Related Party), which has been the Company\u2019s customer since 2018. In January 2024, the Company renewed its customer agreement with the Related Party for a term of two years with a total contract value of $22.5 million. With respect to the Related Party, the Company recognized $6.8 million, $3.7 million, and $2.4 million of revenue for the fiscal years ended January\u00a031, 2024, 2023 and 2022, respectively, and had an accounts receivable balance due from the Related Party of $5.0 million and zero as of January\u00a031, 2024 and 2023, respectively. In March 2024, as a minority investor, the Company made a strategic investment of approximately $5.0 million by purchasing non-marketable equity securities issued by the Related Party.", "entities": [ { "start_character": 404, "end_character": 407, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": 6800000.0 }, { "start_character": 418, "end_character": 421, "label": "revenues", "start_date_for_period": "2022-02-01", "end_date_for_period": "2023-01-31", "currency_/_unit": "iso4217:USD", "value": 3700000.0 }, { "start_character": 436, "end_character": 439, "label": "revenues", "start_date_for_period": "2021-02-01", "end_date_for_period": "2022-01-31", "currency_/_unit": "iso4217:USD", "value": 2400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001818874-24-000121", "filing_date": 1715099164000, "quarter_ending": "20240331", "company_name": "SoFi Technologies, Inc.", "text": "During the three months ended March 31, 2024 and 2023, the Series 1 preferred stockholders were entitled to dividends of $10,079 and $9,968, respectively. Dividends payable were $10,079 as of March\u00a031, 2024. There were no dividends payable as of December\u00a031, 2023. ", "entities": [ { "start_character": 122, "end_character": 128, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 10079000.0 }, { "start_character": 134, "end_character": 139, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 9968000.0 }, { "start_character": 179, "end_character": 185, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 10079000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001964738-24-000013", "filing_date": 1715332380000, "quarter_ending": "20240331", "company_name": "Solventum Corp", "text": "Sales of software and rental includes rental revenue from durable medical devices as part of operating lease arrangements (reported within the MedSurg segment), which was $146 million and $145 million for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 172, "end_character": 175, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 146000000.0 }, { "start_character": 189, "end_character": 192, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 145000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001822479-24-000011", "filing_date": 1709051651000, "quarter_ending": "20231231", "company_name": "Sotera Health Co", "text": "We do business with a number of companies affiliated with Warburg Pincus and GTCR, which we refer to collectively as the \u201cSponsors.\u201d For the year ended December\u00a031, 2022, the Company recorded sales of $3.7 million to Curia Global (\u201cCuria\u201d), an affiliate of GTCR. Amounts due from Curia as of December\u00a031, 2022 were $0.8 million. ", "entities": [ { "start_character": 202, "end_character": 205, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001591956-24-000012", "filing_date": 1715620743000, "quarter_ending": "20240331", "company_name": "Sphere 3D Corp.", "text": "The Company has recurring losses from operations and incurred a net loss of approximately $4.5 million for the three months ended March\u00a031, 2024. Management has projected that based on our hashing rate at March\u00a031, 2024, cash on hand may not be sufficient to allow the Company to continue operations and there is substantial doubt about the Company\u2019s ability to continue as a going concern within 12 months from the date of issuance of the financial statements if we are unable to raise additional funding for operations. We expect our working capital needs to increase in the future as we continue to expand and enhance our operations. Our ability to raise additional funds for working capital through equity or debt financings or other sources may depend on the financial success of our then current business and successful implementation of our key strategic initiatives, financial, economic and market conditions and other factors, some of which are beyond our control. Further equity financings may have a dilutive effect on shareholders and any debt financing, if available, may require restrictions to be placed on our future financing and operating activities. We require additional capital and if we are unsuccessful in raising that capital at a reasonable cost and at the required times, or at all, we may not be able to continue our business operations in the cryptocurrency mining industry or we may be unable to advance our growth initiatives, either of which could adversely impact our business, financial condition and results of operations.", "entities": [ { "start_character": 91, "end_character": 94, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000876883-24-000007", "filing_date": 1710174666000, "quarter_ending": "20231231", "company_name": "Stagwell Inc", "text": "Revenue attributable to Wolfgang, included within the Consolidated Statements of Operations for the year ended December 31, 2023 was $5.7\u00a0million, and Net income was $0.7\u00a0million. Revenue attributable to Wolfgang, included within the Consolidated Statements of Operations for the year ended December 31, 2022 was $2.1\u00a0million, and Net loss was $0.3\u00a0million.", "entities": [ { "start_character": 134, "end_character": 137, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 5700000.0 }, { "start_character": 314, "end_character": 317, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 2100000.0 } ] }, { "form_type": "10-K", "accession_number": "0000876883-24-000007", "filing_date": 1710174666000, "quarter_ending": "20231231", "company_name": "Stagwell Inc", "text": "Revenue attributable to Maru, included within the Consolidated Statements of Operations for the year ended December 31, 2023 was $32.1\u00a0million and Net loss was $10.8\u00a0million. Revenue attributable to Maru, included within the Consolidated Statements of Operations for the year ended December 31, 2022 was $8.8\u00a0million, and Net loss was $2.1\u00a0million.", "entities": [ { "start_character": 130, "end_character": 134, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 32100000.0 }, { "start_character": 305, "end_character": 308, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 8800000.0 } ] }, { "form_type": "10-K", "accession_number": "0000876883-24-000007", "filing_date": 1710174666000, "quarter_ending": "20231231", "company_name": "Stagwell Inc", "text": "Revenue attributable to TMA Direct, included within the Consolidated Statements of Operations for the year ended December 31, 2023 was $11.0\u00a0million, and Net income was $1.1\u00a0million. Revenue attributable to TMA Direct, included within the Consolidated Statements of Operations for the year ended December 31, 2022 was $7.7\u00a0million, and Net income was $0.9\u00a0million.", "entities": [ { "start_character": 136, "end_character": 140, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 11000000.0 }, { "start_character": 319, "end_character": 322, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 7700000.0 } ] }, { "form_type": "10-K", "accession_number": "0000876883-24-000007", "filing_date": 1710174666000, "quarter_ending": "20231231", "company_name": "Stagwell Inc", "text": "Revenue attributable to BNG, included within the Consolidated Statements of Operations for the year ended December 31, 2023 was $30.1\u00a0million, and Net loss was $1.5\u00a0million. Revenue attributable to BNG, included within the Consolidated Statements of Operations for the year ended December 31, 2022 was $20.5\u00a0million, and Net income was $0.1\u00a0million. ", "entities": [ { "start_character": 129, "end_character": 133, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 30100000.0 }, { "start_character": 303, "end_character": 307, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 20500000.0 } ] }, { "form_type": "10-K", "accession_number": "0000876883-24-000007", "filing_date": 1710174666000, "quarter_ending": "20231231", "company_name": "Stagwell Inc", "text": "Revenue attributable to Epicenter, included within the Consolidated Statements of Operations for the year ended December 31, 2023 was $4.3\u00a0million, and Net loss was $0.7\u00a0million. Revenue attributable to Epicenter, included within the Consolidated Statements of Operations for the year ended December 31, 2022 was $1.0\u00a0million, and Net loss was $1.2\u00a0million.", "entities": [ { "start_character": 135, "end_character": 138, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4300000.0 }, { "start_character": 314, "end_character": 317, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 1000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000876883-24-000007", "filing_date": 1710174666000, "quarter_ending": "20231231", "company_name": "Stagwell Inc", "text": "Revenue attributable to MDC, included within the year ended December 31, 2021 Consolidated Statements of Operations was $605.4 million. The net loss included within the year ended December 31, 2021 Consolidated Statements of Operations was nominal. ", "entities": [ { "start_character": 121, "end_character": 126, "label": "revenues", "start_date_for_period": "2021-08-03", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 605400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000876883-24-000014", "filing_date": 1714652718000, "quarter_ending": "20240331", "company_name": "Stagwell Inc", "text": "The Company had an income tax expense for the three months ended March 31, 2024 of $2.6\u00a0million (on a pre-tax income of $1.4\u00a0million resulting in an effective tax rate of 189.5%) compared to income tax expense of $0.2\u00a0million (on pre-tax loss of $2.4\u00a0million resulting in an effective tax rate of (9.8)%) for the three months ended March 31, 2023.", "entities": [ { "start_character": 121, "end_character": 124, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1400000.0 }, { "start_character": 247, "end_character": 250, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -2400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000876883-24-000014", "filing_date": 1714652718000, "quarter_ending": "20240331", "company_name": "Stagwell Inc", "text": "Revenue and Net income attributable to Epiphany, included within the Unaudited Consolidated Statements of Operations for the three months ended March 31, 2024 was $13.4\u00a0million and less than $0.1\u00a0million, respectively.", "entities": [ { "start_character": 164, "end_character": 168, "label": "revenues", "start_date_for_period": "2024-01-02", "end_date_for_period": "2024-01-02", "currency_/_unit": "iso4217:USD", "value": 13400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014808", "filing_date": 1713283254000, "quarter_ending": "20231231", "company_name": "Strategic Environmental & Energy Resources, Inc.", "text": "As\nshown in the accompanying consolidated financial statements, the Company has experienced recurring losses, and has an accumulated deficit\nof approximately $34.4 million as of December 31, 2023, and for the year ended December 31, 2023, we incurred a net loss from continuing\noperations of approximately $2.4 million. As of December 31, 2023, our current liabilities exceeded our current assets by approximately\n$11.6 million. These factors raise substantial doubt about the ability of the Company to continue to operate as a going concern.", "entities": [ { "start_character": 307, "end_character": 310, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020683", "filing_date": 1716221586000, "quarter_ending": "20240331", "company_name": "Strategic Environmental & Energy Resources, Inc.", "text": "As\nshown in the accompanying consolidated financial statements, the Company has experienced recurring losses, and has an accumulated deficit\nof approximately $34.7 million as of March 31, 2024, and for the three months ended March 31, 2024, we incurred a net loss from continuing\noperations of approximately $0.4 million. As of March 31, 2024, our current liabilities exceeded our current assets by approximately\n$11.9 million. These factors raise substantial doubt about the ability of the Company to continue to operate as a going concern.", "entities": [ { "start_character": 309, "end_character": 312, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001599298-24-000031", "filing_date": 1708414376000, "quarter_ending": "20231231", "company_name": "Summit Therapeutics Inc.", "text": "During the year ended December 31, 2023, the Company incurred a net loss of $614,928 and cash flows used in operating activities was $76,760. As of December 31, 2023, the Company had an accumulated deficit of $993,258, and cash and cash equivalents and short term investments in U.S. treasury securities of $186,242. The Company expects to continue to generate operating losses for the foreseeable future. ", "entities": [ { "start_character": 77, "end_character": 84, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -614928000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001599298-24-000085", "filing_date": 1714551071000, "quarter_ending": "20240331", "company_name": "Summit Therapeutics Inc.", "text": "During the three months ended March 31, 2024, the Company incurred a net loss of $43,473 and cash flows used in operating activities for the three months ended March 31, 2024 was $30,134. As of March 31, 2024, the Company had an accumulated deficit of $1,036,731, cash and cash equivalents of $61,294, short-term investments in U.S. treasury securities of $95,386 and current and long-term U.K. research and development tax credits receivable of $1,157. The Company expects to continue to generate operating losses for the foreseeable future. ", "entities": [ { "start_character": 82, "end_character": 88, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -43473000.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-010319", "filing_date": 1715789218000, "quarter_ending": "20231231", "company_name": "SusGlobal Energy Corp.", "text": "The Company incurred a net loss of $8,225,334\u00a0(2022-$12,010,548) for the year ended December 31, 2023 and as at that date had a working capital deficit of $30,390,423\u00a0(December 31, 2022-$21,580,552) and an accumulated deficit of $38,570,531\u00a0(December 31, 2022-$30,345,197) and expects to incur further losses in the development of its business.", "entities": [ { "start_character": 36, "end_character": 45, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8225334.0 }, { "start_character": 53, "end_character": 63, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -12010548.0 } ] }, { "form_type": "10-K", "accession_number": "0001062993-24-010319", "filing_date": 1715789218000, "quarter_ending": "20231231", "company_name": "SusGlobal Energy Corp.", "text": "The Company incurred a net loss of $8,225,334\u00a0(2022-$12,010,548) for the year ended December 31, 2023 and as at that date had a working capital deficit of $30,390,423\u00a0(December 31, 2022-$21,580,552) and an accumulated deficit of $38,570,531\u00a0(December 31, 2022-$30,345,197) and expects to incur further losses in the development of its business.", "entities": [ { "start_character": 36, "end_character": 45, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8225334.0 }, { "start_character": 53, "end_character": 63, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -12010548.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-24-012177", "filing_date": 1717770342000, "quarter_ending": "20240331", "company_name": "SusGlobal Energy Corp.", "text": "The Company incurred a net loss of $1,525,744 (2023-$1,035,172) for the three months ended March 31, 2024 and as at that date had a working capital deficit of $31,002,937 (December 31, 2023-$30,390,423) and an accumulated deficit of $40,096,275 (December 31, 2023-$38,570,531) and expects to incur further losses in the development of its business.", "entities": [ { "start_character": 36, "end_character": 45, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1525744.0 }, { "start_character": 53, "end_character": 62, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1035172.0 } ] }, { "form_type": "10-Q", "accession_number": "0001062993-24-012177", "filing_date": 1717770342000, "quarter_ending": "20240331", "company_name": "SusGlobal Energy Corp.", "text": "The Company incurred a net loss of $1,525,744 (2023-$1,035,172) for the three months ended March 31, 2024 and as at that date had a working capital deficit of $31,002,937 (December 31, 2023-$30,390,423) and an accumulated deficit of $40,096,275 (December 31, 2023-$38,570,531) and expects to incur further losses in the development of its business.", "entities": [ { "start_character": 36, "end_character": 45, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1525744.0 }, { "start_character": 53, "end_character": 62, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1035172.0 } ] }, { "form_type": "10-Q", "accession_number": "0001837240-24-000039", "filing_date": 1707389083000, "quarter_ending": "20231230", "company_name": "Symbotic Inc.", "text": "The Company has customer contracts with C&S relating to systems implementation, software maintenance services and the operations of a warehouse automation system. Revenue of $12.6 million and $5.5 million was recognized for the three months ended December\u00a030, 2023 and December\u00a024, 2022, respectively, relating to these customer contracts. There was $13.8 million accounts receivable due from C&S at December\u00a030, 2023, and $0.9 million accounts receivable due from C&S at September\u00a030, 2023. There was $10.5 million and $9.3 million of deferred revenue related to contracts with C&S at December\u00a030, 2023 and September\u00a030, 2023, respectively.", "entities": [ { "start_character": 175, "end_character": 179, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 12600000.0 }, { "start_character": 193, "end_character": 196, "label": "revenues", "start_date_for_period": "2022-09-25", "end_date_for_period": "2022-12-24", "currency_/_unit": "iso4217:USD", "value": 5500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-005375", "filing_date": 1707379036000, "quarter_ending": "20231231", "company_name": "Synergy Empire Ltd", "text": "For\nthe nine months ended December 31, 2023 and 2022, the Company suffered from a net loss of $ 74,261 and $520,166 respectively.", "entities": [ { "start_character": 96, "end_character": 102, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -74261.0 }, { "start_character": 108, "end_character": 115, "label": "earnings", "start_date_for_period": "2022-04-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -520166.0 } ] }, { "form_type": "10-K", "accession_number": "0001805833-24-000041", "filing_date": 1710520142000, "quarter_ending": "20231231", "company_name": "System1, Inc.", "text": "The following tables reflects the revisions to the previously issued consolidated statement of changes in stockholders' equity for the period from January 27, 2022 through December 31, 2022. Although the impact is pervasive throughout the consolidated statement of changes in stockholders' equity as a result of the errors described above, the most significant impact is an additional net loss of $0.8 million, a reduction of non-controlling interest of $10.2 million, an increase in accumulated deficit of $6.0 million and an increase in additional paid-in-capital of $1.9 million", "entities": [ { "start_character": 398, "end_character": 401, "label": "earnings", "start_date_for_period": "2022-01-27", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001805833-24-000079", "filing_date": 1715272448000, "quarter_ending": "20240331", "company_name": "System1, Inc.", "text": "The following tables reflect the revisions to the previously issued condensed consolidated statement of changes in stockholders' equity for the quarter ended March 31, 2023. Although the impact is pervasive throughout the condensed consolidated statement of changes in stockholders' equity as a result of the errors described above, the most significant impact is a reduction of net loss of $0.2\u00a0million, an increase of non-controlling interest of ", "entities": [ { "start_character": 392, "end_character": 395, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001718939-24-000043", "filing_date": 1711959823000, "quarter_ending": "20231231", "company_name": "T Stamp Inc", "text": "\u2014 The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is a business that has not yet generated profits, with a Net loss in the year ended December 31, 2023 of $7.64 million, negative Net operating cash outflows of $7.85 million for the same period, working capital of $1.98 million and an Accumulated deficit of $50.85 million as of December\u00a031, 2023.", "entities": [ { "start_character": 331, "end_character": 335, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -7640000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001718939-24-000085", "filing_date": 1715795391000, "quarter_ending": "20240331", "company_name": "T Stamp Inc", "text": "\u2014 The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is a business that has not yet generated profits, with a net loss in the three months ended March 31, 2024 of $2.68 million, negative net operating cash outflows of $2.16 million for the same period, working capital of $(0.36) million and an accumulated deficit of $53.53 million as of March\u00a031, 2024.", "entities": [ { "start_character": 356, "end_character": 360, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2680000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001438133-24-000086", "filing_date": 1714666339000, "quarter_ending": "20240331", "company_name": "TANDEM DIABETES CARE INC", "text": "For the three months ended March\u00a031, 2024, the Company recognized income tax expense of $3.2 million on a pre-tax loss of $39.5 million. For the three months ended March\u00a031, 2023, the Company recognized income tax expense of $0.3 million on a pre-tax loss of $123.6 million. Income tax expense for the three months ended March\u00a031, 2024 and 2023, was primarily attributable to federal, state and foreign income tax expense as a result of current taxable income in certain jurisdictions. ", "entities": [ { "start_character": 123, "end_character": 127, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -39500000.0 }, { "start_character": 260, "end_character": 265, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -123600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012486", "filing_date": 1711991518000, "quarter_ending": "20231231", "company_name": "TC BioPharm (Holdings) plc", "text": "As\nof December 31, 2023, the Company\u2019s cash and cash equivalents amounted to \u00a32.5 million. As of December 31, 2023, the Company\nhad working capital of \u00a31.0 million. Cash used in operating activities for the year ended December 31, 2023 was \u00a310.5 million,\nand the Company expects to incur continued outflow of cash for the foreseeable future. Net loss for the year ended December 31, 2023\nwas \u00a35.9 million. ", "entities": [ { "start_character": 393, "end_character": 396, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:GBP", "value": -5900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019840", "filing_date": 1715789187000, "quarter_ending": "20240331", "company_name": "TC BioPharm (Holdings) plc", "text": "As\nof March 31, 2024, the Company\u2019s cash and cash equivalents amounted to approximately \u00a31.0 million. As of March 31, 2024,\nthe Company had a working capital deficit of \u00a30.6 million. Cash used in operating activities for the three months ended March 31,\n2024 was \u00a32.4 million, and the Company expects to incur continued outflow of cash for the foreseeable future. Net loss for the\nthree months ended March 31, 2024 was \u00a33.3 million.", "entities": [ { "start_character": 420, "end_character": 423, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:GBP", "value": -3300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001537435-24-000063", "filing_date": 1715262141000, "quarter_ending": "20240331", "company_name": "TECOGEN INC.", "text": "We incurred a net loss from operations of $1,049,885 during the three months ended March 31, 2024, compared to a net loss from operations of $1,449,746 in the same period in 2023. We have a history of incurring losses from our operations and there can be no assurance we will be able to increase our revenues, manage our expenses and cash flows, and become profitable in the future.", "entities": [ { "start_character": 43, "end_character": 52, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1049885.0 } ] }, { "form_type": "10-Q", "accession_number": "0001537435-24-000063", "filing_date": 1715262141000, "quarter_ending": "20240331", "company_name": "TECOGEN INC.", "text": "We incurred a net loss from operations of $1,049,885 during the three months ended March 31, 2024, compared to a net loss from operations of $1,449,746 in the three months ended March 31, 2023. Historically, we have incurred net losses from operations, including a net loss of $4,598,103 in the year ended December\u00a031, 2023, and, as of March\u00a031, 2024, we had an accumulated deficit of $43,984,623. Our business is capital intensive and, because our products are built to order with customized configurations, the lead time to build and deliver a unit can be significant. We may be required to purchase key components long before we can deliver a unit and receive payment. Changes in customer orders or lack of demand may also impact our profitability. There can be no assurance we will be able to increase our sales and achieve and sustain profitability in the future. Our cash flows from operations are insufficient to fund our business and, currently, we are reliant upon financing provided by a related party to help fund our operations. (", "entities": [ { "start_character": 43, "end_character": 52, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1049885.0 } ] }, { "form_type": "10-K", "accession_number": "0000039899-24-000006", "filing_date": 1709226215000, "quarter_ending": "20231231", "company_name": "TEGNA INC", "text": "Customers that purchase our advertising and marketing services are comprised of local, regional, and national advertisers across our markets. Our subscription revenue customers include cable operators and satellite providers that pay us to carry our programming. In 2023, two customers purchased both advertising and marketing services and paid us compensation related to retransmission consent agreements, which in the aggregate represented more than 10% of consolidated revenue in 2023. These customers represented $415.4\u00a0million and $300.5\u00a0million of consolidated revenue in the year ended December 31, 2023. In 2022, we had two major customers that purchased more than 10% of our revenue with $416.3 million and $387.3\u00a0million while we had two customers that purchased more than 10% of our revenue with $410.8 million and $399.7\u00a0million in 2021.", "entities": [ { "start_character": 518, "end_character": 523, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 415400000.0 }, { "start_character": 537, "end_character": 542, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 300500000.0 }, { "start_character": 698, "end_character": 703, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 416300000.0 }, { "start_character": 717, "end_character": 722, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 387300000.0 }, { "start_character": 808, "end_character": 813, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 410800000.0 }, { "start_character": 827, "end_character": 832, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 399700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000096869-24-000008", "filing_date": 1715086626000, "quarter_ending": "20240331", "company_name": "TEJON RANCH CO", "text": "The Resort/Residential real estate development segment is actively involved in pursuing land entitlement and development processes both internally and through joint ventures. The segment incurs costs and expenses related to land management activities on land held for future development, but currently generates no revenue. The segment generated losses of $1,561,000 and $388,000 for the three months ended March\u00a031, 2024 and 2023, respectively. ", "entities": [ { "start_character": 312, "end_character": 314, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001094285-24-000044", "filing_date": 1708706314000, "quarter_ending": "20231231", "company_name": "TELEDYNE TECHNOLOGIES INC", "text": "(a) Net sales excludes inter-segment sales of $29.4 million, $25.3 million and $20.2 million for fiscal years 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 47, "end_character": 51, "label": "ebit", "start_date_for_period": "2023-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 29400000.0 }, { "start_character": 62, "end_character": 66, "label": "ebit", "start_date_for_period": "2022-01-03", "end_date_for_period": "2023-01-01", "currency_/_unit": "iso4217:USD", "value": 25300000.0 }, { "start_character": 80, "end_character": 84, "label": "ebit", "start_date_for_period": "2021-01-04", "end_date_for_period": "2022-01-02", "currency_/_unit": "iso4217:USD", "value": 20200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000070318-24-000032", "filing_date": 1714493125000, "quarter_ending": "20240331", "company_name": "TENET HEALTHCARE CORP", "text": "During the three months ended March\u00a031,\u00a02024 and 2023, we recorded income tax expense of $750\u00a0million and $84\u00a0million on pre-tax income of $3.084\u00a0billion and $380\u00a0million, respectively. Our provision for income taxes during interim reporting periods is calculated by applying an estimate of the annual effective tax rate to \u201cordinary\u201d income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. In calculating \u201cordinary\u201d income, non\u2011taxable income available to noncontrolling interests was deducted from pre-tax income.", "entities": [ { "start_character": 140, "end_character": 145, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3084000000.0 }, { "start_character": 159, "end_character": 162, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 380000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000097216-24-000099", "filing_date": 1714130844000, "quarter_ending": "20240331", "company_name": "TEREX CORP", "text": "During the three months ended March\u00a031, 2024, the Company recognized income tax expense of $28.0 million on income of $136.5 million, an effective tax rate of 20.5%, as compared to income tax expense of $23.3 million on income of $133.2 million, an effective tax rate of 17.5%, for the three months ended March\u00a031, 2023. The higher effective tax rate for the three months ended March\u00a031, 2024 when compared with the three months ended March\u00a031, 2023 is primarily due to higher tax related to geographic distribution of income and lower favorable discrete items.", "entities": [ { "start_character": 119, "end_character": 124, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 136500000.0 }, { "start_character": 231, "end_character": 236, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 133199999.99999999 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-027185", "filing_date": 1711641712000, "quarter_ending": "20231231", "company_name": "TFF Pharmaceuticals, Inc.", "text": "During\nthe year ended December 31, 2023, the Company recognized approximately $81,000 of revenue related to the SBIR grant. There were no amounts\ndue to the Company related to the SBIR grant as of December 31, 2023", "entities": [ { "start_character": 79, "end_character": 85, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 81000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-027185", "filing_date": 1711641712000, "quarter_ending": "20231231", "company_name": "TFF Pharmaceuticals, Inc.", "text": "For\nthe years ended December 31, 2023 and 2022, the Company reported a net loss of $21.2 million and $31.8 million, respectively, and negative\ncash from operations of $16.0 million and $27.3 million, respectively. As of December 31, 2023, the Company had cash and cash equivalents\nof approximately $5.5 million, a working capital surplus of approximately $5.2 million and an accumulated deficit of $118.3 million.\nThe Company has not generated revenues from commercial operations since inception and expects to continue incurring losses for the foreseeable\nfuture and needs to raise additional capital to continue the pursuit of its product development.", "entities": [ { "start_character": 84, "end_character": 88, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -21200000.0 }, { "start_character": 102, "end_character": 106, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -31800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001393726-24-000032", "filing_date": 1709224597000, "quarter_ending": "20231231", "company_name": "TIPTREE INC.", "text": "Management considers the prior year development for each of these years to be insignificant when considered in the context of our annual earned premiums, net as well as our net losses and loss adjustment expenses and member benefit claims expenses. We analyze our development on a quarterly basis and given the short duration nature of our products, favorable or adverse development emerges quickly and allows for timely reserve strengthening, if necessary, or modifications to our product pricing or offerings. The favorable prior year development of $11,187 in the year ended December 31, 2023 represented 8.6% of our insurance business income before taxes of $129,816 and 3.8% of the opening net liability for losses and loss adjustment expenses of $298,057, as of January 1, 2023. The favorable prior year development of $858 in the year ended December 31, 2022 represented 1.3% of our insurance business income before taxes of $68,150, and 0.6% of the opening net liability for losses and loss adjustment expenses of $154,412, as of January 1, 2022. The unfavorable prior year development of $2,606 in 2021 represented 3.7% of pretax income of $69,857 and 3.1% of the opening net liability for losses and loss adjustment expenses of $83,945, as of January 1, 2021.", "entities": [ { "start_character": 663, "end_character": 670, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 129816000.0 }, { "start_character": 933, "end_character": 939, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 68150000.0 }, { "start_character": 1150, "end_character": 1156, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 69857000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001393726-24-000056", "filing_date": 1714579738000, "quarter_ending": "20240331", "company_name": "TIPTREE INC.", "text": "The unfavorable prior year development of $773 in the three months ended March 31, 2024 represented 2.1% of our insurance business income before taxes of $36,811 and 0.2% of the opening net liability for losses and loss adjustment expenses of $393,455, as of January 1, 2024. ", "entities": [ { "start_character": 155, "end_character": 161, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 36811000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001393726-24-000056", "filing_date": 1714579738000, "quarter_ending": "20240331", "company_name": "TIPTREE INC.", "text": "The unfavorable prior year development of $328 in the three months ended March 31, 2023 represented 1.7% of our insurance business income before taxes of $19,445, and 0.1% of the opening net liability for losses and loss adjustment expenses of $298,057, as of January 1, 2023. ", "entities": [ { "start_character": 155, "end_character": 161, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 19445000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001880661-24-000032", "filing_date": 1715185572000, "quarter_ending": "20240331", "company_name": "TPG Inc.", "text": "Condensed Consolidated Statements of Operations in the amount of $8.0 million and $7.4 million for the three months ended March 31, 2024 and 2023 respectively. During the three months ended March 31, 2024 and 2023, these related parties made payments associated with these arrangements of $1.5 million, and $8.9 million, respectively.", "entities": [ { "start_character": 290, "end_character": 293, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 }, { "start_character": 308, "end_character": 311, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 8900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001880661-24-000032", "filing_date": 1715185572000, "quarter_ending": "20240331", "company_name": "TPG Inc.", "text": "In exchange for services provided by TPG Operating Group, RemainCo pays TPG Operating Group an annual administration fee in the amount of 1% per annum of the net asset value of RemainCo\u2019s assets, with such amount payable quarterly in advance. The fees earned by the Company for the three months ended March 31, 2024 and 2023 were $4.2 million and $4.6 million, respectively, and recorded in fees and other in the", "entities": [ { "start_character": 331, "end_character": 334, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4200000.0 }, { "start_character": 348, "end_character": 351, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001437749-24-018456", "filing_date": 1716912369000, "quarter_ending": "20240330", "company_name": "TRANSCAT INC", "text": "During fiscal year 2024, Complete Calibrations has contributed revenue of $0.4\u00a0million and operating loss of less than $0.1 million.", "entities": [ { "start_character": 75, "end_character": 78, "label": "revenues", "start_date_for_period": "2023-03-26", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 400000.0 }, { "start_character": 120, "end_character": 123, "label": "ebit", "start_date_for_period": "2023-03-26", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": -100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001437749-24-018456", "filing_date": 1716912369000, "quarter_ending": "20240330", "company_name": "TRANSCAT INC", "text": "During fiscal year 2024, e2b has contributed revenue of $3.1\u00a0million and operating income of\u00a0$0.4\u00a0million, which ", "entities": [ { "start_character": 57, "end_character": 60, "label": "revenues", "start_date_for_period": "2023-03-26", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 3100000.0 }, { "start_character": 94, "end_character": 97, "label": "ebit", "start_date_for_period": "2023-03-26", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001437749-24-018456", "filing_date": 1716912369000, "quarter_ending": "20240330", "company_name": "TRANSCAT INC", "text": "During fiscal year 2024, Alliance has contributed revenue of $2.4\u00a0million and operating income of $0.7\u00a0million, whic", "entities": [ { "start_character": 62, "end_character": 65, "label": "revenues", "start_date_for_period": "2023-03-26", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 2400000.0 }, { "start_character": 99, "end_character": 102, "label": "ebit", "start_date_for_period": "2023-03-26", "end_date_for_period": "2024-03-30", "currency_/_unit": "iso4217:USD", "value": 700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000850429-24-000012", "filing_date": 1715242941000, "quarter_ending": "20240331", "company_name": "TREDEGAR CORP", "text": "The Company\u2019s facilities in Pottsville, PA (\u201cPV\u201d) and Guangzhou, China (\u201cGZ\u201d) have a tolling arrangement whereby certain surface protection films are manufactured in GZ for a fee with raw materials supplied from PV that are then shipped by GZ directly to customers principally in the Asian market, but paid by customers directly to PV. Amounts associated with this intercompany tolling arrangement are reported in the table above as export sales from the U.S. to Asia, and include net sales of $6.1\u00a0million and $3.4\u00a0million in the first quarter of 2024 and 2023, respectively.", "entities": [ { "start_character": 496, "end_character": 499, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6100000.0 }, { "start_character": 513, "end_character": 516, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 3400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000850429-24-000012", "filing_date": 1715242941000, "quarter_ending": "20240331", "company_name": "TREDEGAR CORP", "text": "Tredegar recorded tax expense (benefit) of $0.7\u00a0million on pre-tax income (loss) of $3.9\u00a0million in the first three months of 2024. The effective tax rate in the first three months of 2024 was 16.7% and (48.8)% in the first three months of 2023. The change in effective tax rate was primarily due to pre-tax income in the first quarter of 2024 versus a pre-tax loss in the first three months of 2023. ", "entities": [ { "start_character": 85, "end_character": 88, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000842633-24-000053", "filing_date": 1714478083000, "quarter_ending": "20240331", "company_name": "TRIMAS CORP", "text": "On February 1, 2023, the Company acquired Aarts Packaging B.V. (\"Aarts\"), a luxury packaging solutions provider for beauty and lifestyle brands, as well as for customers in the food and life sciences end markets, for a purchase price of $37.8\u00a0million, net of cash acquired. The fair value of assets acquired and liabilities assumed included $20.4\u00a0million of goodwill, $10.9\u00a0million of intangible assets, $8.5\u00a0million of property and equipment, $7.4\u00a0million of net working capital, $3.9\u00a0million of net deferred tax liabilities and $5.5\u00a0million of other liabilities. Aarts, which is reported in the Company's Packaging segment, is located in Waalwijk, The Netherlands, and historically generated \u20ac23\u00a0million in annual revenue.", "entities": [ { "start_character": 695, "end_character": 697, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:EUR", "value": 23000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000842633-24-000053", "filing_date": 1714478083000, "quarter_ending": "20240331", "company_name": "TRIMAS CORP", "text": "On April 21, 2023, the Company acquired Weldmac Manufacturing Company (\"Weldmac\") for a purchase price of $34.0\u00a0million, with additional contingent consideration ranging from zero to $10\u00a0million based on achievement of earnings targets, as defined in the purchase agreement. The fair value of assets acquired and liabilities assumed included $23.7\u00a0million of property and equipment, $20.3\u00a0million of net working capital and $10\u00a0million of contingent consideration liability, with such estimate representing the Company's best estimate of fair value of contingent consideration based on Level 3 inputs under the fair value hierarchy, as defined. Located in El Cajon, California, and reported in the Company's Aerospace segment, Weldmac is a designer and manufacturer of complex metal fabricated components and assemblies for the aerospace, defense and space launch end markets and historically generated $33\u00a0million in annual revenue. On July 10, 2023, the Company made a cash payment of $5.5\u00a0million as additional consideration for the purchase of Weldmac based on achievement of earnings targets, as defined in the purchase agreement. The remaining possible contingent consideration ranges from zero to $4.5\u00a0million, based on achievement of 2023 earnings targets, as defined in the purchase agreement. At March 31, 2024, the Company believes it is probable the maximum contingent consideration will be earned.", "entities": [ { "start_character": 904, "end_character": 906, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 33000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000099780-24-000017", "filing_date": 1708614682000, "quarter_ending": "20231231", "company_name": "TRINITY INDUSTRIES INC", "text": "Our Leasing Group enters into railcar operating leases with third parties with terms generally ranging between one year and ten years. The majority of our fleet operates on leases that earn fixed monthly lease payments. Generally, lease payments are due at the beginning of the applicable month. A portion of our fleet operates on per diem leases that earn usage-based variable lease payments. Some of our leases include options to extend the leases for up to five years, and a small percentage of our leases include early termination options with certain notice requirements and early termination penalties. As of December 31, 2023, non-Leasing Group operating leases were not significant, and we had no direct finance leases. ", "entities": [ { "start_character": 556, "end_character": 558, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0000099780-24-000055", "filing_date": 1714565117000, "quarter_ending": "20240331", "company_name": "TRINITY INDUSTRIES INC", "text": "Our Leasing Group enters into railcar operating leases with third parties with terms generally ranging between one year and ten years. The majority of our fleet operates on leases that earn fixed monthly lease payments. Generally, lease payments are due at the beginning of the applicable month. A portion of our fleet operates on per diem leases that earn usage-based variable lease payments. Some of our leases include options to extend the leases for up to five years, and a small percentage of our leases include early termination options with certain notice requirements and early termination penalties. As of March 31, 2024, non-lease fleet operating leases in which we are the lessor were not significant, and we had no direct finance leases.", "entities": [ { "start_character": 556, "end_character": 558, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-033015", "filing_date": 1713200443000, "quarter_ending": "20240229", "company_name": "TSR INC", "text": "The\nCompany has provided placement services for an entity in which a Board of Director of the Company is the former CEO. Revenues for such\nservices were $8,600 in the three months ended February 29, 2024, and $35,000 in the three months ended February 28, 2023. Revenues for\nsuch services in the nine months ended February 29, 2024, and February 28, 2023 were approximately $25,400 and $70,800, respectively.\nThere were no amounts outstanding as accounts receivable from this entity as of February 29, 2024 or February 28, 2023.", "entities": [ { "start_character": 154, "end_character": 159, "label": "revenues", "start_date_for_period": "2023-12-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 8600.0 }, { "start_character": 210, "end_character": 216, "label": "revenues", "start_date_for_period": "2022-12-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "iso4217:USD", "value": 35000.0 }, { "start_character": 375, "end_character": 381, "label": "revenues", "start_date_for_period": "2023-06-01", "end_date_for_period": "2024-02-29", "currency_/_unit": "iso4217:USD", "value": 25400.0 }, { "start_character": 387, "end_character": 393, "label": "revenues", "start_date_for_period": "2022-06-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "iso4217:USD", "value": 70800.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-033015", "filing_date": 1713200443000, "quarter_ending": "20240229", "company_name": "TSR INC", "text": "Basic\nnet income per common share is computed by dividing net income available to common stockholders of TSR by the weighted average number\nof common shares outstanding during the reporting period, excluding the effects of any potentially dilutive securities. During the quarters\nended February 29, 2024 and February 28, 2021, the Company granted time and performance vesting restricted stock awards under the TSR,\nInc. 2020 Equity Incentive Plan (the \u201cPlan\u201d) (see Note 12 for further information). Diluted earnings per share gives effect\nto all potentially dilutive common shares outstanding during the reporting period. The common stock equivalents associated with these\nrestricted stock awards of 99,940 and 94,829 have been included for dilutive shares outstanding for the three and nine months ended February\n28, 2023. There were no dilutive shares in the three and nine months ended February 29, 2024.", "entities": [ { "start_character": 700, "end_character": 706, "label": "eps", "start_date_for_period": "2022-12-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "xbrli:shares", "value": 99940.0 }, { "start_character": 711, "end_character": 717, "label": "eps", "start_date_for_period": "2022-06-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "xbrli:shares", "value": 94829.0 } ] }, { "form_type": "10-Q", "accession_number": "0001437749-24-015733", "filing_date": 1715274460000, "quarter_ending": "20240331", "company_name": "TUCOWS INC /PA/", "text": "Comparatively, for the three months ended March 31, 2023, the Company recorded an income tax recovery of $1.7\u00a0million on net loss before\u00a0income taxes\u00a0of $20.8 million, using an estimated effective tax rate for the fiscal year ending December 31, 2023 adjusted for certain minimum state taxes. Our effective tax rate\u00a0for the three months ended March 31, 2023\u00a0differs from the U.S. federal statutory rate primarily due to an increase in valuation allowance on net operating losses.\u00a0", "entities": [ { "start_character": 155, "end_character": 159, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -20800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001008654-24-000034", "filing_date": 1711721531000, "quarter_ending": "20230701", "company_name": "TUPPERWARE BRANDS CORP", "text": "Other misstatements of Net sales, Cost of products sold, and Selling, general and administrative expense, which over/(under)stated Operating income by $(2.1)\u00a0million and $0.6 million, for the three months ended June\u00a025, 2022 and March\u00a026, 2022, respectively.", "entities": [ { "start_character": 153, "end_character": 156, "label": "ebit", "start_date_for_period": "2022-03-27", "end_date_for_period": "2022-06-25", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 171, "end_character": 174, "label": "ebit", "start_date_for_period": "2021-12-26", "end_date_for_period": "2022-03-26", "currency_/_unit": "iso4217:USD", "value": -600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001008654-24-000035", "filing_date": 1711721753000, "quarter_ending": "20230930", "company_name": "TUPPERWARE BRANDS CORP", "text": "Other misstatements of Net sales, Cost of products sold, Selling, general and administrative expense, Re-engineering and impairment charges (gains), and Other (income) expense, net, which over/(under)stated Operating income (loss) by $0.9\u00a0million, $(2.1)\u00a0million, and $0.6\u00a0million, for the three months ended September\u00a024, 2022, June\u00a025, 2022, and March\u00a026, 2022, respectively.", "entities": [ { "start_character": 235, "end_character": 238, "label": "ebit", "start_date_for_period": "2023-07-02", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -900000.0 }, { "start_character": 250, "end_character": 253, "label": "ebit", "start_date_for_period": "2022-03-27", "end_date_for_period": "2022-06-25", "currency_/_unit": "iso4217:USD", "value": 2100000.0 }, { "start_character": 269, "end_character": 272, "label": "ebit", "start_date_for_period": "2021-12-26", "end_date_for_period": "2022-03-26", "currency_/_unit": "iso4217:USD", "value": -600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000860731-24-000025", "filing_date": 1713976135000, "quarter_ending": "20240331", "company_name": "TYLER TECHNOLOGIES INC", "text": "In April 2023, we entered into an arm's length lessor agreement under which we lease 25,000 square feet of office space in our Lubbock, Texas facility to a company co-owned by a member of the board of directors. Such member no longer serves on the board of directors. The lease agreement, which commenced on April 1, 2023, has an initial term of five years with a pro-rata base rent of $25,000 per month until December 1, 2023, and a base rent of $60,000 per month thereafter. We recognized rental income of $181,000 under this lease for the three months ended March 31, 2024.", "entities": [ { "start_character": 509, "end_character": 516, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 181000.0 } ] }, { "form_type": "10-K", "accession_number": "0001819790-24-000018", "filing_date": 1709049721000, "quarter_ending": "20231231", "company_name": "Tarsus Pharmaceuticals, Inc.", "text": "License fees and collaboration revenue also includes revenue recognized from satisfaction of performance obligations under an existing clinical supply agreement. The Company recognizes revenue when a customer obtains control of the promised good or service. Revenue recognized under this arrangement for the year ended December\u00a031, 2023 was $0.2\u00a0million. No revenue was recognized under this arrangement for the year ended December\u00a031, 2022.", "entities": [ { "start_character": 342, "end_character": 345, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 }, { "start_character": 355, "end_character": 357, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001681459-24-000070", "filing_date": 1709051305000, "quarter_ending": "20231231", "company_name": "TechnipFMC plc", "text": "For the year ended December 31, 2022, we incurred a net loss; therefore, the impact of any incremental shares from our share-based compensation awards would be anti-dilutive. For the years ended December 31, 2022, 8.9 million shares were anti-dilutive due to a net loss position.", "entities": [ { "start_character": 214, "end_character": 217, "label": "eps", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "xbrli:shares", "value": 8900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018466", "filing_date": 1715272247000, "quarter_ending": "20240331", "company_name": "Tecnoglass Inc.", "text": "In\nthe ordinary course of business, we sell products to Prisma-Glass LLC a distributer and installer of architectural systems in Florida\nthat. is owned and controlled by family members of Christian Daes. We sold $193 to Prisma-Glass LLC during the three months ended March\n31, 2024, and had outstanding accounts receivable of $142 as of March 31, 2024.", "entities": [ { "start_character": 213, "end_character": 216, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 193000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018466", "filing_date": 1715272247000, "quarter_ending": "20240331", "company_name": "Tecnoglass Inc.", "text": "In\nthe ordinary course of business, we sell products to Studio Avanti SAS (\u201cAvanti\u201d), a distributer and installer of architectural\nsystems in Colombia. Avanti is owned and controlled by Alberto Velilla, who is director of Energy Holding Corporation, the controlling\nshareholder of the Company. As of March 31, 2024, and December 31, 2023, the Company had outstanding accounts receivable from Avanti\nof $548 and $460, respectively. During the three months ended March 31, 2024, we sold $196 of products to Avanti, compared to $156 during\nthe three months ended March 31, 2023.", "entities": [ { "start_character": 486, "end_character": 489, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 196000.0 }, { "start_character": 526, "end_character": 529, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 156000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018466", "filing_date": 1715272247000, "quarter_ending": "20240331", "company_name": "Tecnoglass Inc.", "text": "In\nthe ordinary course of business, we sell products to Alutrafic Led SAS (\u201cAlutrafic\u201d), a fabricator of electrical lighting\nequipment. Affiliates of Jose Daes and Christian Daes, the Company\u2019s Chief Executive Officer and Chief Operating Officer, respectively,\nhave an ownership stake in Alutrafic. During the three months ended March 31, 2024, we sold $139, compared to $173 during the three months\nended March 31, 2023. Additionally, we had outstanding accounts receivable from Alutrafic of $276 and $322 as of March 31, 2024, and\nDecember 31, 2023, respectively.", "entities": [ { "start_character": 354, "end_character": 357, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 139000.0 }, { "start_character": 372, "end_character": 375, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 173000.0 } ] }, { "form_type": "10-K", "accession_number": "0001476150-24-000004", "filing_date": 1707321663000, "quarter_ending": "20231231", "company_name": "Terreno Realty Corp", "text": "The Company recorded revenues and net income for the year ended December\u00a031, 2023 of approximately $14.8\u00a0million and $4.9\u00a0million, respectively, related to the 2023 acquisitions.", "entities": [ { "start_character": 100, "end_character": 104, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 14800000.0 }, { "start_character": 118, "end_character": 121, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001476150-24-000004", "filing_date": 1707321663000, "quarter_ending": "20231231", "company_name": "Terreno Realty Corp", "text": "The Company recorded revenues and net income for the year ended December\u00a031, 2022 of approximately $11.4 million and $3.2 million, respectively, related to the 2022 acquisitions.", "entities": [ { "start_character": 100, "end_character": 104, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 11400000.0 }, { "start_character": 118, "end_character": 121, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 3200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001476150-24-000008", "filing_date": 1715184066000, "quarter_ending": "20240331", "company_name": "Terreno Realty Corp", "text": "In accordance with the Company\u2019s policies of determining whether instruments granted in share-based payment transactions are participating securities and accounting for earnings per share, the net income (loss) per common share is adjusted for earnings distributed through declared dividends (if any) and allocated to all participating securities (weighted average common shares outstanding and unvested restricted shares outstanding) under the two-class method. Under this method, allocations were made to 429,583 and 373,985 of weighted average unvested restricted shares outstanding for the three months ended March\u00a031, 2024 and 2023, respectively.", "entities": [ { "start_character": 507, "end_character": 514, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 429583.0 }, { "start_character": 519, "end_character": 526, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 373985.0 } ] }, { "form_type": "10-Q", "accession_number": "0001476150-24-000008", "filing_date": 1715184066000, "quarter_ending": "20240331", "company_name": "Terreno Realty Corp", "text": "The Company recorded revenues and net loss for the three months ended March\u00a031, 2023 of approximately $0.3 million and $0.2 million, respectively, related to the 2023 acquisitions.", "entities": [ { "start_character": 103, "end_character": 106, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 120, "end_character": 123, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-007612", "filing_date": 1708677052000, "quarter_ending": "20231231", "company_name": "Tharimmune, Inc.", "text": "The\naccompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which\ncontemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. During\nthe year ended December 31, 2023, the Company incurred operating losses in the amount of approximately $9.5 million, expended approximately\n$7.3 million in net cash used in operating activities, and had an accumulated deficit of approximately $24.7 million as of December 31,\n2023. Through December 31, 2023, the Company has primarily financed its operations through public and private offerings of equity securities.\nThe Company received net proceeds from its initial public offering (\u201cIPO\u201d) on January 14, 2022 of approximately $12.5 million.\nAdditionally, the Company closed a public offering (the \u201cMay Offering\u201d) of its common stock on May 2, 2023. Net proceeds\nto the Company from the offering were approximately $2.1 million. The Company recently closed an additional public offering (the \u201cNovember\nOffering\u201d) of its common stock on November 30, 2023. Net proceeds to the Company from the offering were approximately $8.7 million.\nAlso see Note 5 to the consolidated financial statements for details regarding the May and November Offerings. The shares of the Company\u2019s\ncommon stock began trading on The Nasdaq Capital Market on January 12, 2022 under the ticker symbol \u201cHILS\u201d and effective\nas of September 25, 2023, are traded under the ticker symbol \u201cTHAR.\u201d", "entities": [ { "start_character": 377, "end_character": 380, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -9500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-018338", "filing_date": 1715243444000, "quarter_ending": "20240331", "company_name": "Tharimmune, Inc.", "text": "The\naccompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern,\nwhich contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. During\nthe three months ended March 31, 2024, the Company incurred operating losses in the amount of approximately $2.3\n", "entities": [ { "start_character": 392, "end_character": 395, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001489096-24-000099", "filing_date": 1717001166000, "quarter_ending": "20240331", "company_name": "Thermon Group Holdings, Inc.", "text": "On January 2, 2024, we announced our acquisition (the \"Vapor Power Acquisition\") of 100% of the issued and outstanding equity interests of Vapor Power International, LLC and its affiliates (\u201cVapor Power\u201d), a leading provider of high-quality industrial process heating solutions, including electric, electrode and gas fired boilers. The acquisition was consummated on December 29, 2023 (the \"Vapor Power Acquisition Date\") and the seller was Stone Pointe, LLC. We have integrated Vapor Power into our US-LAM reportable segment. Vapor Power contributed $10,931 in sales and $698 in net income to our consolidated operating results.", "entities": [ { "start_character": 552, "end_character": 558, "label": "revenues", "start_date_for_period": "2024-01-02", "end_date_for_period": "2024-01-02", "currency_/_unit": "iso4217:USD", "value": 10931000.0 }, { "start_character": 573, "end_character": 576, "label": "earnings", "start_date_for_period": "2024-01-02", "end_date_for_period": "2024-01-02", "currency_/_unit": "iso4217:USD", "value": 698000.0 } ] }, { "form_type": "10-K", "accession_number": "0001489096-24-000099", "filing_date": 1717001166000, "quarter_ending": "20240331", "company_name": "Thermon Group Holdings, Inc.", "text": "On May 31, 2022 (the \"Powerblanket Acquisition Date\"), Thermon Holding Corp., as buyer, acquired 100% of the issued and outstanding equity interests of Flatwork Technologies LLC, GreenHeat IP Holdings, LLC, Heat Authority, LLC, and Warmguard, LLC (collectively, \u201cPowerblanket\u201d) from Glacier Capital LLC, as seller (the \"Powerblanket Acquisition\"). Powerblanket is a North American supplier of heated blankets built upon patented heat spreading technology. The Acquisition increases our exposure to growing industrial and commercial end-markets through its freeze protection, temperature control and flow assurance solutions. We have integrated Powerblanket into our US-LAM reportable segment. From the period May 31, 2022 to March 31, 2023, Powerblanket contributed $17,144 in sales and $1,512 in net income to our consolidated operating results. ", "entities": [ { "start_character": 767, "end_character": 773, "label": "revenues", "start_date_for_period": "2022-05-31", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 17144000.0 }, { "start_character": 788, "end_character": 793, "label": "earnings", "start_date_for_period": "2022-05-31", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 1512000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000794170-24-000035", "filing_date": 1717171681000, "quarter_ending": "20240430", "company_name": "Toll Brothers, Inc.", "text": "In the three-month periods ended April\u00a030, 2024 and 2023, we purchased land from unconsolidated entities, principally related to our acquisition of lots from our Land Development Joint Ventures, totaling $35.0 million and $52.4 million, respectively. In ", "entities": [ { "start_character": 205, "end_character": 209, "label": "revenues", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 35000000.0 }, { "start_character": 223, "end_character": 227, "label": "revenues", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 52400000.0 } ] }, { "form_type": "10-K", "accession_number": "0000837465-24-000016", "filing_date": 1709156845000, "quarter_ending": "20231231", "company_name": "Topgolf Callaway Brands Corp.", "text": "In August 2020, the FASB issued ASU No. 2020-06, \u201cDebt\u2014Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging\u2014Contracts in Entity\u2019s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity\u2019s Own Equity\u201d (\u201cASU 2020-06\u201d), which simplifies the accounting for convertible instruments and also requires application of the if-converted method when calculating diluted earnings per share in periods when net income is reported. We adopted this standard as of January 1, 2022 under the modified retrospective method of transition which allows for amounts reported prior to the adoption date to remain unadjusted. Adoption of the standard resulted in a $57.1\u00a0million reduction in additional paid-in capital, a $57.9\u00a0million increase to long-term debt, net, a $13.2\u00a0million decrease in the deferred taxes, net and a $12.4\u00a0million increase in retained earnings. Additionally, under the if-converted method, the 14.7\u00a0million common shares underlying the Convertible Notes are assumed to have been outstanding as of the beginning of the current reporting period and any interest expense related to the Convertible Notes for the period is excluded from the calculation of diluted earnings per common share. Prior to the adoption of ASU 2020-06, for periods when we recognized net income, we used the treasury stock method to compute dilutive shares of common stock related to the Convertible Notes.", "entities": [ { "start_character": 969, "end_character": 973, "label": "eps", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "xbrli:shares", "value": 14700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001758730-24-000025", "filing_date": 1707494609000, "quarter_ending": "20231231", "company_name": "Tradeweb Markets Inc.", "text": "For the year ended December\u00a031, 2023, total income before the provision for income taxes amounted to $548.0 million, consisting of $533.7 million in the United States and $14.3 million in foreign locations.", "entities": [ { "start_character": 102, "end_character": 107, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 548000000.0 }, { "start_character": 132, "end_character": 137, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 533700000.00000006 }, { "start_character": 172, "end_character": 176, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 14300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001715768-24-000009", "filing_date": 1708445707000, "quarter_ending": "20231231", "company_name": "Transphorm, Inc.", "text": "The Company has incurred significant operating losses since its formation. During the nine months ended December\u00a031, 2023 and 2022, the Company incurred a net loss of $24.6\u00a0million and $21.8\u00a0million, respectively, and used $14.4\u00a0million and $18.6\u00a0million of cash in operating activities, respectively. As of December 31, 2023, the Company had cash of $8.0\u00a0million, an accumulated deficit of $242.1\u00a0million, and working capital of $8.5\u00a0million. Net losses are expected to continue until the Company reaches the necessary scale to generate net cash inflow from operations. Accordingly, the Company has historically relied on the issuance of stock to investors, debt financing, and the license of intellectual property to fund its operations.", "entities": [ { "start_character": 168, "end_character": 172, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -24600000.0 }, { "start_character": 186, "end_character": 190, "label": "earnings", "start_date_for_period": "2022-04-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -21800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001169445-24-000047", "filing_date": 1715353225000, "quarter_ending": "20240331", "company_name": "TruBridge, Inc.", "text": "During 2022, 2023, and 2024, performance share awards were granted to certain executive officers and key employees of the Company that will result in the issuance of common stock if the predefined performance criteria are met. The awards provide for an aggregate target of 512,103 shares, of which none have been included in the calculation of diluted EPS for the three months ended March\u00a031, 2024 because the related threshold award performance levels have not been achieved as of March\u00a031, 2024. See Note 10 - Stock-Based Compensation and Equity for more information.", "entities": [ { "start_character": 299, "end_character": 303, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-045000", "filing_date": 1702647025000, "quarter_ending": "20231031", "company_name": "U.S. GOLD CORP.", "text": "The\naccompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the\nrealization of assets and the satisfaction of liabilities in the normal course of business. As of October 31, 2023, the Company had cash\nof approximately $4.0 million, working capital of approximately $4.0 million, which consists primarily of cash and an accumulated deficit\nof approximately $69.1 million. The Company had a net loss and cash used in operating activities of approximately $3.2 million and $3.9\nmillion, respectively, for the six months ended October 31, 2023. As a result of the utilization of cash in its operating activities,\nand the development of its assets, the Company has incurred losses since it commenced operations. The Company\u2019s primary source\nof operating funds since inception has been equity financings. As of the date of filing the Form 10-Q for the fiscal quarter ended October\n31, 2023, the Company may have sufficient cash to fund its corporate activities and general and administrative costs and currently undertaken\nproject activities related to permitting and engineering studies. However, in order to advance any of its projects past the aforementioned\nobjectives the Company does not have sufficient cash and will need to raise additional funds. These matters raise substantial doubt about\nthe Company\u2019s ability to continue as a going concern for the twelve months following the issuance of these unaudited condensed\nconsolidated financial statements.", "entities": [ { "start_character": 529, "end_character": 532, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2023-10-31", "currency_/_unit": "iso4217:USD", "value": -3200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-010294", "filing_date": 1710777630000, "quarter_ending": "20240131", "company_name": "U.S. GOLD CORP.", "text": "The\naccompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the\nrealization of assets and the satisfaction of liabilities in the normal course of business. As of January 31, 2024, the Company had cash\nof approximately $2.6 million, working capital of approximately $2.7 million, which consists primarily of cash and an accumulated deficit\nof approximately $70.8 million. The Company had a net loss and cash used in operating activities of approximately $4.8 million and $5.2\nmillion, respectively, for the nine months ended January 31, 2024. As a result of the utilization of cash in its operating activities,\nand the development of its assets, the Company has incurred losses since it commenced operations. The Company\u2019s primary source\nof operating funds since inception has been equity financings. As of the filing date of this Form 10-Q, the Company may have sufficient\ncash to fund its corporate activities and general and administrative costs and currently undertaken project activities related to permitting\nand engineering studies. However, in order to advance any of its projects past the aforementioned objectives the Company does not have\nsufficient cash and will need to raise additional funds. These matters raise substantial doubt about the Company\u2019s ability to continue\nas a going concern for the twelve months following the issuance of these unaudited condensed consolidated financial statements.", "entities": [ { "start_character": 529, "end_character": 532, "label": "earnings", "start_date_for_period": "2023-05-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -4800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140361-24-026235", "filing_date": 1715789208000, "quarter_ending": "20240331", "company_name": "U.S. NeuroSurgical Holdings, Inc.", "text": "In\n fiscal year 2023, the Company incurred a net loss of $816,000 compared to $1,572,000 in fiscal year 2022 and a net loss of $312,000\n and $108,000 during the three months ended March 31, 2024 and 2023, respectively.\u00a0 As of March 31, 2024, the Company had\n an accumulated deficit in stockholders\u2019 equity of $2,702,000, cash and cash equivalents of $1,750,000 and a working capital deficit of $396,000.\u00a0\n\n\n\n\n\n\n In addition, the Company currently does not have access to capital through a line of credit nor other readily available sources of capital.\u00a0 Together, these factors raised substantial doubt regarding the Company\u2019s ability to\n continue as a going concern at March 31, 2024.\u00a0 However, management has considered its plans to continue the Company as a going concern, concentrating on the establishment and operation of managed health care plans.\u00a0 As noted above,\n during the first quarter of 2024, the Company raised gross proceeds of $2.1 million in support of this business\n opportunity through the sale of its Common Stock in a private placement and believes it has access to additional capital through the remainder of 2024.\u00a0 Additionally, the Company believes that these activities and resulting expenses\n can be managed to the level of cash resources on hand and expected to be raised. Management believes its plan alleviates the substantial doubt, that it will be successful in its planned business initiatives and will be able to\n continue as a going concern through at least the next twelve months.\u00a0 However, there can be no assurance that sources of capital will be available to the Company at that time or, if available, can be obtained on terms favorable to\n the Company.\n\n", "entities": [ { "start_character": 81, "end_character": 88, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -816000.0 }, { "start_character": 102, "end_character": 111, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1572000.0 }, { "start_character": 151, "end_character": 158, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -312000.0 }, { "start_character": 188, "end_character": 195, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -108000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140361-24-026235", "filing_date": 1715789208000, "quarter_ending": "20240331", "company_name": "U.S. NeuroSurgical Holdings, Inc.", "text": "In\n fiscal year 2023, the Company incurred a net loss of $816,000 compared to $1,572,000 in fiscal year 2022 and a net loss of $312,000\n and $108,000 during the three months ended March 31, 2024 and 2023, respectively.\u00a0 As of March 31, 2024, the Company had\n an accumulated deficit in stockholders\u2019 equity of $2,702,000, cash and cash equivalents of $1,750,000 and a working capital deficit of $396,000.\u00a0\n\n\n\n\n\n\n In addition, the Company currently does not have access to capital through a line of credit nor other readily available sources of capital.\u00a0 Together, these factors raised substantial doubt regarding the Company\u2019s ability to\n continue as a going concern at March 31, 2024.\u00a0 However, management has considered its plans to continue the Company as a going concern, concentrating on the establishment and operation of managed health care plans.\u00a0 As noted above,\n during the first quarter of 2024, the Company raised gross proceeds of $2.1 million in support of this business\n opportunity through the sale of its Common Stock in a private placement and believes it has access to additional capital through the remainder of 2024.\u00a0 Additionally, the Company believes that these activities and resulting expenses\n can be managed to the level of cash resources on hand and expected to be raised. Management believes its plan alleviates the substantial doubt, that it will be successful in its planned business initiatives and will be able to\n continue as a going concern through at least the next twelve months.\u00a0 However, there can be no assurance that sources of capital will be available to the Company at that time or, if available, can be obtained on terms favorable to\n the Company.\n", "entities": [ { "start_character": 81, "end_character": 88, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -816000.0 }, { "start_character": 102, "end_character": 111, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1572000.0 }, { "start_character": 151, "end_character": 158, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -312000.0 }, { "start_character": 188, "end_character": 195, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -108000.0 } ] }, { "form_type": "10-K", "accession_number": "0001090727-24-000008", "filing_date": 1708445907000, "quarter_ending": "20231231", "company_name": "UNITED PARCEL SERVICE INC", "text": "In 2022, we reduced the estimated residual value of our MD-11 aircraft to zero, incurring a one-time charge on our fully-depreciated aircraft. This resulted in an increase in depreciation expense of $76\u00a0million, and a decrease in net income of $58\u00a0million, or $0.07 per share on a basic and diluted basis, for the year ended December 31, 2022. The change in estimate for the remainder of our MD-11 fleet is being accounted for over the remaining useful lives.", "entities": [ { "start_character": 245, "end_character": 247, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -58000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000896264-24-000093", "filing_date": 1709051210000, "quarter_ending": "20231230", "company_name": "USANA HEALTH SCIENCES INC", "text": "As of December\u00a030, 2023, the cumulative amount of undistributed earnings of the Company\u2019s non-U.S. subsidiaries held for indefinite reinvestment is approximately $4,000. If this amount were repatriated to the United States, the amount of incremental taxes would be approximately $400.", "entities": [ { "start_character": 163, "end_character": 168, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-30", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001511737-24-000027", "filing_date": 1715324309000, "quarter_ending": "20240331", "company_name": "Ubiquiti Inc.", "text": "Revenue for the United States was $226.2 million and $214.3 million for the three months ended March\u00a031, 2024 and 2023, respectively. Revenue for the United States was $645.8 million and $634.0 million for the nine months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 35, "end_character": 40, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 226200000.0 }, { "start_character": 54, "end_character": 59, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 214300000.0 }, { "start_character": 169, "end_character": 174, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 645800000.0 }, { "start_character": 188, "end_character": 193, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 634000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001336917-24-000073", "filing_date": 1717000724000, "quarter_ending": "20240331", "company_name": "Under Armour, Inc.", "text": "In connection with the license agreement with the Japanese licensee, the Company recorded license revenues of $34.8\u00a0million for Fiscal 2024 (Fiscal 2023: $36.8\u00a0million; Fiscal 2021: $42.4\u00a0million; Transition Period: $9.9\u00a0million). As of March\u00a031, 2024, the Company had $13.9 million in licensing receivables outstanding, recorded in the prepaid expenses and other current assets line item within the Company's Consolidated Balance Sheets (March\u00a031, 2023: $7.6\u00a0million). ", "entities": [ { "start_character": 111, "end_character": 115, "label": "revenues", "start_date_for_period": "2023-04-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 34800000.0 }, { "start_character": 155, "end_character": 159, "label": "revenues", "start_date_for_period": "2022-04-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 36800000.0 }, { "start_character": 183, "end_character": 187, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 42400000.0 }, { "start_character": 217, "end_character": 220, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": 9900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-028685", "filing_date": 1711986941000, "quarter_ending": "20231231", "company_name": "Unite Acquisition 2 Corp.", "text": "The\nCompany has incurred losses of $83,938 for the year ended December 31, 2023, has working capital deficit and has an accumulated deficit\nof $111,742 as of December 31, 2023. Management believes these conditions raise substantial doubt about the Company\u2019s ability to\ncontinue as a going concern for the twelve months following the date these financial statements are issued. The ability of the Company\nto continue as a going concern is dependent upon management\u2019s plan to find a suitable acquisition or merger candidate, raise additional\ncapital from issuance of stock or receive continued financial support and additional borrowings from the existing promissory note from\nstockholder. Management intends to finance operations over the next twelve months through additional borrowings from the existing Note.\nThe accompanying financial statements do not include any adjustments that might be required should the Company be unable to continue\nas a going concern.", "entities": [ { "start_character": 36, "end_character": 42, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -83938.0 } ] }, { "form_type": "10-Q", "accession_number": "0001451512-23-000062", "filing_date": 1699966928000, "quarter_ending": "20230930", "company_name": "Unrivaled Brands, Inc.", "text": "The Company incurred a pre-tax net loss from continuing operations of $3.05 million and $3.55 million for the three and nine months ended September\u00a030, 2023, respectively, and $123.38 million and $201.18 million for the three and nine months ended September\u00a030, 2022, respectively. As of September\u00a030, 2023 and December\u00a031, 2022, the Company had an accumulated deficit of $444.44 million and $440.05 million, respectively. At September\u00a030, 2023, the Company had a consolidated cash balance of $2.01 million. Management expects to experience further net losses in 2023 and in the foreseeable future. The Company may not be able to generate sufficient cash from operating activities to fund its ongoing operations. The Company's future success is dependent upon its ability to achieve profitable operations and generate cash from operating activities. There is no guarantee that the Company will be able to generate enough revenue or raise capital to support its operations.", "entities": [ { "start_character": 71, "end_character": 75, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -3050000.0 }, { "start_character": 89, "end_character": 93, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -3550000.0 }, { "start_character": 177, "end_character": 183, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -123380000.0 }, { "start_character": 197, "end_character": 203, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -201180000.0 } ] }, { "form_type": "10-K", "accession_number": "0000005513-24-000015", "filing_date": 1708447795000, "quarter_ending": "20231231", "company_name": "Unum Group", "text": "In accordance with standard practice, we regularly review the methodology used in the development of all key estimates. As a result of this review, in 2022, we updated our estimate of the unearned premium reserve for certain of our product lines to utilize a gross unearned premium reserve rather than a net unearned premium reserve. The effect of this change in estimate was to decrease 2022 premium income by $13.4 million and decrease commissions by $1.0 million. This resulted in a decrease to net income of $9.8 million and a decrease to both basic and diluted earnings per share by $0.05.", "entities": [ { "start_character": 414, "end_character": 418, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -13400000.0 }, { "start_character": 516, "end_character": 519, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -9800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001611547-24-000012", "filing_date": 1707894068000, "quarter_ending": "20231231", "company_name": "Urban Edge Properties", "text": "During the years ended December\u00a031, 2023 and 2022, income before income taxes from the Company\u2019s operating activities in the United States was $226.4 million and $41.2 million, respectively, and in Puerto Rico was $51.2 million and $9.1 million, respectively. For the year ended December\u00a031, 2023, the Puerto Rico income tax expense was $18.5 million, as compared to a Puerto Rico income tax expense of $2.9 million for the year ended December\u00a031, 2022 due to the gain previously noted on the mortgage refinancing at the Shops at Caguas. The Company recognized a $0.7\u00a0million state and local income tax benefit for the year ended December\u00a031, 2023 related to an income tax refund from a prior period. Income taxes are accounted for under the asset and liability method. Deferred income taxes are recognized for the tax effect of temporary differences between the financial reporting basis and the tax basis of taxable assets and liabilities and for the tax effect of carried forward tax attributes such as net operating losses and tax credits.", "entities": [ { "start_character": 144, "end_character": 149, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 226400000.0 }, { "start_character": 163, "end_character": 167, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 41200000.0 }, { "start_character": 215, "end_character": 219, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 51200000.0 }, { "start_character": 233, "end_character": 236, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 9100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001611547-24-000012", "filing_date": 1707894068000, "quarter_ending": "20231231", "company_name": "Urban Edge Properties", "text": "A concentration of credit risk arises in our business when a national or regionally-based tenant occupies a substantial amount of space in multiple properties owned by us. In that event, if the tenant suffers a significant downturn in its business, it may become unable to make its contractual rent payments to us, exposing us to potential losses in rental revenue, expense recoveries, and percentage rent. Further, the impact may be magnified if the tenant is renting space in multiple locations. Generally, we do not obtain security from our national or regionally-based tenants in support of their lease obligations to us. We regularly monitor our tenant base to assess potential concentrations of credit risk. None of our tenants accounted for more than 10% of total revenues in the year ended December\u00a031, 2023. As of December\u00a031, 2023, The Home Depot, Inc. was our largest tenant with six stores which comprised an aggregate of 770,742 sf and accounted for approximately $21.5 million, or 5.2% of our total revenue for the year ended December\u00a031, 2023.", "entities": [ { "start_character": 978, "end_character": 982, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 21500000.0 } ] }, { "form_type": "10-K", "accession_number": "0001601548-24-000004", "filing_date": 1709623566000, "quarter_ending": "20231231", "company_name": "V2X, Inc.", "text": "As part of the Merger, V2X acquired certain contracts, including a Transition Services Agreement (TSA) with Crestview Aerospace LLC (Crestview), which was previously divested to American Industrial Partners Capital Fund VI, L.P. (AIP). As of December\u00a031, 2023, the Company recorded $2.8\u00a0million of income related to the TSA with Crestview, which was recorded as a reduction in cost of sales. As of December\u00a031, 2023, AIP held approximately 59.3% of V2X common stock. ", "entities": [ { "start_character": 283, "end_character": 286, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 2800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001601548-24-000009", "filing_date": 1715066758000, "quarter_ending": "20240329", "company_name": "V2X, Inc.", "text": "During the three months ended March 29, 2024 and March 31, 2023, the Company recorded income of $0.5\u00a0million and $0.7\u00a0million, respectively, related to a Transition Services Agreement with Crestview Aerospace LLC (Crestview). The income was recorded as a reduction in cost of sales. Crestview is a subsidiary of American Industrial Partners Capital Fund VI, L.P. (AIP), an affiliate of the majority shareholder of the Company.", "entities": [ { "start_character": 97, "end_character": 100, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 500000.0 }, { "start_character": 114, "end_character": 117, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-028734", "filing_date": 1711987608000, "quarter_ending": "20231231", "company_name": "VASO Corp", "text": "The\nCompany maintains cash balances in certain U.S. financial institutions which exceed the Federal Depository Insurance Corporation (\u201cFDIC\u201d)\ncoverage of $250,000 by approximately $10,054,000.\u00a0 The Company has not experienced any losses on these accounts and believes it\nis not subject to any significant credit risk on these accounts. In addition, the FDIC does not insure the Company\u2019s foreign bank\nbalances, which aggregated approximately $467,000 and $1,234,000 at December 31, 2023 and 2022, respectively.", "entities": [ { "start_character": 155, "end_character": 162, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 250000.0 }, { "start_character": 181, "end_character": 191, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 10054000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001166388-24-000090", "filing_date": 1717520526000, "quarter_ending": "20240430", "company_name": "VERINT SYSTEMS INC", "text": "For the three months ended April 30, 2023, we recorded an income tax provision of $4.4 million on pretax income of $8.0 million, which represented an effective income tax rate of 54.6%. The effective tax rate differs from the U.S. federal statutory rate of 21% primarily due to the U.S. taxation of certain foreign activities, offset by lower statutory rates in certain foreign jurisdictions.", "entities": [ { "start_character": 116, "end_character": 119, "label": "earnings", "start_date_for_period": "2023-02-01", "end_date_for_period": "2023-04-30", "currency_/_unit": "iso4217:USD", "value": 8000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001166388-24-000090", "filing_date": 1717520526000, "quarter_ending": "20240430", "company_name": "VERINT SYSTEMS INC", "text": "For the three months ended April 30, 2024, we recorded an income tax provision of $8.0 million on pretax income of $23.3 million, which represented an effective income tax rate of 34.1%. The effective tax rate differs from the U.S. federal statutory rate of 21% primarily due to the U.S. taxation of certain foreign activities, offset by lower statutory rates in certain foreign jurisdictions.", "entities": [ { "start_character": 116, "end_character": 120, "label": "earnings", "start_date_for_period": "2024-02-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": 23300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001607062-24-000076", "filing_date": 1708412531000, "quarter_ending": "20231231", "company_name": "VERITEC INC", "text": "The\naccompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern,\nwhich contemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the period\nended December 31, 2023, the Company incurred a net loss of $541,000\nand used cash in operating activities of $301,000,\nand on December 31, 2023, the Company had a stockholders\u2019 deficit of $9,211,000.\nIn addition, as of December 31, 2023, the Company is delinquent in payment of $802,000\nof its convertible notes and notes payable. These factors, among others, raise substantial doubt about our ability to continue as a\ngoing concern within one year of the date that the financial statements are issued. In addition, the Company\u2019s independent\nregistered public accounting firm, in its report on the Compant\u2019s June 30, 2023 financial statements, has raised substantial\ndoubt about the Company\u2019s ability to continue as a going concern. The Company\u2019s financial statements do not include any\nadjustments that might be necessary if the Company is unable to continue as a going concern.", "entities": [ { "start_character": 325, "end_character": 332, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -541000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001607062-24-000202", "filing_date": 1716218280000, "quarter_ending": "20240331", "company_name": "VERITEC INC", "text": "The\naccompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which\ncontemplates the realization of assets and satisfaction of liabilities in the normal course of business. During the nine months ended\nMarch 31, 2024, the Company incurred a net loss of $849,000\n", "entities": [ { "start_character": 327, "end_character": 334, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -849000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000732712-24-000029", "filing_date": 1714035652000, "quarter_ending": "20240331", "company_name": "VERIZON COMMUNICATIONS INC", "text": "Service and other revenues and Wireless equipment revenues included in our Business segment were approximately $6.5\u00a0billion and $871\u00a0million, respectively, for the three months ended March\u00a031, 2024, and were approximately $6.6 billion and $882 million, respectively, for the three months ended March\u00a031, 2023.", "entities": [ { "start_character": 112, "end_character": 115, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 6500000000.0 }, { "start_character": 129, "end_character": 132, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 871000000.0 }, { "start_character": 223, "end_character": 226, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 6600000000.0 }, { "start_character": 240, "end_character": 243, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 882000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000732712-24-000029", "filing_date": 1714035652000, "quarter_ending": "20240331", "company_name": "VERIZON COMMUNICATIONS INC", "text": "There were a total of approximately 3.7 million and 3.6 million outstanding dilutive securities, primarily consisting of performance stock units and restricted stock units, included in the computation of diluted earnings per common share for the three months ended March\u00a031, 2024 and ", "entities": [ { "start_character": 36, "end_character": 39, "label": "eps", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "xbrli:shares", "value": 3700000.0 }, { "start_character": 52, "end_character": 55, "label": "eps", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "xbrli:shares", "value": 3600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001111335-24-000096", "filing_date": 1714028754000, "quarter_ending": "20240331", "company_name": "VISTEON CORP", "text": "During the three month period ended March\u00a031, 2024, the Company recorded a provision for income tax of $19\u00a0million which reflects income tax expense in countries where the Company is profitable, accrued withholding taxes, and the inability to record a tax benefit for pretax losses and/or recognize expense for pretax income in certain jurisdictions, due to valuation allowances. Pretax losses in jurisdictions where valuation allowances are maintained and no income tax benefits are recognized totaled $10\u00a0million and $11\u00a0million for the three month periods ended March\u00a031, 2024 and March 31, 2023, respectively, resulting in an increase in the Company's effective tax rate in those years.", "entities": [ { "start_character": 504, "end_character": 506, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 10000000.0 }, { "start_character": 520, "end_character": 522, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 11000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014695", "filing_date": 1713206209000, "quarter_ending": "20231231", "company_name": "VIVIC CORP.", "text": "The\nCompany had $72,907\nof cash and cash equivalents and working capital of approximately $2.19\nmillion as of December 31, 2023, which included a receivable due from a related party in the amount of $2,568,218, and although the\nCompany generated net income of $1.50\nmillion during the year ended December 31, 2023, this was mainly from the gain on disposal of subsidiaries of $1.86\nmillion, while it incurred a net loss of $241,360 from continuing operations, The Company had an accumulated deficit of approximately $3.30 million as of December 31, 2023.", "entities": [ { "start_character": 261, "end_character": 265, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019136", "filing_date": 1715686366000, "quarter_ending": "20240331", "company_name": "VIVIC CORP.", "text": "The\nCompany had $47,224\nof cash and cash equivalents and working capital of approximately $2.78\nmillion as of March 31, 2024, which included a receivable due from a related party in the amount of $2.82\nmillion, and the Company generated net income of $0.61\nmillion and a net loss of $0.33\nmillion during the three months ended March 31, 2024 and 2023, respectively. The Company had an accumulated deficit of approximately\n$2.69\nmillion as of March 31, 2024.", "entities": [ { "start_character": 252, "end_character": 256, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 610000.0 }, { "start_character": 285, "end_character": 289, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -330000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000899689-24-000021", "filing_date": 1715012427000, "quarter_ending": "20240331", "company_name": "VORNADO REALTY TRUST", "text": "Net loss attributable to common shareholders for the quarter ended March 31, 2024 was $9,034,000, or $0.05 per diluted share, compared to net income attributable to common shareholders of $5,168,000, or $0.03 per diluted share, for the prior year\u2019s quarter.\u00a0", "entities": [ { "start_character": 87, "end_character": 96, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9034000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000837010-24-000036", "filing_date": 1715254245000, "quarter_ending": "20240331", "company_name": "VOYA RETIREMENT INSURANCE & ANNUITY Co", "text": "The Company has operating agreements whereby the Company provides or receives services from affiliated entities. For the three months ended March\u00a031, 2024, revenues with affiliated entities related to these agreements were $21. For the three months ended March\u00a031, 2023, revenues with affiliated entities related to these agreements were $19. ", "entities": [ { "start_character": 224, "end_character": 226, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 21000000.0 }, { "start_character": 339, "end_character": 341, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 19000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-044299", "filing_date": 1715875567000, "quarter_ending": "20240331", "company_name": "VPR Brands, LP.", "text": "In\nFebruary 2024, the Company initiated a voluntary recall of approximately 62,200 lighters due to a missing child safety feature. Under\nASC 606, these products are not eligible for revenue recognition, as revenue cannot be recognized for amounts that are not expected to\nbe entitled. Consequently, the Company recorded this as a refund liability. For the year ended December 31, 2023, the total impact of\nthe recall, amounting to $198,068, has been recognized against revenues and receivables for potential credits associated with the recalled\nproducts.", "entities": [ { "start_character": 432, "end_character": 439, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 198068.0 } ] }, { "form_type": "10-K", "accession_number": "0000102752-24-000017", "filing_date": 1709834235000, "quarter_ending": "20231231", "company_name": "VSE CORP", "text": "The operating results of Desser Aerospace were included in our consolidated results of operations from the date of acquisition. From the date of acquisition, our consolidated revenues and operating income include $48.5\u00a0million and $4.8\u00a0million, respectively, for Desser Aerospace. Desser Aerospace's operating income does not include the impact of acquisition-related expenses incurred by VSE Corporation. We incurred $3.2\u00a0million of acquisition-related expenses related to the Desser Aerospace acquisition during the year ended December 31, 2023, which are included in selling, general and administrative expenses.", "entities": [ { "start_character": 232, "end_character": 235, "label": "ebit", "start_date_for_period": "2023-07-03", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-008178", "filing_date": 1709308881000, "quarter_ending": "20231231", "company_name": "VYNE Therapeutics Inc.", "text": "As of December\u00a031, 2023, the Company had cash, cash equivalents, restricted cash and marketable securities of $93.3\u00a0million and an accumulated deficit of $691.3\u00a0million. For the year ended December\u00a031, 2023, the Company incurred a net loss of $28.5\u00a0million and used $25.3\u00a0million of cash in operations. The net loss was comprised of a $27.9\u00a0million loss from continuing operations and a $0.6\u00a0million of loss from discontinued operations. The Company had no outstanding debt as of December 31, 2023. Other than in connection with its legacy commercial business, the Company has funded its operations primarily through private and public placements of its equity, debt and warrants and through fees, cost reimbursements and payments received from its licensees. The Company has incurred losses and experienced negative operating cash flows since its inception and anticipates that it will continue to incur losses until such a time when its product candidates, if approved, are commercially successful, if at all. The Company will not generate any revenue from any current or future product candidates unless and until it obtains regulatory approval and commercializes such products. ", "entities": [ { "start_character": 244, "end_character": 248, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -28500000.0 }, { "start_character": 336, "end_character": 340, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -27900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-022183", "filing_date": 1715270461000, "quarter_ending": "20240331", "company_name": "VYNE Therapeutics Inc.", "text": "As of March\u00a031, 2024, the Company had cash, cash equivalents, restricted cash and marketable securities of $86.0 million and an accumulated deficit of $697.6 million. The Company had no outstanding debt as of March\u00a031, 2024. For the three months ended March\u00a031, 2024, the Company incurred a net loss of $6.2\u00a0million and used\u00a0$8.0 million of cash in operations. Other than in connection with its legacy commercial business, the Company has funded its operations primarily through private and public placements of its equity, debt and warrants and through fees, cost reimbursements and payments received from its licensees. The Company has incurred losses and experienced negative operating cash flows since its inception and anticipates that it will continue to incur losses until such a time when its product candidates, if approved, are commercially successful, if at all. The Company will not generate any revenue from any current or future product candidates unless and until it obtains regulatory approval and commercializes such products.", "entities": [ { "start_character": 304, "end_character": 307, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001681622-24-000009", "filing_date": 1707235761000, "quarter_ending": "20231229", "company_name": "Varex Imaging Corp", "text": "For the three months ended December 29, 2023, the Company recognized income tax benefit of $0.2 million on $0.6 million of pre-tax loss. For the three months ended December 30, 2022, the Company recognized income tax expense of $2.2 million on $5.4 million of pre-tax income. The Company is unable to recognize a tax benefit for pre-tax book losses in certain foreign jurisdictions but has recognized tax expense for profitable foreign jurisdictions.", "entities": [ { "start_character": 108, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-09-30", "end_date_for_period": "2023-12-29", "currency_/_unit": "iso4217:USD", "value": -600000.0 }, { "start_character": 245, "end_character": 248, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2022-12-30", "currency_/_unit": "iso4217:USD", "value": 5400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001681622-24-000059", "filing_date": 1714666137000, "quarter_ending": "20240329", "company_name": "Varex Imaging Corp", "text": "For the three months ended March 29, 2024, the Company recognized income tax expense of $0.7 million on $2.3 million of pre-tax income. For the three months ended March 31, 2023, the Company recognized income tax expense of $3.5 million on $7.8 million of pre-tax income. For the six months ended March 29, 2024, the Company recognized income tax expense of $0.5 million on $1.7 million of pre-tax income. For the six months ended March 31, 2023, the Company recognized income tax expense of $5.7 million on $13.2 million of pre-tax income. The Company is unable to recognize a tax benefit for pre-tax book losses in certain foreign jurisdictions but has recognized tax expense for profitable jurisdictions.", "entities": [ { "start_character": 105, "end_character": 108, "label": "earnings", "start_date_for_period": "2023-12-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 2300000.0 }, { "start_character": 241, "end_character": 244, "label": "earnings", "start_date_for_period": "2022-12-31", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 7800000.0 }, { "start_character": 375, "end_character": 378, "label": "earnings", "start_date_for_period": "2023-09-30", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 1700000.0 }, { "start_character": 509, "end_character": 513, "label": "earnings", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 13200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001967680-24-000059", "filing_date": 1713893989000, "quarter_ending": "20240329", "company_name": "Veralto Corp", "text": "During the three-month periods ended March\u00a029, 2024 and March\u00a031, 2023, Veralto recorded revenues from sales to Danaher and its subsidiaries of $5\u00a0million and $7\u00a0million, respectively. Following the Separation, Veralto continues to enter into revenue arrangements in the ordinary course of business with Danaher and its subsidiaries, although certain agreements were entered into or terminated as a result of the Separation.", "entities": [ { "start_character": 145, "end_character": 146, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-29", "currency_/_unit": "iso4217:USD", "value": 5000000.0 }, { "start_character": 160, "end_character": 161, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 7000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-011506", "filing_date": 1710521524000, "quarter_ending": "20231231", "company_name": "Verano Holdings Corp.", "text": "In addition, the Company\u2019s accounting for distributions from a consolidated entity was corrected in the Restatements to reduce investment in associates and non-controlling interest equity by ($1,675) for the year ended December 31, 2021, and ($100) for the quarter ended March 31, 2021. Also, the investment in associates was corrected to account for distributions in excess of investment resulting in an increase of equity income of $1,537 and $1,638 at December 31, 2021 and March 31, 2022, respectively, with a reduction in disposition of investments of $3,176 at March 31, 2022. Further, after March 31, 2022 but before the March 31, 2022 financials were issued, the Company became aware of information regarding the Connecticut Pharmaceutical Solutions, Inc. and The Healing Center, LLC acquisition purchase price earnouts, as described in ", "entities": [ { "start_character": 435, "end_character": 440, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1537000.0 }, { "start_character": 446, "end_character": 451, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-03-31", "currency_/_unit": "iso4217:USD", "value": 1638000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012416", "filing_date": 1711989081000, "quarter_ending": "20231231", "company_name": "Verb Technology Company, Inc.", "text": "The\naccompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets\nand the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial\nstatements, during the year ended December 31, 2023, the Company incurred a net loss from continuing operations of $14,844 and used cash\nin continuing operations of $8,742. As of December 31, 2023, the Company had cash of $4,353 yet the aforementioned\nfactors raised substantial doubt about the Company\u2019s ability to continue as a going concern within one year after the date these\nfinancial statements were issued.", "entities": [ { "start_character": 397, "end_character": 403, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -14844000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007824", "filing_date": 1709197476000, "quarter_ending": "20231231", "company_name": "Vericel Corp", "text": "The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of December\u00a031, 2023, the Company had an accumulated deficit of $403.2 million and had a net loss of $3.2 million for the year ended December\u00a031, 2023. The Company had cash and cash equivalents of $69.1 million and investments of $65.8 million as of December\u00a031, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient", "entities": [ { "start_character": 379, "end_character": 382, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -3200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021847", "filing_date": 1715196786000, "quarter_ending": "20240331", "company_name": "Vertex Energy Inc.", "text": "For the three month period ended March\u00a031, 2024, the Company calculated an annual effective tax rate of 0% on pre-tax book loss of $17.9 million and booked total tax expenses of $0.", "entities": [ { "start_character": 132, "end_character": 136, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -17900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021847", "filing_date": 1715196786000, "quarter_ending": "20240331", "company_name": "Vertex Energy Inc.", "text": "For the three month period ended March\u00a031, 2023, the Company calculated an annual effective tax rate of 26% on pre-tax income of $4.5 million and recognized income tax expense of $1.0 million on continued operations. ", "entities": [ { "start_character": 130, "end_character": 133, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 4500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-021847", "filing_date": 1715196786000, "quarter_ending": "20240331", "company_name": "Vertex Energy Inc.", "text": "The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company has cash and cash equivalents of $62.1\u00a0million as of March\u00a031, 2024. As shown in the accompanying unaudited consolidated financial statements, the Company generated a net loss from continuing operations of $17.9 million during the three months ended March\u00a031, 2024. The Company had cash outflows from operating activities from continuing operations, which were $29.1 million during the three months ended March\u00a031, 2024. The Company has cash outflows from investing activities from continuing operations due to its investments in capital expenditures partially offset by proceeds of real property sales. The Company has generated significant cash inflows from financing activities from continuing operations, primarily attributed to proceeds from inventory financing agreement.", "entities": [ { "start_character": 345, "end_character": 349, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -17900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001792044-24-000008", "filing_date": 1709136949000, "quarter_ending": "20231231", "company_name": "Viatris Inc", "text": "The goodwill of $6.7\u00a0million arising from the acquisition consisted largely of the value of the employee workforce and the expected value of products to be developed in the future. All of the goodwill was assigned to the Developed Markets segment. None of the goodwill recognized in this transaction is currently expected to be deductible for income tax purposes. The operating results of Oyster Point have been included in the Company\u2019s consolidated statements of operations since the acquisition date. The total revenues of Oyster Point for the period from the acquisition date to December 31, 2023 were $41.7\u00a0million and net loss, net of tax, was approximately $163.1\u00a0million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs. ", "entities": [ { "start_character": 607, "end_character": 611, "label": "revenues", "start_date_for_period": "2023-01-03", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 41700000.0 }, { "start_character": 665, "end_character": 670, "label": "earnings", "start_date_for_period": "2023-01-03", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 163100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-015039", "filing_date": 1713371155000, "quarter_ending": "20231231", "company_name": "Video River Networks, Inc.", "text": "The\nvaluation allowance $4,133,580 As at December 31, 2023 decreased by $125,781 compared to December 31, 2022 of $4,262,546, as a result\nof the Company generating additional net operating income of $496,026 .", "entities": [ { "start_character": 200, "end_character": 207, "label": "ebit", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 496026.0 } ] }, { "form_type": "10-Q", "accession_number": "0001811856-23-000052", "filing_date": 1699982793000, "quarter_ending": "20230930", "company_name": "View, Inc.", "text": "Since inception, the Company has not achieved profitable operations or positive cash flows from operations. The Company\u2019s accumulated deficit totaled $2,931.1 million as of September\u00a030, 2023. For the nine months ended September\u00a030, 2023, the Company had a net loss of approximately $336.7 million and negative cash flows from operations of approximately $139.6 million. In addition, for the nine months ended September 30, 2022, the Company had a net loss of approximately $247.3 million and negative cash flows from operations of approximately $204.2 million. Cash and cash equivalents were $50.6 million as of September\u00a030, 2023. ", "entities": [ { "start_character": 284, "end_character": 289, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -336700000.0 }, { "start_character": 475, "end_character": 480, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -247300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020755", "filing_date": 1716224807000, "quarter_ending": "20240331", "company_name": "Viewbix Inc.", "text": "The\nCompany experienced a decrease in its revenues from the digital content and search segments as a result of a decrease in user\ntraffic acquired from third party advertising platforms, an industry-wide decrease in advertising budget, changes and updates to\ninternet browsers\u2019 technology and other changes in the online advertising industry during the second half of 2023 and the\nthree months ended March 31, 2024. As a result of the foregoing, during the three months ended March 31, 2024, the Company recorded\nan operating loss of $1,011 ", "entities": [ { "start_character": 535, "end_character": 540, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1011000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-020299", "filing_date": 1714753013000, "quarter_ending": "20240331", "company_name": "Vir Biotechnology, Inc.", "text": "The parties mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK is primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, the Company granted or will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program. GSK selected RSV as its first pathogen under the Additional Programs in 2022. During the three months ended March 31, 2024, the Company recognized contract revenue of $51.7 million as GSK\u2019s rights to select the remaining two additional non-influenza target pathogens expired on March 25, 2024. The Company had no other remaining performance obligations under the 2021 GSK Agreement.", "entities": [ { "start_character": 869, "end_character": 873, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 51700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-025781", "filing_date": 1711440950000, "quarter_ending": "20231231", "company_name": "Virpax Pharmaceuticals, Inc.", "text": "The\nCompany incurred a net loss of $15,189,508 and $21,650,720 for the years ended December 31, 2023 and 2022, respectively, and had an accumulated\ndeficit of $59,544,135 as of December 31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it\ncan generate significant revenue from its product candidates currently in development. The Company\u2019s primary source of capital\nhas been the issuance of debt and equity securities.", "entities": [ { "start_character": 36, "end_character": 46, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -15189508.0 }, { "start_character": 52, "end_character": 62, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -21650720.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-013015", "filing_date": 1712162443000, "quarter_ending": "20231231", "company_name": "Vislink Technologies, Inc.", "text": "For\nthe fiscal year ending December 31, 2023, we incurred a net\nloss of approximately $10.6 million and utilized $9.7 million in cash for operating activities. The Company\nmaintained a working capital of $31.8 million, alongside $8.5 million in cash, against $309.2 million in accumulated deficits.", "entities": [ { "start_character": 87, "end_character": 91, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -10600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019750", "filing_date": 1715785476000, "quarter_ending": "20240331", "company_name": "Vislink Technologies, Inc.", "text": "For\nthe three months ended March 31, 2024, the Company incurred an approximate $1.6 million loss from operations and $0.1 million of cash\nused in operating activities. As of March 31, 2024, the Company had $31.3 million in working capital, $310.2 million in accumulated deficits,\nand $8.0 million in cash and cash equivalents.", "entities": [ { "start_character": 80, "end_character": 83, "label": "ebit", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -1600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-009929", "filing_date": 1710425194000, "quarter_ending": "20240131", "company_name": "Vitro Biopharma, Inc.", "text": "The\naccompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going\nconcern. The Company incurred net losses of approximately $4.6 million for the three months ended January 31, 2024 and $5.4 million\nfor the year ended October 31, 2023. The Company had a working capital deficit of approximately $5.7 million as of January 31, 2024.\nIn addition, the revenues of the Company do not provide adequate working capital for the Company to sustain its current and planned business\noperations.", "entities": [ { "start_character": 198, "end_character": 201, "label": "earnings", "start_date_for_period": "2023-11-01", "end_date_for_period": "2024-01-31", "currency_/_unit": "iso4217:USD", "value": -4600000.0 }, { "start_character": 259, "end_character": 262, "label": "earnings", "start_date_for_period": "2022-11-01", "end_date_for_period": "2023-10-31", "currency_/_unit": "iso4217:USD", "value": -5400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-022030", "filing_date": 1717092082000, "quarter_ending": "20240430", "company_name": "Vitro Biopharma, Inc.", "text": "The\naccompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going\nconcern. The Company incurred net losses of approximately $7.7 million for the six months ended April 30, 2024 and $5.4 million for the\nyear ended October 31, 2023. The Company had a working capital deficit of approximately $8.3 million as of April 30, 2024. In addition,\nthe revenues of the Company do not provide adequate working capital for the Company to sustain its current and planned business operations.", "entities": [ { "start_character": 198, "end_character": 201, "label": "earnings", "start_date_for_period": "2023-11-01", "end_date_for_period": "2024-04-30", "currency_/_unit": "iso4217:USD", "value": -7700000.0 }, { "start_character": 255, "end_character": 258, "label": "earnings", "start_date_for_period": "2022-11-01", "end_date_for_period": "2023-10-31", "currency_/_unit": "iso4217:USD", "value": -5400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001829126-24-002582", "filing_date": 1713288828000, "quarter_ending": "20231231", "company_name": "Vivakor, Inc.", "text": "Our\nsales consist of storage services and the sale of crude oil or like products. For the years ended December\u00a031, 2023 and 2022, disaggregated\nrevenue by customer type was as follows: $47,683,331 and $21,409,300 in crude oil sales and $11,268,005 and $5,890,910 in product related\nto natural gas liquids sales.", "entities": [ { "start_character": 186, "end_character": 196, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 47683331.0 }, { "start_character": 202, "end_character": 212, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 21409300.0 }, { "start_character": 237, "end_character": 247, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 11268005.0 }, { "start_character": 253, "end_character": 262, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 5890910.0 } ] }, { "form_type": "10-K", "accession_number": "0001829126-24-002582", "filing_date": 1713288828000, "quarter_ending": "20231231", "company_name": "Vivakor, Inc.", "text": "From\nthe date of acquisition on August\u00a01, 2022 through December\u00a031, 2022, $28,058,374 of sales in aggregate is attributed to SFD\nand WCCC. The unaudited financial information in the table below summarizes the combined results of operations of the Company, SFD, and\nWCCC for the years ended December\u00a031, 2022 and 2021, on a pro forma basis, as though the companies had been combined as of January\u00a01,\n2021. The pro forma earnings for the years ended December\u00a031, 2022 and 2021, were adjusted to include intangible amortization expense\nof contracts acquired of $2,027,832, respectively. The pro forma earnings for the years ended December\u00a031, 2022 and 2021, were adjusted\nto include interest expense on notes payable that were issued as consideration of $1,152,842 and $1,773,603, respectively. The $174,592\nof acquisition-related expenses were excluded from the year ended December\u00a031, 2022, and included in the year ended December\u00a031,\n2021, as if the acquisition occurred at January\u00a01, 2021. The unaudited pro forma financial information does not purport to be indicative\nof the Company\u2019s combined results of operations which would actually have been obtained had the acquisition taken place on January\u00a01,\n2021, nor should it be taken as indicative of future consolidated results of operations.", "entities": [ { "start_character": 75, "end_character": 85, "label": "revenues", "start_date_for_period": "2022-08-02", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 28058374.0 } ] }, { "form_type": "10-Q", "accession_number": "0001753926-24-000959", "filing_date": 1715621225000, "quarter_ending": "20240331", "company_name": "Vivani Medical, Inc.", "text": "During\nthe three months ended March 31, 2024, the Biopharm Division and Neurostimulation Division incurred operating expenses of $5.7\nmillion and $0.5 million, respectively. During the three months ended March 31, 2024, consolidated net loss for the Biopharm Division\nwas $5.5 million and for the Neurostimulation Division was $0.6 million. As of March 31, 2024, total assets for the Biopharm Division\nand the Neurostimulation Division was $52.5 million and $1.3 million, respectively.", "entities": [ { "start_character": 273, "end_character": 276, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 5500000.0 }, { "start_character": 328, "end_character": 331, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011755", "filing_date": 1711643017000, "quarter_ending": "20231231", "company_name": "Vivos Therapeutics, Inc.", "text": "The\nfinancial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of\nthe Company as a going concern. The Company has incurred losses since inception, including $13.6 and $23.8 million for the years ended\nDecember 31, 2023 and 2022, respectively, resulting in an accumulated deficit of approximately $93.1 million as of December 31, 2023.", "entities": [ { "start_character": 231, "end_character": 235, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -13600000.0 }, { "start_character": 241, "end_character": 245, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -23800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019247", "filing_date": 1715703368000, "quarter_ending": "20240331", "company_name": "Vivos Therapeutics, Inc.", "text": "The\nfinancial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of\nthe Company as a going concern. The Company has incurred losses since inception, including $3.8 and $1.7 million for the three months\nended March 31, 2024 and 2023, respectively, resulting in an accumulated deficit of approximately $96.8 million as of March 31, 2024.", "entities": [ { "start_character": 231, "end_character": 234, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -3800000.0 }, { "start_character": 240, "end_character": 243, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -1700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-023379", "filing_date": 1715757094000, "quarter_ending": "20240331", "company_name": "Volato Group, Inc.", "text": "The Company has only recently been formed, has limited operating history, has recorded a net loss of $17.4 million for the three months ended March 31, 2024, has a negative working capital of $11.7 million, and has an accumulated deficit of $81.1 million as of March\u00a031, 2024. Net cash used in operating activities for the three months ended March 31, 2024, was $7.7 million.", "entities": [ { "start_character": 103, "end_character": 107, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -17400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001025378-24-000037", "filing_date": 1707497781000, "quarter_ending": "20231231", "company_name": "W. P. Carey Inc.", "text": "Under the advisory agreement with NLOP, we earn a base administrative amount of approximately $4.0\u00a0million annually, for certain administrative services, including day-to-day management services, investor relations, accounting, tax, legal, and other administrative matters, paid in cash.", "entities": [ { "start_character": 95, "end_character": 98, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001025378-24-000037", "filing_date": 1707497781000, "quarter_ending": "20231231", "company_name": "W. P. Carey Inc.", "text": "Pursuant to the NLOP Advisory Agreements, which we entered into on November 1, 2023, we provide NLOP with strategic management services, including asset management, property disposition support, and various related services. NLOP will pay us an asset management fee of approximately $7.5\u00a0million annually, which will be proportionately reduced following the disposition of a portfolio property. Such fees are included in Asset management revenue on our consolidated statements of income. In addition, NLOP will reimburse us a base administrative amount of approximately $4.0\u00a0million annually, for certain administrative services, including day-to-day management services, investor relations, accounting, tax, legal, and other administrative matters. Such amounts are included in Other advisory income and reimbursements on our consolidated statements of income.", "entities": [ { "start_character": 571, "end_character": 574, "label": "revenues", "start_date_for_period": "2023-11-01", "end_date_for_period": "2023-11-01", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001025378-24-000081", "filing_date": 1714579743000, "quarter_ending": "20240331", "company_name": "W. P. Carey Inc.", "text": "Under the advisory agreement with NLOP, we earn a base administrative amount of approximately $4.0\u00a0million annually, for certain administrative services, including day-to-day management services, investor relations, accounting, tax, legal, and other administrative matters, paid in cash.", "entities": [ { "start_character": 95, "end_character": 98, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 4000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000766704-24-000008", "filing_date": 1707981922000, "quarter_ending": "20231231", "company_name": "WELLTOWER INC.", "text": "For the majority of our Seniors Housing Operating segment, revenue from resident fees and services is predominantly service-based, and as such, resident agreements are accounted for under ASC 606. Within that reportable segment, we also recognize revenue from residential seniors apartment leases in accordance with ASC 842. The amount of revenue related to these leases was $466,162,000, ", "entities": [ { "start_character": 376, "end_character": 387, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 466162000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000766704-24-000022", "filing_date": 1714461502000, "quarter_ending": "20240331", "company_name": "WELLTOWER INC.", "text": "We recognized revenues from consolidated VIEs in the aggregate of $109,930,000 and $49,784,000 for the three months ended March 31, 2024 and 2023, respectively.", "entities": [ { "start_character": 67, "end_character": 78, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 109930000.0 }, { "start_character": 84, "end_character": 94, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 49784000.0 } ] }, { "form_type": "10-K", "accession_number": "0000793074-24-000014", "filing_date": 1708963571000, "quarter_ending": "20231231", "company_name": "WERNER ENTERPRISES INC", "text": "We are the lessor of tractors and trailers under operating leases with initial terms of 3 to 8 years. We recognize revenue for such leases on a straight-line basis over the term of the lease. Revenues for the years ended December\u00a031, 2023, 2022, and 2021 were $10.9 million, $10.7 million, and $11.7 million, respectively. The following table presents information about the maturities of these operating leases as of December\u00a031, 2023 (in thousands):", "entities": [ { "start_character": 261, "end_character": 265, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 10900000.0 }, { "start_character": 276, "end_character": 280, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 10700000.0 }, { "start_character": 295, "end_character": 299, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 11700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000793074-24-000037", "filing_date": 1715270772000, "quarter_ending": "20240331", "company_name": "WERNER ENTERPRISES INC", "text": "We are the lessor of tractors and trailers under operating leases with initial terms of 3 to 8 years. We recognize revenue for such leases on a straight-line basis over the term of the lease. Revenues were $2.4 million and $2.7 million for the three months ended March\u00a031, 2024 and 2023, respectively. ", "entities": [ { "start_character": 207, "end_character": 210, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 2400000.0 }, { "start_character": 224, "end_character": 227, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 2700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000776867-24-000010", "filing_date": 1715271460000, "quarter_ending": "20240331", "company_name": "WHITE MOUNTAINS INSURANCE GROUP LTD", "text": "Ark\u2019s earned insurance premiums based on the location of Ark\u2019s underwriting offices in the United Kingdom and Bermuda are $177.4 and $115.1.", "entities": [ { "start_character": 123, "end_character": 128, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 177400000.0 }, { "start_character": 134, "end_character": 139, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 115100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000776867-24-000010", "filing_date": 1715271460000, "quarter_ending": "20240331", "company_name": "WHITE MOUNTAINS INSURANCE GROUP LTD", "text": "Ark\u2019s earned insurance premiums based on the location of Ark\u2019s underwriting offices in the United Kingdom and Bermuda are $146.0 and $104.0.", "entities": [ { "start_character": 123, "end_character": 128, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 146000000.0 }, { "start_character": 134, "end_character": 139, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 104000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000107263-24-000019", "filing_date": 1708531667000, "quarter_ending": "20231231", "company_name": "WILLIAMS COMPANIES, INC.", "text": "Two members of our Board of Directors are also executive officers at certain of our counterparties. We recorded $90\u00a0million and $180\u00a0million in ", "entities": [ { "start_character": 113, "end_character": 115, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 90000000.0 }, { "start_character": 129, "end_character": 132, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 180000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001015328-24-000083", "filing_date": 1709140842000, "quarter_ending": "20231231", "company_name": "WINTRUST FINANCIAL CORP", "text": "The Company\u2019s income before income taxes in 2023, 2022 and 2021 includes $42.5 million, $27.7 million and $23.1 million, respectively, of foreign income attributable to its Canadian subsidiary.", "entities": [ { "start_character": 74, "end_character": 78, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 42500000.0 }, { "start_character": 89, "end_character": 93, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 27700000.0 }, { "start_character": 107, "end_character": 111, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 23100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001015328-24-000083", "filing_date": 1709140842000, "quarter_ending": "20231231", "company_name": "WINTRUST FINANCIAL CORP", "text": "In addition to the lessee arrangements discussed above, the Company also leases certain owned premises and receives rental income from such lessor agreements. Gross rental income related to the Company\u2019s buildings totaled $6.3 million, $7.8 million and $7.8 million, in 2023, 2022 and 2021, respectively. The approximate annual gross rental receipts under noncancelable agreements with remaining terms in excess of one year as of December\u00a031, 2023, are as follows (in thousands):", "entities": [ { "start_character": 223, "end_character": 226, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 6300000.0 }, { "start_character": 237, "end_character": 240, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 7800000.0 }, { "start_character": 254, "end_character": 257, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 7800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001779474-24-000023", "filing_date": 1716570740000, "quarter_ending": "20231231", "company_name": "WM TECHNOLOGY, INC.", "text": "Net income for the period from June 16, 2021 (Closing Date) to December 31, 2021 was $137.1\u00a0million, which includes change in fair value of warrant liability of $166.5\u00a0million, stock-based compensation expense of $29.3\u00a0million and transaction costs related to the warrant liability of $5.5\u00a0million. The transaction costs related to the warrant liability is included in other expense, net on the consolidated statements of operations.", "entities": [ { "start_character": 86, "end_character": 91, "label": "earnings", "start_date_for_period": "2021-06-17", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 137100000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000895419-24-000012", "filing_date": 1706803592000, "quarter_ending": "20231231", "company_name": "WOLFSPEED, INC.", "text": "For the three and six months ended December\u00a031, 2023, the Company recognized a net loss of $6.6 million and $13.5 million, respectively in non-operating expense (income), net related to the Wafer Supply Agreement, of which a receivable of $0.9\u00a0million is included in other current assets in the consolidated balance sheet as of December\u00a031, 2023. For the three and six months ended December\u00a025, 2022, the Company recognized a net loss of $2.6 million and $2.5 million, respectively, in non-operating income, net related to the Wafer Supply Agreement.", "entities": [ { "start_character": 92, "end_character": 95, "label": "earnings", "start_date_for_period": "2023-09-25", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -6600000.0 }, { "start_character": 109, "end_character": 113, "label": "earnings", "start_date_for_period": "2023-06-26", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -13500000.0 }, { "start_character": 439, "end_character": 442, "label": "earnings", "start_date_for_period": "2022-09-26", "end_date_for_period": "2022-12-25", "currency_/_unit": "iso4217:USD", "value": -2600000.0 }, { "start_character": 456, "end_character": 459, "label": "earnings", "start_date_for_period": "2022-06-27", "end_date_for_period": "2022-12-25", "currency_/_unit": "iso4217:USD", "value": -2500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0000895419-24-000038", "filing_date": 1714665995000, "quarter_ending": "20240331", "company_name": "WOLFSPEED, INC.", "text": "For the three and nine months ended March\u00a031, 2024, the Company recognized a net loss of $6.9 million and $20.4 million, respectively, in non-operating expense (income), net related to the Wafer Supply Agreement, of which a receivable of $2.0\u00a0million is included in other current assets in the consolidated balance sheet as of March\u00a031, 2024. For the three and nine months ended March\u00a026, 2023, the Company recognized a net loss of $4.8 million and $7.3 million, respectively, in non-operating expense (income), net related to the Wafer Supply Agreement.", "entities": [ { "start_character": 90, "end_character": 93, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -6900000.0 }, { "start_character": 107, "end_character": 111, "label": "earnings", "start_date_for_period": "2023-06-26", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -20400000.0 }, { "start_character": 433, "end_character": 436, "label": "earnings", "start_date_for_period": "2022-12-26", "end_date_for_period": "2023-03-26", "currency_/_unit": "iso4217:USD", "value": -4800000.0 }, { "start_character": 450, "end_character": 453, "label": "earnings", "start_date_for_period": "2022-06-27", "end_date_for_period": "2023-03-26", "currency_/_unit": "iso4217:USD", "value": -7300000.0 } ] }, { "form_type": "10-K", "accession_number": "0001842356-24-000042", "filing_date": 1710954563000, "quarter_ending": "20231231", "company_name": "Wag! Group Co.", "text": "During the year ended December\u00a031, 2022, the Company had two customers that accounted for 10% or more of total revenues. These customers each represented $6.6\u00a0million and $8.3\u00a0million of total revenues for the year ended December\u00a031, 2022, and in aggregate, accounted for 27% of the Company\u2019s total revenues for the year ended December\u00a031, 2022. As of December\u00a031, 2022, the Company had four customers that accounted for 10% or more of accounts receivable, and in aggregate, accounted for 65% of the Company\u2019s total accounts receivable as of December\u00a031, 2022.", "entities": [ { "start_character": 155, "end_character": 158, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 6600000.0 }, { "start_character": 172, "end_character": 175, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 8300000.000000001 } ] }, { "form_type": "10-K", "accession_number": "0001842356-24-000042", "filing_date": 1710954563000, "quarter_ending": "20231231", "company_name": "Wag! Group Co.", "text": "Significant customers are those which represent more than 10% of the Company\u2019s total revenues for the period or accounts receivable balance as of the period end date. During the year ended December\u00a031, 2023, the Company had two customers that accounted for 10% or more of total revenues. These customers each represented $13.5\u00a0million and $16.5\u00a0million of total revenues for the year ended December\u00a031, 2023, and in aggregate, accounted for 36% of the Company\u2019s total revenues for the year ended December\u00a031, 2023. As of December\u00a031, 2023, the Company had three customers that accounted for 10% or more of accounts receivable, and in aggregate, accounted for 58% of the Company\u2019s total accounts receivable as of December\u00a031, 2023.", "entities": [ { "start_character": 322, "end_character": 326, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 13500000.0 }, { "start_character": 340, "end_character": 344, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 16500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001618921-24-000035", "filing_date": 1711641698000, "quarter_ending": "20240229", "company_name": "Walgreens Boots Alliance, Inc.", "text": "Due to the anti-dilutive effect resulting from the reported net loss, an incremental 4.8\u00a0million of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding for the six months ended February 28, 2023.", "entities": [ { "start_character": 85, "end_character": 88, "label": "eps", "start_date_for_period": "2022-09-01", "end_date_for_period": "2023-02-28", "currency_/_unit": "xbrli:shares", "value": 4800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001618921-24-000065", "filing_date": 1719504060000, "quarter_ending": "20240531", "company_name": "Walgreens Boots Alliance, Inc.", "text": "Due to the anti-dilutive effect resulting from the reported net loss, an incremental 7.0\u00a0million and 3.3\u00a0million shares of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding for the nine months ended May 31, 2024 and May 31, 2023, respectively.", "entities": [ { "start_character": 85, "end_character": 88, "label": "eps", "start_date_for_period": "2023-09-01", "end_date_for_period": "2024-05-31", "currency_/_unit": "xbrli:shares", "value": 7000000.0 }, { "start_character": 101, "end_character": 104, "label": "eps", "start_date_for_period": "2022-09-01", "end_date_for_period": "2023-05-31", "currency_/_unit": "xbrli:shares", "value": 3300000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001603923-24-000086", "filing_date": 1713976255000, "quarter_ending": "20240331", "company_name": "Weatherford International plc", "text": "The following table disaggregates our revenue from contracts with customers by geographic area and includes equipment rental revenue. Equipment rental revenue was $34 million in the three months ended March 31, 2024 and $33 million for the three months ended March 31, 2023.", "entities": [ { "start_character": 164, "end_character": 166, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 34000000.0 }, { "start_character": 221, "end_character": 223, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 33000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001423902-24-000022", "filing_date": 1708532762000, "quarter_ending": "20231231", "company_name": "Western Midstream Partners, LP", "text": "Total revenues and other includes related-party amounts of $1.8 billion, $1.8 billion, and $1.6 billion for the years ended December 31, 2023, 2022, and 2021, respectively. See ", "entities": [ { "start_character": 60, "end_character": 63, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1800000000.0 }, { "start_character": 74, "end_character": 77, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1800000000.0 }, { "start_character": 92, "end_character": 95, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1600000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001423902-24-000022", "filing_date": 1708532762000, "quarter_ending": "20231231", "company_name": "Western Midstream Partners, LP", "text": "Total revenues and other includes $1.8 billion, $1.8 billion, and $1.6 billion for the years ended December 31, 2023, 2022, and 2021, respectively. See ", "entities": [ { "start_character": 35, "end_character": 38, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1800000000.0 }, { "start_character": 49, "end_character": 52, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 1800000000.0 }, { "start_character": 67, "end_character": 70, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1600000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001423902-24-000037", "filing_date": 1715185242000, "quarter_ending": "20240331", "company_name": "Western Midstream Partners, LP", "text": "Total revenues and other includes related-party amounts of $499.8 million and $448.8 million for the three months ended March 31, 2024 and 2023, respectively. See ", "entities": [ { "start_character": 60, "end_character": 65, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 499800000.0 }, { "start_character": 79, "end_character": 84, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 448800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001423902-24-000037", "filing_date": 1715185242000, "quarter_ending": "20240331", "company_name": "Western Midstream Partners, LP", "text": "Total revenues and other includes related-party amounts of $499.8 million and $448.8 million for the three months ended March 31, 2024 and 2023, respectively. See ", "entities": [ { "start_character": 60, "end_character": 65, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 499800000.0 }, { "start_character": 79, "end_character": 84, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 448800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001527541-24-000055", "filing_date": 1715011268000, "quarter_ending": "20240331", "company_name": "Wheeler Real Estate Investment Trust, Inc.", "text": "The Company performs property management and leasing services for Cedar, a subsidiary of the Company, pursuant to the management agreement entered into by and between the companies (the \"Wheeler Real Estate Company Management Agreement\"). During the three months ended March\u00a031, 2024, Cedar paid the Company $0.3\u00a0million for these services. During the three months ended March\u00a031, 2023, Cedar paid the Company $0.4\u00a0million for these services. The Operating Partnership and Cedar\u2019s operating partnership, Cedar Realty Trust Partnership, L.P., are party to a cost sharing and reimbursement agreement, pursuant to which the parties agreed to share costs and expenses associated with certain employees, certain facilities and property, and certain arrangements with third parties (the \"Cost Sharing Agreement\"). Related party amounts due to the Company from Cedar are comprised of (in thousands):", "entities": [ { "start_character": 309, "end_character": 312, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 300000.0 }, { "start_character": 411, "end_character": 414, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001753706-24-000012", "filing_date": 1715240527000, "quarter_ending": "20240331", "company_name": "Whole Earth Brands, Inc.", "text": "The Company\u2019s income tax provision was $11.5 million for the three months ended March 31, 2023, which includes a discrete tax provision of $1.0 million related primarily to tax expense for a shortfall on the tax benefits on stock-based awards that have vested and the remeasurement of state deferred taxes as a result of state law changes enacted during the quarter. The effective tax rate for the three months ended March 31, 2023 was an income tax provision of (137.6%) on a pre-tax loss of $8.3 million which differs from the statutory federal rate of 21% primarily due to an increase in the valuation allowance related to interest expense for which deductibility is limited under IRC \u00a7163(j), foreign income at different rates, non-deductible permanent differences, state and local taxes, and the U.S. tax effect of international operations including Global Intangible Low-Taxed Income (\u201cGILTI\u201d) recorded during the period, and the discrete tax provision described above.", "entities": [ { "start_character": 494, "end_character": 497, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": -8300000.000000001 } ] }, { "form_type": "10-Q", "accession_number": "0001753706-24-000012", "filing_date": 1715240527000, "quarter_ending": "20240331", "company_name": "Whole Earth Brands, Inc.", "text": "The Company\u2019s income tax provision was $1.9 million for the three months ended March 31, 2024. The effective tax rate for the three months ended March 31, 2024 was (25.2%) on a pre-tax loss of $7.5 million. The effective tax rate differs from the statutory federal rate of 21% primarily due to an increase in the valuation allowance related to interest expense for which deductibility is limited under IRC \u00a7163(j), foreign income at different rates, non-deductible permanent differences, and state and local taxes recorded during the period.", "entities": [ { "start_character": 194, "end_character": 197, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -7500000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001425287-24-000101", "filing_date": 1716224939000, "quarter_ending": "20240331", "company_name": "Workhorse Group Inc.", "text": "We had sales of $1.3\u00a0million, incurred a net loss of $29.2\u00a0million and used $18.0\u00a0million of cash in operating activities during the three months ended March 31, 2024. As of March 31, 2024, the Company had $6.7\u00a0million of cash and cash equivalents, accounts receivable of $1.8\u00a0million, net inventory of $49.9\u00a0million and accounts payable of $14.2\u00a0million. As of March 31, 2024, the Company had working capital of $24.2\u00a0million and an accumulated deficit of $780.7\u00a0million. ", "entities": [ { "start_character": 54, "end_character": 58, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -29200000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-012578", "filing_date": 1711040911000, "quarter_ending": "20231231", "company_name": "X4 Pharmaceuticals, Inc", "text": "(\u201cASU 2014-15\u201d), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company\u2019s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company does not yet have an approved drug product. Since inception, the Company has incurred significant operating losses and negative cash flows from operations. As of December\u00a031, 2023, the Company had $114.2 million of cash, cash equivalents and short-term marketable securities and an accumulated deficit of $477.9 million. For the year ended December 31, 2023, the Company\u2019s net losses were $101.2\u00a0million and net cash used in operating activities of $96.5 million. The Company has a covenant under its Second Amended and Restated Loan and Security Agreement (the \u201cHercules Loan Agreement\u201d) with Hercules Capital Inc. (\u201cHercules\u201d), as most recently amended in August 2023, that requires that the Company currently maintain a minimum level of cash of $20\u00a0million, subject to adjustments beginning January 31, 2025. Based on its cash flow projections, as discussed below, the Company believes it would not maintain the minimum cash required to satisfy this covenant noted above beginning in the first quarter of 2025. In such event, the lender could require the repayment of all outstanding debt. Accordingly, management has concluded that the Company\u2019s accumulated deficit, history of losses, future expected losses and negative cash flows met the ASC 205-40 standard for raising substantial doubt about the Company\u2019s ability to continue as a going concern. The Company does not have adequate financial resources to fund its forecasted operating costs for at least one year after the date that these consolidated financial statements are issued. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.", "entities": [ { "start_character": 697, "end_character": 702, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -101200000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-24-024396", "filing_date": 1716225157000, "quarter_ending": "20240331", "company_name": "XTI Aerospace, Inc.", "text": "As of March\u00a031, 2024, the Company has a working capital deficit of approximately $5.1 million, and cash of approximately $1.8 million. For the three months ended March\u00a031, 2024, the Company had a net loss of approximately $2.7 million. During the three months ended March\u00a031, 2024, the Company used approximately $2.6 million of cash for operating activities.", "entities": [ { "start_character": 223, "end_character": 226, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019887", "filing_date": 1715790049000, "quarter_ending": "20240331", "company_name": "Xtant Medical Holdings, Inc.", "text": "Since\nour inception, we have financed our operations through primarily operating cash flows, private placements of equity securities and convertible\ndebt, debt facilities, common stock rights offerings, and other debt transactions. For the three months ended March 31, 2024, we incurred\na net loss of $4.4 million and negative cash flows from operating activities of $5.8 million. We believe that our $4.6 million of cash\nand cash equivalents as of March 31, 2024, together with our anticipated operating cash flows and amounts available under our recently\namended credit facilities, including additional term loan borrowings of $5.0 million on May 14, 2024, as discussed further in Note 11,\n\u201cDebt,\u201d will be sufficient to meet our anticipated cash requirements through at least May 2025. However, we may require\nor seek additional capital to fund our future operations and business strategy prior to May 2025. Accordingly, there is no assurance\nthat we will not need or seek additional financing prior to such time. Additionally, we can give no assurances that we will be able to\nsecure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will\nbe sufficient to meet our needs or on terms acceptable to us. This is particularly true if economic and market conditions deteriorate\nor our business, financial performance or prospects deteriorate. In addition, prior to raising additional equity or debt financing, we\nmay be required to obtain the consent of MidCap Financial Trust and MidCap Funding IV Trust under our Credit Agreements and/or OrbiMed\nRoyalty Opportunities II, LP (\u201cRoyalty Opportunities\u201d) and ROS Acquisition Offshore LP (\u201cROS\u201d) under our Investor\nRights Agreement with them, and no assurance can be provided that they would provide such consent, which could limit our ability to raise\nadditional financing and the terms thereof.", "entities": [ { "start_character": 302, "end_character": 305, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -4400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014769", "filing_date": 1713267206000, "quarter_ending": "20231231", "company_name": "YCQH Agricultural Technology Co. Ltd", "text": "For\nthe year ended December 31, 2022, the Company generated total revenue of $118,396, of which one customer accounted for more than 10%\nof the Company\u2019s total revenue.", "entities": [ { "start_character": 78, "end_character": 85, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 118396.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-020600", "filing_date": 1716206129000, "quarter_ending": "20240331", "company_name": "YCQH Agricultural Technology Co. Ltd", "text": "For\nthe three months ended March 31, 2024, the Company generated total revenue of $289,866, of which no customer accounted for more than\n10% of the Company\u2019s total revenue. For the three months ended March 31, 2023, the Company generated total revenue of $154,294,\nof which one customer accounted for more than 10% of the Company\u2019s total revenue.", "entities": [ { "start_character": 256, "end_character": 263, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 154294.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011910", "filing_date": 1711717774000, "quarter_ending": "20231231", "company_name": "YUNHONG GREEN CTI LTD.", "text": "The\nCompany\u2019s financial statements are prepared using account principles generally accepted in the United States (\u201cU.S. GAAP\u201d)\napplicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.\nThe Company has a cumulative net loss from inception to December 31, 2023 of approximately $24 million. The accompanying financial statements\nfor the year ended December 31, 2023 have been prepared assuming the Company will continue as a going concern. The Company\u2019s cash\nresources may be insufficient to meet its anticipated needs during the next twelve months. The Company may require additional funding\non acceptable terms to support it is planned future operations. Management\u2019s plans include executing on its business plan and raising\nexternal funds to the extent needed. These factors are indicators that there is substantial doubt about the ability to continue as a\ngoing concern for one year from the issuance of the accompanying consolidated financial statements. The accompanying financial statements\ndo not include any adjustments that might be necessary if the Company is unable to continue as a going concern.", "entities": [ { "start_character": 360, "end_character": 362, "label": "earnings", "start_date_for_period": "2019-01-02", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -24000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001437749-24-010430", "filing_date": 1711992469000, "quarter_ending": "20231231", "company_name": "ZEVRA THERAPEUTICS, INC.", "text": "\u2019s financial statements include\u00a0a total state tax expense of$31,000 related to research and development credits\u00a0on a loss before income taxes of approximately $26.8\u00a0million for the year\u00a0ended December 31, 2022. The Company did not recognize any\u00a0state tax expense during the year ended December 31, 2023. The Company met the requirements to receive a tax credit of $0.8 million for losses in Denmark resulting from research and development costs, which is included in interest and other income, net\u00a0for the year ended December 31, 2022. A reconciliation of the difference between the (expense)/benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands, except amounts pertaining to rate which are shown as a percentage):", "entities": [ { "start_character": 160, "end_character": 164, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 26800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-024404", "filing_date": 1710952896000, "quarter_ending": "20231231", "company_name": "ZION OIL & GAS INC", "text": "The\nCompany\u2019s ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration\nand development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. The\nCompany\u2019s current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements\nand the accuracy of management\u2019s estimates of those requirements. Should those estimates be materially incorrect, the Company\u2019s\nability to continue as a going concern may be in doubt. The consolidated financial statements have been prepared on a going concern basis,\nwhich contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the year ended December\n31, 2023, the Company incurred a net loss of approximately $8.0 million and had an accumulated deficit of approximately $286.6 million.\nThese factors raise substantial doubt about the Company\u2019s ability to continue as a going concern for one year from the date the\nfinancials were issued.", "entities": [ { "start_character": 865, "end_character": 868, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000109380-24-000061", "filing_date": 1708692746000, "quarter_ending": "20231231", "company_name": "ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/", "text": "We enter into certain lease agreements where we are the lessor of real estate. Real estate leases are made from bank-owned and subleased property to generate cash flow from the property, including from leasing vacant suites in which we occupy portions of the building. Operating lease income totaled $14 million during both 2023 and 2022, and $13\u00a0million during 2021.", "entities": [ { "start_character": 344, "end_character": 346, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 13000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007235", "filing_date": 1709050827000, "quarter_ending": "20231231", "company_name": "Zai Lab Ltd", "text": "Zai Lab (AUST) Pty. Ltd. is incorporated in Australia and is subject to corporate income tax at a rate of 30%. Zai Lab (AUST) Pty. Ltd. had no taxable income for the periods presented; therefore, no provision for income taxes is required. ", "entities": [ { "start_character": 140, "end_character": 142, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 }, { "start_character": 196, "end_character": 198, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007235", "filing_date": 1709050827000, "quarter_ending": "20231231", "company_name": "Zai Lab Ltd", "text": "Zai Lab (US) LLC is incorporated in the United States and is subject to U.S. federal corporate income tax at a rate of 21%. Zai Lab (US) LLC is also subject to state income tax in Delaware. Zai Lab (US) LLC had no taxable income for the periods presented; therefore, no provision for income taxes is required. ", "entities": [ { "start_character": 211, "end_character": 213, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 }, { "start_character": 267, "end_character": 269, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007235", "filing_date": 1709050827000, "quarter_ending": "20231231", "company_name": "Zai Lab Ltd", "text": "Zai Lab (Taiwan) Limited is incorporated in Taiwan and is subject to corporate income tax at a rate of 20%. Zai Lab (Taiwan) Limited had no taxable income for the periods presented; therefore, no provision for income taxes is required. ", "entities": [ { "start_character": 137, "end_character": 139, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 }, { "start_character": 193, "end_character": 195, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-043932", "filing_date": 1715809825000, "quarter_ending": "20240331", "company_name": "Zeo Energy Corp.", "text": "In\n2023, some of the Company\u2019s customers financed their obligations with a related party, Solar Leasing, whose CEO is also the CEO\nof the Company. These arrangements are similar to those with the Company\u2019s third-party lenders. As such, Solar Leasing deducts\ntheir financing fees and remits the net amount to the Company. For the three months ended March 31, 2024 and 2023, the Company recognized\n$8,812,769 and $0 of revenue, net of financing fees of $3,856,219 and $0, respectively from these arrangements. As of March 31, 2024\nand December 31, 2023, the Company had $3,089,328 and $396,488 of accounts receivable, $267,006 and $2,415,966 of accrued expenses and\n$106,585 and $1,160,848 of contract liabilities due to related parties relating to these arrangements, respectively.", "entities": [ { "start_character": 397, "end_character": 406, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 8812769.0 }, { "start_character": 412, "end_character": 413, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 }, { "start_character": 467, "end_character": 468, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-03-31", "currency_/_unit": "iso4217:USD", "value": 0.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-026042", "filing_date": 1711469172000, "quarter_ending": "20231231", "company_name": "Zoned Properties, Inc.", "text": "As\nreflected in the accompanying consolidated financial statements, the Company generated a net loss of $540,258 and cash provided by operations\nof $82,547 during the year ended December 31, 2023. Additionally, as of December 31, 2023, the Company had cash of $3,099,795 and stockholders\u2019\nequity of $5,239,683.", "entities": [ { "start_character": 105, "end_character": 112, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -540258.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019517", "filing_date": 1715761841000, "quarter_ending": "20240331", "company_name": "ZyVersa Therapeutics, Inc.", "text": "As\nof March 31, 2024, the Company had cash of approximately $2.0 million and a working capital deficit of approximately $6.7 million. During\nthe three months ended March 31, 2024, the Company incurred a net loss of approximately $2.8 million and used cash in operations of approximately\n$3.8 million. The Company has an accumulated deficit of approximately $106.0 million as of March 31, 2024.", "entities": [ { "start_character": 230, "end_character": 233, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -2800000.0 } ] }, { "form_type": "10-K", "accession_number": "0001213900-24-024363", "filing_date": 1710950774000, "quarter_ending": "20231231", "company_name": "authID Inc.", "text": "As\nof December 31, 2023, the Company had an accumulated deficit of approximately $159.5 million. For the year ended December 31, 2023, the\nCompany earned revenue of approximately $0.19 million, used $8.4 million to fund its operations, and incurred a net loss from continuing\noperations of approximately $19.6 million, of which $11.2 million was non-cash.", "entities": [ { "start_character": 180, "end_character": 184, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 190000.0 }, { "start_character": 305, "end_character": 309, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -19600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001293971-23-000055", "filing_date": 1699340612000, "quarter_ending": "20230930", "company_name": "bluebird bio, Inc.", "text": "2023, the Company had a net loss of $123.4 million and used $221.2 million of cash in operations. As of September\u00a030, 2023, the Company had cash, cash equivalents and marketable securities of $174.3 million.", "entities": [ { "start_character": 37, "end_character": 42, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -123400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-008632", "filing_date": 1709574801000, "quarter_ending": "20231231", "company_name": "fuboTV Inc. /FL", "text": "On December\u00a06, 2021, the Company acquired approximately 98.5% of the equity interests in Molotov S.A.S (\u201cMolotov\u201d), a television streaming platform located in France, for \u20ac101.7 million or $115.0 million (\u201cMolotov Acquisition\u201d). In the first quarter of 2023, the Company acquired the remaining 1.5% of the equity interests in Molotov. The consideration paid in cash totaled \u20ac14.4 million or $16.3 million, and the issuance of 5.7 million shares of the Company\u2019s common stock with a fair value of approximately $98.8 million. Molotov is included in the streaming segment and its contribution to revenue and operating loss during the year ended December\u00a031, 2021 was $1.4 million and $8.1 million, respectively.", "entities": [ { "start_character": 666, "end_character": 669, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1400000.0 }, { "start_character": 683, "end_character": 686, "label": "ebit", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 8100000.0 } ] }, { "form_type": "10-K", "accession_number": "0001720635-24-000012", "filing_date": 1708446702000, "quarter_ending": "20231231", "company_name": "nVent Electric plc", "text": "ECM Industries net sales and operating income for the period from the acquisition date to December\u00a031, 2023 were $240.7\u00a0million and $31.4\u00a0million, respectively. ECM Industries operating income for the period from the acquisition date to December\u00a031, 2023 inclu", "entities": [ { "start_character": 133, "end_character": 137, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 31400000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-010843", "filing_date": 1710332738000, "quarter_ending": "20231231", "company_name": "ADC Therapeutics SA", "text": "The Company will also receive royalties ranging in percentage from the mid-teens to the mid-twenties based on net sales of the product in Sobi\u2019s licensed territories, subject to certain adjustments. The Company recognized $498 of revenue attributable to royalties in the Sobi licensed territories during the year ended December\u00a031, 2023. ", "entities": [ { "start_character": 223, "end_character": 226, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 498000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011751", "filing_date": 1711642774000, "quarter_ending": "20231231", "company_name": "American Picture House Corp", "text": "The\nCompany\u2019s financial statements are prepared using account principles generally accepted in the United States (\u201cU.S. GAAP\u201d)\napplicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.\nAs of December 31, 2023, the Company has an accumulated deficit of approximately $5.0 million and incurred a net loss of $1.4 million\nin 2023. These factors, among others, raise doubt about the Company\u2019s ability to continue as a going concern. The accompanying\nfinancial statements do not include adjustments to reflect the possible future effects on the recoverability and classification of assets\nor the amounts and classification of liabilities that may result from an inability of the Company to continue as a going concern.", "entities": [ { "start_character": 390, "end_character": 393, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -1400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001730463-23-000110", "filing_date": 1699546690000, "quarter_ending": "20230930", "company_name": "Autolus Therapeutics plc", "text": "The Company has incurred recurring losses since its inception, including net losses of $45.8 million and $42.8 million for the three months ended September 30, 2023 and 2022, respectively and $131.2 million and $121.9 million for the nine months ended September 30, 2023 and 2022, respectively. The Company had an accumulated deficit of $801.4 million and $670.2 million as of September 30, 2023 and December 31, 2022, respectively. The Company expects to continue to generate operating losses in the foreseeable future. The Company\u2019s inability to raise additional capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. As of the date these unaudited condensed consolidated financial statements are issued, the Company expects that its cash and cash equivalents at September 30, 2023 of $256.4 million will be sufficient to fund the Company\u2019s operations for at least twelve\u00a0months from the issuance date of these unaudited condensed consolidated financial statements and accordingly they have been prepared on the going concern basis.", "entities": [ { "start_character": 88, "end_character": 92, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -45800000.0 }, { "start_character": 106, "end_character": 110, "label": "earnings", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -42800000.0 }, { "start_character": 193, "end_character": 198, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -131199999.99999999 }, { "start_character": 212, "end_character": 217, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -121900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-010091", "filing_date": 1710518764000, "quarter_ending": "20231231", "company_name": "Azitra, Inc.", "text": "The\nconsolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation\nfor the foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal course of business.\nHowever, management has identified the following conditions and events that created an uncertainty about the ability of the Company to\ncontinue as a going concern. As of and for the year ended December 31, 2023, the Company has an accumulated deficit of $48.6 million,\na loss from operations of $7.6 million and used $7.4 million to fund operations. These factors among others raise substantial doubt about\nthe Company\u2019s ability to continue as a going concern.", "entities": [ { "start_character": 580, "end_character": 583, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -7600000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-012367", "filing_date": 1711988034000, "quarter_ending": "20231231", "company_name": "Boxabl Inc.", "text": "The\nCompany incurred a net loss of $39,526K and $612,395K during the years ended December 31, 2023, and 2022, respectively, and currently\nhas limited revenues.", "entities": [ { "start_character": 36, "end_character": 42, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -39526000.0 }, { "start_character": 49, "end_character": 56, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -612395000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-011730", "filing_date": 1711641672000, "quarter_ending": "20231231", "company_name": "CVD EQUIPMENT CORP", "text": "The\nrevenues and net income of MesoScribe were $0.7 million and $33,000 for the year ended December 31, 2023, including the impairment charge\nof $0.1 million.", "entities": [ { "start_character": 65, "end_character": 71, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 33000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001079973-24-000736", "filing_date": 1715789760000, "quarter_ending": "20240331", "company_name": "Dolphin Entertainment, Inc.", "text": "During the three months ended March 31, 2024, we recorded net revenues of $3,421,141\nfrom the Amazon Agreement upon delivery of the film to Amazon Content Services LLC, our single\nperformance obligation. Under this arrangement, we acted in the capacity of an agent. During the three months ended March 31, 2023,\nwere no revenues recognized from the content licensing arrangement. ", "entities": [ { "start_character": 75, "end_character": 84, "label": "revenues", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 3421141.0 } ] }, { "form_type": "10-K", "accession_number": "0001164863-24-000015", "filing_date": 1709037018000, "quarter_ending": "20231231", "company_name": "Enpro Inc.", "text": "Sales of $8.6\u00a0million and a pre-tax loss of $1.9\u00a0million for NxEdge are included in our Consolidated Statement of Operations for the year ended December 31, 2021. The following unaudited pro forma condensed consolidated financial results of operations for the years ended December 31, 2022 and 2021 are presented as if these acquisitions had been completed before January\u00a01, 2021:", "entities": [ { "start_character": 46, "end_character": 49, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 1900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-23-038349", "filing_date": 1699550757000, "quarter_ending": "20230930", "company_name": "Fathom Holdings Inc.", "text": "\u2014 The Company has a history of negative cash flows from operations and operating losses. The Company generated net losses of approximately $15.5 million and $17.7 million for the nine months ended September\u00a030, 2023 and 2022, respectively. Additionally, the Company anticipates further expenditures associated with the process of expanding its business organically and via acquisitions. The Company received net proceeds of $3.3 million in April 2023 from the issuance of convertible notes. The Company had cash and cash equivalents of $6.6 million and $8.3 million as of September\u00a030, 2023 and December\u00a031, 2022, respectively. Management believes that existing cash along with its planned budget, which includes an increase in agent fees implemented in January 2023, growth from increasing attach rates across the Company\u2019s businesses from internal referrals, reduction of certain expenses given initiatives implemented in early 2023, and the expected ability to achieve sales volumes necessary to cover forecasted expenses, provide sufficient funding to continue as a going concern for a period of at least one year from the date of the issuance of these consolidated financial statements.", "entities": [ { "start_character": 140, "end_character": 144, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -15500000.0 }, { "start_character": 158, "end_character": 162, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": -17700000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-018817", "filing_date": 1715595467000, "quarter_ending": "20231231", "company_name": "First Choice Healthcare Solutions, Inc.", "text": "During\nthe fiscal year ended December 31, 2023, the Company experienced operating losses of approximately $8.2\n", "entities": [ { "start_character": 107, "end_character": 110, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -8199999.999999999 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-014809", "filing_date": 1713283327000, "quarter_ending": "20231231", "company_name": "GameSquare Holdings, Inc.", "text": "GSQ incurred transaction costs of $2.7 million associated with the Arrangement. All such costs were expensed as incurred. The loss attributed\nto Engine\u2019s operations from the acquisition date to December 31, 2023, was $3.8 million, with revenue of $29.8 million.", "entities": [ { "start_character": 218, "end_character": 221, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 3800000.0 }, { "start_character": 248, "end_character": 252, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 29800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-23-037082", "filing_date": 1699289516000, "quarter_ending": "20230930", "company_name": "Gatos Silver, Inc.", "text": "Under the Unanimous Omnibus Partner Agreement, the Company provides certain management and administrative services to the LGJV. The Company earned $1,250 and $1,250 under this agreement for the three months ended September 30, 2023 and 2022, respectively, and during the nine months ended September 30, 2023 and 2022, the Company earned $3,750 and $3,750, respectively. The income from these services has been recorded on the statements of income under other income. The Company received $1,666 and $1,200 in cash from the LGJV under this agreement for the three months ended September 30, 2023 and 2022, respectively, and during the nine months ended September 30, 2023 and 2022, the Company received $3,333 and $4,167, respectively. The Company had receivables under this agreement of $833 and $417 as of September 30, 2023, and December 31, 2022, respectively. The Company also incurs certain LGJV costs that are subsequently reimbursed by the LGJV. On October 24, 2023, the management fee was increased to $6,000 per annum.", "entities": [ { "start_character": 148, "end_character": 153, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1250000.0 }, { "start_character": 159, "end_character": 164, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1250000.0 }, { "start_character": 338, "end_character": 343, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 3750000.0 }, { "start_character": 349, "end_character": 354, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 3750000.0 } ] }, { "form_type": "10-K", "accession_number": "0001493152-24-005474", "filing_date": 1707409672000, "quarter_ending": "20230930", "company_name": "Global AI, Inc.", "text": "$49,000\nand $60,000, or 100% of the Company\u2019s revenue during the years ended September 30, 2023 and 2022, respectively, are derived from\nLandmark-Pegasus, Inc. (\u201cLandmark-Pegasus\u201d) and Skybunker Inc. (\u201cSkybunker\u201d), related parties, or direct clients\nof Landmark-Pegasus. Landmark-Pegasus and Skybunker are both wholly owned by John Moroney, who beneficially owned approximately 59.8%\nof the Company\u2019s common stock prior to the Ingenious Acquisition. Mr. Moroney still acts as Landmark-Pegasus\u2019 President and\nis Landmark-Pegasus\u2019 sole director. As of September 30, 2023 and 2022, $0 and $5,000 of those services were unpaid by the related party.", "entities": [ { "start_character": 1, "end_character": 7, "label": "revenues", "start_date_for_period": "2022-10-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 49000.0 }, { "start_character": 13, "end_character": 19, "label": "revenues", "start_date_for_period": "2021-10-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 60000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-007207", "filing_date": 1709050081000, "quarter_ending": "20231231", "company_name": "Howard Hughes Holdings Inc.", "text": "Total revenues includes hospitality revenues of $35.6 million for the year ended December 31, 2021. Total operating expenses includes hospitality operating costs of $30.5 million for the year ended December 31, 2021. In September 2021, the Company completed the sale of its three hospitality properties. Refer to Note 3 - ", "entities": [ { "start_character": 49, "end_character": 53, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 35600000.0 } ] }, { "form_type": "10-K", "accession_number": "0000059558-24-000013", "filing_date": 1708621868000, "quarter_ending": "20231231", "company_name": "LINCOLN NATIONAL CORP", "text": "Wholesaling-related 12b-1 fees received from separate account fund sponsors as compensation for servicing the underlying mutual funds are recorded as revenues based on a contractual percentage of the market value of mutual fund assets over the period shares are owned by customers. Net investment advisory fees related to asset management of certain separate account funds are recorded as revenues based on a contractual percentage of the customer\u2019s managed assets over the period advisory services are provided. Fee income related to 12b-1 fees and net investment advisory fees, reported primarily within our Annuities segment, was $715\u00a0million, $743\u00a0million and $848\u00a0million for the years ended December 31, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 636, "end_character": 639, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 715000000.0 }, { "start_character": 650, "end_character": 653, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 743000000.0 }, { "start_character": 667, "end_character": 670, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 848000000.0 } ] }, { "form_type": "10-K", "accession_number": "0000726865-24-000086", "filing_date": 1710517909000, "quarter_ending": "20231231", "company_name": "LINCOLN NATIONAL LIFE INSURANCE CO /IN/", "text": "Wholesaling-related 12b-1 fees received from separate account fund sponsors as compensation for servicing the underlying mutual funds are recorded as revenues based on a contractual percentage of the market value of mutual fund assets over the period shares are owned by customers. Net investment advisory fees related to asset management of certain separate account funds are recorded as revenues based on a contractual percentage of the customer\u2019s managed assets over the period advisory services are provided. Fee income related to 12b-1 fees and net investment advisory fees, reported primarily within our Annuities segment, was $715 million, $743 million and $848 million for the years ended December\u00a031, 2023, 2022 and 2021, respectively.", "entities": [ { "start_character": 636, "end_character": 639, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 715000000.0 }, { "start_character": 650, "end_character": 653, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": 743000000.0 }, { "start_character": 667, "end_character": 670, "label": "revenues", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": 848000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-006659", "filing_date": 1708705998000, "quarter_ending": "20231231", "company_name": "Lazard, Inc.", "text": "For the year ended December\u00a031, 2023, the Company\u2019s operating lease income included in \u201crevenue-other\u201d on the consolidated statements of operations was $6,393.", "entities": [ { "start_character": 153, "end_character": 158, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": 6393000.0 } ] }, { "form_type": "10-K", "accession_number": "0001520138-24-000172", "filing_date": 1713202160000, "quarter_ending": "20231231", "company_name": "MIAMI BREEZE CAR CARE INC", "text": "These\nfinancial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities\nand commitments in the normal course of business. As reflected in the accompanying financial statements, the Company had a net loss of\n$850,912 and $1,599,256 for the years ended December 31, 2023 and 2022, respectively.\u00a0", "entities": [ { "start_character": 287, "end_character": 294, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -850912.0 }, { "start_character": 300, "end_character": 309, "label": "earnings", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-12-31", "currency_/_unit": "iso4217:USD", "value": -1599256.0 } ] }, { "form_type": "10-Q", "accession_number": "0001213900-24-043589", "filing_date": 1715789174000, "quarter_ending": "20240331", "company_name": "MOBIX LABS, INC", "text": "The\noperating results of EMI Solutions are included in the Company\u2019s condensed consolidated financial statements for periods subsequent\nto the acquisition date. The amounts of revenues and net loss of EMI Solutions included in the Company\u2019s condensed consolidated\nstatement of operations and comprehensive loss for the six months ended March 31, 2024 were $997 and $454, respectively.", "entities": [ { "start_character": 357, "end_character": 360, "label": "revenues", "start_date_for_period": "2023-10-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": 997000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001140361-23-053260", "filing_date": 1699978981000, "quarter_ending": "20230930", "company_name": "MachTen, Inc.", "text": "The revenue received from these sources for each of the three months ended September 30, 2023 and 2022 were $2.4 million and $2.5 million (59% and 63% of revenue), respectively.\n Revenue received from these sources for each of\u00a0 the nine months ended September 30, 2023 and 2022 were $7.4 million and $7.6 million (62% and 64% of revenue), respectively.", "entities": [ { "start_character": 109, "end_character": 112, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 2400000.0 }, { "start_character": 126, "end_character": 129, "label": "revenues", "start_date_for_period": "2022-07-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 2500000.0 }, { "start_character": 293, "end_character": 296, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 7400000.0 }, { "start_character": 310, "end_character": 313, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 7600000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-040591", "filing_date": 1699894469000, "quarter_ending": "20230930", "company_name": "Marygold Companies, Inc.", "text": "The\nFunds managed by USCF and USCF Advisers are deemed by management to be related parties. The Company\u2019s USCF The Funds managed\nby USCF and USCF Advisers are deemed by management to be related parties. The Company\u2019s USCF Investments revenues, totaling\n$5.0 ", "entities": [ { "start_character": 254, "end_character": 257, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 5000000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001628280-23-039494", "filing_date": 1700239872000, "quarter_ending": "20230930", "company_name": "Net Lease Office Properties", "text": "Other lease-related income on our combined statements of income was primarily comprised of income from a parking garage attached to one of our net-leased properties totaling $0.6 million for both the three months ended September 30, 2023 and 2022, and $1.8 million and $1.9 million for the nine months ended September 30, 2023 and 2022, respectively.", "entities": [ { "start_character": 253, "end_character": 256, "label": "revenues", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1800000.0 }, { "start_character": 271, "end_character": 274, "label": "revenues", "start_date_for_period": "2022-01-01", "end_date_for_period": "2022-09-30", "currency_/_unit": "iso4217:USD", "value": 1900000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-011153", "filing_date": 1711386041000, "quarter_ending": "20231231", "company_name": "Perfect Moment Ltd.", "text": "Through\nDecember 31, 2023, the Company has funded its operations with proceeds from the issuance of convertible debt, preferred stock and common\nstock, alongside existing trade, invoice and shareholder financing arrangements. The Company incurred recurring losses, including a net\nloss of $2,980", "entities": [ { "start_character": 290, "end_character": 295, "label": "earnings", "start_date_for_period": "2023-04-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -2980000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001914496-23-000015", "filing_date": 1699982427000, "quarter_ending": "20230930", "company_name": "Sculptor Diversified Real Estate Income Trust, Inc.", "text": "During the 2023 Q3 Successor Period and 2023 Successor Interim Period, the Company recognized $1.6 million and $3.7 million of rental revenue for the amortization of aggregate below-market leases in excess of above-market leases resulting from the allocation of the purchase price of the applicable properties. Amortization of the in-place leases and leasing commissions during the 2023 Q3 Successor Period and 2023 Successor Interim Period aggregating to $1.2 million and $3.2\u00a0million, respectively, is included in depreciation and amortization in the condensed consolidated statements of operations.", "entities": [ { "start_character": 95, "end_character": 98, "label": "revenues", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 1600000.0 }, { "start_character": 112, "end_character": 115, "label": "revenues", "start_date_for_period": "2023-01-04", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": 3700000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-24-019248", "filing_date": 1715703362000, "quarter_ending": "20240331", "company_name": "Serina Therapeutics, Inc.", "text": "The\nCompany recognized net loss of approximately $9.4 million for the period ended March 31, 2024. The Company used approximately $1.6 million\nin net cash from operating activities for the period ended March 31, 2024 and has historically incurred losses from operations and expects\nto continue to generate negative cash flows as the Company implements its business plan.", "entities": [ { "start_character": 50, "end_character": 53, "label": "earnings", "start_date_for_period": "2024-01-01", "end_date_for_period": "2024-03-31", "currency_/_unit": "iso4217:USD", "value": -9400000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001718939-23-000026", "filing_date": 1699373469000, "quarter_ending": "20230930", "company_name": "T Stamp Inc", "text": "\u2014 The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is a business that has not yet generated profits, with a Net loss in the nine months ended September\u00a030, 2023 of $4.75 million, negative Net operating cash outflows of $5.88 million for the same period, working capital of $2.25 million and an Accumulated deficit of $44.05 million as of September\u00a030, 2023.", "entities": [ { "start_character": 359, "end_character": 363, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -4750000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001493152-23-039775", "filing_date": 1699376543000, "quarter_ending": "20230930", "company_name": "Tharimmune, Inc.", "text": "The\naccompanying condensed consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates,\namong other things, the realization of assets and satisfaction of liabilities in the normal course of business. For the nine months ended\nSeptember 30, 2023, the Company incurred operating losses in the amount of approximately $6.9 million, expended approximately $5.9 million\nin cash used in operating activities, and had an accumulated deficit of approximately $22.2 million as of September 30, 2023. The Company\nfinanced its working capital requirements through September 30, 2023 primarily through the issuance of common stock in its initial public\noffering (\u201cIPO\u201d) on January 14, 2022. Net proceeds to the Company from the IPO were approximately $13.0 million. See Note\n5 to the condensed consolidated financial statements for details regarding the IPO. Additionally, the Company closed a public offering\n(the \u201cMay Offering\u201d) of its common stock on May 2, 2023. Net proceeds to the Company from the offering were approximately\n$2.0 million. Also see Note 5 to the condensed consolidated financial statements for details regarding the May Offering. The shares of\nthe Company\u2019s common stock began trading on The Nasdaq Capital Market on January 12, 2022 under the ticker symbol \u201cHILS\u201d\nand, effective as of September 25, 2023, are traded under the ticker symbol \u201cTHAR.\u201d", "entities": [ { "start_character": 378, "end_character": 381, "label": "ebit", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-09-30", "currency_/_unit": "iso4217:USD", "value": -6900000.0 } ] }, { "form_type": "10-K", "accession_number": "0001169445-24-000017", "filing_date": 1710518741000, "quarter_ending": "20231231", "company_name": "TruBridge, Inc.", "text": "In accordance with its policy, the Company reviews the estimated useful lives of its intangible assets on an ongoing basis. This review indicated that the actual lives of certain developed technology were shorter than the estimated useful lives used for amortization purposes in the Company's financial statements. As a result, effective January 1, 2021, the Company changed its estimates of the useful lives of certain developed technology to better reflect the estimated periods during which these assets will remain in service. The remaining useful life of certain developed technology that was 3.25 years at January 1, 2021 was reduced to 2 years, while the remaining useful life of certain developed technology that was 4.25 years was reduced to 3 years. The effect of this change was to increase 2021 amortization expense by approximately $1.0\u00a0million and decrease 2021 net income and basic and diluted earnings per share by $0.8\u00a0million and $0.06, respectively.", "entities": [ { "start_character": 932, "end_character": 935, "label": "earnings", "start_date_for_period": "2021-01-01", "end_date_for_period": "2021-12-31", "currency_/_unit": "iso4217:USD", "value": -800000.0 } ] }, { "form_type": "10-Q", "accession_number": "0001065949-24-000052", "filing_date": 1713868866000, "quarter_ending": "20231231", "company_name": "VECTOR 21 HOLDINGS, INC.", "text": "Our financial\nstatements are prepared using accounting principles generally accepted in the United States of America (\u201cGAAP\u201d) applicable\nto a going concern, which contemplate the realization of assets and the liquidation of liabilities in the normal course of business.\nWe have no ongoing business or income and for the six-month ended December 31, 2023 we incurred a loss of $26,272 and had an accumulated\ndeficit of $17,791,240 as of December 31, 2023. These conditions raise substantial doubt about our ability to continue as a going\nconcern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability\nand classification of assets or the amounts and classification of liabilities that may result from the outcome of these uncertainties.\nOur ability to continue as a going concern is dependent upon our ability to raise additional debt or equity funding to meet our\nongoing operating expenses and ultimately in merging with another entity with experienced management and profitable operations.\nNo assurances can be given that we will be successful in achieving these objectives.", "entities": [ { "start_character": 377, "end_character": 383, "label": "earnings", "start_date_for_period": "2023-07-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -26272.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-012994", "filing_date": 1711438908000, "quarter_ending": "20231231", "company_name": "Volato Group, Inc.", "text": "The Company has only recently been formed, has limited operating history, has recorded a net loss of approximately $53 million for the year ended December\u00a031, 2023, has a limited positive working capital of approximately $3 million, and has an accumulated deficit of approximately $64 million as of December\u00a031, 2023. Net cash used in operating activities for the year ended December\u00a031, 2023, was approximately $30 million.", "entities": [ { "start_character": 116, "end_character": 118, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -53000000.0 } ] }, { "form_type": "10-K", "accession_number": "0001628280-24-016449", "filing_date": 1713287409000, "quarter_ending": "20231231", "company_name": "XTI Aerospace, Inc.", "text": "As of December\u00a031, 2023, the Company has working capital of approximately $3.6 million and cash of approximately $6.3\u00a0million. For the year ended December\u00a031, 2023, the Company incurred a net loss attributable to common stockholders of approximately $45.9 million and net cash used in operating activities during the year ended December\u00a031, 2023 was $29.2 million.", "entities": [ { "start_character": 251, "end_character": 255, "label": "earnings", "start_date_for_period": "2023-01-01", "end_date_for_period": "2023-12-31", "currency_/_unit": "iso4217:USD", "value": -45900000.0 } ] } ]